In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	B-protein
receptor	E-protein
with	O
hsp90	S-protein
.	O

Using	O
reporter	B-DNA
gene	I-DNA
constructs	E-DNA
driven	O
by	O
the	O
CD4	B-DNA
promoter	E-DNA
,	O
we	O
report	O
that	O
HHV-6	O
can	O
efficiently	O
transactivate	O
such	O
genetic	B-DNA
elements	E-DNA
.	O

Further	O
analysis	O
has	O
revealed	O
that	O
this	O
1-kb	B-DNA
fragment	E-DNA
promotes	O
higher	O
reporter	O
gene	O
activity	O
in	O
MNDA	B-cell_type
-expressing	I-cell_type
cells	E-cell_type
than	O
non-expressing	B-cell_type
cells	E-cell_type
,	O
indicating	O
cell-specific	O
differences	O
in	O
transactivation	O
.	O

We	O
have	O
shown	O
that	O
both	O
activating	O
regions	O
of	O
Oct-2a	S-protein
,	O
isolated	O
from	O
their	O
natural	O
context	O
,	O
can	O
activate	O
transcription	O
as	O
promoter	B-protein
factors	E-protein
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c-jun	B-protein
transcripts	E-protein
.	O

As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined	O
.	O

This	O
Oct-1	S-protein
-binding	O
phenotype	O
remained	O
stable	O
in	O
culture	O
for	O
up	O
to	O
3	O
days	O
prior	O
to	O
activation	O
.	O

One	O
of	O
these	O
NFAT-like	B-DNA
elements	E-DNA
encompassed	O
overlapping	O
Oct-	B-DNA
and	I-DNA
NFATp/c-binding	I-DNA
sites	E-DNA
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O

This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	O
of	O
sialoadhesin	S-protein
expression	O
on	O
rat	B-cell_type
macrophages	E-cell_type
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	O
by	O
IFN-beta	S-protein
,	O
T	B-protein
cell-derived	I-protein
cytokines	E-protein
,	O
or	O
LPS	O
.	O

Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN-alpha	S-protein
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	S-protein
(	O
IL-2	S-protein
,	O
IL-6	S-protein
,	O
TNF-alpha	S-protein
,	O
IL-10	S-protein
)	O
by	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF-kB	S-protein
DNA	O
binding	O
activity	O
by	O
activated	B-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

We	O
conclude	O
that	O
VDR	S-protein
polymorphism	O
does	O
not	O
affect	O
the	O
abundance	O
of	O
the	O
VDR	B-RNA
mRNA	E-RNA
.	O

The	O
allele-specific	O
expression	O
profiles	O
of	O
other	O
imprinted	B-DNA
genes	E-DNA
,	O
IGF2	S-DNA
and	O
H19	S-DNA
,	O
on	O
human	B-DNA
chromosome	I-DNA
11	E-DNA
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

In	O
THP-1	B-cell_line
cells	E-cell_line
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA-protein	B-protein
binding	I-protein
complex	E-protein
formation	O
with	O
the	O
HIV-1	B-DNA
promoter-enhancer	E-DNA
associated	O
with	O
markedly	O
less	O
viral	B-RNA
RNA	E-RNA
production	O
.	O

Abnormalities	O
of	O
retinoblastoma	B-protein
protein	E-protein
(	O
pRB	S-protein
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM-derived	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Removal	O
of	O
the	O
carboxy	B-protein
terminus	E-protein
enables	O
ERP	S-protein
to	O
interact	O
with	O
a	O
variety	O
of	O
ets-binding	B-DNA
sites	E-DNA
including	O
the	O
E74	B-DNA
site	E-DNA
,	O
the	O
IgH	B-DNA
enhancer	I-DNA
pi	I-DNA
site	E-DNA
,	O
and	O
the	O
lck	B-DNA
promoter	I-DNA
ets	I-DNA
site	E-DNA
,	O
suggesting	O
a	O
carboxy-terminal	B-protein
negative	I-protein
regulatory	I-protein
domain	E-protein
.	O

This	O
result	O
implies	O
that	O
development	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
antibody	E-protein
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	B-protein
proinflammatory	I-protein
cytokines	E-protein
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O

Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	E-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	S-protein
.	O

Cyclin	B-protein
A	E-protein
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	B-protein
CD2	E-protein
+	O
CD28	S-protein
whereas	O
stimulation	O
by	O
anti	B-protein
CD2	E-protein
or	O
anti	B-protein
CD28	E-protein
alone	O
was	O
not	O
effective	O
.	O

Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O

Cytokine	B-protein
profiles	E-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
associated	O
with	O
chronic	O
hepatitis	O
B	O
were	O
analysed	O
by	O
RT-PCR	O
.	O

We	O
have	O
previously	O
found	O
a	O
cis-acting	B-DNA
region	E-DNA
spanning	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
region	E-DNA
(	O
positions	O
-95	O
to	O
+27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	B-DNA
genes	E-DNA
in	O
transient	O
transfection	O
assays	O
.	O

The	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus-encoded	I-protein
tax	I-protein
protein	E-protein
is	O
a	O
potent	O
activator	O
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	E-DNA
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	E-protein
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	S-protein
or	O
by	O
transfection	O
with	O
a	O
CD40L	B-DNA
expression	I-DNA
vector	E-DNA
,	O
secreted	O
p40	S-protein
and	O
showed	O
enhanced	O
p40	B-RNA
mRNA	E-RNA
expression	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

RESULTS	O
:	O
BZLF1	S-protein
(	O
ZEBRA	S-protein
)	O
or	O
early	B-protein
gene	I-protein
products	E-protein
(	O
EA-R	S-protein
and	O
EA-D/BHLF1/NotI	S-protein
)	O
were	O
detected	O
in	O
a	O
small	O
proportion	O
(	O
<	O
0.01-5	O
%	O
)	O
of	O
tumour	B-cell_type
cells	E-cell_type
in	O
eight	O
of	O
these	O
17	O
cases	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
.	O

Mutation	O
of	O
the	O
hXBP-1	B-DNA
DNA	I-DNA
target	I-DNA
sequence	E-DNA
decreased	O
DR	B-DNA
alpha	I-DNA
promoter	E-DNA
activity	O
in	O
vivo	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF-kappa	B-protein
B	E-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
(	O
Jurkat	B-cell_line
cells	E-cell_line
)	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNF-	B-protein
alpha	E-protein
)	O
and	O
H2O2	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	B-DNA
Ha-ras	I-DNA
oncogene	E-DNA
in	O
EBV-immortalized	B-cell_line
B	I-cell_line
lymphoblasts	E-cell_line
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	E-protein
,	O
with	O
an	O
impaired	O
immunoglobulin	B-DNA
gene	E-DNA
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum-free	O
medium	O
.	O

Coexpression	O
of	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
CIITA	E-protein
in	O
these	O
cells	O
,	O
which	O
stimulates	O
highly	O
efficient	O
class	O
II	O
processing	O
without	O
the	O
characteristic	O
decline	O
in	O
barrier	O
function	O
seen	O
in	O
polarized	O
monolayers	O
treated	O
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
gamma-IFN	E-protein
,	O
facilitates	O
antigen	O
processing	O
from	O
the	O
basolateral	O
surface	O
.	O

We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B-RNA
and	I-RNA
Id3	I-RNA
mRNA	E-RNA
in	O
human	B-cell_line
leukemia/lymphoma	I-cell_line
lines	E-cell_line
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	E-cell_line
from	O
peripheral	O
blood	O
(	O
PBL	S-cell_type
)	O
.	O

Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O

In	O
contrast	O
,	O
Egr-1	S-protein
expression	O
is	O
abrogated	O
in	O
group	B-cell_line
I	I-cell_line
Burkitt	I-cell_line
tumor	I-cell_line
cells	E-cell_line
,	O
irrespective	O
of	O
the	O
EBV	B-DNA
genome	E-DNA
carrying	O
status	O
.	O

Kappa	B-protein
B	I-protein
binding	I-protein
proteins	E-protein
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	B-cell_line
autocrine	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

HLA	B-protein
class	I-protein
I	I-protein
Ags	E-protein
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	B-protein
class	I-protein
I	I-protein
molecules	E-protein
can	O
induce	O
the	O
proliferation	O
of	O
aortic	B-cell_type
endothelial	E-cell_type
as	O
well	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	E-cell_type
.	O

These	O
findings	O
demonstrate	O
that	O
IFNs	S-protein
inhibit	O
IL-4	S-protein
-induced	O
activation	O
of	O
STAT6	S-protein
and	O
STAT6	S-protein
-dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
expression	O
of	O
SOCS-1	S-DNA
.	O

Thus	O
,	O
the	O
use	O
of	O
DNase	B-protein
I	E-protein
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
correlate	O
the	O
AIR-1	B-DNA
locus	I-DNA
defect	E-DNA
with	O
class	B-DNA
II	I-DNA
promoter	E-DNA
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	B-cell_line
class	I-cell_line
II-negative	I-cell_line
cells	E-cell_line
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	S-protein
,	O
untransformed	B-protein
progestin	I-protein
,	I-protein
estrogen	I-protein
,	I-protein
androgen	I-protein
,	I-protein
and	I-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	E-protein
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B-protein
protein	E-protein
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O
N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269-5275	O
]	O
.	O

In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O

Moreover	O
we	O
present	O
evidence	O
that	O
the	O
component	O
that	O
forms	O
the	O
faster-migrating	O
(	O
``	O
lower	O
''	O
)	O
nuclear	B-protein
NF-AT	I-protein
complex	E-protein
is	O
derived	O
by	O
a	O
calcium-dependent	O
,	O
cyclosporin-sensitive	O
,	O
posttranslational	O
modification	O
of	O
NF-ATp	S-protein
,	O
and	O
that	O
Fos	S-protein
and	O
Jun	S-protein
proteins	O
stabilize	O
its	O
interaction	O
with	O
DNA	O
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
CD28	S-protein
-derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF-kappaB	O
and	O
AP-1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	B-protein
sphingomyelinase	E-protein
and	O
phosphatidylinositol	B-protein
3-kinase	E-protein
-linked	O
pathways	O
.	O

These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel-related	B-protein
transcription	I-protein
factors	E-protein
.	O

Induction	O
of	O
HIV	O
by	O
C.	O
neoformans	O
was	O
enhanced	O
by	O
anti-capsular	B-protein
antibody	E-protein
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti-TNF-alpha	B-protein
antibody	E-protein
.	O

Fos	B-protein
kinase	E-protein
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	B-protein
and	I-protein
CD2	I-protein
receptors	E-protein
in	O
Jurkat	S-cell_line
and	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
and	O
in	O
response	O
to	O
IL-6	S-protein
and	O
anti-IgM	S-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
AF10	E-cell_line
and	O
Ramos	S-cell_line
,	O
respectively	O
.	O

IL-10	S-protein
inhibition	O
of	O
ICAM-1	B-RNA
steady-state	I-RNA
mRNA	E-RNA
was	O
detected	O
at	O
3	O
hours	O
and	O
remained	O
at	O
24	O
hours	O
.	O

Analysis	O
of	O
the	O
molecular	O
differences	O
between	O
primary	O
anaplastic	O
astrocytomas/glioblastomas	O
and	O
their	O
subsequent	O
recurrences	O
,	O
which	O
are	O
clinically	O
indistinguishable	O
,	O
may	O
provide	O
better	O
therapeutic	O
options	O
for	O
treatment	O
.	O

The	O
second	O
(	O
-365/-264	O
)	O
binds	O
to	O
nuclear	B-protein
factors	E-protein
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	S-cell_type
and	O
T	B-cell_type
cells	E-cell_type
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	S-cell_type
and	O
as	O
a	O
positive	O
one	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

LR1	S-protein
is	O
a	O
B	O
cell-specific	O
,	O
sequence-specific	O
DNA	O
binding	O
activity	O
that	O
regulates	O
transcription	O
in	O
activated	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

Differential	O
interaction	O
of	O
nuclear	B-protein
factors	E-protein
with	O
the	O
leukocyte-specific	B-DNA
pp52	I-DNA
promoter	E-DNA
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

This	O
dominant-negative	B-protein
acting	I-protein
Stat-3	I-protein
isoform	E-protein
significantly	O
inhibited	O
apoptosis	O
induced	O
by	O
ligation	O
of	O
MHC-I	S-protein
.	O

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
were	O
observed	O
to	O
contain	O
several	O
IL-2	S-protein
-inducible	O
DNA	O
binding	O
activities	O
.	O

Interestingly	O
,	O
tg	B-cell_type
epsilon26	I-cell_type
thymocytes	E-cell_type
expressed	O
GATA-3	S-protein
and	O
TCF-1	S-protein
,	O
but	O
not	O
LEF-1	S-protein
and	O
PEBP-2alpha	S-protein
,	O
among	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factors	E-protein
that	O
are	O
involved	O
in	O
early	O
T	O
cell	O
development	O
,	O
indicating	O
that	O
GATA-3	S-protein
and	O
TCF-1	S-protein
expressed	O
during	O
thymocyte	O
development	O
do	O
not	O
necessarily	O
determine	O
the	O
cell	O
fate	O
into	O
T	B-cell_type
cell	I-cell_type
lineage	E-cell_type
.	O

We	O
propose	O
that	O
HePTP	S-protein
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	B-protein
kinases	E-protein
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation-induced	O
expression	O
of	O
nuclear	B-protein
dual-specific	I-protein
MAP	I-protein
kinase	I-protein
phosphatases	E-protein
.	O

We	O
identified	O
18	O
nuclear	B-protein
proteins	E-protein
whose	O
phosphorylation	O
level	O
changed	O
more	O
than	O
5-fold	O
upon	O
activation	O
.	O

The	O
IE2	B-protein
gene	I-protein
product	E-protein
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	B-protein
regulatory	I-protein
proteins	E-protein
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	B-cell_type
cell	E-cell_type
.	O

IL-2	B-DNA
promoter	E-DNA
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	B-cell_line
B	I-cell_line
cells	E-cell_line
requires	O
CD28	S-protein
activation	O
.	O

The	O
PAF	S-protein
-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	E-RNA
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

A	O
pair	O
of	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	E-DNA
(	O
RFLPs	S-DNA
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-DNA
constant	I-DNA
region	I-DNA
C	I-DNA
beta	I-DNA
1	E-DNA
and	O
the	O
other	O
to	O
the	O
C	B-DNA
beta	I-DNA
2	I-DNA
gene	E-DNA
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B-DNA
beta	I-DNA
locus	E-DNA
.	O

HIV-1	B-DNA
LTR	E-DNA
activity	O
in	O
human	B-cell_line
CD40-activated	I-cell_line
B	I-cell_line
lymphocytes	E-cell_line
is	O
dependent	O
on	O
NF-kappaB	S-protein
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
by	O
preventing	O
activation	O
of	O
c-Rel/p65	B-protein
heterodimers	E-protein
.	O

Expression	O
studies	O
revealed	O
that	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	E-protein
is	O
ubiquitously	O
expressed	O
in	O
human	O
tissues	O
that	O
do	O
not	O
express	O
beta-globin	S-protein
,	O
being	O
present	O
in	O
48	O
of	O
50	O
tissues	O
and	O
six	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
examined	O
.	O

Mutagenesis	O
of	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
or	I-DNA
Sp-1	I-DNA
elements	E-DNA
within	O
the	O
LTR	S-DNA
resulted	O
in	O
no	O
change	O
in	O
the	O
ability	O
of	O
CD8+	B-cell_type
T	I-cell_type
cell	E-cell_type
supernatants	O
to	O
inhibit	O
Tat-	O
or	O
mitogen-mediated	O
LTR	O
transcription	O
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-protein
nuclear	I-protein
receptor	E-protein
sites	O
in	O
lymphocytes	S-cell_type
.	O

Fos	B-protein
kinase	E-protein
phosphorylates	O
c-Fos	S-protein
at	O
a	O
site	O
near	O
the	O
C-terminus	S-protein
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	B-protein
359-370	E-protein
,	O
RKGSSSNEPSSD	S-protein
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c-Fos	S-protein
phosphorylation	O
.	O

Human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	E-protein
transforms	O
normal	O
T-cells	S-cell_type
in	O
the	O
presence	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	E-protein
in	O
vitro	O
.	O

We	O
distinguish	O
the	O
stimuli-specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF-kappa	B-protein
B	E-protein
activation	O
in	O
only	O
one	O
of	O
two	O
human	B-cell_line
T-cell	I-cell_line
lines	E-cell_line
(	O
Wurzburg	S-cell_line
but	O
not	O
Jurkat	S-cell_line
)	O
,	O
whereas	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

Freshly	O
isolated	O
T	B-cell_type
cells	E-cell_type
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	S-protein
with	O
anti-CD3	S-protein
and	O
anti-CD28	B-protein
Abs	E-protein
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane-mediated	O
signaling	O
events	O
.	O

The	O
Tax	B-protein
mutants	I-protein
M22	E-protein
and	O
M47	S-protein
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	S-protein
to	O
activate	O
transcription	O
through	O
the	O
NF-kappaB	O
or	O
CREB/ATF	O
pathway	O
,	O
respectively	O
.	O

Differential	O
induction	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-inducible	I-protein
protein	I-protein
10	E-protein
following	O
differentiation	O
of	O
a	O
monocyte	S-cell_type
,	O
macrophage	B-cell_type
cell	E-cell_type
lineage	O
is	O
related	O
to	O
the	O
changes	O
of	O
nuclear	B-protein
proteins	E-protein
bound	O
to	O
IFN	B-DNA
stimulus	I-DNA
response	I-DNA
element	E-DNA
and	O
kappaB	B-DNA
sites	E-DNA
.	O

Wild-type	O
and	O
chimeric	B-protein
HLF	I-protein
proteins	E-protein
also	O
bound	O
closely	O
related	O
sites	O
identified	O
previously	O
for	O
bZIP	B-protein
proteins	E-protein
of	O
both	O
the	O
proline	S-protein
-and	O
acidic	O
amino	O
acid-rich	O
(	O
PAR	S-protein
)	O
and	O
C/EBP	B-protein
subfamilies	E-protein
;	O
however	O
,	O
E2A-HLF	S-protein
proteins	O
were	O
significantly	O
less	O
tolerant	O
of	O
certain	O
deviations	O
from	O
the	O
HLF	B-DNA
consensus	I-DNA
binding	I-DNA
site	E-DNA
.	O

Two	O
nuclear	B-protein
factor	I-protein
NF-IL6	E-protein
(	O
positions	O
-153	B-DNA
to	I-DNA
-145	E-DNA
and	O
-83	O
to	O
-75	O
)	O
and	O
one	O
nuclear	B-DNA
factor	I-DNA
NF-kappa	I-DNA
B	I-DNA
(	I-DNA
positions	I-DNA
-72	I-DNA
to	I-DNA
-63	I-DNA
)	I-DNA
motifs	E-DNA
are	O
present	O
within	O
this	O
fragment	O
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	S-protein
was	O
upregulated	O
,	O
whereas	O
CD34	S-protein
,	O
c-kit	S-protein
,	O
PU.1	S-protein
,	O
and	O
GATA-2	S-protein
were	O
barely	O
or	O
not	O
detected	O
.	O

No	O
correlation	O
was	O
found	O
between	O
estrogen	O
and	O
progesterone	O
status	O
,	O
tumor	O
size	O
and	O
polyamine	O
concentrations	O
.	O

PI	B-protein
3-kinase	E-protein
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50/RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
heterodimers	E-protein
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	S-cell_type
.	O

We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	B-protein
factor	I-protein
Sp1	E-protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
differential	O
expression	O
of	O
the	O
genes	O
in	O
the	O
zinc	B-protein
finger	I-protein
and	I-protein
POU	I-protein
families	E-protein
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
cascade	O
of	O
gene	O
expression	O
which	O
occurs	O
following	O
ATRA-induced	O
differentiation	O
.	O

Both	O
MAP	B-protein
ERK	I-protein
kinase	I-protein
kinase-1	E-protein
(	O
MEKK1	S-protein
)	O
and	O
Raf	S-protein
are	O
activated	O
strongly	O
by	O
FMLP	S-protein
,	O
but	O
minimally	O
by	O
PAF	S-protein
.	O

These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	B-cell_type
cells	E-cell_type
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	S-protein
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	S-cell_type
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL-2	S-protein
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	S-DNA
and	O
p53	B-RNA
transcripts	E-RNA
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	B-protein
2c	E-protein
.	O

In	O
transgenic	O
mice	O
,	O
elevated	O
JunB	S-protein
levels	O
caused	O
increased	O
expression	O
of	O
several	O
Th2	B-protein
cytokines	E-protein
in	O
developing	O
Th1	B-cell_type
cells	E-cell_type
.	O

Human	O
immunodeficiency	O
virus-type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O

These	O
data	O
implicate	O
TRAFs	S-protein
in	O
STP-C488	S-protein
-mediated	O
transformation	O
of	O
human	B-cell_type
lymphocytes	E-cell_type
and	O
rodent	O
fibroblasts	S-cell_type
.	O

Expression	O
of	O
LAZ3/BCL6	S-protein
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC-derived	O
non-Hodgkin	O
lymphomas	O
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	S-DNA
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
Sp1	E-protein
and	O
CP1	S-protein
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	B-DNA
sequences	E-DNA
.	O

Patterns	O
of	O
Pan	S-protein
expression	O
and	O
role	O
of	O
Pan	B-protein
proteins	E-protein
in	O
endocrine	O
cell	O
type-specific	O
complex	O
formation	O
.	O

Studies	O
into	O
the	O
effect	O
of	O
tyrosine	B-protein
phosphatase	E-protein
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	S-protein
activation	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
during	O
aging	O
:	O
evidence	O
for	O
altered	O
IkappaB-alpha	S-protein
phosphorylation	O
and	O
degradation	O
.	O

Germline	B-protein
transcripts	E-protein
initiate	O
from	O
promoters	S-DNA
upstream	O
of	O
the	O
immunoglobulin	B-DNA
switch	I-DNA
region	E-DNA
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
HIV-1-LTR	I-DNA
)	I-DNA
CAT	I-DNA
constructs	E-DNA
transfected	O
into	O
monocyte/macrophage-like	B-cell_line
cell	I-cell_line
lines	E-cell_line
but	O
not	O
a	O
T	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O

PGG-Glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1	O
,	O
6	O
)	O
-branched	O
beta-	O
(	O
1	O
,	O
3	O
)	O
-linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti-infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O

NM23	S-protein
was	O
identified	O
in	O
a	O
system	O
of	O
murine	B-cell_line
melanoma	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	S-protein
expression	O
and	O
metastatic	O
ability	O
.	O

Cotransfection	O
with	O
a	O
transdominant	B-protein
negative	I-protein
mutant	E-protein
of	O
the	O
NF-YA	B-protein
subunit	E-protein
abolishes	O
the	O
transcriptional	O
activation	O
by	O
heme	S-protein
,	O
indicating	O
that	O
NF-Y	S-protein
plays	O
an	O
essential	O
role	O
in	O
this	O
activation	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell-type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV-1	O
proviral	O
latency	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U1	E-cell_line
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV-1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor-kappa	B-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
moieties	E-protein
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross-linking	O
studies	O
.	O

In	O
the	O
locus	B-DNA
control	I-DNA
region	E-DNA
(	O
LCR	S-DNA
)	O
of	O
the	O
beta-globin	B-DNA
locus	E-DNA
,	O
in	O
vivo	O
footprints	O
on	O
NF-E2	S-protein
(	O
or	O
AP-1	S-protein
)	O
and	O
GATA-1	B-DNA
motifs	E-DNA
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	B-DNA
globin	I-DNA
genes	E-DNA
are	O
expressed	O
.	O

When	O
cotransfected	O
with	O
the	O
HIV	B-DNA
LTR	I-DNA
CAT	E-DNA
into	O
CV-1	B-cell_line
cells	E-cell_line
,	O
both	O
the	O
pCD41	S-DNA
and	O
pGD41	S-DNA
clones	O
trans-activated	O
the	O
HIV	B-DNA
LTR	E-DNA
.	O

Additionally	O
,	O
IL-13	S-protein
suppresses	O
IL-2-induced	O
NK	O
cytolytic	O
and	O
proliferative	O
activities	O
although	O
less	O
efficiently	O
than	O
IL-4	S-protein
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
examine	O
HB9	B-RNA
RNA	I-RNA
transcripts	E-RNA
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	E-protein
controls	O
T-cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
replication	O
in	O
chronically	B-cell_type
infected	I-cell_type
cells	E-cell_type
.	O

Moreover	O
,	O
IL-6	S-protein
induced	O
macrophage-differentiation	O
and	O
apoptosis	O
of	O
1A9-M	B-cell_line
cells	E-cell_line
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B-protein
interferon	E-protein
is	O
impaired	O
in	O
mononuclear	B-cell_type
phagocytes	E-cell_type
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

We	O
have	O
packaged	O
Flexi-12	S-protein
into	O
a	O
recombinant	O
adeno-associated	O
virus	O
(	O
AAV	O
)	O
and	O
used	O
this	O
vector	O
to	O
infect	O
acute	B-cell_type
myeloid	I-cell_type
leukemic	I-cell_type
(	I-cell_type
AML	I-cell_type
)	I-cell_type
blasts	E-cell_type
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal/neonatal	O
T-cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
elements	E-protein
required	O
for	O
T-cell	O
activation	O
.	O

Precursors	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
intracellular	I-protein
receptor	E-protein
,	O
suggesting	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	S-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go-6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti-Tat	B-protein
single-chain	I-protein
intracellular	I-protein
antibody	E-protein
(	O
sFv	B-protein
intrabody	E-protein
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR	S-DNA
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	E-DNA
.	O

In	O
addition	O
,	O
alpha	B-protein
G2S	E-protein
exhibited	O
increased	O
expression	O
of	O
CD11b	S-protein
and	O
CD54	S-protein
,	O
while	O
alpha	B-cell_line
B5A	I-cell_line
cells	E-cell_line
showed	O
increased	O
expression	O
of	O
CD102	S-protein
,	O
suggesting	O
that	O
RXR-alpha	S-protein
has	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	E-protein
in	O
U937	B-cell_line
cells	E-cell_line
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	S-protein
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	S-cell_type
.	O

NF-kappa	B-protein
B	E-protein
-dependent	O
induction	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
p50	I-DNA
subunit	I-DNA
gene	I-DNA
promoter	E-DNA
underlies	O
self-perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	B-cell_type
cells	E-cell_type
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	S-protein
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

BOB.1/OBF.1	S-protein
is	O
a	O
transcriptional	B-protein
coactivator	E-protein
that	O
is	O
constitutively	O
expressed	O
in	O
B	B-cell_type
cells	E-cell_type
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	B-protein
factors	E-protein
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF-kappaB	B-protein
complexes	E-protein
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	S-cell_type
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	S-cell_type
.	O

The	O
monoclonal	B-protein
antibodies	E-protein
were	O
able	O
to	O
discriminate	O
between	O
the	O
cells	O
of	O
Categories	B-cell_line
Va	I-cell_line
,	I-cell_line
VI	I-cell_line
and	I-cell_line
DFR	I-cell_line
but	I-cell_line
not	I-cell_line
Category	I-cell_line
III	I-cell_line
cells	E-cell_line
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B-protein
cytokines	E-protein
produced	O
by	O
antigen	B-cell_type
presenting	I-cell_type
cells	E-cell_type
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high-affinity	B-DNA
binding	I-DNA
site	E-DNA
for	O
BSAP	S-protein
in	O
known	O
regulatory	B-DNA
regions	E-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
class	I-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
genes	E-DNA
,	O
suggesting	O
that	O
BSAP	S-protein
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B-lymphoid-specific	B-DNA
genes	E-DNA
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	S-protein
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

An	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	E-DNA
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-DNA
Fc	I-DNA
receptor	I-DNA
type	I-DNA
IC	I-DNA
gene	E-DNA
by	O
interferon-gamma	S-protein
.	O

TNFalpha	S-protein
treatment	O
induces	O
a	O
rapid	O
translocation	O
of	O
the	O
65	B-protein
kD	I-protein
transcriptional	I-protein
activator	I-protein
NF-kappaB	I-protein
subunit	E-protein
,	O
Rel	B-protein
A	E-protein
,	O
whose	O
binding	O
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O

NF-kappaB	S-protein
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	O
of	O
its	O
associated	O
inhibitory	O
peptide	O
,	O
inhibitory	B-protein
kappaB-alpha	E-protein
(	O
IkappaB-alpha	S-protein
)	O
.	O

Specific	O
docking	B-protein
sites	E-protein
within	O
individual	O
cytokine	B-protein
receptors	E-protein
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	B-protein
proteins	E-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF-MATp35	S-protein
shows	O
excellent	O
correlation	O
with	O
IL-2	S-protein
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL-2	S-protein
gene	O
expression	O
.	O

LPS-specific	B-protein
Abs	E-protein
thus	O
mediate	O
anti-inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	S-protein
and	O
augmenting	O
uptake	O
through	O
CR1	S-protein
or	O
other	O
cell	B-protein
receptors	E-protein
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O

Nuclear	B-protein
factor-IL6	E-protein
activates	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	E-protein
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	S-DNA
contains	O
a	O
28-bp	B-DNA
core	I-DNA
region	E-DNA
and	O
local	O
adjacent	O
augmentative	O
cis	B-DNA
elements	E-DNA
.	O

Substantial	O
decreases	O
of	O
IL-2	S-protein
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL-2	S-protein
produced	O
by	O
stimulated	O
T	B-cell_type
cells	E-cell_type
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	S-protein
induction	O
in	O
monocytic	B-cell_type
cells	E-cell_type
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	B-DNA
promoter	I-DNA
sequences	E-DNA
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre-monocytic	O
cells	O
,	O
which	O
express	O
Elk-1	O
only	O
when	O
differentiating	O
to	O
monocytes	S-cell_type
.	O

The	O
results	O
showed	O
that	O
the	O
number	O
of	O
GCR	S-protein
in	O
the	O
patients	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
and	O
it	O
was	O
increased	O
when	O
their	O
health	O
state	O
was	O
improved	O
.	O

V3-BH10	S-protein
,	O
which	O
consists	O
of	O
42	B-protein
amino	I-protein
acids	E-protein
and	O
has	O
a	O
loop	B-protein
structure	E-protein
,	O
suppressed	O
IL-2	S-protein
-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	B-cell_line
cells	E-cell_line
[	O
Kit225	S-cell_line
,	O
ED-40515	B-cell_line
(	I-cell_line
+	I-cell_line
)	E-cell_line
,	O
KT-3	S-cell_line
,	O
7-day	B-cell_line
PHA-blasts	E-cell_line
,	O
and	O
fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2-independent	B-cell_line
cell	I-cell_line
lines	E-cell_line
(	O
Hut102	S-cell_line
,	O
Molt-4	S-cell_line
,	O
and	O
Jurkat	S-cell_line
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
expression	O
of	O
Rta	S-protein
is	O
also	O
sufficient	O
for	O
disruption	O
of	O
latency	O
in	O
a	O
permissive	B-cell_line
B-cell	I-cell_line
line	E-cell_line
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/	O
E2A	B-protein
proteins	E-protein
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B-protein
proteins	E-protein
in	O
GH/PRL-	B-cell_line
and	I-cell_line
insulin-producing	I-cell_line
,	I-cell_line
B-	I-cell_line
and	I-cell_line
T-lymphocyte	I-cell_line
cells	E-cell_line
.	O

This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	B-protein
chemokine	E-protein
,	O
interleukin-8	S-protein
(	O
IL-8	O
)	O
.	O

In	O
contrast	O
,	O
p65	B-protein
delta	E-protein
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	B-protein
kappa	I-protein
B	E-protein
protein	O
levels	O
.	O

The	O
resultant	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
DH42	S-cell_line
,	O
was	O
hygromycin	O
resistant	O
,	O
contained	O
VDR	B-DNA
cDNA	E-DNA
,	O
expressed	O
fewer	O
VDRs	S-protein
than	O
controls	O
,	O
and	O
showed	O
a	O
substantial	O
decrease	O
in	O
antiproliferative	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Each	O
volunteer	O
performed	O
these	O
exercise	O
twice	O
,	O
following	O
either	O
an	O
intravenous	O
injection	O
of	O
phosphocreatine	O
(	O
PCr	O
)	O
or	O
a	O
placebo	O
of	O
an	O
isotonic	O
NaCl	O
solution	O
.	O

Because	O
the	O
Nef	S-protein
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	S-protein
-TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	S-protein
protein	O
down-regulates	O
the	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	E-protein
and	O
AP-1	S-protein
in	O
T	B-cell_type
cells	E-cell_type
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR-dependent	O
signal	O
transduction	O
pathway	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	B-cell_type
carotid	I-cell_type
artery	I-cell_type
ECs	E-cell_type
express	O
PPARalpha	S-protein
.	O

We	O
found	O
that	O
although	O
IL-4	S-protein
stimulation	O
of	O
X-SCID	B-cell_type
B	I-cell_type
cells	E-cell_type
did	O
not	O
result	O
in	O
Janus	B-protein
tyrosine	I-protein
kinase-3	E-protein
(	O
JAK3	S-protein
)	O
phosphorylation	O
,	O
other	O
IL-4	B-protein
substrates	E-protein
including	O
JAK1	S-protein
and	O
IRS-1	S-protein
were	O
phosphorylated	O
.	O

Interleukin-7	S-protein
signaling	O
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
and	O
murine	B-cell_line
BAF3	I-cell_line
cells	E-cell_line
involves	O
activation	O
of	O
STAT1	S-protein
and	O
STAT5	S-protein
mediated	O
via	O
the	O
interleukin-7	B-protein
receptor	I-protein
alpha	I-protein
chain	E-protein
.	O

When	O
BALB/c	O
mice	O
were	O
inoculated	O
with	O
E1	S-DNA
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B-protein
Kd-restricted	I-protein
epitope	E-protein
was	O
recognized	O
,	O
and	O
Dd-restricted	O
CTLs	S-cell_type
did	O
not	O
develop	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
chemokine	S-protein
pathways	O
are	O
modulated	O
by	O
DEP-PAHs	O
at	O
the	O
transcriptional	O
level	O
,	O
reinforcing	O
the	O
idea	O
that	O
the	O
development	O
of	O
inflammatory	O
reactions	O
might	O
be	O
affected	O
by	O
diesel	O
exhaust	O
emission	O
.	O

Glucocorticoids	O
induce	O
apoptosis	O
in	O
human	B-cell_type
monocytes	E-cell_type
:	O
potential	O
role	O
of	O
IL-1	B-protein
beta	E-protein
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B-protein
B-binding-proteins	E-protein
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	B-cell_line
cell	I-cell_line
lines	E-cell_line
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNF	B-protein
alpha	E-protein
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
.	O

Soluble	O
interleukin-2	B-protein
receptor-alpha	E-protein
(	O
IL-2Ralpha	S-protein
)	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	O
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	S-protein
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	E-protein
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
human	B-cell_type
cells	E-cell_type
.	O

Suppression	O
of	O
c-jun	S-DNA
by	O
antisense	O
oligonucleotides	O
inhibits	O
cell	O
adhesion	O
but	O
not	O
respiratory	O
burst	O
during	O
phorbol	O
ester-induced	O
differentiation	O
of	O
U937	B-cell_line
human	I-cell_line
monoblastic	I-cell_line
cells	E-cell_line
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	E-protein
and	O
latent	B-protein
membrane	I-protein
protein	E-protein
independently	O
transactivate	O
p53	S-protein
through	O
induction	O
of	O
NF-kappaB	S-protein
activity	O
.	O

An	O
androgen	O
receptor	O
binding	O
assay	O
of	O
cultured	B-cell_line
genital	I-cell_line
skin	I-cell_line
fibroblasts	E-cell_line
was	O
negative	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF-kappa	B-protein
B	E-protein
,	O
AP-1	S-protein
,	O
NFAT	S-protein
,	O
and	O
STAT1	S-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
can	O
be	O
regulated	O
by	O
NLS	S-protein
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
to	O
target	O
members	O
of	O
the	O
importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-alpha	I-protein
beta	I-protein
NLS	I-protein
receptor	I-protein
complex	E-protein
.	O

Consecutive	O
IL-1beta-	B-RNA
,	I-RNA
IL-6-	I-RNA
and	I-RNA
TNF-alpha-mRNA	E-RNA
were	O
elevated	O
(	O
up	O
to	O
1.9	O
+/-	O
0.58-fold	O
)	O
.	O

Five	O
healthy	O
human	O
leukocyte	O
antigen-B8	O
(	O
HLA-B8	O
)	O
-positive	O
virus	O
carriers	O
were	O
studied	O
to	O
investigate	O
the	O
CD8+	B-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	E-cell_type
(	O
CTL	O
)	O
response	O
to	O
an	O
HLA-B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
immediate-early	I-protein
trans-activator	I-protein
protein	E-protein
,	O
BZLF1	S-protein
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
for	O
the	O
requirement	O
of	O
GATA-1	S-protein
and	O
NF-E2	S-protein
in	O
BA-induced	O
differentiation	O
process	O
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	E-protein
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel-related	B-protein
proteins	E-protein
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O

Further	O
,	O
the	O
method	O
described	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
progression	O
.	O

CBP/p300	S-protein
integrates	O
Raf	S-protein
/	O
Rac	S-protein
-signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF-ATc	S-protein
during	O
T	O
cell	O
activation	O
.	O

A	O
TATA-like	B-DNA
motif	E-DNA
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	E-DNA
.	O

The	O
ability	O
of	O
interferon	B-protein
alpha	E-protein
to	O
up-regulate	O
MNDA	B-RNA
mRNA	E-RNA
in	O
phorbol	O
ester	O
treated	O
myeloid	B-cell_line
cell	I-cell_line
lines	E-cell_line
is	O
consistent	O
with	O
the	O
observations	O
made	O
in	O
primary	B-cell_type
monocytes	E-cell_type
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl-2	S-protein
in	O
U937	B-cell_line
cells	E-cell_line
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
binding	O
of	O
interleukin-2	S-protein
(	O
IL-2	S-protein
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	B-cell_type
cells	E-cell_type
induces	O
nuclear	O
expression	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	E-protein
(	O
NF-kappaB	S-protein
)	O
,	O
activation	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
(	I-DNA
IL-2R	I-DNA
)	I-DNA
alpha	I-DNA
chain	I-DNA
gene	E-DNA
,	O
and	O
cell	O
proliferation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	S-protein
and	O
c-Rel	B-protein
NF.kappa	I-protein
B	E-protein
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	B-DNA
B	I-DNA
sequence	E-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	E-DNA
either	O
as	O
p50.p65	S-protein
or	O
as	O
p50.c-Rel	S-protein
heterodimers	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-protein
mitogen	E-protein
(	O
PWM	S-protein
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

Deltorphin	O
also	O
increased	O
accumulation	O
of	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
complexes	E-protein
,	O
suggesting	O
that	O
DOR1	S-protein
augments	O
IL-2	S-protein
secretion	O
by	O
increasing	O
the	O
AP-1	B-protein
component	E-protein
of	O
the	O
NF-AT/AP-1	B-protein
transcription	I-protein
factor	E-protein
.	O

We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O

The	O
CK-1	B-DNA
/CD28RE	E-DNA
of	O
GM-CSF	S-protein
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	B-DNA
CD28RE	E-DNA
and	O
the	O
IL-3	B-DNA
gene	E-DNA
also	O
contains	O
a	O
related	O
region	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	B-cell_line
cells	E-cell_line
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	S-protein
and	O
IRBP	S-protein
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation-dependent	O
transcription	O
of	O
this	O
human	B-DNA
carboxylesterase	I-DNA
gene	E-DNA
.	O

A	O
murine	B-protein
monoclonal	I-protein
antibody	E-protein
raised	O
to	O
an	O
unidentified	B-protein
estrogen	I-protein
receptor-related	I-protein
29-kDa	I-protein
protein	E-protein
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	B-protein
27-kDa	I-protein
protein	E-protein
.	O

Receptor	B-protein
activator	I-protein
of	I-protein
NF-kappaB	E-protein
(	O
RANK	S-protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	E-protein
and	O
is	O
expressed	O
on	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
dendritic	B-cell_type
cells	E-cell_type
.	O

Addition	O
of	O
rIL-2	S-protein
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL-4	S-protein
and	O
IL-5	S-protein
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	S-protein
.	O

The	O
human	B-DNA
IL-16	I-DNA
gene	E-DNA
consists	O
of	O
seven	O
exons	S-DNA
and	O
six	O
introns	S-DNA
.	O

R24	S-protein
-stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin/calcineurin	S-protein
and	O
protein	B-protein
kinase	I-protein
C	E-protein
may	O
be	O
involved	O
in	O
the	O
R24	S-protein
signaling	O
pathway	O
.	O

The	O
sequence	O
of	O
the	O
smallest	O
subunit	O
describes	O
a	O
novel	O
gene	O
,	O
termed	O
RFX-B	S-DNA
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	S-protein
suppression	O
of	O
NF-kappa	B-protein
B	E-protein
activity	O
via	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	E-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

Transcriptional	O
control	O
of	O
the	O
IL-5	S-protein
gene	O
by	O
human	B-cell_type
helper	I-cell_type
T	I-cell_type
cells	E-cell_type
:	O
IL-5	S-protein
synthesis	O
is	O
regulated	O
independently	O
from	O
IL-2	S-protein
or	O
IL-4	S-protein
synthesis	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	B-DNA
pAT	I-DNA
133	E-DNA
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
U-937	E-cell_line
and	O
HL-60	S-cell_line
by	O
12-O-tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

These	O
results	O
suggest	O
that	O
an	O
age-associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	E-protein
in	O
activated	O
T	B-cell_type
cells	E-cell_type
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	E-protein
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O

An	O
isotype-specific	O
activator	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
that	O
is	O
independent	O
of	O
class	B-protein
II	I-protein
transactivator	E-protein
.	O

Recombinant	B-protein
human	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
binding	I-protein
protein-1	E-protein
(	O
r-h	B-protein
TBP-1	E-protein
)	O
and	O
recombinant	B-protein
human	I-protein
soluble	I-protein
dimeric	I-protein
TNF	I-protein
receptor	E-protein
(	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	E-protein
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	S-protein
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine-induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Bone	O
marrow	O
samples	O
from	O
33	O
patients	O
affected	O
by	O
MM	O
and	O
MGUS	O
,	O
and	O
8	O
patients	O
not	O
affected	O
by	O
lymphoproliferative	O
diseases	O
were	O
studied	O
for	O
expression	O
of	O
c-Jun	S-protein
(	O
a	O
component	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	E-protein
)	O
and	O
glutathione-S-transferase	B-protein
pi	E-protein
(	O
GST-pi	S-protein
)	O
using	O
immunocytochemical	O
methods	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	S-protein
and	O
NF-kappa	B-protein
B	E-protein
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	S-protein
secretion	O
.	O

Activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
by	O
the	O
LEF-1	B-protein
HMG	I-protein
protein	E-protein
on	O
nucleosome-assembled	B-DNA
DNA	E-DNA
in	O
vitro	O
.	O

These	O
results	O
demonstrate	O
that	O
c-Rel	S-protein
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
in	O
neighboring	O
cells	O
by	O
inducing	O
jagged1	O
gene	O
expression	O
,	O
and	O
suggest	O
a	O
role	O
for	O
Jagged1	S-protein
in	O
B-cell	O
activation	O
,	O
differentiation	O
or	O
function	O
.	O

Extracts	O
prepared	O
from	O
XP-B	B-cell_line
and	I-cell_line
XP-D	I-cell_line
lymphoblastoid	I-cell_line
cells	E-cell_line
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	B-DNA
major	I-DNA
late	I-DNA
promoter	E-DNA
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
members	E-protein
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL-4	S-protein
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL-4	B-DNA
promoter	E-DNA
.	O

Molecular	O
and	O
biochemical	O
approaches	O
demonstrated	O
that	O
LMP1	S-protein
usurps	O
cellular	O
signaling	O
pathways	O
resulting	O
in	O
the	O
induction	O
of	O
NF-kappaB	S-protein
and	O
AP-1	S-protein
via	O
two	O
C-terminal	B-protein
activating	I-protein
regions	E-protein
.	O

Flow	O
cytometric	O
cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
established	O
that	O
MNDA	S-protein
is	O
initially	O
expressed	O
in	O
myeloid	B-cell_type
blast	I-cell_type
cells	E-cell_type
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	B-protein
(	I-protein
s6k	I-protein
)	E-protein
is	O
able	O
to	O
regulate	O
E2F	S-protein
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL-2	S-protein
receptors	O
,	O
PI	B-protein
3-kinase	E-protein
,	O
and	O
p70	B-protein
(	I-protein
s6k	I-protein
)	E-protein
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non-cytokine	B-DNA
gene	E-DNA
,	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
(	I-DNA
TCRG	I-DNA
)	I-DNA
enhancer	E-DNA
.	O

HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	B-protein
activator	E-protein
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	B-protein
overexpressed	I-protein
HSF3	E-protein
measured	O
by	O
using	O
a	O
heat	B-DNA
shock	I-DNA
element-containing	I-DNA
reporter	I-DNA
construct	E-DNA
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	B-protein
GAL4-HSF3	I-protein
protein	E-protein
on	O
a	O
GAL4	B-DNA
reporter	I-DNA
construct	E-DNA
.	O

An	O
activation-responsive	O
element	O
in	O
single	O
C	B-DNA
motif-1/lymphotactin	I-DNA
promoter	E-DNA
is	O
a	O
site	O
of	O
constitutive	O
and	O
inducible	O
DNA-protein	O
interactions	O
involving	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	E-protein
.	O

FGF-1	S-protein
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB-binding	B-protein
proteins	E-protein
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti-CD3	S-protein
and	O
FGF-1	S-protein
.	O

RALDH2	B-protein
Glucocorticoid	I-protein
receptors	E-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
in	O
relation	O
to	O
age	O
and	O
to	O
sport	O
activity	O
.	O

To	O
isolate	O
cDNA	O
clones	O
that	O
dominantly	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
Oct-2	S-protein
,	O
chosen	O
as	O
a	O
representative	O
factor	O
,	O
we	O
have	O
developed	O
a	O
novel	O
screening	O
system	O
.	O

No	O
RNA-packaging	O
defect	O
could	O
be	O
measured	O
for	O
any	O
of	O
the	O
mutant	O
viruses	O
as	O
determined	O
by	O
quantification	O
of	O
their	O
HIV	B-RNA
genomic	I-RNA
RNA	E-RNA
.	O

The	O
binding	O
of	O
oxidized	O
low-density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte	B-cell_type
-macrophages	E-cell_type
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein-protein	O
and	O
protein-DNA	O
interactions	O
that	O
regulate	O
cell-type-specific	O
and	O
inducible	O
IL-2R	B-protein
alpha	E-protein
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf-1	S-protein
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	E-protein
.	O

ER	S-protein
was	O
positive	O
in	O
13	O
and	O
PR	S-protein
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O

The	O
expression	O
of	O
I	B-protein
kappa	I-protein
B-alpha	E-protein
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	O
by	O
NF-kappa	B-protein
B	E-protein
,	O
was	O
up-regulated	O
in	O
PBMC	S-cell_type
and	O
monocytes	S-cell_type
from	O
patients	O
,	O
but	O
not	O
in	O
mononuclear	B-cell_type
cells	E-cell_type
from	O
healthy	O
subjects	O
or	O
those	O
with	O
nontuberculous	O
lung	O
diseases	O
.	O

Thus	O
,	O
the	O
availability	O
of	O
these	O
variant	O
cells	O
should	O
provide	O
a	O
system	O
for	O
studying	O
the	O
link	O
between	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	S-DNA
,	O
activated	O
the	O
HIV	B-DNA
promoter	I-DNA
construct	E-DNA
containing	O
a	O
mutation	O
in	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	E-DNA
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	B-RNA
species	E-RNA
of	O
2.7	B-RNA
and	I-RNA
4.5	I-RNA
kilobase	I-RNA
pairs	E-RNA
,	O
while	O
an	O
NFATc.beta-specific	B-DNA
probe	E-DNA
detected	O
only	O
the	O
4.5-kilobase	B-RNA
pair	I-RNA
mRNA	E-RNA
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA-binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O

The	O
SM	B-protein
protein	E-protein
derived	O
from	O
the	O
spliced	O
RNA	O
joining	O
BSLF2	S-protein
to	O
BMLF1	S-protein
is	O
much	O
the	O
most	O
abundant	O
protein	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	B-protein
receptor	E-protein
(	O
CD23	S-protein
)	O
in	O
human	B-cell_type
monocytes	E-cell_type
lead	O
to	O
nuclear	B-protein
factor-kappaB	E-protein
activation	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B-protein
hemoglobin	E-protein
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	O
detectable	O
quantities	O
of	O
eicosanoids	O
were	O
found	O
in	O
the	O
non-tumor	O
material	O
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	B-cell_line
cell	E-cell_line
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	S-protein
activity	O
in	O
the	O
lymphocytes	S-cell_type
.	O

Immunological	O
studies	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
patients	O
suggest	O
that	O
the	O
disease	O
progression	O
is	O
accompanied	O
by	O
a	O
defective	O
production	O
of	O
type	O
1	B-protein
cytokines	E-protein
(	O
interleukin-2	S-protein
(	O
IL-2	S-protein
)	O
and	O
IL-12	S-protein
]	O
,	O
an	O
increased	O
production	O
of	O
type	B-protein
2	I-protein
cytokines	E-protein
(	O
IL-4	S-protein
,	O
IL-6	S-protein
,	O
and	O
IL-10	S-protein
)	O
,	O
and	O
an	O
increased	O
production	O
of	O
IgE	S-protein
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel-related	B-DNA
complementary	I-DNA
DNA	E-DNA
that	O
hybridized	O
to	O
a	O
2.6-kilobase	B-RNA
messenger	I-RNA
RNA	E-RNA
present	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

The	O
generation	O
of	O
cell-mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	S-protein
(	O
IL-12	S-protein
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

Conversely	O
,	O
c-jun	S-protein
and	O
jun-B	S-protein
transfection	O
blunted	O
GR	S-protein
-dependent	O
transcription	O
in	O
HeLa	B-cell_line
cells	E-cell_line
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	S-protein
binding	O
.	O

We	O
also	O
show	O
that	O
platelet-activating	B-protein
factor	E-protein
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-	O
platelet-activating	B-protein
factor	E-protein
was	O
again	O
ineffective	O
.	O

Human	O
T	O
cell	O
leukemia	O
virus-I	O
(	O
HTLV-I	O
)	O
Tax	S-protein
-mediated	O
apoptosis	O
in	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
requires	O
an	O
enhanced	O
intracellular	O
prooxidant	O
state	O
.	O

The	O
protease	O
inhibitors	O
N	O
alpha-tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
proteins	E-protein
by	O
preventing	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
.	O

Formation	O
of	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	E-protein
on	O
the	O
IL-2	B-DNA
promoter	E-DNA
is	O
essential	O
for	O
IL-2	S-protein
transcription	O
.	O

This	O
shows	O
that	O
gelatinase	S-protein
granules	O
are	O
functionally	O
important	O
relative	O
to	O
specific	O
granules	O
in	O
mediating	O
early	O
inflammatory	O
responses	O
.	O

HIV-1-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNF	B-protein
alpha	E-protein
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O

TNF-alpha	S-protein
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF-kappa	B-protein
B	E-protein
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	S-protein
and	O
c-rel	S-protein
,	O
and	O
new	O
mRNA	S-RNA
synthesis	O
for	O
c-rel	S-protein
and	O
p105/p50	S-protein
.	O

SCL	B-protein
protein	E-protein
levels	O
in	O
BFU-E-derived	B-cell_line
cells	E-cell_line
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	S-protein
with	O
erythroid	O
proliferation	O
.	O

Intracellular	O
adhesion	O
molecule-1	O
induction	O
by	O
PMA	O
was	O
unaffected	O
by	O
any	O
of	O
the	O
molecules	O
tested	O
.	O

The	O
c-Jun	B-protein
amino-terminal	I-protein
kinase	E-protein
(	O
JNK	S-protein
)	O
phosphorylates	O
NFAT4	S-protein
on	O
two	O
sites	O
.	O

The	O
MTCP1	B-DNA
gene	E-DNA
is	O
involved	O
in	O
the	O
t	B-DNA
(	I-DNA
X	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q28	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
translocation	E-DNA
associated	O
with	O
these	O
T-cell	O
proliferations	O
.	O

DCs	S-cell_type
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	B-protein
B	E-protein
and	O
Rel	B-protein
proteins	E-protein
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	S-protein
,	O
p50	S-protein
,	O
and	O
p65	S-protein
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C/EBP	B-protein
protein	I-protein
LIP	E-protein
inhibited	O
HIV-1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	B-cell_line
U1	I-cell_line
cells	E-cell_line
,	O
demonstrating	O
that	O
C/EBP	B-protein
proteins	E-protein
are	O
required	O
for	O
provirus	O
induction	O
.	O

Differanisole	O
A	O
in	O
combination	O
with	O
9cisRA	O
may	O
have	O
implications	O
for	O
therapy	O
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

Interferon-gamma	S-protein
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon-stimulated	B-DNA
genes	E-DNA
induced	O
by	O
interferon-alpha	B-cell_line
in	I-cell_line
U937	I-cell_line
cells	E-cell_line
.	O

Because	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	S-cell_type
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage-lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T-cell	B-protein
interleukin-2	E-protein
expression	O
at	O
the	O
level	O
of	O
purine-box/nuclear	B-protein
factor	E-protein
of	O
activated	B-cell_type
T-cells	E-cell_type
and	O
NF-kappaB	S-protein
transcriptional	O
activation	O
.	O

Anti-	O
ZEBRA	S-protein
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O

We	O
here	O
present	O
data	O
suggesting	O
that	O
EBF	S-protein
interacts	O
with	O
three	O
independent	O
sites	O
within	O
the	O
mouse	B-DNA
B29	I-DNA
promoter	E-DNA
.	O

In	O
vivo	O
modulation	O
of	O
glucocorticoid	B-RNA
receptor	I-RNA
mRNA	E-RNA
by	O
inhaled	O
fluticasone	O
propionate	O
in	O
bronchial	O
mucosa	O
and	O
blood	B-cell_type
lymphocytes	E-cell_type
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B-protein
inhibitor	E-protein
.	O

However	O
,	O
subsequent	O
analysis	O
of	O
transcription	B-protein
factor	E-protein
generation	O
revealed	O
that	O
B7	O
stimulation	O
induced	O
both	O
activator	B-protein
protein-1	E-protein
(	O
AP-1	S-protein
)	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
complexes	E-protein
,	O
but	O
not	O
NF-AT	S-protein
.	O

These	O
results	O
corroborate	O
previous	O
findings	O
that	O
the	O
presence	O
of	O
ER	S-protein
variants	O
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

PI	B-protein
3-kinase	E-protein
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T-cell	O
differentiation	O
and	O
lymphocyte	S-cell_type
proliferation	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	E-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	S-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	E-protein
with	O
Fos	S-protein
and	O
Jun	S-protein
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	S-DNA
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
PMA	O
induction	O
of	O
c-fos	B-RNA
mRNA	E-RNA
correlated	O
well	O
with	O
TNF	S-protein
gene	O
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	B-protein
complex	E-protein
(	O
junB	S-protein
and	O
junD	S-protein
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B-cell_line
prostatic	I-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	E-cell_line
as	O
induced	O
by	O
T	O
lymphocyte-conditioned	O
medium	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
depended	O
on	O
the	O
SP-1	B-DNA
site	E-DNA
.	O

The	O
proband	O
had	O
no	O
detectable	O
DPD	S-protein
activity	O
.	O

The	O
myeloid-cell-specific	B-DNA
c-fes	I-DNA
promoter	E-DNA
is	O
regulated	O
by	O
Sp1	S-protein
,	O
PU.1	S-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	E-protein
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
is	O
a	O
pleiotropic	B-protein
transcription	I-protein
factor	E-protein
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

In	O
contrast	O
,	O
a	O
cysteine	O
protease	O
inhibitor	O
that	O
also	O
blocks	O
apoptosis	O
had	O
no	O
substantial	O
affect	O
upon	O
cytokine	S-protein
production	O
.	O

Plasma	B-protein
renin	E-protein
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O

This	O
may	O
explain	O
the	O
difference	O
between	O
IL-10	S-protein
and	O
IFN-gamma	S-protein
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL-10	S-protein
on	O
IFN-gamma	S-protein
activities	O
.	O

Mutation	O
analysis	O
demonstrated	O
that	O
binding	O
of	O
the	O
inducible	O
factor	O
to	O
the	O
-120	B-DNA
region	E-DNA
is	O
crucial	O
for	O
the	O
biological	O
function	O
of	O
the	O
CD95L	B-DNA
promoter	E-DNA
upon	O
T	O
cell	O
stimulation	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	B-protein
channels	E-protein
,	O
reducing	O
both	O
Kv1.3	S-protein
and	O
charybdotoxin-resistant	B-protein
components	E-protein
of	O
KV	S-protein
current	O
and	O
KCa	S-protein
current	O
in	O
T	B-cell_type
cells	E-cell_type
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B-protein
KV	I-protein
channels	E-protein
expressed	O
in	O
cell	B-cell_line
lines	E-cell_line
.	O

When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T-cell	O
function	O
during	O
stress	O
.	O

When	O
the	O
HTLV-1	B-DNA
tax	I-DNA
gene	E-DNA
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate-A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	S-protein
expression	O
was	O
induced	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
which	O
otherwise	O
do	O
not	O
express	O
ICSAT	S-protein
.	O

We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon-gamma	S-protein
activation	O
of	O
human	B-cell_type
monocytes	E-cell_type
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF-AT	S-protein
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	B-cell_type
lymphocytes	E-cell_type
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	E-protein
(	O
CAT	S-protein
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	B-DNA
regulatory	I-DNA
region	E-DNA
or	O
of	O
multimers	O
of	O
individual	O
enhancer	B-DNA
sequences	E-DNA
.	O

Solution	O
structure	O
of	O
a	O
POU-specific	B-protein
homeodomain	E-protein
:	O
3D-NMR	O
studies	O
of	O
human	O
B-cell	B-protein
transcription	I-protein
factor	I-protein
Oct-2	E-protein
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
(	O
50	O
microM	O
)	O
inhibited	O
proliferation	O
of	O
rat	B-cell_type
thymocytes	E-cell_type
stimulated	O
with	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
as	O
well	O
as	O
that	O
of	O
human	B-cell_type
Jurkat	I-cell_type
lymphoblastoid	I-cell_type
cells	E-cell_type
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O

To	O
understand	O
the	O
action	O
of	O
FGF-1	S-protein
in	O
T	B-cell_type
cells	E-cell_type
,	O
studies	O
were	O
initiated	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
that	O
express	O
the	O
signaling	O
isoform	O
of	O
FGF	B-protein
receptor-1	E-protein
.	O

The	O
involvement	O
of	O
p21	B-protein
(	I-protein
ras	I-protein
)	E-protein
in	O
the	O
regulation	O
of	O
calcium-dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF-AT	S-protein
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B-DNA
region	E-DNA
encompassing	O
an	O
important	O
positive	B-DNA
regulatory	I-DNA
element	E-DNA
,	O
NF-AT-1	S-DNA
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	E-protein
,	O
NFATp	S-protein
,	O
as	O
well	O
as	O
by	O
AP-1	S-protein
.	O

Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over-lapping	O
sets	O
of	O
genes	O
of	O
T	B-cell_type
cells	E-cell_type
.	O

A	O
dominant-negative	O
mutant	O
of	O
NF-kappaB	B-protein
p50	E-protein
that	O
binds	O
DNA	O
but	O
fails	O
to	O
interact	O
with	O
Ets	B-protein
proteins	E-protein
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV-1	B-DNA
and	I-DNA
HIV-2	I-DNA
enhancers	E-DNA
by	O
NF-kappaB	S-protein
(	O
p50	S-protein
+	O
p65	S-protein
)	O
and	O
Ets-1	S-protein
,	O
suggesting	O
that	O
physical	O
interaction	O
between	O
Ets	S-protein
and	O
NF-kappaB	B-protein
proteins	E-protein
is	O
required	O
for	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	B-DNA
and	I-DNA
HIV-2	I-DNA
enhancers	E-DNA
.	O

Although	O
NF-kappa	B-protein
B	E-protein
activates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
in	O
the	O
induction	O
of	O
IgE	O
synthesis	O
in	O
human	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

The	O
promoter	O
activity	O
of	O
cell	B-DNA
cycle	I-DNA
regulated	I-DNA
histone	I-DNA
H4	I-DNA
genes	E-DNA
is	O
regulated	O
by	O
at	O
least	O
four	O
principal	B-DNA
cis-acting	I-DNA
elements	E-DNA
which	O
mediate	O
G1/S	O
phase	O
control	O
and/or	O
enhancement	O
of	O
transcription	O
during	O
the	O
cell	O
cycle	O
.	O

Like	O
other	O
enhancers	S-DNA
,	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
contains	O
several	O
short	O
sequence	B-DNA
motifs	E-DNA
that	O
bind	O
specific	B-protein
transcription	I-protein
factors	E-protein
.	O

We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	E-protein
in	O
PBL	S-cell_type
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

Interestingly	O
,	O
GATA-2	S-protein
and	O
GATA-3	B-protein
proteins	E-protein
also	O
localized	O
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co-expressing	O
GATA-1	B-protein
and	I-protein
-2	I-protein
or	I-protein
GATA-1	I-protein
and	I-protein
-3	I-protein
gene	I-protein
products	E-protein
.	O

In	O
addition	O
,	O
hormone-mediated	O
survival	O
against	O
apoptosis	O
was	O
concentration	O
dependent	O
,	O
reaching	O
the	O
half-maximal	O
effect	O
at	O
10	O
nM	O
and	O
blocked	O
by	O
the	O
ER	O
antagonist	O
ICI	O
182	O
,	O
780	O
in	O
undifferentiated	B-cell_type
cells	E-cell_type
,	O
further	O
supporting	O
a	O
receptor-mediated	O
mechanism	O
of	O
cell	O
survival	O
.	O

In	O
mammalian	B-cell_type
cells	E-cell_type
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
proteins	E-protein
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF-kappa	B-protein
B	E-protein
through	O
their	O
association	O
with	O
the	O
p65	B-protein
or	I-protein
c-Rel	I-protein
subunits	E-protein
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
oncogene	I-protein
product	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	E-protein
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF-kappaB	O
.	O

Functional	O
studies	O
in	O
extrarenal	B-cell_type
,	I-cell_type
non-epithelial	I-cell_type
cells	E-cell_type
such	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	E-cell_type
and	O
more	O
recently	O
circulating	B-cell_type
human	I-cell_type
lymphocytes	E-cell_type
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
,	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	B-DNA
promoter	E-DNA
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	E-protein
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	B-RNA
mRNA	E-RNA
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF-kappa	B-protein
B	E-protein
binding	O
activities	O
displayed	O
by	O
different	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	S-protein
and	O
GR	S-protein
in	O
aged	O
long-distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O

Specific	O
glucocorticoid	O
binding	O
at	O
different	O
levels	O
of	O
human	O
motor	O
activity	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	B-protein
factor	I-protein
RBP-Jkappa	E-protein
in	O
extracts	O
prepared	O
from	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
T-ALL	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL-10	B-protein
receptor	E-protein
expressed	O
on	O
B-CLL	B-cell_line
cells	E-cell_line
results	O
in	O
the	O
phosphorylation	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	E-protein
(	O
STAT1	S-protein
)	O
and	O
STAT3	S-protein
proteins	O
.	O

When	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
progesterone	O
they	O
released	O
a	O
soluble	B-protein
factor	E-protein
that	O
inhibited	O
cellular	O
immunoreactions	O
(	O
MLR	O
,	O
CRC	O
)	O
and	O
cellular	O
proliferation	O
as	O
measured	O
by	O
thymidine	O
incorporation	O
by	O
spleen-cell	B-cell_line
culture	E-cell_line
.	O

The	O
NFAT	S-protein
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
than	O
the	O
CMAT	B-protein
protein	E-protein
did	O
.	O

Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	S-protein
,	O
including	O
interferons	S-protein
,	O
interleukins	S-protein
,	O
and	O
growth	B-protein
factors	E-protein
,	O
involves	O
activation	O
of	O
JAK	B-protein
kinases	E-protein
and	O
Stat	B-protein
(	I-protein
Signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	E-protein
.	O

Since	O
sequence	B-DNA
variations	E-DNA
in	O
the	O
3	B-DNA
'	I-DNA
UTR	E-DNA
of	O
VDR	S-protein
have	O
been	O
linked	O
to	O
the	O
different	O
haplotypes	O
,	O
investigators	O
have	O
proposed	O
that	O
the	O
stability	O
of	O
VDR	B-RNA
mRNA	E-RNA
is	O
influenced	O
by	O
allelic	O
variations	O
.	O

During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	B-cell_type
dividing	I-cell_type
immature	I-cell_type
single	I-cell_type
positive	I-cell_type
cells	E-cell_type
.	O

Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B-protein
C	E-protein
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c-fos	S-DNA
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c-fos	S-DNA
well	O
.	O

This	O
activity	O
may	O
be	O
relevant	O
to	O
the	O
mechanisms	O
whereby	O
HTLV-I	O
which	O
does	O
not	O
contain	O
oncogenes	S-DNA
induces	O
neoplasia	O
.	O

In	O
these	O
cells	O
,	O
nuclear	B-protein
factors	E-protein
involved	O
in	O
activation	O
of	O
the	O
HIV-1	B-DNA
LTR	E-DNA
,	O
which	O
contains	O
the	O
transcriptional	B-DNA
control	I-DNA
elements	E-DNA
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Structural	O
analysis	O
demonstrated	O
that	O
the	O
mouse	B-DNA
CPO	I-DNA
gene	E-DNA
spans	O
approximately	O
11	O
kb	O
and	O
consists	O
of	O
seven	B-DNA
exons	E-DNA
,	O
just	O
like	O
its	O
human	O
counterpart	O
.	O

Although	O
removal	O
of	O
the	O
first	B-protein
67	I-protein
amino	I-protein
acids	E-protein
of	O
p95vav	S-protein
activates	O
its	O
transforming	O
potential	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	E-cell_line
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Both	O
cytokines	S-protein
induced	O
assembly	O
of	O
STAT5A	S-protein
and	O
STAT5B	S-protein
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	E-DNA
(	O
GAS	S-DNA
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL-2-	B-cell_line
or	I-cell_line
IL-7-treated	I-cell_line
cells	E-cell_line
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	S-protein
and	O
IL-7	S-protein
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
1	E-protein
,	O
JAK3	S-protein
,	O
STAT5	S-protein
,	O
and	O
STAT6	S-protein
,	O
in	O
pre-B	B-cell_type
cells	E-cell_type
transformed	O
by	O
v-Abl	S-protein
.	O

The	O
disruption	O
of	O
HIV-TF1-binding	B-DNA
site	E-DNA
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	E-DNA
in	O
vivo	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

The	O
mechanism	O
by	O
which	O
early	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
are	O
selectively	O
transformed	O
by	O
v-Abl	S-protein
is	O
currently	O
unknown	O
.	O

Expression	O
of	O
the	O
stimulatory	O
G	B-protein
protein	E-protein
,	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	E-protein
,	O
can	O
vary	O
over	O
a	O
3-fold	O
range	O
in	O
human	O
tissues	O
and	O
in	O
rodent	O
central	O
nervous	O
system	O
.	O

Thus	O
,	O
IL-2	S-protein
may	O
be	O
another	O
important	O
cytokine	S-protein
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

The	O
inducible	B-protein
factors	I-protein
NK-kappa	I-protein
B	E-protein
,	O
beta	B-protein
E2	E-protein
,	O
CD28RC	S-protein
,	O
and	O
AP-1	S-protein
are	O
not	O
expressed	O
in	O
resting	B-cell_type
cells	E-cell_type
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

BACKGROUND	O
:	O
In	O
vivo	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	E-protein
(	O
GR	S-protein
)	O
by	O
glucocorticoids	O
provides	O
a	O
means	O
of	O
modulating	O
sensitivity	O
of	O
targeted	O
cells	O
.	O

A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-5	B-DNA
promoter	E-DNA
.	O

An	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
cDNA	I-DNA
clone	E-DNA
,	O
pCD41	S-DNA
,	O
encoding	O
for	O
a	O
41-kDa	B-protein
nuclear	I-protein
protein	E-protein
was	O
identified	O
and	O
characterized	O
previously	O
(	O
Chang	O
and	O
Balachandran	O
,	O
J.	O
Virol.	O
65	O
,	O
2884-2894	O
and	O
7085	O
,	O
1991	O
)	O
.	O

Furthermore	O
,	O
transfection	O
with	O
LMP1	B-DNA
expression	I-DNA
vector	E-DNA
into	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
Daudi	S-cell_line
,	O
led	O
to	O
p40	S-protein
production	O
with	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	E-protein
activation	O
.	O

Although	O
NF-AT	S-protein
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2-7	O
)	O
.	O

Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
motif	E-DNA
is	O
critical	O
for	O
the	O
gamma	B-DNA
3	I-DNA
ECS	E-DNA
responsiveness	O
to	O
both	O
CD40L	S-protein
and	O
IL-4	S-protein
,	O
while	O
a	O
STAT-6-binding	B-DNA
site	E-DNA
is	O
additionally	O
required	O
for	O
IL-4	S-protein
inducibility	O
.	O

Gel-shift	O
assay	O
was	O
also	O
examined	O
to	O
show	O
the	O
formation	O
of	O
Stat1alpha-DNA	B-protein
complexes	E-protein
.	O

The	O
effect	O
of	O
Dex	O
was	O
completely	O
reversed	O
by	O
a	O
glucocorticoid	B-protein
receptor	E-protein
antagonist	O
,	O
RU38486	O
.	O

In	O
contrast	O
,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL-2	S-protein
ligation	O
,	O
whereas	O
tyrosine-phosphorylated	B-protein
stat1	I-protein
proteins	E-protein
(	O
91	B-protein
and	I-protein
84	I-protein
kDa	I-protein
proteins	E-protein
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon-gamma	S-protein
treatment	O
of	O
HeLa	B-cell_line
cells	E-cell_line
.	O

These	O
results	O
suggest	O
that	O
cell-specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c-fos	S-DNA
induction	O
and	O
may	O
be	O
relevant	O
for	O
c-fos	S-DNA
control	O
through	O
B	B-protein
and	I-protein
T	I-protein
cell	I-protein
antigen	I-protein
receptors	E-protein
.	O

Our	O
studies	O
show	O
that	O
the	O
mechanism	O
of	O
IL-10	S-protein
regulation	O
of	O
quiescent	O
CD4	O
(	O
+	O
)	O
T-cell	O
activation	O
is	O
mainly	O
by	O
blocking	O
induction	O
of	O
IL-2	S-protein
that	O
is	O
critical	O
to	O
downregulation	O
of	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	E-protein
and	O
upregulation	O
of	O
D	B-protein
cyclins	E-protein
in	O
T-cell	O
activation	O
and	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B-protein
protein	E-protein
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B-DNA
enhancer	E-DNA
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B-protein
phytohemagglutinin	E-protein
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

Pd-C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O
5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
interaction	O
with	O
thymic	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
(	O
TEC	S-cell_type
)	O
induces	O
a	O
high-level	O
replication	O
of	O
the	O
T-tropic	B-protein
primary	I-protein
isolate	I-protein
HIV-1	E-protein
(	O
B-LAIp	S-protein
)	O
exclusively	O
in	O
the	O
mature	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	E-cell_type
.	O

We	O
identified	O
several	O
genes	O
up-regulated	O
by	O
IL-12	S-protein
,	O
namely	O
,	O
MIP-1alpha	S-protein
,	O
MIP-1beta	S-protein
,	O
IL-1RA	S-protein
,	O
and	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	I-protein
IRF-1	I-protein
)	E-protein
.	O

In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	B-protein
antibody	I-protein
KN	I-protein
382/EC1	E-protein
raised	O
against	O
the	O
rabbit	B-protein
59-kDa	I-protein
protein	E-protein
reacts	O
with	O
9S	S-protein
,	O
untransformed	B-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	E-protein
in	O
cytosol	O
prepared	O
from	O
human	B-cell_line
IM-9	I-cell_line
lymphocytes	E-cell_line
but	O
not	O
with	O
4S	B-protein
salt-transformed	I-protein
receptors	E-protein
.	O

We	O
found	O
that	O
AES	O
peptides	O
G75	O
(	O
128-135	S-protein
)	O
and	O
G76	O
(	O
128-135	S-protein
)	O
(	O
L128G	O
)	O
reconstituted	O
CTL	O
recognition	O
at	O
concentrations	O
ranging	O
between	O
200-500	O
nM	O
.	O

In	O
addition	O
,	O
these	O
mAECA	S-protein
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	E-protein
.	O

This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	B-DNA
repeats	E-DNA
in	O
SBMA	O
but	O
also	O
other	O
polymorphic	B-DNA
dinucleotide	E-DNA
and	O
trinucleotide	B-DNA
repeats	E-DNA
.	O

However	O
,	O
cell	B-cell_line
lines	E-cell_line
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	S-protein
in	O
vitro	O
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	B-DNA
B-driven	I-DNA
genes	E-DNA
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	B-protein
factors	E-protein
.	O

A	O
new	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	E-DNA
has	O
been	O
identified	O
3	O
'	O
of	O
E4	B-DNA
and	I-DNA
the	I-DNA
octamerlike	I-DNA
motifs	E-DNA
in	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	I-DNA
enhancer	E-DNA
.	O

Retroviral	O
induction	O
of	O
TIMP-1	S-protein
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O

IL-3	S-protein
,	O
IL-4	S-protein
,	O
and	O
IL-5	S-protein
independently	O
up-regulated	O
TGF-beta1	B-RNA
mRNA	E-RNA
and	O
product	O
expression	O
by	O
eosinophils	S-cell_type
in	O
all	O
donors	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	S-cell_line
or	O
U937	B-cell_line
cells	E-cell_line
could	O
not	O
by	O
itself	O
induce	O
NF-kappa	B-protein
B	E-protein
activation	O
.	O

However	O
,	O
the	O
C26	B-DNA
element	E-DNA
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	S-protein
,	O
unlike	O
other	O
NF-kappa	B-DNA
B-binding	I-DNA
elements	E-DNA
.	O

A	O
cell	B-DNA
type-specific	I-DNA
enhancer	E-DNA
in	O
the	O
human	B-DNA
B7.1	I-DNA
gene	E-DNA
regulated	O
by	O
NF-kappaB	S-protein
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
IL-4	S-protein
induces	O
expression	O
of	O
the	O
IL-4	B-DNA
gene	E-DNA
are	O
not	O
known	O
,	O
although	O
the	O
IL-4-activated	B-protein
transcription	I-protein
factor	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
6	E-protein
(	O
Stat6	S-protein
)	O
is	O
required	O
for	O
this	O
effect	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c-Maf	S-protein
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c-Myb	S-protein
regulated	O
targets	O
,	O
such	O
as	O
Bcl-2	S-protein
and	O
CD13/APN	S-protein
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation-promoting	B-DNA
genes	E-DNA
.	O

In	O
4	O
cases	O
,	O
including	O
3	O
AML	O
with	O
immature	O
morphology	O
(	O
1	O
AML-M0	O
and	O
2	O
AML-M1	O
)	O
and	O
1	O
ALL	O
,	O
the	O
signals	O
of	O
the	O
CALM	B-DNA
YACS	E-DNA
were	O
separated	O
in	O
interphase	O
cells	O
,	O
indicating	O
a	O
translocation	O
breakpoint	O
within	O
the	O
CALM	B-DNA
region	E-DNA
.	O

Costimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	E-cell_type
activation	O
by	O
human	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat-activated	B-DNA
,	I-DNA
transduced	I-DNA
interferon	I-DNA
gene	E-DNA
:	O
targeted	O
expression	O
to	O
human	B-cell_type
immunodeficiency	I-cell_type
virus	I-cell_type
type	I-cell_type
1-infected	I-cell_type
cells	E-cell_type
.	O

Because	O
HIV-1	O
requires	O
active	O
NF-kappa	B-protein
B	E-protein
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	B-protein
105K	I-protein
precursor	E-protein
.	O

The	O
ability	O
of	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFNs	E-protein
to	O
inhibit	O
IL-4	S-protein
/	O
IL-13	S-protein
-induced	O
STAT6	S-protein
activity	O
is	O
dose-	O
and	O
time-dependent	O
,	O
and	O
is	O
not	O
unique	O
to	O
monocytes	S-cell_type
because	O
IFNs	S-protein
induce	O
the	O
same	O
effects	O
in	O
fibroblasts	S-cell_type
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	S-protein
and	O
cyclosporine	O
.	O

Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	B-protein
M10	E-protein
did	O
not	O
alter	O
the	O
secretion	O
of	O
interleukin	B-protein
2	E-protein
in	O
response	O
to	O
mitogen	O
stimulation	O
of	O
EL-4	S-cell_line
and	O
Jurkat	B-cell_line
cells	E-cell_line
.	O

[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	B-cell_line
monoblastic	I-cell_line
cells	E-cell_line
,	O
THP-1	S-cell_line
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B-DNA
binding	I-DNA
sites	E-DNA
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C/EBP	B-protein
proximal	E-protein
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	B-protein
medial	E-protein
)	O
,	O
respectively	O
.	O

These	O
results	O
identify	O
TCF-1	S-protein
as	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	E-protein
,	O
which	O
might	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	E-cell_type
.	O

Analysis	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
suggests	O
that	O
overall	O
protein	B-protein
structure	E-protein
is	O
conserved	O
,	O
but	O
the	O
receptor	O
binding	O
sites	O
are	O
not	O
.	O

Transfectants	S-cell_line
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors/cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	S-protein
expression	O
in	O
glucocorticoid-sensitive	B-cell_line
6TG1.1	I-cell_line
cells	E-cell_line
before	O
steroid	O
treatment	O
.	O

Dramatic	O
stimulation	O
of	O
actin	S-protein
assembly	O
is	O
linked	O
to	O
the	O
formation	O
of	O
a	O
ternary	O
IcsA-N-WASP-Arp2/3	B-protein
complex	E-protein
,	O
which	O
nucleates	O
actin	S-protein
polymerization	O
.	O

Whereas	O
different	O
anti-CD4	B-protein
mAb	E-protein
or	O
HIV-1	B-protein
gp120	E-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	E-protein
and	O
p59fyn	S-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	E-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	S-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	S-protein
.	O

The	O
Ah	B-protein
receptor	E-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	E-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	E-protein
,	O
BSAP	S-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	E-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	S-protein
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B-protein
-TRAF2	E-protein
interaction	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	E-DNA
and	O
demonstrated	O
its	O
tissue-specific	B-DNA
promoter	E-DNA
activity	O
.	O

The	O
underlying	O
molecular	O
mechanism	O
for	O
Pb	O
's	O
complex	O
effects	O
on	O
the	O
immune	O
system	O
remain	O
obscure	O
.	O

The	O
inhibition	O
of	O
IL-2	S-protein
production	O
was	O
observed	O
in	O
the	O
CD3	S-protein
(	O
+	O
)	O
T-lymphocyte	O
cytoplasm	O
as	O
early	O
as	O
4	O
h	O
after	O
activation	O
by	O
PMA+ionomycin	O
.	O

A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	E-DNA
homologous	O
to	O
a	O
rodent	B-DNA
gene	E-DNA
encoding	O
a	O
zinc-binding	B-protein
potential	I-protein
transcription	I-protein
factor	E-protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c-jun	S-DNA
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O

In	O
contrast	O
to	O
anti-CD3/IL-2-activated	B-cell_line
LN	I-cell_line
cells	E-cell_line
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor-draining	B-cell_type
LN	I-cell_type
T	I-cell_type
cells	E-cell_type
has	O
no	O
therapeutic	O
activity	O
.	O

Regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	E-protein
expression	O
and	O
nuclear	B-protein
factor.kappa	I-protein
B	E-protein
activation	O
by	O
protein	B-protein
kinase	I-protein
C	E-protein
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B-protein
protein	E-protein
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B-protein
proteins	E-protein
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	S-protein
,	O
binds	O
specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	S-protein
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	O
.	O

N-formyl-methionyl-leucyl-phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42-	B-protein
and	I-protein
44-kDa	I-protein
proteins	E-protein
,	O
which	O
were	O
identified	O
as	O
extracellular	B-protein
signal-regulated	I-protein
kinase	E-protein
(	O
ERK	S-protein
)	O
,	O
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c-jun	S-DNA
in	O
both	O
cell	O
proliferation	O
and	O
PMA-induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA-induced	O
respiratory	O
burst	O
in	O
U937	B-cell_line
cells	E-cell_line
.	O

Immunocytochemistry	O
identified	O
the	O
cells	O
in	O
the	O
infiltrate	O
as	O
cytotoxic	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL-2	S-protein
-and	O
IL-3	S-protein
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS-3	S-protein
.	O

These	O
in	O
vivo	O
anti-inflammatory	O
effects	O
of	O
IL-11	S-protein
were	O
associated	O
with	O
reduced	O
NF-kappaB	S-protein
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up-regulation	O
of	O
lung	B-protein
vascular	I-protein
ICAM-1	E-protein
.	O

B	B-cell_type
cells	E-cell_type
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	B-protein
CD20	I-protein
monoclonal	I-protein
antibody	E-protein
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

Monocyte	O
adhesion	O
and	O
spreading	O
on	O
human	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
is	O
dependent	O
on	O
Rho	S-protein
-regulated	O
receptor	O
clustering	O
.	O

STAT1	B-protein
alpha	E-protein
activation	O
by	O
IL-12	S-protein
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	O
tyrosine	O
.	O

Finally	O
,	O
GATA-1	S-protein
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA-treated	B-cell_line
but	I-cell_line
not	I-cell_line
in	I-cell_line
DOX-treated	I-cell_line
cells	E-cell_line
.	O

In	O
addition	O
,	O
no	O
CIITA	S-protein
protein	O
is	O
detectable	O
in	O
clone	B-cell_line
13	E-cell_line
nuclear	O
extracts	O
.	O

When	O
introduced	O
in	O
front	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	E-DNA
,	O
this	O
promoter	O
is	O
able	O
to	O
direct	O
a	O
high	O
luciferase	S-protein
activity	O
in	O
a	O
human	B-cell_line
B-LCL	E-cell_line
.	O

More	O
strikingly	O
,	O
the	O
80-kDa	B-protein
protein	E-protein
was	O
downregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
;	O
this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O

However	O
,	O
stimulation	O
with	O
MBP	S-protein
did	O
not	O
produce	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	E-protein
or	O
activator	B-protein
protein-1	E-protein
.	O

A	O
novel	O
form	O
of	O
the	O
myeloid-specific	B-protein
zinc	I-protein
finger	I-protein
protein	E-protein
(	O
MZF-2	S-protein
)	O
.	O

HIVs	O
in	O
which	O
the	O
NF-kappa	B-DNA
B/Sp1	I-DNA
enhancer	E-DNA
plus	O
the	O
downstream	B-DNA
TATA	I-DNA
element	E-DNA
were	O
replaced	O
with	O
heterologous	B-DNA
enhancer/promoters	E-DNA
were	O
also	O
constructed	O
.	O

These	O
data	O
demonstrate	O
that	O
B95-8	B-cell_type
cells	E-cell_type
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B-protein
receptor	E-protein
.	O

This	O
enhancer	S-DNA
in	O
HIV-1	O
is	O
the	O
T-cell	B-DNA
activation	I-DNA
response	I-DNA
element	E-DNA
;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	B-DNA
enhancer	E-DNA
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	O
activators	O
.	O

We	O
propose	O
that	O
adherent	B-cell_type
monocytes	E-cell_type
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	E-RNA
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	E-DNA
transcription	O
.	O

Cooperation	O
of	O
binding	B-protein
sites	E-protein
for	O
STAT6	S-protein
and	O
NF	B-protein
kappa	I-protein
B/rel	E-protein
in	O
the	O
IL-4	S-protein
-induced	O
up-regulation	O
of	O
the	O
human	B-DNA
IgE	I-DNA
germline	I-DNA
promoter	E-DNA
.	O

The	O
myeloid	B-DNA
zinc	I-DNA
finger	I-DNA
gene	E-DNA
,	O
MZF-1	S-DNA
,	O
regulates	O
the	O
CD34	B-DNA
promoter	E-DNA
in	O
vitro	O
.	O

METHODS	O
:	O
The	O
DNA	O
binding	O
activity	O
of	O
these	O
nucleoproteins	S-protein
was	O
examined	O
in	O
purified	O
synovial	B-cell_type
and	I-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	E-cell_type
from	O
patients	O
with	O
various	O
chronic	O
rheumatic	O
diseases	O
(	O
12	O
:	O
four	O
with	O
rheumatoid	O
arthritis	O
;	O
five	O
with	O
spondyloarthropathies	O
;	O
and	O
three	O
with	O
osteoarthritis	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	S-protein
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF-kappaB	B-protein
subunits	E-protein
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF-kappaB	S-protein
activation	O
in	O
U937	B-cell_line
cells	E-cell_line
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF-kappaB	S-protein
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

Many	O
cytokines	S-protein
activate	O
signal	B-protein
transducer	I-protein
and	I-protein
activation	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
transcription	I-protein
factors	E-protein
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

Prolactin	O
activates	O
Stat5	S-protein
,	O
and	O
interleukin-4	S-protein
(	O
IL-4	S-protein
)	O
activates	O
Stat6	S-protein
.	O

The	O
interleukin-2	B-protein
IL-2	I-protein
receptor	I-protein
beta-chain	E-protein
(	O
IL-2Rbeta	S-protein
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL-2	S-protein
and	O
IL-15	S-protein
.	O

Activation	O
of	O
the	O
CDC42	B-protein
effector	I-protein
N-WASP	E-protein
by	O
the	O
Shigella	B-protein
flexneri	I-protein
IcsA	I-protein
protein	E-protein
promotes	O
actin	S-protein
nucleation	O
by	O
Arp2/3	B-protein
complex	E-protein
and	O
bacterial	O
actin	S-protein
-based	O
motility	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

In	O
vivo	O
protein-DNA	O
interactions	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	E-DNA
in	O
erythroid	B-cell_type
cells	E-cell_type
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	B-DNA
gene	E-DNA
program	O
.	O

Silencing	O
of	O
human	O
fetal	O
globin	S-protein
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	B-protein
beta-globin	I-protein
gene	I-protein
activator	I-protein
protein	I-protein
EKLF	E-protein
.	O

These	O
findings	O
indicate	O
that	O
IL-6	S-protein
production	O
and	O
Stat3	S-protein
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN-mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O

Constitutive	O
STAT5	S-protein
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	S-protein
or	O
EPOR	S-protein
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	B-protein
/PKB/Akt	E-protein
pathway	O
to	O
protect	O
the	O
EPO-independent	B-cell_line
HCD57-SREI	I-cell_line
cells	E-cell_line
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Furthermore	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
optimal	O
activation	O
of	O
T	B-cell_type
cells	E-cell_type
by	O
IL-12	S-protein
and	O
IL-2	S-protein
may	O
depend	O
on	O
an	O
interaction	O
between	O
the	O
p38	B-protein
MAP	I-protein
kinase	E-protein
and	O
Janus	B-protein
kinase/STAT	E-protein
signaling	O
pathways	O
.	O

Oct-2	B-RNA
mRNA	E-RNA
induction	O
during	O
antigen-driven	O
T-cell	S-cell_type
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	B-protein
factor	E-protein
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	B-protein
B	E-protein
and	O
permanently	O
increased	O
HIV	B-DNA
enhancer	E-DNA
activity	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-protein
integrin	E-protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	B-cell_type
leukocytes	E-cell_type
.	O

The	O
TCL1	B-DNA
locus	E-DNA
on	O
chromosome	B-DNA
14q32.1	E-DNA
is	O
frequently	O
involved	O
in	O
chromosomal	O
translocations	O
and	O
inversions	O
with	O
one	O
of	O
the	O
T-cell	B-DNA
receptor	I-DNA
loci	E-DNA
in	O
human	O
T-cell	O
leukemias	O
and	O
lymphomas	O
.	O

These	O
data	O
show	O
that	O
human	B-protein
PCD/DCoH	E-protein
is	O
not	O
only	O
present	O
in	O
cells	O
where	O
tetrahydrobiopterin	S-protein
is	O
synthesized	O
or	O
HNF1	S-protein
is	O
present	O
but	O
is	O
a	O
widely	O
distributed	O
protein	O
.	O

It	O
was	O
identified	O
as	O
NF-E1	S-protein
(	O
YY1	S-protein
)	O
.	O

The	O
signal	O
transduction	O
events	O
involved	O
in	O
gp120	S-protein
-mediated	O
enhancement	O
of	O
ICAM-1	S-protein
appear	O
to	O
involve	O
activation	O
of	O
both	O
protein	B-protein
kinase	I-protein
C	E-protein
and	O
tyrosine	B-protein
kinase	E-protein
,	O
because	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
and	O
tyrosine	B-protein
kinase	E-protein
abrogate	O
gp120	S-protein
-mediated	O
ICAM-1	S-protein
expression	O
in	O
both	O
astrocytes	S-cell_type
and	O
microglia	S-cell_type
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	E-cell_line
with	O
mAb	B-protein
J393	E-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	B-protein
substrates	E-protein
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	B-protein
receptor	E-protein
costimulation	O
.	O

When	O
data	O
obtained	O
preoperatively	O
and	O
after	O
12	O
months	O
were	O
compared	O
,	O
it	O
was	O
found	O
that	O
out	O
of	O
23	O
patients	O
whose	O
PBMCs	S-cell_type
had	O
experienced	O
a	O
drop	O
in	O
their	O
PHA	S-protein
-induced	O
proliferation	O
,	O
14	O
(	O
61	O
%	O
)	O
had	O
developed	O
metastatic	O
disease	O
within	O
the	O
subsequent	O
24	O
months	O
(	O
i.e.	O
36	O
months	O
after	O
surgery	O
)	O
.	O

A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B-protein
:	I-protein
TRE	I-protein
complex	E-protein
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	B-cell_line
JEG-3	I-cell_line
cells	E-cell_line
.	O

A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	E-DNA
in	O
families	O
with	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
.	O

When	O
analyzed	O
by	O
DNase	S-protein
footprinting	O
,	O
region	B-DNA
II	E-DNA
was	O
protected	O
preferentially	O
in	O
monocytic	B-cell_type
cells	E-cell_type
.	O

One	O
of	O
these	O
enhancers	S-DNA
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
.	O

BSAP	S-protein
failed	O
to	O
trans-activate	O
CD19	B-DNA
promoter	I-DNA
constructs	E-DNA
in	O
B	B-cell_type
cells	E-cell_type
or	O
non-B	B-cell_type
cells	E-cell_type
,	O
suggesting	O
that	O
cis	O
elements	O
such	O
as	O
the	O
PyG	B-DNA
and	I-DNA
GC	I-DNA
boxes	E-DNA
are	O
also	O
necessary	O
for	O
high	O
level	O
CD19	B-DNA
promoter	E-DNA
expression	O
.	O

Characterization	O
of	O
expression	O
of	O
the	O
gene	O
for	O
human	B-protein
pterin	I-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	E-protein
of	O
HNF1	S-protein
.	O

PPARgamma	S-protein
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	B-DNA
fatty	I-DNA
acid	I-DNA
binding	I-DNA
protein	I-DNA
gene	E-DNA
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	B-cell_type
cells	E-cell_type
can	O
activate	O
transcription	O
of	O
the	O
GM-CSF	B-DNA
gene	E-DNA
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptors	E-protein
(	O
PPARs	S-protein
)	O
,	O
members	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
superfamily	E-protein
of	O
transcription	B-protein
factors	E-protein
,	O
are	O
activated	O
by	O
fatty	O
acid	O
metabolites	O
,	O
peroxisome	O
proliferators	O
,	O
and	O
thiazolidinediones	O
and	O
are	O
now	O
recognized	O
as	O
important	O
mediators	O
in	O
the	O
inflammatory	O
response	O
.	O

Direct	O
exposure	O
to	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
increases	O
infectivity	O
of	O
human	B-cell_type
erythrocytes	E-cell_type
to	O
a	O
malarial	O
parasite	O
.	O

The	O
percentage	O
of	O
cells	O
expressing	O
CD40	S-protein
in	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
co-cultures	E-cell_line
increased	O
from	O
4.2	O
%	O
to	O
13.8	O
%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4.7	O
%	O
to	O
48.6	O
%	O
in	O
healthy	O
controls	O
.	O

The	O
role	O
of	O
SCL	S-protein
in	O
Steel	B-protein
factor	E-protein
-induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

A	O
Western	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
HER-2/neu	S-protein
expression	O
,	O
whereas	O
a	O
chromium-release	O
assay	O
using	O
the	O
K562	B-cell_line
cell	I-cell_line
line	E-cell_line
as	O
target	O
was	O
used	O
to	O
measure	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	E-cell_type
activity	O
.	O

Activated	B-cell_type
platelets	E-cell_type
induce	O
monocyte	B-protein
chemotactic	I-protein
protein-1	E-protein
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	E-cell_type
on	O
endothelial	B-cell_type
cells	E-cell_type
[	O
see	O
comments	O
]	O

As	O
a	O
first	O
step	O
toward	O
elucidating	O
the	O
function	O
of	O
Cbl	S-protein
in	O
TCR	S-protein
-initiated	O
signaling	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
wild-type	B-protein
Cbl	E-protein
or	O
a	O
transforming	O
Cbl	B-protein
mutant	E-protein
(	O
70Z/3	O
)	O
to	O
induce	O
transcriptional	O
activation	O
of	O
a	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
element	E-DNA
derived	O
from	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL2	I-DNA
)	I-DNA
promoter	E-DNA
in	O
transiently	O
cotransfected	O
Jurkat-TAg	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O

It	O
was	O
also	O
shown	O
that	O
mixture	O
of	O
heparin-like	O
GAGs	O
with	O
MCP-1	S-protein
inhibited	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
phosphatidylinositol	B-protein
3-kinase	E-protein
which	O
is	O
normally	O
produced	O
by	O
treatment	O
of	O
mononuclear	B-cell_type
leucocytes	E-cell_type
with	O
this	O
chemokine	S-protein
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto-differentiating	O
effects	O
on	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
.	O

We	O
thus	O
conclude	O
that	O
PTPases	S-protein
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	S-cell_type
activation	O
.	O

NF-AT	S-protein
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi-purified	B-protein
AP1	I-protein
proteins	E-protein
mixed	O
with	O
cytosol	O
from	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

Reactive	O
oxygen	O
intermediate-dependent	O
NF-kappaB	S-protein
activation	O
by	O
interleukin-1beta	S-protein
requires	O
5-lipoxygenase	S-protein
or	O
NADPH	O
oxidase	O
activity	O
.	O

Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	B-DNA
genes	E-DNA
,	O
and	O
bind	O
transcription	B-protein
factors	E-protein
of	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	E-protein
(	O
CREB	B-protein
)	I-protein
/activating	I-protein
transcription	I-protein
factor-1	I-protein
(	I-protein
ATF-1	I-protein
)	I-protein
family	E-protein
.	O

Jak2	B-protein
kinase	E-protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B-protein
nuclear	I-protein
proteins	E-protein
.	O

We	O
found	O
that	O
they	O
reduced	O
the	O
initial	O
interleukin-1beta	B-RNA
mRNA	E-RNA
transcription	O
rate	O
through	O
prevention	O
of	O
degradation	O
of	O
inhibitor-kappaB	B-protein
alpha	E-protein
.	O

We	O
now	O
report	O
that	O
galectin-3	S-protein
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	B-cell_line
T	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
(	I-cell_line
HTLV	I-cell_line
)	I-cell_line
-I-infected	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
including	O
F6T	S-cell_line
,	O
HUT	B-cell_line
102	E-cell_line
,	O
K3T	S-cell_line
,	O
MT-2	S-cell_line
,	O
and	O
SLB-I	S-cell_line
,	O
but	O
is	O
not	O
expressed	O
in	O
non-HTLV-I-infected	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
such	O
as	O
Jurkat	S-cell_line
,	O
CEM	S-cell_line
,	O
and	O
MOLT-4	S-cell_line
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	S-DNA
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	B-RNA
genes	E-RNA
,	O
for	O
which	O
cDNAs	S-DNA
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
and/or	O
activating	B-protein
protein-1	E-protein
(	O
AP-1	S-protein
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

The	O
functions	O
of	O
NFAT	B-protein
proteins	E-protein
are	O
directly	O
controlled	O
by	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-	I-protein
dependent	I-protein
phosphatase	I-protein
calcineurin	E-protein
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
Rho	S-protein
in	O
regulating	O
the	O
distribution	O
of	O
the	O
monocyte-binding	B-protein
receptors	I-protein
E-selectin	E-protein
,	O
ICAM-1	S-protein
,	O
and	O
VCAM-1	S-protein
in	O
human	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
cells	E-cell_type
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	S-protein
and	O
LYL-1	S-protein
is	O
low	O
or	O
undetectable	O
in	O
normal	B-cell_type
T	I-cell_type
cell	I-cell_type
populations	E-cell_type
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	E-cell_type
from	O
these	O
patients	O
is	O
that	O
RelA	S-protein
,	O
a	O
member	O
of	O
the	O
Rel	B-protein
homology	I-protein
family	E-protein
which	O
is	O
part	O
of	O
the	O
normal	O
NF-kappa	B-protein
B	I-protein
complex	E-protein
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

It	O
contains	O
a	O
number	O
of	O
structural	B-protein
motifs	E-protein
,	O
including	O
Src	B-protein
homology	I-protein
2	I-protein
,	I-protein
Src	I-protein
homology	I-protein
3	I-protein
,	I-protein
and	I-protein
pleckstrin	I-protein
homology	I-protein
domains	E-protein
and	O
a	O
putative	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
domain	E-protein
.	O

Transcription	B-protein
factor	I-protein
GATA-3	E-protein
is	O
differentially	O
expressed	O
in	O
murine	B-cell_line
Th1	I-cell_line
and	I-cell_line
Th2	I-cell_line
cells	E-cell_line
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	B-DNA
gene	E-DNA
.	O

Only	O
NF-AT1	S-protein
and	O
NF-AT4	S-protein
,	O
but	O
not	O
NF-AT2	S-protein
and	O
NF-AT3	S-protein
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL-4-	B-cell_line
or	I-cell_line
IL-5-stimulated	I-cell_line
eosinophils	E-cell_line
.	O

Band	B-protein
A	E-protein
contains	O
the	O
serum	B-protein
response	I-protein
factor	E-protein
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	S-protein
and	O
the	O
PC4	S-protein
-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	S-protein
and	O
another	O
,	O
USA-derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1	B-protein
/OCA-B	E-protein
in	O
the	O
reconstituted	O
system	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML-RAR	B-protein
alpha	E-protein
and	O
PLZF-RAR	B-protein
alpha	E-protein
APLs	O
to	O
RA	O
treatment	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	B-protein
(	I-protein
100	I-protein
)	E-protein
and	O
p65	B-protein
NF-kappa	I-protein
B	E-protein
can	O
act	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	E-protein
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	B-RNA
RNA	E-RNA
.	O

PMA	B-protein
-but	I-protein
not	I-protein
TG-induced	I-protein
IL-2R	I-protein
alpha	E-protein
is	O
inhibited	O
by	O
the	O
PKC	S-protein
inhibitor	O
H7	O
,	O
whereas	O
TG	B-protein
-but	I-protein
not	I-protein
PMA-induced	I-protein
IL-2R	I-protein
alpha	E-protein
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9-dideoxy	O
forskolin	O
.	O

PU.1/Pip	S-protein
and	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
zipper	I-protein
transcription	I-protein
factors	E-protein
interact	O
with	O
binding	B-DNA
sites	E-DNA
in	O
the	O
CD20	B-DNA
promoter	E-DNA
to	O
help	O
confer	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
CD20	S-protein
in	O
B	B-cell_type
lymphocytes	E-cell_type
.	O

Virtually	O
all	O
B-cell	B-cell_line
lines	E-cell_line
,	O
with	O
the	O
exception	O
of	O
some	O
myeloma	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
are	O
positive	O
for	O
BSAP	S-protein
,	O
which	O
is	O
the	O
transcription	B-protein
factor	E-protein
for	O
promoters	S-DNA
for	O
several	O
B-cell	B-protein
markers	E-protein
,	O
including	O
VpreB1	S-protein
,	O
lambda	B-protein
5	E-protein
,	O
CD19	S-protein
,	O
and	O
CD20	S-protein
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	B-protein
receptors	E-protein
that	O
are	O
related	O
to	O
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
receptor	I-protein
1	E-protein
(	O
BLR1	S-protein
)	O
and	O
are	O
expressed	O
in	O
activated	B-cell_type
lymphocytes	E-cell_type
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B-protein
transmembrane	I-protein
receptor	E-protein
termed	O
BLR2	S-protein
.	O

Although	O
hypoxia	O
alone	O
did	O
not	O
induce	O
ICAM-1	S-protein
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
+/-	O
0.4-fold	O
over	O
normoxia	O
)	O
ICAM-1	S-protein
expression	O
.	O

To	O
define	O
the	O
activation	O
of	O
the	O
STAT5	B-protein
homologues	E-protein
and	O
lower	O
molecular	O
weight	O
variant	O
in	O
human	B-cell_type
monocytes	E-cell_type
and	O
monocytes	S-cell_type
differentiated	O
into	O
macrophages	S-cell_type
by	O
culture	O
in	O
macrophage-CSF	S-protein
(	O
M-CSF	S-protein
)	O
,	O
we	O
measured	O
the	O
GM-CSF	S-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	S-protein
,	O
STAT5B	S-protein
,	O
and	O
any	O
lower	O
molecular	O
weight	O
STAT5	B-protein
isoforms	E-protein
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptors	E-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	E-cell_type
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

The	O
range	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	E-protein
expression	O
produced	O
was	O
found	O
to	O
mimic	O
a	O
physiologically	O
relevant	O
spectrum	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	E-protein
expression	O
in	O
membranes	O
derived	O
from	O
human	O
tissues	O
and	O
rat	O
brain	O
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF-kappa	B-protein
B	E-protein
(	O
p50-p65	B-protein
heterodimer	E-protein
)	O
,	O
and	O
AP-1	B-protein
transcriptional	I-protein
factors	E-protein
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	E-cell_line
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Peptide	O
binding	O
affinity	O
and	O
pH	O
variation	O
establish	O
functional	O
thresholds	O
for	O
activation	O
of	O
HLA-DQ	S-DNA
-restricted	O
T	O
cell	O
recognition	O
.	O

NGAL	S-protein
levels	O
varied	O
in	O
these	O
tumors	O
from	O
undetectable	O
to	O
exceeding	O
those	O
in	O
normal	O
breast	O
parenchyma	O
.	O

We	O
discuss	O
the	O
utility	O
of	O
MTHC	S-cell_line
in	O
analyzing	O
the	O
relationships	O
between	O
DC	S-cell_type
and	O
macrophages	S-cell_type
,	O
and	O
suggest	O
that	O
DC	S-cell_type
and	O
macrophages	S-cell_type
represent	O
extreme	O
phenotypes	O
in	O
a	O
spectrum	O
of	O
antigen	B-cell_type
handling	I-cell_type
cells	E-cell_type
that	O
are	O
somewhat	O
interchangeable	O
,	O
depending	O
on	O
their	O
immediate	O
environment	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	B-DNA
octamer	I-DNA
motif	E-DNA
of	O
the	O
interleukin	B-DNA
2	I-DNA
enhancer	E-DNA
by	O
AP-1	S-protein
,	O
Oct-2	S-protein
,	O
and	O
retinoic	B-protein
acid	I-protein
receptor	E-protein
.	O

Here	O
,	O
we	O
show	O
that	O
OCA-B	S-protein
alters	O
the	O
activity	O
of	O
Oct-1	S-protein
in	O
two	O
ways	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-RNA
mRNA	E-RNA
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	S-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

However	O
,	O
while	O
IL2	S-protein
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
protein	B-protein
kinase	I-protein
C	E-protein
-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	B-protein
IL4	E-protein
transcription	O
through	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B-protein
kinase	I-protein
C	E-protein
stimulation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O

At	O
the	O
same	O
time	O
,	O
we	O
observed	O
a	O
down-regulation	O
of	O
progenitor-specific	B-protein
surface	I-protein
markers	E-protein
and	O
the	O
up-regulation	O
of	O
differentiation	B-protein
markers	E-protein
restricted	O
to	O
the	O
eosinophil	S-cell_type
and	O
myeloid	B-cell_type
lineages	E-cell_type
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	E-protein
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	O
sufficient	O
for	O
E-selectin	S-protein
expression	O
in	O
EC	S-cell_line
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	B-protein
mBob1	I-protein
clone	E-protein
.	O

The	O
development	O
of	O
improved	O
glucocorticoid-based	O
drugs	O
will	O
require	O
the	O
separation	O
of	O
beneficial	O
from	O
deleterious	O
effects	O
.	O

In	O
particular	O
,	O
these	O
cell	B-cell_line
lines	E-cell_line
may	O
help	O
understand	O
the	O
relative	O
contribution	O
of	O
HHV-8	O
and	O
EBV	O
to	O
PEL	O
growth	O
and	O
development	O
and	O
may	O
facilitate	O
the	O
identification	O
of	O
recurrent	O
cytogenetic	O
abnormalities	O
highlighting	O
putative	O
novel	O
cancer	O
related	O
loci	O
relevant	O
to	O
PEL	S-cell_line
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF-kappaB/Rel	B-protein
members	E-protein
,	O
predominantly	O
c-Rel	S-protein
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	S-protein
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL-2	S-protein
-induced	O
T-cell	O
proliferation	O
.	O

The	O
cytokine	S-protein
-dependent	O
upregulation	O
of	O
the	O
murine	B-protein
macrophage	I-protein
12-lipoxygenase	E-protein
and	O
its	O
induction	O
during	O
experimental	O
anemia	O
suggests	O
its	O
close	O
relatedness	O
with	O
the	O
human	B-protein
reticulocyte-type	I-protein
15-lipoxygenase	E-protein
despite	O
their	O
differences	O
in	O
the	O
positional	O
specificity	O
of	O
arachidonic	O
acid	O
oxygenation	O
.	O

Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

This	O
adhesion	O
molecule	O
was	O
also	O
expressed	O
by	O
T	B-cell_type
cells	E-cell_type
obtained	O
from	O
one	O
patient	O
with	O
HTLV-1-associated	O
myelopathy/tropical	O
spastic	O
paraparesis	O
but	O
not	O
by	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
isolated	O
from	O
one	O
normal	O
blood	O
donor	O
.	O

Stimulation	O
through	O
the	O
Fas/APO-1	B-protein
receptor	E-protein
results	O
in	O
apoptosis	O
through	O
an	O
incompletely	O
characterized	O
signaling	O
pathway	O
.	O

NF-IL6	S-protein
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	B-cell_type
monocytes/macrophages	E-cell_type
,	O
and	O
NF-IL6	S-protein
is	O
the	O
only	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
family	E-protein
member	O
whose	O
steady-state	O
mRNA	O
levels	O
increase	O
upon	O
activation	O
of	O
monocytes	S-cell_type
(	O
1	O
)	O
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	B-protein
interleukin-1	I-protein
alpha	I-protein
cytokine	E-protein
was	O
increased	O
.	O

Concomitant	O
downregulation	O
of	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	E-DNA
activity	O
and	O
c-myc	S-DNA
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c-myc	S-DNA
.	O

However	O
,	O
IL-4	S-protein
-induced	O
effects	O
were	O
clearly	O
improved	O
following	O
JAK3	S-protein
expression	O
.	O

The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid-cell-specific	O
genes	O
in	O
that	O
it	O
contains	O
no	O
TATAAA	B-DNA
box	E-DNA
but	O
has	O
a	O
number	O
of	O
purine-rich	B-DNA
stretches	E-DNA
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	B-protein
family	E-protein
of	O
transcriptional	B-protein
regulators	E-protein
.	O

eGLs	S-cell_type
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	E-cell_type
in	O
a	O
dose-dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2+	O
.	O

Anti-	O
CD28	B-protein
MoAb	E-protein
costimulation	O
increased	O
NF	B-protein
kappa	I-protein
B	E-protein
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	B-DNA
beta	E-DNA
-	O
MYH11	B-RNA
transcripts	E-RNA
in	O
the	O
absence	O
of	O
apparent	O
chromosome	B-DNA
16	E-DNA
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT-PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	B-RNA
transcript	E-RNA
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	B-DNA
AP-1	I-DNA
recognition	I-DNA
sequence	E-DNA
predicted	O
for	O
the	O
HIV-1	O
NRE	S-DNA
.	O

The	O
suppression	O
of	O
basophils	S-cell_type
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O

6.	O
Partitioning	O
of	O
SMX-NHOH	O
into	O
red	B-cell_type
blood	I-cell_type
cells	E-cell_type
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channel	E-protein
is	O
not	O
associated	O
with	O
changes	O
in	O
cell-cycle	O
gene	O
activation	O
,	O
IL-2	S-protein
production	O
,	O
IL-2R	S-protein
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

TPA-GR	O
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR-responsive	B-DNA
element	E-DNA
(	O
GRE	S-DNA
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	B-DNA
mutants	E-DNA
or	O
synthetic	B-DNA
GRE	I-DNA
oligonucleotides	E-DNA
driving	O
chloramphenicol	B-protein
acetyl-transferase	E-protein
expression	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	B-protein
cytokine	E-protein
production	O
by	O
human	B-cell_type
monocytes	E-cell_type
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	B-protein
SOD	E-protein
,	O
2	O
)	O
endotoxin	S-protein
-mediated	O
induction	O
of	O
Mn	B-protein
SOD	E-protein
and	O
inflammatory	O
cytokines	S-protein
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	B-protein
endotoxin	E-protein
to	O
induce	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen-activated	B-protein
protein	I-protein
kinase	E-protein
.	O

These	O
data	O
suggest	O
that	O
the	O
B29	B-DNA
gene	E-DNA
is	O
a	O
genetic	O
target	O
for	O
EBF	S-protein
in	O
early	O
B-cell	O
development	O
.	O

Three	O
of	O
these	O
mutants	O
contained	O
targeted	O
disruptions	O
of	O
potential	O
functional	O
motifs	O
:	O
the	O
acidic	B-protein
activation	I-protein
domain	E-protein
,	O
a	O
putative	O
GTP-binding	B-protein
motif	E-protein
and	O
two	O
leucine	B-protein
charged	I-protein
domains	E-protein
(	O
LCD	B-protein
motifs	E-protein
)	O
.	O

Activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoter	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
requires	O
cooperative	O
binding	O
of	O
Elf-1	S-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	E-protein
.	O

We	O
have	O
performed	O
domain	O
analysis	O
of	O
NFATx1	S-protein
by	O
examining	O
the	O
effects	O
of	O
deletion	O
mutations	O
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin-1beta	S-protein
(	O
IL-1beta	S-protein
)	O
in	O
non-monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	B-DNA
IL-1beta	I-DNA
promoter	E-DNA
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

Functional	O
block	O
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3-mediated	O
gene	O
regulation	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

In	O
addition	O
,	O
PEBP2betaMYH11	S-protein
inhibited	O
neutrophilic	O
differentiation	O
in	O
colonies	O
derived	O
from	O
hematopoietic	B-cell_type
progenitors	E-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
several	O
of	O
these	O
agents	O
can	O
significantly	O
increase	O
HIV	O
replication	O
and	O
accelerate	O
CD4	S-protein
-positive	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O

Most	O
New	O
World	O
primate	O
(	O
NWP	O
)	O
genera	O
evolved	O
to	O
require	O
high	O
circulating	O
levels	O
of	O
steroid	O
hormones	O
and	O
vitamin	O
D	O
.	O

Membrane-associated	B-protein
lymphotoxin	E-protein
on	O
natural	B-cell_type
killer	I-cell_type
cells	E-cell_type
activates	O
endothelial	B-cell_type
cells	E-cell_type
via	O
an	O
NF-kappaB	S-protein
-dependent	O
pathway	O
.	O

Fas	B-protein
ligand	E-protein
induction	O
in	O
human	B-cell_type
NK	I-cell_type
cells	E-cell_type
is	O
regulated	O
by	O
redox	O
through	O
a	O
calcineurin-nuclear	B-protein
factors	E-protein
of	O
activated	O
T	O
cell-dependent	O
pathway	O
.	O

The	O
cDNA	B-DNA
sequence	E-DNA
has	O
an	O
813-bp	B-DNA
open	I-DNA
reading	I-DNA
frame	E-DNA
(	O
ORF	S-DNA
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6	O
%	O
identical	O
to	O
the	O
272	B-protein
carboxy-terminal	I-protein
amino	I-protein
acids	E-protein
of	O
the	O
human	B-protein
ets-1	I-protein
protein	E-protein
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	B-DNA
chromosomes	E-DNA
lacking	O
XIST	S-DNA
expression	O
(	O
XISTE-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

Interleukin-6	S-protein
(	O
IL-6	S-protein
)	O
is	O
an	O
important	O
B-cell	B-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	E-protein
.	O

We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	E-protein
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O

We	O
identified	O
several	O
anti-Ig	O
response	O
elements	O
within	O
Zp	S-DNA
,	O
which	O
were	O
originally	O
defined	O
as	O
12-O-tetradecanoylphorbol-13-acetate	B-DNA
(	I-DNA
TPA	I-DNA
)	I-DNA
response	I-DNA
elements	E-DNA
(	O
ZI	O
repeats	O
and	O
ZII	S-DNA
,	O
an	O
AP-1-like	B-DNA
domain	E-DNA
)	O
.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF-kappa	B-RNA
B	I-RNA
p65	I-RNA
mRNA	E-RNA
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF-kappa	B-protein
B	E-protein
,	O
p50	S-protein
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide-induced	O
NF-kappa	B-protein
B	E-protein
activation	O
.	O

Are	O
there	O
effects	O
of	O
CyA	O
and	O
FK	O
506	O
all	O
attributable	O
to	O
CN	O
inhibition	O
,	O
and	O
how	O
much	O
of	O
them	O
are	O
mediated	O
through	O
the	O
NFATC	B-protein
family	E-protein
of	O
transcription	B-protein
factors	E-protein
?	O

One	O
contains	O
hsp90	S-protein
bound	O
to	O
hsp70	S-protein
and	O
p60	S-protein
and	O
this	O
complex	O
forms	O
spontaneously	O
in	O
the	O
absence	O
of	O
ATP	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	E-protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

Both	O
c-Rel	S-protein
and	O
RelA	S-protein
induced	O
jagged1	O
gene	O
expression	O
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	O
.	O

The	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	E-protein
activation	O
by	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TcR	I-protein
)	I-protein
/CD3	I-protein
complex	E-protein
in	O
primary	O
human	O
T	B-cell_type
cells	E-cell_type
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	B-DNA
promoter	E-DNA
(	O
-62	O
to	O
+54	O
)	O
that	O
displays	O
erythroid-specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B-protein
receptors	E-protein
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O

Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O

Thus	O
HIV-1	O
gp41	S-protein
-induced	O
IL-10	S-protein
up-regulation	O
in	O
monocytes	S-cell_type
may	O
not	O
involve	O
NF-kappaB	S-protein
,	O
MAPK	S-protein
,	O
or	O
PI	B-protein
3-kinase	E-protein
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	B-protein
cyclase	E-protein
and	O
pertussis-toxin-sensitive	B-protein
Gi/Go	I-protein
protein	E-protein
to	O
effect	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
-kinase	E-protein
activation	O
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl-terminal	B-protein
region	E-protein
of	O
Stat6	S-protein
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	B-protein
DNA	I-protein
binding	I-protein
domain	E-protein
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	S-protein
.	O

Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49/p65	S-protein
in	O
transiently	B-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T-leukemia	I-cell_line
cells	E-cell_line
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD-3	S-protein
.	O

ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF-1	B-DNA
gene	E-DNA
activation	O
.	O

The	O
onset	O
of	O
apoptosis	O
in	O
both	O
cell	O
types	O
can	O
be	O
delayed	O
by	O
hemopoietins	S-protein
and	O
inflammatory	B-protein
mediators	E-protein
.	O

Induction	O
of	O
cytochrome	B-protein
P-4501A1	E-protein
(	O
CYP1A1	S-protein
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Low	O
levels	O
of	O
c-jun	B-protein
transcripts	E-protein
were	O
detectable	O
in	O
resting	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	E-cell_type
.	O

Purified	O
recombinant	O
Jun	B-protein
and	I-protein
Fos	I-protein
proteins	E-protein
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	B-DNA
motif	E-DNA
.	O

The	O
data	O
demonstrate	O
that	O
the	O
IL-10R	S-protein
,	O
unlike	O
other	O
members	O
of	O
the	O
interferon	O
receptor	O
family	O
,	O
is	O
highly	O
effective	O
in	O
recruiting	O
the	O
signaling	O
pathways	O
of	O
IL-6-type	B-protein
cytokine	I-protein
receptors	E-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-protein
B	E-protein
in	O
U937	S-cell_line
and	O
THP-1	B-cell_line
cells	E-cell_line
.	O

The	O
involvement	O
of	O
the	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	E-protein
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	E-protein
antagonist	O
PD-135	O
,	O
158	O
.	O

The	O
catalytic	B-protein
domain	E-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	E-protein
,	O
but	O
not	O
its	O
regulatory	B-protein
domain	E-protein
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	S-protein
production	O
.	O

A20	O
can	O
be	O
regulated	O
by	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	E-protein
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	B-protein
LMP-1	I-protein
protein	E-protein
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD-responsive	B-DNA
genes	E-DNA
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi-1	B-cell_line
cells	E-cell_line
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

Interleukin-6	S-protein
protein	O
and	O
IL-6	B-RNA
mRNA	E-RNA
were	O
measured	O
in	O
control	O
and	O
CMV	B-cell_type
immediate	I-cell_type
early	I-cell_type
transfected	I-cell_type
cells	E-cell_type
.	O

GR	S-protein
binding	O
parameters	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
(	O
Kd	O
8.98	O
+/-	O
1.07	O
nM	O
,	O
Bmax	O
183	O
+/-	O
29.8	O
fmol/mg	O
)	O
and	O
controls	O
(	O
Kd	O
9.36	O
+/-	O
1.17	O
nM	O
,	O
Bmax	O
158	O
+/-	O
16	O
fmol/mg	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
NF-kappa	B-protein
B	E-protein
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10-15	O
min	O
,	O
and	O
returning	O
to	O
near-basal	O
levels	O
by	O
30	O
min	O
.	O

Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
the	O
ETS	B-protein
protein	I-protein
Elf-1	E-protein
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
(	O
NF-AT	S-protein
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	B-DNA
enhancer	E-DNA
and	O
to	O
an	O
NF-AT-like	B-DNA
response	I-DNA
element	E-DNA
present	O
in	O
the	O
IL4	B-DNA
enhancer	E-DNA
was	O
abnormal	O
.	O

Oct-1	S-protein
and	O
Oct-2	S-protein
are	O
human	O
transcriptional	B-protein
activators	E-protein
that	O
bind	O
to	O
the	O
same	O
DNA	O
element	O
but	O
activate	O
distinct	O
sets	O
of	O
genes	O
.	O

C5a-induced	O
reporter	B-DNA
gene	E-DNA
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	B-DNA
sites	E-DNA
and	O
by	O
coexpression	O
of	O
a	O
dominant	B-DNA
negative	I-DNA
IkappaBalpha	I-DNA
construct	E-DNA
resistant	O
to	O
agonist-induced	O
phosphorylation	O
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	B-DNA
IL-2-responsive	I-DNA
element	E-DNA
(	O
mIL-2rE	S-DNA
)	O
.	O

The	O
inability	O
of	O
prolonged	O
stimulation	O
of	O
conventional	O
B-2	B-cell_type
cells	E-cell_type
with	O
anti-Ig	S-protein
,	O
a	O
treatment	O
sufficient	O
to	O
induce	O
CD5	S-protein
expression	O
,	O
to	O
result	O
in	O
sustained	O
STAT3	S-protein
activation	O
suggests	O
that	O
STAT3	S-protein
is	O
a	O
specific	O
nuclear	O
marker	O
for	O
B-1	B-cell_type
cells	E-cell_type
.	O

In	O
this	O
study	O
on	O
the	O
number	O
and	O
function	O
of	O
GR	S-protein
in	O
lymphocytes	S-cell_type
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
relation	O
between	O
the	O
functionality	O
of	O
the	O
GR	S-protein
and	O
the	O
development	O
of	O
NRDS	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	S-DNA
sequence	O
has	O
an	O
AP1-binding	B-DNA
site	E-DNA
and	O
is	O
associated	O
with	O
an	O
NF-AT-like	B-protein
factor	E-protein
,	O
termed	O
NF-CLE0	B-protein
gamma	E-protein
.	O

Cross-linking	O
of	O
CD30	S-protein
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	B-cell_type
cells	E-cell_type
.	O

The	O
nature	O
of	O
CD40	S-protein
-dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	B-cell_line
Epstein-Barr	I-cell_line
virus-negative	I-cell_line
B	I-cell_line
lymphocytes	E-cell_line
is	O
currently	O
unknown	O
.	O

The	O
phosphorylation	O
of	O
CREB	S-protein
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	B-protein
kinase	I-protein
C	E-protein
rather	O
than	O
by	O
protein	B-protein
kinase	I-protein
A	E-protein
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNFalpha	S-protein
,	O
a	O
proinflammatory	B-protein
cytokine	E-protein
)	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	E-protein
(	O
an	O
anti-inflammatory	B-protein
cytokine	E-protein
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	B-cell_type
monocytes	I-cell_type
/macrophages	E-cell_type
to	O
glucocorticoids	O
.	O

DNA-binding	O
studies	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	E-protein
(	O
EBNA-2	S-protein
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	B-protein
membrane	I-protein
protein	I-protein
gene	I-protein
promoter-binding	I-protein
proteins	E-protein
in	O
EBNA-2-positive	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin-1	S-protein
,	O
or	O
double-stranded	B-RNA
RNA	E-RNA
,	O
I	B-protein
kappaB	I-protein
alpha	E-protein
is	O
not	O
degraded	O
,	O
as	O
a	O
result	O
of	O
an	O
absence	O
of	O
induced	O
phosphorylation	O
on	O
serines	O
32	O
and	O
36	O
.	O

When	O
the	O
cells	O
were	O
exposed	O
to	O
increasing	O
concentrations	O
of	O
tetracyclines	O
,	O
surface	O
expression	O
of	O
the	O
chimeric	B-protein
receptor	E-protein
was	O
suppressed	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
this	O
suppression	O
was	O
sufficient	O
to	O
result	O
in	O
complete	O
loss	O
of	O
responsiveness	O
to	O
the	O
targeted	B-protein
Ag	E-protein
.	O

Viral	O
DNA	O
synthesis	O
and	O
late	O
gene	O
expression	O
were	O
found	O
to	O
be	O
defective	O
in	O
U937	B-cell_line
cells	E-cell_line
infected	O
with	O
E1B	B-protein
19K	E-protein
mutants	O
compared	O
with	O
wild-type	O
virus	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co-transfection	O
of	O
HIV-1	B-DNA
LTR	I-DNA
reporter	I-DNA
constructs	E-DNA
in	O
a	O
different	O
T	B-cell_line
cell	I-cell_line
line	E-cell_line
demonstrated	O
that	O
v-src	S-DNA
activated	O
this	O
promoter	S-protein
in	O
a	O
kappa	O
B-dependent	O
manner	O
.	O

Finally	O
,	O
an	O
abbreviated	B-DNA
TSP	I-DNA
1	I-DNA
promoter/5'-flank	E-DNA
,	O
containing	O
the	O
SRE-	B-DNA
and	I-DNA
NF-Y-binding	I-DNA
sites	E-DNA
,	O
mediated	O
a	O
serum	O
response	O
that	O
was	O
close	O
in	O
magnitude	O
to	O
that	O
of	O
the	O
parent	B-DNA
promoter	E-DNA
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
role	O
of	O
HTLV-I	B-protein
TaxI	E-protein
in	O
the	O
up-regulation	O
of	O
ICAM-I	S-protein
and	O
LFA-3	S-protein
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
transformed	O
with	O
HTLV-I	O
and	O
the	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	S-protein
and	O
LFA-I	S-protein
in	O
ATL-derived	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	B-protein
channels	E-protein
in	O
T	B-cell_type
cells	E-cell_type
by	O
progesterone	O
contributes	O
to	O
progesterone-induced	O
immunosuppression	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct-2	B-DNA
gene	E-DNA
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct-1	S-protein
was	O
unaffected	O
.	O

Clusters	O
of	O
genes	S-DNA
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	B-cell_type
cells	E-cell_type
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O

The	O
DNA	O
and	O
steroid	B-protein
binding	I-protein
domains	E-protein
of	O
the	O
glucocorticoid	B-protein
receptor	E-protein
are	O
not	O
altered	O
in	O
mononuclear	B-cell_type
cells	E-cell_type
of	O
treated	O
CLL	O
patients	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well-known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O

We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O

In	O
attempting	O
to	O
investigate	O
its	O
effect	O
on	O
activation	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
,	O
we	O
found	O
triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	B-cell_line
cell	I-cell_line
hybridomas	E-cell_line
and	O
peripheral	B-cell_type
T	I-cell_type
cells	E-cell_type
but	O
not	O
that	O
of	O
thymocytes	S-cell_type
.	O

Activated	O
ras	S-protein
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	S-protein
stimulation	O
in	O
activation	O
of	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NF-AT	E-protein
.	O

In	O
addition	O
,	O
a	O
significant	O
correlation	O
was	O
noted	O
between	O
the	O
degree	O
of	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50	O
)	O
and	O
the	O
binding	O
affinity	O
of	O
dexamethasone	O
to	O
the	O
GCR	S-protein
.	O

Elf-1	S-protein
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	S-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	E-cell_type
apoptosis	O
,	O
and	O
the	O
B-cell	B-protein
lymphoma/leukemia-2	I-protein
gene	I-protein
product	E-protein
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant-dependent	O
manner	O
.	O

IL-12	S-protein
-induced	O
activation	O
of	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	E-cell_type
occurs	O
in	O
the	O
absence	O
of	O
immediate-early	B-DNA
activation	I-DNA
gene	E-DNA
expression	O
.	O

Interleukin-10	S-protein
and	O
transforming	B-DNA
growth	I-DNA
factor-beta	I-DNA
promoter	I-DNA
polymorphisms	E-DNA
in	O
allergies	O
and	O
asthma	O
.	O

A	O
novel	O
B-cell	B-protein
lineage-specific	I-protein
transcription	I-protein
factor	E-protein
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O
differentiation	O
.	O

T.	B-cell_type
annulata-infected	I-cell_type
leucocytes	E-cell_type
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	S-protein
activities	O
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	B-cell_type
and	I-cell_type
0-lymphocytes	E-cell_type
.	O

In	O
the	O
first	O
patients	O
studied	O
,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B-protein
kDa	I-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	E-protein
by	O
Western	O
blotting	O
using	O
the	O
PL/IM	B-protein
430	I-protein
monoclonal	I-protein
antibody	E-protein
which	O
specifically	O
recognized	O
this	O
isoform	O
.	O

When	O
this	O
membrane-proximal	B-protein
TRAF6	I-protein
interaction	I-protein
domain	E-protein
was	O
deleted	O
,	O
RANK	S-protein
-mediated	O
NF-kappaB	S-protein
signaling	O
was	O
completely	O
inhibited	O
while	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	E-protein
activation	O
was	O
partially	O
inhibited	O
.	O

BACKGROUND	O
:	O
We	O
reported	O
on	O
the	O
constitutive	O
interferon-gamma	B-protein
receptor	E-protein
(	O
IFN-gammaR	S-protein
)	O
expression	O
on	O
eosinophils	S-cell_type
.	O

Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1/Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL-12	S-protein
and	O
IL-4	S-protein
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-DNA
site	E-DNA
at	O
-150	B-DNA
bp	E-DNA
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	S-protein
responsiveness	O
in	O
the	O
IL-2	B-DNA
promoter	E-DNA
.	O

The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	B-cell_type
cells	E-cell_type
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	B-protein
alpha	E-protein
expression	O
increased	O
in	O
H9	S-cell_line
and	O
U937	B-cell_line
cells	E-cell_line
but	O
not	O
in	O
CEM	B-cell_line
cells	E-cell_line
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	S-protein
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c-jun	B-RNA
mRNA	E-RNA
by	O
okadaic	O
acid	O
.	O

In	O
the	O
case	O
of	O
IgE	S-protein
class	O
switching	O
,	O
IL-4	S-protein
activates	O
the	O
IgE	B-DNA
germline	I-DNA
promoter	E-DNA
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT6	E-protein
(	O
IL-4STAT	S-protein
)	O
with	O
a	O
responsive	B-DNA
DNA	I-DNA
element	E-DNA
in	O
the	O
proximal	B-DNA
region	E-DNA
of	O
the	O
promoter	S-DNA
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
,	O
protein	B-protein
kinase	I-protein
A	E-protein
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	E-protein
and	O
IL-6	B-RNA
mRNA	E-RNA
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

Surprisingly	O
,	O
G28-5	B-protein
sFv	E-protein
was	O
a	O
potent	O
CD40	B-protein
agonist	E-protein
that	O
rapidly	O
crosslinked	O
CD40	S-protein
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	O
CD40-Ig	S-protein
in	O
solution	O
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	S-protein
in	O
IL-4	B-DNA
gene	E-DNA
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O

Diffusible	B-protein
endothelial	I-protein
proteins	E-protein
such	O
as	O
soluble	O
E-selectin	S-protein
,	O
PAI-1	S-protein
and	O
vWf	S-protein
to	O
a	O
minimal	O
extent	O
,	O
increased	O
in	O
supernatants	O
from	O
HUVEC	S-cell_type
cocultured	O
for	O
24	O
h	O
with	O
prestimulated	O
THP-1	B-cell_line
cells	E-cell_line
.	O

Partial	O
sequences	O
from	O
exons	B-DNA
1-8	E-DNA
were	O
nearly	O
identical	O
to	O
the	O
published	O
sequence	O
of	O
the	O
human	B-RNA
ER	I-RNA
mRNA	E-RNA
.	O

Interleukin-12	S-protein
(	O
IL-12	S-protein
)	O
,	O
a	O
heterodimeric	B-protein
cytokine	E-protein
produced	O
by	O
activated	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	E-protein
production	O
and	O
in	O
the	O
generation	O
of	O
IFN-gamma-producing	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
(	I-cell_type
Th1	I-cell_type
)	I-cell_type
cells	E-cell_type
.	O

The	O
induction	O
of	O
STAT	S-protein
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B-protein
factor	E-protein
produced	O
by	O
the	O
activated	O
T	B-cell_type
cells	E-cell_type
.	O

Addition	O
of	O
activated	B-cell_type
platelets	E-cell_type
to	O
adherent	O
monocytes	S-cell_type
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
activation	O
.	O

This	O
was	O
associated	O
with	O
the	O
down-regulation	O
of	O
IL-12p40	B-RNA
mRNA	E-RNA
expression	O
.	O

These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF-R	S-protein
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O

We	O
conclude	O
that	O
increased	O
expression	O
of	O
GCR-beta	S-protein
is	O
cytokine	S-protein
inducible	O
and	O
may	O
account	O
for	O
GC	O
insensitivity	O
in	O
this	O
common	O
inflammatory	O
condition	O
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	S-protein
and	O
NFATc	S-protein
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	S-protein
activity	O
.	O

Optimal	O
T	O
cell	O
activation	O
requires	O
two	O
signals	O
,	O
one	O
generated	O
by	O
TCR	S-protein
and	O
another	O
by	O
the	O
CD28	B-protein
costimulatory	I-protein
receptor	E-protein
.	O

Rhom-2	B-RNA
mRNA	E-RNA
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

Moreover	O
,	O
ectopic	B-protein
Id1	E-protein
repressed	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	E-DNA
-directed	O
but	O
not	O
EA/S	S-DNA
-directed	O
MLV	O
transcription	O
in	O
lymphoid	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

The	O
regulation	O
of	O
collagenase	S-protein
expression	O
is	O
cell-type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	S-protein
expression	O
in	O
macrophages	S-cell_type
,	O
but	O
do	O
not	O
alter	O
fibroblast	B-protein
collagenase	E-protein
expression	O
.	O

Invariably	O
,	O
the	O
BCL-6	S-protein
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	E-DNA
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	B-DNA
partner	E-DNA
.	O

Tax	O
activates	O
the	O
GM-CSF	B-DNA
promoter	E-DNA
through	O
the	O
CK-1	B-DNA
/CD28RE	E-DNA
region	O
and	O
also	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
the	O
coiled-coil	O
region	O
of	O
Stat5b	S-protein
as	O
the	O
bait	O
in	O
a	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	S-protein
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N-Myc	S-protein
interactor	O
.	O

The	O
A	B-DNA
site	E-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	E-DNA
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	B-DNA
sites	E-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
AP-2	E-protein
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	B-DNA
gene	E-DNA
in	O
cell	B-cell_line
lines	E-cell_line
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease-free	O
survival	O
.	O

Corticosteroid	B-protein
receptors	E-protein
and	O
lymphocyte	B-cell_type
subsets	E-cell_type
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
in	O
aging	O
.	O

The	O
expression	O
of	O
AP-1	S-protein
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	S-protein
activation	O
.	O

We	O
have	O
identified	O
a	O
negative	B-DNA
regulatory	I-DNA
element	E-DNA
located	O
in	O
the	O
region	O
between	O
-685	B-DNA
and	I-DNA
-395	E-DNA
.	O

Our	O
results	O
indicate	O
that	O
p24rex	S-protein
of	O
HTLV-II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-DNA
gene	E-DNA
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

This	O
dephosphorylation	O
was	O
inhibited	O
by	O
treatment	O
of	O
T	B-cell_type
cells	E-cell_type
with	O
cyclosporin	O
A	O
or	O
FK506	O
prior	O
to	O
stimulation	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	B-protein
molecules	E-protein
.	O

Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	B-cell_type
monocytes	E-cell_type
.	O

In	O
addition	O
to	O
finding	O
hLH-2	S-DNA
expression	O
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	O
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
but	O
not	O
in	O
primary	O
cases	O
of	O
acute	O
myelogenous	O
leukaemia	O
.	O

We	O
further	O
characterize	O
which	O
AP1	B-protein
family	I-protein
members	E-protein
can	O
assume	O
this	O
role	O
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	B-DNA
region	E-DNA
of	O
the	O
human	B-DNA
retinoblastoma	I-DNA
gene	E-DNA
.	O

These	O
data	O
suggest	O
that	O
NF-kappa	B-protein
B	E-protein
may	O
be	O
an	O
important	O
molecular	O
mediator	O
of	O
Pb-induced	O
immunotoxicity	O
.	O

Effects	O
of	O
intranasal	O
glucocorticoids	O
on	O
endogenous	O
glucocorticoid	O
peripheral	O
and	O
central	O
function	O
.	O

Primer	O
extension	O
analysis	O
of	O
C/EBP-epsilon	B-RNA
mRNA	E-RNA
detected	O
a	O
single	O
major	O
transcription	B-DNA
start	I-DNA
site	E-DNA
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	B-DNA
codon	E-DNA
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	B-cell_type
marmoset	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	B-cell_type
lymphocytes	E-cell_type
and	O
rodent	B-cell_type
fibroblasts	E-cell_type
.	O

The	O
ZAP-70	S-protein
mutant	O
studied	O
here	O
could	O
be	O
phosphorylated	O
on	O
tyrosine	O
when	O
associated	O
to	O
the	O
TCR	B-protein
zeta	I-protein
chain	E-protein
and	O
was	O
able	O
to	O
bind	O
p56	B-protein
(	I-protein
lck	I-protein
)	E-protein
.	O

Thus	O
,	O
the	O
binding	O
of	O
V3	B-protein
loop	E-protein
of	O
gp120	S-protein
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL-2	S-protein
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2	S-protein
-induced	O
T	O
cell	O
growth	O

We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c-Fos	S-protein
and	O
c-Jun	S-protein
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
enhancer	O
activity	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	O
the	O
activation	O
of	O
PKC	O
.	O

Forced	O
expression	O
of	O
SOCS-1	S-DNA
in	O
a	O
macrophage	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
RAW264	S-cell_line
,	O
markedly	O
suppressed	O
trans-activation	O
of	O
an	O
IL-4-inducible	B-DNA
reporter	E-DNA
as	O
well	O
as	O
IL-6-	O
and	O
IFN-gamma-induced	O
reporter	O
gene	O
activity	O
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	I-protein
B	E-protein
,	O
NF-AT	S-protein
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	S-protein
response	O
element	O
of	O
the	O
IL-2	B-DNA
promoter	E-DNA
.	O

Thus	O
,	O
in	O
lymphocytes	S-cell_type
,	O
growth-affecting	B-DNA
genes	E-DNA
other	O
than	O
immune	B-protein
receptors	E-protein
risk	O
rearrangements	O
.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	S-protein
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.095	O
)	O
.	O

The	O
function	O
of	O
SSB	B-cell_line
T	I-cell_line
cells	E-cell_line
in	O
controls	O
remains	O
to	O
be	O
defined	O
.	O

We	O
also	O
found	O
that	O
IL-2	S-protein
protects	O
T	B-cell_line
cell	I-cell_line
clones	E-cell_line
from	O
IL-2	S-protein
deprivation	O
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
P53	S-protein
,	O
Rb	S-protein
and	O
Bcl-xL	B-protein
proteins	E-protein
.	O

NF-kappa	B-protein
B	E-protein
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

We	O
reported	O
here	O
that	O
the	O
E1B	B-protein
19K	E-protein
mutant	O
viruses	O
were	O
unable	O
to	O
replicate	O
efficiently	O
in	O
a	O
monocyte	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
U937	S-cell_line
.	O

In	O
nonlymphoid	B-cell_type
cells	E-cell_type
,	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	E-protein
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	B-protein
antigens	E-protein
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

Binding	O
of	O
the	O
four	O
complexes	O
to	O
CRE	S-DNA
is	O
prevented	O
by	O
dephosphorylation	O
of	O
nuclear	O
extracts	O
and	O
is	O
restored	O
by	O
rephosphorylation	O
with	O
cAMP-dependent	B-protein
protein	I-protein
kinase	E-protein
or	O
endogenous	B-protein
kinases	E-protein
.	O

Although	O
all	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
had	O
seroconverted	O
to	O
Ad5	O
,	O
virus	O
was	O
not	O
detected	O
in	O
these	O
groups	O
either	O
by	O
viral	O
plaque	O
assay	O
or	O
in	O
situ	O
hybridization	O
.	O

PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	B-cell_line
cells	E-cell_line
acts	O
in	O
inducing	O
NF-KB	S-protein
expression	O
in	O
the	O
nuclei	O
.	O

Reactivation	O
of	O
Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	B-protein
50	I-protein
transactivator	E-protein
,	O
a	O
homolog	O
of	O
the	O
EBV	B-protein
R	I-protein
protein	E-protein
.	O

This	O
minimal	B-DNA
promoter	E-DNA
exhibits	O
B-cell-specific	O
activity	O
and	O
contains	O
SP1	B-DNA
,	I-DNA
ETS	I-DNA
,	I-DNA
OCT	I-DNA
,	I-DNA
and	I-DNA
IKAROS/LYF-1	I-DNA
transcription	I-DNA
factor	I-DNA
motifs	E-DNA
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	E-protein
(	O
EBNA2	S-protein
)	O
,	O
a	O
protein	O
involved	O
in	O
cell	O
transformation	O
,	O
interferes	O
with	O
the	O
cellular	O
response	O
to	O
type	B-protein
I	I-protein
interferons	E-protein
(	O
IFN-alpha/beta	S-protein
)	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
IL-2	S-protein
regulates	O
transcription	O
of	O
different	O
genes	O
is	O
presently	O
unknown	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	S-protein
at	O
serine	O
133	O
.	O

Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	S-cell_type
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O

Furthermore	O
,	O
CD28	S-protein
-dependent	O
elevation	O
of	O
c-jun	B-RNA
mRNA	E-RNA
does	O
not	O
appear	O
to	O
be	O
mediated	O
at	O
the	O
level	O
of	O
mRNA	O
stability	O
.	O

In	O
this	O
study	O
,	O
we	O
cloned	O
two	O
cDNAs	S-DNA
encoding	O
proteins	O
which	O
bind	O
to	O
an	O
oligonucleotide	O
in	O
silencer	B-DNA
I	E-DNA
containing	O
a	O
BP1	S-protein
binding	O
site	O
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	S-protein
-activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	B-protein
kinase	E-protein
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	S-protein
.	O

Two	O
of	O
these	O
DESTs	S-DNA
,	O
GIG10	S-DNA
and	O
GIG18	S-DNA
,	O
are	O
rapidly	O
induced	O
by	O
dexamethasone	O
within	O
2	O
h	O
of	O
treatment	O
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10-fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	S-protein
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome	S-protein
-dependent	O
cytoplasmic-to-nuclear	O
localization	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor-kappa	I-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
subunit	E-protein
.	O

Transcription	B-protein
factor	I-protein
GATA-1	E-protein
and	O
erythroid	O
development	O
.	O

Here	O
we	O
identify	O
the	O
cell	B-protein
cycle	I-protein
regulator	I-protein
E2F	E-protein
as	O
an	O
IL-2	S-protein
target	O
in	O
T	O
lymphocytes	S-cell_type
and	O
PI3K	S-protein
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

5-LOX	S-protein
and	O
5-LOX	B-protein
activating	I-protein
protein	E-protein
(	O
FLAP	S-protein
)	O
are	O
coexpressed	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
but	O
not	O
in	O
monocytic	B-cell_type
or	I-cell_type
epithelial	I-cell_type
cells	E-cell_type
.	O

Moreover	O
,	O
anti-	O
STAT3	B-protein
antibodies	E-protein
specifically	O
precipitated	O
a	O
protein	O
of	O
92	B-protein
kDa	E-protein
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O

Although	O
several	O
class	B-protein
II	I-protein
promoter-specific	I-protein
DNA	I-protein
binding	I-protein
factors	E-protein
have	O
been	O
described	O
,	O
only	O
the	O
X	B-DNA
box	I-DNA
region	E-DNA
factor	O
,	O
RFX	S-protein
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
derived	O
from	O
patients	O
with	O
class	O
II-deficient	O
congenital	O
immunodeficiency	O
.	O

TNF-alpha	B-RNA
mRNA	E-RNA
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL-10	S-protein
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O

Tax	S-protein
,	O
the	O
viral	B-protein
protein	E-protein
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	B-cell_type
T	I-cell_type
cells	E-cell_type
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O

Thus	O
,	O
the	O
ability	O
of	O
HIV-1	O
replication	O
to	O
activate	O
NF-kappaB	S-protein
is	O
crucial	O
to	O
the	O
intense	O
self-perpetuated	O
viral	O
transcription	O
observed	O
in	O
cells	O
of	O
the	O
monocytic	B-cell_type
lineage	E-cell_type
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF-kappaB	S-protein
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF-kappaB	S-protein
formation	O
.	O

The	O
carboxyl	B-protein
portion	E-protein
of	O
Sp140	S-protein
contained	O
a	O
zinc-finger	B-protein
domain	E-protein
and	O
a	O
bromodomain	S-protein
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

In	O
addition	O
to	O
its	O
well-recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	S-cell_type
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O

These	O
data	O
indicated	O
that	O
c-Fos	B-protein
/c-Jun	E-protein
,	O
c-Rel	B-protein
/p65	E-protein
,	O
and	O
Sp1	S-protein
regulate	O
TF	B-DNA
gene	E-DNA
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
.	O

Through	O
the	O
same	O
or	O
a	O
reciprocal	O
mechanism	O
,	O
states	O
associated	O
with	O
chronic	O
hyperactivity	O
or	O
hypoactivity	O
of	O
the	O
stress	O
system	O
might	O
influence	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
certain	O
autoimmune	O
,	O
allergic	O
,	O
infectious	O
,	O
or	O
neoplastic	O
diseases	O
.	O

These	O
results	O
indicate	O
that	O
Fc	B-protein
gamma	I-protein
R	E-protein
can	O
mediate	O
a	O
TNF-alpha	S-protein
-dependent	O
induction	O
of	O
HIV-1	B-DNA
gene	E-DNA
transcription	O
and	O
suggest	O
that	O
immune	B-protein
complexes	E-protein
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	S-cell_type
.	O

We	O
detected	O
binding	O
for	O
the	O
EWS/FLI-1	O
peptide	O
and	O
for	O
5	O
RAS	O
peptides	O
(	O
1	O
wild	O
type	O
and	O
4	O
mutated	O
)	O
.	O

The	O
regulation	O
of	O
IL-6	S-protein
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	S-protein
.	O

Altogether	O
,	O
the	O
CD4	B-DNA
gene	E-DNA
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	S-protein
ligation	O
by	O
mAb	S-protein
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	S-protein
-sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	S-protein
in	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Recently	O
it	O
has	O
become	O
clear	O
that	O
these	O
cytokines	S-protein
activate	O
a	O
number	O
of	O
important	O
intracellular	B-protein
signaling	I-protein
molecules	E-protein
,	O
including	O
the	O
Janus	B-protein
kinases	I-protein
JAK1	E-protein
and	O
JAK3	S-protein
and	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
family	E-protein
of	O
signal	B-protein
transducers	E-protein
and	O
activators	B-protein
of	I-protein
transcription	E-protein
(	O
STATs	S-protein
)	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	B-protein
binding	I-protein
complex	E-protein
of	O
NF-kappaB	B-protein
subunits	E-protein
(	O
c-Rel	S-protein
and	O
p65	S-protein
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV-LTR-kappaB	B-DNA
site	E-DNA
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c-Rel	S-protein
and	O
p50	S-protein
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	B-cell_line
T-lymphoid	I-cell_line
HTLV-II	I-cell_line
infected	I-cell_line
cells	E-cell_line
.	O

FK506.FKBP12	O
drug-immunophilin	O
complexes	O
inhibited	O
the	O
interaction	O
of	O
NFAT	S-protein
with	O
activated	O
calcineurin	S-protein
much	O
more	O
effectively	O
than	O
they	O
inhibited	O
the	O
interaction	O
with	O
inactive	O
calcineurin	S-protein
,	O
suggesting	O
that	O
part	O
of	O
the	O
interaction	O
with	O
activated	O
calcineurin	S-protein
involved	O
the	O
enzyme	B-DNA
active	I-DNA
site	E-DNA
.	O

Stimulation	O
of	O
mature	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	E-cell_type
by	O
TCR	S-protein
engagement	O
results	O
in	O
activation	O
of	O
signals	O
that	O
drive	O
induction	O
of	O
cytokine	S-protein
gene	O
expression	O
and	O
clonal	O
expansion	O
.	O

Additional	O
work	O
,	O
employing	O
sequential	O
and	O
internal	O
deletions	O
of	O
ZEBRA	S-protein
's	O
N-terminal	B-protein
activation	I-protein
domain	E-protein
,	O
indicates	O
that	O
its	O
separate	O
activities	O
are	O
not	O
attributable	O
to	O
specific	O
subdomains	S-protein
but	O
are	O
spread	O
throughout	O
its	O
N	B-protein
terminus	E-protein
and	O
therefore	O
can	O
not	O
be	O
inactivated	O
by	O
deleting	O
localized	O
regions	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	O
in	O
the	O
regulation	O
of	O
c-fos/c-jun	S-DNA
at	O
the	O
mRNA	O
or	O
protein	O
level	O
might	O
underlie	O
the	O
age-associated	O
impairments	O
of	O
AP-1	S-protein
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

No	O
biological	O
function	O
has	O
yet	O
been	O
described	O
for	O
Bcl-3	S-protein
,	O
but	O
it	O
was	O
noted	O
recently	O
that	O
Bcl-3	S-protein
interferes	O
with	O
DNA-binding	O
of	O
the	O
p50	B-protein
subunit	E-protein
of	O
NF-kappa	B-protein
B	E-protein
in	O
vitro	O
.	O

Although	O
p45	B-RNA
mRNA	E-RNA
is	O
transcribed	O
from	O
two	O
different	O
promoters	O
,	O
aNF-E2	B-DNA
promoter	E-DNA
and	O
fNF-E2	B-DNA
promoter	E-DNA
,	O
in	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineage	I-cell_type
cells	E-cell_type
,	O
p45	B-RNA
mRNA	E-RNA
is	O
transcribed	O
only	O
from	O
aNF-E2	B-DNA
promoter	E-DNA
.	O

Steroid	O
mediated	O
lysis	O
of	O
lymphoblasts	S-cell_type
requires	O
the	O
DNA	O
binding	O
region	O
of	O
the	O
steroid	O
hormone	O
receptor	O
.	O

As	O
such	O
it	O
serves	O
as	O
a	O
good	O
prototype	O
for	O
B	B-DNA
cell-specific	I-DNA
genes	E-DNA
whose	O
expression	O
begins	O
shortly	O
after	O
lineage	O
commitment	O
.	O

The	O
concentration	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
c-myc	I-RNA
,	I-RNA
junB	I-RNA
,	I-RNA
and	I-RNA
fra-1	I-RNA
mRNAs	E-RNA
was	O
increased	O
in	O
activated	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
that	O
in	O
untreated	O
controls	O
.	O

Leukocyte	B-protein
integrins	E-protein
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O

Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O

Among	O
these	O
sequences	O
we	O
have	O
identified	O
the	O
alpha-tubulin	S-protein
,	O
the	O
TaxREB	B-protein
protein	E-protein
and	O
two	O
ribosomal	B-DNA
protein	I-DNA
sequences	E-DNA
which	O
had	O
not	O
been	O
previously	O
described	O
as	O
differentially	O
expressed	O
.	O

In	O
addition	O
,	O
both	O
SCL	S-protein
and	O
GATA-1	S-protein
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	B-cell_type
erythroleukemia	I-cell_type
cells	E-cell_type
and	O
are	O
down-modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
K562	I-cell_line
cells	E-cell_line
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	S-protein
in	O
erythroid	O
differentiation	O
events	O
.	O

The	O
expression	O
of	O
CD4	S-protein
,	O
a	O
marker	O
for	O
T-derived	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL-4Ralpha	B-protein
chain	E-protein
is	O
sufficient	O
to	O
transduce	O
Jak1	S-protein
-dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	B-protein
isotype	E-protein
switching	O
.	O

IL-1	B-DNA
beta	I-DNA
and	I-DNA
IL-6	I-DNA
genes	E-DNA
contain	O
AP-1	B-DNA
binding	I-DNA
sites	E-DNA
as	O
regulatory	B-DNA
elements	E-DNA
,	O
the	O
AP-1	S-protein
protein	O
being	O
composed	O
of	O
c-jun	B-protein
and	I-protein
c-fos	I-protein
gene	I-protein
products	E-protein
.	O

The	O
retinoblastoma	B-protein
gene	I-protein
product	E-protein
(	O
pRB	S-protein
)	O
plays	O
an	O
important	O
role	O
in	O
controlling	O
both	O
cell	O
release	O
from	O
the	O
G1	O
phase	O
and	O
apoptosis	O
.	O

Relative	O
expressions	O
of	O
SERCA	S-protein
2	O
and	O
3	O
isoforms	O
and	O
Ras-related	B-protein
protein	I-protein
(	I-protein
Rap	I-protein
)	I-protein
1	E-protein
in	O
platelet	O
membranes	O
were	O
determined	O
by	O
Western	O
immunoblots	O
.	O

In	O
fact	O
,	O
8e51	B-cell_line
cells	E-cell_line
that	O
had	O
almost	O
lost	O
their	O
syncytia-forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF-kappaB	B-protein
DNA-binding	I-protein
complex	E-protein
than	O
the	O
actively	B-cell_type
fusing	I-cell_type
cells	E-cell_type
.	O

Characterization	O
of	O
a	O
mutant	B-cell_line
cell	I-cell_line
line	E-cell_line
that	O
does	O
not	O
activate	O
NF-kappaB	S-protein
in	O
response	O
to	O
multiple	O
stimuli	O
.	O

A	O
clinically	O
relevant	O
dose	O
(	O
25	O
mM	O
)	O
of	O
acute	O
ethanol	O
treatment	O
in	O
vitro	O
increased	O
NF-kappa	B-protein
B	E-protein
binding	O
activity	O
in	O
monocytes	S-cell_type
with	O
a	O
preferential	O
induction	O
of	O
the	O
inhibitory	O
,	O
p50/p50	S-protein
,	O
NF-kappa	B-protein
B/Rel	I-protein
homodimer	E-protein
,	O
and	O
resulted	O
in	O
no	O
induction	O
of	O
the	O
p65/p50	B-protein
heterodimer	E-protein
.	O

PGG-glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1	O
,	O
3	O
)	O
-glucan	O
,	O
enhances	O
the	O
oxidative	O
burst	O
response	O
,	O
microbicidal	O
activity	O
,	O
and	O
activates	O
an	O
NF-kappa	B-protein
B-like	I-protein
factor	E-protein
in	O
human	B-cell_type
PMN	E-cell_type
:	O
evidence	O
for	O
a	O
glycosphingolipid	B-protein
beta-	I-protein
(	I-protein
1	I-protein
,	I-protein
3	I-protein
)	I-protein
-glucan	I-protein
receptor	E-protein
.	O

Activation	O
of	O
STAT5	S-protein
by	O
IL-4	S-protein
relies	O
on	O
Janus	B-protein
kinase	E-protein
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O

Our	O
results	O
identify	O
a	O
molecular	O
switch	O
for	O
lineage	O
specification	O
in	O
early	B-cell_type
lymphoid	I-cell_type
precursors	E-cell_type
of	O
humans	O
.	O

Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21.7	O
+/-	O
5.1	O
fmol/mg	O
protein	O
,	O
mean	O
+/-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60.7	O
+/-	O
4.0	O
)	O
.	O

Since	O
both	O
these	O
proteins	O
become	O
phosphorylated	O
in	O
response	O
to	O
IL-4	B-protein
receptor	E-protein
stimulation	O
,	O
the	O
influence	O
of	O
tyrosine	O
phosphorylation	O
on	O
their	O
mutual	O
contact	O
was	O
analyzed	O
.	O

T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
/CD3	E-protein
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
(	O
NFAT	S-protein
)	O
,	O
activator	B-protein
protein-1	E-protein
(	O
AP-1	S-protein
)	O
,	O
and	O
nuclear	B-protein
factor	I-protein
kappaB	E-protein
(	O
NFkappaB	S-protein
)	O
,	O
whereas	O
the	O
CD28	B-protein
responsive	I-protein
complex	E-protein
(	O
CD28RC	S-protein
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	S-protein
signal	O
.	O

The	O
Bcd	B-DNA
gene	E-DNA
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
growth	O
and	O
development	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
TCR	S-protein
-stimulated	O
apoptosis	O
requires	O
expression	O
of	O
CD95	B-protein
ligand	E-protein
on	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
followed	O
by	O
an	O
interaction	O
between	O
CD95	B-protein
ligand	E-protein
and	O
the	O
CD95	B-protein
receptor	E-protein
also	O
expressed	O
on	O
this	O
population	O
.	O

The	O
NR2	B-cell_line
hybrid	E-cell_line
allowed	O
us	O
to	O
exclude	O
three	O
candidate	B-DNA
genes	E-DNA
for	O
AGS	O
:	O
hepatic	B-DNA
nuclear	I-DNA
factor	I-DNA
3	I-DNA
beta	E-DNA
(	O
HNF3	B-DNA
beta	E-DNA
)	O
,	O
paired	B-DNA
box	I-DNA
1	E-DNA
(	O
PAX1	S-DNA
)	O
,	O
and	O
cystatin	B-DNA
C	E-DNA
(	O
CST3	S-DNA
)	O
as	O
shown	O
by	O
their	O
localization	O
outside	O
of	O
the	O
deletion	O
.	O

We	O
show	O
that	O
PRE-I	S-DNA
interacts	O
with	O
PMA	O
-and	O
PMA/ionomycin-inducible	O
,	O
cyclosporin	O
A-sensitive	O
nuclear	B-protein
factors	E-protein
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	S-protein
in	O
PHA-activated	B-cell_line
peripheral	I-cell_line
mononuclear	I-cell_line
cells	E-cell_line
from	O
10	O
XLH	O
patients	O
.	O

RESULTS	O
:	O
Co-culture	O
of	O
NK	B-cell_type
cells	E-cell_type
with	O
transfected	O
EC	S-cell_type
enhanced	O
E-selectin	S-protein
,	O
IL-8	S-protein
,	O
and	O
NF-kappaB	S-protein
-dependent	O
promoter	O
activity	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
STAT	O
proteins	O
during	O
growth	O
and	O
differentiation	O
of	O
granulocytes	O
,	O
we	O
evaluated	O
differentiation	O
of	O
human	B-cell_line
CD34+	I-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	E-cell_line
ex	O
vivo	O
toward	O
eosinophils	S-cell_type
and	O
neutrophils	O
.	O

Here	O
we	O
provide	O
evidence	O
showing	O
that	O
15	O
amino	O
acids	O
in	O
the	O
carboxyl-terminal	B-protein
end	E-protein
of	O
NFATx1	S-protein
are	O
required	O
for	O
its	O
maximum	O
transactivation	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O

Rapid	O
shuttling	O
of	O
NF-AT	S-protein
in	O
discrimination	O
of	O
Ca2+	O
signals	O
and	O
immunosuppression	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
PBMC	S-cell_type
of	O
11	O
women	O
with	O
advanced	O
chronic	O
renal	O
failure	O
(	O
A-CRF	O
)	O
,	O
6	O
women	O
with	O
mild-moderate	O
renal	O
insufficiency	O
(	O
M-CRF	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O

Transcripts	O
encoding	O
gp350/220	S-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	E-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	S-DNA
or	O
EBER-1	B-DNA
loci	E-DNA
in	O
infected	O
thymocytes	S-cell_type
.	O

A	O
protein	O
of	O
the	O
AP-1	B-protein
family	E-protein
is	O
a	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
.	O

Inhibition	O
of	O
protein	B-protein
phosphatase	I-protein
2A	E-protein
induces	O
serine/threonine	O
phosphorylation	O
,	O
subcellular	O
redistribution	O
,	O
and	O
functional	O
inhibition	O
of	O
STAT3	S-protein
.	O

These	O
observations	O
imply	O
that	O
during	O
persistent	O
infection	O
Ad5	O
underwent	O
spontaneous	O
mutations	O
by	O
sequence-specific	O
breakage	O
and	O
nonhomologous	O
end-end	O
joining	O
recombination	O
events	O
.	O

The	O
rate	O
of	O
LTR	S-DNA
-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
if	O
either	O
the	O
NFAT-1	S-protein
or	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	E-DNA
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
phenotype	O
of	O
mouse	B-cell_line
transgenic	I-cell_line
lines	E-cell_line
obtained	O
by	O
inducing	O
tal-1	B-protein
protein	E-protein
expression	O
in	O
lymphoid	O
tissues	O
using	O
the	O
LCK	B-DNA
promoter	E-DNA
.	O

This	O
process	O
requires	O
calcium-dependent	O
dephosphorylation	O
of	O
NFAT	S-protein
caused	O
by	O
the	O
phosphatase	B-protein
calcineurin	E-protein
.	O

The	O
synergistic	O
effect	O
on	O
growth	O
inhibition	O
and	O
induction	O
of	O
differentiation	O
required	O
simultaneous	O
treatment	O
with	O
differanisole	O
A	O
and	O
9cisRA	O
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	E-cell_type
.	O

This	O
phenotype	O
is	O
distinct	O
from	O
that	O
of	O
G-CSF	O
receptor-/-	O
mice	O
,	O
suggesting	O
that	O
other	O
genes	O
are	O
likely	O
to	O
be	O
adversely	O
affected	O
by	O
loss	O
of	O
C/EBPalpha	S-protein
.	O

The	O
constitutive	O
NF-kappa	B-protein
B	E-protein
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	B-RNA
necrosis	I-RNA
factor	I-RNA
(	I-RNA
TNF	I-RNA
)	I-RNA
transcript	E-RNA
is	O
detectable	O
in	O
monocytes	S-cell_type
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

Using	O
the	O
[	O
3H	O
]	O
thymidine	O
proliferation	O
assay	O
,	O
we	O
determined	O
reactivity	O
to	O
purified	B-protein
recombinant	I-protein
SSB	E-protein
(	O
rSSB	S-protein
)	O
in	O
20	O
patients	O
with	O
SS	O
and	O
19	O
controls	O
.	O

As	O
a	O
first	O
step	O
in	O
understanding	O
the	O
mechanism	O
of	O
decreased	O
binding	O
affinity	O
in	O
New	O
World	O
primates	O
,	O
we	O
used	O
reverse	O
transcription-PCR	O
to	O
clone	O
the	O
glucocorticoid	B-protein
receptor	E-protein
from	O
squirrel	O
monkey	O
liver	O
and	O
have	O
compared	O
the	O
sequence	O
to	O
receptor	O
sequences	O
obtained	O
from	O
owl	O
monkey	O
liver	O
,	O
cotton-top	B-cell_line
tamarin	I-cell_line
B95-8	I-cell_line
cells	E-cell_line
,	O
and	O
human	B-cell_type
lymphocytes	E-cell_type
.	O

This	O
effect	O
of	O
the	O
CMV	B-protein
immediate	I-protein
early	I-protein
1	I-protein
gene	I-protein
product	E-protein
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	E-DNA
in	O
the	O
IL-6	B-DNA
promoter	E-DNA
.	O

Stimulation	O
with	O
different	O
GC	O
at	O
therapeutic	O
concentrations	O
resulted	O
in	O
monocyte	O
apoptosis	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O

In	O
vitro	O
,	O
chronically	B-cell_line
HIV-infected	I-cell_line
cells	E-cell_line
of	O
the	O
lymphoid	B-cell_line
CEM	I-cell_line
line	E-cell_line
displayed	O
resistance	O
to	O
glucocorticoid-induced	O
apoptosis	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	S-protein
of	O
the	O
mapped	O
60	B-protein
residues	E-protein
leads	O
to	O
its	O
nuclear	O
translocation	O
independent	O
of	O
calcium	O
signaling	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	B-protein
family	E-protein
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	E-protein
.	O

Similar	O
repeat	B-protein
motifs	E-protein
are	O
found	O
in	O
a	O
number	O
of	O
diverse	B-protein
regulatory	I-protein
proteins	E-protein
but	O
the	O
motifs	O
of	O
Bcl-3	S-protein
are	O
most	O
closely	O
related	O
to	O
those	O
found	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	E-protein
in	O
which	O
the	O
ankyrin	B-protein
repeat	E-protein
domain	O
is	O
thought	O
to	O
be	O
directly	O
involved	O
in	O
inhibition	O
of	O
NF-kappa	B-protein
B	E-protein
activity	O
.	O

Some	O
evidence	O
suggests	O
that	O
the	O
LCR	S-DNA
and	O
the	O
beta-globin	B-DNA
promoter	E-DNA
interact	O
in	O
adult	B-cell_type
erythroid	I-cell_type
cells	E-cell_type
,	O
and	O
the	O
network	O
of	O
protein-protein	O
interactions	O
that	O
exists	O
between	O
these	O
two	O
elements	O
may	O
regulate	O
how	O
EKLF	S-protein
is	O
recruited	O
to	O
the	O
LCR	S-DNA
.	O

Immunocytochemical	O
analysis	O
of	O
MNDA	S-protein
in	O
tissue	O
sections	O
and	O
sorted	O
normal	O
bone	O
marrow	O
cells	O
documents	O
expression	O
only	O
in	O
maturing	O
normal	O
and	O
neoplastic	O
myelomonocytic	O
cells	O
and	O
a	O
subset	O
of	O
normal	O
and	O
neoplastic	O
B	O
lymphocytes	O
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	E-DNA
of	O
the	O
human	B-DNA
alpha-globin	I-DNA
gene	E-DNA
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B-DNA
sequence	E-DNA
for	O
the	O
Sp1	B-DNA
binding	I-DNA
site	E-DNA
.	O

Hence	O
,	O
we	O
have	O
investigated	O
whether	O
Stat	B-protein
proteins	E-protein
are	O
present	O
in	O
platelets	S-cell_type
and	O
,	O
if	O
so	O
,	O
whether	O
they	O
become	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
thrombopoietin	S-protein
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus-mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

Stimulation	O
of	O
activated	B-cell_type
LN	I-cell_type
cells	E-cell_type
with	O
D5	B-cell_type
tumor	I-cell_type
cells	E-cell_type
induced	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	S-protein
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF-kappa	B-protein
B	E-protein
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	B-protein
acetyl-transferase	E-protein
(	O
CAT	S-protein
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	E-DNA
in	O
uninfected	B-cell_type
cells	E-cell_type
.	O

The	O
kinases	O
that	O
couple	O
ligand	O
binding	O
to	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
substrates	E-protein
by	O
the	O
G-CSFR	O
with	O
activation	O
of	O
specific	O
functional	O
programs	O
are	O
largely	O
unknown	O
.	O

These	O
results	O
show	O
that	O
IL-2	S-protein
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF-kappaB	S-protein
in	O
primary	B-cell_line
CD8+	I-cell_line
T-PLL	I-cell_line
cells	E-cell_line
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O

Dominant	B-protein
negative	I-protein
mutants	E-protein
of	O
NIK	S-protein
,	O
IKKalpha	S-protein
,	O
or	O
IKKbeta	S-protein
substantially	O
inhibited	O
NF-kappaB	S-protein
activation	O
by	O
LMP1	S-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	E-protein
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	S-protein
with	O
each	O
STAT5	B-protein
isomer	E-protein
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	E-DNA
(	O
kappa	B-DNA
E3	I-DNA
'	E-DNA
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	B-DNA
and	I-DNA
negative-acting	I-DNA
elements	E-DNA
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix-turn-helix	O
transcription	B-protein
factor	E-protein
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein-DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	S-protein
,	O
a	O
protein	B-protein
kinase	I-protein
A/protein	I-protein
kinase	I-protein
C	I-protein
inhibitor	E-protein
,	O
blocked	O
c-fos	S-DNA
induction	O
,	O
whereas	O
no	O
effect	O
was	O
observed	O
with	O
bisindolylmaleimide	O
,	O
a	O
specific	O
protein	B-protein
kinase	I-protein
C	E-protein
inhibitor	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	E-protein
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	B-protein
antigen	E-protein
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	E-cell_type
.	O

Although	O
CD40	B-protein
ligand	E-protein
(	O
CD40L	S-protein
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	S-protein
and	O
proliferation	O
of	O
B	B-cell_type
cells	E-cell_type
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	S-protein
to	O
CD40L	S-protein
-treated	O
B	B-cell_type
cells	E-cell_type
does	O
not	O
alter	O
either	O
pRB	S-protein
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	B-cell_line
cells	E-cell_line
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P-like	B-DNA
elements	E-DNA
and	O
their	O
binding	B-protein
factors	E-protein
in	O
the	O
native	B-DNA
promoter	E-DNA
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	B-cell_type
macrophages	E-cell_type
,	O
suppressed	O
activation	O
of	O
lung	B-protein
NF-kappaB	E-protein
in	O
the	O
inflammatory	O
model	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	E-protein
(	O
RAR	B-protein
alpha	E-protein
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

To	O
propel	O
itself	O
in	O
infected	B-cell_type
cells	E-cell_type
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	S-protein
-controlled	O
machinery	O
responsible	O
for	O
actin	S-protein
assembly	O
during	O
filopodia	O
formation	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
promonocytic	B-cell_line
THP-1	I-cell_line
cells	E-cell_line
require	O
prestimulation	O
in	O
order	O
to	O
activate	O
HUVEC	S-cell_type
and	O
that	O
TNF	B-protein
alpha	E-protein
contributes	O
to	O
this	O
phenomenon	O
.	O

This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen-processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	E-protein
much	O
less	O
immunogenic	O
.	O

The	O
induction	O
of	O
AP-1	S-protein
by	O
p21ras	S-protein
also	O
requires	O
Rac-1	S-protein
function	O
.	O

One	O
clone	O
(	O
DEG5	S-cell_line
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	B-cell_line
cells	E-cell_line
pulsed	O
with	O
BCR1/25	O
.	O

Importantly	O
,	O
despite	O
high	O
ligand	O
binding	O
affinity	O
,	O
the	O
prototypic	O
dissociated	O
compound	O
,	O
RU24858	O
,	O
acted	O
as	O
a	O
weak	O
agonist	O
and	O
did	O
not	O
efficiently	O
antagonize	O
dexamethasone-induced	O
transcription	O
in	O
transfected	B-cell_type
cells	E-cell_type
.	O

The	O
most	O
characterized	O
pathway	O
is	O
via	O
JAK	B-protein
-STAT	E-protein
signaling	O
.	O

This	O
activation	B-protein
domain	E-protein
of	O
CIITA	S-protein
interacts	O
with	O
the	O
32	B-protein
kDa	I-protein
subunit	E-protein
of	O
the	O
general	B-protein
transcription	I-protein
complex	I-protein
TFIID	E-protein
,	O
TAFII32	S-protein
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

In	O
mice	O
deficient	O
only	O
of	O
p52/NF-kappaB	S-protein
,	O
BLR1	S-protein
expression	O
was	O
unaffected	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
HL60	B-cell_line
cells	E-cell_line
were	O
treated	O
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
all-trans	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
.	O

The	O
proteins	O
may	O
prove	O
useful	O
in	O
protecting	O
adenovirus	B-DNA
gene	I-DNA
therapy	I-DNA
vectors	E-DNA
and	O
transplanted	B-cell_line
cells	E-cell_line
from	O
the	O
immune	O
system	O
.	O

We	O
present	O
a	O
model	O
in	O
which	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	E-protein
alters	O
DNA	O
conformation	O
to	O
allow	O
binding	O
of	O
repressor	B-protein
proteins	E-protein
,	O
and	O
in	O
which	O
the	O
relative	O
amount	O
of	O
HMG-I	O
(	O
Y	O
)	O
helps	O
to	O
determine	O
the	O
repressive	O
state	O
of	O
the	O
beta-globin	B-DNA
gene	E-DNA
.	O

However	O
,	O
cytokine-induced	O
NF-kappaB	S-protein
activation	O
and	O
VCAM-1	S-protein
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

Diminished	O
responses	O
to	O
IL-13	S-protein
by	O
human	O
monocytes	O
differentiated	O
in	O
vitro	O
:	O
role	O
of	O
the	O
IL-13Ralpha1	B-protein
chain	E-protein
and	O
STAT6	S-protein
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	B-DNA
elements	E-DNA
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-DNA
binding	I-DNA
site	E-DNA
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	B-DNA
binding	I-DNA
motifs	E-DNA
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B-protein
complex	E-protein
containing	O
both	O
the	O
cellular	O
SRF	S-protein
and	O
ELK-1	B-protein
proteins	E-protein
.	O

Effects	O
of	O
prostaglandin	B-protein
E2	E-protein
on	O
Th0-type	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	E-cell_line
:	O
modulation	O
of	O
functions	O
of	O
nuclear	B-protein
proteins	E-protein
involved	O
in	O
cytokine	S-protein
production	O
.	O

Characterization	O
of	O
defensin	S-protein
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B-DNA
virulence	I-DNA
regulon	E-DNA
of	O
Salmonella	O
typhimurium	O
.	O

We	O
demonstrate	O
the	O
utility	O
of	O
using	O
primary	O
lymphocyte	O
models	O
to	O
study	O
HTLV-I	O
transcription	O
in	O
the	O
context	O
of	O
cell	O
signaling	O
and	O
suggest	O
that	O
activated	O
PBMC	S-cell_type
maintain	O
elevated	O
levels	O
of	O
P-CREB	S-protein
,	O
which	O
promote	O
basal	O
HTLV-I	O
transcription	O
and	O
enhance	O
viral	O
persistence	O
in	O
vivo	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	B-protein
DNA-binding	I-protein
domain	E-protein
,	O
whereas	O
amino-	B-protein
or	I-protein
carboxyl-terminal	I-protein
domains	E-protein
were	O
dispensable	O
.	O

One	O
family	O
of	O
host	B-protein
transcription	I-protein
factors	E-protein
whose	O
activity	O
is	O
altered	O
by	O
Tax	S-protein
includes	O
NF-kappa	B-protein
B/Rel	E-protein
.	O

The	O
observation	O
that	O
IL-4	S-protein
can	O
differentially	O
regulate	O
the	O
expression	O
of	O
TGF-alpha	S-protein
and	O
TGF-beta1	S-protein
suggests	O
that	O
IL-4	S-protein
may	O
serve	O
as	O
a	O
physiologic	O
molecular	O
switch	O
of	O
TGF	S-protein
expression	O
by	O
the	O
infiltrating	O
eosinophils	S-cell_type
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O

Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV-positive	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O

After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	S-protein
-induced	O
proliferation	O
of	O
PBMCs	S-cell_type
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Alternatively	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
neither	O
AP-1	S-protein
nor	O
the	O
c-myc	B-protein
protein	E-protein
are	O
involved	O
in	O
the	O
MDHM-induced	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
or	O
TNF	O
alpha	O
mRNA	O
levels	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	B-DNA
response	I-DNA
element-driven	I-DNA
reporter	I-DNA
construct	E-DNA
.	O

The	O
PML	B-DNA
gene	E-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	E-DNA
(	O
RAR	B-DNA
alpha	E-DNA
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF-kappa	B-protein
B	E-protein
was	O
maximum	O
after	O
the	O
0.5-Gy	O
exposure	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post-receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	E-protein
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	B-DNA
kappa	I-DNA
B	I-DNA
motif	E-DNA
functions	O
as	O
a	O
potent	O
IL-1/tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
element	E-DNA
in	O
nonlymphoid	B-cell_type
cells	E-cell_type
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
such	O
as	O
a	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	E-cell_line
.	O

These	O
findings	O
suggest	O
that	O
LTR	B-DNA
sequence	E-DNA
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	S-DNA
function	O
and	O
transcription	B-protein
factor	E-protein
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

Interleukin	B-protein
4	E-protein
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	E-protein
which	O
interacts	O
with	O
an	O
interferon-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	E-DNA
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	E-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

In	O
contrast	O
,	O
E1A-positive	B-cell_type
cells	E-cell_type
were	O
no	O
more	O
susceptible	O
to	O
injury-induced	O
necrosis	O
than	O
E1A-negative	B-cell_type
cells	E-cell_type
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
in	O
non-B	B-cell_type
cells	E-cell_type
,	O
perhaps	O
due	O
to	O
a	O
non-permissive	O
chromatin	S-DNA
structure	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
locus	E-DNA
.	O

Because	O
this	O
segment	O
presumably	O
folds	O
upon	O
specific	O
DNA	O
binding	O
,	O
its	O
flexibility	O
in	O
solution	O
may	O
reduce	O
the	O
intrinsic	O
DNA	O
affinity	O
of	O
POUHD	S-protein
in	O
the	O
absence	O
of	O
POUs	S-protein
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
cord	B-cell_type
blood-derived	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem/progenitor	I-cell_type
cells	E-cell_type
,	O
and	O
murine	B-cell_line
bone	I-cell_line
marrow	I-cell_line
repopulating	I-cell_line
stem	I-cell_line
cells	E-cell_line
.	O

The	O
pattern	O
of	O
kappaB	S-protein
-binding	O
activity	O
in	O
T	B-cell_type
cells	E-cell_type
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	B-cell_type
cells	E-cell_type
obtained	O
from	O
normal	O
volunteers	O
.	O

The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	B-DNA
delta	I-DNA
1	I-DNA
segment	E-DNA
corresponded	O
to	O
the	O
previously	O
reported	O
germ-line	O
sequence	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	B-DNA
gene	E-DNA
rearrangement	O
.	O

Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	S-protein
regulates	O
c-jun	S-DNA
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	B-RNA
transcripts	E-RNA
.	O

In	O
promoter	O
transactivation	O
as	O
well	O
as	O
primary	O
B	O
cell	O
transformation	O
assays	O
these	O
chimeric	O
EBNA2	S-protein
proteins	O
are	O
able	O
to	O
substitute	O
for	O
wild-type	B-protein
EBNA2	E-protein
in	O
the	O
presence	O
of	O
oestrogen	O
.	O

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	B-protein
acid	I-protein
lipase	E-protein
(	O
LAL	S-protein
)	O
expression	O
in	O
THP-1	B-cell_line
cells	E-cell_line
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	S-protein
and	O
AP-2	S-protein
.	O

HIV-1	B-protein
tat	E-protein
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	B-protein
cell-specific	I-protein
transcription	I-protein
factor	E-protein
and	O
downregulates	O
MIP-1	B-DNA
alpha	I-DNA
gene	E-DNA
expression	O
in	O
activated	B-cell_type
T-cells	E-cell_type
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	S-protein
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O

Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	O
transcriptional	O
activation	O
.	O

Charybdotoxin-sensitive	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	B-cell_type
or	I-cell_type
B	I-cell_type
cell	E-cell_type
activation	O
and	O
proliferation	O
.	O

These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	S-protein
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O

It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	B-protein
ALAS	I-protein
precursor	I-protein
protein	E-protein
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	B-protein
housekeeping	I-protein
ALAS	I-protein
precursor	E-protein
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-345	O
and	O
-540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	B-cell_line
cells	E-cell_line
and	O
nonrelated	B-cell_type
cells	E-cell_type
as	O
well	O
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	S-protein
is	O
markedly	O
inhibited	O
in	O
cells	O
co-transfected	O
with	O
p50	S-protein
or	O
other	O
NF-kappaB	B-protein
subunits	E-protein
,	O
including	O
RelA	S-protein
and	O
c-Rel	S-protein
,	O
that	O
physically	O
interact	O
with	O
p105	S-protein
.	O

The	O
AP-1	B-protein
binding	I-protein
proteins	E-protein
contained	O
c-Jun	S-protein
,	O
Jun-D	S-protein
,	O
and	O
Fra-1	S-protein
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	S-protein
and	O
c-Fos	S-protein
.	O

Herpesvirus	B-cell_line
saimiri	I-cell_line
immortalized	I-cell_line
gamma	I-cell_line
delta	I-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
activated	O
by	O
IL-12	S-protein
.	O

Simultaneous	O
activation	O
of	O
Ig	S-protein
and	O
Oct-2	S-protein
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	B-protein
class	I-protein
II	E-protein
expression	O
by	O
IL-6	S-protein
.	O

Their	O
retinoidal	O
activity	O
were	O
examined	O
in	O
terms	O
of	O
the	O
differentiation-inducing	O
ability	O
toward	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	E-cell_line
.	O

We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	B-protein
factor	I-protein
SP1	E-protein
in	O
the	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
BL60	E-cell_line
during	O
anti-IgM	S-protein
-induced	O
apoptosis	O
.	O

This	O
RT-PCR	O
assay	O
can	O
detect	O
one	O
leukemic	B-cell_type
cell	E-cell_type
in	O
10	O
(	O
2	O
)	O
normal	B-cell_type
cells	E-cell_type
in	O
vitro	O
.	O

Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	B-protein
binding	I-protein
proteins	E-protein
from	O
their	O
cytoplasmic	O
pools	O
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	S-protein
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	S-protein
-activated	O
Janus	B-protein
kinase	I-protein
-STAT	E-protein
signaling	O
pathway	O
.	O

TCF-1	B-RNA
mRNA	E-RNA
was	O
expressed	O
uniquely	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	B-cell_type
cells	E-cell_type
are	O
examined	O
for	O
IFN-gamma	S-protein
responsiveness	O
;	O
these	O
cells	O
can	O
respond	O
to	O
IFN-gamma	S-protein
and	O
express	O
beta-chain	S-protein
.	O

Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFAT1	E-protein
at	O
its	O
proximal	B-DNA
binding	I-DNA
element	I-DNA
P0	E-DNA
in	O
the	O
IL-4	B-DNA
promoter	E-DNA
associated	O
with	O
enhanced	O
IL-4	B-DNA
gene	E-DNA
transcription	O
in	O
T	B-cell_type
cells	E-cell_type
of	O
atopic	O
patients	O
.	O

This	O
core	O
contains	O
a	O
GATA	B-DNA
site	E-DNA
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E-box	B-DNA
motif	E-DNA
.	O

Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O

Maximal	O
induction	O
of	O
the	O
c-fos	B-DNA
gene	E-DNA
was	O
followed	O
by	O
that	O
for	O
the	O
fos-B	B-DNA
gene	E-DNA
.	O

First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	B-DNA
site	E-DNA
inhibit	O
the	O
activity	O
of	O
multimerized	B-DNA
copies	E-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	E-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
,	O
and	O
that	O
LEF-1/GAL4	S-protein
can	O
activate	O
a	O
GAL4-substituted	B-DNA
HIV-1	I-DNA
enhancer	E-DNA
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O

Switching	O
gears	O
during	O
T-cell	O
maturation	O
:	O
RANTES	S-protein
and	O
late	O
transcription	O
.	O

A	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B-protein
helicase	E-protein
defect	O
in	O
repair/transcription	B-protein
factor	I-protein
TFIIH	E-protein
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O

Transfection	O
of	O
a	O
GRbeta	S-protein
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL-2	B-DNA
promoter	E-DNA
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O

MDS1/EVI1	S-DNA
is	O
inappropriately	O
activated	O
in	O
myeloid	B-cell_type
leukemias	E-cell_type
following	O
chromosomal	O
rearrangements	O
involving	O
band	B-protein
3q26	E-protein
.	O

In	O
fibroblasts	S-cell_type
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	E-protein
did	O
not	O
exceed	O
10	O
%	O
of	O
their	O
content	O
in	O
normal	B-cell_type
cells	E-cell_type
.	O

IFN	S-protein
signaling	O
is	O
mediated	O
by	O
binding	O
of	O
IFNs	S-protein
to	O
their	O
receptors	O
and	O
subsequent	O
activation	O
of	O
Janus	O
tyrosine	O
kinase	O
(	O
JAK	S-protein
)	O
-	O
STAT	S-protein
signaling	O
pathway	O
.	O

We	O
concluded	O
that	O
CTCF	S-protein
expression	O
and	O
activity	O
is	O
controlled	O
at	O
transcriptional	O
and	O
post-transcriptional	O
levels	O
.	O

In	O
contrast	O
to	O
IL-4	S-protein
,	O
interferon-gamma	S-protein
(	O
IFN-gamma	S-protein
)	O
had	O
no	O
demonstrable	O
effect	O
on	O
the	O
differentiation	O
of	O
monocytes	S-cell_type
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	B-DNA
enhancers	E-DNA
of	O
other	O
genes	O
including	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	E-protein
,	O
interferon	B-protein
beta	E-protein
,	O
and	O
interferon-inducible	B-DNA
genes	E-DNA
.	O

Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	B-protein
protein	E-protein
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA-binding	B-protein
domain	E-protein
of	O
ZEBRA	S-protein
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	B-protein
protein	E-protein
in	O
disruption	O
of	O
EBV	O
latency	O
.	O

Dose-dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c-fos	S-DNA
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c-fos	S-DNA
induction	O
via	O
H2	B-protein
receptors	E-protein
.	O

This	O
suggests	O
that	O
mutated	B-protein
Ras	E-protein
activates	O
mechanisms	O
,	O
which	O
favor	O
tumor	O
growth	O
,	O
enhance	O
the	O
metastatic	O
capacity	O
of	O
tumors	O
or	O
modulate	O
tumor-specific	O
immune	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	S-protein
-mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O

The	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
/FK506-sensitive	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
(	O
NFAT	S-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	B-DNA
genes	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	B-cell_type
cells	E-cell_type
can	O
be	O
submitted	O
to	O
a	O
prolonged	B-cell_line
cyclic	I-cell_line
pressure-stretching	I-cell_line
strain	E-cell_line
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O

At	O
the	O
cellular	O
level	O
,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	B-cell_type
lymphocytes	E-cell_type
.	O

Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O

Expression	O
of	O
human	B-DNA
MHC	I-DNA
HLA-DRA	I-DNA
class	I-DNA
II	I-DNA
gene	E-DNA
can	O
be	O
up-regulated	O
in	O
B	B-cell_type
cells	E-cell_type
by	O
Ig	O
cross-linking	O
as	O
well	O
as	O
by	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O

This	O
conclusion	O
was	O
based	O
upon	O
several	O
independent	O
criteria	O
,	O
including	O
more	O
vigorous	O
tyrosine	O
phosphorylation	O
of	O
JAK3	S-protein
,	O
more	O
marked	O
enzymatic	O
activation	O
of	O
JAK3	S-protein
as	O
well	O
as	O
higher	O
abundance	O
of	O
JAK3	S-protein
in	O
activated	O
IL-2	B-protein
receptor	I-protein
complexes	E-protein
.	O

CD4+	B-cell_type
lymphocytes	E-cell_type
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1/25	O
in	O
an	O
HLA-DR	S-protein
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	B-cell_type
antigen-presenting	I-cell_type
cell	E-cell_type
(	O
APC	S-cell_type
)	O
or	O
by	O
APC	S-cell_type
expressing	O
the	O
HLA-DR11	B-protein
restricting	I-protein
molecule	E-protein
.	O

Maximal	O
accumulation	O
of	O
either	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
messenger	I-RNA
RNA	E-RNA
(	O
mRNA	O
)	O
occurred	O
30	O
minutes	O
after	O
LPS	O
addition	O
.	O

T-cell	O
prolymphocytic	O
leukemia	O
(	O
T-PLL	O
)	O
,	O
a	O
rare	O
form	O
of	O
mature	O
T-cell	O
leukemias	O
,	O
and	O
ataxia	O
telangiectasia	O
clonal	O
proliferation	O
,	O
a	O
related	O
condition	O
occurring	O
in	O
patients	O
suffering	O
from	O
ataxia	O
telangiectasia	O
,	O
have	O
been	O
associated	O
to	O
translocations	O
involving	O
the	O
14q32.1	S-DNA
or	O
Xq28	B-DNA
regions	E-DNA
,	O
where	O
are	O
located	O
the	O
TCL1	B-DNA
and	I-DNA
MTCP1	I-DNA
putative	I-DNA
oncogenes	E-DNA
,	O
respectively	O
.	O

Inhibition	O
of	O
IL-4	S-protein
-inducible	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	E-cell_type
by	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
interferons	E-protein
.	O

Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O
:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B-protein
JH4	I-protein
domain	E-protein
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	S-protein
JH2	O
domain	O
.	O

Tyrosine	O
phosphorylation	O
of	O
IFN-gammaR	S-protein
,	O
Jak1	S-protein
,	O
Jak2	S-protein
,	O
and	O
Stat1alpha	S-protein
was	O
examined	O
by	O
immunoblotting	O
.	O

The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O
,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	O
was	O
decreased	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B-cell_line
cell	I-cell_line
lines	E-cell_line
as	O
compared	O
with	O
control	B-cell_line
cell	I-cell_line
lines	E-cell_line
was	O
observed	O
.	O

Estrogen	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
via	O
its	O
intracellular	B-protein
receptor	E-protein
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	S-protein
than	O
for	O
OKT3	S-protein
.	O

Although	O
the	O
TNF-alpha	S-protein
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti-	O
TNF-alpha	S-protein
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV-1	O
production	O
.	O

Induction	O
of	O
HSF3	S-protein
DNA-binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	S-protein
.	O

Therefore	O
,	O
we	O
have	O
constructed	O
a	O
single	O
cDNA	S-DNA
that	O
encodes	O
a	O
single-chain	B-protein
protein	E-protein
,	O
called	O
Flexi-12	S-protein
,	O
which	O
retains	O
all	O
of	O
the	O
biological	O
characteristics	O
of	O
recombinant	O
IL-12	S-protein
(	O
rIL-12	S-protein
)	O
.	O

Interaction	O
of	O
fibronectin	S-protein
with	O
VLA-5	B-protein
receptor	E-protein
on	O
CD4	B-cell_line
cells	E-cell_line
induces	O
the	O
AP-1	B-protein
transcription	I-protein
factor	E-protein
.	O

Nonetheless	O
,	O
CREB	S-protein
,	O
Ets-1	S-protein
,	O
and	O
AML1	S-protein
bind	O
and	O
activate	O
cooperatively	O
and	O
very	O
efficiently	O
through	O
the	O
nonconsensus	B-DNA
binding	I-DNA
sites	E-DNA
at	O
the	O
core	B-DNA
promoter	I-DNA
region	E-DNA
.	O

This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O

We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	B-protein
receptors	E-protein
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	S-protein
in	O
monocytes	S-cell_type
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	S-protein
and	O
IL-12	S-protein
synergized	O
in	O
the	O
induction	O
of	O
IFN-gamma	S-protein
and	O
GM-CSF	S-protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
mRNAs	E-RNA
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	S-protein
or	O
antibodies	B-protein
to	I-protein
CD3	E-protein
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	B-protein
antibodies	E-protein
or	O
B7-positive	B-cell_type
(	I-cell_type
B	I-cell_type
cells	I-cell_type
)	E-cell_type
or	O
B7-negative	B-cell_type
(	I-cell_type
endothelial	I-cell_type
)	I-cell_type
accessory	I-cell_type
cells	I-cell_type
,	E-cell_type
are	O
mediated	O
through	O
the	O
same	O
cis-elements	S-DNA
.	O

In	O
further	O
studies	O
we	O
have	O
shown	O
that	O
purified	O
hsp90	S-protein
can	O
bind	O
to	O
purified	O
p23	S-protein
and	O
this	O
interaction	O
requires	O
both	O
ATP	O
and	O
molybdate	O
.	O

Abnormality	O
of	O
Oct-1	S-protein
DNA	O
binding	O
in	O
T	B-cell_type
cells	E-cell_type
from	O
Sjogren	O
's	O
syndrome	O
patients	O
.	O

The	O
substitution	O
of	O
Ile	O
for	O
Val	O
augmented	O
STAT6	S-protein
activation	O
,	O
proliferation	O
,	O
and	O
transcription	O
activity	O
of	O
the	O
Iepsilon	B-DNA
promoter	E-DNA
by	O
IL-4	S-protein
,	O
whereas	O
that	O
of	O
Arg	O
for	O
Gln	O
did	O
not	O
change	O
these	O
IL-4	S-protein
signals	O
.	O

Initially	O
,	O
four	O
novel	O
,	O
frequently	O
occurring	O
sequence	B-DNA
variants	E-DNA
were	O
identified	O
that	O
associated	O
with	O
two	O
common	O
haplotypes	O
that	O
were	O
described	O
previously	O
.	O

The	O
chemokine	B-protein
receptor	E-protein
,	O
BLR1	S-protein
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	B-cell_type
cells	E-cell_type
in	O
lymphoid	O
organs	O
.	O

However	O
,	O
Spi-C	S-protein
may	O
represent	O
a	O
novel	O
subgroup	O
within	O
the	O
Ets	B-protein
protein	I-protein
family	E-protein
,	O
as	O
it	O
differed	O
significantly	O
from	O
Spi-B	S-protein
and	O
PU.1	S-protein
within	O
helix	B-protein
1	E-protein
of	O
the	O
Ets	B-protein
domain	E-protein
.	O

NF-ATp	S-protein
and	O
NF-ATc	S-protein
bind	O
to	O
two	O
sites	O
around	O
positions	B-DNA
-585	I-DNA
and	I-DNA
-650	E-DNA
located	O
upstream	O
of	O
the	O
proximal	B-DNA
CD25	I-DNA
promoter	E-DNA
.	O

S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure-based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
age-related	O
impairments	O
in	O
the	O
activation	O
of	O
AP-1	S-protein
and	O
NF-AT	S-protein
are	O
closely	O
associated	O
with	O
decreased	O
expression	O
of	O
IL-2	S-protein
and	O
further	O
suggest	O
that	O
aberrancies	O
in	O
the	O
signaling	O
pathways	O
important	O
for	O
the	O
induction	O
of	O
transcriptionally	O
active	O
c-Fos/c-Jun	B-protein
AP-1	E-protein
may	O
contribute	O
to	O
the	O
impaired	O
activation	O
of	O
NF-AT	S-protein
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	B-RNA
mRNA	E-RNA
,	O
IL-6	S-protein
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	B-protein
protein	E-protein
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B-protein
kinase	E-protein
in	O
phytohemagglutinin-stimulated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	E-cell_line
and	O
in	O
the	O
p16-negative	B-cell_line
human	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
MOLT-4	S-cell_line
and	O
CEM	S-cell_line
.	O

Oral	O
administration	O
of	O
276	O
mumol	O
cortisol	O
to	O
normal	O
subjects	O
also	O
decreased	O
LPS-induced	O
IL-1ra	S-protein
synthesis	O
in	O
cultured	B-cell_line
monocytes	E-cell_line
.	O

In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	E-protein
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O

Analysis	O
of	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
-driven	O
secreted	O
alkaline	B-protein
phosphatase	E-protein
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
possesses	O
an	O
enhancer	B-DNA
region	E-DNA
just	O
upstream	O
of	O
the	O
NF-kappaB	B-DNA
element	E-DNA
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
sites	E-DNA
.	O

During	O
humoral	O
immune	O
responses	O
,	O
B-lymphocyte	O
activation	O
is	O
followed	O
by	O
differentiation	O
along	O
either	O
the	O
plasma	O
cell	O
pathway	O
or	O
the	O
memory	O
B-cell	O
pathway	O
.	O

Tyrosine	O
phosphorylation	O
STAT1	S-protein
or	O
STAT3	S-protein
was	O
not	O
detected	O
in	O
human	B-cell_type
erythroid	I-cell_type
precursors	E-cell_type
after	O
stimulation	O
with	O
erythropoietin	S-protein
.	O

It	O
is	O
stated	O
that	O
GCR	S-protein
of	O
healthy	O
controls	O
and	O
GCS-untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol-dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O

None	O
of	O
these	O
polymorphisms	S-DNA
change	O
the	O
translated	B-protein
protein	E-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA-resistant	B-protein
NFAT	I-protein
complex	E-protein
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	E-cell_type
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	S-protein
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	S-protein
,	O
STAT5A	S-protein
and	O
STAT5B	S-protein
,	O
to	O
IL-2-	O
and	O
IL-7-induced	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphoblasts	E-cell_type
.	O

Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	S-cell_type
from	O
SCID-HU-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O

The	O
phosphorylation	O
of	O
STAT	B-protein
proteins	E-protein
on	O
serine	O
residues	O
is	O
also	O
required	O
for	O
competent	O
STAT	S-protein
transcription	O
.	O

Histologic	O
examination	O
showed	O
an	O
extensive	O
inflammatory	O
cell	O
infiltration	O
around	O
the	O
airways	O
,	O
with	O
epithelial	O
necrosis	O
and	O
an	O
alveolar	O
exudate	O
that	O
caused	O
localized	O
alveolar	O
collapse	O
in	O
the	O
infected	O
areas	O
.	O

The	O
overlapping	O
expression	O
patterns	O
and	O
similar	O
in	O
vitro	O
binding	O
and	O
trans-activation	O
activities	O
on	O
various	O
promoter	B-DNA
elements	E-DNA
of	O
NF-AT-regulated	B-DNA
genes	E-DNA
suggest	O
some	O
redundancy	O
in	O
the	O
function	O
of	O
these	O
proteins	O
.	O

Analysis	O
of	O
Gal4-Elf-1	B-protein
fusion	I-protein
proteins	E-protein
revealed	O
that	O
the	O
N-terminal	O
86	O
amino	O
acids	O
of	O
Elf-1	S-protein
contain	O
a	O
transcriptional	B-protein
activation	I-protein
domain	E-protein
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	B-protein
repression	I-protein
domain	E-protein
.	O

We	O
show	O
that	O
both	O
CREB	B-protein
isoforms	E-protein
are	O
expressed	O
in	O
many	B-cell_type
cell	I-cell_type
types	E-cell_type
and	O
mammalian	O
species	O
.	O

To	O
test	O
whether	O
disordered	O
memory	B-cell_type
T	I-cell_type
cell	E-cell_type
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1-dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	B-cell_type
CD4+	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	E-cell_type
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
in	O
vitro	O
.	O

Cosmid	B-DNA
probe	E-DNA
of	O
BCL6	S-DNA
hybridized	O
to	O
14q11	S-DNA
and	O
3q27	S-DNA
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Female	O
family	O
members	O
were	O
also	O
studied	O
to	O
identify	O
heterozygote	O
carriers	O
.	O

Previous	O
work	O
has	O
demonstrated	O
that	O
SLP-76	S-protein
,	O
a	O
Grb2-associated	B-protein
tyrosine-phosphorylated	I-protein
protein	E-protein
,	O
augments	O
Interleukin-2	B-DNA
promoter	E-DNA
activity	O
when	O
overexpressed	O
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

BACKGROUND	O
.	O

The	O
type	O
I	O
human	O
T-cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	B-cell_type
cells	E-cell_type
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T-cell	O
malignancy	O
termed	O
adult	O
T-cell	O
leukemia	O
.	O

However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2.3-kb	B-DNA
cDNA	E-DNA
.	O

This	O
was	O
due	O
to	O
an	O
increase	O
in	O
the	O
half-life	O
of	O
p65	B-RNA
mRNA	E-RNA
(	O
75	O
vs	O
150	O
minutes	O
)	O
.	O

A	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	E-protein
containing	O
c-Rel-like	B-protein
proteins	E-protein
preferentially	O
interacts	O
with	O
interleukin-6	B-DNA
kappa	I-DNA
B-related	I-DNA
motifs	E-DNA
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
.	O

Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	E-cell_type
by	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	I-protein
factors	E-protein
.	O

Proliferation	O
of	O
T	B-cell_type
cells	E-cell_type
was	O
induced	O
by	O
immobilized	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	E-protein
(	O
mAb	S-protein
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti-CD28	B-protein
mAb	E-protein
.	O

In	O
contrast	O
,	O
the	O
expression	O
pattern	O
of	O
LOX-1	S-protein
is	O
different	O
from	O
that	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	E-protein
;	O
LOX-1	S-protein
is	O
expressed	O
in	O
vascular-rich	O
organs	O
,	O
but	O
not	O
in	O
lymphocytes	S-cell_type
.	O

New	O
data	O
on	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
glucocorticoids	O
have	O
suggested	O
alternative	O
approaches	O
in	O
ALL	O
.	O

These	O
findings	O
indicate	O
that	O
cortisol	O
and	O
its	O
receptors	O
are	O
critically	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
function	O
in	O
HIV	O
infection	O
.	O

Interestingly	O
,	O
evidence	O
for	O
the	O
presence	O
of	O
B	B-cell_type
cells	E-cell_type
that	O
have	O
already	O
switched	O
to	O
IgE	S-protein
was	O
seen	O
in	O
PBMCs	S-cell_type
of	O
several	O
patients	O
with	O
asthma	O
or	O
HIE	O
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

For	O
comparison	O
,	O
we	O
recruited	O
a	O
control	O
group	O
consisting	O
of	O
32	O
healthy	O
males	O
and	O
females	O
with	O
similar	O
age	O
distribution	O
and	O
without	O
a	O
history	O
of	O
exposure	O
to	O
MTBE	O
or	O
benzene	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	B-protein
growth	I-protein
factors	E-protein
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF-kappaB	S-protein
to	O
DNA	O
in	O
TNF-alpha-stimulated	B-cell_line
Jurkat	I-cell_line
cells	E-cell_line
.	O

Expression	O
of	O
CD30	S-protein
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	S-protein
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	S-protein
and	O
IL-12	S-protein
.	O

This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O

Stimulation	O
of	O
NK	B-cell_type
cells	E-cell_type
with	O
CD16	S-protein
ligands	O
induces	O
NFAT	S-protein
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Rat	B-cell_type
splenocytes	E-cell_type
were	O
found	O
to	O
have	O
greater	O
sensitivity	O
to	O
MPL	O
(	O
EC50	O
=	O
7.9	O
nM	O
)	O
than	O
do	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
(	O
EC50	O
=	O
28	O
nM	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	B-cell_type
B	I-cell_type
cells	E-cell_type
and	O
monocytes	S-cell_type
differ	O
following	O
CD40	S-protein
stimulation	O
.	O

The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti-TNF-alpha	B-protein
antibody	E-protein
and	O
various	O
inhibitors	O
.	O

NF-X2	S-protein
that	O
binds	O
to	O
the	O
DRA	B-DNA
X2-box	E-DNA
is	O
activator	B-protein
protein	I-protein
1	E-protein
.	O

The	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	E-protein
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	B-DNA
NF-kappa	I-DNA
B	I-DNA
site	E-DNA
but	O
not	O
the	O
intact	B-DNA
element	E-DNA
,	O
suggesting	O
that	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	E-protein
-driven	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	E-protein
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	B-cell_type
B	I-cell_type
cells	E-cell_type
into	O
the	O
cell	O
cycle	O
.	O

The	O
Tax	B-protein
protein	E-protein
,	O
encoded	O
by	O
HTLV-I	O
,	O
is	O
a	O
potent	O
transcription	O
activator	O
of	O
viral	O
and	O
several	O
cellular	B-DNA
genes	E-DNA
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	E-protein
in	O
LN	B-cell_type
T	I-cell_type
cells	E-cell_type
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

In	O
conclusion	O
,	O
we	O
provide	O
evidence	O
that	O
PP2A	S-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
STAT3	S-protein
phosphorylation	O
and	O
subcellular	O
distribution	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

As2O3	O
was	O
administered	O
intravenously	O
at	O
the	O
dose	O
of	O
10	O
mg/d	O
.	O

M-TAT	S-cell_line
is	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	E-cell_line
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	E-cell_type
.	O

Selective	O
activation	O
of	O
STAT5	B-protein
homologues	E-protein
in	O
addition	O
to	O
generation	O
of	O
lower	O
molecular	O
isoforms	O
may	O
provide	O
specificity	O
and	O
control	O
to	O
genes	O
expressed	O
in	O
response	O
to	O
cytokines	S-protein
such	O
as	O
GM-CSF	S-protein
.	O

HIV-1	O
infects	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
PBMCs	S-cell_type
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	S-protein
partially	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
activate	O
the	O
IL-2	B-DNA
promoter	I-DNA
elements	I-DNA
IL-2A	E-DNA
(	O
which	O
binds	O
the	O
factors	O
OAP	S-protein
and	O
Oct-1	S-protein
)	O
and	O
IL-2E	S-DNA
(	O
which	O
binds	O
NF-AT	S-protein
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
stimulate	O
an	O
NF-kappa	B-protein
B	E-protein
-dependent	O
element	O
.	O

IL-2	S-protein
production	O
by	O
CsA-treated	B-cell_line
cells	E-cell_line
is	O
therefore	O
dramatically	O
reduced	O
.	O

Radiolabeled	B-protein
VDR	E-protein
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse/chase-experiments	O
)	O
.	O

Other	O
steroid	O
receptor	O
drugs	O
such	O
as	O
Raloxifene	O
,	O
RU486	O
,	O
or	O
the	O
ICI	O
182	O
,	O
780	O
in	O
PMA-differentiated	B-cell_line
cells	E-cell_line
displayed	O
agonist	O
activity	O
by	O
preventing	O
TNF-alpha	S-protein
-induced	O
apoptosis	O
as	O
efficiently	O
as	O
the	O
hormones	O
alone	O
,	O
providing	O
further	O
evidence	O
to	O
the	O
notion	O
that	O
steroid	O
receptor	O
drugs	O
may	O
manifest	O
agonist	O
or	O
antagonist	O
activities	O
depending	O
on	O
the	O
cellular	O
context	O
in	O
which	O
they	O
are	O
studied	O
.	O

Thrombin	S-protein
stimulation	O
of	O
the	O
T	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	E-cell_line
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	B-cell_type
(	I-cell_type
MNC	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	E-cell_type
(	O
PMNL	S-cell_type
)	O
.	O

Differentiation-associated	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
protein	E-protein
in	O
oral	O
hairy	O
leukoplakia	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

Stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
by	O
zinc	O
and	O
related	O
cations	O
.	O

None	O
of	O
33	O
PBMC	S-cell_type
specimens	O
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	B-DNA
DNA	E-DNA
by	O
nested	O
PCR	O
assay	O
.	O

The	O
lymphocyte-specific	B-DNA
immunoglobulin	I-DNA
mu	I-DNA
heavy-chain	I-DNA
gene	I-DNA
intronic	I-DNA
enhancer	E-DNA
is	O
regulated	O
by	O
multiple	O
nuclear	B-protein
factors	E-protein
.	O

The	O
amplified	O
product	O
showed	O
an	O
identical	B-DNA
nucleotide	I-DNA
sequence	E-DNA
to	O
the	O
DNA-binding	B-protein
domain	E-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	E-protein
.	O

Because	O
the	O
-180	B-DNA
site	E-DNA
is	O
not	O
required	O
for	O
trans-activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	B-DNA
IL-2	I-DNA
enhancer	E-DNA
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
cross-linking	O
of	O
cell	B-protein
surface	I-protein
CD4	E-protein
by	O
gp120-anti-gp120	B-protein
immune	I-protein
complexes	E-protein
or	O
heat-inactivated	O
HIV-1	O
(	O
iHIV-1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA-protein	B-protein
complex	E-protein
is	O
comprised	O
of	O
the	O
AP-1	S-protein
components	O
,	O
Fos	S-protein
and	O
Jun	S-protein
.	O

Oct2	S-protein
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	B-DNA
octamer	I-DNA
enhancer	I-DNA
element	E-DNA
in	O
HeLa	B-cell_line
cells	E-cell_line
,	O
however	O
.	O

This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis-acting	B-DNA
elements	E-DNA
that	O
interact	O
with	O
members	O
of	O
the	O
NF	B-protein
kappa	I-protein
B/rel	I-protein
transcription	I-protein
factor	I-protein
family	E-protein
in	O
an	O
IL-4	S-protein
-independent	O
fashion	O
.	O

Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	E-protein
and	O
PMA-induced	O
IL-2	S-protein
production	O
was	O
resistant	O
.	O

IL-4	S-protein
is	O
secreted	O
by	O
activated	O
Th2	S-cell_type
but	O
not	O
Th1	B-cell_type
cells	E-cell_type
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	B-cell_type
Th	I-cell_type
cells	E-cell_type
toward	O
the	O
Th2	B-cell_type
phenotype	E-cell_type
.	O

The	O
transactivator	B-DNA
(	I-DNA
IE-2	I-DNA
)	I-DNA
gene	E-DNA
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	S-cell_type
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	B-protein
transcription	I-protein
factor	I-protein
Pit-1	E-protein
,	O
designated	O
Pit-1b	S-protein
.	O

Agonistic	O
activity	O
of	O
a	O
CD40-specific	B-protein
single-chain	I-protein
Fv	E-protein
constructed	O
from	O
the	O
variable	B-protein
regions	E-protein
of	O
mAb	B-protein
G28-5	E-protein
.	O

Both	O
positive	B-DNA
and	I-DNA
negative	I-DNA
regulatory	I-DNA
elements	E-DNA
were	O
identified	O
in	O
the	O
proximal	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	E-DNA
of	O
the	O
IL-3	B-DNA
gene	E-DNA
.	O

The	O
total	O
protein	O
content	O
of	O
NF-kappaB	B-protein
subunit	E-protein
(	O
P65	S-protein
)	O
in	O
MNC	S-cell_type
lysates	O
also	O
showed	O
a	O
decrease	O
following	O
hydrocortisone	O
injection	O
.	O

4	O
.	O

The	O
role	O
of	O
caspases	O
in	O
T	O
cell	O
development	O
and	O
the	O
control	O
of	O
immune	O
responses	O
.	O

After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	O
anti-CD18	B-protein
antibody	E-protein
.	O

Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O

Steroid-resistant	O
asthma	O
.	O

Hence	O
,	O
phosphorylation	O
of	O
linker	B-protein
proteins	E-protein
not	O
only	O
bridges	O
the	O
TCR-associated	B-protein
PTK	E-protein
,	O
ZAP-70	S-protein
,	O
with	O
downstream	O
effector	O
proteins	O
,	O
but	O
also	O
provides	O
a	O
scaffold	O
to	O
integrate	O
distinct	O
signaling	B-protein
complexes	E-protein
to	O
regulate	O
T	B-cell_type
cell	E-cell_type
function	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF-kappa	B-protein
B/Rel	E-protein
activation	O
induced	O
by	O
mAb	B-protein
OKT3	E-protein
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	E-cell_type
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	B-protein
recombinant	I-protein
tumor	I-protein
necrosis	I-protein
factor	E-protein
,	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1alpha	E-protein
,	O
IL-1beta	S-protein
,	O
IL-4	S-protein
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B-protein
TCF-1	E-protein
.	O

To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
CD69	S-protein
by	O
leukocytes	S-cell_type
,	O
we	O
isolated	O
the	O
promoter	B-DNA
region	E-DNA
of	O
the	O
CD69	S-protein
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O

The	O
detection	O
of	O
both	O
M-CSF	O
and	O
c-fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	B-cell_type
lineage	E-cell_type
has	O
suggested	O
that	O
M-CSF	S-protein
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O

In	O
addition	O
,	O
the	O
galectin-3	S-protein
level	O
was	O
markedly	O
increased	O
in	O
human	B-cell_type
thymocytes	E-cell_type
after	O
infection	O
with	O
HTLV-I	O
as	O
compared	O
with	O
uninfected	B-cell_type
thymocytes	E-cell_type
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-protein
isoforms	E-protein
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	B-cell_type
cells	E-cell_type
.	O

We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	B-DNA
response	I-DNA
element	E-DNA
from	O
the	O
germline	B-DNA
IgE	I-DNA
promoter	E-DNA
was	O
highly	O
induced	O
by	O
IL-4	S-protein
in	O
Stat6-expressing	B-cell_type
Jurkat	I-cell_type
cells	E-cell_type
,	O
the	O
intact	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA
was	O
repressed	O
under	O
similar	O
conditions	O
.	O

Moreover	O
,	O
integrin	S-protein
-ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O

Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	B-DNA
linked	I-DNA
binding	I-DNA
sites	E-DNA
for	O
CBF	S-protein
,	O
AP-1	S-protein
,	O
and	O
NFATp	S-protein
.	O

When	O
the	O
binding	O
of	O
ICSAT	S-protein
to	O
four	O
different	O
ICSs	S-DNA
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	S-DNA
were	O
determined	O
.	O

A	O
DNA	B-DNA
fragment	E-DNA
containing	O
128	B-DNA
bp	I-DNA
of	I-DNA
upstream	I-DNA
sequence	E-DNA
had	O
strong	O
,	O
monocyte-specific	O
promoter	O
activity	O
in	O
the	O
CD14	B-cell_line
positive	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	E-cell_line
as	O
compared	O
to	O
the	O
nonmonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
HeLa	E-cell_line
and	O
REX	S-cell_line
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK-beta	S-protein
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O

FGF-1	S-protein
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune-mediated	O
inflammation	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591/EGR2	S-protein
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

CIF	S-protein
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	B-protein
element	E-protein
.	O

This	O
study	O
suggests	O
that	O
the	O
pattern	O
of	O
pro-/antiinflammatory	O
cytokine	S-protein
secretion	O
may	O
alter	O
the	O
response	O
of	O
patients	O
to	O
glucocorticoid	O
therapy	O
.	O

The	O
BZLF1	B-DNA
gene	I-DNA
promoter	E-DNA
(	O
Zp	S-DNA
)	O
was	O
activated	O
by	O
crosslinking	O
of	O
cell	B-protein
surface	I-protein
immunoglobulin	E-protein
(	O
Ig	S-protein
)	O
with	O
anti-Ig	B-protein
antibody	E-protein
in	O
B	B-cell_type
cells	E-cell_type
,	O
even	O
in	O
the	O
absence	O
of	O
other	O
viral	O
genes	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94.4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8	O
%	O
of	O
PML/RARalpha	S-protein
transgenic	O
mice	O
.	O

An	O
enhancement	O
of	O
NK	O
activity	O
by	O
E2	O
was	O
also	O
seen	O
in	O
large	B-cell_type
granular	I-cell_type
lymphocytes	E-cell_type
obtained	O
from	O
normal	O
subjects	O
,	O
and	O
it	O
was	O
again	O
suppressed	O
by	O
Tx	O
.	O

These	O
data	O
identify	O
C/EBP	B-protein
proteins	E-protein
as	O
regulators	O
of	O
HIV-1	O
expression	O
in	O
monocytes/macrophages	S-cell_type
.	O

However	O
,	O
we	O
could	O
not	O
prove	O
that	O
Th2	B-protein
type	I-protein
cytokines	E-protein
had	O
a	O
protective	O
effect	O
on	O
hepatocytes	S-cell_type
.	O

At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	S-protein
expression	O
and	O
activity	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	E-cell_line
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
B	I-cell_type
cells	E-cell_type
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	S-protein
and	O
c-Rel	S-protein
,	O
whereas	O
nuclear	O
c-Rel	S-protein
,	O
but	O
not	O
RelB	S-protein
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	S-DNA
,	O
hck	S-DNA
,	O
and	O
actin	B-DNA
genes	E-DNA
.	O

Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
(	O
TIS	S-DNA
)	O
showed	O
no	O
canonical	O
TATA	S-DNA
or	O
CAAT	B-DNA
elements	E-DNA
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA-less	B-DNA
promoters	E-DNA
encompassed	O
the	O
TIS	S-DNA
.	O

Since	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	E-cell_type
express	O
cryptic	B-protein
epitopes	E-protein
for	O
mAb	B-protein
J393	E-protein
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	S-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-cell	I-cell_type
lineages	E-cell_type
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite-induced	O
constitutive	O
NF-kappaB	S-protein
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	B-cell_type
cells	E-cell_type
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O

These	O
results	O
indicate	O
that	O
the	O
somatic	O
hypermutation	O
mechanism	O
active	O
in	O
GC	B-cell_type
B	I-cell_type
cells	E-cell_type
physiologically	O
targets	O
non-Ig	B-DNA
sequences	E-DNA
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

Tyrosine	B-protein
kinase	E-protein
and	O
cAMP-dependent	B-protein
protein	I-protein
kinase	E-protein
activities	O
in	O
CD40-activated	B-cell_line
human	I-cell_line
B	I-cell_line
lymphocytes	E-cell_line
.	O

In	O
contrast	O
to	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	E-cell_line
,	O
lipopolysaccharide-stimulated	O
Rel-/-	B-cell_line
macrophages	E-cell_line
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM-CSF	S-protein
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	B-DNA
subunit	I-DNA
promoter	I-DNA
region	E-DNA
.	O

Coupling	O
of	O
the	O
upstream	B-DNA
beta	I-DNA
globin	I-DNA
sequence	E-DNA
from	O
approximately	O
-500	O
to	O
-250	O
bp	O
to	O
the	O
truncated	O
delta	B-DNA
promoter	E-DNA
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	B-DNA
globin	I-DNA
gene	I-DNA
upstream	I-DNA
element	E-DNA
(	O
s	O
)	O
.	O

Vitamin	O
D	O
analogs	O
,	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
,	O
-trihomo-1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-vitamin	O
D3	O
,	O
1	O
,	O
24	O
(	O
OH	O
)	O
2-22-ene-24-cyclopropyl-vitamin	O
D3	O
and	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-lumisterol3	O
prime	O
NB4	B-cell_line
leukemia	I-cell_line
cells	E-cell_line
for	O
monocytic	O
differentiation	O
via	O
nongenomic	O
signaling	O
pathways	O
,	O
involving	O
calcium	O
and	O
calpain	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	B-protein
factor	E-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
(	O
NFATp	S-protein
)	O
,	O
a	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
-sensitive	I-protein
factor	E-protein
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	S-protein
,	O
mediates	O
CD16	S-protein
-induced	O
activation	O
of	O
cytokine	B-protein
genes	E-protein
in	O
human	B-cell_type
NK	I-cell_type
cells	E-cell_type
.	O

The	O
HIV-2	B-DNA
LTR	E-DNA
was	O
found	O
to	O
contain	O
two	O
enhancers	S-DNA
.	O

Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell-type	O
specific	O
.	O

The	O
expression	O
of	O
STAT1	B-RNA
,	I-RNA
STAT3	I-RNA
and	I-RNA
STAT5	I-RNA
mRNAs	E-RNA
were	O
also	O
induced	O
by	O
a	O
T-cell	B-protein
mitogen	E-protein
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
.	O

Thereafter	O
,	O
PML	S-protein
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	S-protein
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	B-protein
TNF-alpha	E-protein
or	O
IL-10	S-protein
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up-regulation	O
of	O
TNF-alpha	B-protein
receptors	E-protein
.	O

Addition	O
of	O
ubiquitin	B-protein
protein	I-protein
ligase	I-protein
E3	E-protein
substantially	O
enhanced	O
the	O
E214K	S-protein
-mediated	O
ubiquitinylation	O
of	O
c-Jun	S-protein
and	O
c-Fos	S-protein
.	O

These	O
extrathymic	B-cell_type
T-cell	I-cell_type
populations	E-cell_type
include	O
cells	O
expressing	O
elevated	O
levels	O
of	O
V	B-protein
beta	I-protein
T-cell	I-protein
receptors	E-protein
that	O
are	O
normally	O
deleted	O
in	O
thymic	O
development	O
.	O

The	O
induction	O
of	O
Tax	S-protein
expression	O
in	O
JPX9	B-cell_line
cells	E-cell_line
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	S-RNA
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	S-protein
itself	O
.	O

In	O
the	O
present	O
in-vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady-state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

Because	O
the	O
binding	B-DNA
site	E-DNA
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
binding	I-DNA
site	E-DNA
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O

Induction	O
of	O
activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	E-protein
and	O
nuclear	B-protein
factor-kappaB	E-protein
by	O
CD28	S-protein
stimulation	O
involves	O
both	O
phosphatidylinositol	B-protein
3-kinase	E-protein
and	O
acidic	B-protein
sphingomyelinase	E-protein
signals	O
.	O

In	O
conclusion	O
,	O
elevated	O
IFN	B-protein
alpha	E-protein
levels	O
in	O
AIDS-GR	O
may	O
be	O
due	O
to	O
the	O
lack	O
of	O
inhibitory	O
effect	O
of	O
cortisol	O
on	O
IFN	B-protein
alpha	E-protein
production	O
due	O
to	O
cortisol	O
resistance	O
in	O

Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	B-protein
ligand	E-protein
,	O
a	O
required	O
step	O
for	O
TCR	S-protein
-induced	O
apoptosis	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O

NF-kappaB	S-protein
activation	O
is	O
required	O
for	O
C5a-induced	B-DNA
interleukin-8	I-DNA
gene	E-DNA
expression	O
in	O
mononuclear	B-cell_type
cells	E-cell_type
.	O

Transcripts	O
for	O
osteoprotegerin	B-protein
ligand	E-protein
(	O
OPGL	S-protein
)	O
,	O
an	O
osteoclast	B-protein
differentiation	I-protein
factor	E-protein
(	O
also	O
known	O
as	O
RANKL	S-protein
and	O
TRANCE	S-protein
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	B-cell_type
cells	E-cell_type
.	O

T	B-cell_type
cells	E-cell_type
express	O
multiple	O
isotypes	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	S-protein
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B-protein
isotypes	E-protein
.	O

By	O
contrast	O
,	O
phosphatidic	O
acid	O
accumulation	O
,	O
pleckstrin	O
phosphorylation	O
,	O
and	O
calcium	O
mobilization	O
produced	O
by	O
the	O
combination	O
of	O
NE	S-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	E-protein
were	O
not	O
significantly	O
different	O
from	O
those	O
measured	O
with	O
threshold	O
of	O
cathepsin	B-protein
G	E-protein
alone	O
(	O
p	O
>	O
0.05	O
)	O
,	O
indicating	O
that	O
the	O
phospholipase	B-protein
C	I-protein
/protein	I-protein
kinase	I-protein
C	E-protein
pathway	O
is	O
not	O
involved	O
in	O
the	O
potentiation	O
of	O
aggregation	O
.	O

Infection	O
of	O
target	B-cell_type
cells	E-cell_type
with	O
cytopathic	O
viruses	O
inhibits	O
IFN	S-protein
induction	O
of	O
cytolytic	O
resistance	O
to	O
NK	O
cell-mediated	O
cytolysis	O
[	O
IFN	S-protein
-mediated	O
cytoprotection	O
(	O
IFN	S-protein
-MCP	O
)	O
]	O
.	O

Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG-Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	B-cell_type
isolated	I-cell_type
blood	I-cell_type
leukocytes	E-cell_type
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	B-protein
kappaB	I-protein
family	I-protein
proteins	E-protein
,	O
specifically	O
the	O
failure	O
of	O
p65	S-protein
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta-chain	S-protein
.	O

By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	B-DNA
clones	E-DNA
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	B-DNA
1-42	E-DNA
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

Cross-linking	O
of	O
this	O
lymphocyte-specific	B-protein
protein	E-protein
,	O
designated	O
TACI	S-protein
(	O
transmembrane	B-protein
activator	I-protein
and	I-protein
CAML-interactor	E-protein
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	B-cell_line
Jurkat	I-cell_line
cells	E-cell_line
with	O
TACI-specific	B-protein
antibodies	E-protein
led	O
to	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-AT	E-protein
,	O
AP-1	S-protein
,	O
and	O
NFkappaB	S-protein
.	O

The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	B-cell_type
cells	E-cell_type
to	O
DFX	O
decreases	O
the	O
bioavailability	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV-1	O
replication	O
.	O

These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O

Glucocorticoid	B-protein
receptor	E-protein
regulates	O
expression	O
of	O
L-selectin	S-protein
and	O
CD11/CD18	S-protein
on	O
human	B-cell_type
neutrophils	E-cell_type
[	O
see	O
comments	O
]	O

Finally	O
,	O
CD27	S-protein
cross-linking	O
resulted	O
in	O
the	O
up-regulation	O
of	O
positive	B-protein
regulatory	I-protein
domain	I-protein
I-binding	I-protein
factor-1	E-protein
.	O

Tal-1	O
transcription	O
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	S-cell_line
,	O
a	O
T-cell	O
line	O
that	O
expresses	O
tal-1	S-DNA
in	O
the	O
absence	O
of	O
apparent	O
genomic	O
alteration	O
of	O
the	O
locus	O
.	O

Antioxidants	O
inhibit	O
monocyte	S-cell_type
adhesion	O
by	O
suppressing	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
mobilization	O
and	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	E-protein
in	O
endothelial	B-cell_type
cells	E-cell_type
stimulated	O
to	O
generate	O
radicals	O
.	O

Control	O
of	O
lymphocyte	O
development	O
by	O
the	O
Ikaros	B-DNA
gene	I-DNA
family	E-DNA
.	O

In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	S-protein
in	O
red	B-cell_type
cell	E-cell_type
development	O
at	O
a	O
genetic	O
level	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	E-protein
.	O

Polyclonal	B-cell_line
and	I-cell_line
clonal	I-cell_line
CTL	E-cell_line
that	O
were	O
generated	O
by	O
stimulating	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
with	O
an	O
HLA	B-cell_line
B8+	I-cell_line
homozygous	I-cell_line
LCL	I-cell_line
lysed	I-cell_line
T	I-cell_line
cell	I-cell_line
blasts	E-cell_line
pulsed	O
with	O
the	O
peptide	O
,	O
RAKFKQLLQ	O
;	O
lysis	O
of	O
certain	O
HLA	O
B8+	O
LCL	O
targets	O
was	O
associated	O
with	O
the	O
abundance	O
of	O
BZLF1	B-RNA
transcripts	E-RNA
.	O

However	O
,	O
a	O
role	O
for	O
NF-kappaB	S-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	E-cell_type
has	O
not	O
been	O
described	O
.	O

The	O
oxidant	O
stress-induced	O
signaling	O
resulted	O
in	O
an	O
increased	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	S-protein
,	O
ICAM-1	S-protein
,	O
E-selectin	S-protein
,	O
and	O
VCAM-1	S-protein
in	O
HUVEC	S-cell_line
.	O

In	O
addition	O
,	O
assay	O
of	O
PBMC	S-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O

The	O
flow	O
of	O
information	O
from	O
calcium-mobilizing	B-protein
receptors	E-protein
to	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
-dependent	I-DNA
genes	E-DNA
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	B-protein
calcineurin	E-protein
and	O
the	O
transcription	B-protein
factor	I-protein
NFAT	E-protein
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	S-protein
nuclear	O
translocation	O
and	O
stimulation	O
of	O
virus	O
production	O
by	O
iHIV-1	O
were	O
strictly	O
linked	O
to	O
the	O
concentrations	O
of	O
viral	B-protein
proteins	E-protein
used	O
as	O
exogenous	O
stimuli	O
.	O

Although	O
case-oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
is/are	O
largely	O
unknown	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B-protein
B	E-protein
activity	O
through	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	E-protein
synthesis	O
[	O
see	O
comments	O
]	O

Addition	O
of	O
TFE-3	S-protein
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	E-DNA
upstream	O
of	O
the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	E-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	B-protein
tyrosine	I-protein
and	I-protein
serine/threonine	I-protein
kinases	E-protein
.	O

As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild-type	O
DRA	B-DNA
promoter	E-DNA
but	O
not	O
from	O
a	O
DRA	B-DNA
promoter	E-DNA
bearing	O
clustered	O
point	O
mutations	O
in	O
the	O
X2	B-DNA
box	E-DNA
.	O

The	O
leukocyte-specific	O
,	O
cytoskeleton-binding	O
pp52	O
(	O
LSP-1	O
,	O
WP-34	O
)	O
protein	O
is	O
widely	O
expressed	O
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
,	O
granulocytes	S-cell_type
,	O
and	O
macrophages	S-cell_type
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up-regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

The	O
percentage	O
of	O
the	O
OKT8+	B-cell_line
suppressor/cytotoxic	I-cell_line
T	I-cell_line
cells	E-cell_line
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T-C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	S-protein
results	O
in	O
overexpression	O
of	O
gamma-globin	S-protein
in	O
adult	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	E-cell_type
(	O
HPFH	S-cell_type
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	B-DNA
promoter	E-DNA
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	S-protein
does	O
not	O
bind	O
to	O
this	O
mutant	B-DNA
sequence	E-DNA
.	O

We	O
propose	O
a	O
model	O
for	O
the	O
regulation	O
of	O
Bcl-2	S-protein
expression	O
via	O
Aiolos	S-protein
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	B-cell_line
cells	E-cell_line
,	O
IL-6	S-protein
controls	O
junB	S-DNA
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	E-cell_type
(	O
HPC	S-cell_type
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O

HIV-infected	O
individuals	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

In	O
summary	O
,	O
CD40	S-protein
signaling	O
preferentially	O
induces	O
SAPK	S-protein
but	O
not	O
MAPK	S-protein
.	O

Permanently	O
arresting	O
this	O
ongoing	O
immune	O
response	O
with	O
either	O
pharmaceutical	O
agents	O
or	O
immunotherapy	O
is	O
a	O
major	O
challenge	O
for	O
immunology	O
.	O

Nonresponders	O
had	O
a	O
significant	O
increase	O
both	O
in	O
the	O
number	O
of	O
binding	B-protein
sites	E-protein
and	O
in	O
the	O
apparent	O
dissociation	O
constant	O
compared	O
with	O
responders	O
(	O
P	O
=	O
0.045	O
;	O
P	O
=	O
0.029	O
)	O
.	O

IL-10	S-protein
cooperates	O
with	O
TNF-alpha	S-protein
to	O
activate	O
HIV-1	O
from	O
latently	B-cell_type
and	I-cell_type
acutely	I-cell_type
infected	I-cell_type
cells	E-cell_type
of	O
monocyte/macrophage	B-cell_type
lineage	E-cell_type
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	B-protein
828	E-protein
and	O
9.3	S-protein
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
Jurkat	B-cell_type
cells	E-cell_type
(	O
p56	B-protein
(	I-protein
lck	I-protein
)	E-protein
activation	O
,	O
association	O
of	O
phosphatidylinositol	B-protein
3-kinase	E-protein
with	O
CD28	S-protein
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	S-protein
changes	O
with	O
activation	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	S-protein
and	O
TES2	S-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	S-protein
activation	O
.	O

Bcd	S-DNA
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	S-cell_type
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	B-cell_line
human	I-cell_line
B-cell	I-cell_line
lines	E-cell_line
and	O
not	O
in	O
50	O
%	O
of	O
B-cells	S-cell_type
from	O
B-CLL	O
patients	O
.	O

The	O
state	O
of	O
maturation	O
of	O
monocytes	S-cell_type
into	O
macrophages	S-cell_type
determines	O
the	O
effects	O
of	O
IL-4	S-protein
and	O
IL-13	S-protein
on	O
HIV	O
replication	O
.	O

RESULTS	O
:	O
In	O
the	O
OM-10.1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF-alpha-induced	O
HIV-1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B-protein
kd	I-protein
TNF	I-protein
receptor	E-protein
(	O
TR75	S-protein
)	O
expression	O
although	O
55	B-protein
kD	I-protein
TNF	I-protein
receptor	E-protein
(	O
TR55	S-protein
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	B-protein
kinase	I-protein
C	E-protein
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	E-protein
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	S-protein
in	O
a	O
number	O
of	O
responsive	B-cell_type
cell	I-cell_type
types	E-cell_type
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v-abl	B-protein
protein	E-protein
specifically	O
interferes	O
with	O
light-chain	B-DNA
gene	E-DNA
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B-cell	S-cell_type
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	B-DNA
gene	E-DNA
expression	O
.	O

METHODS	O
:	O
CD23	S-protein
was	O
cross-linked	O
in	O
human	B-cell_type
monocytes	E-cell_type
and	O
U937	B-cell_line
cells	E-cell_line
with	O
IgE	B-protein
immune	I-protein
complexes	E-protein
.	O

We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	S-protein
localized	O
in	O
the	O
nucleus	O
from	O
isolated	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	E-cell_type
as	O
well	O
as	O
from	O
single	B-cell_type
tumor	I-cell_type
cells	E-cell_type
derived	O
from	O
malignant	O
effusions	O
.	O

Glucocorticoid	B-protein
receptor	E-protein
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+/-	O
9.4	O
fmol/million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+/-	O
2.6	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
+/-	O
2.3	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal-regulated	B-protein
protein	I-protein
kinase	E-protein
(	O
ERK	S-protein
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	S-protein
induced	O
by	O
chemotactic	B-protein
factors	E-protein
or	O
PMA	O
.	O

These	O
observations	O
suggest	O
that	O
TNF	S-protein
and	O
PMA	S-protein
do	O
not	O
lead	O
to	O
NF-kappa	B-protein
B	E-protein
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O

To	O
further	O
investigate	O
the	O
effects	O
of	O
E2a-Pbx1	S-protein
on	O
the	O
B	B-cell_type
cell	I-cell_type
progenitors	E-cell_type
,	O
we	O
conditionally	O
expressed	O
E2a-Pbx1	S-protein
under	O
control	O
of	O
a	O
metal	O
response	O
element	O
in	O
hematopoietic	B-cell_line
precursor	I-cell_line
cell	I-cell_line
lines	E-cell_line
in	O
vitro	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-1	E-protein
(	O
TNFR-1	S-protein
)	O
and	O
CD95	S-protein
(	O
also	O
called	O
Fas	S-protein
or	O
APO-1	S-protein
)	O
are	O
cytokine	B-protein
receptors	E-protein
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
``	O
death	B-protein
domain	E-protein
.	O
''	O
Another	O
death	B-protein
domain-containing	I-protein
member	E-protein
of	O
the	O
TNFR	B-protein
family	E-protein
,	O
death	B-protein
receptor	I-protein
3	E-protein
(	O
DR3	S-protein
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	E-protein
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
subunit	O
involved	O
in	O
this	O
mechanism	O
has	O
not	O
been	O
defined	O
.	O

Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	E-cell_line
remarkably	O
promoted	O
differentiation	O
into	O
plasma	B-cell_type
cells	E-cell_type
in	O
the	O
presence	O
of	O
IL-4	S-protein
and	O
CD40	S-protein
signaling	O
.	O

The	O
IL-10	S-protein
effect	O
on	O
c-fos	S-DNA
expression	O
was	O
not	O
blocked	O
by	O
polymyxin	O
B	O
.	O

Signals	O
from	O
TES1	S-protein
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	S-cell_type
,	O
but	O
most	O
lymphoblastoid	B-cell_type
cells	E-cell_type
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	B-protein
residues	E-protein
beyond	O
TES1	S-protein
fail	O
to	O
grow	O
as	O
long-term	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
construct	E-DNA
containing	O
the	O
NF-chi	B-DNA
B	E-DNA
or	O
the	O
NF-IL6	B-DNA
enhancer	E-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
enhancer	E-DNA
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF-kappaB	B-DNA
sites	E-DNA
in	O
their	O
promoter	B-DNA
regions	E-DNA
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up-regulation	O
of	O
nuclear	O
NF-kappaB	S-protein
levels	O
.	O

The	O
HVS	O
STP-C488	S-protein
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T-lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild-type	O
phenotype	O
for	O
marmoset	O
T-lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

HTLV-1	B-protein
Tax	E-protein
induces	O
expression	O
of	O
various	O
immediate	B-DNA
early	I-DNA
serum	I-DNA
responsive	I-DNA
genes	E-DNA
.	O

The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	S-protein
and	O
sIgD	S-protein
in	O
B104	B-cell_line
cells	E-cell_line
is	O
discussed	O
.	O

CD	O
patients	O
are	O
victimized	O
by	O
this	O
self-distructed	O
immune	O
response	O
because	O
of	O
inheritance	O
of	O
certain	O
combinations	O
of	O
HLA-DQ	O
and	O
DR	O
haplotypes	O
.	O

By	O
using	O
PD-98059	O
and	O
SB203580	O
,	O
two	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MEK1	S-protein
(	O
a	O
kinase	S-protein
upstream	O
of	O
ERK1/2	S-protein
)	O
and	O
p38	S-protein
,	O
respectively	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
ERK1/2	O
and	O
p38	O
cascades	O
play	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
IL-8	S-protein
by	O
monocytes	S-cell_type
and	O
PMN	S-cell_type
stimulated	O
with	O
bacterial	O
fractions	O
.	O

As	O
shown	O
for	O
all-trans	O
RA	O
,	O
9-cis	O
RA	O
cooperated	O
with	O
D3	O
to	O
promote	O
monocyte	O
differentiation	O
.	O

Lymphocytes	S-cell_type
from	O
CML	O
patients	O
lack	O
a	O
47	B-protein
kDa	I-protein
factor	E-protein
having	O
affinity	O
for	O
a	O
genomic	B-DNA
sterol	I-DNA
regulatory	I-DNA
sequence	E-DNA
.	O

We	O
have	O
used	O
a	O
32P-labeled	O
oligonucleotide	O
derived	O
from	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sequence	E-DNA
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	B-protein
factor	E-protein
.	O

The	O
decreased	O
T	O
cell	O
reactivity	O
to	O
thyroid	B-protein
antigens	E-protein
after	O
thyroidectomy	O
could	O
be	O
the	O
result	O
of	O
removal	O
of	O
a	O
major	O
part	O
of	O
the	O
thyroid	O
gland	O
or	O
redistribution	O
of	O
suppressor-inducer	O
T	B-cell_type
cells	E-cell_type
.	O

GATA-1	S-protein
and	O
ER	S-protein
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

Furthermore	O
,	O
recombinant	O
TIMP-1	S-protein
,	O
but	O
not	O
TIMP-2	S-protein
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB-94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95-dependent	O
and	O
-independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma-radiation	O
)	O
pathways	O
in	O
TIMP-1-negative	B-cell_line
BL	I-cell_line
lines	E-cell_line
.	O

In	O
21	O
of	O
27	O
informative	O
female	O
patients	O
the	O
majority	O
of	O
the	O
granulocytes	S-cell_type
were	O
clonally	O
derived	O
.	O

Treatment	O
of	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	E-cell_line
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
resulted	O
in	O
sub-optimal	O
neutrophil	O
differentiation	O
(	O
up	O
to	O
25	O
%	O
mature	O
cells	O
)	O
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
is	O
a	O
critical	O
transcription	B-protein
factor	E-protein
for	O
maximal	O
expression	O
of	O
many	O
cytokines	S-protein
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O

A	O
cDNA	B-DNA
clone	E-DNA
,	O
CHEMR1	S-DNA
,	O
resembling	O
the	O
typical	O
G	B-protein
protein-coupled	I-protein
receptor	E-protein
,	O
was	O
isolated	O
from	O
a	O
mouse	B-DNA
cytotoxic	I-DNA
T-lymphocyte	I-DNA
(	I-DNA
CTL	I-DNA
)	I-DNA
library	E-DNA
.	O

Large	O
part	O
of	O
the	O
activated	B-DNA
genes	E-DNA
were	O
under	O
very	O
stringent	O
regulation	O
being	O
expressed	O
only	O
after	O
stimulation	O
.	O

NF-kappa	B-protein
B	E-protein
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	S-protein
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up-regulation	O
of	O
ICAM-1	S-protein
and	O
LFA-1	S-protein
.	O

Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF-kappa	B-protein
B	E-protein
-binding	O
activity	O
in	O
blood	B-cell_type
monocytes	E-cell_type
,	O
pleural	B-cell_type
macrophages	E-cell_type
and	O
alveolar	B-cell_type
macrophages	E-cell_type
.	O

Analysis	O
of	O
X-chromosome	S-DNA
inactivation	O
patterns	O
can	O
be	O
used	O
to	O
determine	O
whether	O
proliferative	O
disorders	O
are	O
clonal	O
in	O
origin	O
.	O

METHODS	O
:	O
Platelets	S-cell_type
were	O
collected	O
from	O
112	O
drug-free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
in	O
contrast	O
to	O
SLP-76	S-protein
,	O
overexpression	O
of	O
SLAP-130	S-protein
diminishes	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	E-protein
-induced	O
activation	O
of	O
the	O
interleukin-2	B-DNA
promoter	E-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
and	O
interferes	O
with	O
the	O
augmentation	O
of	O
interleukin-2	B-DNA
promoter	E-DNA
activity	O
seen	O
when	O
SLP-76	S-protein
is	O
overexpressed	O
in	O
these	O
cells	O
.	O

Functional	O
analysis	O
of	O
cis-linked	B-DNA
regulatory	I-DNA
sequences	E-DNA
in	O
the	O
HLA	B-DNA
DRA	I-DNA
promoter	E-DNA
by	O
transcription	O
in	O
vitro	O
.	O

We	O
have	O
constructed	O
an	O
HIV-1	B-DNA
genome	E-DNA
carrying	O
the	O
cDNA	S-DNA
of	O
a	O
proteolysis-resistant	B-protein
nuclear	I-protein
factor-kappaB	I-protein
inhibitor	E-protein
(	O
IkappaB-alphaS32/36A	S-protein
)	O
in	O
the	O
nef	B-DNA
region	E-DNA
.	O

These	O
effects	O
of	O
D-ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N-acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O

Transcription	O
of	O
a	O
minimal	B-DNA
promoter	E-DNA
from	O
the	O
NF-IL6	B-DNA
gene	E-DNA
is	O
regulated	O
by	O
CREB/ATF	S-protein
and	O
SP1	B-protein
proteins	E-protein
in	O
U937	B-cell_line
promonocytic	I-cell_line
cells	E-cell_line
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-RNA
mRNA	E-RNA
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	E-cell_line
studied	O
.	O

This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	S-protein
or	O
stat1	B-protein
mAb	E-protein
or	O
antisera	O
.	O

Studies	O
with	O
5	B-DNA
'	I-DNA
deletion	I-DNA
CD20	I-DNA
promoter-CAT	I-DNA
constructs	E-DNA
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	S-DNA
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	B-DNA
regulatory	I-DNA
elements	E-DNA
.	O

Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	E-cell_type
mediated	O
by	O
the	O
T	O
cell	O
receptor	O
induces	O
a	O
series	O
of	O
biochemical	O
events	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150-200	O
kd	O
fractions	O
after	O
Sephacryl	O
G-200	O
ultrafiltration	O
.	O

GCII	S-protein
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O

NK	B-cell_type
cells	E-cell_type
do	O
not	O
express	O
NFATc	S-protein
constitutively	O
,	O
but	O
NFATc	B-RNA
mRNA	E-RNA
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

All	O
cases	O
had	O
a	O
remarkably	O
poor	O
prognosis	O
,	O
with	O
a	O
mean	O
survival	O
of	O
9.6	O
+/-	O
6.6	O
months	O
.	O

The	O
presence	O
of	O
TN	S-protein
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	B-protein
CD3	E-protein
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF-AT1	B-protein
transcription	I-protein
factor	I-protein
complexes	E-protein
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O

Similarly	O
,	O
N19RhoA	S-protein
inhibited	O
receptor	O
clustering	O
.	O

We	O
have	O
investigated	O
the	O
role	O
that	O
C/EBP	B-protein
proteins	E-protein
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV-1	O
.	O

Furthermore	O
,	O
B	B-cell_type
cells	E-cell_type
transfected	O
with	O
a	O
chimeric	B-protein
CD8alpha/IL-4Ralpha	I-protein
receptor	E-protein
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	S-protein
,	O
constitutively	O
expressed	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	E-RNA
.	O

One	O
is	O
the	O
21-base-pair	B-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
core	I-DNA
element	E-DNA
that	O
is	O
responsible	O
for	O
trans-activation	O
by	O
the	O
HTLV-I	O
trans-activator	B-protein
p40tax	E-protein
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic-AMP	B-protein
responsive	I-protein
element	I-protein
binding	I-protein
factor	I-protein
(	I-protein
CREB	I-protein
)	I-protein
-like	I-protein
factor	E-protein
(	O
s	O
)	O
.	O

Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O

Tax	S-protein
was	O
transfected	O
into	O
HTLV-I-negative	B-cell_line
human	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O

At	O
least	O
one	O
of	O
them	O
appears	O
to	O
be	O
myeloid	O
specific	O
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	S-protein
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	B-cell_type
lymphocytes	E-cell_type
and	O
in	O
viral	O
pathogenesis	O
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	E-protein
.	O

cis-acting	B-DNA
sequences	E-DNA
required	O
for	O
inducible	O
interleukin-2	B-DNA
enhancer	E-DNA
function	O
bind	O
a	O
novel	O
Ets-related	B-protein
protein	E-protein
,	O
Elf-1	S-protein
.	O

Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	B-protein
receptor	E-protein
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	E-cell_type
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	B-protein
gp41	E-protein
(	O
aa565-647	S-protein
)	O
,	O
the	O
extracellular	B-protein
domain	E-protein
of	O
HIV-1	B-protein
transmembrane	I-protein
glycoprotein	E-protein
,	O
stimulates	O
interleukin-10	S-protein
(	O
IL-10	S-protein
)	O
production	O
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF-alpha	S-protein
transcription	O
via	O
a	O
Tat	S-protein
-induced	O
tar-independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF-kappaB	S-protein
activation	O
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O

We	O
have	O
examined	O
the	O
DRA	B-DNA
promoter	E-DNA
for	O
protein-DNA	O
interactions	O
in	O
the	O
intact	B-cell_type
cell	E-cell_type
,	O
which	O
may	O
mediate	O
transcriptional	O
activation	O
.	O

When	O
grown	O
in	O
serum-free	O
medium	O
,	O
CEM-C7	S-cell_line
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B-protein
receptor	E-protein
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	B-protein
synthetase	E-protein
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	E-protein
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Regulation	O
of	O
the	O
tissue	B-DNA
factor	I-DNA
gene	E-DNA
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
.	O

The	O
initiation	O
of	O
this	O
growth	O
transforming	O
infection	O
depends	O
on	O
a	O
viral	B-DNA
promoter	E-DNA
in	O
BamHI	O
W	O
(	O
Wp	O
)	O
whose	O
regulation	O
is	O
poorly	O
understood	O
.	O

gp41	S-protein
induced	O
cAMP	O
accumulation	O
in	O
monocytes	S-cell_type
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
and	O
the	O
adenylate	B-protein
cyclase	E-protein
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41	S-protein
-induced	O
IL-10	S-protein
production	O
in	O
monocytes	S-cell_type
.	O

Regulation	O
of	O
c-jun	S-DNA
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
Rta	I-protein
protein	E-protein
activates	O
lytic	B-DNA
cycle	I-DNA
genes	E-DNA
and	O
can	O
disrupt	O
latency	O
in	O
B	B-cell_type
lymphocytes	E-cell_type
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c-fos	B-RNA
transcript	E-RNA
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN-alpha	S-protein
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	S-cell_type
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	B-cell_type
cells	E-cell_type
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	S-cell_type
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	B-RNA
mRNA	E-RNA
levels	O
of	O
the	O
hybrid	B-DNA
bcr/abl	E-DNA
,	O
c-myc	S-DNA
and	O
p53	S-DNA
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN-alpha	S-protein
is	O
accompanied	O
by	O
upregulation	O
of	O
c-fos	S-DNA
and	O
downregulation	O
of	O
c-myc	B-RNA
mRNA	E-RNA
levels	O
in	O
responder	O
patients	O
.	O

The	O
IL-2	S-protein
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	B-cell_type
lymphocytes	E-cell_type
during	O
a	O
developing	O
immune	O
response	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	S-protein
are	O
differentially	O
regulated	O
.	O

Receptor	B-RNA
transcripts	E-RNA
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O

The	O
level	O
of	O
Oct-1	B-protein
binding	I-protein
proteins	E-protein
remained	O
similar	O
in	O
all	O
samples	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	S-DNA
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3-responsive	B-DNA
reporter	I-DNA
gene	E-DNA
containing	O
the	O
CAII-specific	B-DNA
erbA-binding	I-DNA
site	E-DNA
.	O

Also	O
,	O
an	O
induction	O
specific	B-protein
DNA	I-protein
binding	I-protein
protein	E-protein
was	O
purified	O
from	O
HeLa	B-cell_line
cells	E-cell_line
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	B-DNA
sequence	E-DNA
and	O
the	O
PRDI	B-DNA
domain	E-DNA
.	O

Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL-receptor	B-DNA
gene	E-DNA
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B-protein
kDa	I-protein
factor	E-protein
to	O
the	O
SRE	B-DNA
sequence	E-DNA
.	O

Although	O
LYSP100	S-DNA
is	O
expressed	O
only	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
,	O
LANDs	O
could	O
be	O
visualized	O
in	O
HeLa	B-cell_line
cells	E-cell_line
by	O
transfection	O
of	O
a	O
LYSP100	B-DNA
cDNA	E-DNA
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c-jun	B-DNA
early	I-DNA
response	I-DNA
gene	E-DNA
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

Differential	O
responsiveness	O
of	O
the	O
IL-5	B-DNA
and	I-DNA
IL-4	I-DNA
genes	E-DNA
to	O
transcription	B-protein
factor	I-protein
GATA-3	E-protein
.	O

When	O
the	O
wild-type	B-protein
hGR	E-protein
and	O
hGR-Ile	B-protein
729	E-protein
were	O
expressed	O
in	O
COS-1	B-cell_line
cells	E-cell_line
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
+/-	O
0.068	O
and	O
1.54	O
+/-	O
0.06	O
nM	O
(	O
mean	O
+/-	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O

With	O
the	O
exception	O
of	O
LEF1	S-protein
,	O
these	O
factors	O
activate	O
transcription	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Nevertheless	O
,	O
none	O
of	O
the	O
genes	O
originally	O
thought	O
to	O
be	O
regulated	O
by	O
Oct2	S-protein
were	O
affected	O
in	O
their	O
expression	O
in	O
Oct2-deficient	B-cell_line
B	I-cell_line
cells	E-cell_line
.	O

Tax1	S-protein
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	B-cell_line
HeLa	E-cell_line
and	O
lymphoid	O
Jurkat	B-cell_line
cells	E-cell_line
.	O

The	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
has	O
neither	O
a	O
TATA	S-DNA
nor	O
a	O
CAAT	B-DNA
consensus	I-DNA
site	E-DNA
.	O

However	O
,	O
synthesis	O
of	O
the	O
26-kDa	B-protein
membrane	I-protein
form	E-protein
of	O
TNF	S-protein
was	O
effectively	O
blocked	O
by	O
CNI-1493	O
.	O

When	O
32Dcl3	B-cell_line
cells	E-cell_line
expressing	O
exogenous	O
Bcl-2	S-protein
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O

HTLV-I	O
encodes	O
a	O
potent	O
transactivator	S-protein
protein	O
termed	O
Tax	S-protein
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T-cell	O
immortalization	O
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr-1	S-protein
and	O
NF-kappa	B-protein
B	E-protein
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF-kappa	B-DNA
B1	E-DNA
gene	O
expression	O
.	O

CONCLUSIONS	O
:	O
NF-kappaB	S-protein
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	S-protein
in	O
monocytes	S-cell_type
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
and	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O

Induction	O
of	O
IL-8	S-protein
expression	O
in	O
T	B-cell_type
cells	E-cell_type
uses	O
the	O
CD28	S-protein
costimulatory	O
pathway	O
.	O

Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML/RARalpha	S-protein
mice	O
enhanced	O
granulocyte	S-cell_type
recovery	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	B-DNA
II	I-DNA
gene	E-DNA
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	S-protein
by	O
the	O
glucocorticoid	B-protein
receptor	E-protein
.	O

These	O
findings	O
establish	O
that	O
Rel	S-protein
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	B-cell_type
lymphocytes	E-cell_type
for	O
production	O
of	O
IL-3	S-protein
and	O
GM-CSF	S-protein
.	O

T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	B-protein
B	E-protein
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	E-protein
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O

Activation	O
of	O
p38	B-protein
MAPK	E-protein
correlates	O
closely	O
with	O
the	O
stimulation	O
of	O
T	O
cell	O
proliferation	O
.	O

Two	O
other	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
CEM	S-cell_line
and	O
RPMI	B-cell_line
8402	E-cell_line
,	O
have	O
essentially	O
identical	O
deletions	O
.	O

Antibody	O
cross-linking	O
of	O
TR55	S-protein
,	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
TNF-alpha	E-protein
,	O
induced	O
maximal	O
HIV-1	O
expression	O
,	O
an	O
up-modulation	O
of	O
surface	O
TR75	S-protein
,	O
and	O
nuclear	O
NF-kappa	B-protein
B	E-protein
activity	O
in	O
OM-10.1	O
cultures	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
decidualization	O
at	O
eutopic	O
and	O
ectopic	O
implantation	O
sites	O
.	O

Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O

IkappaBalpha	S-protein
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	S-protein
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	S-protein
.	O

Forty-five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O

In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	B-cell_type
cells	E-cell_type
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	S-protein
.	O

We	O
evaluated	O
the	O
immunoreactivity	O
of	O
the	O
regulatory	B-protein
and	I-protein
catalytic	I-protein
subunits	E-protein
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	E-protein
(	O
protein	B-protein
kinase	I-protein
A	E-protein
)	O
and	O
1	O
of	O
its	O
substrates	O
,	O
Rap1	S-protein
,	O
in	O
platelets	S-cell_type
from	O
untreated	O
euthymic	O
,	O
manic	O
,	O
and	O
depressed	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

Ten	O
HIV-infected	O
patients	O
with	O
normal	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS-C	O
)	O
,	O
10	O
HIV-infected	O
patients	O
with	O
low	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS-GR	O
)	O
,	O
and	O
20	O
healthy	O
subjects	O
were	O
studied	O
.	O

Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O
anti-sera	O
(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	E-cell_type
(	O
fibrosarcoma	O
:	O
8	O
,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6	O
,	O
rhabdomyosarcoma	O
:	O
10	O
,	O
leiomyosarcoma	O
:	O
10	O
,	O
liposarcoma	O
:	O
5	O
)	O
.	O

The	O
product	O
of	O
the	O
B-cell-specific	B-DNA
B29	I-DNA
gene	E-DNA
(	O
B29	S-protein
,	O
Ig	B-protein
beta	E-protein
,	O
CD79b	S-protein
)	O
is	O
essential	O
for	O
Ig-mediated	O
B-cell	O
activation	O
via	O
the	O
B-cell	B-protein
antigen	I-protein
receptor	I-protein
complex	E-protein
(	O
BCR	S-protein
)	O
on	O
human	B-cell_type
and	I-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

IL-4	S-protein
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B-protein
transcription	I-protein
factor	E-protein
,	O
STAT6	S-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-6	E-protein
)	O
.	O

Anti-CD2	B-protein
receptor	I-protein
antibodies	E-protein
activate	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

Highly	O
polarized	O
HLA	B-protein
class	I-protein
II	I-protein
antigen	E-protein
processing	O
and	O
presentation	O
by	O
human	B-cell_type
intestinal	I-cell_type
epithelial	I-cell_type
cells	E-cell_type
.	O

Differences	O
in	O
pre-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O
PGE2	O
and	O
6-k-PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	S-protein
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	S-protein
,	O
CD95	O
,	O
TNFalpha	S-protein
,	O
or	O
doxorubicin	O
,	O
NFkappaB	S-protein
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	S-protein
inhibitor	O
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	B-protein
IkappaBalpha	E-protein
.	O

The	O
regulation	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
following	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	E-protein
by	O
mAb	B-protein
L243	E-protein
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	B-cell_line
cells	E-cell_line
.	O

In	O
ductal	O
carcinomas	O
,	O
chromosome	B-DNA
1	E-DNA
alterations	O
increased	O
with	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c-erb	B-protein
B-2	E-protein
expression	O
.	O

These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS-isolated	O
)	O
subsets	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	E-cell_type
identified	O
by	O
expression	O
of	O
both	O
CD45RA	S-protein
and	O
CD62L	S-protein
.	O

Calcineurin	S-protein
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B-protein
kappa	I-protein
B/MAD3	E-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

Previous	O
studies	O
found	O
that	O
P1	S-DNA
,	O
an	O
element	O
of	O
the	O
interleukin	B-DNA
4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
promoter	E-DNA
that	O
binds	O
AP-1	O
,	O
is	O
important	O
for	O
Th2-restricted	O
IL-4	S-protein
expression	O
.	O

In	O
the	O
presence	O
of	O
Epo	S-protein
,	O
c-myb	B-RNA
mRNA	E-RNA
declined	O
and	O
20	O
%	O
of	O
K562	B-cell_line
cells	E-cell_line
synthesized	O
Hb	S-protein
regardless	O
of	O
antisense	B-RNA
myb	I-RNA
RNA	E-RNA
expression	O
.	O

A	O
truncation	B-protein
mutant	E-protein
of	O
LEF-1	S-protein
(	O
HMG-88	S-protein
)	O
,	O
which	O
contains	O
the	O
HMG	B-protein
box	E-protein
but	O
lacks	O
the	O
trans-activation	B-protein
domain	E-protein
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	E-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B-protein
domain	E-protein
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	S-protein
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	S-protein
component	O
to	O
the	O
nucleus	O
.	O

Thrombopoietin	S-protein
(	O
TPO	S-protein
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Proliferation	O
in	O
response	O
to	O
TG	S-protein
was	O
observed	O
in	O
T	B-cell_type
cells	E-cell_type
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
NF-kappaB	S-protein
activation	O
is	O
required	O
for	O
C5a-induced	O
IL-8	S-protein
gene	O
expression	O
and	O
that	O
this	O
response	O
is	O
mediated	O
primarily	O
through	O
a	O
pertussis	O
toxin-insensitive	O
pathway	O
.	O

The	O
AD1	S-protein
and	O
AD2	S-protein
transactivation	O
domains	O
of	O
E2A	S-protein
are	O
essential	O
for	O
the	O
antiapoptotic	O
activity	O
of	O
the	O
chimeric	B-protein
oncoprotein	I-protein
E2A-HLF	E-protein
.	O

Interferon	O
affects	O
nuclear	B-protein
proteins	E-protein
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	B-RNA
mRNA	E-RNA
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	B-DNA
-170	I-DNA
and	I-DNA
-139	E-DNA
of	O
the	O
human	O
IL-2Rbeta	B-DNA
promoter	E-DNA
.	O

Interferons	S-protein
(	O
IFNs	S-protein
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B-protein
proteins	E-protein
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

Modulation	O
of	O
CD28	S-protein
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

With	O
the	O
use	O
of	O
specific	B-protein
antibodies	E-protein
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
NF-M	S-protein
,	O
the	O
chicken	B-protein
homolog	E-protein
of	O
C/EBP	B-protein
beta	E-protein
,	O
is	O
specifically	O
expressed	O
in	O
myelomonocytic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
cells	E-cell_type
of	O
the	O
hematopoietic	O
system	O
.	O

Multiple	O
proteins	O
exhibiting	O
ARRE-2	S-DNA
binding	O
activity	O
have	O
been	O
isolated	O
,	O
including	O
a	O
heterodimer	S-protein
from	O
stimulated	O
T-cell	O
nuclear	O
extracts	O
consisting	O
of	O
Mr	O
=	O
90	O
000	O
(	O
NF90	S-protein
)	O
and	O
Mr	O
=	O
45	O
000	O
(	O
NF45	S-protein
)	O
subunits	O
.	O

Dexamethasone	O
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
repressed	O
chloramphenicol	B-protein
acetyltransferase	E-protein
(	O
CAT	S-protein
)	O
production	O
by	O
75	O
%	O
in	O
the	O
wild-type	B-DNA
fragment	E-DNA
but	O
not	O
in	O
a	O
deletion	B-DNA
mutant	E-DNA
lacking	O
the	O
19-bp	B-DNA
site	E-DNA
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	B-cell_type
cells	E-cell_type
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	B-protein
factors	E-protein
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	E-DNA
in	O
stimulated	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
.	O

Mechanisms	O
for	O
transduction	O
of	O
IL-6	S-protein
-induced	O
signals	O
were	O
then	O
evaluated	O
in	O
IL-6-stimulated	B-cell_line
1A9-M	I-cell_line
cells	E-cell_line
.	O

Peritoneal	B-cell_type
macrophages	E-cell_type
of	O
transgenic	O
mice	O
that	O
systemically	O
overexpress	O
IL-4	S-protein
exhibited	O
a	O
threefold	O
to	O
fourfold	O
higher	O
12-lipoxygenase	S-protein
activity	O
than	O
cells	O
prepared	O
from	O
control	O
animals	O
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA	S-protein
-mediated	O
differentiation	O
arrest	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-RNA
mRNA	E-RNA
by	O
67	O
%	O
in	O
the	O
IM-9	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O

A	O
transcript	O
of	O
the	O
ALAS	B-DNA
IRE	E-DNA
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	S-DNA
,	O
did	O
not	O
readily	O
form	O
this	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	E-protein
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	B-DNA
cDNAs	E-DNA
encoding	O
mouse	B-protein
Oct2	E-protein
from	O
a	O
mature	B-cell_line
B-cell	I-cell_line
line	E-cell_line
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	B-protein
factor	E-protein
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL-10	S-protein
to	O
suppress	O
IFN	S-protein
-induced	O
assembly	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	E-protein
to	O
specific	B-DNA
promoter	I-DNA
motifs	E-DNA
on	O
IFNalpha-	B-DNA
and	I-DNA
IFNgamma-inducible	I-DNA
genes	E-DNA
.	O

Treatment	O
of	O
chronically	B-cell_line
HIV-infected	I-cell_line
PBMC	E-cell_line
with	O
anti-CD2	B-protein
mAb	E-protein
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	B-cell_type
thymocytes	E-cell_type
in	O
vitro	O
.	O

Transfection	O
of	O
Jurkat	B-cell_line
cells	E-cell_line
with	O
the	O
NF-kappaB	B-protein
subunits	I-protein
p50	E-protein
and	O
p65	S-protein
confers	O
resistance	O
against	O
Fas-mediated	O
apoptosis	O
.	O

In	O
vivo	O
differentiation	O
therapy	O
with	O
retinoids	O
in	O
APL	O
patients	O
follows	O
strict	O
guidelines	O
related	O
both	O
to	O
the	O
APL	O
cell	O
and	O
the	O
biodisposal	O
of	O
all-trans	O
retinoic	O
acid	O
.	O

The	O
E2A-HLF	B-DNA
(	I-DNA
for	I-DNA
hepatic	I-DNA
leukaemia	I-DNA
factor	I-DNA
)	I-DNA
fusion	I-DNA
gene	E-DNA
,	O
formed	O
by	O
action	O
of	O
the	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
p13	I-DNA
)	E-DNA
chromosomal	O
translocation	O
,	O
drives	O
the	O
leukaemic	O
transformation	O
of	O
early	O
B-cell	B-cell_type
precursors	E-cell_type
,	O
but	O
the	O
mechanism	O
of	O
this	O
activity	O
remains	O
unknown	O
.	O

Overexpression	O
of	O
Bcl-2	S-protein
in	O
tumor	B-cell_type
cells	E-cell_type
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	S-protein
-mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

The	O
results	O
of	O
reporter	B-DNA
gene	E-DNA
analyses	O
revealed	O
that	O
the	O
insulin	B-DNA
gene	I-DNA
promoter	E-DNA
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta-actin	B-DNA
gene	I-DNA
promoter	E-DNA
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	B-DNA
gene	I-DNA
promoter	E-DNA
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D-ribose	O
,	O
respectively	O
.	O

StatG	S-protein
in	O
normal	B-cell_type
immature	I-cell_type
human	I-cell_type
myeloid	I-cell_type
cells	E-cell_type
,	O
i.e	O
.	O
adult	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	E-cell_type
,	O
was	O
composed	O
of	O
Stat3beta	S-protein
.	O

Single	B-protein
C	I-protein
motif-1	I-protein
(	I-protein
SCM-1	I-protein
)	I-protein
/lymphotactin	E-protein
is	O
a	O
C-type	B-protein
chemokine	E-protein
whose	O
expression	O
is	O
activation	O
dependent	O
,	O
cyclosporin	O
A	O
sensitive	O
and	O
restricted	O
to	O
CD8+	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
double-negative	B-cell_type
thymocytes	E-cell_type
,	O
gammadelta-type	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
and	O
NK	B-cell_type
cells	E-cell_type
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

This	O
unidentified	O
factor	O
binds	O
immediately	O
3	O
'	O
of	O
the	O
PU.1/Elf-1	B-DNA
sites	E-DNA
and	O
appears	O
to	O
be	O
myeloid	O
cell	O
specific	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	S-protein
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
``	B-DNA
B-subunit	I-DNA
knock-out	I-DNA
''	I-DNA
(	I-DNA
BKO	I-DNA
)	I-DNA
construct	E-DNA
suppressed	O
reporter	B-DNA
gene	E-DNA
activity	O
driven	O
by	O
NF-AT	S-protein
,	O
the	O
pivotal	O
promoter	B-DNA
element	E-DNA
for	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	E-DNA
induction	O
.	O

NF-kappaB	S-protein
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	B-DNA
gene	E-DNA
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O

Remixing	O
of	O
purified	B-cell_type
T	I-cell_type
cells	E-cell_type
showed	O
that	O
naive	B-cell_type
T	I-cell_type
cells	E-cell_type
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
that	O
memory	B-cell_type
T	I-cell_type
cells	E-cell_type
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	S-cell_line
and	O
HCD57	B-cell_line
cells	E-cell_line
correlated	O
with	O
the	O
activity	O
of	O
PKB/Akt	S-protein
;	O
however	O
,	O
PKB/Akt	S-protein
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
the	O
effect	O
of	O
CIITA	S-protein
on	O
promoter	O
occupation	O
is	O
mediated	O
by	O
an	O
effect	O
on	O
the	O
cooperative	O
stabilization	O
of	O
the	O
DNA-bound	B-protein
multi-protein	I-protein
complexes	E-protein
.	O

The	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	E-cell_line
was	O
inhibited	O
by	O
recombinant	B-protein
human	I-protein
nm23-H1	I-protein
,	I-protein
-H2	I-protein
,	I-protein
mouse	I-protein
nm23-M1	I-protein
,	I-protein
and	I-protein
-M2	I-protein
proteins	E-protein
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-protein
protein	E-protein
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
and	O
ionomycin	O
,	O
which	O
synergized	O
to	O
fully	O
activate	O
c-Jun	B-protein
N-terminal	I-protein
kinase	E-protein
,	O
was	O
also	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
.	O

The	O
CHO-DR/B7/LFA-3	B-cell_line
triple	I-cell_line
transfectant	E-cell_line
induced	O
a	O
further	O
increase	O
in	O
AP-1	S-protein
and	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	E-protein
compared	O
with	O
the	O
double	B-cell_line
transfectants	E-cell_line
.	O

No	O
effect	O
of	O
age	O
,	O
sex	O
,	O
course	O
,	O
duration	O
or	O
severity	O
of	O
disease	O
,	O
or	O
prior	O
steroid	O
treatments	O
was	O
detected	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	B-cell_type
cell	E-cell_type
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L-selectin	B-RNA
mRNA	E-RNA
in	O
fresh	O
leukemic	B-cell_type
cells	E-cell_type
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L-selectin	B-DNA
promoter	E-DNA
to	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	E-protein
,	O
which	O
is	O
a	O
viral	B-protein
transcriptional	I-protein
transactivator	E-protein
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	E-protein
,	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	E-protein
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O

In	O
contrast	O
,	O
Grb2	S-protein
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	S-protein
and	O
Sos2	S-protein
but	O
not	O
with	O
SLP-76	S-protein
.	O

Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	E-cell_line
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	E-DNA
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	B-DNA
-128	I-DNA
to	I-DNA
-70	E-DNA
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	S-protein
expression	O
.	O

Although	O
a	O
role	O
of	O
p16	S-protein
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	B-DNA
suppressor	I-DNA
gene	E-DNA
really	O
affects	O
E2F	S-protein
-mediated	O
regulations	O
.	O

Modulation	O
of	O
mRNA	O
expression	O
of	O
a	O
novel	B-DNA
human	I-DNA
myeloid-selective	I-DNA
CCAAT/enhancer	I-DNA
binding	I-DNA
protein	I-DNA
gene	E-DNA
(	O
C/EBP	B-DNA
epsilon	E-DNA
)	O
.	O

Ras-related	B-protein
GTP-binding	I-protein
proteins	E-protein
and	O
leukocyte	S-cell_type
signal	O
transduction	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	E-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	S-protein
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-protein
gene	I-protein
products	E-protein
.	O

Beta-catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B-DNA
segment	I-DNA
polarity	I-DNA
gene	I-DNA
Armadillo	E-DNA
and	O
plays	O
roles	O
in	O
both	O
cell-cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Thiol	O
modulation	O
inhibits	O
the	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	E-protein
-mediated	O
activation	O
of	O
an	O
IL-1	B-protein
receptor-associated	I-protein
protein	I-protein
kinase	E-protein
and	O
NF-kappa	B-protein
B	E-protein
.	O

It	O
is	O
surprising	O
that	O
the	O
faster-migrating	B-protein
complex	E-protein
was	O
composed	O
also	O
of	O
p50	S-protein
and	O
p65	S-protein
.	O

Endothelial	B-cell_type
cells	E-cell_type
were	O
treated	O
with	O
TCP	O
,	O
alpha-tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha-tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
or	O
interleukin-1	B-protein
beta	E-protein
(	O
IL-1	B-protein
beta	E-protein
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro-monocytic	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
THP-1	S-cell_line
,	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
interleukin	B-protein
1beta	E-protein
is	O
dependent	O
on	O
tyrosine	B-protein
kinase	E-protein
activation	O
.	O

We	O
found	O
that	O
the	O
adenylate	B-protein
cyclase	E-protein
activator	O
,	O
forskolin	O
,	O
inhibits	O
anti-CD3	S-protein
-induced	O
shift	O
in	O
Lck	S-protein
electrophoretic	O
mobility	O
,	O
suggesting	O
an	O
intervention	O
at	O
the	O
TCR	S-protein
-coupled	O
phosphoinositide	O
turnover	O
that	O
precedes	O
the	O
activation	O
of	O
PKC	S-protein
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	S-protein
,	O
TNF	S-protein
,	O
and	O
some	O
commonly	O
known	O
lymphokines	S-protein
.	O

In	O
contrast	O
,	O
luciferase	S-protein
expression	O
was	O
not	O
stimulated	O
after	O
IFN-gamma	S-protein
treatment	O
when	O
the	O
construct	O
was	O
transfected	O
in	O
macrophage	O
or	O
in	O
epithelial	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	O
to	O
affect	O
proliferation	O
and	O
differentiation	O
of	O
U937	B-cell_line
cells	E-cell_line
.	O

A	O
single-chain	B-protein
Fv	E-protein
(	O
sFv	S-protein
)	O
was	O
expressed	O
from	O
the	O
variable	B-protein
regions	E-protein
of	O
the	O
CD40-specific	O
mAb	B-protein
G28-5	E-protein
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	B-DNA
gamma	E-DNA
,	O
is	O
active	O
in	O
both	O
HeLa	B-cell_line
cervical	I-cell_line
carcinoma	I-cell_line
cells	E-cell_line
and	O
Huh7	B-cell_line
hepatoma	I-cell_line
cells	E-cell_line
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

We	O
conclude	O
that	O
the	O
NF-IL6	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
sites	E-DNA
mediate	O
IL-6	S-protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	S-protein
,	O
acting	O
as	O
bacterial	B-DNA
or	I-DNA
mycobacterial	I-DNA
response	I-DNA
elements	E-DNA
.	O

A-myb	S-DNA
was	O
undetectable	O
in	O
4	O
prolymphocytic	O
leukemias	O
(	O
PLL	O
)	O
but	O
was	O
strongly	O
expressed	O
in	O
5/20	O
(	O
25	O
%	O
)	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
samples	O
.	O

In	O
conclusion	O
,	O
we	O
propose	O
that	O
Bcl-xL	S-protein
expression	O
is	O
associated	O
with	O
differentiation	O
and	O
survival	O
of	O
hematopoietic	B-cell_type
cells	E-cell_type
along	O
the	O
monocyte/macrophage	B-cell_type
lineage	E-cell_type
.	O

MyD88	S-protein
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	B-DNA
response	I-DNA
gene	E-DNA
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	S-protein
(	O
IL-1	S-protein
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	B-protein
receptor	I-protein
complex	E-protein
and	O
IL-1	B-protein
receptor-associated	I-protein
kinase	E-protein
(	O
IRAK	S-protein
)	O
.	O

Previous	O
studies	O
established	O
a	O
potential	O
role	O
for	O
the	O
Src-family	B-protein
kinase	I-protein
Lck	E-protein
in	O
JAK	B-protein
-STAT	E-protein
signaling	O
.	O

IL-10	S-protein
effected	O
dose-dependent	O
inhibition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
release	O
in	O
PBMC	S-cell_type
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U/ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U/ml	O
.	O

Activation	O
of	O
the	O
NF-kappaB	S-protein
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	B-cell_type
neutrophils	E-cell_type
.	O

Transient	O
cotransfection	O
of	O
tat	B-DNA
cDNA	E-DNA
in	O
sense	O
orientation	O
(	O
tat/S	S-DNA
)	O
,	O
together	O
with	O
a	O
plasmid	S-DNA
containing	O
the	O
c-fos	B-DNA
promoter	E-DNA
(	O
FC3	S-DNA
,	O
from-	O
711	B-DNA
to	I-DNA
+42	E-DNA
)	O
in	O
front	O
of	O
the	O
bacterial	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	E-DNA
significantly	O
enhanced	O
CAT	S-protein
activity	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
activated	O
by	O
the	O
addition	O
of	O
15	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms/mL	O
phytohemagglutinin	S-protein
plus	O
10	O
(	O
-7	O
)	O
mol/L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	B-cell_line
cells	E-cell_line
activated	O
by	O
15	O
%	O
FCS	O
or	O
10	O
(	O
-7	O
)	O
mol/L	O
PMA	O
.	O

HLA-DM	S-protein
is	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II-like	I-protein
molecule	E-protein
that	O
facilitates	O
antigen	O
processing	O
by	O
catalyzing	O
the	O
exchange	O
of	O
invariant	O
chain-derived	O
peptides	O
(	O
CLIP	O
)	O
from	O
class	B-protein
II	I-protein
molecules	E-protein
for	O
antigenic	O
peptides	O
.	O

The	O
kappa	B-DNA
B	I-DNA
sequence	E-DNA
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF-kappa	B-protein
B	E-protein
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	B-cell_type
lymphocytes	E-cell_type
.	O

Anti-	O
HBx	S-protein
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

The	O
MHC	B-protein
class	I-protein
II	I-protein
homologous	I-protein
proteins	I-protein
HLA-DMA	E-protein
and	O
HLA-DMB	S-protein
function	O
in	O
the	O
loading	O
of	O
peptides	O
onto	O
class	B-protein
II	I-protein
molecules	E-protein
.	O

These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	E-cell_type
.	O

Activation	O
of	O
the	O
enhancer	S-DNA
in	O
non-B	B-cell_type
cells	E-cell_type
upon	O
overexpression	O
of	O
the	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
protein	I-protein
E2A	E-protein
appears	O
to	O
be	O
mediated	O
not	O
only	O
by	O
the	O
binding	O
of	O
E2A	S-protein
to	O
its	O
cognate	O
E	B-DNA
box	E-DNA
but	O
also	O
by	O
the	O
resulting	O
displacement	O
of	O
a	O
repressor	S-protein
from	O
that	O
same	O
site	O
.	O

In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	B-protein
binding	I-protein
proteins	E-protein
,	O
Oct-1	S-protein
or	O
Oct-2	S-protein
,	O
were	O
found	O
.	O

Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML/RAR	B-protein
alpha	E-protein
or	O
AML1/ETO	S-protein
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	B-cell_type
subsets	E-cell_type
involved	O
in	O
antitumor	O
immunity	O
.	O

Active	O
Stat3	S-protein
,	O
but	O
not	O
Stat1	S-protein
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA-1	S-protein
to	O
consensus	B-DNA
sites	E-DNA
in	O
the	O
beta-globin	B-DNA
loci	E-DNA
.	O

Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	S-protein
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR/tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606-611	O
)	O
.	O

There	O
are	O
other	O
elements	O
regulating	O
IL-4	B-DNA
gene	E-DNA
expression	O
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O

The	O
presence	O
of	O
STAT-1	S-protein
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Adenoviruses	O
encode	O
proteins	O
that	O
block	O
responses	O
to	O
interferons	S-protein
,	O
intrinsic	O
cellular	O
apoptosis	O
,	O
killing	O
by	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
and	O
killing	O
by	O
the	O
death	B-protein
ligands	I-protein
TNF	E-protein
,	O
Fas	B-protein
ligand	E-protein
and	O
TRAIL	S-protein
.	O

Characterization	O
and	O
understanding	O
of	O
the	O
basic	O
mechanisms	O
involved	O
in	O
the	O
different	O
pathways	O
protecting	O
or	O
leading	O
to	O
cell	O
death	O
may	O
provide	O
novel	O
ways	O
to	O
control	O
inappropriate	O
apoptosis	O
involved	O
in	O
several	O
diseases	O
.	O

IL-13	S-protein
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	B-protein
Janus	I-protein
kinase	E-protein
in	O
human	B-cell_line
colon	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	E-cell_line
:	O
similarities	O
between	O
IL-4	S-protein
and	O
IL-13	S-protein
signaling	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	E-DNA
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell-specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	B-DNA
control	I-DNA
region	E-DNA
(	O
LCR	S-DNA
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c-myc	B-DNA
oncogene	E-DNA
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	B-DNA
locus	E-DNA
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	B-DNA
gene	I-DNA
class	E-DNA
switch	O
recombination	O
.	O

Our	O
present	O
study	O
shows	O
that	O
IFN-alpha	B-protein
and	I-protein
-beta	E-protein
mediate	O
anti-apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL-2	S-protein
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	S-DNA
(	O
HZF	B-DNA
1-10	E-DNA
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	B-DNA
11-42	E-DNA
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	B-protein
Kruppel-related	I-protein
zinc	I-protein
finger	I-protein
proteins	E-protein
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	B-protein
fingers	E-protein
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy-terminal	B-protein
regions	E-protein
of	O
the	O
proteins	O
.	O

In	O
selenium-deprived	B-cell_line
Jurkat	E-cell_line
and	O
ESb-L	B-cell_line
T	I-cell_line
lymphocytes	E-cell_line
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	S-protein
activity	O
.	O

H2O2-induced	O
NF-kappaB	S-protein
activation	O
in	O
Wurzburg	B-cell_line
cells	E-cell_line
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

The	O
GAS	B-DNA
element	E-DNA
from	O
the	O
70-bp	B-DNA
motif	E-DNA
is	O
sufficient	O
to	O
confer	O
responsiveness	O
to	O
IFN-gamma	S-protein
using	O
a	O
heterologous	O
minimal	O
promoter	O
.	O

We	O
have	O
developed	O
a	O
three-layer	O
Percoll	O
density	O
gradient	O
that	O
allows	O
separation	O
of	O
the	O
different	O
granules	O
and	O
vesicles	O
from	O
human	B-cell_type
neutrophils	E-cell_type
;	O
in	O
particular	O
,	O
it	O
allows	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
.	O

NF-kappaB	S-protein
functions	O
as	O
both	O
a	O
proapoptotic	B-protein
and	I-protein
antiapoptotic	I-protein
regulatory	I-protein
factor	E-protein
within	O
a	O
single	O
cell	O
type	O
.	O

Molecular	O
events	O
that	O
underlie	O
the	O
well-defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	B-cell_type
thymocyte	E-cell_type
are	O
poorly	O
understood	O
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	E-protein
in	O
interleukin-1	B-cell_line
(	I-cell_line
IL-1	I-cell_line
)	I-cell_line
-responsive	I-cell_line
cells	E-cell_line
blocked	O
IL-1-induced	B-DNA
gene	E-DNA
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
enhancer	E-DNA
or	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
.	O

Since	O
C3a	S-protein
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	S-cell_type
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a	S-protein
-mediated	O
enhancement	O
of	O
LPS-	O
and	O
IL-1beta-induced	O
IL-6	O
production	O
.	O

A	O
carboxy	B-DNA
terminal	I-DNA
Tax	I-DNA
deletion	I-DNA
mutant	E-DNA
was	O
deficient	O
in	O
transactivation	O
of	O
both	O
the	O
PTHrP	B-DNA
and	I-DNA
IL2R	I-DNA
alpha	I-DNA
promoters	E-DNA
but	O
not	O
the	O
HTLV-I	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	S-cell_type
during	O
active	O
tuberculosis	O
and	O
by	O
M.	O
tuberculosis	O
.	O

T	O
cell	O
reactivity	O
to	O
Sjogren	O
's	O
syndrome	O
related	O
antigen	O
La	B-protein
(	I-protein
SSB	I-protein
)	E-protein
.	O

NF-kappa	B-protein
B	E-protein
,	O
a	O
50	B-protein
kDa/65	I-protein
kDa	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	E-protein
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	E-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B-DNA
genes	E-DNA
.	O

However	O
,	O
TGF-beta	B-protein
1	E-protein
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	S-protein
in	O
EBV	B-cell_line
(	I-cell_line
or	I-cell_line
LMP-1	I-cell_line
)	I-cell_line
-positive	I-cell_line
cells	E-cell_line
as	O
opposed	O
to	O
EBV-negative	B-cell_line
cells	E-cell_line
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF-beta	B-protein
1	E-protein
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O

Intrafollicular	O
CD57+	B-cell_type
cells	E-cell_type
did	O
not	O
stain	O
for	O
Bcl-6	S-protein
,	O
and	O
were	O
also	O
depleted	O
in	O
AITL/GC	O
.	O

Selective	O
activation	O
of	O
STAT1alpha	S-protein
at	O
the	O
IFN-gamma	B-protein
receptor	E-protein
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	B-protein
tyrosine	I-protein
motif	E-protein
including	O
Y440	S-protein
in	O
the	O
IFN-gamma	B-protein
receptor	I-protein
alpha-chain	E-protein
and	O
the	O
SH2	B-protein
domain	E-protein
of	O
STAT1alpha	S-protein
.	O

Several	O
neuroendocrine-immune	O
interactions	O
could	O
be	O
responsible	O
for	O
reduced	O
GR	S-protein
levels	O
with	O
age	O
and	O
sport	O
activity	O
in	O
man	O
.	O

By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	B-RNA
transcript	I-RNA
1	E-RNA
(	O
leukocyte-type	O
)	O
,	O
but	O
not	O
PAFR	B-RNA
transcript	I-RNA
2	E-RNA
(	O
tissue-type	O
)	O
,	O
are	O
upregulated	O
by	O
PAF	S-protein
as	O
well	O
as	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	B-cell_line
stomach	I-cell_line
cancer	I-cell_line
cell	I-cell_line
line	E-cell_line
(	O
JR-St	B-cell_line
cells	E-cell_line
)	O
which	O
expresses	O
both	O
functional	O
PAFR	B-RNA
transcript	I-RNA
1	E-RNA
and	O
PAFR	B-RNA
transcript	I-RNA
2	E-RNA
endogenously	O
.	O

We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60-kDa	B-protein
protein	E-protein
binding	O
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino-terminal	B-protein
sequence	E-protein
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	B-DNA
probes	E-DNA
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP-1	B-cell_line
cells	E-cell_line
.	O

Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	O
production	O
of	O
inflammatory	B-protein
cytokines	E-protein
,	O
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
,	O
interleukin-1	B-protein
beta	E-protein
,	O
and	O
interleukin-6	S-protein
by	O
disrupting	O
NF-kappa	B-protein
B	E-protein
signaling	O
in	O
monocytes	S-cell_type
.	O

In	O
conclusion	O
,	O
intranasal	O
glucocorticoids	O
at	O
clinically	O
recommended	O
doses	O
have	O
not	O
only	O
significant	O
systemic	O
effects	O
on	O
adrenal	O
function	O
,	O
but	O
also	O
have	O
an	O
effect	O
on	O
specific	O
gene	O
expression	O
in	O
peripheral	B-cell_type
lymphocytes	E-cell_type
.	O

Oct-1	S-protein
has	O
also	O
been	O
shown	O
to	O
repress	O
interleukin	B-protein
8	E-protein
promoter	O
activity	O
.	O

The	O
ZR-75-1	B-cell_line
cell	I-cell_line
line	E-cell_line
showed	O
an	O
expression	O
of	O
642	O
fmol/mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol/mg	O
.	O

We	O
conclude	O
that	O
cord	O
lymphocyte	O
activation	O
exhibits	O
an	O
adult-type	O
profile	O
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10-fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium-mobilizing	O
potency	O
as	O
VD	O
.	O

This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL-2	S-protein
.	O

LMP1	S-protein
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	E-protein
,	O
one	O
through	O
interactions	O
with	O
TRAF	B-protein
proteins	E-protein
and	O
the	O
other	O
with	O
the	O
TRADD	B-protein
protein	E-protein
.	O

Transcription	B-protein
factor	I-protein
AP-2	E-protein
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full-length	B-protein
BOB.1/OBF.1	E-protein
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
elements	E-DNA
in	O
non	B-cell_type
B	I-cell_type
cells	E-cell_type
,	O
the	O
GAL4	B-protein
fusions	E-protein
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O

The	O
gammac	B-protein
chain	E-protein
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	B-protein
receptors	E-protein
(	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	E-protein
,	O
IL-4	S-protein
,	O
IL-7	S-protein
,	O
IL-9	S-protein
,	O
and	O
IL-15	S-protein
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	B-cell_type
lineages	E-cell_type
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC/Sp1	S-protein
and	O
GATA	B-DNA
binding	I-DNA
sites	E-DNA
can	O
drive	O
efficient	O
and	O
tissue-specific	O
expression	O
of	O
this	O
R-PK	B-DNA
minimal	I-DNA
promoter	E-DNA
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
via	O
CD21	S-protein
,	O
the	O
CR2	B-protein
complement	I-protein
receptor	E-protein
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

Diminished	O
receptor	O
density	O
in	O
RA	O
patients	O
does	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	S-cell_type
contained	O
p50	S-protein
and	O
p65	B-protein
protein	E-protein
in	O
response	O
to	O
LPS	O
and	O
IFN-gamma	S-protein
stimulation	O
.	O

After	O
LPS	O
stimulation	O
in	O
human	B-cell_type
monocytes	E-cell_type
,	O
IkappaB-alpha	S-protein
protein	O
levels	O
decreased	O
,	O
and	O
NF-kappaB	S-protein
DNA	O
binding	O
increased	O
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	B-protein
and	I-protein
nuclear	I-protein
NF-kappaB	I-protein
proteins	E-protein
binding	O
to	O
the	O
GM-CSF	B-DNA
element	E-DNA
.	O

The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O

In	O
addition	O
,	O
ALY	S-protein
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	S-protein
and	O
AML	B-protein
proteins	E-protein
.	O

The	O
glutamine-rich	B-protein
activation	I-protein
domain	E-protein
present	O
in	O
the	O
amino-terminal	B-protein
portion	I-protein
of	I-protein
Oct2	E-protein
and	O
the	O
POU	B-protein
domain	E-protein
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

Surfactant	B-protein
protein	I-protein
A	E-protein
activates	O
NF-kappa	B-protein
B	E-protein
in	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

Tumor	O
proliferative	O
activity	O
as	O
evaluated	O
by	O
the	O
monoclonal	B-protein
antibody	I-protein
Ki-67	E-protein
seems	O
to	O
be	O
an	O
effective	O
indicator	O
of	O
prognosis	O
in	O
breast	O
cancer	O
for	O
DFS	O
and	O
OS	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B-protein
binding	I-protein
proteins	E-protein
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	B-cell_type
mouse	I-cell_type
astrocytes	E-cell_type
.	O

The	O
discovery	O
of	O
EBV	O
in	O
certain	O
T	O
cell	O
malignancies	O
and	O
the	O
expression	O
of	O
the	O
EBV	B-protein
receptor	E-protein
,	O
CR2/CD21	S-protein
,	O
on	O
a	O
population	O
of	O
immature	B-cell_type
thymocytes	E-cell_type
,	O
T	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
and	O
childhood	B-cell_type
acute	I-cell_type
T	I-cell_type
lymphoblastic	I-cell_type
leukemia	I-cell_type
cells	E-cell_type
suggested	O
that	O
EBV-receptor	O
interactions	O
on	O
T	B-cell_type
cells	E-cell_type
may	O
be	O
of	O
importance	O
.	O

Quantitative	O
thin-layer	O
chromatography	O
(	O
TLC	O
)	O
analyses	O
showed	O
that	O
HL60	S-cell_line
and	O
normal	B-cell_type
cells	E-cell_type
are	O
able	O
to	O
generate	O
estrone	O
(	O
E1	O
)	O
from	O
estradiol	O
(	O
E2	O
)	O
.	O

It	O
plays	O
an	O
important	O
role	O
in	O
modulating	O
the	O
balance	O
of	O
T	B-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cell	I-cell_type
subsets	E-cell_type
,	O
favoring	O
expansion	O
of	O
the	O
Th2	B-cell_type
lineage	E-cell_type
relative	O
to	O
Th1	S-cell_type
.	O

These	O
perivascular	B-cell_type
DC	E-cell_type
migrate	O
across	O
the	O
activated	O
endothelium	O
from	O
blood	O
and	O
receive	O
differentiative	O
signals	O
within	O
the	O
joint	O
from	O
monocyte-derived	B-protein
cytokines	E-protein
and	O
CD40-ligand+	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Alagille	O
syndrome	O
(	O
AGS	O
)	O
is	O
a	O
well-defined	O
genetic	O
entity	O
assigned	O
to	O
the	O
short	B-DNA
arm	E-DNA
of	O
Chromosome	B-DNA
(	I-DNA
Chr	I-DNA
)	I-DNA
20	E-DNA
by	O
a	O
series	O
of	O
observations	O
of	O
AGS	O
patients	O
associated	O
with	O
microdeletions	O
in	O
this	O
region	O
.	O

By	O
using	O
Jurkat	S-cell_line
and	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	S-protein
-initiated	O
signal	O
transduction	O
,	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
and	O
calcineurin	S-protein
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	B-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	E-protein
but	O
not	O
of	O
another	O
putative	B-protein
IkappaBalpha	I-protein
kinase	E-protein
,	O
p90	B-protein
(	I-protein
rsk	I-protein
)	E-protein
.	O

Circulating	B-cell_type
T-cells	E-cell_type
from	O
individuals	O
with	O
filaria-induced	O
lymphatic	O
pathology	O
(	O
LP	O
)	O
had	O
significantly	O
greater	O
migration	O
through	O
unstimulated	O
HUVEC	B-cell_type
monolayers	E-cell_type
than	O
did	O
T-cells	O
from	O
asymptomatic	O
infected	O
(	O
MF	O
)	O
individuals	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Males	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-DNA
receptor	I-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	E-DNA
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	S-protein
(	O
IL-2	S-protein
)	O
,	O
IL-4	S-protein
,	O
IL-7	S-protein
,	O
IL-9	S-protein
,	O
and	O
IL-15	S-protein
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	S-protein
in	O
Jurkat	B-cell_line
cells	E-cell_line
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	S-protein
-induced	O
transactivation	O
of	O
a	O
GRE-dependent	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	E-DNA
either	O
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-and	O
dexamethasone-induced	O
apoptosis	O
in	O
human	B-cell_type
thymocytes	E-cell_type
at	O
a	O
concentration	O
of	O
1-10	O
microM	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B-protein
receptor	E-protein
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Infection	O
of	O
human	B-cell_type
B	I-cell_type
cells	E-cell_type
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O

Increases	O
in	O
CAT	S-protein
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
cells	E-cell_line
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	S-DNA
that	O
contains	O
the	O
AP-1	B-DNA
binding	I-DNA
site	E-DNA
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	B-DNA
gene	E-DNA
in	O
infected	O
thymocytes	S-cell_type
was	O
transcribed	O
from	O
the	O
Fp	B-DNA
promoter	E-DNA
,	O
rather	O
than	O
from	O
the	O
Cp/Wp	B-DNA
promoter	E-DNA
which	O
is	O
used	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	E-cell_type
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	S-protein
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	B-cell_type
cells	E-cell_type
.	O

Their	O
IL-2	S-protein
transcription	O
seems	O
to	O
be	O
controlled	O
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	B-protein
transcription	I-protein
factor	E-protein
binding	O
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O
in	O
resting	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	E-cell_type
the	O
activator	S-DNA
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	B-cell_line
cells	E-cell_line
it	O
is	O
functional	O
in	O
promoting	O
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O

Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA-1	S-protein
foci	O
seen	O
by	O
immunofluorescence	O
.	O

p60	S-protein
phosphorylation	O
was	O
time	O
and	O
PMA	O
dose	O
dependent	O
,	O
and	O
was	O
induced	O
by	O
cell-permeable	O
diacylglycerol	O
,	O
but	O
not	O
by	O
inactive	O
phorbol	O
esters	O
.	O

Most	O
mutations	O
were	O
outside	O
the	O
motifs	O
potentially	O
important	O
for	O
transcription	O
,	O
suggesting	O
they	O
were	O
not	O
important	O
in	O
lymphomagenesis	O
but	O
may	O
,	O
like	O
Ig	O
mutation	O
,	O
represent	O
an	O
inherent	O
feature	O
of	O
the	O
lymphoma	B-cell_type
precursor	I-cell_type
cells	E-cell_type
.	O

Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta-estradiol	O
for	O
type	B-protein
II	I-protein
EBS	E-protein
in	O
PBMC	S-cell_type
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O

We	O
have	O
cloned	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	I-protein
LMP1	I-protein
)	I-protein
homologs	E-protein
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

It	O
will	O
further	O
elaborate	O
on	O
the	O
attempts	O
to	O
develop	O
successful	O
immunotherapy	O
and	O
drug	O
therapy	O
targeting	O
Ras	S-protein
expressing	O
tumors	O
.	O

Ovarian	O
and	O
breast	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
can	O
recognize	O
peptides	O
from	O
the	O
amino	O
enhancer	O
of	O
split	O
protein	O
of	O
the	O
Notch	B-protein
complex	E-protein
.	O

Addition	O
of	O
untreated	O
THP-1	B-cell_line
cells	E-cell_line
had	O
little	O
effect	O
on	O
HUVEC	S-cell_type
adhesiveness	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	S-protein
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B-protein
variant	E-protein
(	O
FAB	B-protein
AML-M3v	E-protein
)	O
.	O

In	O
order	O
to	O
study	O
the	O
transcriptional	O
control	O
of	O
15-LO	S-protein
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	B-DNA
15-LO	I-DNA
promoter	I-DNA
region	E-DNA
.	O

Rather	O
,	O
IFN-gamma	S-protein
antagonized	O
the	O
effect	O
of	O
IL-4	S-protein
and	O
suppressed	O
the	O
DC	S-cell_type
and	O
MGC	S-cell_type
formation	O
induced	O
by	O
GM-CSF	S-protein
+	O
IL-4	S-protein
and	O
M-CSF	S-protein
+	O
IL-4	S-protein
,	O
respectively	O
.	O

Therefore	O
,	O
we	O
investigated	O
their	O
normal	O
cell	O
counterparts	O
microdissected	O
from	O
a	O
reactive	O
tonsil	O
.	O

RESULTS	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
day	O
4	O
onward	O
.	O

The	O
GM-CSF	B-DNA
promoter	E-DNA
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	S-protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	S-protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Induction	O
of	O
NF-kB	S-protein
and	O
HIV	O
replication	O
by	O
cytokines	S-protein
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB-defective	B-cell_line
cells	E-cell_line
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	S-DNA
inducibility	O
.	O

Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

New	O
knowledge	O
on	O
the	O
mechanism	O
of	O
steroid	O
resistance	O
may	O
have	O
important	O
implications	O
for	O
the	O
treatment	O
of	O
chronic	O
asthma	O
and	O
other	O
diseases	O
.	O

Decreased	O
adhesion	B-protein
molecule	E-protein
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

The	O
persistence	O
of	O
TGF-beta1-transcribing	B-cell_type
macrophages	E-cell_type
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Unlike	O
Oct-1	S-protein
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct-2	S-protein
expression	O
is	O
restricted	O
primarily	O
to	O
B	B-cell_type
lymphocytes	E-cell_type
and	O
can	O
be	O
induced	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	E-cell_type
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	S-protein
under	O
control	O
of	O
simian	B-DNA
virus	I-DNA
40	I-DNA
or	I-DNA
Moloney	I-DNA
murine	I-DNA
leukemia	I-DNA
virus	I-DNA
promoters	E-DNA
resulted	O
in	O
increased	O
LMP1	S-protein
expression	O
in	O
P3HR-1-infected	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	E-cell_line
and	O
the	O
P3HR-1	S-cell_line
or	O
Daudi	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O

Using	O
as	O
a	O
probe	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
both	O
antioxidant	O
and	O
antiproliferative	O
activity	O
,	O
we	O
have	O
identified	O
erk2	S-protein
,	O
a	O
key	O
element	O
of	O
the	O
MAP	O
kinase	O
pathway	O
,	O
as	O
being	O
responsive	O
to	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans-disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o'-bismyristoyl	O
esterification	O
of	O
TDS	O
.	O

Cytogenetic	O
examination	O
of	O
the	O
patient	O
's	O
younger	O
brother	O
,	O
who	O
had	O
fathered	O
three	O
healthy	O
children	O
,	O
showed	O
an	O
identical	O
karyotype	O
.	O

The	O
shift	O
of	O
Lck	S-protein
following	O
direct	O
PKC	S-protein
activation	O
by	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
,	O
which	O
bypasses	O
early	O
receptor-triggered	O
biochemical	O
events	O
,	O
is	O
insensitive	O
to	O
forskolin	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF-kappaB	S-protein
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	B-protein
negative	I-protein
mutant	E-protein
forms	O
of	O
components	O
of	O
the	O
NF-kappaB	S-protein
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	S-protein
or	O
p65	S-protein
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Thus	O
,	O
Elf-1	S-protein
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	S-cell_type
.	O

Stimulation	O
of	O
B	B-cell_type
lymphocytes	E-cell_type
by	O
either	O
ligation	O
of	O
CD40	B-protein
Ag	E-protein
or	O
cross-linking	O
the	O
Ig	B-protein
receptor	E-protein
is	O
also	O
insufficient	O
to	O
render	O
B	B-cell_type
lymphocytes	E-cell_type
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Using	O
recombinant	B-protein
HBxAg	I-protein
protein	E-protein
,	O
we	O
found	O
HBxAg	S-protein
-specific	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	O
in	O
healthy	O
individuals	O
.	O

Elf-1	S-protein
physically	O
associated	O
with	O
HMG-I	S-protein
and	O
with	O
NF-kappa	B-protein
B	I-protein
p50	E-protein
and	O
c-Rel	S-protein
in	O
vitro	O
,	O
suggesting	O
that	O
protein-protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
positive	I-DNA
regulatory	I-DNA
elements	E-DNA
.	O

Latent	B-protein
membrane	I-protein
protein	I-protein
1	E-protein
(	O
LMP1	S-protein
)	O
acts	O
like	O
a	O
permanently	B-protein
activated	I-protein
receptor	E-protein
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-receptor	I-protein
superfamily	E-protein
and	O
is	O
absolutely	O
required	O
for	O
B	O
cell	O
immortalization	O
by	O
Epstein-Barr	O
virus	O
.	O

Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	S-protein
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	E-cell_type
,	O
but	O
not	O
on	O
normal	B-cell_type
circulating	I-cell_type
granulocytes	E-cell_type
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c-Rel/p50	B-protein
heterodimers	E-protein
as	O
well	O
as	O
p50/p65	S-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
kappa	O
B	O
DNA-binding	O
complexes	O
in	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	E-cell_line
.	O

LPS	O
tolerance	O
in	O
monocytes/macrophages	S-cell_type
:	O
three	O
3	O
'	O
cytosins	O
are	O
required	O
in	O
the	O
DNA	B-DNA
binding	I-DNA
motif	E-DNA
for	O
detection	O
of	O
upregulated	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
homodimers	E-protein
.	O

However	O
,	O
a	O
minority	O
of	O
LYSP100	S-DNA
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	S-cell_type
and	O
SP100	S-protein
.	O

Our	O
data	O
support	O
the	O
notion	O
that	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	E-protein
and	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
proteases	E-protein
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O

In	O
vivo	O
,	O
this	O
could	O
lead	O
to	O
inappropriate	O
binding	O
of	O
cortisol	O
to	O
mineralocorticoid	O
receptors	O
.	O

Pax-5a	S-protein
was	O
detectable	O
in	O
pro-	B-cell_line
,	I-cell_line
pre-	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B-cell	I-cell_line
lines	E-cell_line
,	O
but	O
not	O
in	O
two	O
plasmacytomas	O
;	O
Pax-5b	S-protein
was	O
shown	O
to	O
be	O
present	O
at	O
low	O
levels	O
in	O
mature	B-cell_line
B-cell	I-cell_line
lines	E-cell_line
and	O
,	O
unexpectedly	O
,	O
in	O
one	O
plasma	O
cell	O
line	O
,	O
but	O
not	O
in	O
pro-B-cell	B-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O

The	O
number	O
of	O
estrogen	B-protein
receptors	E-protein
(	O
ER	S-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	E-cell_type
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O

Despite	O
the	O
dual	O
specificity	O
of	O
HTLV-1	O
Tax	S-protein
for	O
IkappaBalpha	S-protein
and	O
IkappaBbeta	S-protein
at	O
the	O
protein	O
level	O
,	O
Tax	S-protein
selectively	O
stimulates	O
NF-kappaB	S-protein
-directed	O
transcription	O
of	O
the	O
IkappaBalpha	B-DNA
gene	E-DNA
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	B-DNA
box	E-DNA
,	O
and	O
a	O
TA-rich	O
sequence	O
present	O
in	O
the	O
CD21	B-DNA
promoter	E-DNA
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B-protein
proteins	E-protein
suggesting	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	E-protein
were	O
Oct-1	S-protein
and	O
Oct-2	S-protein
.	O

Notably	O
,	O
the	O
lack	O
of	O
pRB	S-protein
in	O
these	O
U937-derived	B-cell_line
clones	E-cell_line
renders	O
these	O
p53-null	B-cell_line
cells	E-cell_line
highly	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
serum	O
withdrawal	O
,	O
calphostin	O
C	O
,	O
and	O
ceramide	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	B-protein
ER	E-protein
reduced	O
the	O
binding	O
activities	O
of	O
chicken	B-protein
immature	I-protein
erythrocyte	I-protein
nuclear	I-protein
extracted	I-protein
proteins	E-protein
to	O
GATA	B-DNA
and	I-DNA
CACCC	I-DNA
sites	E-DNA
in	O
the	O
H5	B-DNA
promoter	I-DNA
and	I-DNA
enhancer	E-DNA
.	O

Both	O
GATA-1	S-protein
and	O
CACCC-binding	B-protein
proteins	E-protein
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid-specific	B-DNA
genes	E-DNA
.	O

Cytokine	S-protein
and	O
growth	B-protein
factor	I-protein
receptor	E-protein
engagement	O
leads	O
to	O
the	O
rapid	O
phosphorylation	O
and	O
activation	O
of	O
latent	O
,	O
cytosolic	B-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	E-protein
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
regulate	O
transcriptional	O
events	O
from	O
specific	B-DNA
promoter	I-DNA
sequences	E-DNA
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-DNA
genomic	I-DNA
locus	E-DNA
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-DNA
locus	E-DNA
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B-DNA
part	E-DNA
of	O
chromosome	B-DNA
14	E-DNA
.	O

Since	O
promoter	O
elements	O
controlling	O
collagenase	S-protein
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis-acting	B-DNA
elements	E-DNA
of	O
the	O
collagenase	B-DNA
promoter	E-DNA
in	O
transiently	O
transfected	O
human	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
and	I-cell_line
murine	I-cell_line
(	I-cell_line
J774	I-cell_line
)	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

These	O
findings	O
,	O
therefore	O
,	O
could	O
have	O
clinical	O
significance	O
to	O
AIDS	O
patients	O
with	O
malignancies	O
who	O
are	O
undergoing	O
radiotherapy	O
and	O
chemotherapy	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
BRCA1	S-DNA
and	O
BRCA2	S-DNA
mutations	O
to	O
the	O
pathogenesis	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
,	O
the	O
country	O
with	O
the	O
highest	O
male	O
breast	O
cancer	O
mortality	O
rates	O
in	O
continental	O
Europe	O
,	O
a	O
series	O
of	O
18	O
male	O
breast	O
cancer	O
patients	O
and	O
three	O
patients	O
with	O
gynecomastia	O
was	O
analyzed	O
for	O
germ-line	O
mutations	O
in	O
both	O
BRCA1	S-DNA
and	O
BRCA2	S-DNA
.	O

Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron-dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O

p38	O
also	O
forms	O
a	O
complex	O
with	O
the	O
tyrosine	B-protein
kinase	I-protein
csk	E-protein
in	O
stimulated	B-cell_type
cells	E-cell_type
and	O
is	O
a	O
substrate	O
for	O
the	O
kinase	S-protein
.	O

Octamer	B-protein
binding	I-protein
factors	E-protein
and	O
their	O
coactivator	S-protein
can	O
activate	O
the	O
murine	B-DNA
PU.1	I-DNA
(	I-DNA
spi-1	I-DNA
)	I-DNA
promoter	E-DNA
.	O

Age-related	O
decreases	O
in	O
IL-2	S-protein
production	O
by	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	B-protein
transcriptional	I-protein
factors	I-protein
AP-1	E-protein
and	O
NF-AT	S-protein
.	O

NAC	O
caused	O
an	O
expected	O
dramatic	O
increase	O
in	O
the	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
EC	S-cell_type
.	O

Induction	O
of	O
a	O
functional	O
vitamin	B-protein
D	I-protein
receptor	E-protein
in	O
all-trans-retinoic	O
acid-induced	O
monocytic	O
differentiation	O
of	O
M2-type	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	E-cell_line
.	O

[	O
Glucocorticoid	B-protein
receptors	E-protein
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	E-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O

Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	E-DNA
and	O
the	O
kappa	B-DNA
B	I-DNA
site	E-DNA
abolished	O
LPS	O
induction	O
.	O

GC	B-protein
receptor	E-protein
was	O
blocked	O
with	O
mifepristone	O
.	O

A-myb	S-protein
expression	O
has	O
also	O
been	O
studied	O
in	O
a	O
wide	O
range	O
of	O
neoplastic	B-cell_type
B	I-cell_type
cells	E-cell_type
,	O
representing	O
the	O
whole	O
spectrum	O
of	O
B	O
cell	O
differentiation	O
.	O

Although	O
NGFI-B/nur77	S-protein
is	O
essential	O
for	O
TCR-mediated	O
apoptosis	O
in	O
T-cell	B-protein
hybridomas	E-protein
,	O
the	O
reports	O
on	O
nur77	O
knock-out	O
mice	O
and	O
nur77	O
dominant	O
negative	O
transgenic	O
mice	O
suggest	O
that	O
there	O
is	O
a	O
functional	O
redundancy	O
among	O
NGFI-B/nur77	B-protein
family	E-protein
.	O

This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O

We	O
have	O
investigated	O
the	O
antigenic	O
specificity	O
of	O
47	O
HSV-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	E-cell_line
recovered	O
from	O
the	O
HSV-2	O
buttock	O
and	O
thigh	O
lesions	O
of	O
five	O
patients	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	B-protein
B	E-protein
mobilization	O
,	O
induction	O
of	O
VCAM-1	S-protein
and	O
E-selectin	S-protein
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	B-cell_type
cells	E-cell_type
stimulated	O
by	O
TNF	S-protein
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
this	O
transformation	O
is	O
the	O
result	O
of	O
double	O
infection	O
of	O
a	O
cell	O
with	O
two	O
virions	O
,	O
the	O
P3HR1	B-DNA
virus	I-DNA
genome	E-DNA
and	O
a	O
mini-EBV	B-DNA
plasmid	E-DNA
carrying	O
the	O
chimeric	O
EBNA2	B-DNA
gene	E-DNA
.	O

Blockade	O
of	O
this	O
intracellular	O
signalling	O
event	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
normal	O
transendothelial	O
migration	O
response	O
towards	O
MCP-1	S-protein
.	O

The	O
fact	O
that	O
BCL-6	S-protein
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Augmented	O
expression	O
of	O
VCAM-1	S-protein
led	O
to	O
increased	O
SS	B-cell_type
RBC	E-cell_type
adhesion	O
,	O
inhibitable	O
by	O
a	O
VCAM-1	B-protein
antibody	E-protein
.	O

Studies	O
with	O
20-epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon-20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20-methyl	O
derivatives	O
of	O
VD	O
.	O

Another	O
unexpected	O
finding	O
was	O
that	O
T-cell	O
leukemias	O
and	O
T-cell	B-cell_line
lines	E-cell_line
often	O
expressed	O
either	O
Id2	S-RNA
or	O
Id3	B-RNA
mRNA	E-RNA
.	O

We	O
also	O
show	O
that	O
both	O
Fos	S-protein
and	O
Jun	S-protein
components	O
of	O
the	O
AP-1	S-protein
factors	O
participate	O
in	O
the	O
OAP40	B-protein
complex	E-protein
.	O

ALY	S-protein
,	O
a	O
context-dependent	B-protein
coactivator	E-protein
of	O
LEF-1	S-protein
and	O
AML-1	S-protein
,	O
is	O
required	O
for	O
TCRalpha	B-DNA
enhancer	E-DNA
function	O
.	O

The	O
binding	B-DNA
site	E-DNA
for	O
nuclear	B-protein
factor-kappaB	E-protein
(	O
NF-kappaB	S-protein
)	O
is	O
present	O
at	O
the	O
promoter	B-DNA
region	E-DNA
of	O
the	O
germline	B-DNA
Cepsilon	I-DNA
gene	E-DNA
,	O
but	O
there	O
is	O
little	O
information	O
on	O
whether	O
this	O
factor	O
is	O
involved	O
in	O
regulating	O
IgE	S-protein
synthesis	O
by	O
human	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4+	B-cell_line
infected	I-cell_line
T-lymphoid	I-cell_line
cells	E-cell_line
.	O

An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	B-DNA
interleukin	I-DNA
4	I-DNA
gene	E-DNA
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O

But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O

Protein	B-protein
kinase	I-protein
C	E-protein
activation	O
and	O
protooncogene	S-DNA
expression	O
in	O
differentiation/retrodifferentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
.	O

The	O
putative	B-DNA
NFAT-1	I-DNA
region	E-DNA
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti-CD3	S-protein
or	O
to	O
mitogens	S-protein
in	O
T-cell	S-cell_line
,	O
B-cell	S-cell_line
,	O
or	O
monocyte/macrophage	B-cell_line
leukemia	I-cell_line
lines	E-cell_line
,	O
nor	O
is	O
it	O
a	O
cis-acting	B-DNA
negative	I-DNA
regulatory	I-DNA
element	E-DNA
.	O

These	O
results	O
suggest	O
that	O
blasts	S-cell_type
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	S-cell_type
of	O
both	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	E-cell_type
.	O

In	O
contrast	O
,	O
cdc2	B-RNA
mRNA	E-RNA
could	O
not	O
be	O
induced	O
in	O
granulocytes	S-cell_type
and	O
monocytes	S-cell_type
even	O
after	O
the	O
culture	O
with	O
the	O
appropriate	O
stimulants	O
.	O

The	O
amount	O
of	O
trypsin	S-protein
-resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O

Transient	O
expression	O
of	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	E-DNA
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'-flanking	B-DNA
region	E-DNA
of	O
the	O
IL-9	B-DNA
gene	E-DNA
has	O
revealed	O
several	O
positive	O
and	O
negative	B-DNA
regulatory	I-DNA
elements	E-DNA
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	E-DNA
in	O
C5MJ2	B-cell_line
cells	E-cell_line
.	O

HIV-1-infected	O
myeloid	B-cell_type
cells	E-cell_type
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	S-protein
-stimulated	O
nuclear	B-protein
factor-kappaB	E-protein
activation	O
between	O
HUVECs	S-cell_type
and	O
HUAECs	S-cell_type
.	O

Induction	O
of	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	E-RNA
by	O
IL-4	S-protein
in	O
B	B-cell_type
cells	E-cell_type
that	O
lack	O
the	O
gammac	B-protein
chain	E-protein
may	O
involve	O
signaling	O
via	O
the	O
IL-13R	S-protein
.	O

On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus-like	O
particles	O
(	O
RVLPs	O
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	B-cell_line
T	I-cell_line
cells	E-cell_line
from	O
a	O
patient	O
with	O
MS	O
.	O

Moreover	O
T	O
cell	O
proliferation	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
blocking	O
Abs	S-protein
to	O
both	O
IL-2	S-protein
and	O
the	O
IL-2	B-protein
receptor	E-protein
,	O
demonstrating	O
that	O
this	O
form	O
of	O
costimulation	O
by	O
CD28	S-protein
was	O
independent	O
of	O
IL-2	S-protein
.	O

Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
``	O
late	O
''	O
T	B-protein
lymphocyte	I-protein
associated	I-protein
transcription	I-protein
factor	E-protein
and	O
named	O
it	O
``	O
RANTES	B-protein
Factor	I-protein
of	I-protein
Late	I-protein
Activated	I-protein
T	I-protein
Lymphocytes-1	E-protein
``	O
(	O
RFLAT-1	S-protein
)	O
.	O

There	O
was	O
a	O
more	O
marked	O
rise	O
of	O
the	O
number	O
of	O
receptors	S-protein
in	O
middle-aged	O
(	O
44-55	O
years	O
)	O
hypertensives	O
vs	O
elderly	O
(	O
61-80	O
years	O
)	O
subjects	O
after	O
captopril	O
treatment	O
.	O

We	O
also	O
considered	O
associations	O
of	O
these	O
variables	O
with	O
plasma	O
renin	S-protein
activity	O
,	O
aldosterone	O
,	O
cortisol	O
,	O
corticotropin	O
,	O
and	O
electrolyte	O
concentrations	O
.	O

Interleukin	B-protein
2	E-protein
(	O
IL-2	S-protein
)	O
stimulates	O
IL-2R	B-protein
alpha	E-protein
.	O

The	O
T/NK	B-cell_type
subsets	E-cell_type
in	O
the	O
BM	O
of	O
MRD-negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-/LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O

By	O
Southern	O
hybridization	O
analyses	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
with	O
murine	B-DNA
cDNA	I-DNA
probe	E-DNA
,	O
fluorescence	O
chromosomal	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
human	B-DNA
genomic	I-DNA
clones	E-DNA
,	O
and	O
analysis	O
of	O
recombinant	B-cell_line
inbred	I-cell_line
mouse	I-cell_line
strains	E-cell_line
,	O
we	O
have	O
found	O
single	O
sites	O
for	O
EBF	B-DNA
homologous	I-DNA
sequences	E-DNA
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
5	O
,	O
band	B-DNA
q34	E-DNA
,	O
and	O
on	O
proximal	B-DNA
mouse	I-DNA
Chr	I-DNA
11	E-DNA
,	O
in	O
an	O
evolutionarily	B-DNA
conserved	I-DNA
region	E-DNA
.	O

However	O
,	O
the	O
sensitivity	O
of	O
cells	O
to	O
these	O
agents	O
is	O
not	O
merely	O
governed	O
by	O
the	O
expression	O
of	O
their	O
receptors	O
and	O
the	O
availability	O
of	O
ligand	O
to	O
bind	O
them	O
.	O

The	O
promoter	S-DNA
of	O
the	O
TP1	B-DNA
gene	E-DNA
was	O
chosen	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
molecular	O
mechanism	O
of	O
EBNA2	S-protein
mediated	O
transactivation	O
.	O

Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha-zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O

Tap	S-protein
associated	O
with	O
Tip	S-protein
following	O
transient	O
expression	O
in	O
COS-1	B-cell_line
cells	E-cell_line
and	O
stable	O
expression	O
in	O
human	B-cell_line
Jurkat-T	I-cell_line
cells	E-cell_line
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF-binding	B-protein
sites	E-protein
within	O
the	O
CD30	B-protein
cytoplasmic	I-protein
domain	E-protein
.	O

The	O
serine	O
phosphorylation	O
of	O
these	O
STATs	S-protein
was	O
a	O
continuous	O
process	O
,	O
as	O
incubation	O
of	O
CLL	B-cell_line
cells	E-cell_line
with	O
the	O
kinase	B-protein
inhibitor	I-protein
H7	E-protein
led	O
to	O
the	O
dephosphorylation	O
of	O
these	O
serine	O
residues	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	B-DNA
133	I-DNA
gene	E-DNA
encodes	O
a	O
transcription	B-protein
factor	E-protein
with	O
a	O
specific	O
biological	O
function	O
.	O

The	O
combination	O
of	O
the	O
immune	B-protein
costimulatory	I-protein
molecule	I-protein
B7.1	E-protein
and	O
IL-12	S-protein
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

We	O
present	O
evidence	O
that	O
the	O
development	O
of	O
thymic	B-cell_type
DC	E-cell_type
and	O
of	O
T-lineage	B-cell_type
cells	E-cell_type
is	O
linked	O
via	O
a	O
common	O
precursor	O
at	O
an	O
early	O
stage	O
of	O
thymocyte	O
development	O
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	S-protein
and	O
Grb2	S-protein
in	O
T	B-cell_type
cells	E-cell_type
.	O

The	O
measured	O
binding	O
to	O
a	O
TCF-1	B-DNA
site	E-DNA
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
,	I-cell_type
activated	I-cell_type
,	I-cell_type
and	I-cell_type
anergized	I-cell_type
cells	E-cell_type
.	O

The	O
lytic	O
cycle	O
of	O
EBV	O
infection	O
was	O
induced	O
by	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
BRLF1/BZLF1	B-DNA
coding	I-DNA
region	E-DNA
of	O
the	O
P3HR-1	B-DNA
defective	I-DNA
genome	E-DNA
.	O

ERP	S-protein
,	O
a	O
new	O
member	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor/oncoprotein	I-protein
family	E-protein
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B-lymphocyte	O
development	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
by	O
dopamine	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
and	O
in	O
primary	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
PBMC	S-cell_type
)	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	B-DNA
consensus	E-DNA
to	O
Jurkat	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
inhibited	O
interleukin-2	S-protein
(	O
IL-2	S-protein
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	B-DNA
octamer	I-DNA
site	E-DNA
in	O
the	O
IL-2	B-DNA
enhancer	E-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	E-cell_type
,	O
CD28	S-protein
-mediated	O
signal	O
transduction	O
involves	O
the	O
rel	B-protein
family	I-protein
proteins	E-protein
--	O
c-Rel	S-protein
,	O
p50	S-protein
,	O
and	O
p65	S-protein
.	O

All	O
cells	O
tested	O
express	O
TAFII105	B-RNA
mRNA	E-RNA
,	O
but	O
only	O
B	B-cell_type
cells	E-cell_type
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	S-protein
.	O

Inhibition	O
of	O
cytokine	S-protein
production	O
by	O
PBMC	S-cell_type
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Of	O
these	O
,	O
the	O
XPB	B-DNA
and	I-DNA
XPD	I-DNA
genes	E-DNA
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	B-protein
transcription	I-protein
factor	E-protein
,	O
TFIIH	S-protein
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	B-protein
polymerase	I-protein
II	E-protein
.	O

It	O
has	O
been	O
proposed	O
that	O
their	O
expression	O
is	O
controlled	O
by	O
the	O
non-clonal	O
,	O
or	O
innate	O
,	O
component	O
of	O
immunity	O
that	O
preceded	O
in	O
evolution	O
the	O
development	O
of	O
an	O
adaptive	O
immune	O
system	O
in	O
vertebrates	O
.	O

The	O
ability	O
of	O
mutants	O
to	O
activate	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
MHC	B-protein
class	I-protein
II	E-protein
conserved	O
W-X-Y	B-DNA
or	I-DNA
X-Y	I-DNA
regulatory	I-DNA
elements	E-DNA
was	O
determined	O
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	S-protein
elicited	O
a	O
rapid	O
but	O
short-lived	O
induction	O
of	O
IKK	S-protein
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK-alpha	S-protein
than	O
on	O
IKK-beta	S-protein
,	O
peaking	O
at	O
5	O
min	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	S-protein
in	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	E-cell_line
after	O
PMA	O
stimulation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Stat3	S-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Stat1	S-protein
was	O
also	O
detected	O
following	O
G-CSF	S-protein
stimulation	O
.	O

The	O
X-inactivation	O
patterns	O
of	O
circulating	O
PMNCs	S-cell_type
and	O
T	B-cell_type
lymphocytes	E-cell_type
as	O
well	O
as	O
individual	O
granulocyte	B-cell_line
colonies	E-cell_line
grown	O
in	O
vitro	O
from	O
bone	O
marrow	O
cells	O
were	O
analyzed	O
.	O

Macrophages	S-cell_type
and	O
granulocytes	S-cell_type
,	O
which	O
are	O
developed	O
from	O
a	O
common	O
progenitor	O
cell	O
,	O
are	O
the	O
cellular	O
components	O
of	O
the	O
specific	O
and	O
non-specific	O
immunoreaction	O
.	O

Since	O
T	B-cell_type
cells	E-cell_type
normally	O
express	O
Bcl-2	S-protein
and	O
Bcl-xL	S-protein
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	S-protein
-mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self-reactive	B-cell_type
cells	E-cell_type
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Signaling	O
through	O
the	O
lymphotoxin-beta	B-protein
receptor	E-protein
stimulates	O
HIV-1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane-bound	B-protein
TNF-alpha	E-protein
.	O

The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
-driven	O
gene	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
kappaB	E-protein
(	O
NF-kappaB	S-protein
)	O
activation	O
were	O
also	O
examined	O
.	O

Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	B-RNA
motif	E-RNA
formed	O
a	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	E-protein
with	O
cytosolic	O
extracts	O
from	O
human	B-cell_line
K562	I-cell_line
cells	E-cell_line
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	B-RNA
transcripts	E-RNA
from	O
ferritin	B-RNA
or	I-RNA
transferrin	I-RNA
receptor	I-RNA
mRNAs	E-RNA
.	O

gamma-Interferon	S-protein
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O

Functional	O
roles	O
of	O
the	O
transcription	B-protein
factor	I-protein
Oct-2A	E-protein
and	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
I/Y	E-protein
in	O
HLA-DRA	B-DNA
gene	E-DNA
expression	O
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	S-protein
and	O
Mi-2-HDAC	S-protein
,	O
we	O
propose	O
that	O
Ikaros	B-protein
family	I-protein
members	E-protein
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	B-protein
deacetylase	I-protein
complexes	E-protein
to	O
specific	B-DNA
promoters	E-DNA
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	S-protein
reveals	O
that	O
HSF3	S-protein
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	S-protein
and	O
HSF2	S-protein
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O

These	O
observations	O
suggest	O
that	O
PMA	O
exerts	O
its	O
inhibitory	O
effects	O
by	O
activation	O
of	O
a	O
tyrosine	B-protein
phosphatase	E-protein
which	O
selectively	O
regulates	O
Tyk2	S-protein
but	O
not	O
Jak1	S-protein
activity	O
.	O

NF-kappa	B-protein
B	E-protein
is	O
a	O
protein	B-protein
complex	E-protein
which	O
functions	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	E-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	S-protein
and	O
NF-KB	S-protein
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

Latent	B-protein
membrane	I-protein
protein-1	E-protein
induces	O
cyclin	B-protein
D2	E-protein
expression	O
,	O
pRb	S-protein
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF-beta	B-protein
1	E-protein
-mediated	O
growth	O
inhibition	O
in	O
EBV-positive	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

GATA	B-protein
transcription	I-protein
factors	E-protein
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	S-cell_type
and	O
megakaryocytes	S-cell_type
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	B-DNA
expression	I-DNA
vector	E-DNA
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	B-protein
protein	E-protein
enhanced	O
DRA	B-DNA
gene	E-DNA
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	B-DNA
element	E-DNA
.	O

A	O
cDNA	B-DNA
clone	E-DNA
,	O
B4-2	S-DNA
,	O
was	O
isolated	O
from	O
a	O
natural	B-DNA
killer	I-DNA
(	I-DNA
NK	I-DNA
)	I-DNA
minus	I-DNA
T	I-DNA
cell	I-DNA
subtractive	I-DNA
library	E-DNA
.	O

Stimulation	O
with	O
either	O
PAF	S-protein
or	O
FMLP	S-protein
resulted	O
in	O
equivalent	O
phosphorylation	O
and	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
MAPk	I-protein
)	I-protein
homologue	I-protein
38-kD	I-protein
murine	I-protein
MAP	I-protein
kinase	E-protein
homologous	O
to	O
HOG-1	B-protein
(	I-protein
p38	I-protein
)	I-protein
MAPk	E-protein
.	O

A	O
15-base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine-rich	B-DNA
region	E-DNA
in	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	E-DNA
,	O
which	O
overlaps	O
the	O
kappaB	B-DNA
element	E-DNA
.	O

One	O
substrate	O
is	O
p95vav	S-protein
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
trophoblast	I-cell_type
cells	E-cell_type
.	O

These	O
data	O
suggest	O
a	O
ROI-dependent	O
NF-kappaB	S-protein
mediated	O
transcription	O
of	O
inflammatory	B-protein
cytokines	E-protein
in	O
bronchial	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
.	O

The	O
TCR	B-protein
alpha	I-protein
beta	I-protein
or	I-protein
-gamma	I-protein
delta	I-protein
chains	E-protein
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B-protein
delta	I-protein
epsilon	I-protein
gamma	E-protein
and	O
TCR	B-protein
zeta	I-protein
subunits	E-protein
couple	O
the	O
TCR	S-protein
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation-deficient	B-protein
glucocorticoid	I-protein
receptor	I-protein
mutant	E-protein
is	O
as	O
effective	O
as	O
the	O
wild-type	B-protein
receptor	E-protein
in	O
repression	O
of	O
AP-1	S-protein
activity	O
,	O
inhibition	O
of	O
interleukin-2	S-protein
production	O
,	O
inhibition	O
of	O
c-myc	S-DNA
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

The	O
promoters	S-DNA
were	O
used	O
without	O
enhancers	S-DNA
,	O
or	O
with	O
enhancers	S-DNA
derived	O
from	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	E-DNA
and	O
the	O
alpha-globin	B-DNA
HS-40	I-DNA
enhancer	E-DNA
.	O

Translocations	O
involving	O
the	O
BCL-6	B-DNA
gene	E-DNA
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
.	O

The	O
number	O
of	O
morning	B-protein
glucocorticoid	I-protein
receptors	E-protein
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole-cell	O
binding	O
assay	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
PEER	S-cell_line
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+/-	O
0.53	O
nmol/L	O
,	O
mean	O
+/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2+	O
ionophore	O
A23187	O
.	O

Hence	O
,	O
we	O
propose	O
that	O
a	O
necessary	O
prerequisite	O
of	O
enhancer	S-DNA
activity	O
is	O
the	O
B-cell-specific	O
displacement	O
of	O
a	O
ZEB-like	B-protein
repressor	E-protein
by	O
bHLH	B-protein
proteins	E-protein
.	O

Glucocorticoid	B-protein
receptors	E-protein
in	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
of	O
healthy	O
neonates	O
and	O
of	O
preterms	O
suffering	O
from	O
respiratory	O
distress	O
syndrome	O
.	O

PO-B	S-protein
was	O
originally	O
characterized	O
as	O
a	O
transcriptional	B-protein
regulatory	I-protein
factor	E-protein
of	O
the	O
pro-opiomelanocortin	B-DNA
(	I-DNA
POMC	I-DNA
)	I-DNA
gene	E-DNA
;	O
however	O
,	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
this	O
protein	O
may	O
be	O
active	O
in	O
tissues	O
outside	O
the	O
pituitary	O
,	O
since	O
it	O
is	O
present	O
in	O
diverse	O
cell	O
types	O
,	O
including	O
differentiated	O
HL-60	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	E-cell_type
.	O

1.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically-reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

Our	O
results	O
demonstrate	O
that	O
PMLRAR	B-protein
alpha	E-protein
impairs	O
neutrophil	O
differentiation	O
and	O
initiates	O
the	O
development	O
of	O
APL	O
.	O

Our	O
results	O
demonstrate	O
that	O
short-term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	B-protein
activated	I-protein
p50/p65	E-protein
containing	O
NF-kappa	B-protein
B	I-protein
dimers	E-protein
and	O
induced	O
the	O
expression	O
of	O
the	O
target	B-DNA
gene	I-DNA
IL-8	E-DNA
.	O

The	O
pattern	O
of	O
PML	S-protein
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	B-protein
pRb	I-protein
105	E-protein
.	O

Structure-function	O
studies	O
of	O
the	O
GATA-1	S-protein
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O

[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	S-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
]	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	E-protein
.	O

The	O
studies	O
described	O
herein	O
demonstrate	O
that	O
the	O
activation	O
domain	O
.	O

Prompted	O
by	O
these	O
results	O
,	O
we	O
have	O
investigated	O
in	O
man	O
a	O
possible	O
relationship	O
between	O
GR	S-protein
binding	O
capacity	O
in	O
the	O
PBMCs	S-cell_type
and	O
age	O
,	O
in	O
relation	O
also	O
to	O
plasma	O
testosterone	O
and	O
cortisol	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL-1beta	S-protein
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti-inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS-mediated	O
TF	O
expression	O
of	O
human	B-cell_type
monocytes	E-cell_type
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

Northern	O
blot	O
analysis	O
in	O
mouse	O
cell	O
lines	O
suggests	O
that	O
its	O
expression	O
is	O
found	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
T	B-cell_type
cells	E-cell_type
,	O
B	B-cell_type
cells	E-cell_type
,	O
and	O
macrophages	S-cell_type
.	O

We	O
have	O
shown	O
that	O
an	O
estradiol-dependent	O
activation	O
of	O
human	O
T	O
cell	O
leukemia	O
virus-I	O
Tax	S-protein
leads	O
to	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
and	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	S-protein
-and	O
E7	S-protein
-expressing	O
human	B-cell_line
fibroblastic	I-cell_line
or	I-cell_line
keratinocyte-derived	I-cell_line
human	I-cell_line
cells	E-cell_line
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	S-cell_type
or	O
interferon	B-cell_line
(	I-cell_line
IFN	I-cell_line
)	I-cell_line
-activated	I-cell_line
NK	I-cell_line
cells	E-cell_line
.	O

Additionally	O
,	O
preincubation	O
of	O
HUVEC	S-cell_line
with	O
a	O
synthetic	O
peptide	O
Arg-Gly-Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	S-protein
-mediated	O
adhesion	O
of	O
SS	B-cell_type
RBC	E-cell_type
reduced	O
the	O
surface	O
expression	O
of	O
VCAM-1	S-protein
and	O
NF-kB	S-protein
activation	O
.	O

Regulation	O
of	O
Id3	S-protein
cell	O
cycle	O
function	O
by	O
Cdk-2-dependent	O
phosphorylation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN-gamma-treated	B-cell_line
human	I-cell_line
cells	E-cell_line
infected	O
with	O
an	O
Ad5	O
E1A	S-DNA
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	B-DNA
E1A	I-DNA
gene	E-DNA
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
pTh	I-cell_type
)	I-cell_type
cells	E-cell_type
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	B-cell_type
cells	E-cell_type
(	O
eTh1	S-cell_type
and	O
eTh2	S-cell_type
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	S-protein
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

High	O
c-myc	B-RNA
mRNA	E-RNA
expression	O
was	O
detected	O
on	O
acinar	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
.	O

LPS-induced	O
activation	O
of	O
NF-kappaB-responsive	B-DNA
reporter	I-DNA
gene	E-DNA
was	O
not	O
inhibited	O
by	O
IL-1	S-protein
receptor	O
antagonist	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
Ar-5	E-cell_line
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isozymes	E-protein
of	O
PKC	S-protein
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	B-RNA
mRNA	E-RNA
and	O
protein	S-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	S-protein
,	O
but	O
not	O
IL-10	S-protein
,	O
inhibited	O
nuclear	O
NF-kappaB	S-protein
activity	O
,	O
and	O
that	O
IL-4	S-protein
and	O
IL-10	S-protein
did	O
not	O
affect	O
NF-	O
IL-6	S-protein
activity	O
.	O

Since	O
DCs	S-cell_type
and	O
memory	O
T	B-cell_type
cells	E-cell_type
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	B-cell_type
syncytia	E-cell_type
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O

Time-course	O
experiments	O
showed	O
that	O
nuclear	O
levels	O
of	O
GATA-1	S-protein
and	O
p45	B-protein
NF-E2	E-protein
proteins	O
increased	O
during	O
BA	O
treatment	O
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B-lymphocyte	O
and	O
T-lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O

The	O
role	O
of	O
p16	S-protein
in	O
the	O
E2F-dependent	B-protein
thymidine	I-protein
kinase	E-protein
regulation	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	S-protein
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	S-protein
in	O
Th1	B-cell_type
cells	E-cell_type
or	O
in	O
a	O
non-lymphoid	B-cell_line
,	I-cell_line
non-IL-5-producing	I-cell_line
cell	I-cell_line
line	E-cell_line
activated	O
the	O
IL-5	B-DNA
promoter	E-DNA
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin-encoding	B-DNA
genes	E-DNA
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	S-DNA
in	O
human	B-cell_type
cells	E-cell_type
in	O
continuous	O
culture	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	E-cell_line
with	O
SEA	O
presented	O
on	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-DR	I-cell_line
transfectants	E-cell_line
coexpressing	O
either	O
B7	S-protein
or	O
LFA-3	S-protein
resulted	O
in	O
distinct	O
cytokine	S-protein
profiles	O
.	O

T-helper-cell	B-protein
determinants	E-protein
in	O
protein	B-protein
antigens	E-protein
are	O
preferentially	O
located	O
in	O
cysteine-rich	B-protein
antigen	I-protein
segments	E-protein
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	E-protein
.	O

Flutamide	O
affects	O
androgen	B-protein
receptor	E-protein
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O

In	O
chronic	O
bronchitis	O
,	O
few	O
cells	O
were	O
GCRbeta-positive	S-cell_type
and	O
their	O
numbers	O
did	O
not	O
differ	O
significantly	O
from	O
normal	O
control	O
subjects	O
.	O

The	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	E-DNA
was	O
also	O
required	O
for	O
TCR	S-protein
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	S-cell_line
but	O
not	O
HeLa	B-cell_line
cells	E-cell_line
,	O
confirming	O
that	O
TCF-1	B-protein
alpha	E-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	E-protein
.	O

TCF-1	B-RNA
mRNA	E-RNA
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell-specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

These	O
results	O
suggest	O
that	O
CN	S-protein
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM-CSF	B-DNA
and	I-DNA
IL-2	I-DNA
genes	E-DNA
and	O
that	O
the	O
CLE0	B-DNA
sequence	E-DNA
of	O
the	O
GM-CSF	B-DNA
gene	E-DNA
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF-AT-binding	B-DNA
site	E-DNA
in	O
the	O
IL-2	B-DNA
promoter	E-DNA
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

The	O
importance	O
of	O
TNF-alpha	S-protein
release	O
in	O
NF-kappaB	S-protein
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF-kappaB	S-protein
was	O
promoted	O
in	O
untreated	B-cell_line
cells	E-cell_line
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF-alpha	S-protein
and	O
HOCl	O
was	O
detected	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	S-protein
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	B-protein
(	I-protein
lck	I-protein
)	E-protein
(	O
mutated	O
at	O
the	O
dicysteine	B-protein
motif	E-protein
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	B-protein
tail	E-protein
underwent	O
apoptosis	O
like	O
wild-	B-protein
type	I-protein
CD4	E-protein
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	S-protein
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57-SREI	B-cell_line
cells	E-cell_line
)	O
.	O

MHC-peptide	O
ligand	O
interactions	O
establish	O
a	O
functional	O
threshold	O
for	O
antigen-specific	O
T	O
cell	O
recognition	O
.	O

The	O
Arp2/3	B-protein
complex	E-protein
is	O
essential	O
in	O
initiation	O
of	O
actin	S-protein
assembly	O
and	O
Shigella	O
movement	O
,	O
as	O
previously	O
observed	O
for	O
Listeria	O
monocytogenes	O
.	O

We	O
also	O
investigated	O
the	O
effects	O
of	O
stimulating	O
T	B-cell_type
cell	I-cell_type
blasts	E-cell_type
with	O
CD80	S-protein
alone	O
and	O
found	O
that	O
there	O
was	O
a	O
limited	O
requirement	O
for	O
IL-2	S-protein
in	O
this	O
system	O
.	O

NF-AT	S-protein
and	O
NF-kappaB	S-protein
were	O
not	O
significantly	O
induced	O
by	O
IL-2	S-protein
stimulation	O
.	O

Although	O
devoid	O
of	O
any	O
effect	O
by	O
itself	O
,	O
a	O
mutant	B-protein
p53	E-protein
cooperated	O
with	O
Spi-1	S-protein
and	O
EpoR	B-protein
(	I-protein
R129C	I-protein
)	E-protein
to	O
reinforce	O
both	O
phenotypes	O
.	O

Four	O
patients	O
(	O
22	O
%	O
)	O
had	O
a	O
family	O
history	O
of	O
breast/ovarian	O
cancer	O
in	O
at	O
least	O
one	O
first-	O
or	O
second-degree	O
relative	O
;	O
however	O
,	O
no	O
BRCA2	S-DNA
mutation	O
was	O
identified	O
among	O
them	O
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
to	O
the	O
consensus	B-DNA
DNA	I-DNA
sequence	E-DNA
in	O
the	O
cis-acting	B-DNA
elements	E-DNA
of	O
various	B-DNA
genes	E-DNA
.	O

A	O
significant	O
proportion	O
of	O
transcripts	S-RNA
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	S-protein
.	O

This	O
influence	O
was	O
sufficient	O
for	O
establishment	O
of	O
antigen-induced	O
allergic	O
airway	O
hyperresponsiveness	O
on	O
a	O
disease-resistant	O
background	O

Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	B-cell_line
plasmacytoma	I-cell_line
x	I-cell_line
fibroblast	I-cell_line
environment	E-cell_line
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	E-DNA
is	O
transcriptionally	O
inactive	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	B-protein
lipoproteins	E-protein
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	S-protein
cosignaling	O
and	O
regulation	O
of	O
IL-2	S-protein
secretion	O
in	O
LP	B-cell_type
T	I-cell_type
cells	E-cell_type
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

A	O
Tat-responsive	B-DNA
element	E-DNA
is	O
found	O
upstream	O
within	O
the	O
viral	B-DNA
promoter	E-DNA
that	O
in	O
glial-derived	B-cell_line
cell	I-cell_line
lines	E-cell_line
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	S-RNA
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B-protein
2	E-protein
(	O
IL-2	S-protein
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	S-protein
which	O
are	O
induced	O
during	O
T-cell	O
activation	O
.	O

RESULTS	O
:	O
No	O
significant	O
partial	O
correlations	O
of	O
the	O
number	O
of	O
the	O
peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	E-protein
(	O
6821	O
+/-	O
5669	O
binding	O
sites	O
per	O
cell	O
)	O
and	O
the	O
affinity	O
(	O
Kd	O
:	O
16.5	O
+/-	O
13.51	O
nmol/L	O
)	O
for	O
the	O
glucocorticoid	B-protein
receptors	E-protein
with	O
the	O
symptom	O
score	O
(	O
placebo	O
:	O
4.3	O
+/-	O
2.45	O
pts	O
;	O
fluticasone	O
:	O
2.4	O
+/-	O
1.55	O
pts	O
)	O
after	O
active	O
treatment	O
were	O
found	O
.	O

The	O
modulation	O
by	O
anti-LPS	B-protein
mAbs	E-protein
of	O
mCD14	S-protein
-mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS-induced	B-protein
nuclear	I-protein
factor-kappaB	E-protein
(	O
NF-kappaB	S-protein
)	O
translocation	O
and	O
TNF-alpha	S-protein
secretion	O
in	O
CHO-CD14	B-cell_line
cells	E-cell_line
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-	O
mCD14	S-protein
-mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	S-protein
,	O
p52	S-protein
and	O
RelB	S-protein
are	O
restricted	O
to	O
accessory	B-cell_type
cells	E-cell_type
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	S-cell_type
in	O
GC	O
,	O
and	O
DC	S-cell_type
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	B-cell_type
macrophages	E-cell_type
from	O
GC	S-cell_type
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	S-protein
and	O
RelB	S-protein
,	O
whereas	O
macrophages	S-cell_type
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	B-cell_type
cells	E-cell_type
,	O
do	O
have	O
both	O
nuclear	O
p52	S-protein
and	O
RelB	S-protein
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	S-protein
and	O
RelB	S-protein
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	S-cell_line
,	O
CD68+	S-cell_line
or	O
both	O
,	O
cells	O
APC	S-cell_type
,	O
whereas	O
p50	S-protein
is	O
restricted	O
to	O
CD1a-	S-cell_type
and	O
CD68-	B-cell_type
APC	E-cell_type
.	O

In	O
both	O
cell	O
lines	O
LIF	S-protein
increased	O
NF-kB	S-protein
activity	O
.	O

musculin	S-DNA
:	O
a	O
murine	B-DNA
basic	I-DNA
helix-loop-helix	I-DNA
transcription	I-DNA
factor	I-DNA
gene	E-DNA
expressed	O
in	O
embryonic	O
skeletal	O
muscle	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	B-protein
receptor	E-protein
,	O
but	O
also	O
suggest	O
that	O
T	B-cell_type
cells	E-cell_type
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal-induced	O
activation	O
.	O

We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	B-cell_line
cells	E-cell_line
.	O

The	O
CD4	B-protein
coreceptor	E-protein
interacts	O
with	O
non-polymorphic	B-protein
regions	E-protein
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
molecules	E-protein
on	O
antigen-presenting	B-cell_type
cells	E-cell_type
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

In	O
the	O
absence	O
of	O
TCR	S-protein
-mediated	O
activation	O
,	O
Vpr	S-protein
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	S-protein
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

On	O
the	O
basis	O
of	O
cross-linking	O
results	O
with	O
21	O
different	O
EMCV	B-DNA
IRES	I-DNA
fragments	E-DNA
and	O
cytoplasmic	O
HeLa	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
as	O
the	O
source	O
of	O
polypeptides	O
,	O
consensus	B-DNA
binding	I-DNA
sites	E-DNA
for	O
p52	S-protein
,	O
p57	S-protein
,	O
p70	S-protein
,	O
and	O
p100	S-protein
are	O
proposed	O
.	O

Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	O
to	O
accumulation	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	E-RNA
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	E-DNA
transcription	O
,	O
we	O
suggest	O
that	O
low	O
cytoplasmic	O
levels	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	E-RNA
are	O
maintained	O
by	O
a	O
translation-dependent	O
degradation	O
mechanism	O
.	O

The	O
major	O
focus	O
of	O
this	O
research	O
is	O
to	O
define	O
the	O
cis	B-DNA
-acting	I-DNA
elements	E-DNA
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
these	O
domains	O
of	O
unique	O
chromatin	O
structure	O
.	O

Constitutive	O
expression	O
of	O
p50	B-protein
homodimer	E-protein
in	O
freshly	B-cell_type
isolated	I-cell_type
human	I-cell_type
monocytes	E-cell_type
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	S-cell_type
and	O
mature	O
macrophages	O
.	O

Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	B-cell_type
progeny	E-cell_type
of	O
transduced	B-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	E-cell_line
.	O

Two	O
families	O
of	O
transcription	B-protein
factors	E-protein
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c-Myb	S-protein
and	O
Ets	S-protein
.	O

Antioxidant-mediated	O
inhibition	O
of	O
cytokine	S-protein
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	B-RNA
RNAs	E-RNA
.	O

The	O
understanding	O
of	O
LPS-	O
and	O
TNF-induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis-associated	O
disease	O
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	B-DNA
13	I-DNA
CIITA	I-DNA
alleles	E-DNA
bore	O
a	O
mutation	O
that	O
allowed	O
HLA-DQ	S-DNA
,	O
but	O
not	O
HLA-DR	O
or	O
-DP	O
transcription	O
.	O

When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B-protein
kinase	I-protein
p59fyn	E-protein
,	O
the	O
reporter	B-DNA
gene	E-DNA
was	O
activated	O
by	O
PMA	S-protein
alone	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	S-DNA
gene	O
expression	O
in	O
HL-60	B-cell_line
cells	E-cell_line
during	O
monocytic	O
differentiation	O
.	O

Strong	O
nuclear	O
positivity	O
for	O
the	O
BCL-6	B-protein
protein	E-protein
was	O
detected	O
in	O
tumor	B-cell_type
(	I-cell_type
L	I-cell_type
&	I-cell_type
H	I-cell_type
)	I-cell_type
cells	E-cell_type
in	O
all	O
cases	O
of	O
NLPHD	O
.	O

Factors	O
binding	O
to	O
site	B-DNA
C	E-DNA
(	O
nt	B-DNA
4681	I-DNA
to	I-DNA
4701	E-DNA
)	O
had	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	B-DNA
B	E-DNA
,	O
except	O
for	O
PU.1/Spi-1	S-protein
.	O

(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA-2	S-protein
transactivated	O
LMP1	S-protein
as	O
well	O
as	O
the	O
EBV	B-protein
type	I-protein
1	I-protein
EBNA-2	E-protein
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
kinase	E-protein
similarly	O
impaired	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
EL4	B-cell_line
cells	E-cell_line
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	S-DNA
modification	O
.	O

Since	O
kappa	B-DNA
B	I-DNA
motifs	E-DNA
are	O
present	O
in	O
VCAM-1	B-DNA
and	I-DNA
intercellular	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
(	I-DNA
ICAM-1	I-DNA
)	I-DNA
promoters	E-DNA
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM-1	S-protein
and	O
ICAM-1	S-protein
induction	O
and	O
subsequent	O
monocyte	S-cell_type
adhesion	O
in	O
TNF-treated	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	E-cell_line
(	O
HUVECs	S-cell_line
)	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA-	B-protein
and	I-protein
the	I-protein
steroid-binding	I-protein
region	E-protein
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B-protein
receptor	E-protein
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O

Transient	O
expression	O
experiments	O
of	O
5'-deletion	B-DNA
fragments	E-DNA
of	O
the	O
CD36	B-DNA
promoter	E-DNA
coupled	O
to	O
luciferase	S-protein
demonstrated	O
that	O
as	O
few	O
as	O
158	B-DNA
base	I-DNA
pairs	I-DNA
upstream	E-DNA
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
were	O
sufficient	O
to	O
direct	O
the	O
monocyte-specific	O
transcription	O
of	O
the	O
reporter	B-DNA
gene	E-DNA
.	O

To	O
investigate	O
whether	O
both	O
lipoxygenase	B-protein
isoforms	E-protein
exhibit	O
a	O
similar	O
regulatory	O
response	O
toward	O
cytokine	S-protein
stimulation	O
,	O
we	O
studied	O
the	O
regulation	O
of	O
the	O
leukocyte-type	B-protein
12-lipoxygenase	E-protein
of	O
murine	B-cell_type
peritoneal	I-cell_type
macrophages	E-cell_type
by	O
interleukins	S-protein
and	O
found	O
that	O
the	O
activity	O
of	O
this	O
enzyme	S-protein
is	O
upregulated	O
in	O
a	O
dose-dependent	O
manner	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IL-4	S-protein
or	O
IL-13	S-protein
but	O
not	O
by	O
IL-10	S-protein
.	O

Protein	O
kinase	O
C	O
(	O
PKC	S-protein
)	O
depletion	O
generated	O
by	O
a	O
long-term	O
phorbol	O
12	O
myristate	O
13-acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O

Multiple	O
factors	O
including	O
Stat5	S-protein
,	O
Elf-1	S-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	E-protein
and	O
GATA	B-protein
family	I-protein
proteins	E-protein
bind	O
to	O
the	O
IL-2	B-DNA
response	I-DNA
element	E-DNA
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

Steel	B-protein
factor	E-protein
is	O
one	O
of	O
the	O
growth	B-protein
factors	E-protein
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	E-cell_type
and	O
SCL	S-protein
,	O
also	O
known	O
as	O
Tcl-5	S-protein
or	O
Tal-1	S-protein
,	O
is	O
a	O
transcription	B-protein
factor	E-protein
involved	O
in	O
erythropoiesis	O
.	O

Effect	O
of	O
environmental	O
estrogens	O
on	O
IL-1beta	B-DNA
promoter	E-DNA
activity	O
in	O
a	O
macrophage	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O

The	O
induction	O
of	O
promoters	S-DNA
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O

Molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

The	O
region	O
downstream	O
of	O
the	O
enhancer	S-DNA
(	O
DEN	S-DNA
)	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
of	O
the	O
mink	O
cell	O
focus-forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O

We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	B-DNA
Factor	I-DNA
(	I-DNA
TF	I-DNA
)	I-DNA
gene	E-DNA
and	O
the	O
function	O
of	O
the	O
TF	B-protein
protein	E-protein
.	O

The	O
mechanism	O
of	O
action	O
of	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
the	O
inactivation	O
of	O
the	O
Ca2+/calmodulin-dependent	B-protein
serine-threonine	I-protein
phosphatase	I-protein
calcineurin	E-protein
by	O
the	O
drug-immunophilin	B-protein
complex	E-protein
.	O

We	O
found	O
very	O
little	O
detectable	O
activation	O
of	O
AP-1	S-protein
,	O
as	O
assessed	O
in	O
a	O
gel	O
shift	O
assay	O
,	O
in	O
alveolar	B-cell_type
macrophages	E-cell_type
,	O
whereas	O
monocytes	S-cell_type
showed	O
a	O
substantial	O
activation	O
of	O
AP-1	S-protein
by	O
PMA	O
.	O

Primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
an	O
autoimmune	O
rheumatic	O
disease	O
characterized	O
by	O
T	O
cell	O
hypoactivity	O
.	O

In	O
order	O
to	O
analyse	O
the	O
immune	O
function	O
data	O
effectively	O
,	O
low	O
responders	O
were	O
identified	O
with	O
stringent	O
cut-off	O
values	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O

The	O
IL-1	S-protein
-induced	O
NF-kappa	B-protein
B	E-protein
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor-initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

Its	O
differential	O
expression	O
in	O
different	O
tissues	O
and	O
cells	O
is	O
regulated	O
not	O
only	O
at	O
the	O
transcriptional	O
level	O
but	O
also	O
at	O
the	O
translational	O
level	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice/d	O
,	O
30	O
min/exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

cAMP	O
inhibited	O
the	O
induction	O
of	O
expression	O
of	O
IL-2	B-protein
receptor	I-protein
components	E-protein
,	O
but	O
did	O
not	O
inhibit	O
IL-4	B-protein
receptor	I-protein
alpha-chain	E-protein
and	O
CD69	S-protein
expression	O
or	O
the	O
induction	O
of	O
activator	B-protein
protein	I-protein
1	I-protein
transcription	I-protein
factors	E-protein
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL-60	B-cell_line
cells	E-cell_line
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E-BP1	S-protein
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E-BP2	S-protein
amount	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	B-protein
TCF-1	E-protein
.	O

A	O
2.3-kb	B-protein
LCR	E-protein
in	O
the	O
human	B-DNA
adenosine	I-DNA
deaminase	I-DNA
(	I-DNA
ADA	I-DNA
)	I-DNA
gene	I-DNA
first	I-DNA
intron	E-DNA
,	O
which	O
controls	O
expression	O
in	O
thymocytes	S-cell_type
,	O
is	O
composed	O
of	O
a	O
200-bp	B-DNA
enhancer	I-DNA
domain	E-DNA
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	S-DNA
.	O

Thus	O
,	O
HTLV-I	B-protein
Tax	E-protein
,	O
HTLV-II	B-protein
Tax	E-protein
,	O
and	O
c-jun	S-protein
transactivate	O
PTHrP	S-protein
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
hypercalcemia	O
in	O
adult	O
T-cell	O
leukemia	O
.	O

One	O
(	O
site	B-DNA
B	E-DNA
)	O
contained	O
a	O
palindromic	B-DNA
sequence	E-DNA
with	O
homology	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
response	I-DNA
elements	E-DNA
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O

In	O
contrast	O
,	O
the	O
beta	B-protein
isoform	E-protein
is	O
expressed	O
at	O
very	O
low	O
constitutive	O
levels	O
in	O
both	O
cell	O
types	O
but	O
is	O
only	O
up-regulated	O
in	O
response	O
to	O
mast	O
cell	O
activation	O
signals	O
delivered	O
through	O
the	O
FcepsilonRI	S-protein
or	O
via	O
calcium	O
ionophores	O
.	O

In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
.	O

Furthermore	O
,	O
the	O
MRD	O
in	O
PBSC	S-cell_type
harvests	O
is	O
less	O
than	O
in	O
the	O
corresponding	O
bone	O
marrow	O
obtained	O
on	O
the	O
day	O
of	O
the	O
PBSC	S-cell_type
collection	O
.	O

By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	B-RNA
transcript	E-RNA
was	O
detected	O
from	O
the	O
early	O
stage	O
of	O
development	O
.	O

In	O
A20	B-cell_line
B	I-cell_line
cells	E-cell_line
,	O
the	O
TNF-alpha	B-DNA
gene	E-DNA
is	O
not	O
regulated	O
by	O
NFATp	S-protein
bound	O
to	O
the	O
kappa	B-DNA
3	I-DNA
element	E-DNA
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
DRA	I-DNA
promoter	E-DNA
and	O
corresponding	O
binding	B-protein
factors	E-protein
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	B-protein
I	E-protein
footprint	O
.	O

LSF	S-protein
(	O
also	O
known	O
as	O
LBP-1	S-protein
,	O
UBP	S-protein
,	O
and	O
CP-2	S-protein
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	S-protein
has	O
no	O
effect	O
on	O
LTR	S-DNA
activity	O
in	O
vivo	O
.	O

These	O
contained	O
the	O
luciferase	B-DNA
gene	E-DNA
under	O
the	O
control	O
of	O
either	O
the	O
human	B-DNA
IL2	I-DNA
upstream	I-DNA
enhancer	E-DNA
region	O
(	O
segments	O
-326	O
to	O
+45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	B-DNA
element	E-DNA
contained	O
within	O
it	O
(	O
segments	O
-255	O
to	O
-285	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	B-cell_line
cell	I-cell_line
line	I-cell_line
NK92	E-cell_line
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell-mediated	O
EC	S-cell_type
activation	O
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	E-DNA
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	B-DNA
negative-acting	I-DNA
elements	E-DNA
.	O

In	O
5	O
patients	O
the	O
granulocytes	S-cell_type
appeared	O
polyclonal	O
and	O
in	O
1	O
patient	O
unilateral	O
X	O
inactivation	O
was	O
observed	O
in	O
both	O
granulocytes	S-cell_type
and	O
T	B-cell_type
cells	E-cell_type
.	O

Proximal	O
signal	O
transduction	O
events	O
and	O
immediate	B-DNA
early	I-DNA
gene	E-DNA
transcription	O
were	O
unaffected	O
.	O

Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	O
that	O
the	O
G0S24	B-protein
product	E-protein
has	O
a	O
similar	O
role	O
.	O

The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	E-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
(	O
PBL	S-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	E-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	E-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	E-protein
measured	O
by	O
gel	O
retardation	O
.	O

Immobilization	O
and	O
recovery	O
of	O
fusion	B-protein
proteins	E-protein
and	O
B-lymphocyte	B-cell_type
cells	E-cell_type
using	O
magnetic	O
separation	O
.	O

T	B-cell_type
cells	E-cell_type
were	O
separated	O
into	O
CD4	S-cell_type
and	O
CD8	S-cell_type
.	O

The	O
transactivator	B-protein
CIITA	E-protein
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	E-DNA
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O

ALF1	S-protein
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	E-DNA
equally	O
,	O
whereas	O
E2A	B-protein
protein	E-protein
required	O
the	O
promoter-proximal	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	E-DNA
motif	O
.	O

Significantly	O
,	O
expression	O
of	O
the	O
newly	O
identified	O
Fas-regulatory	B-DNA
gene	E-DNA
,	O
TDAG51	S-DNA
,	O
was	O
found	O
to	O
be	O
dependent	O
upon	O
the	O
activity	O
of	O
PKC	S-protein
.	O

In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O

Rather	O
,	O
helenalin	O
modifies	O
the	O
NF-kappaB/IkappaB	B-protein
complex	E-protein
,	O
preventing	O
the	O
release	O
of	O
IkappaB	S-protein
.	O

CIITA	S-protein
is	O
a	O
positive	O
regulator	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	E-DNA
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex-negative	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
CIITA	S-protein
,	O
interactions	O
between	O
class	B-DNA
II	I-DNA
promoters	E-DNA
and	O
Bob1	S-protein
are	O
independent	O
of	O
the	O
octamer-binding	B-RNA
site	E-RNA
.	O

This	O
could	O
partly	O
be	O
explained	O
by	O
the	O
antenatal	O
steroid	O
treatment	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	B-protein
kinases	E-protein
.	O

Intriguingly	O
,	O
the	O
major	B-protein
E2F	I-protein
complex	E-protein
that	O
we	O
detected	O
in	O
quiescent	B-cell_type
human	I-cell_type
B-lymphocytes	E-cell_type
is	O
consisted	O
of	O
pRB	S-protein
,	O
E2F4	S-protein
,	O
and	O
DP1	S-protein
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom-2	S-DNA
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
11	E-DNA
at	O
band	B-DNA
11p13	E-DNA
,	O
where	O
a	O
cluster	O
of	O
T-cell	B-DNA
leukemia-specific	I-DNA
translocations	E-DNA
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	S-DNA
are	O
upstream	O
of	O
the	O
Rhom-2	B-DNA
gene	E-DNA
.	O

Thus	O
,	O
human	B-cell_type
erythroid	I-cell_type
precursors	E-cell_type
can	O
be	O
expanded	O
in	O
vitro	O
in	O
sufficient	O
numbers	O
and	O
purity	O
to	O
allow	O
its	O
usage	O
in	O
signal	O
transduction	O
studies	O
.	O

This	O
pattern	O
of	O
EBNA	S-protein
expression	O
is	O
generated	O
by	O
usage	O
of	O
the	O
BamHI-Q	B-DNA
promoter	E-DNA
(	O
Qp	S-DNA
)	O
.	O

Activation	O
of	O
normal	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	E-cell_type
resulted	O
in	O
increased	O
expression	O
of	O
Egr-1	B-protein
,	I-protein
-2	I-protein
,	I-protein
and	I-protein
-3	E-protein
.	O

Our	O
observations	O
indicate	O
that	O
changes	O
in	O
the	O
intracellular	O
redox	O
status	O
may	O
be	O
a	O
determining	O
factor	O
in	O
Tax	S-protein
-mediated	O
DNA	O
damage	O
,	O
apoptosis	O
,	O
and	O
selection	O
against	O
the	O
long-term	O
expression	O
of	O
Tax	S-protein
function	O
.	O

The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	S-protein
inhibitor	O
:	O
in	O
CD45RA+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	B-protein
alpha	E-protein
.	O

Our	O
data	O
suggest	O
that	O
interferon-alpha	S-protein
/beta-induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	S-protein
-	O
STAT2	B-protein
signaling	I-protein
complex	E-protein
.	O

Overexpression	O
of	O
BXB	S-protein
,	O
a	O
constitutive	O
active	O
version	O
of	O
c-Raf	S-protein
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	S-protein
-	O
Raf	S-protein
-	O
Erk	S-protein
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	S-protein
-mediated	O
promoter-enhancer	O
induction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

The	O
interaction	O
of	O
the	O
transcription	B-protein
factors	E-protein
,	O
activator	B-protein
protein-1	E-protein
(	O
AP-1	S-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF	B-protein
kappa	I-protein
B	E-protein
)	O
,	O
and	O
cAMP-responsive	B-protein
element	I-protein
binding	I-protein
protein	E-protein
(	O
CREB	S-protein
)	O
with	O
DNA	O
and	O
glucocorticoid	B-protein
receptors	E-protein
(	O
GR	S-protein
)	O
was	O
analyzed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	B-protein
binding	I-protein
sites	E-protein
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	B-protein
proteins	E-protein
.	O

In	O
a	O
panel	O
of	O
32	O
B-cell	B-cell_line
lines	E-cell_line
,	O
A-myb	S-DNA
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
4	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
6	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
and	O
6	O
myeloma	B-cell_line
lines	E-cell_line
.	O

However	O
,	O
VDR	S-protein
concentration	O
was	O
significantly	O
decreased	O
in	O
A-CRF	O
(	O
0.8	O
+/-	O
0.5	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
,	O
p	O
<	O
0.001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
M-CRF	O
(	O
1.7	O
+/-	O
0.7	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O

In	O
parallel	O
,	O
CD2	S-protein
+	O
CD28	S-protein
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	B-protein
molecules	E-protein
.	O

Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	B-protein
molecules	E-protein
and	O
prolactin-inducible	B-DNA
target	I-DNA
genes	E-DNA
that	O
participate	O
in	O
these	O
responses	O
.	O

Therefore	O
,	O
we	O
also	O
evaluated	O
activation	O
of	O
the	O
MAP	B-protein
kinase	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
2	E-protein
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

Thus	O
,	O
GATA-1	S-protein
plays	O
important	O
in	O
vivo	O
roles	O
for	O
directing	O
definitive	O
hematopoietic	B-cell_type
progenitors	E-cell_type
to	O
differentiate	O
along	O
both	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

We	O
demonstrate	O
that	O
IL-12	S-protein
induces	O
STAT4	S-protein
only	O
in	O
freshly	O
isolated	O
primary	B-cell_type
NK	I-cell_type
cells	E-cell_type
,	O
but	O
not	O
in	O
primary	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
consistent	O
with	O
the	O
lack	O
of	O
the	O
IL-12	B-protein
receptor	E-protein
in	O
resting	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Scatchard	O
analysis	O
of	O
glucocorticoid	B-protein
receptor	E-protein
-	O
GRE	S-DNA
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	S-protein
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid-resistant	O
patients	O
.	O

These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O

These	O
results	O
further	O
support	O
the	O
concept	O
that	O
NLPHD	O
is	O
an	O
histogenetically	O
distinct	O
,	O
B-cell-derived	O
subtype	O
of	O
HD	O
and	O
suggest	O
a	O
role	O
for	O
BCL-6	S-protein
in	O
its	O
development	O
.	O

The	O
mAECA	S-protein
,	O
but	O
not	O
normal	B-protein
human	I-protein
IgG	E-protein
,	O
had	O
anti-human	O
aortic	O
EC	O
activity	O
.	O

BSAP	S-protein
is	O
required	O
for	O
B-lineage	O
commitment	O
in	O
the	O
fetal	O
liver	O
and	O
for	O
progression	O
beyond	O
an	O
early	O
pro-B	O
cell	O
stage	O
in	O
adult	O
bone	O
marrow	O
.	O

Given	O
the	O
critical	O
role	O
that	O
LT-alpha1beta2	S-protein
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT-alpha1beta2	S-protein
may	O
be	O
involved	O
in	O
HIV-associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O

Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	S-protein
by	O
T	B-cell_type
cells	E-cell_type
remain	O
poorly	O
understood	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	S-protein
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	B-cell_type
cells	E-cell_type
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	S-protein
subunits	O
c-Rel	S-protein
and	O
NF-kappaB2	B-protein
p100	E-protein
and	O
a	O
moderate	O
increase	O
in	O
NF-kappaB2	B-protein
p52	E-protein
and	O
RelA	B-protein
(	I-protein
p65	I-protein
)	E-protein
were	O
detected	O
in	O
HIV-1-infected	B-cell_line
cells	E-cell_line
,	O
whereas	O
NF-kappaB1	B-protein
p105/p50	E-protein
levels	O
were	O
not	O
altered	O
relative	O
to	O
the	O
levels	O
in	O
uninfected	B-cell_type
cells	E-cell_type
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	B-DNA
construct	E-DNA
containing	O
as	O
an	O
enhancer	S-DNA
four	O
copies	O
of	O
the	O
NF-AT	B-DNA
site	E-DNA
and	O
one	O
copy	O
of	O
the	O
octamer	B-DNA
site	E-DNA
(	O
4X	B-DNA
NF-AT-Oct	E-DNA
)	O
.	O

Cotransfection	O
of	O
Sp3	S-protein
along	O
with	O
CD11c	B-DNA
promoter-luciferase	I-DNA
constructs	E-DNA
into	O
Sp-deficient	B-cell_line
Drosophila	I-cell_line
Schneider	I-cell_line
2	I-cell_line
cells	E-cell_line
showed	O
that	O
Sp3	S-protein
could	O
activate	O
the	O
CD11c	B-DNA
promoter	E-DNA
.	O

We	O
identified	O
this	O
92-kDa	B-protein
protein	E-protein
as	O
STAT5	S-protein
,	O
but	O
not	O
as	O
STATs1	B-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
6	E-protein
nor	O
c-fes	S-protein
and	O
vav	B-protein
protooncogene	I-protein
products	E-protein
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM-CSF	S-protein
.	O

Both	O
FMLP	S-protein
and	O
PAF	B-protein
activated	I-protein
MAP	I-protein
kinase	I-protein
kinase-3	E-protein
(	O
MKK3	S-protein
)	O
,	O
a	O
known	O
activator	O
of	O
p38	B-protein
MAPk	E-protein
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	B-DNA
site	E-DNA
on	O
the	O
translocated	O
c-myc	B-DNA
allele	E-DNA
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

Members	O
of	O
this	O
family	O
have	O
been	O
isolated	O
from	O
invertebrates	O
as	O
well	O
as	O
vertebrates	O
.	O

In	O
nonerythroid	B-cell_line
NIH3T3	I-cell_line
cells	E-cell_line
,	O
however	O
,	O
the	O
GATA	B-DNA
site	E-DNA
is	O
not	O
required	O
.	O

Binding	O
of	O
plasma	B-protein
Factor	I-protein
VII/VIIa	E-protein
to	O
the	O
tissue	B-protein
factor	I-protein
(	I-protein
TF	I-protein
)	I-protein
receptor	E-protein
initiates	O
the	O
coagulation	B-protein
protease	E-protein
cascades	O
.	O

In	O
contrast	O
,	O
induction	O
of	O
differentiation	O
but	O
not	O
of	O
proliferation	O
was	O
followed	O
by	O
a	O
25-	O
to	O
30-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
p53	E-protein
(	O
wild	O
type	O
)	O
,	O
pRb	S-protein
,	O
and	O
p130/Rb2	S-protein
and	O
of	O
the	O
p53-dependent	B-protein
cyclin	I-protein
kinase	I-protein
inhibitor	I-protein
p21/Cip1	E-protein
.	O

Recent	O
analysis	O
of	O
gene-targeted	O
mice	O
has	O
allowed	O
a	O
direct	O
assessment	O
of	O
the	O
functional	O
roles	O
of	O
several	B-protein
E-protein	I-protein
family	I-protein
members	E-protein
in	O
hematopoiesis	O
.	O

DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH-20	O
column	O
.	O

N-Acetylcysteine	O
,	O
alpha	O
,	O
alpha'-dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	O
show	O
any	O
effect	O
.	O

Fos	O
expression	O
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand-receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O

In	O
contrast	O
,	O
GATA-2	S-protein
is	O
strongly	O
expressed	O
in	O
both	O
most	B-cell_type
primitive	I-cell_type
and	I-cell_type
committed	I-cell_type
progenitors	I-cell_type
cells	E-cell_type
,	O
whereas	O
GATA-3	S-protein
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O

However	O
,	O
sequence	O
specificity	O
of	O
NF-AT	S-protein
was	O
more	O
similar	O
to	O
that	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	E-protein
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	S-protein
was	O
detected	O
in	O
NF	B-protein
(	I-protein
P	I-protein
)	E-protein
.	O

Erythropoietin	O
(	O
Epo	O
)	O
is	O
essential	O
for	O
the	O
later	O
stages	O
of	O
erythropoiesis	O
,	O
acting	O
to	O
promote	O
cell	O
survival	O
and	O
proliferation	O
,	O
but	O
its	O
role	O
in	O
differentiation	O
remains	O
to	O
be	O
defined	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT-PCR	O
positive	O
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	B-cell_type
cells	E-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	S-cell_type
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Activated	B-cell_type
macrophages	E-cell_type
contribute	O
to	O
chronic	O
inflammation	O
by	O
the	O
secretion	O
of	O
cytokines	S-protein
and	O
proteinases	S-protein
.	O

This	O
analysis	O
identified	O
one	O
such	O
element	O
repeated	O
four	O
times	O
within	O
the	O
CD11b	B-DNA
promoter	E-DNA
.	O

It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20/12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

However	O
,	O
using	O
ATL-16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA-4	S-protein
is	O
the	O
only	O
GATA-binding	B-protein
protein	E-protein
that	O
forms	O
specific	O
DNA-protein	B-protein
complex	E-protein
with	O
the	O
-70	B-DNA
GATA	I-DNA
site	E-DNA
.	O

In	O
these	O
same	O
animals	O
,	O
E1A	B-protein
protein	E-protein
was	O
detected	O
20	O
days	O
after	O
infection	O
in	O
two	O
and	O
47	O
days	O
after	O
infection	O
in	O
one	O
while	O
persistent	O
bronchiolitis	O
was	O
observed	O
in	O
four	O
and	O
three	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
,	O
respectively	O
.	O

All	O
clones	O
derived	O
from	O
K46	B-cell_line
B	I-cell_line
cells	E-cell_line
showed	O
increased	O
expression	O
of	O
CD44	S-protein
.	O

Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O

Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	S-protein
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	S-cell_line
and	O
HEL	B-cell_line
cells	E-cell_line
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	S-protein
recognizing	O
the	O
T	B-protein
cell	I-protein
NFATc	E-protein
revealed	O
no	O
detectable	O
NFATc	S-protein
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	B-cell_line
ester-stimulated	I-cell_line
cells	E-cell_line
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
TNF-alpha	S-protein
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	B-protein
NF-kappa	I-protein
B	E-protein
.	O

The	O
inhibitory	O
action	O
of	O
alpha-lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N-acetylcysteine	O
.	O

Transcriptional	O
differences	O
between	O
these	O
LTRs	S-DNA
were	O
further	O
enhanced	O
by	O
two-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
or	O
by	O
cotransfection	O
with	O
plasmids	S-DNA
expressing	O
NF	B-protein
kappa	I-protein
B	E-protein
subunits	O
.	O

Correlations	O
of	O
TCRzeta	S-protein
or	O
p56	B-protein
(	I-protein
lck	I-protein
)	E-protein
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	S-protein
levels	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

HIV	B-protein
glycoprotein	I-protein
120	E-protein
enhances	O
intercellular	B-protein
adhesion	I-protein
molecule-1	E-protein
gene	O
expression	O
in	O
glial	B-cell_type
cells	E-cell_type
.	O

From	O
a	O
murine	B-DNA
B-cell	I-DNA
cDNA-library	E-DNA
we	O
have	O
cloned	O
a	O
cDNA	S-DNA
encoding	O
the	O
murine	B-protein
B-cell	I-protein
specific	I-protein
coactivator	I-protein
mBob1	E-protein
.	O

To	O
analyze	O
the	O
mechanisms	O
that	O
lead	O
to	O
the	O
expression	O
of	O
IL-1alpha	S-protein
in	O
HTLV-I-infected	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
we	O
studied	O
regulatory	O
regions	O
of	O
the	O
human	O
IL-1alpha	B-DNA
promoter	E-DNA
involved	O
in	O
activation	O
of	O
the	O
IL-1alpha	B-DNA
gene	E-DNA
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	S-protein
and	O
LMO	S-protein
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	B-DNA
target	I-DNA
genes	E-DNA
regulated	O
by	O
TAL1	S-protein
and	O
LMO	S-protein
by	O
a	O
subtractive	O
PCR	O
method	O
.	O

Thus	O
,	O
stable	O
expression	O
of	O
HB24	S-DNA
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	B-protein
factor	E-protein
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

Thus	O
,	O
the	O
55	B-protein
kd	I-protein
TNFR	E-protein
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
's	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
promoter	E-DNA
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B-protein
enhancer	I-protein
binding-protein	I-protein
2	I-protein
(	I-protein
PEBP2	I-protein
)	I-protein
transcription	I-protein
factor	E-protein
,	O
which	O
consists	O
of	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	E-protein
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B-protein
B	E-protein
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
,	E-protein
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	B-protein
A	E-protein
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	B-cell_type
cells	E-cell_type
.	O

Advances	O
in	O
gene	O
technology	O
have	O
allowed	O
the	O
manipulation	O
of	O
molecular	O
interactions	O
that	O
shape	O
the	O
T	O
cell	O
repertoire	O
.	O

Positive	O
induction	O
of	O
GR	B-RNA
mRNA	E-RNA
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	B-cell_line
and	I-cell_line
dex-resistant	I-cell_line
CEM	I-cell_line
cells	E-cell_line
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

These	O
binding	O
studies	O
were	O
paralleled	O
by	O
specific	O
T	O
cell	O
recognition	O
of	O
the	O
class	B-protein
II-peptide	I-protein
complex	E-protein
,	O
in	O
which	O
the	O
substituted	O
peptide	O
abolished	O
T	O
cell	O
reactivity	O
,	O
which	O
was	O
directed	O
to	O
the	O
DQ3.2-peptide	B-protein
complex	E-protein
,	O
whereas	O
the	O
same	O
T	B-cell_line
cell	I-cell_line
clone	E-cell_line
recognized	O
the	O
substituted	O
peptide	O
presented	O
by	O
DQ3.3	O
,	O
a	O
class	O
II	O
restriction	O
element	O
differing	O
from	O
DQ3.2	O
only	O
at	O
residue	O
57	O
.	O

Serum	O
cortisol	O
decreased	O
after	O
1	O
week	O
of	O
treatment	O
whereas	O
urinary	O
cortisol	O
was	O
not	O
affected	O
until	O
the	O
second	O
week	O
of	O
treatment	O
.	O

The	O
present	O
study	O
examined	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
.	O

These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	S-protein
and	O
its	O
circulating	O
des-Arg	B-protein
form	E-protein
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O

Copyright	O
1998	O
Elsevier	O
Science	O
Ireland	O
Ltd	O
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	S-protein
-regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

In	O
the	O
STLV-I-bearing	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
tax1-related	B-protein
antigen	I-protein
molecules	E-protein
detected	O
by	O
Lt-4	S-protein
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd	O
.	O

B-cell-specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	B-DNA
domain	E-DNA
containing	O
transcription	B-protein
factor	I-protein
Oct-1	E-protein
or	O
Oct-2	S-protein
,	O
with	O
the	O
B-cell-specific	B-protein
coactivator	I-protein
OCA-B	E-protein
(	O
Bob-1	S-protein
,	O
OBF-1	S-protein
)	O
and	O
a	O
prototype	B-DNA
octamer	I-DNA
element	E-DNA
.	O

These	O
abnormalities	O
can	O
be	O
reproduced	O
by	O
transfection	O
of	O
cell	B-cell_line
lines	E-cell_line
with	O
the	O
GCR-beta	S-protein
gene	O
resulting	O
in	O
significant	O
reduction	O
of	O
their	O
GCR-alpha	S-protein
DNA	O
binding	O
capacity	O
.	O

Multiple	O
prolactin-responsive	B-DNA
elements	E-DNA
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	B-DNA
regulatory	I-DNA
factor-1	I-DNA
gene	E-DNA
.	O

Overexpression	O
of	O
SRF	S-protein
in	O
B	B-cell_type
cells	E-cell_type
causes	O
the	O
IL-2R	B-DNA
enhancer	E-DNA
to	O
function	O
as	O
well	O
as	O
it	O
does	O
in	O
T	B-cell_type
cells	E-cell_type
,	O
suggesting	O
that	O
the	O
high	O
level	O
of	O
SRF	S-protein
binding	O
in	O
T	B-cell_type
cells	E-cell_type
is	O
functionally	O
important	O
.	O

However	O
,	O
the	O
NF-kappaB	S-protein
activation	O
pathway	O
involving	O
the	O
acidic	B-protein
sphingomyelinase	E-protein
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS-induced	O
NF-kappaB	S-protein
activation	O
in	O
U937	B-cell_line
cells	E-cell_line
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM-CSF	S-protein
,	O
IL-3	S-protein
,	O
M-CSF	B-protein
receptor	E-protein
(	O
C-FMS	S-protein
)	O
,	O
early	B-DNA
growth	I-DNA
response	I-DNA
gene-1	E-DNA
(	O
EGR-1	S-DNA
)	O
and	O
M-CSF	B-DNA
genes	E-DNA
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

This	O
Tax1	S-protein
-induced	O
activation	O
of	O
cellular	B-DNA
genes	E-DNA
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T-cell	O
transformation	O
by	O
HTLV-I	O
.	O

Expression	O
of	O
Egr-1	S-protein
correlates	O
with	O
the	O
transformed	O
phenotype	O
and	O
the	O
type	O
of	O
viral	O
latency	O
in	O
EBV	B-cell_line
genome	I-cell_line
positive	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Transcription	O
is	O
initiated	O
at	O
one	O
major	O
site	O
.	O

The	O
ligand-binding	B-protein
domain	E-protein
(	O
amino	B-protein
acids	I-protein
528-777	E-protein
)	O
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptor	E-protein
contains	O
four	O
amino	O
acid	O
differences	O
(	O
Ser551	O
to	O
Thr	O
,	O
Ser616	O
to	O
Ala	O
,	O
Ala618	O
to	O
Ser	O
,	O
and	O
Ile761	O
to	O
Leu	O
)	O
,	O
all	O
of	O
which	O
are	O
present	O
in	O
owl	B-protein
monkey	I-protein
and	I-protein
cotton-top	I-protein
tamarin	I-protein
receptors	E-protein
.	O

In	O
contrast	O
,	O
the	O
C-terminal	B-protein
region	E-protein
of	O
the	O
GM-CSFRalpha	B-protein
cytoplasmic	I-protein
domain	E-protein
was	O
not	O
necessary	O
for	O
cell	O
differentiation	O
mediated	O
by	O
hGM-CSF	S-protein
,	O
but	O
the	O
removal	O
of	O
this	O
region	O
severely	O
impaired	O
the	O
ability	O
of	O
hGM-CSF	S-protein
to	O
support	O
cell	O
survival	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP-2	S-protein
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	B-DNA
LTR	E-DNA
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	B-DNA
cDNA	E-DNA
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

RB	S-protein
and	O
a	O
novel	O
E2F-1	B-protein
binding	I-protein
protein	E-protein
in	O
MHC	B-cell_line
class	I-cell_line
II	I-cell_line
deficient	I-cell_line
B-cell	I-cell_line
lines	E-cell_line
and	O
normal	O
IFN-gamma	S-protein
induction	O
of	O
the	O
class	B-DNA
IL	I-DNA
transactivator	I-DNA
CIITA	E-DNA
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
RB-defective	I-cell_line
tumor	I-cell_line
lines	E-cell_line
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	E-protein
induced	O
by	O
Tax	S-protein
through	O
the	O
NF-kappaB	S-protein
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	B-cell_line
cells	E-cell_line
after	O
IL-2	S-protein
deprivation	O
.	O

TCR	S-protein
-contact	O
site	O
heterogeneity	O
was	O
excluded	O
as	O
the	O
selective	O
force	O
in	O
diversity	O
generation	O
since	O
the	O
epitope-encoded	O
sequences	O
were	O
found	O
to	O
be	O
identical	O
within	O
endogenous	O
virus	O
isolates	O
.	O

The	O
hormone	O
delayed	O
terminal	O
differentiation	O
into	O
erythrocytes	S-cell_type
,	O
which	O
was	O
assayed	O
by	O
morphology	O
,	O
hemoglobin	S-protein
accumulation	O
,	O
and	O
the	O
expression	O
of	O
genes	O
characteristic	O
for	O
immature	B-cell_type
cells	E-cell_type
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

PG490	O
inhibits	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	E-protein
expression	O
by	O
normal	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	S-protein
(	O
IC50	O
of	O
10	O
ng/ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng/ml	O
)	O
.	O

Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR	S-protein
-stimulated	O
activation	O
of	O
the	O
Ras	S-protein
signaling	O
pathway	O
is	O
required	O
for	O
optimal	O
activation	O
of	O
CD95	B-protein
ligand	E-protein
.	O

Furthermore	O
,	O
PU.1	S-protein
transactivates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	E-DNA
in	O
nonmacrophage	B-cell_type
cells	E-cell_type
.	O

Transcription	B-protein
factors	I-protein
USF1	E-protein
and	O
USF2	S-protein
up-regulate	O
gene	O
expression	O
(	O
i.e.	O
,	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeats	E-DNA
)	O
via	O
interaction	O
with	O
an	O
E	B-DNA
box	E-DNA
on	O
their	O
target	O
promoters	O
,	O
which	O
is	O
also	O
a	O
binding	B-DNA
site	E-DNA
for	O
c-Myc	S-protein
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B-DNA
upstream	I-DNA
regulatory	I-DNA
region	E-DNA
from	O
the	O
ER-positive	B-cell_line
MCF-7	E-cell_line
and	O
the	O
ER-negative	B-cell_line
MDA-MB-231	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	E-cell_line
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	S-protein
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O

First	O
,	O
previous	O
studies	O
have	O
shown	O
this	O
integrin	S-protein
to	O
be	O
particularly	O
prone	O
to	O
proteolytic	O
regulation	O
of	O
its	O
function	O
.	O

In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	B-cell_type
cells	E-cell_type
from	O
the	O
pleural	O
effusions	O
.	O

We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	E-DNA
present	O
at	O
the	O
cap	B-DNA
site	E-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	E-DNA
are	O
required	O
for	O
full	O
promoter	S-DNA
function	O
.	O

The	O
helper	O
activity	O
for	O
IgE	S-protein
synthesis	O
by	O
the	O
CD27	S-protein
/CD70	O
interaction	O
did	O
not	O
contribute	O
to	O
the	O
enhancement	O
of	O
germline	B-RNA
epsilon	I-RNA
transcripts	E-RNA
.	O

In	O
contrast	O
,	O
APC	S-cell_type
pulsed	O
with	O
Ala-substituted	O
peptides	O
430-444	O
,	O
442A	O
or	O
433-442A	O
at	O
neutral	O
pH	O
failed	O
to	O
stimulate	O
the	O
T	B-cell_line
cell	I-cell_line
clone	E-cell_line
,	O
while	O
APC	S-cell_type
pulsed	O
at	O
acidic	O
pH	O
and	O
subsequently	O
washed	O
led	O
to	O
successful	O
T	O
cell	O
activation	O
.	O

In	O
addition	O
,	O
resting	B-cell_type
PBL	E-cell_type
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B-RNA
mRNA	E-RNA
,	O
but	O
not	O
Id3	B-RNA
mRNA	E-RNA
.	O

After	O
short-term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P-glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place	O
.	O

However	O
,	O
the	O
histone	B-protein
deacetylase	I-protein
(	I-protein
HDAC	I-protein
)	I-protein
inhibitor	E-protein
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR-RAR	B-DNA
reporter	I-DNA
construct	E-DNA
in	O
the	O
multipotent	O
EML	B-cell_type
cells	E-cell_type
but	O
not	O
in	O
the	O
committed	O
MPRO	B-cell_type
promyelocytes	E-cell_type
,	O
indicating	O
that	O
differences	O
in	O
HDAC-containing	B-protein
repressor	I-protein
complexes	E-protein
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	B-cell_type
lineages	E-cell_type
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR-RARalpha403	B-protein
heterodimers	E-protein
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

The	O
transcriptional	B-DNA
start	I-DNA
sites	E-DNA
were	O
identified	O
by	O
an	O
RNase	S-protein
protection	O
assay	O
.	O

Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV-associated	O
nasopharyngeal	O
carcinomas	O
.	O

This	O
suggests	O
that	O
NF-kappa	B-protein
B	E-protein
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV-I-associated	O
disease	O
.	O

Fos	B-protein
kinase	E-protein
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c-Fos	S-protein
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP-1	S-protein
,	O
but	O
not	O
nuclear	B-protein
factor-kappaB	E-protein
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	S-protein
transcription	O
in	O
macrophagelike	B-cell_type
cells	E-cell_type
.	O

Effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
activation	O
in	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	S-protein
can	O
transactivate	O
GM-CSF	S-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	S-protein
(	O
nuclear	B-protein
factor	E-protein
of	O
activated	B-cell_type
T-cells	E-cell_type
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B-protein
factor	E-protein
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	S-protein
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	E-protein
(	O
P	O
=	O
0.029	O
)	O
but	O
not	O
CD3epsilon	S-protein
(	O
P	O
=	O
0.131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

Gel	O
shift	O
analysis	O
revealed	O
that	O
oxidative	O
suppression	O
of	O
NF-AT	S-protein
represented	O
inhibition	O
in	O
the	O
early	O
generation	O
of	O
NFAT	B-protein
complexes	E-protein
rather	O
than	O
the	O
binding	O
of	O
preformed	O
NF-AT	B-protein
complexes	E-protein
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
of	O
two	O
DNA	B-protein
topoisomerase	I-protein
II	E-protein
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O

Transfection	O
of	O
trans-dominant	B-DNA
negative	I-DNA
expression	I-DNA
vectors	E-DNA
of	O
ras	S-DNA
and	O
raf	S-DNA
,	O
together	O
with	O
AP-1-dependent	B-DNA
reporter	I-DNA
constructs	E-DNA
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti-ERK	B-protein
(	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
)	I-protein
antibodies	E-protein
,	O
indicated	O
that	O
the	O
Ras/Raf/ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O

No	O
such	O
increase	O
was	O
observed	O
in	O
control	O
U937	B-cell_line
cells	E-cell_line
.	O

We	O
found	O
that	O
cortisol	O
incubation	O
induced	O
a	O
decrease	O
in	O
IL-1ra	B-RNA
mRNA	E-RNA
expression	O
and	O
a	O
significant	O
inhibition	O
of	O
IL-1ra	B-protein
protein	E-protein
secretion	O
in	O
cell	O
cultures	O
of	O
human	B-cell_type
peripheral	I-cell_type
monocytes	E-cell_type
stimulated	O
with	O
the	O
bacterial	O
endotoxin	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Despite	O
this	O
,	O
there	O
are	O
still	O
significant	O
gaps	O
in	O
our	O
understanding	O
of	O
this	O
process	O
and	O
its	O
consequences	O
.	O

Analysis	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
promoter	I-DNA
DRA	E-DNA
has	O
previously	O
identified	O
at	O
least	O
five	O
cis-acting	B-DNA
regions	E-DNA
required	O
for	O
maximal	O
expression	O
.	O

The	O
type	B-protein
I	I-protein
interleukin-1	I-protein
receptor	E-protein
(	O
IL-1R	S-protein
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	S-DNA
expression	O
.	O

Similar	O
kinetics	O
of	O
c-jun	S-DNA
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B-cell_line
U-937	E-cell_line
and	O
THP-1	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
.	O

The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	B-protein
zinc-finger	I-protein
sequences	E-protein
of	O
the	O
type	O
Cys2-Xaa12-His2	S-protein
.	O

This	O
study	O
has	O
investigated	O
DHEA	O
modulation	O
of	O
LPS-induced	O
monocyte	O
cytotoxicity	O
.	O

Microtubules	S-protein
mediate	O
cellular	O
25-hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
monocytes	E-cell_type
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg-crosslinking-induced	O
Egr-1	B-RNA
mRNA	E-RNA
expression	O
in	O
a	O
dose-dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg-crosslinking-induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
Id3	E-protein
in	O
committed	B-cell_type
T	I-cell_type
cell	I-cell_type
progenitors	E-cell_type
.	O

This	O
protein-DNA	B-protein
complex	E-protein
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	B-protein
human	I-protein
p65	I-protein
NF-kappa	I-protein
B	I-protein
subunit	E-protein
and	O
binding	O
was	O
inhibited	O
by	O
I	B-protein
kappa	I-protein
B-alpha	E-protein
and	O
-beta	O
proteins	O
.	O

The	O
interleukin-1	B-protein
receptor	I-protein
type	I-protein
I	E-protein
(	O
IL-1RI	S-protein
)	O
is	O
associated	O
with	O
other	O
proteins	O
thus	O
forming	O
a	O
complex	B-protein
system	E-protein
by	O
which	O
IL-1	S-protein
exerts	O
its	O
various	O
signals	O
.	O

Structurally	O
,	O
the	O
LCR	S-DNA
is	O
defined	O
by	O
the	O
presence	O
of	O
four	O
domains	O
of	O
erythroid-specific	O
chromatin	O
structure	O
.	O

SCL	B-protein
protein	E-protein
was	O
detected	O
in	O
erythroid	B-cell_line
,	I-cell_line
megakaryocyte	I-cell_line
,	I-cell_line
mast	I-cell_line
and	I-cell_line
early	I-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	E-cell_line
which	O
are	O
known	O
to	O
harbor	O
SCL	B-DNA
gene	I-DNA
rearrangements	E-DNA
.	O

ZAP-70	S-protein
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	S-protein
and	O
CD45	S-protein
,	O
whereas	O
only	O
CD3	S-protein
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O

Tobacco	O
smoke	O
induces	O
coordinate	O
activation	O
of	O
HSF	S-protein
and	O
inhibition	O
of	O
NFkappaB	S-protein
in	O
human	B-cell_type
monocytes	E-cell_type
:	O
effects	O
on	O
TNFalpha	S-protein
release	O
.	O

AIDS-related	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O

Three	O
E2F	S-protein
DNA-binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	B-cell_type
cells	E-cell_type
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	S-protein
complexes	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
JAK3	S-protein
represents	O
a	O
pharmacological	O
target	O
to	O
control	O
certain	O
lymphoid-derived	O
diseases	O
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	B-protein
proteins	E-protein
and	O
recombinant	B-protein
thyroid	I-protein
hormone	I-protein
receptors	E-protein
(	O
TRs	S-protein
)	O
to	O
the	O
palindromic	B-DNA
thyroid	I-DNA
hormone	I-DNA
responsive	I-DNA
element	E-DNA
AGGTCATGACCT	O
(	O
TREp	S-DNA
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

A	O
few	O
47.10	B-cell_line
cells	E-cell_line
(	O
3-5	O
%	O
)	O
do	O
not	O
express	O
lineage	O
specific	O
markers	O
;	O
they	O
differentiate	O
spontaneously	O
to	O
lineage-positive	B-cell_line
cells	E-cell_line
after	O
replating	O
on	O
2M-1	B-cell_line
cells	E-cell_line
.	O

Our	O
results	O
indicate	O
that	O
CCK-8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
through	O
stimulation	O
of	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptors	E-protein
by	O
modulation	O
of	O
expression	O
of	O
AP-1-regulated	B-DNA
genes	E-DNA
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

Efficient	O
gene	O
activation	O
requires	O
the	O
heterodimerization	O
of	O
VDR	S-protein
with	O
Retinoid	B-protein
X	I-protein
Receptors	E-protein
(	O
RXR	S-protein
)	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	S-cell_type
express	O
the	O
GH-N	B-DNA
gene	E-DNA
but	O
not	O
the	O
GH-V	B-DNA
gene	E-DNA
.	O

In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
through	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein/activating	I-protein
transcription	I-protein
factor	I-protein
(	I-protein
CREB/ATF	I-protein
)	I-protein
family	E-protein
of	O
transcription	B-protein
factors	E-protein
,	O
Tax	S-protein
activates	O
the	O
expression	O
of	O
multiple	B-DNA
cellular	I-DNA
promoters	E-DNA
through	O
the	O
NF-kappaB	S-protein
pathway	O
of	O
transcriptional	O
activation	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-DNA
gene	E-DNA
on	O
Rex	S-protein
protein	O
production	O
and	O
function	O
.	O

IL-13	S-protein
caused	O
rapid	O
phosphorylation	O
of	O
the	O
three	O
out	O
of	O
four	O
members	O
of	O
the	O
known	O
Janus	B-protein
family	I-protein
of	I-protein
kinases	E-protein
(	O
JAKs	S-protein
)	O
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	B-DNA
X2-box	E-DNA
with	O
the	O
DRA	B-DNA
X2-box	E-DNA
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	B-DNA
promoter	E-DNA
in	O
the	O
mutant	B-cell_line
cell	E-cell_line
.	O

RESULTS	O
:	O
In	O
all	O
cells	O
tested	O
,	O
ER	B-RNA
mRNA	E-RNA
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O

We	O
further	O
demonstrate	O
that	O
Tax1	S-protein
specifically	O
activated	O
the	O
NF-Y-responsive	B-DNA
DQbeta	I-DNA
promoter	E-DNA
,	O
as	O
well	O
as	O
a	O
minimal	B-DNA
promoter	E-DNA
which	O
contains	O
only	O
the	O
Y-box	B-DNA
element	E-DNA
.	O

RT-PCR	O
demonstrated	O
that	O
NL	S-cell_type
of	O
both	O
subtypes	O
expressed	O
EBNAI	S-protein
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	B-protein
membrane	I-protein
proteins	E-protein
,	O
LMP1	B-protein
and	I-protein
2	E-protein
and	O
the	O
BamHI	B-RNA
A	I-RNA
rightward	I-RNA
transcripts	E-RNA
in	O
the	O
absence	O
of	O
EBNA2	B-RNA
mRNAs	E-RNA
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

By	O
immunization	O
with	O
a	O
recombinant	B-protein
fusion	I-protein
protein	E-protein
,	O
we	O
show	O
that	O
TCF-1	S-protein
knock-out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O

Cotransfection	O
of	O
JAK3	S-protein
with	O
IL-4	B-protein
Stat	E-protein
into	O
COS-7	B-cell_line
cells	E-cell_line
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	E-DNA
and	O
comigrated	O
with	O
IL-4	B-protein
NAF	E-protein
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Naturally	O
processed	O
forms	O
of	O
these	O
structures	O
are	O
likely	O
to	O
occur	O
given	O
the	O
importance	O
and	O
frequency	O
of	O
deamidation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Another	O
known	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	S-protein
and	O
subsequent	O
activation	O
of	O
ERK	B-protein
kinase	E-protein
is	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
activator	I-protein
protein-1	E-protein
(	O
AP-1	S-protein
)	O
.	O

Therefore	O
,	O
BA	O
is	O
currently	O
under	O
clinical	O
investigation	O
as	O
a	O
potential	O
therapy	O
for	O
the	O
treatment	O
of	O
sickle	O
cell	O
disease	O
and	O
cancer	O
.	O

To	O
confirm	O
that	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptors	E-protein
are	O
involved	O
in	O
AP-1	S-protein
response	O
,	O
we	O
investigated	O
the	O
CCK-8	O
effect	O
on	O
interleukin-2	S-protein
expression	O
,	O
a	O
natural	O
endogenous	B-DNA
gene	E-DNA
regulated	O
by	O
several	O
factors	O
,	O
including	O
AP-1	S-protein
.	O

The	O
IL-4-induced	B-protein
complex	E-protein
reacted	O
with	O
anti-STAT	B-protein
(	I-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
6	E-protein
,	O
resulting	O
in	O
a	O
supershift	O
whereas	O
the	O
formation	O
of	O
the	O
IFN-gamma-induced	B-protein
complex	E-protein
was	O
inhibited	O
by	O
anti-STAT	B-protein
1	E-protein
.	O

Butyric	O
acid	O
(	O
BA	O
)	O
is	O
known	O
to	O
induce	O
overexpression	O
of	O
fetal	B-protein
hemoglobin	E-protein
and	O
then	O
erythroid	O
differentiation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-protein
protein	E-protein
,	O
TF	B-RNA
mRNA	E-RNA
and	O
TF	S-protein
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

However	O
,	O
even	O
the	O
cells	O
expressing	O
very	O
high	O
levels	O
of	O
exogenous	O
Bcl-2	S-protein
eventually	O
underwent	O
differentiation	O
without	O
a	O
significant	O
decrease	O
in	O
the	O
synthesis	O
of	O
Bcl-2	S-protein
.	O

The	O
Pan	B-DNA
gene	E-DNA
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	S-protein
and	O
Pan-2	S-protein
(	O
also	O
known	O
as	O
E47	S-protein
and	O
E12	S-protein
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

The	O
increase	O
in	O
LT-293	B-protein
CAT	E-protein
activity	O
mirrored	O
the	O
increase	O
in	O
LT	S-protein
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte-specific	B-protein
nuclear	I-protein
proteins	E-protein
acting	O
as	O
positive	B-protein
transcription	I-protein
factors	E-protein
.	O

Expression	O
of	O
the	O
kappa	O
immunoglobulin	O
light	O
chain	O
gene	O
requires	O
developmental-	O
and	O
tissue-specific	O
regulation	O
by	O
trans-acting	B-protein
factors	E-protein
which	O
interact	O
with	O
two	O
distinct	O
enhancer	B-DNA
elements	E-DNA
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	S-protein
production	O
by	O
macrophages	S-cell_type
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

In	O
the	O
absence	O
of	O
tetracyclines	O
,	O
the	O
transfected	O
T	B-cell_type
cells	E-cell_type
were	O
shown	O
to	O
express	O
the	O
chimeric	B-protein
receptor	E-protein
on	O
the	O
cell	O
surface	O
and	O
could	O
be	O
activated	O
by	O
its	O
cognate	B-protein
Ag	E-protein
,	O
leading	O
to	O
the	O
secretion	O
of	O
IL-2	S-protein
.	O

Deletion	O
of	O
this	O
region	O
significantly	O
impaired	O
IL-9	S-protein
-induced	O
cell	O
growth	O
,	O
activation	O
of	O
JAK	B-protein
kinases	E-protein
,	O
insulin	B-protein
receptor	I-protein
substrate-2	E-protein
,	O
and	O
STAT3	S-protein
and	O
expression	O
of	O
early	B-DNA
response	I-DNA
genes	E-DNA
.	O

Under	O
identical	O
conditions	O
,	O
FMLP	S-protein
but	O
not	O
PAF	S-protein
,	O
resulted	O
in	O
significant	O
p42/44	B-protein
(	I-protein
ERK	I-protein
)	I-protein
MAPk	E-protein
activation	O
.	O

BACKGROUND	O
:	O
Cytokines	S-protein
produced	O
by	O
helper	B-cell_type
T	I-cell_type
cells	E-cell_type
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

Furthermore	O
,	O
R24	S-protein
treatment	O
resulted	O
in	O
translocation	O
of	O
c-rel	S-protein
,	O
but	O
little	O
or	O
no	O
NF	B-protein
kappa	I-protein
B	I-protein
p50	E-protein
or	O
p65	S-protein
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
complexes	E-protein
containing	O
c-rel	S-protein
and	O
p50	S-protein
.	O

Lymphocyte	O
glucocorticoid	B-protein
receptor	E-protein
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

These	O
two	O
cell	B-cell_line
lines	E-cell_line
are	O
representative	O
of	O
different	O
virologic	O
subtypes	O
of	O
PEL	S-cell_line
,	O
i.e	O
.	O
HHV-8+/EBV-	B-cell_line
PEL	E-cell_line
in	O
the	O
case	O
of	O
CRO-AP/3	B-cell_line
and	I-cell_line
HHV-8+/EBV+	I-cell_line
PEL	E-cell_line
in	O
the	O
case	O
of	O
CRO-AP/5	S-cell_line
.	O

Transient	O
pseudohypoaldosteronism	O
in	O
obstructive	O
renal	O
disease	O
with	O
transient	O
reduction	O
of	O
lymphocytic	B-protein
aldosterone	I-protein
receptors	E-protein
.	O

The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF-kappaB	S-protein
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB-Sp1	B-DNA
element	E-DNA
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation-dependent	O
fas	O
promoter	O
induction	O
.	O

IL-2R	B-protein
alpha	E-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	E-protein
,	O
PRRI	S-DNA
and	O
PRRII	S-DNA
.	O

adipocytes	B-cell_type
.	E-cell_type
Identification	O
of	O
a	O
physical	O
interaction	O
between	O
calcineurin	S-protein
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
(	O
NFATp	S-protein
)	O
.	O

The	O
results	O
suggest	O
that	O
the	O
SRG3	B-protein
protein	E-protein
associates	O
with	O
a	O
mouse	B-protein
SWI2	E-protein
.	O

In	O
an	O
effort	O
to	O
better	O
understand	O
the	O
biology	O
of	O
this	O
tumor	O
additional	O
immunohistochemical	O
studies	O
for	O
the	O
protein	B-protein
product	E-protein
of	O
p53	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	E-DNA
and	O
estrogen	B-protein
receptor	E-protein
expression	O
by	O
tumor	B-cell_type
cells	E-cell_type
,	O
as	O
well	O
as	O
the	O
type	O
of	O
immune	B-cell_type
cells	E-cell_type
infiltrating	O
the	O
tumor	O
were	O
performed	O
.	O

Mouse	B-cell_line
thymoma	I-cell_line
line	I-cell_line
EL-4	I-cell_line
cells	E-cell_line
produce	O
cytokines	S-protein
such	O
as	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	E-protein
,	O
IL-3	S-protein
,	O
IL-4	S-protein
,	O
IL-10	S-protein
,	O
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	E-protein
in	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

In	O
contrast	O
,	O
CREB	S-protein
appears	O
to	O
dampen	O
transcription	O
from	O
this	O
element	O
.	O

The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O

However	O
,	O
Nef	S-protein
does	O
not	O
affect	O
the	O
DNA-binding	O
activity	O
of	O
other	O
transcription	B-protein
factors	E-protein
implicated	O
in	O
HIV-1	O
regulation	O
,	O
including	O
SP-1	S-protein
,	O
USF	S-protein
,	O
URS	S-protein
,	O
and	O
NF-AT	S-protein
.	O

The	O
binding	O
activity	O
is	O
greatly	O
inducible	O
in	O
pre-B	B-cell_type
cells	E-cell_type
by	O
bacterial	O
lipopolysaccharide	O
and	O
interleukin-1	S-protein
but	O
specific	O
complexes	O
are	O
found	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
tested	O
.	O

Likewise	O
,	O
NF-AT1	B-RNA
mRNA	E-RNA
and	O
NF-AT4	B-RNA
mRNA	E-RNA
have	O
been	O
detected	O
in	O
resting	B-cell_type
eosinophils	E-cell_type
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up-regulated	O
by	O
the	O
Th2-associated	B-protein
cytokines	I-protein
IL-4	E-protein
and	O
IL-5	S-protein
.	O

IL-8	S-protein
secretion	O
was	O
accompanied	O
by	O
accumulation	O
of	O
IL-8	B-RNA
mRNA	E-RNA
in	O
the	O
cytosol	O
and	O
by	O
nuclear	O
expression	O
of	O
a	O
kappaB	S-protein
DNA	O
binding	O
activity	O
within	O
30	O
minutes	O
.	O

Stable	O
expression	O
of	O
HB24	S-DNA
,	O
a	O
diverged	B-DNA
human	I-DNA
homeobox	I-DNA
gene	E-DNA
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B-DNA
gene	E-DNA
with	O
an	O
adenovirus	B-DNA
E2	I-DNA
promoter	E-DNA
,	O
results	O
in	O
beta-galactosidase	S-protein
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	S-cell_line
and	O
primary	B-cell_type
cells	E-cell_type
.	O

Mutational	O
analyses	O
of	O
I	B-protein
kappa	I-protein
B	E-protein
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B-protein
sites	E-protein
by	O
the	O
bound	O
kinase	S-protein
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	B-protein
acidic	I-protein
domain	E-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
.	O

Stat	S-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	E-protein
)	O
and	O
Jak	S-protein
(	O
Janus	B-protein
kinases	E-protein
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
epithelial	I-cell_type
cells	E-cell_type
.	O

The	O
measurement	O
of	O
the	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	E-protein
may	O
be	O
useful	O
in	O
predicting	O
response	O
to	O
glucocorticoids	O
.	O

Infected	O
AML	B-cell_type
blasts	E-cell_type
produced	O
between	O
2	O
and	O
6	O
ng	O
of	O
IL-12/10	O
(	O
6	O
)	O
cells	O
per	O
ml	O
per	O
48	O
hr	O
.	O

B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	E-DNA
requires	O
the	O
Oct1	S-protein
or	O
Oct2	B-protein
protein	E-protein
and	O
additional	O
B	B-protein
cell-restricted	I-protein
cofactors	E-protein
.	O

We	O
conclude	O
that	O
sodium	O
phenylacetate	O
treatment	O
of	O
K562	B-cell_line
cells	E-cell_line
increases	O
gamma-globin	B-RNA
mRNA	E-RNA
and	O
induces	O
cell	O
maturation	O
as	O
judged	O
by	O
morphology	O
without	O
affecting	O
the	O
expression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factors	E-protein
,	O
some	O
of	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
beta-like	B-DNA
globin	I-DNA
genes	E-DNA
.	O

Regulation	O
of	O
GR	O
binding	O
by	O
FKBP51	S-protein
represents	O
a	O
previously	O
unrecognized	O
mechanism	O
for	O
regulating	O
glucocorticoid	O
sensitivity	O
.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/CD14	B-cell_line
cells	E-cell_line
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
to	O
the	O
CD14	S-protein
receptor	O
system	O
.	O

Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP-1	S-protein
and	O
NF-AT	S-protein
,	O
but	O
not	O
of	O
NF-kB	S-protein
and	O
OCT-1/OAF	S-protein
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	E-DNA
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF-kappa	B-protein
B	E-protein
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	B-protein
protein	E-protein
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	B-cell_type
epidermal	I-cell_type
cells	E-cell_type
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	B-protein
B	E-protein
,	O
AP-1	S-protein
,	O
AP-3	S-protein
,	O
OCT-1	S-protein
,	O
and	O
NF-AT	S-protein
.	O

Synthetic	O
glucocorticoids	O
that	O
dissociate	O
transactivation	O
and	O
AP-1	S-protein
transrepression	O
exhibit	O
antiinflammatory	O
activity	O
in	O
vivo	O
.	O

The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L-selectin	S-protein
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+/-	O
SD	O
,	O
4	O
,	O
215.4	O
+/-	O
4	O
,	O
111	O
ng/mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+/-	O
SD	O
,	O
1	O
,	O
148.0	O
+/-	O
269.0	O
ng/mL	O
and	O
991.9	O
+/-	O
224	O
ng/mL	O
,	O
respectively	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL-10	S-protein
on	O
the	O
activation	O
of	O
HIV-1	O
from	O
infected	B-cell_type
monocytes	E-cell_type
and	O
macrophages	S-cell_type
.	O

Propylthiouracil	O
(	O
50	O
mumol/L	O
)	O
did	O
not	O
affect	O
the	O
action	O
of	O
T3SO4	O
,	O
suggesting	O
that	O
deiodination	O
was	O
not	O
important	O
for	O
this	O
activity	O
of	O
T3SO4	O
.	O

RNase	S-protein
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

Selection	O
and	O
long-term	O
persistence	O
of	O
reactive	O
CTL	B-cell_line
clones	E-cell_line
during	O
an	O
EBV	O
chronic	O
response	O
are	O
determined	O
by	O
avidity	O
,	O
CD8	S-protein
variable	O
contribution	O
compensating	O
for	O
differences	O
in	O
TCR	S-protein
affinities	O
.	O

On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF-kappaB	S-protein
activation	O
by	O
LPS	O
.	O

The	O
activation	O
of	O
Jak	B-protein
2	E-protein
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	B-protein
kinase	E-protein
.	O

These	O
findings	O
suggest	O
that	O
Zp	S-DNA
responds	O
directly	O
to	O
changes	O
in	O
the	O
activity	O
of	O
both	O
PKC	S-protein
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	E-protein
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR/CD3	S-protein
signals	O
is	O
biphasic	O
:	O
TcR/CD3	S-protein
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF-alpha	S-protein
is	O
present	O
.	O

In	O
RAW264.7	B-cell_line
cells	E-cell_line
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	B-cell_line
marrow-derived	I-cell_line
macrophages	E-cell_line
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon-gamma	S-protein
inducible	O
.	O

Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
family	E-protein
of	O
DNA	B-protein
binding	I-protein
proteins	E-protein
,	O
hereby	O
designated	O
IL-4	B-protein
Stat	E-protein
.	O

Transcription	B-protein
factor	I-protein
NF-E2	E-protein
is	O
crucial	O
for	O
regulation	O
of	O
erythroid-specific	O
gene	O
expression	O
.	O

The	O
levels	O
of	O
glucocorticoid	B-protein
receptors	E-protein
in	O
lymphocytes	S-cell_type
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

SCL	B-protein
protein	E-protein
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	B-cell_line
cell	I-cell_line
lines	E-cell_line
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
family	E-protein
(	O
pRb	S-protein
,	O
p107	S-protein
,	O
and	O
p130	S-protein
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	B-cell_line
B-cells	E-cell_line
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha-interferon	S-protein
(	O
alpha-IFN	S-protein
)	O
.	O

NF-kappaB	S-protein
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	B-protein
complex	E-protein
in	O
unstimulated	B-cell_line
cells	E-cell_line
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	B-protein
subunit	E-protein
,	O
IkappaB	S-protein
.	O

The	O
-326	B-DNA
to	I-DNA
-615	I-DNA
region	E-DNA
contained	O
positive	B-DNA
regulatory	I-DNA
elements	E-DNA
.	O

Although	O
phenotypically	O
normal	O
,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens	O
'	O
T	B-cell_type
cells	E-cell_type
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	S-protein
(	O
IL-2	S-protein
)	O
.	O

We	O
found	O
that	O
RARs	S-protein
were	O
involved	O
in	O
RA-mediated	O
apoptosis	O
of	O
myeloid	O
progenitor	O
cells	O
,	O
whereas	O
RARs	S-protein
as	O
well	O
as	O
RXRs	S-protein
were	O
involved	O
in	O
RA-mediated	O
apoptosis	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	E-cell_type
.	O

The	O
difference	O
in	O
the	O
number	O
of	O
recognized	O
peptides	O
by	O
patients	O
'	O
PBMC	S-cell_type
before	O
RAI	O
and	O
surgery	O
may	O
reflect	O
the	O
effect	O
of	O
long	O
term	O
therapy	O
with	O
ATD	O
in	O
the	O
patients	O
before	O
RAI	O
vs.	O
the	O
shorter	O
period	O
in	O
patients	O
before	O
surgery	O
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full-length	B-DNA
IL-1beta	I-DNA
promoter	E-DNA
connected	O
to	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	E-DNA
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

The	O
effects	O
of	O
Ara-C	O
on	O
JNK	S-protein
activity	O
may	O
be	O
mediated	O
through	O
secondary	O
response	O
pathways	O
.	O

CD27	S-protein
/CD70	O
interaction	O
enhanced	O
B	B-cell_type
cell	E-cell_type
proliferation	O
in	O
the	O
presence	O
of	O
IL-4	S-protein
or	O
IL-4	S-protein
plus	O
anti-CD40	S-protein
.	O

TF	S-protein
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	B-protein
protease	E-protein
cascades	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein-DNA	B-protein
complex	E-protein
,	O
referred	O
to	O
as	O
CMAT	S-protein
for	O
c-myb	B-protein
in	I-protein
activated	I-protein
T	I-protein
cells	E-protein
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

The	O
class	B-protein
II	I-protein
trans-activator	I-protein
CIITA	E-protein
interacts	O
with	O
the	O
TBP-associated	B-protein
factor	I-protein
TAFII32	E-protein
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
induces	O
an	O
NF-kappa	B-protein
B	E-protein
-like	O
binding	O
activity	O
to	O
the	O
B2	S-DNA
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	E-DNA
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	B-protein
complex	E-protein
,	O
reflecting	O
the	O
binding	O
of	O
p75	S-protein
and	O
p85	S-protein
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	B-DNA
element	E-DNA
.	O

The	O
antagonistic	O
effects	O
of	O
gamma-IFN	S-protein
are	O
not	O
merely	O
restricted	O
to	O
enzymatic	O
activities	O
.	O

Eicosanoids	O
were	O
measured	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	E-cell_type
and	O
mammary	O
tissue	O
by	O
means	O
of	O
HPLC	O
;	O
furthermore	O
,	O
TXA2	O
,	O
6-keto-PGF1	O
alpha	O
,	O
and	O
PGE2	O
were	O
determined	O
by	O
RIA	O
.	O

The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	O
show	O
structural	O
alterations	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
or	I-DNA
CDK4	I-DNA
genes	E-DNA
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	S-DNA
and	O
p15	S-DNA
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O

Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O

K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	S-protein
and	O
KCa	S-protein
channels	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	E-cell_line
(	O
HUVECs	S-cell_line
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	B-cell_line
HUVECs	E-cell_line
to	O
human	B-cell_type
neutrophils	E-cell_type
.	O

Here	O
the	O
wild	B-DNA
type	I-DNA
motif	E-DNA
gives	O
efficient	O
binding	O
of	O
p50p50	S-protein
that	O
again	O
is	O
upregulated	O
in	O
tolerant	B-cell_type
cells	E-cell_type
whereas	O
a	O
mutant	O
with	O
a	O
3	O
'	O
G	O
shows	O
hardly	O
any	O
binding	O
of	O
p50p50	S-protein
.	O

In	O
previous	O
experiments	O
,	O
the	O
-70	B-DNA
to	I-DNA
-65	I-DNA
and	I-DNA
-121	I-DNA
to	I-DNA
-103	I-DNA
regions	E-DNA
of	O
the	O
CD11c	B-DNA
promoter	E-DNA
and	O
the	O
-66	B-DNA
to	I-DNA
-59	I-DNA
region	E-DNA
of	O
the	O
CD11b	B-DNA
promoter	E-DNA
were	O
shown	O
to	O
be	O
essential	O
for	O
Sp1-	S-protein
mediated	O
activation	O
of	O
these	O
genes	O
.	O

Thus	O
,	O
localization	O
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
high	O
WT1	S-DNA
expression	O
in	O
hematopoietic	B-cell_type
cells	E-cell_type
is	O
incompatible	O
with	O
differentiation	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	B-DNA
genes	E-DNA
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	B-cell_type
cells	E-cell_type
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	S-protein
expression	O
.	O

METHODS	O
.	O

Gel-shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	B-cell_line
T	I-cell_line
cells	E-cell_line
with	O
CHO-DR	S-protein
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	E-protein
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	B-protein
binding	I-protein
proteins	E-protein
required	O
costimulation	O
.	O

G0S2	B-RNA
mRNA	E-RNA
increases	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	S-protein
or	O
cycloheximide	O
to	O
cultured	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
.	O

Using	O
a	O
yeast	O
two-hybrid	O
screen	O
to	O
identify	O
Syk	B-protein
kinases-interacting	I-protein
proteins	E-protein
(	O
SKIPs	S-protein
)	O
,	O
we	O
isolated	O
3BP2	S-protein
,	O
an	O
Abl	B-protein
SH3-interacting	I-protein
protein	E-protein
of	O
unknown	O
function	O
.	O

Although	O
erythropoietin	S-protein
(	O
Epo	S-protein
)	O
is	O
essential	O
for	O
the	O
production	O
of	O
mature	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	E-cell_type
,	O
the	O
cooperation	O
with	O
other	O
factors	O
is	O
required	O
for	O
a	O
proper	O
balance	O
between	O
progenitor	O
proliferation	O
and	O
differentiation	O
.	O

The	O
results	O
suggest	O
that	O
PYBF	S-protein
and	O
the	O
pyrimidine-rich	B-DNA
region	E-DNA
upstream	O
from	O
HBD	S-DNA
can	O
specifically	O
enhance	O
HBB	S-DNA
transcription	O
in	O
adult	B-cell_type
erythroid	I-cell_type
cells	E-cell_type
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF-1	B-DNA
gene	E-DNA
expression	O
in	O
HL-60	S-cell_line
,	O
U937	S-cell_line
,	O
and	O
THP-1	B-cell_line
cells	E-cell_line
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
activators	E-protein
target	O
human	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
to	O
inhibit	O
leukocyte	B-cell_type
-endothelial	I-cell_type
cell	E-cell_type
interaction	O
.	O

The	O
ED50	O
(	O
the	O
cortisol	O
concentration	O
giving	O
50	O
%	O
inhibition	O
of	O
the	O
thymidine	O
incorporation	O
)	O
,	O
however	O
,	O
was	O
identical	O
in	O
all	O
three	O
groups	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30-40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	S-protein
activity	O
in	O
tissue	O
homogenates	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	S-protein
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	S-protein
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	O
in	O
the	O
preferential	O
suppression	O
of	O
Stat1	S-protein
activity	O
.	O

These	O
data	O
indicate	O
that	O
PLD	S-protein
stimulation	O
can	O
activate	O
the	O
transcription	B-protein
factor	I-protein
AP-1	E-protein
in	O
T	B-cell_type
lymphocytes	E-cell_type
,	O
and	O
suggest	O
that	O
the	O
induction	O
of	O
AP-1	B-DNA
enhancer	E-DNA
factor	O
activity	O
by	O
PA	O
is	O
mediated	O
via	O
PKC	S-protein
stimulation	O
,	O
either	O
through	O
a	O
direct	O
activating	O
effect	O
of	O
PA	O
or	O
through	O
PA-derived	O
diacylglycerol	O
formation	O
.	O

Activation	O
of	O
expression	O
of	O
genes	S-DNA
encoding	O
transcription	B-protein
factors	E-protein
:	O
c-fos	S-DNA
and	O
c-jun	S-DNA
and	O
formation	O
of	O
AP1	B-protein
transcriptional	I-protein
complex	E-protein
in	O
human	B-cell_type
monocytes	E-cell_type
was	O
investigated	O
.	O

In	O
an	O
attempt	O
to	O
find	O
such	O
elusive	O
Oct2	B-DNA
target	I-DNA
genes	E-DNA
and	O
to	O
understand	O
the	O
molecular	O
function	O
of	O
Oct2	S-protein
in	O
B	O
cell	O
development	O
,	O
we	O
isolated	O
cDNAs	S-DNA
for	O
Oct2	B-DNA
target	I-DNA
genes	E-DNA
.	O

The	O
mechanism	O
by	O
which	O
eosinophil-specific	B-DNA
genes	E-DNA
encoding	O
primary	O
and	O
secondary	B-protein
granule	I-protein
proteins	E-protein
(	O
e.g	O
.	O
ECP	S-protein
,	O
EDN	S-protein
,	O
EPO	S-protein
,	O
MBP	S-protein
,	O
and	O
CLC	S-protein
)	O
are	O
expressed	O
and	O
regulated	O
during	O
eosinophilopoiesis	O
is	O
also	O
unknown	O
.	O

Expression	O
of	O
gamma-IFN	B-DNA
responsive	I-DNA
genes	E-DNA
in	O
scavenger	O
receptor	O
over-expressing	B-cell_type
monocytes	E-cell_type
is	O
associated	O
with	O
xanthomatosis	O
.	O

Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density	O
;	O
thus	O
,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-DNA
-phoQ	E-DNA
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B-protein
proteins	E-protein
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	S-cell_type
.	O

Whereas	O
ligand-binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	S-protein
,	O
bHLH-	O
hsp90	S-protein
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA-binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O

The	O
role	O
of	O
the	O
protooncogene	B-DNA
c-fos	E-DNA
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
6	E-protein
-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

With	O
hot	O
acetic	O
+	O
p-toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd-C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	E-RNA
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	B-cell_line
promyelocytes	E-cell_line
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	S-cell_type
.	O

-256	B-DNA
to	I-DNA
-250	I-DNA
.	E-DNA
An	O
81	O
%	O
increment	O
in	O
promoter	O
activity	O
was	O
obtained	O
when	O
a	O
mutation	O
was	O
introduced	O
in	O
the	O
GATA-3	B-DNA
binding	I-DNA
site	E-DNA
of	O
the	O
bp	B-DNA
-267	I-DNA
to	I-DNA
+12	I-DNA
construct	E-DNA
,	O
which	O
is	O
comparable	O
to	O
that	O
of	O
the	O
bp	B-DNA
-245	I-DNA
to	I-DNA
+12	I-DNA
construct	E-DNA
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng/ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	B-DNA
gene	E-DNA
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O

Tandem	O
copies	O
of	O
this	O
67-bp	B-DNA
MnlI-AluI	I-DNA
fragment	E-DNA
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	E-DNA
driven	O
by	O
the	O
conalbumin	B-DNA
promoter	E-DNA
,	O
stimulated	O
transcription	O
in	O
B	B-cell_type
cells	E-cell_type
but	O
not	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
or	O
HeLa	B-cell_line
cells	E-cell_line
.	O

Thus	O
,	O
c-Fos/c-Jun	B-protein
heterodimers	E-protein
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-DNA
gene	E-DNA
expression	O
.	O

Using	O
RT-PCR	O
we	O
were	O
able	O
to	O
identify	O
both	O
the	O
full	B-protein
length	I-protein
wild-type	I-protein
form	E-protein
and	O
an	O
isoform	O
of	O
the	O
ER	S-protein
which	O
precisely	O
lacks	O
exon	B-DNA
V	E-DNA
in	O
both	O
patient	O
and	O
normal	O
individuals	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	S-protein
is	O
a	O
constitutively	B-protein
activated	I-protein
receptor	E-protein
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
tail	E-protein
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct-1	B-protein
POU	I-protein
domain	E-protein
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	B-DNA
and	I-DNA
R	I-DNA
regions	E-DNA
of	O
proviral	B-DNA
DNA	E-DNA
from	O
CEMxl74	B-cell_line
cells	E-cell_line
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-protein
B	E-protein
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B-DNA
LTR	E-DNA
or	O
the	O
HIV	B-DNA
enhancer	E-DNA
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	S-protein
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	B-cell_line
cells	E-cell_line
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	E-cell_line
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
6	I-DNA
gene	E-DNA
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	B-protein
factors	I-protein
NF-IL6	E-protein
and	O
NF-kappa	B-protein
B	E-protein
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

Chromosomal	O
translocations	O
involving	O
the	O
genes	O
encoding	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	E-protein
of	O
the	O
Pebp2/Cbf	B-protein
transcription	I-protein
factor	E-protein
have	O
been	O
associated	O
with	O
human	O
acute	O
myeloid	O
leukemia	O
and	O
the	O
preleukemic	O
condition	O
,	O
myelodysplasia	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B-protein
kinase	E-protein
inhibitor	O
,	O
blocked	O
the	O
R24	S-protein
-stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	B-protein
kinases	E-protein
.	O

The	O
differences	O
in	O
P-CREB	S-protein
levels	O
between	O
PBMC	S-cell_type
and	O
Jurkat	B-cell_line
cells	E-cell_line
were	O
directly	O
correlated	O
with	O
basal	O
transcription	O
of	O
HTLV-I	O
in	O
the	O
two	O
cell	O
types	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL-4	S-protein
on	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	E-DNA
in	O
monocytes	S-cell_type
evoked	O
by	O
other	O
T-helper	B-protein
cell	I-protein
cytokines	E-protein
:	O
IL-2	S-protein
,	O
IL-3	S-protein
,	O
and	O
GM-CSF	S-protein
.	O

Glucocorticoid	B-protein
receptor	E-protein
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
RFX1	E-protein
can	O
bind	O
to	O
NRE	B-DNA
gamma	E-DNA
and	O
transactivate	O
the	O
core	B-DNA
promoter	E-DNA
through	O
this	O
site	O
.	O

Characterization	O
of	O
CD40	S-protein
signaling	O
determinants	O
regulating	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
activation	O
in	O
B	B-cell_type
lymphocytes	E-cell_type
.	O

Disruption	O
of	O
the	O
human	B-DNA
SCL	I-DNA
locus	E-DNA
by	O
``	O
illegitimate	O
''	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
.	O

Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	B-cell_type
cells	E-cell_type
,	O
bronchial	B-cell_type
cells	E-cell_type
,	O
and	O
fibroblasts	S-cell_type
failed	O
to	O
produce	O
IL-8	S-protein
in	O
response	O
to	O
a	O
prolonged	O
cyclic	O
pressure-stretching	O
load	O
.	O

The	O
transendothelial	O
migration	O
of	O
monocytes	S-cell_type
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM-1	S-protein
.	O

However	O
IL-7	S-protein
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	S-cell_type
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF-kappaB	S-protein
activation	O
elicited	O
by	O
TNF	S-protein
or	O
IL-1	S-protein
.	O

In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta-catenin	S-protein
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF/TCF	S-protein
(	O
for	O
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
and	I-protein
T-cell	I-protein
factor	E-protein
)	O
transcription	B-protein
factors	E-protein
to	O
activate	O
gene	O
expression	O
.	O

The	O
Fy	O
(	O
a-b-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non-Ashkenazi	O
Jewish	O
groups	O
.	O

IL-5	S-protein
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T-cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL-2	S-protein
receptor	O
stimulation	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2-like	B-protein
adaptor	I-protein
molecule	E-protein
designated	O
as	O
Grb2-related	B-protein
protein	I-protein
of	I-protein
the	I-protein
lymphoid	I-protein
system	E-protein
(	O
GrpL	S-protein
)	O
.	O

These	O
regulatory	B-DNA
elements	E-DNA
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	B-protein
factors	E-protein
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

Our	O
results	O
show	O
that	O
Tax	S-protein
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	B-cell_type
cells	E-cell_type
,	O
and	O
suggest	O
that	O
Tax	S-protein
plays	O
a	O
crucial	O
role	O
in	O
IL-2	S-protein
-independent	O
T-cell	O
transformation	O
induced	O
by	O
HTLV-1	O
,	O
in	O
addition	O
to	O
its	O
well-known	O
IL-2	S-protein
-dependent	O
cell	O
transformation	O
.	O

In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	B-protein
protein	E-protein
of	O
both	O
HTLV-I	O
and	O
HTLV-II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL-1alpha	B-DNA
promoter	E-DNA
in	O
an	O
uninfected	B-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	S-cell_type
,	O
LPS	O
and	O
TNFalpha	S-protein
induce	O
a	O
NF-kappaB	S-protein
DNA-binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50/RelA	B-protein
dimers	E-protein
,	O
and	O
that	O
IFNgamma	S-protein
promotes	O
the	O
binding	O
of	O
STAT1	B-protein
homodimers	E-protein
to	O
the	O
IFNgamma	B-DNA
response	I-DNA
region	E-DNA
of	O
the	O
FcgammaRI	B-DNA
promoter	E-DNA
.	O

Gene	O
targeting	O
experiments	O
in	O
the	O
mouse	O
revealed	O
a	O
differential	O
dependency	O
of	O
fetal	O
and	O
adult	O
B-lymphopoiesis	O
on	O
this	O
transcription	B-protein
factor	E-protein
.	O

Involvement	O
of	O
NF-chi	B-protein
B	E-protein
and	O
NF-IL6	S-protein
in	O
induction	O
of	O
IL-6	S-protein
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	B-DNA
promoter	E-DNA
.	O

With	O
these	O
clones	O
,	O
we	O
demonstrated	O
that	O
NFAT	S-protein
activation	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
(	O
IC50	O
=	O
8	O
nM	O
)	O
and	O
FK506	O
(	O
IC50	O
=	O
160	O
pM	O
)	O
,	O
presumably	O
by	O
inhibition	O
of	O
calcineurin	S-protein
activity	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	B-protein
LDL	E-protein
(	O
oxLDL	S-protein
)	O
on	O
the	O
NF-kappa	B-protein
B	E-protein
system	O
in	O
human	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	E-cell_line
as	O
well	O
as	O
adherent	B-cell_type
monocytes	E-cell_type
.	O

Five	O
members	O
of	O
this	O
family	O
(	O
MYC	S-protein
,	O
SCL	S-protein
,	O
TAL-2	S-protein
,	O
LYL-1	S-protein
and	O
E2A	S-protein
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell-specific	O
repressor	O
function	O
,	O
designated	O
SIR	S-DNA
(	O
suppressor	B-DNA
of	I-DNA
immune	I-DNA
response	I-DNA
genes	E-DNA
)	O
,	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	B-DNA
II	I-DNA
genes	E-DNA
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR-1	B-DNA
gene	E-DNA
,	O
whose	O
product	O
,	O
the	O
class	B-protein
II	I-protein
transactivator	E-protein
(	O
CIITA	S-protein
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
.	O

It	O
is	O
conceivable	O
that	O
GC	O
exert	O
their	O
anti-inflammatory	O
capacity	O
in	O
various	O
diseases	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
in	O
monocytes	S-cell_type
.	O

Mutational	O
studies	O
of	O
the	O
-236	B-DNA
to	I-DNA
-96	I-DNA
sequence	E-DNA
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-130	B-DNA
AP-1-like	I-DNA
site	E-DNA
(	O
-187	B-DNA
to	I-DNA
-181	E-DNA
)	O
and	O
the	O
-150	B-DNA
proximal	I-DNA
AP-1	I-DNA
site	E-DNA
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

We	O
also	O
found	O
that	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
is	O
capable	O
of	O
inducing	O
the	O
surface	O
expression	O
of	O
the	O
CD69	S-protein
molecule	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
of	O
fusion	O
plasmids	O
that	O
contain	O
5'-flanking	O
sequences	O
of	O
the	O
CD69	S-protein
gene	O
,	O
suggesting	O
that	O
this	O
cytokine	O
may	O
regulate	O
in	O
vivo	O
the	O
expression	O
of	O
CD69	S-protein
.	O

Molecular	O
characterization	O
and	O
pattern	O
of	O
tissue	O
expression	O
of	O
the	O
gene	O
for	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	E-protein
from	O
humans	O
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O

We	O
show	O
that	O
TLR2	S-protein
associates	O
with	O
the	O
high-affinity	B-protein
LPS	I-protein
binding	I-protein
protein	E-protein
membrane	O
CD14	S-protein
to	O
serve	O
as	O
an	O
LPS	B-protein
receptor	I-protein
complex	E-protein
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	S-protein
.	O

One	O
contraction	O
generated	O
an	O
allele	O
in	O
an	O
intermediate	O
size	O
range	O
(	O
33-39	O
repeats	O
)	O
.	O

The	O
role	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	E-protein
(	O
MAPK	S-protein
)	O
pathway	O
on	O
TCC	S-protein
-inducible	O
mitotic	O
signaling	O
was	O
evaluated	O
by	O
assessing	O
DNA	O
synthesis	O
and	O
activator	B-protein
protein	I-protein
1	E-protein
(	O
AP-1	S-protein
)	O
DNA-binding	O
activity	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-protein
B	E-protein
or	O
the	O
entire	O
interleukin-2	B-DNA
enhancer	E-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-protein
factors	E-protein
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	E-DNA
.	O

IL-10-activated	B-protein
STAT1	E-protein
could	O
bind	O
to	O
the	O
GAS-motif	B-DNA
sequence	E-DNA
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	B-protein
receptor	E-protein
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	B-DNA
region	E-DNA
of	O
the	O
COX-2	B-DNA
gene	E-DNA
,	O
whereas	O
IFN-gamma-activated	B-protein
STAT1	E-protein
and	O
STAT5	S-protein
could	O
bind	O
to	O
both	O
sequences	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
,	O
the	O
ZIP	B-DNA
site	E-DNA
serves	O
as	O
an	O
activator	O
for	O
IL-2	S-protein
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	S-DNA
and	O
NFAT	B-DNA
binding	I-DNA
sites	E-DNA
is	O
required	O
for	O
maximal	O
IL-2	B-DNA
promoter	E-DNA
activity	O
.	O

Nuclear	O
T3R	S-protein
in	O
lymphocytes	S-cell_type
was	O
determined	O
by	O
radio-ligand	O
binding	O
analysis	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
inv	B-DNA
(	I-DNA
16	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q22	I-DNA
)	E-DNA
on	O
myelopoiesis	O
,	O
we	O
used	O
the	O
hMRP8	B-DNA
promoter	I-DNA
element	E-DNA
to	O
generate	O
transgenic	O
mice	O
expressing	O
the	O
Pebp2beta	B-protein
Smmhc	I-protein
chimeric	I-protein
fusion	I-protein
protein	E-protein
in	O
myeloid	B-cell_type
cells	E-cell_type
.	O

Human	B-RNA
TR	I-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
in	O
lymphocytes	S-cell_type
were	O
1.8	O
+/-	O
0.4	O
,	O
1.9	O
+/-	O
0.5	O
,	O
1.1	O
+/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol/microgram	O
RNA	O
in	O
hypo-	O
,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O

IL-7	S-protein
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c-Myc	S-protein
,	O
Bcl-2	S-protein
,	O
and	O
Bcl-xL	S-protein
that	O
occur	O
upon	O
loss	O
of	O
v-Abl	S-protein
kinase	O
activity	O
.	O

regulatory	B-DNA
gene	I-DNA
BZLF	I-DNA
1	E-DNA
Costimulation	O
of	O
cAMP	O
and	O
protein	B-protein
kinase	I-protein
C	E-protein
pathways	O
inhibits	O
the	O
CD3	S-protein
-dependent	O
T	O
cell	O
activation	O
and	O
leads	O
to	O
a	O
persistent	O
expression	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	E-protein
.	O

Isolation	O
of	O
a	O
candidate	O
repressor/activator	O
,	O
NF-E1	S-protein
(	O
YY-1	S-protein
,	O
delta	S-protein
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	E-DNA
and	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
mu	I-DNA
E1	I-DNA
site	E-DNA
.	O

Both	O
Stat3	S-protein
-activation	O
and	O
Stat3	S-protein
-independent	O
BCL2	S-protein
downregulation	O
are	O
important	O
for	O
interleukin-6	S-protein
-induced	O
apoptosis	O
of	O
1A9-M	B-cell_line
cells	E-cell_line
.	O

Importantly	O
,	O
jagged1	B-protein
transcripts	E-protein
were	O
also	O
upregulated	O
by	O
endogenous	O
NF-kappaB	S-protein
activation	O
and	O
this	O
effect	O
was	O
inhibited	O
by	O
a	O
dominant	O
mutant	O
of	O
IkappaBalpha	S-protein
,	O
a	O
physiological	O
inhibitor	O
of	O
NF-kappaB	S-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti-inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL-12	S-protein
production	O
and	O
Th1	O
cell	O
development	O
.	O

The	O
importance	O
of	O
the	O
central	B-protein
nervous	I-protein
system-enriched	I-protein
kappa	I-protein
B	I-protein
transcription	I-protein
factor	E-protein
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B-protein
proteins	E-protein
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
(	O
PBLs	S-cell_type
)	O
by	O
cytokines	S-protein
with	O
shared	O
and	O
distinct	O
actions	O
.	O

This	O
antibody	O
also	O
recognizes	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
a	O
70-kDa	O
protein	O
corresponding	O
in	O
size	O
to	O
that	O
predicted	O
for	O
the	O
fkhrl1	B-DNA
gene	E-DNA
product	O
.	O

A	O
thymus-specific	B-protein
member	E-protein
of	O
the	O
HMG	B-protein
protein	I-protein
family	E-protein
regulates	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
enhancer	E-DNA
.	O

These	O
results	O
suggest	O
that	O
Fli-1	S-protein
is	O
likely	O
to	O
regulate	O
lineage-specific	B-DNA
genes	E-DNA
during	O
megakaryocytopoiesis	O
.	O

There	O
is	O
general	O
agreement	O
on	O
the	O
inflammatory	O
pathogenesis	O
of	O
bronchial	O
asthma	O
:	O
an	O
accumulation	O
of	O
activated	B-cell_type
eosinophils	E-cell_type
,	O
degranulated	B-cell_type
mast	I-cell_type
cells	E-cell_type
,	O
T	B-cell_type
lymphocytes	E-cell_type
and	O
in	O
very	O
severe	O
forms	O
,	O
granulocytes	S-cell_type
has	O
constantly	O
been	O
found	O
in	O
the	O
bronchial	O
mucosa	O
.	O

The	O
proliferative	O
responses	O
of	O
purified	B-cell_type
CD4+	I-cell_type
or	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	E-cell_type
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti-CD28	S-protein
rather	O
than	O
the	O
phorbol	O
ester	O
PMA	O
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	S-protein
.	O

Upon	O
infection	O
,	O
Wp	S-DNA
is	O
initially	O
active	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	S-DNA
for	O
the	O
duration	O
of	O
latency	O
.	O

Selective	O
expression	O
of	O
an	O
interleukin-12	B-protein
receptor	I-protein
component	E-protein
by	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
cells	E-cell_type
.	O

Signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-3	E-protein
(	O
STAT3	S-protein
)	O
is	O
constitutively	O
activated	O
in	O
normal	O
,	O
self-renewing	B-cell_type
B-1	I-cell_type
cells	E-cell_type
but	O
only	O
inducibly	O
expressed	O
in	O
conventional	O
B	B-cell_type
lymphocytes	E-cell_type
[	O
see	O
comments	O
]	O

All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3/BCL6	S-protein
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O

In	O
contrast	O
to	O
the	O
increase	O
of	O
C/EBP	O
epsilon	O
in	O
9-cis	O
RA-mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO-induced	O
differentiation	O
of	O
HL-60	B-cell_line
cells	E-cell_line
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	E-RNA
levels	O
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B-protein
and	I-protein
NFATc	I-protein
family	I-protein
members	E-protein
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	S-protein
and	O
mRNA	O
induction	O
of	O
NFATc	S-protein
.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'-flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	B-DNA
promoter	E-DNA
in	O
decidualized	O
endometrial	B-cell_type
stromal	I-cell_type
cells	E-cell_type
actively	O
secreting	O
PRL	S-protein
,	O
but	O
did	O
not	O
allow	O
transcription	O
in	O
undifferentiated	O
non-PRL-secreting	B-cell_type
endometrial	I-cell_type
stromal	I-cell_type
cells	E-cell_type
.	O

Both	O
PPARalpha	S-protein
activators	O
decreased	O
cytokine-induced	O
VCAM-1	S-protein
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half-life	O
.	O

Cellular	O
haptenation	O
by	O
SMX-NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

In	O
contrast	O
,	O
long-term	O
treatment	O
with	O
oxLDL	S-protein
prevented	O
the	O
lipopolysaccharide-induced	O
depletion	O
of	O
I	B-protein
kappa	I-protein
B-alpha	E-protein
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF-kappa	B-protein
B	E-protein
activation	O
and	O
the	O
expression	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
and	I-DNA
interleukin-1	I-DNA
beta	I-DNA
genes	E-DNA
.	O

The	O
proximal	B-DNA
element	E-DNA
contains	O
the	O
sequence	O
5'-GGCCAATGGG-3	O
'	O
,	O
which	O
closely	O
resembles	O
the	O
consensus	O
binding	O
motif	O
for	O
the	O
CCAAT-binding	B-protein
factor	I-protein
NF-Y	E-protein
(	O
CBF	S-protein
,	O
CP1	S-protein
,	O
alpha	B-protein
CP1	E-protein
)	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid-MR	B-protein
complex	E-protein
and	O
the	O
antibody-MR	B-protein
complex	E-protein
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	B-DNA
site	E-DNA
of	O
PMA/ionomycin-induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti-JunD	S-protein
or	O
c-Fos	B-protein
antibody	E-protein
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

All	O
other	O
molecules	O
studied	O
were	O
found	O
to	O
be	O
expressed	O
at	O
this	O
stage	O
of	O
differentiation	O
.	O

Furthermore	O
,	O
multimerized	B-DNA
region	I-DNA
II	I-DNA
sequence	I-DNA
elements	E-DNA
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	B-cell_type
cells	E-cell_type
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

Overexpression	O
of	O
p65	S-protein
increases	O
endogenous	O
I	B-protein
kappa	I-protein
B	E-protein
protein	O
in	O
both	O
carcinoma	B-cell_type
and	I-cell_type
lymphoid	I-cell_type
cells	E-cell_type
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
mRNA	E-RNA
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8+	O
T-cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	S-protein
ligation	O
.	O

The	O
half-life	O
of	O
c-jun	B-RNA
RNA	E-RNA
as	O
determined	O
by	O
treating	O
HL-60	B-cell_line
cells	E-cell_line
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O

These	O
E1a	O
reiteration	O
mutants	O
could	O
be	O
propagated	O
in	O
HeLa	S-cell_line
,	O
A549	S-cell_line
,	O
and	O
KB	B-cell_line
cells	E-cell_line
;	O
they	O
were	O
genetically	O
stable	O
;	O
and	O
they	O
killed	O
CREF	B-cell_line
cells	E-cell_line
at	O
a	O
strikingly	O
high	O
frequency	O
.	O

Treatment	O
of	O
the	O
more	O
immature	B-cell_line
B-cell	I-cell_line
line	E-cell_line
,	O
Ramos	S-cell_line
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium-dependent	O
apoptosis	O
.	O

Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O

1	B-protein
,	I-protein
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	E-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
from	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
.	O

[	O
Changes	O
in	O
levels	O
of	O
leucocytic	B-protein
estrogen	I-protein
receptor	E-protein
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O

While	O
Jurkat	B-cell_line
cells	E-cell_line
both	O
secrete	O
and	O
respond	O
to	O
IFN-gamma	S-protein
in	O
an	O
autocrine	O
loop	O
,	O
it	O
seems	O
likely	O
that	O
the	O
responding	O
cells	O
may	O
differ	O
from	O
those	O
synthesizing	O
this	O
cytokine	S-protein
in	O
the	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	E-cell_line
in	O
the	O
light	O
of	O
the	O
recent	O
report	O
that	O
Th1	B-cell_line
cells	E-cell_line
lack	O
the	O
IFN-gamma	S-protein
receptor	O
chain	O
necessary	O
for	O
activation	O
of	O
STAT1	S-protein
(	O
Pernis	O
,	O
A.	O
,	O
Gupta	O
,	O
S.	O
,	O
Gollob	O
,	O
K.J.	O
,	O
Garfein	O
,	O
E.	O
,	O
Coffman	O
,	O
R.L.	O
,	O
Schindler	O
,	O
C.	O
,	O
and	O
Rothman	O
,	O
P.	O
,	O
Science	O
1995.	O
269	O
:	O
245	O
)	O
.	O

Three	O
subtypes	O
of	O
retinoic	B-protein
acid	I-protein
receptors	E-protein
(	O
RAR	S-protein
)	O
,	O
termed	O
RAR	B-protein
alpha	E-protein
,	O
RAR	B-protein
beta	E-protein
,	O
and	O
RAR	B-protein
gamma	E-protein
,	O
have	O
been	O
described	O
.	O

Messenger	B-RNA
RNA	E-RNA
production	O
coding	O
for	O
IL-8	S-protein
,	O
RANTES	S-protein
,	O
and	O
MCP-1	S-protein
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	B-protein
proteins	E-protein
.	O

Activated	O
Jurkat	B-cell_line
cells	E-cell_line
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	B-DNA
genes	E-DNA
expressing	O
truncated	O
Nefs	S-protein
survived	O
,	O
which	O
rendered	O
Nef	S-protein
nonfunctional	O
.	O

This	O
atrophy	O
induction	O
does	O
not	O
involve	O
apoptotic	O
mechanisms	O
in	O
thymocytes	S-cell_type
affected	O
by	O
the	O
bcl-2	B-DNA
proto-oncogene	E-DNA
.	O

Deletions	O
delineated	O
a	O
carboxy-terminal	B-protein
dimerization	I-protein
region	E-protein
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	B-protein
domains	E-protein
of	O
basic-helix-loop-helix	B-protein
proteins	E-protein
.	O

Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O

Prostaglandin	O
E2	O
Up-regulates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
-driven	O
gene	O
activity	O
in	O
T	B-cell_type
cells	E-cell_type
via	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

Thus	O
,	O
Sp1	S-protein
and	O
Egr-1	S-protein
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL-2Rbeta	B-DNA
promoter	E-DNA
activity	O
.	O

Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	B-cell_type
leukocytes	E-cell_type
.	O

Finally	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
evidence	O
was	O
obtained	O
that	O
IL-4	S-protein
inhibits	O
LPS-induced	O
expression	O
of	O
AP-1	S-protein
protein	O
.	O

This	O
observation	O
may	O
explain	O
,	O
in	O
part	O
,	O
some	O
of	O
the	O
functional	O
differences	O
observed	O
for	O
alveolar	B-cell_type
macrophages	E-cell_type
compared	O
with	O
monocytes	S-cell_type
.	O

Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O

(	O
2E	O
)	O
-3-	O
[	O
5-	O
(	O
2	O
,	O
3-Dimethoxy-6-methyl-1	O
,	O
4-benzoquinoyl	O
)	O
]	O
-2-nonyl-2-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

Furthermore	O
,	O
STATs1	B-protein
and	I-protein
-3	E-protein
are	O
effectively	O
phosphorylated	O
and	O
activated	O
to	O
bind	O
DNA	O
in	O
the	O
absence	O
of	O
Lck	S-protein
expression	O
in	O
IFN-alpha-treated	B-cell_line
cells	E-cell_line
.	O

Expression	O
of	O
the	O
chemokine	B-protein
receptor	I-protein
BLR2/EBI1	E-protein
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	E-protein
.	O

By	O
contrast	O
,	O
the	O
monocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	E-protein
was	O
largely	O
absent	O
at	O
this	O
stage	O
and	O
in	O
the	O
CD34+Thy-1-CD45RA-	B-cell_line
subsets	E-cell_line
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	S-protein
and	O
activation	O
of	O
c-Rel	S-protein
and	O
related	O
NF-kappa	B-protein
B	E-protein
proteins	O
in	O
human	B-cell_line
monocytic	I-cell_line
THP-1	I-cell_line
cells	E-cell_line
.	O

Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
PBMC	S-cell_type
)	O
and	O
Jurkat	B-cell_line
cells	E-cell_line
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	B-protein
factors	E-protein
with	O
TRE-1	S-DNA
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
analysis	O
showed	O
that	O
the	O
longer	O
5	B-DNA
'	I-DNA
UTR	E-DNA
resulted	O
in	O
about	O
a	O
35	O
%	O
decrease	O
in	O
translation	O
efficiency	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	E-RNA
appearance	O
in	O
response	O
to	O
LPS	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A-ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	B-cell_line
C7	I-cell_line
cells	E-cell_line
(	O
a	O
human	B-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
T-cell	I-cell_line
line	E-cell_line
)	O
.	O

Role	O
of	O
IKK1	S-protein
and	O
IKK2	S-protein
in	O
lipopolysaccharide	O
signaling	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
.	O

The	O
novel	O
astrocyte-derived	O
kappa	O
B-binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	S-protein
affinity	O
column	O
,	O
while	O
prototypical	O
NF-kappa	B-protein
B	E-protein
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
is	O
not	O
.	O

One	O
such	O
example	O
is	O
the	O
excessive	O
expression	O
of	O
``	B-protein
normal	I-protein
''	I-protein
lymphokines	E-protein
of	O
cytokines	S-protein
which	O
accompanies	O
many	O
lymphoproliferative	O
diseases	O
.	O

Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	S-protein
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	O
recognized	O
by	O
p50	B-protein
homodimers	E-protein
.	O

Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose-dependent	O
manner	O
,	O
e.g.	O
,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ-treated	O
dead	O
cells	O
by	O
70	O
%	O
.	O

We	O
propose	O
that	O
growth	O
inhibition	O
of	O
established	O
B	B-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	E-cell_line
is	O
a	O
novel	O
function	O
of	O
EBNA2	S-protein
which	O
has	O
not	O
been	O
detected	O
in	O
the	O
absence	O
of	O
an	O
inducible	O
system	O
.	O

Thus	O
,	O
substitutions	O
within	O
the	O
ligand-binding	B-protein
domain	E-protein
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptor	E-protein
can	O
not	O
account	O
for	O
the	O
decreased	O
binding	O
affinity	O
of	O
these	O
receptors	O
in	O
squirrel	B-cell_type
monkey	I-cell_type
cells	E-cell_type
.	O

Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-DNA
5	I-DNA
'	I-DNA
regulatory	I-DNA
region	E-DNA
.	O

calcineurin	S-protein
Expression	O
of	O
NFAT-family	B-protein
proteins	E-protein
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

By	O
contrast	O
,	O
UAS1	S-DNA
(	O
-140	B-DNA
to	I-DNA
-87	E-DNA
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
's	O
increased	O
activity	O
in	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1/MEK1/	O
ERK1/2	S-protein
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF-kappa	B-protein
B	E-protein
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

Selection	O
of	O
down-regulated	B-DNA
sequences	E-DNA
along	O
the	O
monocytic	O
differentiation	O
of	O
leukemic	B-cell_line
HL60	I-cell_line
cells	E-cell_line
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	B-cell_line
corneal	I-cell_line
endothelial	I-cell_line
cells	E-cell_line
is	O
mediated	O
by	O
the	O
CD18	B-protein
antigen	E-protein
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NFkappaB	S-protein
)	O
.	O

MCP-1	B-RNA
RNA	E-RNA
level	O
was	O
also	O
increased	O
in	O
RA-treated	O
cells	O
.	O

Interleukin	B-protein
2	I-protein
and	I-protein
15	E-protein
activate	O
Stat3alpha	S-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
.	O

In	O
addition	O
,	O
IL-13	S-protein
phosphorylated	O
insulin	B-protein
response	I-protein
substrate-1	E-protein
,	O
IL-4R	B-protein
p140	E-protein
,	O
JAK1	S-protein
,	O
and	O
Tyk2	S-protein
,	O
but	O
not	O
JAK3	B-protein
kinase	E-protein
.	O

IFN-gamma	S-protein
triggers	O
a	O
well-defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	S-protein
or	O
arginine-glycine-aspartate	B-protein
(	I-protein
RGD	I-protein
)	I-protein
-coated	I-protein
substrata	E-protein
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix-adherent	B-cell_type
cells	E-cell_type
.	O

Both	O
cell	B-cell_line
lines	E-cell_line
are	O
devoid	O
of	O
genetic	O
lesions	O
of	O
c-MYC	S-protein
,	O
BCL-2	S-protein
and	O
p53	S-protein
as	O
well	O
as	O
gross	O
rearrangements	O
of	O
BCL-6	S-protein
.	O

The	O
effect	O
of	O
the	O
pRB	S-protein
posttranslational	O
modification	O
during	O
apoptosis	O
was	O
investigated	O
by	O
determining	O
the	O
E2F-1	S-protein
levels	O
and	O
by	O
isolating	O
and	O
characterizing	O
pRB-null	B-cell_line
clones	E-cell_line
from	O
U937	B-cell_line
cells	E-cell_line
.	O

The	O
immature	B-cell_line
CEM	I-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	B-RNA
alpha	I-RNA
mRNA	E-RNA
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	O
esters	O
.	O

Expression	O
of	O
the	O
beta	B-DNA
2-integrin	I-DNA
genes	E-DNA
,	O
CD11a	S-DNA
and	O
CD11b	S-DNA
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O

The	O
B	B-protein
cell	I-protein
NFAT	I-protein
complex	E-protein
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	O
transcription	O
from	O
an	O
NFAT-driven	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
construct	E-DNA
.	O

We	O
investigated	O
the	O
CD8+	B-protein
cytotoxic	I-protein
T	I-protein
lymphocyte	I-protein
(	I-protein
CTL	I-protein
)	I-protein
repertoire	E-protein
to	O
an	O
HLA	O
B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
immediate-early	I-protein
protein	E-protein
,	O
BZLF1	S-protein
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-protein
B	E-protein
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	B-DNA
latent	I-DNA
genes	E-DNA
and	O
p53	S-protein
,	O
p53	S-protein
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	E-cell_type
;	O
the	O
induced	O
p53	S-protein
was	O
transcriptionally	O
active	O
.	O

In	O
addition	O
,	O
DNA-binding	O
activities	O
of	O
Jun-Fos	B-protein
heterodimers	E-protein
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR-alpha	S-protein
.	O

The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	B-protein
protein	E-protein
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	B-DNA
viral	I-DNA
promoters	E-DNA
in	O
a	O
chromatinized	B-DNA
viral	I-DNA
episome	E-DNA
.	O

In	O
the	O
mouse	B-DNA
IL-4	I-DNA
promoter	E-DNA
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	B-DNA
sequence	E-DNA
designated	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	E-DNA
(	O
CLE0	S-DNA
)	O
,	O
P	S-DNA
,	O
P2	S-DNA
,	O
P3	S-DNA
and	O
P4	S-DNA
.	O

Constitutive	O
nuclear	B-protein
NF-kappa	I-protein
B	E-protein
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O

The	O
palindromic	B-DNA
site	E-DNA
(	O
site	B-DNA
B	E-DNA
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	B-DNA
binding	I-DNA
sites	E-DNA
of	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	E-protein
.	O

HIV1	O
infection	O
of	O
human	B-cell_type
monocytes	E-cell_type
and	O
macrophages	S-cell_type
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB-related	B-protein
factors	E-protein
.	O

Treatment	O
with	O
E2	O
was	O
also	O
associated	O
with	O
a	O
time-dependent	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
the	O
proapoptotic	B-protein
Nip-2	I-protein
protein	E-protein
,	O
supporting	O
the	O
hypothesis	O
that	O
hormone	O
responsiveness	O
of	O
U937	B-cell_line
cells	E-cell_line
is	O
mediated	O
by	O
target	O
gene	O
transcription	O
.	O

Pretreatment	O
with	O
the	O
broad	O
serine/threonine	O
kinase	O
inhibitor	O
staurosporine	O
partly	O
blocked	O
the	O
calyculin	B-protein
A	E-protein
-induced	O
STAT3	S-protein
phosphorylation	O
,	O
whereas	O
inhibitors	O
of	O
serine/threonine	B-protein
kinases	E-protein
,	O
such	O
as	O
mitogen-activated	B-protein
protein	I-protein
kinase-1	I-protein
extracellular-regulated	I-protein
kinase-kinase	E-protein
,	O
mitogen-activated	B-protein
protein	I-protein
p38	I-protein
kinase	E-protein
,	O
and	O
phosphatidylinositol	B-protein
3-kinase	E-protein
,	O
did	O
not	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	S-protein
surface	O
expression	O
is	O
down-regulated	O
during	O
tumor	O
progression	O
.	O

Th1	O
and	O
Th2	O
effector	O
functions	O
and	O
their	O
development	O
are	O
attributable	O
to	O
their	O
distinct	O
cytokine	S-protein
expression	O
patterns	O
.	O

Diminished	O
glucocorticoid	B-protein
receptors	E-protein
do	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

Other	O
factors	O
are	O
induced	O
by	O
lectin	S-protein
,	O
antibody	S-protein
,	O
and/or	O
PMA	O
alone	O
.	O

To	O
examine	O
whether	O
the	O
AP-1	B-DNA
enhancer	E-DNA
activity	O
is	O
involved	O
in	O
RA-induced	O
monocytic	O
differentiation	O
,	O
THP-1	B-cell_line
cells	E-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
-reporter	I-DNA
gene	E-DNA
containing	O
5	O
copies	O
of	O
the	O
AP-1	B-DNA
binding	I-DNA
sites	E-DNA
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B-DNA
domain	E-DNA
.	O

NF-kappa	B-protein
B	E-protein
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	E-protein
.	O

This	O
tight	O
correlation	O
between	O
c-jun	S-DNA
expression	O
,	O
the	O
generation	O
of	O
AP-1	S-protein
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B-protein
complex	E-protein
during	O
this	O
process	O
.	O

Comparison	O
of	O
HTLV-I	O
basal	O
transcription	O
and	O
expression	O
of	O
CREB/ATF-1/CREM	B-protein
family	I-protein
members	E-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O

HSF	S-protein
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	S-protein
.	O

The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone-receptor	O
interactions	O
.	O

Glucocorticoids	O
induced	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptor	E-protein
mRNA	O
expression	O
in	O
asthma	O
.	O

The	O
adenovirus	B-DNA
E1B	I-DNA
19K	I-DNA
gene	E-DNA
plays	O
an	O
essential	O
role	O
in	O
transformation	O
of	O
primary	B-cell_type
rodent	I-cell_type
cells	E-cell_type
in	O
cooperation	O
with	O
E1A	S-protein
and	O
in	O
the	O
inhibition	O
of	O
apoptosis	O
during	O
lytic	O
infection	O
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	B-cell_type
human	I-cell_type
T	I-cell_type
cells	E-cell_type
to	O
varicella-zoster	O
virus	O
peptides	O
by	O
dendritic	B-cell_type
cells	E-cell_type
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Cytotoxicity	B-protein
markers	E-protein
assessed	O
include	O
tumor	O
cell	O
killing	O
,	O
IL-1	S-protein
secretion	O
,	O
reactive	O
oxygen	O
intermediate	O
release	O
,	O
nitric	B-protein
oxide	I-protein
synthetase	E-protein
activity	O
as	O
measured	O
by	O
the	O
release	O
of	O
reactive	O
nitrogen	O
intermediates	O
,	O
complement	B-protein
receptor-1	I-protein
cell	I-protein
surface	I-protein
protein	E-protein
,	O
and	O
TNF-alpha	B-protein
protein	E-protein
presence	O
.	O

This	O
role	O
for	O
c-Myc	S-protein
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	S-protein
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation-induced	O
apoptosis	O
.	O

We	O
concluded	O
that	O
,	O
in	O
healthy	O
subjects	O
,	O
decreased	O
PBMC	S-cell_type
capacity	O
to	O
amplify	O
GC-R	S-protein
numbers	O
in	O
response	O
to	O
mitogen	S-protein
is	O
correlated	O
with	O
GC	O
resistance	O
,	O
whereas	O
in	O
CRF	O
patients	O
the	O
resistant	O
mechanism	O
is	O
not	O
correlated	O
with	O
GC-R	S-protein
parameters	O
.	O

We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF-kappaB	B-DNA
sequence	E-DNA
following	O
activation	O
of	O
CD36-producing	B-cell_line
CHO	I-cell_line
cells	E-cell_line
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
tumor	I-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
.	O

Tissue	O
transglutaminase-dependent	O
posttranslational	O
modification	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	E-protein
in	O
promonocytic	B-cell_line
cells	E-cell_line
undergoing	O
apoptosis	O
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c-Rel	S-protein
,	O
p105	S-protein
,	O
and	O
p50	S-protein
in	O
the	O
cytosol	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti-thrombin	B-protein
III	E-protein
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O

Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	B-cell_type
human	I-cell_type
lymphocytes	E-cell_type
,	O
stimulation	O
of	O
a	O
548	B-DNA
bp	I-DNA
IL-2	I-DNA
promoter-luciferase	I-DNA
reporter	I-DNA
construct	E-DNA
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	S-protein
expression	O
vector	O
.	O

Jun	S-protein
is	O
essential	O
for	O
activation-induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	S-protein
.	O

Our	O
results	O
demonstrate	O
that	O
NF-IL6	S-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
.	O

At	O
>	O
0.5	O
micromol/L	O
,	O
genistein	O
inhibited	O
NK	O
cytotoxicity	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF-beta	S-protein
decreases	O
B	O
lymphocyte	O
Ig	S-protein
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	B-RNA
mRNA	E-RNA
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	E-RNA
to	O
the	O
secreted	B-RNA
forms	E-RNA
of	O
mu	B-RNA
and	I-RNA
gamma	I-RNA
mRNA	E-RNA
.	O

Cross-competition	O
assays	O
among	O
the	O
P-like	B-DNA
elements	E-DNA
revealed	O
element-specific	B-protein
and	I-protein
common	I-protein
complexes	E-protein
.	O

Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	S-protein
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O

In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	S-cell_type
was	O
studied	O
.	O

Furthermore	O
,	O
LTalpha	S-protein
was	O
secreted	O
in	O
NK	B-cell_line
:	I-cell_line
EC	I-cell_line
co-cultures	E-cell_line
.	O

Regulation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
in	O
stably	O
transfected	O
Jurkat	B-cell_line
cell	I-cell_line
clones	E-cell_line
.	O

Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-605	O
motif	O
of	O
the	O
human	B-DNA
TNF	I-DNA
promoter	E-DNA
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	E-cell_line
there	O
is	O
a	O
predominance	O
of	O
p50p50	S-protein
of	O
NF-kappa	B-protein
B	E-protein
.	O

Interestingly	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
monoamine	B-protein
oxidase	I-protein
B	E-protein
enzyme	O
activity	O
in	O
blood	B-cell_type
cells	E-cell_type
(	O
platelets	S-cell_type
)	O
and	O
the	O
binding	O
pattern	O
of	O
two	O
uncharacterized	O
transcription	B-protein
factors	E-protein
.	O

Gene	O
targeting	O
studies	O
have	O
demonstrated	O
crucial	O
roles	O
for	O
the	O
transcription	B-protein
factors	I-protein
Ikaros	E-protein
and	O
Aiolos	S-protein
in	O
regulating	O
multiple	O
stages	O
of	O
B	O
and	O
T	O
cell	O
development	O
.	O

Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	B-DNA
DNA	E-DNA
.	O

We	O
have	O
previously	O
shown	O
that	O
neu	O
oncogene-initiated	O
rat	O
mammary	O
carcinomas	O
uniquely	O
over-express	O
neu-related	B-protein
lipocalin	E-protein
(	O
NRL	S-protein
)	O
,	O
a	O
member	O
of	O
the	O
calycin	B-protein
protein	I-protein
superfamily	E-protein
.	O

Indeed	O
,	O
monocytes	S-cell_type
pretreated	O
with	O
IL-10	S-protein
are	O
able	O
so	O
inhibit	O
NF-kappa	B-protein
B	E-protein
nuclear	O
activity	O
in	O
purified	O
T	B-cell_type
lymphocytes	E-cell_type
stimulated	O
with	O
OKT3	S-protein
.	O

The	O
relationship	O
between	O
Ca2+-ATPase	S-protein
and	O
freely	O
exchangeable	O
Ca2+	O
in	O
the	O
dense	O
tubules	O
:	O
a	O
study	O
in	O
platelets	S-cell_type
from	O
women	O
.	O

We	O
also	O
find	O
that	O
NF-E2	S-protein
,	O
another	O
trans-acting	B-protein
factor	E-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	E-cell_type
,	O
is	O
present	O
in	O
megakaryocytes	S-cell_line
.	O

To	O
determine	O
whether	O
the	O
IL-10R	S-protein
has	O
signaling	O
functions	O
similar	O
to	O
IL-6R	S-protein
in	O
cells	O
normally	O
expressing	O
these	O
receptors	O
,	O
leukocytes	S-cell_type
of	O
the	O
B-	B-cell_type
,	I-cell_type
T-	I-cell_type
,	I-cell_type
and	I-cell_type
NK-cell	I-cell_type
lineages	E-cell_type
were	O
treated	O
with	O
either	O
cytokine	O
.	O

The	O
glucocorticoid	B-protein
receptor	E-protein
levels	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
correlated	O
with	O
those	O
in	O
polymorphonuclear	B-cell_type
leukocytes	E-cell_type
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	E-protein
levels	O
and	O
glucocorticoid-mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O-methyl-D-glucose	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
.	O

Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss-of-function	O
mutation	O
in	O
one	O
allele	S-DNA
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild-type	B-DNA
allele	E-DNA
of	O
the	O
same	O
gene	O
.	O

The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	S-cell_type
remain	O
unknown	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	E-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	E-protein
.	O

Because	O
monocytes	S-cell_type
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1-type	O
responses	O
,	O
such	O
as	O
delayed-type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL-10	S-protein
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma-	O
and	O
IFNalpha-induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

More	O
than	O
50	O
%	O
of	O
TPO-treated	B-cell_line
UT-7/GMT	I-cell_line
cells	E-cell_line
positively	O
stained	O
for	O
Hb	S-protein
.	O

A	O
small	O
but	O
significant	O
reduction	O
of	O
the	O
24-hour	O
urinary	O
cortisol	O
excretion	O
was	O
observed	O
(	O
233	O
+/-	O
109	O
and	O
157	O
+/-	O
66	O
nmol/L	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
,	O
whereas	O
the	O
feedback	O
regulation	O
of	O
glucocorticoid	O
synthesis	O
by	O
means	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
as	O
assessed	O
by	O
the	O
adrenocorticotropic	O
hormone	O
test	O
remained	O
normal	O
after	O
treatment	O
with	O
FP	O
.	O

Both	O
alpha-	O
and	O
beta-bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28+	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
and	O
in	O
some	O
transformed	B-cell_line
B	I-cell_line
cells	E-cell_line
.	O

The	O
IL-2	B-DNA
gene	E-DNA
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	E-cell_type
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	B-DNA
arm	E-DNA
of	O
human	B-DNA
chromosome	I-DNA
11	E-DNA
at	O
band	B-DNA
11p15	E-DNA
disrupts	O
the	O
rhombotin	B-DNA
gene	E-DNA
.	O

Both	O
cytokines	S-protein
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

Stimulation	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	E-cell_line
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	S-protein
like	O
tumor	B-protein
necrosis	I-protein
factor	E-protein
(	O
TNF	S-protein
)	O
.	O

C/EBP	B-protein
alpha	E-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	E-protein
(	O
C/EBP	S-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	E-cell_line
.	O

NF-kappaB	S-protein
nuclear	O
activation	O
was	O
not	O
detectable	O
before	O
1	O
h	O
after	O
cell	O
contact	O
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O

Stimulation	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
through	O
their	O
antigen	B-protein
receptor	E-protein
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B-protein
factors	E-protein
,	O
including	O
NF-AT	S-protein
and	O
NF-kappa	B-protein
B	E-protein
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

Upon	O
PHA	S-protein
-stimulation	O
,	O
Id2	S-protein
expression	O
decreased	O
and	O
Id3	S-protein
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O

We	O
also	O
show	O
that	O
the	O
IL-7	S-protein
-induced	O
enhancement	O
of	O
the	O
AP-1	S-protein
-DNA	O
binding	O
activity	O
is	O
not	O
cyclosporin	O
A-sensitive	O
.	O

We	O
measured	O
glucocorticoid	B-protein
receptors	E-protein
(	O
GR	S-protein
)	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
(	O
MNL	S-cell_type
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393/	O
CD43	S-protein
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
NF-kappaB	E-protein
and	O
proteins	O
binding	O
the	O
interferon-inducible	B-DNA
regulatory	I-DNA
element	E-DNA
.	O

The	O
PML/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	E-DNA
resulting	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
translocation	E-DNA
is	O
a	O
specific	O
marker	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Thus	O
,	O
Tax	S-protein
,	O
through	O
enhancement	O
of	O
the	O
DNA-binding	O
activity	O
of	O
E2F	S-protein
,	O
may	O
be	O
capable	O
of	O
regulating	O
cellular	O
gene	O
expression	O
implicated	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
T	B-cell_type
cells	E-cell_type
in	O
ATL	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-protein
receptor	E-protein
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	S-RNA
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	B-RNA
and	I-RNA
GATA-1	I-RNA
mRNAs	E-RNA
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half-lives	O
of	O
these	O
mRNAs	S-RNA
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
MS-2	S-protein
mediates	O
induction	O
of	O
the	O
CD11b	B-DNA
gene	E-DNA
as	O
cells	O
of	O
the	O
monocytic	O
lineage	O
mature	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	S-protein
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	S-protein
transforms	O
mouse	B-cell_type
fibroblasts	E-cell_type
but	O
not	O
thymocytes	S-cell_type
,	O
despite	O
comparable	O
levels	O
of	O
tax	S-protein
expression	O
in	O
both	O
tissues	O
.	O

Activation	O
of	O
human	B-cell_line
CD4	I-cell_line
T	I-cell_line
lymphocytes	E-cell_line
.	O

We	O
propose	O
a	O
model	O
where	O
basal	O
transcription	O
is	O
maintained	O
by	O
binding	O
of	O
various	O
transcription	B-protein
factors	E-protein
to	O
the	O
IFN-gamma	B-DNA
promoter	E-DNA
,	O
whereas	O
PMA+	O
PHA	S-protein
-inducible	O
IFN-gamma	S-protein
transcription	O
in	O
CD45R0	B-cell_type
T	I-cell_type
cells	E-cell_type
is	O
associated	O
with	O
binding	O
of	O
AP-1	S-protein
to	O
the	O
C-site	S-DNA
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	S-protein
with	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	E-protein
reveals	O
that	O
both	O
NH2-	B-protein
and	I-protein
COOH-terminal	I-protein
domains	E-protein
of	O
BOB.1/OBF.1	S-protein
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH-terminal	B-protein
domain	E-protein
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF-kappa	B-DNA
B-	I-DNA
,	I-DNA
AP-1-	I-DNA
and	I-DNA
NF-AT-binding	I-DNA
sequences	E-DNA
is	O
required	O
for	O
induction	O
of	O
the	O
GM-CSF	B-DNA
gene	E-DNA
through	O
PKC-	O
and	O
Ca2+-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

The	O
induction	O
of	O
E2F	S-protein
activity	O
preceded	O
the	O
appearance	O
of	O
cdc2	B-RNA
mRNA	E-RNA
,	O
which	O
is	O
consistent	O
with	O
the	O
role	O
of	O
E2F	S-protein
in	O
the	O
regulation	O
of	O
cdc2	B-cell_type
mRNA	I-cell_type
expression	E-cell_type
.	O

In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	B-RNA
mRNA	E-RNA
seen	O
in	O
IM-9	B-cell_line
cells	E-cell_line
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16-18	O
h	O
,	O
treatment	O
of	O
6TG1.1	B-cell_line
cells	E-cell_line
resulted	O
in	O
an	O
8-fold	O
increase	O
in	O
GR	B-RNA
mRNA	E-RNA
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	S-protein
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3-	O
to	O
4-fold	O
increase	O
in	O
GR	B-protein
protein	E-protein
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	S-protein
or	O
Bcl-X	B-protein
(	I-protein
L	I-protein
)	E-protein
.	O

We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	S-DNA
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	B-DNA
enhancer	E-DNA
and	O
the	O
entire	O
IL-2	B-DNA
promoter-enhancer	E-DNA
,	O
while	O
overexpression	O
of	O
both	O
GABP	B-protein
factors	E-protein
enhanced	O
the	O
IL-2	B-DNA
promoter-enhancer	E-DNA
induction	O
.	O

It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	B-protein
domain	E-protein
of	O
TF	S-protein
with	O
VIIa	S-protein
to	O
form	O
the	O
binary	O
TF.VIIa	B-protein
complex	E-protein
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	B-protein
domain	E-protein
of	O
VIIa	S-protein
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	B-protein
substrate	E-protein
.	O

Activation	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
1	I-DNA
gene	E-DNA
transcription	O
and	O
pp90rsk	S-protein
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	S-protein
made	O
from	O
one	O
of	O
these	O
pre-B	B-cell_line
cells	E-cell_line
or	O
from	O
HeLa	B-cell_line
cells	E-cell_line
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	B-DNA
gene	E-DNA
.	O

The	O
hypothesis	O
to	O
be	O
tested	O
was	O
whether	O
or	O
not	O
humans	O
exhibit	O
a	O
similar	O
susceptibility	O
to	O
PCDDs/PCDFs	O
with	O
respect	O
to	O
the	O
surface	B-protein
receptors	E-protein
found	O
previously	O
to	O
respond	O
to	O
small	O
doses	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
in	O
Callithrix	O
jacchus	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	S-protein
and	O
Smad7	S-protein
are	O
human	B-protein
bone	I-protein
morphogenetic	I-protein
protein-2	E-protein
(	O
hBMP-2	S-protein
)	O
-inducible	O
antagonists	O
of	O
hBMP-2	S-protein
-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
HS-72	I-cell_line
cells	E-cell_line
.	O

Secretion	O
of	O
myeloid	B-protein
cell-derived	I-protein
cytokines	E-protein
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O

IL-10	S-protein
attenuated	O
LPS-stimulated	O
TNF-alpha	S-protein
production	O
(	O
297+/-54	O
;	O
p	O
<	O
.001	O
versus	O
LPS	O
alone	O
)	O
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O

Ligation	O
of	O
Fas	S-protein
by	O
specific	B-protein
Abs	E-protein
or	O
Fas	B-protein
ligand	E-protein
(	O
FasL/CD95	B-protein
ligand	E-protein
)	O
induces	O
rapid	O
apoptotic	O
cell	O
death	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-protein
ALAS	I-protein
isozymes	E-protein
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O

After	O
the	O
DNA	B-DNA
fragment	E-DNA
containing	O
the	O
CAG	B-DNA
repeats	E-DNA
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O
the	O
extension	O
of	O
the	O
end-labelled	B-DNA
reverse	I-DNA
primer	E-DNA
adjacent	O
to	O
3	B-DNA
'	I-DNA
end	E-DNA
of	O
CAG	B-DNA
repeats	E-DNA
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	B-DNA
repeats	E-DNA
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O

Mutual	O
association	O
of	O
signal	B-protein
transducing	I-protein
proteins	E-protein
within	O
the	O
receptor	O
complex	O
was	O
then	O
studied	O
in	O
dependence	O
of	O
ligand	O
stimulation	O
.	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

The	O
tax	B-protein
protein	E-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c-sis/platelet-derived	B-DNA
growth	I-DNA
factor-B	I-DNA
promoter	E-DNA
through	O
interactions	O
with	O
the	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
Sp1	E-protein
and	O
NGFI-A/Egr-1	S-protein
.	O

UT-7	B-protein
Epo	E-protein
and	O
UT-7	S-cell_line
expressed	O
similar	O
levels	O
of	O
GATA-1	B-RNA
mRNA	E-RNA
and	O
binding	O
activity	O
.	O

GM2	S-DNA
defines	O
a	O
binding	B-DNA
site	E-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	B-cell_line
cell	I-cell_line
line	E-cell_line
(	O
NS-Meg	S-cell_line
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	E-protein
inhibits	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF	B-protein
kappa	I-protein
B	E-protein
)	O
activation	O
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

Intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	E-protein
(	O
ICAM-1	S-protein
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B-protein
affinity	I-protein
CVZ	I-protein
binding	I-protein
site	E-protein
.	O

An	O
acidic	B-protein
activation	I-protein
domain	E-protein
is	O
located	O
between	O
the	O
N-terminal	B-protein
conserved	I-protein
region	E-protein
of	O
clone	B-protein
18	E-protein
and	O
its	O
zinc	B-protein
fingers	E-protein
.	O

The	O
requirement	O
for	O
TNF	S-protein
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
thymocytes	E-cell_type
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	S-protein
production	O
during	O
their	O
interaction	O
with	O
TEC	S-cell_type
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF-kappaB	S-protein
activity	O
in	O
these	O
freshly	B-cell_type
isolated	I-cell_type
thymocytes	E-cell_type
.	O

We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A-MYB	S-protein
and	O
its	O
regulation	O
in	O
several	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	E-cell_line
using	O
co-transfection	O
assays	O
and	O
show	O
that	O
A-MYB	S-protein
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
studied	O
,	O
but	O
not	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Here	O
,	O
we	O
analyzed	O
large	O
genomic	B-DNA
IL-4	I-DNA
regions	E-DNA
for	O
enhancer	O
activity	O
and	O
interaction	O
with	O
transcription	B-protein
factors	E-protein
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O

Detailed	O
studies	O
establish	O
that	O
this	O
cytokine	O
mediates	O
biological	O
effects	O
on	O
a	O
broad	O
spectrum	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	E-cell_type
,	O
including	O
stem	B-cell_type
cells	E-cell_type
.	O

The	O
intensity	O
of	O
C/EBP	B-protein
beta	E-protein
staining	O
was	O
greater	O
(	O
P	O
<	O
0.001	O
)	O
in	O
synovial	B-cell_type
fluid	I-cell_type
monocytes	E-cell_type
than	O
in	O
those	O
from	O
normal	B-cell_type
or	I-cell_type
rheumatoid	I-cell_type
peripheral	I-cell_type
blood	E-cell_type
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	S-protein
costimulatory	O
pathway	O
.	O

Oligoclonal	O
expansion	O
of	O
B	B-cell_type
cells	E-cell_type
in	O
the	O
livers	O
with	O
ILFs	O
was	O
confirmed	O
by	O
an	O
analysis	O
of	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	E-DNA
rearrangement	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	B-cell_type
tissues	E-cell_type
.	O

Overexpression	O
of	O
SLP-76	S-protein
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	E-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
assay	O
using	O
an	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sequence	E-DNA
from	O
the	O
kappa	B-protein
light	I-protein
chain	E-protein
as	O
a	O
probe	O
,	O
revealed	O
that	O
both	O
p65	S-protein
(	O
RelA	S-protein
)	O
and	O
c-Rel	S-protein
were	O
present	O
in	O
CD40-stimulated	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

We	O
analyzed	O
the	O
ability	O
of	O
the	O
trans-dimer	O
encoded	O
by	O
HLA-DQA1*0501/DQB1*0302	S-protein
to	O
bind	O
a	O
peptide	O
antigen	O
which	O
interacts	O
with	O
DQ	B-protein
molecules	E-protein
encoded	O
by	O
both	O
parental	O
haplotypes	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	B-DNA
promoter	I-DNA
region	E-DNA
identified	O
a	O
C/EBP	B-DNA
(	I-DNA
CCAAT/enhancer-binding	I-DNA
protein	I-DNA
)	I-DNA
consensus	I-DNA
binding	I-DNA
site	E-DNA
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA-binding	B-DNA
site	E-DNA
in	O
the	O
MBP	B-DNA
gene	E-DNA
.	O

OBJECTIVE	O
:	O
The	O
NF-kappa	B-protein
B/Rel	I-protein
family	E-protein
of	O
transcription	B-protein
factors	E-protein
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O

Furthermore	O
,	O
a	O
mutant	B-DNA
E6	I-DNA
motif	E-DNA
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	B-protein
regulator	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	E-protein
.	O

NFATc	S-protein
overcame	O
a	O
blockade	O
at	O
reverse	O
transcription	O
and	O
permitted	O
active	O
HIV-1	O
replication	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

Since	O
HUVECs	S-cell_line
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	O
,	O
and	O
H2O2	O
induces	O
VCAM-1	S-protein
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O

c-Myb	S-DNA
and	O
Ets	B-protein
proteins	E-protein
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	S-protein
.	O

The	O
interaction	O
of	O
Tax1	S-protein
with	O
NF-YB	S-protein
was	O
specific	O
in	O
that	O
NF-YB	S-protein
did	O
not	O
interact	O
with	O
a	O
variety	O
of	O
other	O
transcription	B-protein
factors	E-protein
,	O
including	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
Tat	E-protein
,	O
human	B-protein
papillomavirus	I-protein
E6	E-protein
,	O
and	O
Bicoid	S-protein
,	O
or	O
with	O
the	O
M7	B-protein
(	I-protein
amino	I-protein
acids	I-protein
29CP-AS	I-protein
)	I-protein
Tax1	I-protein
mutant	E-protein
.	O

Interferon	B-protein
gamma	E-protein
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	B-cell_line
cell	I-cell_line
line	E-cell_line
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O

The	O
DNA-binding	O
properties	O
of	O
two	B-protein
heat	I-protein
shock	I-protein
factors	E-protein
,	O
HSF1	S-protein
and	O
HSF3	S-protein
,	O
are	O
induced	O
in	O
the	O
avian	B-cell_line
erythroblast	I-cell_line
cell	I-cell_line
line	I-cell_line
HD6	E-cell_line
.	O

G-CSF	B-protein
receptors	E-protein
lack	O
intrinsic	O
tyrosine	B-protein
kinase	E-protein
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

The	O
effect	O
of	O
18C7	S-protein
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

Impaired	O
binding	O
of	O
a	O
DQ2	S-protein
and	O
DQ8	S-protein
-binding	O
HSV	O
VP16	O
peptide	O
to	O
a	O
DQA1*0501/DQB1*0302	B-protein
trans	I-protein
class	I-protein
II	I-protein
heterodimer	E-protein
.	O

Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	S-protein
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	B-DNA
promoter	E-DNA
activity	O
.	O

In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	E-cell_type
stimulated	O
in	O
the	O
same	O
way	O
.	O

In	O
lymphoid	B-cell_line
cell	I-cell_line
lines	E-cell_line
only	O
,	O
the	O
E	B-protein
(	I-protein
gre	I-protein
)	I-protein
-binding	I-protein
protein	I-protein
complexes	E-protein
included	O
ALF1	S-protein
or	O
HEB	S-protein
and	O
E2A	B-protein
basic	I-protein
helix-loop-helix	I-protein
proteins	E-protein
.	O

Downstream	O
activation	O
of	O
a	O
TATA-less	B-DNA
promoter	E-DNA
by	O
Oct-2	S-protein
,	O
Bob1	O
,	O
and	O
NF-kappaB	S-protein
directs	O
expression	O
of	O
the	O
homing	B-protein
receptor	I-protein
BLR1	E-protein
to	O
mature	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

While	O
the	O
binding	O
of	O
IL-2	S-protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	S-protein
,	O
Jak-1	S-protein
and	O
Jak-3	S-protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O

In	O
mammalian	O
cells	O
the	O
MAPK	B-protein
p38	E-protein
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	B-protein
molecules	E-protein
.	O

In	O
recent	O
investigations	O
,	O
using	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	E-cell_line
,	O
we	O
observed	O
that	O
all-trans	O
RA	O
,	O
at	O
10	O
(	O
-7	O
)	O
M	O
,	O
did	O
not	O
induce	O
neutrophil	O
differentiation	O
and	O
that	O
all-trans	O
RA	O
,	O
at	O
10	O
(	O
-8	O
)	O
M	O
,	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	S-cell_type
differentiation	O
to	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
.	O

NAC	O
had	O
no	O
effect	O
on	O
the	O
half-life	O
of	O
E-selectin	B-RNA
or	I-RNA
VCAM-1	I-RNA
mRNA	E-RNA
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF-kappa	B-protein
B	E-protein
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O

Effects	O
of	O
glucocorticoids	O
in	O
rheumatoid	O
arthritis	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
monocytes	E-cell_type
were	O
isolated	O
by	O
density	O
centrifugation	O
methods	O
with	O
a	O
purity	O
of	O
>	O
90	O
%	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
.	O

Importantly	O
,	O
two	O
previously	O
characterized	O
mutants	S-protein
with	O
point	O
mutations	O
in	O
Tax	S-protein
,	O
M32	S-protein
(	O
Y196A	O
,	O
K197S	O
)	O
and	O
M41	S-protein
(	O
H287A	O
,	O
P288S	O
)	O
,	O
which	O
were	O
shown	O
to	O
be	O
defective	O
in	O
Tax	S-protein
-activated	O
transcription	O
were	O
unable	O
to	O
interact	O
with	O
TFIIA	S-protein
in	O
this	O
assay	O
.	O

We	O
have	O
previously	O
shown	O
that	O
nuclear	O
extracts	O
from	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
form	O
two	O
inducible	O
NF-AT	B-protein
complexes	E-protein
with	O
an	O
oligonucleotide	O
corresponding	O
to	O
the	O
distal	B-DNA
NF-AT	I-DNA
site	E-DNA
of	O
the	O
murine	B-DNA
IL-2	I-DNA
promoter	E-DNA
,	O
although	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	B-cell_type
cells	E-cell_type
form	O
a	O
single	O
complex	O
containing	O
NF-ATp	S-protein
.	O

CONCLUSIONS	O
:	O
The	O
diagnosis	O
of	O
GCT	O
should	O
be	O
based	O
primarily	O
on	O
the	O
typical	O
morphology	O
revealed	O
by	O
conventional	O
stains	O
,	O
but	O
additional	O
immunohistochemical	O
staining	O
with	O
a	O
small	O
panel	O
of	O
selected	O
antibodies	O
(	O
for	O
example	O
,	O
against	O
keratin	S-protein
,	O
vimentin	S-protein
,	O
and	O
inhibin	B-protein
A	E-protein
)	O
may	O
be	O
helpful	O
in	O
a	O
few	O
cases	O
.	O

Site-directed	O
mutagenesis	O
of	O
these	O
cis	B-DNA
elements	E-DNA
demonstrated	O
that	O
Cp	S-DNA
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	B-DNA
box	E-DNA
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	B-DNA
CCAAT	I-DNA
box	E-DNA
apparent	O
only	O
when	O
the	O
proximal	B-DNA
CCAAT	I-DNA
box	E-DNA
was	O
deleted	O
or	O
mutated	O
.	O

A	O
salient	O
difference	O
between	O
solution	O
and	O
crystal	O
structures	O
is	O
observed	O
in	O
the	O
C-terminal	B-protein
segment	E-protein
of	O
alpha-helix	B-protein
3	E-protein
(	O
the	O
HTH	B-protein
recognition	I-protein
helix	E-protein
)	O
,	O
which	O
is	O
not	O
well	O
ordered	O
in	O
solution	O
.	O

We	O
used	O
mononuclear	B-cell_line
cell	I-cell_line
priming	I-cell_line
cultures	E-cell_line
and	O
inflammatory	B-cell_type
synovial	I-cell_type
fluids	E-cell_type
(	O
SFs	S-cell_type
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	S-protein
production	O
and	O
STAT	S-protein
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Aside	O
from	O
an	O
N-terminal	B-DNA
acidic	I-DNA
transcriptional	I-DNA
activation	I-DNA
domain	E-DNA
,	O
little	O
is	O
known	O
about	O
how	O
this	O
factor	O
functions	O
.	O

ZEB	S-protein
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh-1	S-protein
,	O
binds	O
a	O
subset	O
of	O
E	B-DNA
boxes	E-DNA
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	B-DNA
genes	E-DNA
.	O

This	O
suggests	O
that	O
for	O
senescent	B-cell_type
T	I-cell_type
cells	E-cell_type
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	S-protein
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	O
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells	O
.	O

Furthermore	O
,	O
while	O
ligand-activated	O
c-erbA/TR	S-protein
accelerated	O
differentiation	O
,	O
unliganded	O
c-erbA/TR	S-protein
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrated	O
that	O
phorbol	O
ester	O
treatment	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
dramatically	O
inhibits	O
activation	O
of	O
IFN-alpha/B-stimulated	O
early	O
response	O
genes	O
but	O
by	O
a	O
mechanism	O
which	O
does	O
not	O
involve	O
abrogation	O
of	O
the	O
ISRE	O
binding	O
of	O
ISGF3gamma	O
.	O

These	O
results	O
indicate	O
that	O
both	O
a	O
decrease	O
and	O
an	O
increase	O
of	O
human	O
motor	O
activity	O
resulted	O
in	O
significant	O
changes	O
of	O
specific	O
glucocorticoid	O
binding	O
which	O
were	O
not	O
influenced	O
by	O
changes	O
of	O
circulating	O
hormone	O
concentrations	O
in	O
blood	O
but	O
by	O
some	O
other	O
factors	O
affected	O
by	O
physical	O
activity	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	B-protein
receptor	E-protein
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

Thus	O
a	O
primary	O
effect	O
of	O
these	O
immunosuppressive	O
reagents	O
is	O
to	O
control	O
the	O
subcellular	O
localization	O
of	O
the	O
NF-AT	S-protein
family	O
of	O
transcription	B-protein
factors	E-protein
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T-cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	S-protein
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	B-protein
surface	I-protein
activation	I-protein
markers	E-protein
and	O
cytokine	O
production	O
in	O
mitogen-stimulated	O
Rel-/-	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

GABP	B-protein
factors	E-protein
bind	O
to	O
a	O
distal	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
enhancer	E-DNA
and	O
contribute	O
to	O
c-Raf	S-protein
-mediated	O
increase	O
in	O
IL-2	S-protein
induction	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
interaction	O
of	O
Tax	S-protein
with	O
the	O
transcription	B-protein
factor	I-protein
TFIIA	E-protein
may	O
play	O
a	O
role	O
in	O
Tax	S-protein
-mediated	O
transcriptional	O
activation	O
.	O

MDS1/EVI1	S-DNA
enhances	O
TGF-beta1	S-protein
signaling	O
and	O
strengthens	O
its	O
growth-inhibitory	O
effect	O
but	O
the	O
leukemia-associated	B-protein
fusion	I-protein
protein	I-protein
AML1/MDS1/EVI1	E-protein
,	O
product	O
of	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
,	O
abrogates	O
growth-inhibition	O
in	O
response	O
to	O
TGF-beta1	S-protein
.	O

The	O
specificity	O
of	O
CIITA	S-protein
for	O
three	O
major	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
,	O
DR	S-DNA
,	O
DQ	S-DNA
and	O
DP	S-DNA
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C-terminal	B-protein
residues	E-protein
(	O
amino	B-protein
acids	I-protein
317-1130	E-protein
)	O
.	O

The	O
mutation	O
is	O
present	O
in	O
Fy	O
(	O
b-	O
)	O
individuals	O
,	O
who	O
have	O
wild-type	B-DNA
FY*B	I-DNA
GATA	E-DNA
and	O
carry	O
the	O
previously	O
described	O
304G	O
--	O
>	O
A	O
substitution	O
.	O

In	O
the	O
four	O
representative	O
mutants	O
investigated	O
,	O
the	O
DNA	B-DNA
reiterations	E-DNA
all	O
started	O
within	O
a	O
six-base-pair	B-DNA
consensus	I-DNA
sequence	E-DNA
,	O
G	O
(	O
or	O
C	O
)	O
CTGTG	O
,	O
located	O
in	O
the	O
second	O
exon	S-DNA
of	O
the	O
E1a	B-DNA
region	E-DNA
(	O
at	O
nt	O
1333	O
,	O
1367	O
,	O
or	O
1419	O
)	O
.	O

The	O
human	B-protein
myeloid	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	E-protein
(	O
MNDA	S-protein
)	O
is	O
expressed	O
specifically	O
in	O
maturing	B-cell_type
cells	E-cell_type
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	S-cell_type
and	O
granulocytes	S-cell_type
.	O

Recently	O
,	O
fibromyalgia	O
(	O
FMS	O
)	O
was	O
shown	O
to	O
be	O
a	O
disorder	O
associated	O
with	O
an	O
altered	O
functioning	O
of	O
the	O
stress	O
response	O
system	O
.	O

Isoforms	O
Pax-5d	O
and	O
Pax-5e	S-protein
have	O
deleted	O
the	O
3'-region	S-protein
,	O
which	O
encodes	O
the	O
transactivating	O
domain	O
,	O
and	O
replaced	O
it	O
with	O
a	O
novel	O
sequence	O
.	O

In	O
conclusion	O
,	O
the	O
enhanced	O
nuclear	O
staining	O
for	O
C/EBP	B-protein
beta	E-protein
in	O
the	O
synovial	O
lining	O
,	O
compared	O
to	O
the	O
sublining	O
,	O
suggesting	O
activation	O
in	O
the	O
lining	O
,	O
and	O
the	O
positive	O
correlation	O
of	O
lining	O
layer	O
depth	O
with	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
lining	O
positive	O
for	O
nuclear	O
C/EBP	B-protein
beta	E-protein
,	O
suggest	O
a	O
potential	O
role	O
for	O
C/EBP	B-protein
beta	E-protein
in	O
chronic	O
inflammation	O
.	O

Thus	O
,	O
BOB.1/OBF.1	S-protein
is	O
a	O
transcriptional	B-protein
coactivator	E-protein
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type-specific	O
gene	O
expression	O
.	O

Incidentally	O
,	O
Grf40	S-protein
binds	O
to	O
linker	B-protein
for	I-protein
activation	I-protein
of	I-protein
T	I-protein
cells	E-protein
(	O
LAT	S-protein
)	O
possibly	O
via	O
its	O
SH2	B-protein
domain	E-protein
.	O

Purified	O
bcl-2	S-protein
is	O
cleaved	O
by	O
HIV	B-protein
protease	E-protein
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

Moreover	O
,	O
IL-5	S-protein
induced	O
at	O
least	O
two	O
DNA-binding	B-protein
complexes	E-protein
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B-cell_type
eosinophils	E-cell_type
and	O
the	O
IL-6/interferon-gamma	B-DNA
response	I-DNA
element	E-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	E-DNA
(	O
ICAM-1	B-DNA
pIRE	E-DNA
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O

Overall	O
,	O
TSH-R	S-protein
transcript	O
levels	O
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	E-protein
(	O
MHC	B-protein
I	I-protein
or	I-protein
II	E-protein
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	B-protein
I	E-protein
,	O
r	O
=	O
-0.791	O
;	O
P	O
<	O
0.01	O
;	O
MHC	B-protein
II	E-protein
,	O
r	O
=	O
-0.784	O
;	O
P	O
<	O
0.01	O
)	O
.	O

We	O
conclude	O
that	O
NF-kappaB	S-protein
is	O
a	O
context-dependent	O
apoptosis	O
regulator	O
.	O

The	O
biological	O
significance	O
of	O
NF-kappaB	S-protein
activation	O
in	O
T.	B-cell_type
parva-infected	I-cell_type
cells	E-cell_type
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	B-protein
proteins	E-protein
and	O
selected	O
human	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
has	O
been	O
developed	O
.	O

We	O
have	O
recently	O
developed	O
a	O
novel	O
RAR	S-protein
-selective	O
antagonist	O
(	O
ER27191	O
)	O
which	O
prevents	O
RAR	S-protein
activation	O
by	O
retinoids	O
.	O

In	O
addition	O
,	O
new	O
technology	O
allows	O
the	O
sensitive	O
identification	O
of	O
gene	O
hypermethylation	O
in	O
a	O
background	O
of	O
normal	B-cell_type
cells	E-cell_type
,	O
suggesting	O
possible	O
new	O
strategies	O
for	O
the	O
detection	O
of	O
minimal	O
residual	O
disease	O
.	O

Differential	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	E-protein
expression	O
in	O
human	B-cell_line
T-	I-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	E-cell_line
.	O

Treatment	O
of	O
cells	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	E-protein
(	O
MEK	S-protein
)	O
,	O
inhibited	O
TPA-induced	O
ERK2	S-protein
activity	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	E-DNA
7-fold	O
and	O
the	O
c-jun	B-DNA
gene	E-DNA
1.4-fold	O
.	O

Statistical	O
analysis	O
was	O
performed	O
in	O
order	O
to	O
determine	O
the	O
prognostic	O
value	O
of	O
the	O
polyamine	O
patterns	O
of	O
tumor	O
tissues	O
and	O
erythrocytes	O
in	O
comparison	O
with	O
clinical	O
and	O
histological	O
prognostic	O
factors	O
.	O

A	O
mouse	O
carrying	O
genetic	O
defect	O
in	O
the	O
choice	O
between	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	B-cell_line
cells	E-cell_line
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl-2	B-protein
protein	E-protein
.	O

We	O
conclude	O
that	O
NF-kappa	B-protein
B	E-protein
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	B-DNA
B-responsive	I-DNA
genes	E-DNA
is	O
enhanced	O
in	O
phagocytosing	B-cell_type
neutrophils	E-cell_type
.	O

The	O
endothelial	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	E-protein
(	O
VCAM-1	S-protein
)	O
,	O
E-selectin	S-protein
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	E-protein
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady-state	O
levels	O
of	O
VCAM-1	B-RNA
mRNA	E-RNA
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

Four	O
specific	O
protein-DNA	B-protein
complexes	E-protein
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B-cell_line
pituitary	I-cell_line
(	I-cell_line
GH3	I-cell_line
)	I-cell_line
cells	E-cell_line
with	O
a	O
TREp-containing	B-DNA
DNA	I-DNA
fragment	E-DNA
.	O

HIV-1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O

Taken	O
together	O
,	O
this	O
review	O
supports	O
the	O
notion	O
that	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
is	O
multifactorial	O
,	O
involving	O
genetic	O
alterations	O
as	O
well	O
as	O
dysregulated	O
cytokine	S-protein
expression	O
.	O

COS-1	B-cell_line
cells	E-cell_line
,	O
co-expressing	O
the	O
human	O
IL-10R	S-protein
and	O
individual	O
STAT	B-protein
proteins	E-protein
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	S-protein
for	O
STAT3	S-protein
and	O
STAT1	S-protein
.	O

Cytokines	O
stimulate	O
granulopoiesis	O
through	O
signaling	O
via	O
receptors	O
whose	O
expression	O
is	O
controlled	O
by	O
lineage-specific	O
transcription	B-protein
factors	E-protein
.	O

THP-1	S-cell_line
Activation	O
of	O
Ras	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	E-protein
pathway	O
by	O
terminal	B-protein
complement	I-protein
complexes	E-protein
is	O
G	B-protein
protein	E-protein
dependent	O
.	O

At	O
the	O
5	B-DNA
'	I-DNA
end	E-DNA
,	O
this	O
70-bp	B-DNA
IFN-gamma	I-DNA
response	I-DNA
element	E-DNA
contains	O
sequence	O
similarity	O
to	O
the	O
gamma	B-DNA
activated	I-DNA
site	E-DNA
(	O
GAS	S-DNA
)	O
.	O

We	O
demonstrate	O
here	O
,	O
however	O
,	O
that	O
NFAT	S-protein
can	O
be	O
activated	O
,	O
and	O
significant	O
levels	O
of	O
IL-2	S-protein
can	O
be	O
produced	O
by	O
the	O
CsA-resistant	O
CD28	S-protein
-signaling	O
pathway	O
.	O

These	O
observations	O
suggest	O
that	O
p65	B-protein
and	I-protein
c-Rel	I-protein
complexes	E-protein
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF-kappa	B-protein
B	E-protein
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	B-cell_type
cells	E-cell_type
.	O

This	O
failure	O
to	O
degrade	O
IkappaBalpha	S-protein
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	S-protein
induction	O
and	O
the	O
IL-2	S-protein
receptor	O
expression	O
in	O
TNF-treated	B-cell_line
T	I-cell_line
cells	E-cell_line
during	O
aging	O
.	O

Such	O
alterations	O
may	O
have	O
clinical	O
consequences	O
,	O
including	O
the	O
possibility	O
of	O
a	O
relatively	O
longer	O
life	O
span	O
of	O
infected	B-cell_type
CD4+	I-cell_type
T-lymphocytes	E-cell_type
,	O
as	O
well	O
as	O
systemic	O
effects	O
of	O
chronically	O
elevated	O
cortisol	O
level	O
.	O

In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	B-RNA
and	I-RNA
FOSB	I-RNA
mRNAs	E-RNA
increase	O
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF-ATp	S-protein
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF-AT	S-protein
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O

Anti-	O
HLA-DR	S-protein
abrogated	O
proliferation	O
to	O
SSB	S-protein
and	O
tetanus	O
toxoid	O
.	O

Moreover	O
,	O
23.3	O
%	O
of	O
patients	O
with	O
breast	O
cancer	O
showed	O
an	O
overexpression	O
of	O
HER-2/neu	B-protein
protein	E-protein
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	B-DNA
and	I-DNA
trans-acting	I-DNA
elements	E-DNA
involved	O
in	O
the	O
tissue-specific	O
activity	O
of	O
the	O
L	B-DNA
gene	I-DNA
erythroid	I-DNA
promoter	E-DNA
.	O

Even	O
so	O
,	O
medullary	B-cell_type
thymocytes	E-cell_type
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O

Transcription	B-protein
factors	E-protein
of	O
the	O
NFAT	B-protein
family	E-protein
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	E-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

The	O
I	B-DNA
gamma	I-DNA
3	I-DNA
ECS	E-DNA
lies	O
upstream	O
of	O
the	O
major	B-DNA
I	I-DNA
gamma	I-DNA
3	I-DNA
transcription	I-DNA
initiation	I-DNA
site	E-DNA
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	B-DNA
I	I-DNA
gamma	I-DNA
1	E-DNA
,	O
I	B-DNA
gamma	I-DNA
2	E-DNA
,	O
and	O
I	B-DNA
gamma	I-DNA
4	E-DNA
regions	O
.	O

TRAMP	S-protein
is	O
abundantly	O
expressed	O
on	O
thymocytes	S-cell_type
and	O
lymphocytes	S-cell_type
.	O

The	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
of	O
S-LB1	S-cell_line
was	O
comparable	O
to	O
the	O
well-characterized	O
chick	B-protein
intestinal	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	E-protein
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5-20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA-cellulose	O
.	O

Upon	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	S-protein
.	O

This	O
B	B-protein
cell	I-protein
restricted	I-protein
coactivator	E-protein
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	S-protein
mediated	O
by	O
the	O
octamer	B-DNA
site	E-DNA
.	O

The	O
human	B-DNA
gene	E-DNA
encoding	O
the	O
lectin-type	B-protein
oxidized	I-protein
LDL	I-protein
receptor	E-protein
(	O
OLR1	S-protein
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	E-protein
with	O
a	O
unique	O
expression	O
profile	O
.	O

The	O
c-Myc	B-protein
oncoprotein	E-protein
is	O
important	O
in	O
control	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
,	O
while	O
Yin-Yang	B-protein
1	E-protein
(	O
YY1	S-protein
)	O
has	O
been	O
shown	O
to	O
control	O
the	O
expression	O
of	O
a	O
number	O
of	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	E-DNA
.	O

We	O
conclude	O
that	O
apoptotic	B-cell_type
VSMCs	E-cell_type
possess	O
a	O
significant	O
thrombin	S-protein
-generating	O
capacity	O
secondary	O
to	O
phosphatidylserine	O
exposure	O
.	O

A	O
series	O
of	O
hybrid	B-DNA
DRA/DQB	I-DNA
reporter	I-DNA
constructs	E-DNA
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis-elements	S-DNA
in	O
this	O
system	O
.	O

Many	O
of	O
these	O
events	O
are	O
dependent	O
upon	O
the	O
ability	O
of	O
CD40	S-protein
to	O
activate	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	E-DNA
.	O

At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	B-protein
cationic	I-protein
protein	E-protein
,	O
eosinophil-derived	O
neurotoxin	O
,	O
and	O
eosinophil	B-protein
peroxidase	E-protein
did	O
not	O
stimulate	O
significant	O
levels	O
of	O
IL-8	S-protein
production	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL-1RI	B-protein
complex	E-protein
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
protein	I-protein
kinase	E-protein
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL-1	S-protein
signaling	O
leading	O
to	O
NF-kappa	B-protein
B	E-protein
activation	O
.	O

Circulating	B-cell_type
dendritic	I-cell_type
cells	E-cell_type
(	O
DC	S-cell_type
)	O
are	O
phenotypically	O
and	O
functionally	O
identical	O
with	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
(	I-cell_type
PB	I-cell_type
)	I-cell_type
DC	E-cell_type
.	O

Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD-positive	O
.	O

In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL-2-producing	B-cell_type
cells	E-cell_type
and	O
a	O
significant	O
increase	O
in	O
well-differentiated	O
Th1	B-cell_type
cells	E-cell_type
that	O
produced	O
IFN-gamma	S-protein
but	O
not	O
IL-2	S-protein
were	O
evident	O
after	O
priming	O
with	O
anti-CD3	S-protein
and	O
anti-CD28	S-protein
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	S-protein
and	O
the	O
HsN3	B-protein
subunit	E-protein
of	O
the	O
human	B-protein
proteasome	E-protein
.	O

Some	O
mice	O
showed	O
marked	O
splenic	O
lymphocyte	O
depletion	O
.	O

Suppression	O
of	O
NF-kappaB	S-protein
activation	O
in	O
normal	B-cell_type
T	I-cell_type
cells	E-cell_type
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	S-protein
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	S-protein
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	E-protein
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	S-protein
and	O
that	O
phosphatase	S-protein
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	S-protein
to	O
CD40	S-protein
.	O

In	O
addition	O
,	O
the	O
Ets	S-protein
-	O
NF-kappaB	S-protein
/	O
NFAT	S-protein
interaction	O
requires	O
the	O
presence	O
of	O
DNA	B-DNA
binding	I-DNA
sites	E-DNA
for	O
both	O
proteins	O
,	O
as	O
it	O
is	O
abolished	O
by	O
the	O
DNA	O
intercalating	O
agents	O
propidium	O
iodide	O
and	O
ethidium	O
bromide	O
and	O
enhanced	O
by	O
the	O
presence	O
of	O
synthetic	O
oligonucleotides	O
containing	O
binding	B-DNA
sites	E-DNA
for	O
Ets	S-protein
and	O
NF-kappaB	B-protein
proteins	E-protein
.	O

Cross-linking	O
CD19	S-protein
on	O
early	O
human	B-cell_type
B	I-cell_type
lineage	I-cell_type
cells	E-cell_type
induces	O
the	O
formation	O
of	O
a	O
CD19/Vav/phosphatidylinositol-3	B-protein
kinase	I-protein
complex	E-protein
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	S-protein
and	O
Vav	S-protein
,	O
and	O
activation	O
of	O
the	O
Ras	S-protein
pathway	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	S-DNA
is	O
composed	O
of	O
adjacent	B-DNA
binding	I-DNA
sites	E-DNA
for	O
Ets	S-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	E-protein
.	O

Treatment	O
of	O
PAEC	S-cell_line
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF-kappa	B-protein
B	E-protein
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl-phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	S-cell_line
treated	O
with	O
human	O
serum	O
alone	O
.	O

The	O
B	B-protein
cell-specific	I-protein
cell	I-protein
surface	I-protein
molecule	I-protein
CD19	E-protein
is	O
expressed	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	O
with	O
cytoplasmic	B-protein
effector	I-protein
proteins	E-protein
.	O

At	O
least	O
four	O
distinct	O
genes	O
encode	O
the	O
various	O
family	O
members	O
,	O
and	O
several	O
isoforms	O
of	O
these	O
have	O
been	O
identified	O
as	O
well	O
.	O

However	O
,	O
binding	O
of	O
SHP2	S-protein
to	O
SIT	S-protein
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF-AT	S-protein
induction	O
,	O
suggesting	O
that	O
SIT	S-protein
not	O
only	O
regulates	O
NF-AT	S-protein
activity	O
but	O
also	O
controls	O
NF-AT	S-protein
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	S-protein
.	O

Initial	O
signaling	O
through	O
the	O
CD4	B-protein
receptor	E-protein
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV-infected	B-cell_type
T	I-cell_type
cells	E-cell_type
to	O
undergo	O
apoptosis	O
.	O

In	O
unstimulated	O
THP-1	S-cell_line
,	O
CRE-binding	B-protein
protein	E-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c-Jun	B-protein
complexes	E-protein
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	B-DNA
site	E-DNA
.	O

LPS-stimulated	B-cell_type
monocytes	E-cell_type
showed	O
an	O
increased	O
expression	O
of	O
p105	B-RNA
mRNA	E-RNA
,	O
the	O
precursor	O
of	O
the	O
p50	B-protein
subunit	E-protein
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
,	O
while	O
no	O
effect	O
was	O
noticed	O
on	O
the	O
expression	O
of	O
p65	B-RNA
mRNA	E-RNA
.	O

IFN-gamma	S-protein
priming	O
of	O
monocytes	S-cell_type
enhances	O
LPS-induced	O
TNF	S-protein
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

Inhibition	O
of	O
cyclooxygenase-2	S-protein
expression	O
by	O
4-trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
.	O

Monocytic	O
cell	O
adhesion	O
to	O
EC	S-cell_type
in	O
response	O
to	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha-thrombin	S-protein
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O

In	O
addition	O
to	O
the	O
CD11b	B-DNA
gene	E-DNA
,	O
the	O
homologous	O
genes	O
encoding	O
CD11a	S-protein
and	O
CD11c	S-protein
also	O
exhibit	O
inducible	O
expression	O
during	O
myeloid	O
differentiation	O
.	O

Continuous	O
treatment	O
of	O
monocytes	S-cell_type
with	O
IL-1beta	S-protein
,	O
but	O
not	O
with	O
TNF-alpha	S-protein
,	O
could	O
almost	O
completely	O
prevent	O
GC-induced	O
cell	O
death	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	B-cell_type
cells	E-cell_type
to	O
release	O
TNF-alpha	S-protein
after	O
triggering	O
of	O
HLA-DR	B-protein
antigens	E-protein
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF-alpha	S-protein
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B-cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	B-protein
surface	I-protein
HLA-DR	I-protein
antigens	E-protein
;	O
(	O
c	O
)	O
secreted	O
TNF-alpha	S-protein
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF-kappa	B-protein
B	E-protein
and	O
AP-1	S-protein
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF-alpha	S-protein
release	O
by	O
B	B-cell_type
cells	E-cell_type
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

However	O
other	O
possibilities	O
,	O
such	O
as	O
altered	O
distribution	O
of	O
lymphocyte	O
subpopulations	O
with	O
different	O
receptor	O
concentrations	O
and	O
with	O
different	O
cytokine	S-protein
production	O
,	O
can	O
not	O
be	O
excluded	O
.	O

Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	B-DNA
type	I-DNA
2	I-DNA
genome	E-DNA
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O

Flow	O
cytometry	O
showed	O
that	O
L-selectin	S-protein
was	O
expressed	O
on	O
fresh	O
ATL	B-cell_line
cells	E-cell_line
along	O
with	O
other	O
activation	B-protein
antigens	E-protein
.	O

Other	O
DNA	B-DNA
elements	E-DNA
present	O
include	O
a	O
cluster	O
of	O
Myb	B-DNA
sites	E-DNA
,	O
several	O
Ets	S-DNA
,	O
an	O
Ets	B-DNA
related	I-DNA
PU.1	I-DNA
site	E-DNA
and	O
an	O
Sp1	B-DNA
site	E-DNA
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	B-DNA
start	I-DNA
sites	E-DNA
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O

Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors	O
,	O
whereas	O
PMA-induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	S-cell_type
.	O

However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	S-DNA
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha-globin	B-DNA
promoter	E-DNA
retaining	O
this	O
region	O
.	O

Here	O
we	O
show	O
that	O
blockade	O
of	O
NF-kappaB	S-protein
activity	O
,	O
using	O
a	O
dominant	B-protein
negative	I-protein
IkappaBalpha	E-protein
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O

Furthermore	O
,	O
the	O
nuclear	B-protein
protein	I-protein
complexes	E-protein
binding	O
the	O
SRE	B-DNA
motif	E-DNA
induced	O
in	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	B-protein
response	I-protein
factor	E-protein
and	O
Elk-1	S-protein
pointing	O
toward	O
age-related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	E-protein
distinct	O
from	O
c-jun/AP-1	S-protein
.	O

ngal	O
gene	O
expression	O
was	O
found	O
at	O
moderate	O
levels	O
in	O
only	O
2	O
of	O
17	O
human	O
tissues	O
examined	O
,	O
breast	O
and	O
lung	O
.	O

Immunodepletion	O
studies	O
show	O
that	O
PTF	B-protein
beta	E-protein
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	B-DNA
genes	E-DNA
in	O
vitro	O
.	O

In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O

The	O
abnormal	O
adherence	O
of	O
sickle	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	E-cell_type
(	O
SS	B-cell_type
RBC	E-cell_type
)	O
to	O
endothelial	B-cell_type
cells	E-cell_type
has	O
been	O
thought	O
to	O
contribute	O
to	O
vascular	O
occlusion	O
,	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
.	O

These	O
studies	O
have	O
indicated	O
that	O
the	O
individual	O
repeats	O
are	O
not	O
identical	O
with	O
respect	O
to	O
the	O
cellular	B-protein
factors	E-protein
with	O
which	O
they	O
interact	O
.	O

The	O
third	O
member	O
of	O
the	O
family	S-protein
,	O
A-myb	S-protein
,	O
shows	O
the	O
most	O
restricted	O
pattern	O
of	O
expression	O
,	O
suggesting	O
a	O
very	O
specific	O
role	O
for	O
this	O
transcription	B-protein
factor	E-protein
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	S-protein
or	O
alkaline	B-protein
phosphatase	E-protein
restores	O
NFATp	S-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	E-protein
with	O
Fos	S-protein
and	O
Jun	S-protein
proteins	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c-jun	B-DNA
gene	E-DNA
is	O
autoinduced	O
by	O
Jun/AP-1	S-protein
,	O
we	O
also	O
studied	O
transcription	O
of	O
c-jun	B-DNA
promoter	I-DNA
(	I-DNA
positions	I-DNA
-132/+170	I-DNA
)	I-DNA
-reporter	I-DNA
gene	I-DNA
constructs	E-DNA
with	O
and	O
without	O
a	O
mutated	O
AP-1	B-DNA
element	E-DNA
.	O

Transcriptional	O
down-regulation	O
of	O
c-myc	S-DNA
expression	O
by	O
protein	O
synthesis-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

Modulation	O
of	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	E-protein
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

Long-lasting	O
IL-2	S-protein
receptivity	O
is	O
associated	O
with	O
high-level	O
expression	O
of	O
the	O
inducible	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	E-DNA
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Demonstration	O
of	O
a	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3-responsive	I-protein
protein	E-protein
in	O
human	B-cell_type
lymphocytes	E-cell_type
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	B-protein
D	I-protein
receptor	E-protein
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	B-DNA
'	I-DNA
polyA	I-DNA
site	E-DNA
to	O
a	O
more	O
proximal	B-DNA
polyA	I-DNA
site	E-DNA
,	O
NF-ATc	S-protein
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	B-cell_type
T	I-cell_type
cells	E-cell_type
to	O
that	O
of	O
short	O
isoform	B-protein
A	E-protein
in	O
T	B-cell_type
effector	I-cell_type
cells	E-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	B-protein
factors	E-protein
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Indeed	O
,	O
the	O
combination	O
of	O
NE	S-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	E-protein
increased	O
the	O
binding	O
of	O
PAC-1	S-protein
approximately	O
5.5-fold	O
over	O
basal	O
values	O
measured	O
on	O
nontreated	B-cell_type
platelets	E-cell_type
,	O
whereas	O
this	O
binding	O
raised	O
only	O
by	O
approximately	O
3-fold	O
in	O
threshold	O
of	O
cathepsin	B-cell_type
G-stimulated	I-cell_type
platelets	E-cell_type
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA-associated	B-protein
proteins	E-protein
and	O
T	B-cell_type
cells	E-cell_type
recognizing	O
T	B-protein
antigen	E-protein
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B-protein
ag	E-protein
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O

Here	O
we	O
demonstrate	O
that	O
B-1	B-cell_type
lymphocytes	E-cell_type
constitutively	O
express	O
nuclear	B-protein
activated	I-protein
STAT3	E-protein
,	O
which	O
is	O
not	O
expressed	O
by	O
unmanipulated	B-cell_type
conventional	I-cell_type
(	I-cell_type
B-2	I-cell_type
)	I-cell_type
lymphocytes	E-cell_type
.	O

RelA	S-protein
(	O
p65	S-protein
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	B-protein
p50-p65	I-protein
NF-kappa	I-protein
B	I-protein
complex	E-protein
and	O
contains	O
a	O
high-affinity	B-protein
binding	I-protein
site	E-protein
for	O
its	O
cytoplasmic	B-protein
inhibitor	E-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
.	O

Aging	O
is	O
classically	O
accompanied	O
by	O
a	O
dysregulation	O
of	O
the	O
immunologic	O
machinery	O
.	O

Transcriptional	O
control	O
by	O
META	S-DNA
parallels	O
that	O
of	O
several	O
lymphokine	B-DNA
genes	E-DNA
,	O
being	O
specific	O
to	O
T	B-cell_type
cells	E-cell_type
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

This	O
is	O
the	O
first	O
non-mammalian	B-DNA
cytokine	I-DNA
gene	E-DNA
to	O
be	O
mapped	O
.	O

Anti-TNF-alpha	S-protein
also	O
prevented	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O

Chloramphenicol	B-protein
acetyltransferase	E-protein
(	O
CAT	S-protein
)	O
activities	O
directed	O
by	O
5	B-DNA
'	I-DNA
upstream	I-DNA
promoter	E-DNA
were	O
detected	O
preferentially	O
in	O
perforin-expressing	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

ETS1	S-protein
transactivates	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	E-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

After	O
stimulation	O
of	O
progesterone	O
the	O
expression	O
of	O
receptors	O
was	O
augmented	O
2-3	O
times	O
.	O

If	O
they	O
can	O
not	O
,	O
chimeric	B-protein
proteins	E-protein
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O

We	O
have	O
shown	O
that	O
the	O
apparent	O
binding	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	E-protein
in	O
squirrel	B-cell_type
monkey	I-cell_type
lymphocytes	E-cell_type
is	O
5-fold	O
lower	O
than	O
that	O
in	O
human	B-cell_type
lymphocytes	E-cell_type
(	O
apparent	O
Kd	O
,	O
20.9	O
+/-	O
1.8	O
and	O
4.3	O
+/-	O
0.2	O
nmol/L	O
,	O
respectively	O
;	O
n	O
=	O
3	O
)	O
,	O
consistent	O
with	O
previous	O
studies	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
isolated	O
from	O
the	O
two	O
species	O
.	O

Moreover	O
,	O
using	O
a	O
heterologous	B-DNA
promoter	I-DNA
(	I-DNA
herpes	I-DNA
thymidine	I-DNA
kinase	I-DNA
)	I-DNA
construct	E-DNA
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
consensus	I-DNA
sequence	E-DNA
,	O
it	O
is	O
shown	O
that	O
NF-kappa	B-protein
B	E-protein
binding	O
by	O
an	O
IL-2-induced	B-protein
monocyte-derived	I-protein
nuclear	I-protein
protein	E-protein
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
Tax	S-protein
stimulates	O
RNA	B-DNA
polymerase	I-DNA
III-dependent	I-DNA
gene	E-DNA
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	B-protein
initiation	I-protein
complex	E-protein
assembly	O
.	O

IL-2	S-protein
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	B-DNA
segment	E-DNA
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	E-DNA
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	S-cell_type
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

Members	O
of	O
this	O
group	O
have	O
three	B-protein
tetraproline	I-protein
repeats	E-protein
.	O

Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	O
LPS-induced	O
TF	O
activity	O
of	O
human	B-cell_type
monocytes	E-cell_type
.	O

Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	B-cell_type
cells	E-cell_type
recognize	O
the	O
SL3	B-DNA
core	E-DNA
remains	O
to	O
be	O
elucidated	O
.	O

Patients	O
with	O
GC-insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta-immunoreactive	B-cell_type
cells	E-cell_type
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC-sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O

One	O
protein	O
,	O
NF-GM2	S-protein
is	O
similar	O
to	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	E-protein
.	O

PKC-zeta	B-cell_line
cells	E-cell_line
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	B-protein
enzyme	E-protein
activities	O
and	O
were	O
distinct	O
from	O
parental	B-cell_line
U937	I-cell_line
cells	E-cell_line
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

Autocrine	O
activation	O
by	O
interferon-gamma	S-protein
of	O
STAT	B-protein
factors	E-protein
following	O
T	O
cell	O
activation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant-based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

In	O
this	O
communication	O
,	O
we	O
present	O
evidence	O
to	O
show	O
that	O
these	O
proteins	O
inhibit	O
tumor	O
cell	O
proliferation	O
by	O
participating	O
in	O
the	O
activation	O
of	O
tumor	O
cell	O
differentiation	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	B-protein
factor	E-protein
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	S-cell_type
and	O
macrophages	S-cell_type
as	O
a	O
DNA-binding	B-protein
protein	E-protein
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O

The	O
native	O
peptide	O
VP16	O
430-444	O
contains	O
an	O
Asp	O
at	O
position	B-protein
442	E-protein
,	O
binds	O
to	O
DQ0302	O
strongly	O
,	O
with	O
a	O
Kd	O
value	O
of	O
50nM	O
at	O
acidic	O
pH	O
and	O
very	O
weakly	O
,	O
with	O
a	O
Kd	O
value	O
of	O
greater	O
than	O
10	O
microM	O
at	O
neutral	O
pH	O
.	O

The	O
physiological	O
significance	O
and	O
possible	O
clinical	O
relevance	O
of	O
the	O
variant	O
ER	S-protein
forms	O
remain	O
to	O
be	O
elucidated	O
.	O

These	O
data	O
indicate	O
that	O
TNFalpha	S-protein
induces	O
a	O
delayed	O
ROS-dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF-kappaB	S-protein
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O

We	O
focused	O
on	O
the	O
contribution	O
of	O
two	O
major	O
products	O
of	O
activated	O
monocytes	S-cell_type
,	O
prostaglandin	O
E2	O
and	O
interleukin	B-protein
1beta	E-protein
(	O
IL-1beta	S-protein
)	O
,	O
to	O
the	O
MCM	O
modulatory	O
action	O
.	O

We	O
found	O
that	O
treatment	O
with	O
dexamethasone	O
induced	O
eosinophil	S-cell_type
apoptosis	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	B-RNA
mRNA	E-RNA
and	O
secretion	O
(	O
85	O
+/-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+/-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+/-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin-stimulated	B-cell_line
THP-1	E-cell_line
,	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

We	O
have	O
recently	O
described	O
an	O
inherited	O
over-expression	O
of	O
the	O
macrophage	B-protein
scavenger	I-protein
receptor	E-protein
(	O
SR	S-protein
)	O
in	O
blood	B-cell_type
monocytes	E-cell_type
from	O
members	O
of	O
a	O
kindred	O
,	O
only	O
two	O
of	O
whom	O
displayed	O
extensive	O
xanthomatosis	O
.	O

The	O
binding	O
of	O
the	O
mAECA	S-protein
to	O
human	B-cell_type
aortic	I-cell_type
EC	E-cell_type
was	O
studied	O
by	O
immunohistochemistry	O
.	O

Transcription	O
factor	O
jun-B	O
is	O
target	O
of	O
autoreactive	B-cell_type
T-cells	E-cell_type
in	O
IDDM	O
.	O

No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA-1	S-protein
can	O
transactivate	O
the	O
EpoR	B-DNA
promoter	E-DNA
,	O
the	O
level	O
of	O
hEpoR	B-DNA
gene	E-DNA
expression	O
does	O
not	O
depend	O
on	O
GATA-1	S-protein
alone	O
.	O

The	O
results	O
define	O
the	O
rhombotin	S-DNA
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	B-DNA
oncogenes	E-DNA
with	O
duplicated	O
cysteine-rich	B-DNA
LIM	I-DNA
domains	E-DNA
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	S-protein
activation	O
of	O
NF-kappa	B-protein
B/Rel	E-protein
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
and	O
RelA	S-protein
(	O
p65	S-protein
)	O
-mediated	O
induction	O
of	O
the	O
c-rel	B-DNA
gene	E-DNA
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	B-cell_type
,	I-cell_type
immature	I-cell_type
cells	E-cell_type
expresses	O
CD21	S-protein
.	O

That	O
is	O
,	O
a	O
dominant	B-protein
negative	I-protein
GSK-3beta	E-protein
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	S-protein
)	O
that	O
inhibit	O
GSK-3beta	S-protein
activity	O
also	O
do	O
not	O
activate	O
Tcf	B-DNA
reporter	I-DNA
genes	E-DNA
.	O

Moreover	O
,	O
Elf-1	S-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	B-protein
cell-specific	I-protein
coactivators	E-protein
.	O

AML1a	S-protein
but	O
not	O
AML1b	S-protein
inhibits	O
erythroid	O
differentiation	O
induced	O
by	O
sodium	O
butyrate	O
and	O
enhances	O
the	O
megakaryocytic	O
differentiation	O
of	O
K562	B-cell_type
leukemia	I-cell_type
cells	E-cell_type
.	O

Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	B-DNA
gene	E-DNA
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi-1	S-protein
,	O
Fli-1	S-protein
,	O
and	O
megakaryocytic	B-DNA
genes	E-DNA
in	O
an	O
erythropoietin	S-protein
-dependent	O
manner	O
.	O

The	O
3'-CAGGTG	B-DNA
E-box	E-DNA
could	O
bind	O
USF	B-protein
proteins	E-protein
,	O
the	O
ubiquitous	B-protein
repressor	I-protein
ZEB	E-protein
,	O
or	O
the	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
E2A	E-protein
and	O
HEB	S-protein
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	S-protein
and	O
E2A/HEB	B-protein
proteins	E-protein
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

Tax-expressing	B-cell_line
cell	I-cell_line
lines	E-cell_line
produce	O
LT	S-protein
biologic	O
activity	O
.	O

Whereas	O
GRalpha	S-protein
is	O
a	O
hormone-activated	O
transcription	B-protein
factor	E-protein
,	O
GRbeta	S-protein
does	O
not	O
bind	O
glucocorticoids	O
(	O
GCs	O
)	O
,	O
is	O
transcriptionally	O
inactive	O
,	O
and	O
is	O
a	O
potential	O
inhibitor	O
of	O
activated	O
GRalpha	S-protein
.	O

Abundant	O
expression	O
of	O
erythroid	B-RNA
transcription	I-RNA
factor	I-RNA
P45	I-RNA
NF-E2	I-RNA
mRNA	E-RNA
in	O
human	B-cell_type
peripheral	I-cell_type
granurocytes	E-cell_type
.	O

This	O
sequence	B-DNA
motif	E-DNA
is	O
a	O
binding	O
site	O
for	O
nuclear	B-protein
proteins	E-protein
,	O
the	O
so-called	O
octamer	B-protein
transcription	I-protein
factors	E-protein
(	O
Oct	S-protein
or	O
OTF	B-protein
factors	E-protein
)	O
.	O

This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13-myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O

Interleukin-6	S-protein
(	O
IL-6	S-protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

ZEBRA	S-protein
is	O
also	O
indispensable	O
for	O
viral	O
replication	O
and	O
binds	O
directly	O
to	O
the	O
EBV	O
lytic	O
origin	O
of	O
replication	O
.	O

Pretreatment	O
of	O
cells	O
with	O
vanadate	O
prevented	O
the	O
effects	O
of	O
PMA	O
with	O
regard	O
to	O
PMA-induced	O
Tyk2	S-protein
dephosphorylation	O
.	O

Increased	O
activity	O
of	O
various	O
proteases	S-protein
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O

Responses	O
of	O
PBMC	S-cell_type
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate/marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B-protein
receptor	E-protein
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Using	O
hPR	B-DNA
cDNA	I-DNA
region-specific	I-DNA
probes	E-DNA
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	B-DNA
G	E-DNA
of	O
the	O
hPR	B-DNA
gene	E-DNA
.	O

We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	O
of	O
the	O
human	B-protein
p75TNF-R	E-protein
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF-kappaB	S-protein
activity	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	E-cell_type
compartment	O
.	O

Induction	O
of	O
relA	B-protein
(	I-protein
p65	I-protein
)	E-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
subunit	E-protein
expression	O
during	O
differentiation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	E-cell_type
to	O
macrophages	S-cell_type
.	O

Here	O
we	O
describe	O
an	O
alternative	O
approach	O
,	O
based	O
on	O
in	O
vitro	O
stimulation	O
with	O
epitope	B-cell_line
peptide-loaded	I-cell_line
dendritic	I-cell_line
cells	E-cell_line
(	O
DCs	S-cell_line
)	O
,	O
which	O
allows	O
one	O
to	O
probe	O
the	O
CTL	O
repertoire	O
for	O
any	O
individual	O
reactivity	O
of	O
choice	O
;	O
this	O
method	O
proved	O
significantly	O
more	O
efficient	O
than	O
stimulation	O
with	O
peptide	O
alone	O
.	O

[	O
Glucocorticoid	B-protein
receptors	E-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptors	E-protein
(	O
PPAR	S-protein
)	O
control	O
discrete	O
genes	O
involved	O
in	O
fatty	O
acid	O
and	O
lipid	O
metabolism	O
.	O

Moreover	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
level	O
of	O
STAT3	S-protein
phosphorylation	O
is	O
balanced	O
between	O
a	O
staurosporine-sensitive	B-protein
kinase	E-protein
(	O
s	O
)	O
and	O
PP2A	S-protein
.	O

Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
K562	E-cell_line
.	O

These	O
data	O
demonstrate	O
that	O
the	O
15-amino	B-protein
acid	I-protein
sequence	E-protein
of	O
NFATx1	S-protein
is	O
a	O
major	B-protein
transactivation	I-protein
sequence	E-protein
required	O
for	O
induction	O
of	O
genes	O
by	O
NFATx1	S-protein
in	O
T	B-cell_type
cells	E-cell_type
and	O
possibly	O
regulates	O
NFAT	S-protein
activity	O
through	O
tissue-specific	O
alternative	O
splicing	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	B-DNA
box	I-DNA
sequence	E-DNA
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	B-DNA
expression	I-DNA
vector	E-DNA
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	B-DNA
sequence	E-DNA
in	O
HeLa	B-cell_line
cells	E-cell_line
.	O

Thrombopoietin	S-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Stat3	S-protein
and	O
Stat5	S-protein
in	O
human	B-cell_type
blood	I-cell_type
platelets	E-cell_type
.	O

Finally	O
,	O
receptor	O
clusters	O
colocalized	O
with	O
ezrin/moesin/radixin	B-protein
proteins	E-protein
.	O

In	O
addition	O
,	O
cell-free	B-protein
synthesized	I-protein
hGR	E-protein
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
GRE	I-DNA
)	I-DNA
-containing	I-DNA
DNA	I-DNA
fragments	E-DNA
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	S-protein
content	O
in	O
lymphocytes	S-cell_type
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B-protein
protein	E-protein
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	B-DNA
box	E-DNA
,	O
but	O
potential	O
sites	O
for	O
CCAAT-box	B-protein
binding	I-protein
factors	E-protein
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	B-DNA
repeat	I-DNA
element	E-DNA
.	O

Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	B-cell_line
cells	E-cell_line
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	B-cell_type
cells	E-cell_type
.	O

BSAP	S-protein
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell-specific	O
regulation	O
of	O
the	O
blk	S-DNA
gene	O
.	O

TRAMP	S-protein
,	O
a	O
novel	O
apoptosis-mediating	B-protein
receptor	E-protein
with	O
sequence	O
homology	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
1	E-protein
and	O
Fas	S-protein
(	O
Apo-1/CD95	S-protein
)	O
.	O

To	O
understand	O
the	O
role	O
of	O
MARs	S-protein
in	O
IgH	B-DNA
enhancer	E-DNA
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR-binding	B-protein
protein	E-protein
,	O
MAR-BP1	S-protein
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	S-protein
associated	O
with	O
the	O
IgH	B-DNA
enhancer	E-DNA
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	S-protein
,	O
while	O
human	B-protein
beta-globin	E-protein
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma-globin	B-RNA
transcripts	E-RNA
are	O
elevated	O
approximately	O
5-fold	O
.	O

Androgen	B-RNA
receptor	I-RNA
mRNA	E-RNA
was	O
translated	O
in	O
vitro	O
,	O
and	O
androgen-	B-protein
and	I-protein
antiandrogen-bound	I-protein
receptor	I-protein
complexes	E-protein
were	O
studied	O
using	O
limited	O
proteolytic	O
digestion	O
by	O
trypsin	S-protein
.	O

Thus	O
,	O
although	O
the	O
kappa	B-DNA
3	I-DNA
element	E-DNA
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp-binding	B-DNA
sites	E-DNA
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin-sensitive	B-DNA
promoter	I-DNA
element	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	S-protein
.	O

RXR	S-protein
,	O
RAR	S-protein
,	O
and	O
c-erbA/TR	S-protein
-specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid-specific	B-DNA
gene	E-DNA
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O

Regulation	O
of	O
NF-kappa	B-protein
B	E-protein
activity	O
by	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
stability	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	S-cell_type
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	E-protein
in	O
the	O
N9	B-cell_line
murine	I-cell_line
microglial	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	S-protein
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

2	O
.	O

Polyubiquitinylated	O
c-Jun	S-protein
,	O
wbFos	S-protein
,	O
and	O
wbJun	S-protein
,	O
but	O
not	O
E220K-ubiquitinylated	B-protein
c-Jun	E-protein
,	O
were	O
readily	O
degraded	O
by	O
the	O
ATP-dependent	B-protein
26	I-protein
S	I-protein
multicatalytic	I-protein
proteases	E-protein
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B-protein
neutralizing	I-protein
antibodies	E-protein
.	O

TCR	S-protein
affinities	O
were	O
then	O
indirectly	O
estimated	O
by	O
blocking	O
CD8	S-protein
interaction	O
with	O
an	O
anti-CD8	B-protein
mAb	E-protein
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	B-protein
domain	E-protein
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3K	S-protein
are	O
not	O
known	O
.	O

In	O
NK3.3	B-cell_line
cells	E-cell_line
,	O
IL-2	S-protein
induced	O
comparable	O
formation	O
of	O
c-fos	B-protein
promoter	I-protein
sis-inducible	I-protein
element	I-protein
IFN-gamma-activated	I-protein
sequence-binding	I-protein
complexes	E-protein
containing	O
STAT3	S-protein
alone	O
with	O
complexes	O
containing	O
STAT3	S-protein
and	O
STAT1	B-protein
alpha	E-protein
,	O
while	O
in	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
cells	E-cell_line
,	O
it	O
preferentially	O
induced	O
complexes	O
containing	O
STAT3	S-protein
and	O
STAT1	B-protein
alpha	E-protein
.	O

CD30	S-protein
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)	O
-1	O
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-dependent	O
cell-free	O
activation	O
system	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
phosphorylation	O
.	O

M0/M1	B-cell_line
leukemic	I-cell_line
cells	E-cell_line
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	B-cell_line
leukemic	I-cell_line
cells	E-cell_line
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
activated	O
HLA-DRA	S-protein
expression	O
in	O
response	O
to	O
TPA	O
treatment	O
is	O
strictly	O
dependent	O
on	O
PKC	S-protein
activation	O
acting	O
on	O
the	O
X2	B-DNA
box	E-DNA
of	O
the	O
DRA	B-DNA
promoter	E-DNA
and	O
that	O
selective	O
inhibition	O
of	O
PKC	S-protein
enzymatic	O
activity	O
does	O
not	O
influence	O
subcellular	O
localization	O
of	O
expressed	O
PKC	B-protein
isoenzymes	E-protein
.	O

Using	O
deletion	B-DNA
mutants	E-DNA
,	O
the	O
downstream	O
parathyroid	B-DNA
hormone-related	I-DNA
protein	I-DNA
(	I-DNA
PTHrP	I-DNA
)	I-DNA
promoter	E-DNA
is	O
shown	O
to	O
be	O
responsive	O
to	O
both	O
HTLV-I	B-protein
and	I-protein
HTLV-II	I-protein
Tax	E-protein
as	O
well	O
as	O
the	O
AP1/c-jun	B-DNA
proto-oncogene	E-DNA
.	O

ML-9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	B-cell_line
cells	E-cell_line
but	O
increased	O
the	O
expression	O
of	O
monocyte-macrophage	B-protein
lineage-associated	I-protein
surface	I-protein
antigen	E-protein
,	O
CD14	S-protein
,	O
to	O
some	O
extent	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus-encoded	I-protein
dUTPase	E-protein
:	O
patients	O
with	O
acute	O
,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	S-protein
against	O
the	O
enzyme	S-protein
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-protein
receptor	E-protein
characteristics	O
on	O
mononuclear	B-cell_type
leukocytes	E-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-protein
receptor	E-protein
activation	O
.	O

Fab	O
fragment	O
of	O
anti-E.	B-protein
chaffeensis	I-protein
immunoglobulin	I-protein
G	E-protein
complexed	O
with	O
E.	O
chaffeensis	O
did	O
not	O
induce	O
any	O
of	O
these	O
three	O
cytokines	O
,	O
indicating	O
that	O
ehrlichial	O
binding	O
is	O
required	O
for	O
IL-1beta	B-RNA
mRNA	E-RNA
expression	O
and	O
that	O
binding	O
of	O
the	O
immune	B-protein
complex	E-protein
to	O
the	O
Fc	B-protein
gamma	I-protein
receptor	E-protein
is	O
required	O
for	O
TNF-alpha	S-protein
and	O
IL-6	B-RNA
mRNA	E-RNA
expression	O
and	O
enhanced	O
IL-1beta	B-RNA
mRNA	E-RNA
expression	O
.	O

Smad6	S-protein
and	O
Smad7	S-protein
prevent	O
ligand-induced	O
activation	O
of	O
signal-transducing	B-protein
Smad	I-protein
proteins	E-protein
in	O
the	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
family	E-protein
.	O

In	O
addition	O
,	O
negative	O
correlations	O
were	O
observed	O
between	O
FECa2+	O
in	O
the	O
dense	O
tubules	O
and	O
age	O
.	O

CD40	S-protein
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	B-cell_type
marrow-derived	I-cell_type
cells	E-cell_type
.	O

Increased	O
expression	O
of	O
Egr-1	S-protein
was	O
observed	O
with	O
macrophage	O
differentiation	O
.	O

We	O
expressed	O
these	O
factors	O
in	O
S.	O
cerevisiae	O
and	O
observed	O
greater	O
than	O
5-fold	O
stimulation	O
of	O
a	O
lacZ	B-DNA
reporter	I-DNA
gene	E-DNA
only	O
with	O
Oct-2	S-protein
.	O

Activation	O
of	O
T	B-cell_type
cells	E-cell_type
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	B-cell_type
presenting	I-cell_type
cells	E-cell_type
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

HIV	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	E-cell_type
stimulated	O
with	O
CD3/CD28	S-protein
.	O

We	O
have	O
found	O
that	O
Bcl-2	S-protein
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	S-protein
and	O
blocks	O
paclitaxel-induced	O
apoptosis	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	B-DNA
3	I-DNA
'	I-DNA
regions	E-DNA
acting	O
as	O
a	O
Locus	B-DNA
Control	I-DNA
Region	E-DNA
(	O
LCR	S-DNA
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	B-DNA
locus	E-DNA
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	S-DNA
activity	O
.	O

One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	B-protein
zinc	I-protein
finger	I-protein
protein	E-protein
was	O
found	O
to	O
derepress	O
beta-galactosidase	S-protein
activity	O
in	O
the	O
Oct-2	S-protein
-harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O

Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	O
in	O
VDR	S-protein
levels	O
was	O
associated	O
with	O
a	O
2-fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	O
in	O
c-myc	B-RNA
mRNA	E-RNA
expression	O
.	O

NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
by	O
cycloheximide	O
,	O
double-stranded	B-RNA
RNA	E-RNA
,	O
calcium	O
ionophore	O
,	O
TNF-alpha	S-protein
,	O
active	O
phorbol	O
ester	O
,	O
interleukin-1	S-protein
,	O
lipopolysaccharide	O
and	O
lectin	S-protein
.	O

5'HS3	S-DNA
contains	O
six	O
G-rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O

Lactobacilli	O
also	O
increased	O
tumor	B-protein
necrosis	I-protein
factor	E-protein
-alphaand	O
interleukin	S-protein
-1betaproduction	O
and	O
activated	O
NF-kappaB	S-protein
in	O
THP-1	B-protein
cells	E-protein
and	O
increased	O
tumor	B-protein
necrosis	I-protein
factor	E-protein
-alphaproduction	O
by	O
human	B-cell_type
monocytes	E-cell_type
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

A	O
novel	O
DNA	B-DNA
sequence	I-DNA
element	E-DNA
termed	O
the	O
J	B-DNA
element	E-DNA
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	E-DNA
was	O
recently	O
described	O
.	O

A	O
4-bp	O
mutation	O
of	O
the	O
core	B-DNA
Sp1	I-DNA
consensus	I-DNA
element	E-DNA
(	O
GC	B-DNA
box	E-DNA
)	O
(	O
-20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1-kb	B-DNA
fragment	E-DNA
.	O

Mutational	O
analyses	O
of	O
the	O
HIV-1	B-DNA
LTR	E-DNA
showed	O
that	O
one	O
C/EBP	B-DNA
site	E-DNA
is	O
required	O
for	O
normal	O
LTR	S-DNA
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C/EBP	B-DNA
sites	E-DNA
are	O
functionally	O
equivalent	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	B-protein
alpha	E-protein
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	B-protein
alpha	E-protein
through	O
distinct	O
pathways	O
.	O

Protein	B-protein
kinase	I-protein
C	E-protein
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	S-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	S-protein
,	O
and	O
inducible	O
NFkappaB	S-protein
and	O
AP1	S-protein
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	B-protein
complex	E-protein
in	O
activated	O
T	B-cell_type
cells	E-cell_type
.	O

However	O
,	O
this	O
region	O
directed	O
extremely	O
low	O
reporter	O
mRNA	O
levels	O
relative	O
to	O
endogenous	O
IL-4	B-RNA
mRNA	E-RNA
,	O
suggesting	O
that	O
full	O
gene	O
activity	O
requires	O
additional	O
enhancer	B-DNA
elements	E-DNA
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	S-protein
knockout	O
mice	O
have	O
no	O
dendritic	B-cell_type
cells	E-cell_type
(	O
DC	S-cell_type
)	O
.	O

Although	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-12	E-protein
was	O
originally	O
purified	O
from	O
an	O
Epstein-Barr	B-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
B	I-cell_line
cell	I-cell_line
line	E-cell_line
and	O
the	O
high	O
correlation	O
of	O
EBV	O
infection	O
and	O
IL-12	S-protein
expression	O
has	O
been	O
suggested	O
,	O
no	O
study	O
has	O
reported	O
whether	O
EBV	O
infection	O
is	O
directly	O
linked	O
to	O
IL-12	S-protein
expression	O
.	O

In	O
monocytes	S-cell_type
,	O
the	O
nuclear	B-protein
factor	I-protein
NF-kappa	I-protein
B	E-protein
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	B-protein
factor	E-protein
in	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	E-DNA
,	O
of	O
cell-surface	B-protein
receptors	E-protein
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	E-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	E-cell_line
to	O
NK	B-cell_type
cells	E-cell_type
.	O

In	O
comparison	O
to	O
K562	S-cell_line
,	O
nucleated	B-cell_line
erythroblasts	E-cell_line
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	B-protein
factor	E-protein
binding	O
in	O
vivo	O
at	O
the	O
HS-40	S-DNA
region	O
.	O

The	O
pAT	B-DNA
133	I-DNA
gene	E-DNA
is	O
immediately	O
induced	O
,	O
with	O
FOS	S-protein
-like	O
kinetics	O
,	O
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
in	O
fibroblasts	S-cell_type
.	O

HIV-1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low-level	O
expression	O
of	O
type	B-protein
1	I-protein
interferon	E-protein
(	O
IFN	S-protein
)	O
at	O
the	O
mRNA	O
level	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

However	O
,	O
B	B-cell_type
cells	E-cell_type
can	O
also	O
synthesize	O
IL-2	S-protein
.	O

Eosinophils	S-cell_type
play	O
an	O
important	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
inflammation	O
.	O

Interestingly	O
,	O
while	O
increases	O
in	O
both	O
IL-1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	B-cell_type
monocytes	E-cell_type
,	O
cytoplasmic	O
levels	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	E-RNA
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	E-RNA
did	O
not	O
.	O

Similarly	O
,	O
IL-2	S-protein
neither	O
activates	O
JNK	S-protein
nor	O
increases	O
AP-1	S-protein
binding	O
activity	O
to	O
a	O
consensus	O
o-tetradecanoylphorbol	B-DNA
13-acetate	I-DNA
(	I-DNA
TPA	I-DNA
)	I-DNA
response	I-DNA
element	E-DNA
.	O

Estrogen	B-protein
receptors	E-protein
influence	O
non-genomic	O
events	O
,	O
which	O
are	O
rapid	O
in	O
onset	O
and	O
genomic	O
events	O
,	O
which	O
are	O
longer	O
acting	O
responses	O
.	O

An	O
association	O
between	O
hSIE	S-DNA
and	O
Stat-3	S-protein
after	O
MHC-I	S-protein
ligation	O
was	O
directly	O
demonstrated	O
by	O
precipitating	O
Stat-3	S-protein
from	O
nuclear	O
extracts	O
with	O
biotinylated	O
hSIE	B-DNA
probe	E-DNA
and	O
avidin	S-protein
-coupled	O
agarose	O
.	O

Cross	O
talk	O
between	O
cell	O
death	O
and	O
cell	O
cycle	O
progression	O
:	O
BCL-2	S-protein
regulates	O
NFAT	S-protein
-mediated	O
activation	O
.	O

The	O
glucocorticoid	B-protein
receptor	E-protein
cooperates	O
with	O
the	O
erythropoietin	B-protein
receptor	E-protein
and	O
c-Kit	S-protein
to	O
enhance	O
and	O
sustain	O
proliferation	O
of	O
erythroid	B-cell_type
progenitors	E-cell_type
in	O
vitro	O
.	O

We	O
analyzed	O
the	O
activation	O
of	O
STATs	S-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
and	I-cell_type
NK	I-cell_type
cells	E-cell_type
by	O
a	O
variety	O
of	O
specific	O
cytokines	S-protein
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

The	O
function	O
of	O
LEF-1	S-protein
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B-protein
domain	E-protein
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B-protein
domain	E-protein
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer-binding	B-protein
proteins	E-protein
.	O

Induction	O
of	O
Mn	B-protein
SOD	E-protein
in	O
human	B-cell_type
monocytes	E-cell_type
without	O
inflammatory	B-protein
cytokine	E-protein
production	O
by	O
a	O
mutant	B-protein
endotoxin	E-protein
.	O

Electrophoretic	O
mobility-shift	O
assays	O
of	O
HUVEC	B-protein
nuclear	I-protein
proteins	E-protein
revealed	O
a	O
decrease	O
in	O
TNF-alpha-stimulated	B-protein
nuclear	I-protein
factor-kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	S-cell_line
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O

These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF-kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O

Analogs	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Endothelial	B-cell_type
cells	E-cell_type
(	O
EC	S-cell_type
)	O
act	O
as	O
APC	O
for	O
resting	B-cell_type
PBL	E-cell_type
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B-protein
weight	I-protein
species	I-protein
of	I-protein
24	I-protein
and	I-protein
22	I-protein
kDa	E-protein
.	O

Transcription	O
from	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	E-DNA
was	O
inhibited	O
when	O
either	O
the	O
Elf-1	B-DNA
or	I-DNA
the	I-DNA
HMG-I	I-DNA
(	I-DNA
Y	I-DNA
)	I-DNA
binding	I-DNA
site	E-DNA
was	O
mutated	O
.	O

Furthermore	O
,	O
longer-term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	B-cell_line
human	I-cell_line
monocyte-derived	I-cell_line
M	I-cell_line
phi	E-cell_line
,	O
with	O
greater	O
increases	O
in	O
5-day	O
M	B-cell_line
phi	E-cell_line
uptake	O
of	O
apoptotic	B-cell_type
cells	E-cell_type
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	B-cell_line
phi	E-cell_line
.	O

The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	B-protein
receptors	E-protein
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O

Thus	O
,	O
in	O
HIV	O
infection	O
,	O
elevated	O
cortisol	O
levels	O
suppress	O
cell-mediated	O
immunity	O
and	O
stimulate	O
humoral	O
immunity	O
,	O
whereas	O
this	O
response	O
is	O
not	O
detected	O
in	O
cortisol-resistant	O
patients	O
.	O

The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL-4	S-protein
and	O
IL-13	S-protein
on	O
HIV	O
infection	O
in	O
human	B-cell_type
monocytes	E-cell_type
as	O
they	O
matured	O
into	O
monocyte-derived	B-cell_type
macrophages	E-cell_type
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV-1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O

The	O
interaction	O
between	O
lymphoid	B-cell_type
and	I-cell_type
prostatic	I-cell_type
cells	E-cell_type
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	B-cell_type
cells	E-cell_type
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	B-protein
GATA-4	E-protein
(	O
hGATA-4	S-protein
)	O
and	O
show	O
that	O
hGATA-4	S-protein
selectively	O
interacts	O
with	O
the	O
-70	B-DNA
GATA	I-DNA
site	E-DNA
within	O
the	O
IL-5	B-DNA
proximal	I-DNA
promoter	I-DNA
region	E-DNA
.	O

Our	O
results	O
point	O
to	O
an	O
important	O
difference	O
between	O
antiandrogens	O
and	O
antagonists	O
of	O
other	O
steroid	B-protein
hormone	I-protein
receptors	E-protein
.	O

Transforming	B-protein
growth	I-protein
factor-beta	E-protein
suppresses	O
human	B-protein
B	I-protein
lymphocyte	I-protein
Ig	E-protein
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	E-RNA
to	O
the	O
secreted	B-RNA
form	E-RNA
of	O
Ig	B-RNA
mRNA	E-RNA
.	O

Three	O
3rd	O
base	O
substitution	O
polymorphisms	O
were	O
also	O
detected	O
during	O
direct	O
sequencing	O
of	O
PCR	B-DNA
products	E-DNA
.	O

Analysis	O
of	O
the	O
modulation	O
of	O
transcriptional	O
activity	O
in	O
myelopoiesis	O
and	O
leukemogenesis	O
.	O

Binding	O
parameters	O
of	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
were	O
Kd	O
=	O
5.53	O
nM	O
and	O
Bmax	O
=	O
2	O
,	O
647	O
sites/cell	O
.	O

The	O
DNA	O
sequence	O
at	O
-120	S-DNA
also	O
contains	O
two	O
DNA	B-DNA
motifs	E-DNA
homologous	O
to	O
the	O
binding	O
site	O
for	O
NF-AT	S-protein
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF-kappaB	S-protein
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	S-protein
.	O

Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta-luciferase	B-DNA
constructs	E-DNA
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O

Growth	B-protein
factor	I-protein
receptors	E-protein
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

Myb-transformed	B-cell_type
hematopoietic	I-cell_type
cells	E-cell_type
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	B-cell_type
cells	E-cell_type
and	O
macrophages	S-cell_type
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
sought	O
to	O
utilize	O
the	O
nonhuman	O
primate	O
model	O
to	O
study	O
intracellular	O
signaling	O
events	O
in	O
cells	O
from	O
disease-susceptible	O
rhesus	O
macaques	O
and	O
disease-resistant	O
sooty	O
mangabeys	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	B-protein
regulatory	I-protein
domain	E-protein
is	O
sufficient	O
to	O
mediate	O
CD4	S-protein
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	B-protein
domain	E-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	E-protein
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	S-protein
production	O
,	O
mimicking	O
TCR	S-protein
ligation	O
.	O

Expression	O
of	O
MIP-1alpha-R	B-RNA
mRNA	E-RNA
in	O
these	O
cells	O
suggests	O
an	O
autocrine	O
role	O
for	O
this	O
chemokine	S-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
T-cells	E-cell_type
.	O

C/EBPepsilon	B-RNA
mRNA	E-RNA
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	B-cell_type
primary	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	E-cell_type
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O

We	O
transfected	O
promoter-luciferase	B-DNA
reporter	I-DNA
plasmids	E-DNA
into	O
THP-1	B-cell_line
cells	E-cell_line
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

Repeated	O
cold-air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O

Sterol	B-DNA
regulatory	I-DNA
element	E-DNA
(	O
SRE	S-DNA
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	S-DNA
coding	O
for	O
especially	O
low	B-protein
density	I-protein
lipoprotein	I-protein
(	I-protein
LDL	I-protein
)	I-protein
-receptor	E-protein
,	O
3-hydroxy-3-methylglutaryl	B-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG-CoA	I-protein
)	I-protein
reductase	E-protein
and	O
HMG-CoA	B-protein
synthase	E-protein
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell-receptor	O
engagement	O
,	O
we	O
identified	O
ALG-4F	S-protein
,	O
a	O
truncated	B-protein
transcript	E-protein
that	O
prevents	O
T	O
cell-receptor-induced	O
FasL	S-protein
upregulation	O
and	O
cell	O
death	O
.	O

Reversal	O
of	O
apoptosis	O
by	O
the	O
leukaemia-associated	O
E2A-HLF	B-protein
chimaeric	I-protein
transcription	I-protein
factor	E-protein
.	O

The	O
'octamer	B-DNA
'	I-DNA
sequence	E-DNA
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
in	O
B-lymphocytes	S-cell_type
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B-DNA
genes	E-DNA
in	O
all	O
cell	O
types	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	B-DNA
DNA	E-DNA
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	E-protein
(	O
GM-CSF	S-protein
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O

Mutation	O
of	O
either	O
of	O
the	O
putative	O
NF-kappaB-binding	B-DNA
sites	E-DNA
in	O
the	O
enhancer	O
element	O
decreased	O
the	O
LPS-stimulated	O
transcriptional	O
activity	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
DNA-binding	B-protein
factor	E-protein
specific	O
to	O
adult	B-cell_type
hematopoietic	I-cell_type
cells	E-cell_type
(	O
polypryrimidine-binding	B-protein
factor	E-protein
,	O
PYBF	S-protein
)	O
binds	O
to	O
a	O
pyrimidine-rich	B-DNA
region	I-DNA
1	I-DNA
kb	I-DNA
upstream	E-DNA
from	O
the	O
human	B-DNA
delta-globin-encoding	I-DNA
gene	E-DNA
(	O
HBD	S-DNA
)	O
.	O

Ubiquitin-mediated	O
processing	O
of	O
NF-kappa	B-protein
B	I-protein
transcriptional	I-protein
activator	I-protein
precursor	I-protein
p105	E-protein
.	O

No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O

The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c-Jun	S-protein
is	O
governed	O
by	O
a	O
27-amino	B-protein
acid	I-protein
regulatory	I-protein
motif	E-protein
,	O
labeled	O
the	O
delta-domain	S-protein
,	O
which	O
is	O
deleted	O
in	O
v-Jun	S-protein
.	O

gamma	B-protein
B*CaM-K	E-protein
and	O
delta	B-protein
CaM-AI	E-protein
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2+	O
)	O
-independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL-2	B-DNA
promoter	E-DNA
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	E-DNA
.	O

IL-11	B-RNA
mRNA	E-RNA
and	O
protein	O
were	O
both	O
up-regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

The	O
effects	O
of	O
TGF-beta	S-protein
on	O
two	O
transcriptional	B-protein
regulatory	I-protein
factors	E-protein
,	O
Oct-2	S-protein
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
kappa	I-protein
B	E-protein
,	O
known	O
to	O
be	O
important	O
in	O
Ig	S-protein
gene	O
transcription	O
were	O
examined	O
.	O

The	O
percentage	O
of	O
CD3+	B-cell_type
cells	E-cell_type
among	O
all	O
immunocompetent	B-cell_type
cells	E-cell_type
in	O
the	O
tubal	O
epithelium	O
was	O
46.6	O
%	O
(	O
39.9	O
%	O
of	O
CD3+	S-cell_type
were	O
also	O
CD8+	S-cell_type
)	O
;	O
the	O
other	O
53.4	O
%	O
were	O
CD68+	B-cell_type
cells	E-cell_type
.	O

In	O
vivo	O
function	O
of	O
an	O
interleukin	B-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
(	I-protein
IL-2Rbeta	I-protein
)	I-protein
/IL-4Ralpha	I-protein
cytokine	I-protein
receptor	I-protein
chimera	E-protein
potentiates	O
allergic	O
airway	O
disease	O
.	O

Although	O
the	O
mutant	O
strain	O
was	O
able	O
to	O
kill	O
HL-60-	B-cell_type
and	I-cell_type
THP-1-derived	I-cell_type
macrophages	E-cell_type
,	O
it	O
could	O
not	O
replicate	O
within	O
a	O
protozoan	O
host	O
,	O
Acanthamoeba	O
castellanii	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti-CD40	S-protein
+	O
interleukin-4	S-protein
(	O
IL-4	S-protein
)	O
-mediated	O
B-cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
RA	O
was	O
studied	O
in	O
anti-CD40	S-protein
(	O
1	O
microgram/mL	O
)	O
+	O
IL-4	S-protein
(	O
5	O
ng/mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
PBMC	S-cell_type
)	O
and	O
B	B-cell_type
cells	E-cell_type
in	O
healthy	O
donors	O
.	O

This	O
pro-inflammatory	B-protein
cytokine	E-protein
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell-mediated	O
immune	O
responses	O
.	O

1	B-RNA
,	I-RNA
25-Dihydroxyvitamin	I-RNA
D3	I-RNA
receptor	I-RNA
RNA	E-RNA
:	O
expression	O
in	O
hematopoietic	B-cell_type
cells	E-cell_type
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	E-cell_type
to	O
produce	O
cytokines	S-protein
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein-tyrosine	B-protein
kinases	E-protein
and	O
protein-tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

GR	S-protein
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate-limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	S-protein
-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
(	I-DNA
MMTV	I-DNA
)	I-DNA
LTR	I-DNA
reporter	I-DNA
gene	E-DNA
was	O
observed	O
.	O

We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	S-protein
,	O
a	O
member	O
of	O
the	O
cytoplasmic	B-protein
tyrosine	I-protein
kinase	I-protein
Tec	I-protein
family	E-protein
,	O
in	O
T	O
cell	O
activation	O
.	O

Physiological	O
concentrations	O
of	O
estradiol	O
significantly	O
reduced	O
the	O
chemotaxis	O
of	O
PMNs	S-cell_type
(	O
10	O
(	O
-10	O
)	O
mol	O
)	O
.	O

Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	E-protein
by	O
the	O
Rac	B-protein
GTP-binding	I-protein
proteins	E-protein
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O

Expression	O
of	O
c-fos	B-protein
and	I-protein
c-jun	I-protein
proteins	E-protein
and	O
AP-1	S-protein
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	B-cell_line
cells	E-cell_line
and	O
phytohemagglutinin-stimulated	B-cell_line
lymphocytes	E-cell_line
.	O

We	O
have	O
isolated	O
the	O
5	B-DNA
'	I-DNA
region	E-DNA
of	O
the	O
ecto-5'-nucleotidase	B-DNA
(	I-DNA
low	I-DNA
K	I-DNA
(	I-DNA
m	I-DNA
)	I-DNA
5'-NT	I-DNA
)	I-DNA
gene	E-DNA
and	O
established	O
that	O
a	O
969-base	B-DNA
pair	I-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
fragment	E-DNA
confers	O
cell-specific	O
expression	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
gene	E-DNA
that	O
correlates	O
with	O
the	O
expression	O
of	O
endogenous	B-RNA
ecto-5'-NT	I-RNA
mRNA	E-RNA
and	O
enzymatic	O
activity	O
.	O

The	O
involvement	O
of	O
Jak	B-protein
2	E-protein
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
effects	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
on	O
apoptosis	O
of	O
human	B-cell_type
CD34+	I-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	E-cell_type
isolated	O
from	O
normal	O
bone	O
marrow	O
.	O

Tyrosine	B-protein
kinase	E-protein
-dependent	O
,	O
and	O
not	O
protein	B-protein
kinase	I-protein
C	E-protein
-dependent	O
,	O
pathways	O
mediate	O
CD23	S-protein
-triggered	O
NF-kappaB	S-protein
activation	O
but	O
do	O
not	O
participate	O
in	O
the	O
direct	O
phosphorylation	O
of	O
IkappaBalpha	S-protein
.	O

We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA-binding	O
of	O
NF-kappaB	S-protein
in	O
vitro	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
mitogen	S-protein
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
induces	O
nuclear	O
factors	O
that	O
form	O
complexes	O
with	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	E-protein
(	O
CREB	S-protein
)	O
.	O

A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U/ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	B-cell_type
cell	E-cell_type
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O

One	O
of	O
the	O
nuclear	B-protein
factors	E-protein
(	O
NFs	S-protein
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	B-DNA
promoter	E-DNA
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	S-protein
for	O
activated	B-cell_type
t	I-cell_type
cell	E-cell_type
.	O

The	O
patient	O
whose	O
disease	O
had	O
numerous	O
atypical	O
clinical	O
features	O
,	O
had	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q13	I-DNA
;	I-DNA
121	I-DNA
)	E-DNA
.	O

Point	O
mutation	O
of	O
the	O
c-Myb	B-DNA
site	E-DNA
within	O
the	O
intact	O
2.3-kb	B-protein
LCR	E-protein
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	S-DNA
activity	O
in	O
transgenic	B-cell_line
thymocytes	E-cell_line
.	O

As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	S-protein
and	O
ICAM-1	S-protein
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O

Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	B-cell_type
leukocytes	E-cell_type
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-DNA
cDNAs	E-DNA
,	O
and	O
the	O
entire	O
hGR	B-DNA
cDNA	E-DNA
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B-protein
domain	E-protein
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	E-protein
is	O
necessary	O
for	O
IL-7R	S-protein
signal	O
transduction	O
.	O

Expression	O
of	O
DR3	S-protein
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	S-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Therefore	O
,	O
we	O
suggest	O
that	O
SHP1	S-protein
is	O
not	O
actively	O
recruited	O
to	O
inhibit	O
TCR	S-protein
signaling	O
induced	O
by	O
ligation	O
of	O
this	O
receptor	O
alone	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
the	O
first	O
dicarba-closo-dodecaborane	O
(	O
carborane	O
)	O
derivatives	O
of	O
retinoids	O
are	O
described	O
.	O

Exons	B-DNA
2	I-DNA
to	I-DNA
8	E-DNA
of	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	E-DNA
were	O
analyzed	O
using	O
a	O
combination	O
of	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
DNA	O
sequencing	O
.	O

This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	B-DNA
heat	I-DNA
shock	I-DNA
element	E-DNA
.	O

In	O
consistence	O
,	O
the	O
c-Myc	S-protein
and	O
E1A	S-protein
overexpressing	O
fibroblasts	S-cell_type
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell-derived	O
granules	O
than	O
parental	B-cell_type
cells	E-cell_type
.	O

ER	S-protein
-mediated	O
repression	O
of	O
GATA-1	S-protein
activity	O
occurs	O
on	O
an	O
artificial	B-DNA
promoter	E-DNA
containing	O
a	O
single	O
GATA-binding	B-DNA
site	E-DNA
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	B-DNA
promoter	E-DNA
which	O
is	O
normally	O
regulated	O
by	O
GATA-1	S-protein
.	O

Dose-response	O
studies	O
showed	O
that	O
10	O
(	O
-7	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
9-cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	E-RNA
;	O
but	O
even	O
10	O
(	O
-10	O
)	O
mol/L	O
9-cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O

BSAP	S-protein
:	O
a	O
key	O
regulator	O
of	O
B-cell	S-cell_type
development	O
and	O
differentiation	O
.	O

Since	O
these	O
latter	O
compounds	O
were	O
known	O
to	O
activate	O
NF-kappa	B-protein
B	E-protein
translocation	O
in	O
a	O
redox-sensitive	O
way	O
,	O
we	O
have	O
demonstrated	O
that	O
NF-kappa	B-protein
B	E-protein
activation	O
by	O
PMA	O
was	O
resistant	O
to	O
antioxidant	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
and	O
sensitive	O
to	O
kinase	O
inhibitors	O
staurosporine	O
and	O
H7	O
while	O
activation	O
by	O
H2O2	O
or	O
TNF-alpha	S-protein
were	O
not	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	S-protein
concentration-dependent	O
assembly	O
of	O
transcription	B-protein
complexes	E-protein
at	O
the	O
promoter	S-DNA
.	O

Exogenous	O
provision	O
of	O
NFkB	S-protein
rescued	O
IL2R	S-protein
alpha	O
expression	O
but	O
not	O
the	O
PTHrP	B-DNA
promoter	E-DNA
.	O

Hypothetically	O
,	O
on/off	O
switches	O
of	O
lineage-restricted	B-protein
transactivators	E-protein
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	B-cell_type
progenitors	E-cell_type
.	O

Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

The	O
BCL-6	B-RNA
gene	E-RNA
encoding	O
a	O
nuclear-located	B-protein
Kruppel-type	I-protein
zinc	I-protein
finger	I-protein
protein	E-protein
is	O
rearranged	O
in	O
about	O
30	O
%	O
diffuse	O
large	O
B-cell	B-cell_type
lymphomas	E-cell_type
and	O
is	O
expressed	O
predominantly	O
in	O
normal	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	E-cell_type
and	O
related	O
lymphomas	O
.	O

We	O
determined	O
whether	O
Hsp70	S-protein
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	B-protein
transcription	I-protein
factor	E-protein
,	O
HSF	S-protein
.	O

Whereas	O
anti-CD28	S-protein
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans-activation	O
activity	O
of	O
NF-kappa	B-protein
B	E-protein
,	O
PMA-induced	O
activation	O
of	O
AP-1	S-protein
was	O
significantly	O
suppressed	O
.	O

L227	S-protein
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2+	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	B-RNA
mRNA	E-RNA
,	O
whereas	O
2.06	S-protein
plus	O
GAM	S-protein
induced	O
an	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
from	O
both	O
the	O
intracellular	O
and	O
,	O
in	O
particular	O
,	O
the	O
extracellular	O
pools	O
.	O

Another	O
LTR	B-DNA
size	I-DNA
variation	E-DNA
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	E-DNA
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	B-DNA
upstream	I-DNA
sequence	E-DNA
and	O
showed	O
its	O
basal	B-DNA
promoter	E-DNA
activity	O
in	O
CHO	B-cell_line
cells	E-cell_line
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O

We	O
show	O
that	O
the	O
PPAR	O
activators	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-prostaglandin	O
J	O
(	O
2	O
)	O
(	O
15d-PGJ	O
(	O
2	O
)	O
)	O
,	O
Wyeth	O
14643	O
,	O
ciglitazone	O
,	O
and	O
troglitazone	O
,	O
but	O
not	O
BRL	O
49653	O
,	O
partially	O
inhibit	O
the	O
induced	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	E-protein
(	O
VCAM-1	S-protein
)	O
,	O
as	O
measured	O
by	O
ELISA	O
,	O
and	O
monocyte	O
binding	O
to	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	E-cell_type
(	O
HAECs	S-cell_type
)	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
.	O

All	O
erythroid	B-cell_line
colonies	E-cell_line
consisted	O
of	O
ringed	B-cell_type
sideroblasts	E-cell_type
exclusively	O
showed	O
one	O
pattern	O
dominant	O
in	O
those	O
of	O
PMNCs	S-cell_type
.	O

Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc-mediated	O
immune	O
modulation	O
.	O

Surprisingly	O
,	O
the	O
levels	O
of	O
SRF	S-protein
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	E-cell_type
are	O
consistently	O
higher	O
than	O
in	O
other	O
cell	O
types	O
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	B-cell_type
cells	E-cell_type
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	B-protein
gamma	E-protein
(	O
IFNgamma	S-protein
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	S-cell_type
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	S-protein
footprinting	O
of	O
the	O
TNF-alpha	B-DNA
promoter	E-DNA
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	S-protein
demonstrated	O
that	O
the	O
-76	B-DNA
site	E-DNA
binds	O
to	O
NFATp	S-protein
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	B-DNA
3	I-DNA
site	E-DNA
.	O

Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T/NK-cell	S-cell_type
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O

These	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
molecular	O
mechanisms	O
of	O
IL-5	S-protein
signaling	O
in	O
human	B-cell_type
eosinophils	E-cell_type
involve	O
members	O
of	O
the	O
JAK	B-protein
kinase	I-protein
family	E-protein
as	O
well	O
as	O
members	O
of	O
the	O
Stat	B-protein
family	E-protein
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	B-cell_type
lymphocytes	E-cell_type
(	O
B	B-cell_type
cells	E-cell_type
)	O
.	O

Nuclear	O
run-on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate-early	B-DNA
cytokine	I-DNA
genes	E-DNA
,	O
such	O
as	O
the	O
interleukin	B-DNA
1	I-DNA
beta	I-DNA
(	I-DNA
IL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	E-DNA
,	O
were	O
transcriptionally	O
activated	O
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	E-DNA
transcription	O
remained	O
constant	O
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
enhancer	E-DNA
,	O
by	O
activating	O
the	O
T-cell-specific	B-protein
transcription	I-protein
factors	I-protein
NF-AT	E-protein
and	O
NF-IL2A	S-protein
.	O

Modulation	O
of	O
E2F	B-protein
complexes	E-protein
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	E-cell_type
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	B-cell_type
monocytes	E-cell_type
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng/ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine/threonine	B-protein
protein	I-protein
kinase	E-protein
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan-	O
PKC	S-protein
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	S-protein
genistein	O
(	O
Gen	O
)	O
.	O

Binding	O
to	O
kappaB	B-DNA
sequence	E-DNA
was	O
accompanied	O
by	O
an	O
initial	O
decrease	O
and	O
subsequent	O
increase	O
in	O
the	O
cytoplasmic	O
IkappaBalpha	S-protein
levels	O
,	O
as	O
detected	O
by	O
Western	O
blotting	O
using	O
an	O
anti-IkappaBalpha	B-protein
antibody	E-protein
.	O

Two-color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	S-cell_type
and	O
fibroblast-like	B-cell_type
synoviocytes	E-cell_type
were	O
positive	O
for	O
nuclear	O
C/EBP	B-protein
beta	E-protein
.	O

In	O
order	O
to	O
study	O
CD14	B-DNA
gene	E-DNA
regulation	O
,	O
the	O
human	B-DNA
CD14	I-DNA
gene	E-DNA
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	B-DNA
digested	I-DNA
chromosome	I-DNA
5	I-DNA
library	E-DNA
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	B-protein
factors	E-protein
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL-2	S-protein
,	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	E-cell_type
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF-kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

The	O
GATA-1	B-DNA
gene	E-DNA
,	O
though	O
virtually	O
silent	O
in	O
quiescent	B-cell_type
progenitors	E-cell_type
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Transcriptional	O
activity	O
of	O
core	B-protein
binding	I-protein
factor-alpha	I-protein
(	I-protein
AML1	I-protein
)	I-protein
and	I-protein
beta	E-protein
subunits	O
on	O
murine	B-DNA
leukemia	I-DNA
virus	I-DNA
enhancer	I-DNA
cores	E-DNA
.	O

Experimental	O
expression	O
in	O
mice	O
and	O
spontaneous	O
expression	O
in	O
human	O
SLE	O
of	O
polyomavirus	B-protein
T-antigen	E-protein
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20-methyl-	O
and	O
20-methyl-23-eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

Retinoic	O
acid-induced	O
modulation	O
of	O
IL-2	B-RNA
mRNA	E-RNA
production	O
and	O
IL-2	S-protein
receptor	O
expression	O
on	O
T	B-cell_type
cells	E-cell_type
.	O

NGAL	S-protein
was	O
expressed	O
in	O
bone	O
marrow	O
and	O
in	O
tissues	O
that	O
are	O
prone	O
to	O
exposure	O
to	O
microorganisms	O
.	O

The	O
NH2-terminal	B-protein
126	I-protein
amino	I-protein
acids	E-protein
of	O
BOB.1/OBF.1	S-protein
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	B-protein
domains	E-protein
of	O
either	O
Oct1	S-protein
or	O
Oct2	S-protein
.	O

Using	O
a	O
structure-function	O
mutagenesis	O
approach	O
,	O
two	O
tyrosine	O
residues	O
(	O
Tyr427	O
and	O
Tyr477	O
)	O
in	O
the	O
intracellular	B-protein
domain	E-protein
of	O
the	O
murine	O
IL-10	S-protein
receptor	O
were	O
found	O
to	O
be	O
redundantly	O
required	O
for	O
receptor	O
function	O
and	O
for	O
activation	O
of	O
Stat3	S-protein
but	O
not	O
for	O
Stat1	S-protein
or	O
Stat5	S-protein
.	O

Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	B-DNA
sites	E-DNA
mediated	O
basal	O
expression	O
in	O
uninduced	B-cell_type
cells	E-cell_type
.	O

The	O
tissue-specific	B-DNA
core	I-DNA
promoter	I-DNA
structure	E-DNA
is	O
apparently	O
conserved	O
in	O
other	O
T-cell-specifically	B-DNA
expressed	I-DNA
genes	E-DNA
such	O
as	O
the	O
CD4	B-DNA
gene	E-DNA
.	O

Since	O
the	O
co-expression	O
with	O
a	O
dominant	O
negative	O
c-Fos	S-protein
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	B-DNA
gene	E-DNA
depends	O
on	O
interactions	O
between	O
the	O
X2	B-DNA
box	E-DNA
and	O
NF-X2	S-DNA
,	O
which	O
contains	O
c-Fos	S-protein
.	O

Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	E-DNA
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O

A	O
transcription	O
start	O
site	O
is	O
located	O
approximately	O
4	O
kilobases	O
5	O
'	O
to	O
the	O
translation	B-DNA
initiation	I-DNA
codon	E-DNA
,	O
and	O
an	O
RNA	O
splice	O
of	O
3863	O
bases	O
occurs	O
in	O
the	O
5'-untranslated	B-DNA
region	E-DNA
to	O
generate	O
mature	B-RNA
HeLa	I-RNA
cell	I-RNA
mRNA	E-RNA
.	O

We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	E-protein
levels	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	E-cell_type
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	B-cell_type
leukocytes	E-cell_type
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	B-protein
receptor	E-protein
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation-dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	S-protein
expression	O
,	O
were	O
studied	O
.	O

Interferon	B-protein
gamma	E-protein
activated	O
strongly	O
c-fos	S-DNA
and	O
weakly	O
c-jun	S-DNA
and	O
AP1	S-protein
.	O

We	O
conclude	O
that	O
a	O
VDRE-binding	B-protein
protein	E-protein
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	S-protein
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	B-cell_line
vitamin	I-cell_line
D-resistant	I-cell_line
NWP	E-cell_line
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR-RXR	S-protein
heterodimer	O
binding	O
to	O
the	O
VDRE	S-DNA
.	O

These	O
lymphoid/DC	B-cell_type
precursors	E-cell_type
have	O
little	O
capacity	O
to	O
form	O
myeloid	B-cell_type
cells	E-cell_type
,	O
indicating	O
that	O
thymic	B-cell_type
DC	E-cell_type
are	O
a	O
lymphoid-related	O
rather	O
than	O
myeloid-related	B-cell_type
lineage	E-cell_type
.	O

SCL	S-protein
is	O
expressed	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
populations	E-cell_type
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	S-protein
,	O
a	O
zinc-finger	B-protein
transcription	I-protein
factor	E-protein
)	O
.	O

The	O
data	O
indicate	O
that	O
cellular	B-DNA
genes	E-DNA
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	B-protein
gene	I-protein
products	E-protein
could	O
be	O
detected	O
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	S-cell_type
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL-1beta	B-protein
protein	E-protein
.	O

Significantly	O
increased	O
oestrogen	B-protein
receptor	E-protein
expression	O
,	O
bcl-2	S-protein
expression	O
and	O
numbers	O
of	O
CD8+	O
leukocytes	S-cell_type
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

The	O
-1053/+34	B-DNA
construct	E-DNA
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	B-cell_type
origin	E-cell_type
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
increased	O
level	O
of	O
PLC	B-protein
gamma	I-protein
1	E-protein
becomes	O
evident	O
after	O
90	O
min	O
of	O
IFN-beta	S-protein
treatment	O
and	O
is	O
still	O
detectable	O
after	O
24	O
h	O
.	O

Susceptibility	O
of	O
these	O
transformed	O
cell	B-cell_line
lines	E-cell_line
to	O
NK	B-cell_type
cells	E-cell_type
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	S-cell_line
and	O
A1-VDR	B-cell_line
cells	E-cell_line
where	O
elution	O
from	O
DNA-cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	E-protein
.	O

Upon	O
activation	O
by	O
antigens	S-protein
,	O
helper	B-cell_type
T	I-cell_type
cells	E-cell_type
differentiate	O
into	O
one	O
of	O
several	O
subsets	O
,	O
characterized	O
by	O
their	O
distinct	O
cytokine	S-protein
-production	O
patterns	O
.	O

To	O
define	O
the	O
CD40	S-protein
signaling	O
components	O
upstream	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
,	O
we	O
examined	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
transfectants	E-cell_line
expressing	O
wild-type	B-protein
or	I-protein
mutant	I-protein
human	I-protein
CD40	E-protein
.	O

Induction	O
of	O
proto-oncogene	S-DNA
and	O
cytokine	S-protein
expression	O
in	O
human	O
peripheral	O
blood	O
monocytes	S-cell_type
and	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	E-cell_line
after	O
stimulation	O
with	O
mycoplasma-derived	O
material	O
MDHM	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	B-cell_line
cells	E-cell_line
,	O
continuous	O
NF-kappa	B-protein
B	E-protein
(	O
p50/p65	S-protein
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF-kappa	B-protein
B	E-protein
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

BSAP	S-protein
is	O
unique	O
among	O
the	O
transcription	B-protein
factors	E-protein
that	O
regulate	O
epsilon	O
germline	S-DNA
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	S-protein
switching	O
.	O

We	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
MDS1/EVI1	S-DNA
has	O
no	O
effect	O
on	O
granulocytic	O
differentiation	O
induced	O
by	O
G-CSF	S-protein
,	O
expression	O
of	O
AML1/MDS1/EVI1	S-protein
blocks	O
differentiation	O
resulting	O
in	O
cell	O
death	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	O
but	O
opposing	O
transcription	B-protein
factors	E-protein
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O

By	O
using	O
the	O
yeast	O
two-hybrid	O
system	O
,	O
we	O
also	O
show	O
that	O
EVI1	S-protein
(	O
contained	O
in	O
its	O
entirety	O
in	O
MDS1/EVI1	S-DNA
and	O
AML1/MDS1/EVI1	S-protein
)	O
physically	O
interacts	O
with	O
SMAD3	S-protein
,	O
which	O
is	O
an	O
intracellular	O
mediator	O
of	O
TGF-beta1	S-protein
signaling	O
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK-cell	O
and	O
4	O
as	O
T-cell	O
tumours	O
.	O

We	O
show	O
that	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	S-protein
(	O
Trx	S-protein
)	O
plays	O
a	O
major	O
role	O
in	O
activation	O
of	O
the	O
DNA	O
binding	O
of	O
NF	B-protein
kappa	I-protein
B	E-protein
in	O
vitro	O
and	O
stimulation	O
of	O
transcription	O
from	O
the	O
NF	B-protein
kappa	I-protein
B	E-protein
-dependent	O
gene	O
expression	O
.	O

The	O
structural	O
classes	O
of	O
transcription	B-protein
factors	E-protein
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	B-protein
factors	E-protein
are	O
detailed	O
.	O

Alternative	O
splicing	O
of	O
exon	B-RNA
10	E-RNA
of	O
the	O
TSC2	B-DNA
gene	E-DNA
may	O
be	O
a	O
normal	O
variant	O
.	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	S-protein
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal-transduction	O
pathway	O
emanating	O
from	O
the	O
T-cell	B-protein
receptor	E-protein
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Mitogen	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
induces	O
the	O
formation	O
of	O
new	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
nuclear	I-protein
complexes	E-protein
.	O

Sequencing	O
of	O
the	O
GR	B-DNA
cDNA	E-DNA
and	O
gene	O
including	O
the	O
2.3-kb	O
coding	O
region	O
,	O
the	O
intron/exon	O
junctions	O
,	O
the	O
known	O
5'-regulatory	B-DNA
region	E-DNA
,	O
and	O
approximately	O
300	O
bp	O
of	O
the	O
3'-region	S-DNA
revealed	O
no	O
alterations	O
.	O

NF-E1	S-protein
is	O
also	O
the	O
human	B-protein
homologue	E-protein
of	O
the	O
mouse	B-DNA
delta	I-DNA
protein	E-DNA
,	O
which	O
binds	O
to	O
ribosomal	B-DNA
protein	I-DNA
gene	I-DNA
promoters	E-DNA
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G-protein-coupled	B-protein
chemoattractant	I-protein
receptors	E-protein
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	B-DNA
Thy-1	I-DNA
promoter	E-DNA
and	O
show	O
that	O
the	O
dominant	B-DNA
promoter	I-DNA
elements	E-DNA
consist	O
of	O
multiple	B-DNA
binding	I-DNA
sites	E-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
Sp1	E-protein
,	O
an	O
inverted	O
CCAAT	B-DNA
box	E-DNA
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
.	O

Our	O
results	O
indicated	O
that	O
,	O
in	O
the	O
context	O
of	O
T	O
cell-dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	S-cell_type
clusters	O
,	O
p50	S-protein
is	O
mainly	O
related	O
to	O
FDC	S-cell_type
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	S-protein
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	S-cell_type
and	O
c-Rel	O
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	S-cell_type
from	O
FDC	S-cell_type
clusters	O
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	B-DNA
gene	E-DNA
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1-	B-protein
and	I-protein
PU.1-family	I-protein
members	E-protein
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	S-protein
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	B-DNA
element	E-DNA
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	E-cell_line
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	B-DNA
gene	E-DNA
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	B-protein
factors	E-protein
that	O
are	O
essential	O
for	O
Ig	B-DNA
gene	E-DNA
transcription	O
.	O

SOCS-3	S-protein
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL-2	S-protein
stimulation	O
,	O
while	O
CIS	S-protein
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O

In	O
addition	O
,	O
these	O
promoters	O
respond	O
only	O
indirectly	O
to	O
the	O
viral	B-DNA
immediate-early	I-DNA
transactivator	E-DNA
,	O
ZEBRA	S-DNA
.	O

Central	B-cell_type
nervous	I-cell_type
system-derived	I-cell_type
cells	E-cell_type
express	O
a	O
kappa	O
B-binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	S-DNA
-independent	O
transactivation	O
by	O
Tat	S-protein
.	O

AR	B-protein
protein	E-protein
decreased	O
by	O
70	O
%	O
and	O
PSA	S-protein
levels	O
in	O
supernatants	O
from	O
LNCaP	B-cell_line
cells	E-cell_line
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O

We	O
recently	O
identified	O
the	O
winged-helix	B-protein
transcription	I-protein
factor	I-protein
Trident	E-protein
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	B-cell_type
fibroblasts	E-cell_type
.	O

RFX-B	S-DNA
complements	O
the	O
predominant	O
BLS	B-protein
complementation	I-protein
group	E-protein
(	O
group	B-protein
B	E-protein
)	O
and	O
was	O
found	O
to	O
be	O
mutant	O
in	O
cell	B-cell_line
lines	E-cell_line
from	O
this	O
BLS	O
group	O
.	O

We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	S-protein
during	O
erythroid	O
ontogeny	O
.	O

The	O
effects	O
of	O
IFN-gamma	S-protein
on	O
the	O
transcription	B-protein
factors	E-protein
were	O
specific	O
,	O
since	O
no	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
NF-IL-6	S-protein
or	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
,	O
the	O
inhibitor	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-1	E-protein
.	O

The	O
observed	O
cooperativities	O
between	O
either	O
9-cis	O
RA	O
or	O
all-trans	O
RA	O
and	O
D3	O
have	O
important	O
implications	O
for	O
the	O
use	O
of	O
combinations	O
of	O
these	O
agents	O
in	O
differentiation	O
therapy	O
.	O

Demonstration	O
of	O
clonal	O
cell	O
growth	O
by	O
analysis	O
of	O
X-chromosome	S-DNA
inactivation	O
(	O
XCI	O
)	O
patterns	O
in	O
females	O
provides	O
a	O
promising	O
tool	O
for	O
diagnosis	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
RT-PCR	O
based	O
approach	O
to	O
compare	O
the	O
stability	O
of	O
the	O
big	B-DNA
T	I-DNA
and	I-DNA
small	I-DNA
t	I-DNA
allele	E-DNA
in	O
normal	B-cell_type
heterozygous	I-cell_type
lymphocytes	E-cell_type
and	O
the	O
heterozygous	B-cell_line
cell	I-cell_line
lines	I-cell_line
NB4	E-cell_line
(	O
myeloid	O
leukemia	O
)	O
and	O
PC-3	S-cell_line
and	O
DU	B-cell_line
145	E-cell_line
(	O
prostate	O
cancers	O
)	O
.	O

We	O
found	O
a	O
good	O
correlation	O
in	O
the	O
transfected	B-cell_line
cells	E-cell_line
between	O
PLD	S-protein
activation	O
and	O
induction	O
of	O
AP-1	B-DNA
enhancer	E-DNA
activity	O
under	O
different	O
experimental	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
IFN-U937	B-cell_line
cells	E-cell_line
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	S-protein
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel/nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
factors	E-protein
in	O
primary	B-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B-protein
NP-1	E-protein
,	O
NP-5	S-protein
,	O
and	O
HNP-1	S-protein
to	O
activate	O
pag	S-DNA
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

Changes	O
in	O
c-fos	S-DNA
expression	O
induced	O
by	O
radiation	O
therapy	O
in	O
tumor	O
tissues	O
have	O
not	O
yet	O
been	O
reported	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	B-cell_type
leukocytes	E-cell_type
:	O
is	O
there	O
a	O
membrane	B-protein
receptor	E-protein
for	O
mineralocorticoids	O
?	O

Previous	O
studies	O
have	O
also	O
demonstrated	O
a	O
role	O
for	O
endogenous	O
ceramide	O
release	O
in	O
Fas-mediated	O
apoptosis	O
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

TAR	S-DNA
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

Characterisation	O
of	O
regulatory	O
sequences	O
at	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
BamHI	I-DNA
W	I-DNA
promoter	E-DNA
.	O

ATRA	O
also	O
induced	O
expression	O
of	O
C/EBP	B-protein
epsilon	I-protein
protein	E-protein
in	O
NB4	B-cell_line
cells	E-cell_line
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	S-protein
ligation	O
.	O

METHODS	O
:	O
TNF	S-protein
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	B-protein
antibody	E-protein
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O

In	O
UCSD-AML1	S-cell_line
,	O
we	O
have	O
also	O
identified	O
fusion	B-RNA
transcripts	E-RNA
between	O
the	O
ecotropic	B-DNA
viral	I-DNA
insertion	I-DNA
site	I-DNA
I	I-DNA
(	I-DNA
EVI1	I-DNA
)	I-DNA
gene	E-DNA
in	O
3q26	S-DNA
and	O
GR6	S-DNA
and	O
between	O
EVI1	S-DNA
and	O
Ribophorin	B-DNA
I	E-DNA
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	S-DNA
in	O
3q21	S-DNA
.	O

Although	O
the	O
CD8+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
latently	B-cell_type
infected	I-cell_type
cells	E-cell_type
is	O
well	O
characterized	O
,	O
very	O
little	O
is	O
known	O
about	O
T	O
cell	O
controls	O
over	O
lytic	O
infection	O
;	O
this	O
imbalance	O
in	O
our	O
understanding	O
belies	O
the	O
importance	O
of	O
virus-replicative	O
lesions	O
in	O
several	O
aspects	O
of	O
EBV	O
disease	O
pathogenesis	O
.	O

We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	B-DNA
gene	E-DNA
is	O
also	O
regulated	O
by	O
a	O
cognate	O
motif	O
for	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	E-protein
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	S-cell_type
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	S-protein
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	B-cell_line
monocytes	E-cell_line
to	O
TNF-stimulated	B-cell_line
HUVECs	E-cell_line
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM-1	S-protein
and	O
E-selectin	S-protein
upregulation	O
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	B-DNA
LTR	E-DNA
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	S-protein
or	O
NF	B-protein
kappa	I-protein
B	E-protein
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B-protein
factors	E-protein
and	O
of	O
the	O
transcription	O
of	O
genes	S-DNA
for	O
pro-inflammatory	B-protein
cytokines	E-protein
.	O

An	O
NMR	O
model	O
is	O
obtained	O
from	O
Oct-2	S-protein
,	O
a	O
human	B-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	E-protein
which	O
participates	O
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	E-DNA
.	O

We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	S-cell_type
on	O
T	B-protein
cell	I-protein
nuclear	I-protein
factors	E-protein
known	O
to	O
regulate	O
IL-2	S-protein
transcription	O
,	O
including	O
c-jun	S-protein
and	O
c-fos-two	B-protein
components	E-protein
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	E-protein
,	O
NFAT	S-protein
,	O
and	O
others	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	S-protein
-like	O
activity	O
in	O
non-erythroid	B-cell_type
cells	E-cell_type
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	S-DNA
expressed	O
in	O
such	O
cells	O
.	O

Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	S-protein
can	O
upregulate	O
CD21	S-protein
in	O
some	O
B	B-cell_type
cells	E-cell_type
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	S-protein
on	O
reporter	B-DNA
plasmids	E-DNA
which	O
contain	O
the	O
CD21	B-DNA
promoter	E-DNA
.	O

Stress	O
response	O
of	O
senescent	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
:	O
reduced	O
hsp70	S-protein
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Members	O
of	O
the	O
recently	O
discovered	O
SOCS/CIS/SSI	B-protein
family	E-protein
have	O
been	O
proposed	O
as	O
regulators	O
of	O
cytokine	S-protein
signaling	O
,	O
and	O
while	O
targets	O
and	O
mechanisms	O
have	O
been	O
suggested	O
for	O
some	O
family	O
members	O
,	O
the	O
precise	O
role	O
of	O
these	O
proteins	O
remains	O
to	O
be	O
defined	O
.	O

Furthermore	O
,	O
the	O
VitD3	O
-and	O
the	O
PMA-induced	O
CD14	S-protein
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA-induced	O
differentiation	O
.	O

General	B-protein
transcription	I-protein
factors	E-protein
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	B-protein
polymerase	I-protein
II	E-protein
.	O

In	O
addition	O
to	O
Bcl-x	S-protein
,	O
a	O
known	O
CD40-regulated	B-protein
antiapoptotic	I-protein
molecule	E-protein
,	O
we	O
identified	O
a	O
related	O
antiapoptotic	B-protein
molecule	E-protein
,	O
A1/Bfl-1	S-protein
,	O
as	O
a	O
CD40-inducible	B-DNA
gene	E-DNA
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

When	O
tested	O
in	O
cytotoxicity	O
assays	O
using	O
T-lymphocytes	S-cell_type
from	O
VZV	O
immune	O
human	O
donors	O
,	O
the	O
range	O
of	O
precursor	O
frequencies	O
for	O
T-lymphocytes	S-cell_type
that	O
recognized	O
VZV	B-protein
gE	E-protein
or	O
VZV	B-protein
IE62	E-protein
was	O
similar	O
whether	O
these	O
proteins	O
were	O
expressed	O
by	O
HSV-1	O
or	O
a	O
vaccinia	O
vector	O
.	O

Neither	O
IL-10	S-protein
nor	O
IL-4	S-protein
inhibited	O
LPS-induced	O
NF-kappa	B-protein
B	E-protein
binding	O
activity	O
.	O

Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	S-protein
-deficient	O
mouse	O
strain	O
.	O

Heparin	O
is	O
a	O
polyanionic	O
glycosaminoglycan	O
(	O
GAG	O
)	O
that	O
can	O
bind	O
with	O
high	O
affinity	O
to	O
a	O
range	O
of	O
cytokines	S-protein
including	O
interferon-gamma	S-protein
(	O
IFN-gamma	S-protein
)	O
and	O
members	O
of	O
the	O
chemokine	B-protein
superfamily	E-protein
.	O

Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O

In	O
addition	O
,	O
both	O
RelA	S-protein
and	O
c-Rel	S-protein
,	O
but	O
not	O
NF-kappa	B-protein
B1	E-protein
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM-1	B-DNA
kappa	I-DNA
B-reporter	I-DNA
construct	E-DNA
.	O

The	O
capacity	O
of	O
Syk	S-protein
to	O
reconstitute	O
the	O
MAPK	S-protein
response	O
required	O
the	O
catalytic	O
activity	O
of	O
Syk	S-protein
,	O
an	O
intact	O
autophosphorylation	B-protein
site	E-protein
(	O
Y518	O
and	O
Y519	O
)	O
,	O
both	O
Src	B-protein
homology	I-protein
2	I-protein
domains	E-protein
and	O
it	O
was	O
blocked	O
by	O
the	O
inhibitory	B-protein
N17-mutated	I-protein
dominant-negative	I-protein
Ras	I-protein
construct	E-protein
.	O

They	O
bind	O
to	O
the	O
kappa	B-DNA
B	I-DNA
motifs	E-DNA
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	S-DNA
.	O

Fifty-three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	B-cell_type
abnormal	I-cell_type
eosinophils	E-cell_type
(	O
AML	O
M4	O
``	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
a	O
55	O
year	O
old	O
Japanese	O
woman	O
with	O
a	O
seminoma	O
but	O
relatively	O
normal	O
menses	O
.	O

We	O
now	O
describe	O
another	O
series	O
(	O
B	O
)	O
of	O
such	O
variants	O
,	O
which	O
differ	O
from	O
A	O
series	O
cells	O
grown	O
in	O
similar	O
concentrations	O
of	O
1	O
,	O
25D3	O
in	O
that	O
they	O
express	O
the	O
CD14	B-protein
antigen	E-protein
and	O
nonspecific	O
esterase	S-protein
,	O
characteristic	O
of	O
the	O
monocyte	O
,	O
while	O
continuing	O
to	O
proliferate	O
and	O
they	O
develop	O
hypotetraploid	O
DNA	O
(	O
4C	O
)	O
content	O
at	O
higher	O
concentrations	O
of	O
ambient	O
1	O
,	O
25D3	O
than	O
the	O
A	O
series	O
cells	O
.	O

Reverse	O
transcription-PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV-positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	B-RNA
nuclear	I-RNA
antigen	I-RNA
(	I-RNA
EBNA	I-RNA
)	I-RNA
1	I-RNA
mRNA	E-RNA
,	O
but	O
not	O
EBNA2	B-RNA
mRNA	E-RNA
.	O

However	O
,	O
IL2	S-protein
does	O
not	O
reverse	O
CsA	O
inhibition	O
,	O
suggesting	O
that	O
at	O
least	O
one	O
other	O
NFAT-sensitive	B-DNA
gene	E-DNA
may	O
be	O
involved	O
.	O

Detection	O
in	O
non-erythroid	B-cell_type
cells	E-cell_type
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
EF1	E-protein
.	O

By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy-corticosterone	O
(	O
18-OH-B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O

The	O
NF90	S-protein
protein	O
was	O
found	O
to	O
be	O
expressed	O
not	O
only	O
in	O
T-cells	S-cell_type
,	O
but	O
also	O
in	O
nonimmune	B-cell_line
HeLa	I-cell_line
cells	E-cell_line
.	O

Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid-specific	B-protein
octamer-binding	I-protein
factor	E-protein
in	O
DRA	O
gene	O
transcription	O
.	O

Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF-kappa	O
B	O
activation	O
in	O
natural	B-cell_type
killer	I-cell_type
cells	E-cell_type
.	O

Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	S-protein
production	O
shows	O
that	O
epsilon	O
germline	S-DNA
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon-gamma	S-protein
(	O
IFN-gamma	S-protein
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B-protein
PMLRAR	I-protein
alpha	E-protein
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	B-DNA
alpha	I-DNA
cDNA	E-DNA
in	O
myeloid	B-cell_type
cells	E-cell_type
of	O
transgenic	O
mice	O
.	O

We	O
report	O
that	O
certain	O
NF-AT	B-protein
(	I-protein
Rel	I-protein
)	I-protein
family	I-protein
members	E-protein
productively	O
bind	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	E-DNA
,	O
synergize	O
with	O
NF-kappaB	S-protein
and	O
Tat	S-protein
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	E-protein
(	O
STATs	S-protein
)	O
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
in	O
response	O
to	O
cytokine	S-protein
and	O
growth	B-protein
factor	E-protein
stimulation	O
of	O
cell	B-protein
surface	I-protein
receptors	E-protein
.	O

Tal-1	S-protein
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

This	O
RXR	S-protein
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	S-protein
-specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross-talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	B-protein
-RARalpha403	I-protein
heterodimer	E-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stress-activated	B-protein
protein	I-protein
kinases	E-protein
(	O
SAPK	S-protein
)	O
are	O
activated	O
after	O
CD40	S-protein
cross-linking	O
on	O
various	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
or	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	E-cell_type
.	O

ACH-2	S-cell_line
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	S-protein
(	O
TNF-alpha	S-protein
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	S-protein
,	O
YY1	S-protein
,	O
and	O
octamer-like	B-protein
factors	E-protein
binding	O
to	O
the	O
-90/-79	B-DNA
sequence	E-DNA
within	O
the	O
proximal	B-DNA
IL-5	I-DNA
promoter	E-DNA
are	O
involved	O
in	O
suppression	O
of	O
IL-5	S-protein
transcription	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

The	O
impaired	O
transcription	B-protein
factor	I-protein
AP-1	E-protein
DNA	O
binding	O
activity	O
in	O
lymphocytes	S-cell_type
derived	O
from	O
subjects	O
with	O
some	O
symptoms	O
of	O
premature	O
aging	O
.	O

Expression	O
of	O
v-src	S-DNA
in	O
T	B-cell_type
cells	E-cell_type
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

Point	O
mutation	O
of	O
a	O
GATA-1	B-DNA
site	E-DNA
at	O
-230	O
reduced	O
promoter	O
activity	O
by	O
37	O
%	O
.	O

In	O
this	O
regard	O
,	O
anti-inflammatory	B-protein
cytokines	E-protein
inhibited	O
LPS	O
plus	O
GM-CSF	S-protein
-stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL-1	B-protein
beta	E-protein
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up-regulation	O
of	O
endogenous	O
IL-1ra	O
production	O
.	O

Finally	O
,	O
IL-2	S-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
JAK1	S-protein
and	O
JAK3	S-protein
,	O
while	O
IL-12	S-protein
induced	O
phosphorylation	O
of	O
JAK2	S-protein
and	O
TYK2	S-protein
in	O
both	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
and	I-cell_line
NK3.3	I-cell_line
cells	E-cell_line
.	O

Inclusion	O
of	O
this	O
LTR	S-DNA
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	B-cell_line
simian	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	E-cell_line
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
T-lymphocytes	S-cell_type
,	O
also	O
inhibited	O
IL-2	S-protein
secretion	O
,	O
IL-2R	B-protein
alpha	E-protein
cell	O
surface	O
expression	O
,	O
and	O
T-cell	O
proliferation	O
.	O

Role	O
for	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	E-protein
in	O
viral	B-DNA
promoter	E-DNA
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O

Here	O
we	O
show	O
that	O
the	O
binding	O
of	O
calcineurin	S-protein
to	O
NFAT	S-protein
is	O
substantially	O
increased	O
when	O
calcineurin	S-protein
is	O
activated	O
with	O
calmodulin	S-protein
and	O
calcium	O
.	O

The	O
pigment	O
also	O
inhibited	O
apoptosis	O
in	O
dexamethasone-treated	B-cell_line
rat	I-cell_line
thymocytes	E-cell_line
and	O
in	O
UV-irradiated	B-cell_line
Jurkat	I-cell_line
cells	E-cell_line
as	O
judged	O
by	O
DNA	O
ladder	O
formation	O
,	O
cellular	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
analysis	O
.	O

In	O
resting	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
many	O
of	O
these	O
NF-kappa	B-protein
B/Rel	I-protein
factors	E-protein
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin-rich	B-protein
inhibitory	I-protein
proteins	E-protein
,	O
including	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
.	O

Immune	O
functions	O
,	O
clinical	O
parameters	O
and	O
hormone	O
receptor	O
status	O
in	O
breast	O
cancer	O
patients	O
.	O

These	O
data	O
are	O
the	O
first	O
demonstration	O
of	O
a	O
role	O
for	O
a	O
STAT	B-protein
family	I-protein
member	E-protein
in	O
the	O
regulation	O
of	O
a	O
viral	B-DNA
promoter	E-DNA
.	O

In	O
contrast	O
,	O
c-fos	B-RNA
mRNA	E-RNA
is	O
absent	O
from	O
resting	O
T	B-cell_type
cells	E-cell_type
and	O
is	O
induced	O
on	O
PHA	S-protein
activation	O
.	O

Expression	O
of	O
Ah	B-protein
receptor	E-protein
(	O
TCDD	B-protein
receptor	E-protein
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

This	O
finding	O
may	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
reasons	O
for	O
the	O
prevalence	O
of	O
lupus	O
in	O
females	O
and	O
of	O
the	O
estrogenic	O
effects	O
on	O
SLE	O
disease	O
activity	O
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	S-protein
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	E-protein
and	O
upregulation	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecule	I-protein
ICAM-1	E-protein
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	S-protein
function	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA-nonresponsive	O
cases	O
from	O
ATRA-responsive	O
true	O
APL	O
.	O

We	O
suggest	O
that	O
HSF2-beta	S-protein
acts	O
as	O
a	O
negative	O
regulator	O
of	O
HSF2	S-protein
activity	O
during	O
hemin-mediated	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	E-cell_line
.	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl-6	S-protein
,	O
suggesting	O
up-regulation	O
of	O
Bcl-6	S-protein
expression	O
in	O
this	O
tumor	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
.	O

The	O
data	O
presented	O
here	O
indicate	O
that	O
(	O
1	O
)	O
the	O
12-lipoxygenase	S-protein
activity	O
of	O
murine	O
macrophages	O
is	O
upregulated	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
IL-4	S-protein
and/or	O
IL-13	S-protein
,	O
(	O
2	O
)	O
this	O
upregulation	O
requires	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT6	E-protein
,	O
and	O
(	O
3	O
)	O
the	O
constitutive	O
expression	O
of	O
the	O
enzyme	O
appears	O
to	O
be	O
STAT6	S-protein
independent	O
.	O

Tax1	S-protein
does	O
not	O
bind	O
DNA	O
directly	O
but	O
regulates	O
transcription	O
through	O
protein-protein	O
interactions	O
with	O
sequence-specific	B-protein
transcription	I-protein
factors	E-protein
.	O

Thus	O
,	O
the	O
cooperation	O
of	O
two	O
general	O
cellular	O
transcription	O
factors	O
may	O
allow	O
for	O
the	O
selective	O
downregulation	O
of	O
HIV	O
transcription	O
.	O

Thymocytes	S-cell_type
expressed	O
four-	O
to	O
10-fold	O
greater	O
amounts	O
of	O
the	O
3.5	B-RNA
kb	I-RNA
transcript	E-RNA
than	O
other	O
tissues	O
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	B-protein
binding	I-protein
proteins	E-protein
of	O
85	B-protein
,	I-protein
75	I-protein
,	I-protein
and	I-protein
54	I-protein
kDa	E-protein
,	O
whereas	O
in	O
Tax	B-cell_line
expressing	I-cell_line
cells	E-cell_line
the	O
85-kDa	B-protein
protein	E-protein
and	O
a	O
92-kDa	B-protein
DNA	I-protein
binding	I-protein
protein	E-protein
were	O
constitutively	O
induced	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	E-DNA
only	O
in	O
lymphocytes	S-cell_type
is	O
a	O
ubiquitously	B-protein
active	I-protein
transcription	I-protein
factor	E-protein
.	O

Simple	O
activation	O
of	O
RXRs	S-protein
is	O
not	O
sufficient	O
to	O
induce	O
apoptosis	O
of	O
the	O
cells	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti-tumor	O
CTL	O
responses	O
.	O

Tax	S-protein
activation	O
of	O
the	O
CD28RE	S-DNA
is	O
partially	O
mediated	O
by	O
a	O
member	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
,	O
NF-AT1	S-protein
.	O

Using	O
this	O
technique	O
we	O
have	O
isolated	O
several	O
differentially	B-DNA
expressed	I-DNA
sequence	I-DNA
tags	E-DNA
(	O
DESTs	S-DNA
)	O
from	O
the	O
mouse	B-cell_line
thymocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
WEHI	I-cell_line
7.2	E-cell_line
.	O

Overexpression	O
of	O
UDG	S-protein
in	O
Saos	B-cell_line
2	I-cell_line
cells	E-cell_line
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

Stimulation	O
of	O
the	O
cAMP-dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	B-cell_type
cells	E-cell_type
.	O

Costimulation	O
requirement	O
for	O
AP-1	S-protein
and	O
NF-kappa	B-protein
B	E-protein
transcription	O
factor	O
activation	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

The	O
critical	O
region	O
of	O
THR	S-protein
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B-protein
box	E-protein
of	O
the	O
DNA	B-protein
binding	I-protein
domain	E-protein
.	O

After	O
exercise	O
following	O
placebo	O
administration	O
we	O
observed	O
increases	O
in	O
concentrations	O
of	O
blood	O
substrates	O
,	O
plasma	B-protein
adrenocorticotropin	E-protein
(	O
ACTH	S-protein
)	O
,	O
growth	O
hormone	O
and	O
cortisol	O
and	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	E-protein
in	O
lymphocytes	S-cell_type
without	O
changes	O
in	O
the	O
dissociation	O
constant	O
.	O

Some	O
of	O
these	O
oxidants	O
are	O
known	O
to	O
modulate	O
the	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Dex	O
inhibited	O
the	O
IL-2	B-DNA
promoter	E-DNA
and	O
the	O
AP-1	S-DNA
,	O
but	O
not	O
the	O
NF-AT	S-DNA
and	O
NF-kB	B-DNA
plasmids	E-DNA
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	B-DNA
and	I-DNA
muB	I-DNA
sites	E-DNA
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B-protein
proteins	E-protein
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
investigated	O
the	O
trophic	O
effect	O
resulting	O
from	O
activation	O
of	O
such	O
a	O
receptor	O
by	O
using	O
the	O
reporter	B-DNA
gene	E-DNA
strategy	O
.	O

Therefore	O
,	O
Tat	S-protein
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	E-DNA
in	O
transfected	O
K562	B-cell_line
cells	E-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	E-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA
sites	E-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
.	O

Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
``	O
dose-sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O

Histamine	O
modulates	O
the	O
expression	O
of	O
c-fos	S-DNA
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	B-protein
receptor	E-protein
in	O
the	O
human	B-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	E-cell_line
.	O

An	O
LT	B-DNA
promoter	I-DNA
(	I-DNA
LT-293	I-DNA
)	I-DNA
CAT	I-DNA
construct	E-DNA
that	O
contained	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	E-DNA
was	O
active	O
in	O
the	O
LT-producing	B-cell_line
C81-66-45	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
which	O
contains	O
defective	O
HTLV-I	O
but	O
expresses	O
tax	S-protein
.	O

Thus	O
,	O
replication	O
of	O
the	O
transcriptional	B-DNA
template	E-DNA
is	O
not	O
a	O
prerequisite	O
for	O
expression	O
with	O
late	O
kinetics	O
,	O
a	O
finding	O
inconsistent	O
with	O
the	O
current	O
models	O
which	O
posit	O
a	O
cis-active	O
relationship	O
between	O
lytic	O
EBV	O
DNA	O
replication	O
and	O
late	O
gene	O
expression	O
.	O

Nasal	B-cell_type
T/NK-cell	I-cell_type
lymphomas	E-cell_type
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
lineage	E-cell_type
or	O
of	O
T-cell	B-cell_type
lineage	E-cell_type
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T-cell	B-DNA
receptor	I-DNA
(	I-DNA
TcR	I-DNA
)	I-DNA
gene	E-DNA
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O

Viral	B-DNA
DNA	I-DNA
fragments	E-DNA
that	O
potentially	O
contain	O
oriP	S-DNA
were	O
cloned	O
into	O
a	O
plasmid	S-DNA
that	O
contains	O
the	O
hygromycin	B-DNA
resistance	I-DNA
gene	E-DNA
.	O

When	O
activated	O
,	O
glucocorticoid	B-protein
receptors	E-protein
form	O
a	O
dimer	S-protein
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

However	O
,	O
TNF	S-protein
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	S-protein
to	O
induce	O
NF-kappa	B-protein
B	E-protein
in	O
T	B-cell_type
lymphocytes	E-cell_type
from	O
TNFRp55	S-protein
-deficient	O
mice	O
.	O

Exposure	O
of	O
cells	O
to	O
adverse	O
environmental	O
conditions	O
invokes	O
a	O
genetically	O
programmed	O
series	O
of	O
events	O
resulting	O
in	O
the	O
induction	O
of	O
specific	B-DNA
genes	E-DNA
.	O

The	O
tal-1	B-DNA
gene	E-DNA
,	O
frequently	O
activated	O
in	O
human	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
,	O
is	O
expressed	O
in	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	E-cell_type
during	O
normal	O
hematopoiesis	O
.	O

The	O
B	B-protein
cell-associated	I-protein
surface	I-protein
molecule	I-protein
CD40	E-protein
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Lymphocyte	O
glucocorticoid	B-protein
receptor	E-protein
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	B-DNA
motifs	E-DNA
and	O
of	O
a	O
related	O
16-bp	O
SEE	S-DNA
(	O
SRF/ETS	B-DNA
element	E-DNA
)	O
motif	O
found	O
in	O
the	O
HCMV	B-DNA
and	I-DNA
chimpanzee	I-DNA
CMV	I-DNA
MIE	I-DNA
enhancers	E-DNA
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	B-DNA
wild-type	I-DNA
and	I-DNA
mutant	I-DNA
elements	E-DNA
added	O
upstream	O
to	O
the	O
SCMV	B-DNA
MIE	E-DNA
or	O
simian	B-DNA
virus	I-DNA
40	I-DNA
minimal	I-DNA
promoter	I-DNA
regions	E-DNA
in	O
the	O
U-937	S-cell_line
,	O
K-562	S-cell_line
,	O
HL-60	S-cell_line
,	O
THP-1	S-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

HIV-1	O
reactivation	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	S-protein
cross-linking	O
by	O
ligands	O
of	O
the	O
CDR2-loop	S-protein
in	O
extracellular	B-protein
domain	I-protein
1	E-protein
.	O

Among	O
these	O
cytokines	S-protein
,	O
the	O
expression	O
of	O
IFN-gamma	S-protein
was	O
associated	O
with	O
high	O
levels	O
of	O
serum	B-protein
AST/ALT	E-protein
.	O

We	O
calculated	O
binding	O
affinity	O
(	O
Kd	O
;	O
nmol/L	O
)	O
and	O
capacity	O
(	O
Bmax	O
;	O
sites/cell	O
)	O
for	O
dexamethasone	O
and	O
cortisol	O
from	O
homologous	O
and	O
heterologous	O
competition	O
curves	O
for	O
specific	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
sites	O
on	O
HML	S-cell_type
isolated	O
from	O
the	O
blood	O
of	O
normotensive	O
volunteers	O
and	O
subjects	O
with	O
essential	O
hypertension	O
.	O

The	O
distribution	O
of	O
myeloid	B-protein
lineage-associated	I-protein
cytokine	I-protein
receptors	E-protein
and	O
lysosomal	B-protein
proteins	E-protein
was	O
analyzed	O
in	O
human	B-cell_line
CD34+	I-cell_line
cord	I-cell_line
blood	I-cell_line
cell	I-cell_line
(	I-cell_line
CB	I-cell_line
)	I-cell_line
subsets	E-cell_line
at	O
different	O
stages	O
of	O
myeloid	O
commitment	O
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

Glucocorticoid	B-protein
receptors	E-protein
in	O
normal	B-cell_type
leukocytes	E-cell_type
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	E-protein
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
promoters	E-DNA
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA-B	S-protein
is	O
a	O
tissue-	B-protein
,	I-protein
promoter-	I-protein
,	I-protein
and	I-protein
factor-specific	I-protein
coactivator	E-protein
and	O
that	O
OCA-B	S-protein
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell-specific	O
activation	O
of	O
immunoglobulin	B-DNA
promoters	E-DNA
.	O

Cortivazol	O
significantly	O
induced	O
GR	B-RNA
mRNA	E-RNA
in	O
the	O
normal	B-cell_line
CEM-C7	E-cell_line
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex-resistant	B-cell_line
clones	E-cell_line
,	O
although	O
the	O
dex-resistant	B-cell_line
clones	E-cell_line
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	B-cell_type
cells	E-cell_type
for	O
significant	O
GR	B-RNA
mRNA	E-RNA
induction	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
Stat4	S-protein
,	O
which	O
is	O
necessary	O
for	O
the	O
differentiation	O
of	O
naive	B-cell_type
T	I-cell_type
cells	E-cell_type
into	O
polarized	O
Th1	B-cell_type
cells	E-cell_type
,	O
is	O
not	O
sufficient	O
to	O
induce	O
phenotype	O
reversal	O
of	O
human	B-cell_type
Th2	I-cell_type
cells	E-cell_type
.	O

Overexpression	O
of	O
NF-IL6	S-protein
enhanced	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
reporter	I-DNA
gene	E-DNA
linked	O
to	O
the	O
PRE-I-thymidine	B-protein
kinase	E-protein
or	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	E-DNA
more	O
than	O
10-fold	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
.	O

Preparation	O
and	O
analysis	O
of	O
bone	B-cell_type
marrow	I-cell_type
cells	E-cell_type
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	B-cell_type
population	E-cell_type
.	O

By	O
fusing	O
lymphoblastoid	B-cell_type
cells	E-cell_type
of	O
an	O
AGS	O
patient	O
that	O
exhibited	O
a	O
microdeletion	O
in	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
Chr	I-DNA
20	E-DNA
encompassing	O
bands	O
p11.23	B-DNA
to	I-DNA
p12.3	E-DNA
with	O
rodent	B-cell_line
thermosensitive	I-cell_line
mutant	I-cell_line
cells	E-cell_line
(	O
CHOtsH1-1	S-cell_line
)	O
deficient	O
in-leucyl-tRNA	B-protein
synthetase	E-protein
,	O
we	O
isolated	O
a	O
somatic	B-cell_line
cell	I-cell_line
hybrid	E-cell_line
segregating	O
the	O
deleted	O
human	O
Chr	B-DNA
20	E-DNA
.	O

Imbalanced	O
expression	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
isoforms	E-protein
in	O
cultured	B-cell_type
lymphocytes	E-cell_type
from	O
a	O
patient	O
with	O
systemic	O
glucocorticoid	O
resistance	O
and	O
chronic	O
lymphocytic	O
leukemia	O
.	O

IFN-alpha/beta	S-protein
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
2	I-protein
protein	E-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
clones	E-cell_line
.	O

The	O
immunolabeling	O
of	O
Rap1	S-protein
was	O
significantly	O
higher	O
(	O
P	O
<	O
.001	O
)	O
in	O
untreated	O
euthymic	O
,	O
depressed	O
,	O
and	O
manic	O
patients	O
than	O
in	O
healthy	O
persons	O
.	O

Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	B-cell_type
cells	E-cell_type
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O

A	O
critical	O
role	O
of	O
Sp1-	B-protein
and	I-protein
Ets-related	I-protein
transcription	I-protein
factors	E-protein
in	O
maintaining	O
CTL-specific	O
expression	O
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	E-DNA
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	S-protein
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	S-protein
not	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	E-protein
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

In	O
contrast	O
,	O
eosinophils	S-cell_type
purified	O
from	O
a	O
patient	O
with	O
Churg-Strauss	O
syndrome	O
and	O
from	O
six	O
patients	O
with	O
reactive	O
eosinophilias	O
attributed	O
to	O
allergy	O
,	O
parasitic	O
infection	O
,	O
or	O
drug	O
reaction	O
showed	O
a	O
polyclonal	O
pattern	O
of	O
X-inactivation	O
by	O
HUMARA	S-DNA
analysis	O
.	O

Repression	O
by	O
Ikaros	S-protein
and	O
Aiolos	S-protein
is	O
mediated	O
through	O
histone	B-protein
deacetylase	I-protein
complexes	E-protein
.	O

There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O

This	O
study	O
demonstrates	O
that	O
a	O
T	O
cell-mediated	O
immune	O
response	O
as	O
well	O
as	O
an	O
endotoxic	O
challenge	O
during	O
pregnancy	O
can	O
induce	O
anomalies	O
in	O
HPA	O
axis	O
function	O
in	O
adulthood	O
.	O

The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	B-protein
protein	E-protein
(	O
also	O
called	O
E4bp4	S-protein
)	O
,	O
but	O
not	O
of	O
Hlf	S-protein
,	O
Dbp	S-protein
,	O
or	O
Tef	S-protein
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL-3	S-protein
in	O
mouse	B-cell_line
pro-B	I-cell_line
cell	I-cell_line
lines	E-cell_line
(	O
Baf-3	S-cell_line
and	O
FL5.12	S-cell_line
)	O
.	O

The	O
suppressive	O
effect	O
of	O
liposomal	O
MPL	O
in	O
comparison	O
with	O
free	O
drug	O
was	O
significantly	O
prolonged	O
(	O
>	O
120	O
h	O
vs	O
<	O
18	O
h	O
)	O
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	S-protein
and	O
tissue	B-protein
factor	E-protein
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Thus	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
of	O
cytolytic	O
effector	O
cell	O
function	O
with	O
HER-2/neu	S-protein
expression	O
of	O
the	O
tumor	O
(	O
P	O
=	O
0.003	O
)	O
,	O
and	O
HER-2/neu	S-protein
overexpression	O
correlated	O
with	O
a	O
negative	O
estrogen	B-protein
receptor	E-protein
status	O
(	O
P	O
=	O
0.005	O
)	O
.	O

These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	O
and	O
the	O
regulated	O
degradation	O
of	O
IkappaB-alpha	S-protein
,	O
induced	O
by	O
TNF	S-protein
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	S-protein
,	O
independent	O
of	O
age	O
.	O

Recently	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signal	O
transduction	O
pathways	O
activated	O
by	O
these	O
cytokines	S-protein
in	O
eosinophils	S-cell_type
.	O

In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	B-cell_type
subsets	E-cell_type
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	S-RNA
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT-PCR	O
.	O

Multiple	O
transcription	B-protein
factors	E-protein
are	O
required	O
for	O
activation	O
of	O
human	B-DNA
interleukin	I-DNA
9	I-DNA
gene	E-DNA
in	O
T	B-cell_type
cells	E-cell_type
.	O

Jak3	S-protein
is	O
associated	O
with	O
CD40	S-protein
and	O
is	O
critical	O
for	O
CD40	S-protein
induction	O
of	O
gene	O
expression	O
in	O
B	B-cell_type
cells	E-cell_type
.	O

Campomelic	O
dysplasia	O
(	O
CMPD1	O
)	O
and	O
autosomal	O
XY	O
sex	O
reversal	O
(	O
SRA1	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
SRY-related	B-DNA
gene	I-DNA
SOX9	E-DNA
on	O
17q	S-DNA
.	O

The	O
distribution	O
of	O
this	O
integral	B-protein
membrane	I-protein
protein	E-protein
is	O
restricted	O
to	O
certain	O
tissues	O
where	O
its	O
level	O
of	O
expression	O
is	O
modulated	O
by	O
multiple	O
exogenous	O
stimuli	O
.	O

Changes	O
in	O
triiodothyronine	O
(	O
T3	O
)	O
mononuclear	O
leukocyte	O
receptor	O
kinetics	O
after	O
T3	O
administration	O
and	O
multiple	O
cold-air	O
exposures	O
.	O

The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B-DNA
3'-UTR	E-DNA
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	S-DNA
for	O
CN	B-protein
A	I-protein
(	I-protein
catalytic	I-protein
)	I-protein
and	I-protein
CN	I-protein
B	I-protein
(	I-protein
regulatory	I-protein
)	I-protein
subunits	E-protein
also	O
augments	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	E-DNA
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O

No	O
unifying	O
hypothesis	O
has	O
yet	O
emerged	O
explaining	O
this	O
collection	O
of	O
data	O
.	O

Whether	O
a	O
cortisol	O
resistance	O
or	O
a	O
reduced	O
availability	O
of	O
the	O
metabolic	O
substrates	O
necessary	O
to	O
develop	O
the	O
effect	O
of	O
glucocorticoids	O
is	O
responsible	O
for	O
this	O
has	O
not	O
been	O
established	O
.	O

Dysregulation	O
of	O
monocytic	B-protein
nuclear	I-protein
factor-kappa	I-protein
B	E-protein
by	O
oxidized	O
low-density	B-protein
lipoprotein	E-protein
.	O

Human	B-cell_type
endothelial	I-cell_type
cells	E-cell_type
were	O
exposed	O
to	O
hypoxia	O
in	O
the	O
presence	O
or	O
absence	O
of	O
added	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
examined	O
for	O
expression	O
of	O
functional	O
ICAM-1	S-protein
.	O

v-erbA	S-protein
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	S-protein
function	O
in	O
erythroid	B-cell_type
cell	E-cell_type
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	B-DNA
target	I-DNA
gene	I-DNA
CAII	E-DNA
.	O

Immature	O
thymocytes	S-cell_type
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	B-DNA
genome	E-DNA
and	O
its	O
transcriptional	O
activity	O
.	O

Transcription	B-protein
factors	I-protein
Sp1	E-protein
and	O
AP-2	S-protein
mediate	O
induction	O
of	O
acid	B-protein
sphingomyelinase	E-protein
during	O
monocytic	O
differentiation	O
.	O

EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	S-protein
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O

Both	O
NF-kappa	B-protein
B	E-protein
precursors	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O

In	O
the	O
rare	O
hybrids	O
that	O
continue	O
to	O
express	O
Ig	O
,	O
all	O
other	O
tested	O
B	B-DNA
lymphocyte-specific	I-DNA
genes	E-DNA
also	O
remain	O
active	O
.	O

Furthermore	O
,	O
these	O
conditions	O
did	O
not	O
result	O
in	O
an	O
accumulation	O
of	O
the	O
less	O
mature	O
forms	O
of	O
TF	S-protein
.	O

Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M-CSF	S-protein
by	O
MM-LDL	S-protein
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C-depleted	O
endothelial	B-cell_type
cells	E-cell_type
.	O

The	O
Oct-2	B-protein
transcription	I-protein
factor	E-protein
.	O

Interleukin-6	S-protein
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	S-protein
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	S-protein
in	O
response	O
to	O
IL-1	S-protein
.	O

Although	O
the	O
binding	O
of	O
this	O
complex	O
is	O
not	O
cyclosporin-sensitive	O
,	O
promoter	O
induction	O
is	O
inhibited	O
by	O
cyclosporin	O
treatment	O
.	O

Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	S-protein
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O

The	O
NFAT-controlled	B-DNA
luciferase	I-DNA
gene	I-DNA
system	E-DNA
distinguishes	O
CIF	S-protein
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B-protein
beta	I-protein
1	E-protein
and	O
TGF	B-protein
beta	I-protein
2	E-protein
and	O
the	O
glucocorticoids	O
.	O

These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	B-protein
kappa	I-protein
B	E-protein
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

We	O
hypothesize	O
that	O
this	O
110-kDa	B-protein
protein	E-protein
may	O
be	O
a	O
functionally	O
important	O
B	B-protein
cell-specific	I-protein
co-activator	E-protein
of	O
A-MYB	S-protein
.	O

Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	S-cell_type
.	O

These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	S-protein
-mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	B-cell_type
samples	E-cell_type
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	O
glucocorticoid	B-protein
receptor	E-protein
binding	O
is	O
altered	O
in	O
this	O
'stressful	O
'	O
disease	O
.	O

Human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
2	I-DNA
gene	E-DNA
.	O

Similar	O
to	O
IL-4	S-protein
,	O
IL-13	B-RNA
mRNA	E-RNA
expression	O
was	O
highest	O
in	O
T-cell	B-cell_line
populations	E-cell_line
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL-13	B-DNA
and	I-DNA
IL-4	I-DNA
genes	E-DNA
in	O
a	O
coordinate	O
manner	O
.	O

A	O
third	O
tyrosine	O
within	O
the	O
amino-terminal	B-protein
region	E-protein
(	O
Y145	O
)	O
appears	O
to	O
be	O
the	O
most	O
important	O
for	O
optimal	O
SLP-76	S-protein
function	O
,	O
as	O
altering	O
it	O
alone	O
to	O
phenylalanine	O
has	O
a	O
potent	O
impact	O
on	O
SLP-76	S-protein
augmentation	O
of	O
NFAT	B-DNA
promoter	E-DNA
activity	O
.	O

Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL-6	S-protein
gene	O
expression	O
.	O

Because	O
FasL	O
gene	O
activation	O
following	O
CD16	S-protein
cross-linking	O
is	O
regulated	O
by	O
the	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
(	O
NFAT	S-protein
)	O
,	O
we	O
examined	O
the	O
effect	O
of	O
oxidative	O
stresses	O
on	O
NFAT	S-protein
activation	O
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF-AT	S-protein
were	O
similar	O
to	O
those	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	E-protein
and	O
only	O
a	O
small	O
amount	O
of	O
P65	S-protein
was	O
detected	O
in	O
NF	B-protein
(	I-protein
P	I-protein
)	E-protein
in	O
crude	O
nuclear	O
extracts	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B-DNA
elements	E-DNA
in	O
their	O
long	B-DNA
terminal	I-DNA
repeats	E-DNA
(	O
LTRs	S-DNA
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B-DNA
elements	E-DNA
in	O
the	O
HIV-2	B-DNA
LTR	E-DNA
.	O

The	O
IL-2	S-protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-DNA
response	I-DNA
element	E-DNA
(	O
CD28RE	S-DNA
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage-competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	E-cell_type
and	O
CEMx174	B-cell_line
cultures	E-cell_line
.	O

In	O
1G5	S-cell_line
,	O
a	O
Jurkat-derived	B-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
stably	O
transfected	O
with	O
a	O
luciferase	B-DNA
gene	E-DNA
driven	O
by	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	S-DNA
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	B-DNA
LTR	E-DNA
-mediated	O
reporter	B-DNA
gene	E-DNA
activity	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
tTG	S-protein
,	O
acting	O
on	O
the	O
pRB	B-protein
protein	E-protein
,	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
cell	O
progression	O
through	O
the	O
death	O
program	O
.	O

Overexpression	O
of	O
beta-adrenergic	O
receptor	O
kinase	O
1	O
carboxyl-terminal	O
peptide	O
in	O
JY25	B-cell_line
cells	E-cell_line
also	O
inhibited	O
Raf-1	S-protein
and	O
ERK1	S-protein
activity	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
G	O
betagamma	O
subunits	O
in	O
the	O
signal	O
transduction	O
generated	O
through	O
activation	O
of	O
MAPK	S-protein
pathway	O
by	O
TCC	S-protein
assembly	O
in	O
the	O
plasma	O
membrane	O
.	O

A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	B-protein
factors	E-protein
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	S-protein
activation	O
,	O
occurring	O
in	O
mononuclear	B-cell_type
cells	E-cell_type
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

The	O
v-erbA	B-protein
oncoprotein	E-protein
represents	O
a	O
retrovirus-transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	B-protein
hormone	I-protein
(	I-protein
T3/T4	I-protein
)	I-protein
receptor	I-protein
c-erbA	I-protein
(	I-protein
type	I-protein
alpha	I-protein
)	E-protein
.	O

The	O
effect	O
of	O
Rho	S-protein
on	O
AP-1	S-protein
is	O
independent	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	E-protein
pathway	O
,	O
as	O
a	O
dominant-negative	B-protein
MEK	E-protein
and	O
a	O
MEK	S-protein
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	S-protein
-induced	O
AP-1	S-protein
activity	O
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	B-cell_type
cells	E-cell_type
we	O
observed	O
that	O
this	O
RXR	S-protein
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	S-protein
-mediated	O
commitment	O
of	O
EML	B-cell_type
cells	E-cell_type
to	O
the	O
granulocyte	B-cell_type
lineage	E-cell_type
or	O
in	O
transactivating	O
RAR-RXR	B-DNA
response	I-DNA
elements	E-DNA
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	B-protein
PKC	I-protein
isoenzymes	E-protein
,	O
including	O
PKC-zeta	S-protein
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
and	O
macrophages	S-cell_type
.	O

The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	B-cell_line
granulocyte-macrophage	I-cell_line
colony-stimulating	I-cell_line
factor	I-cell_line
(	I-cell_line
GM-CSF	I-cell_line
)	I-cell_line
-dependent	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
UT-7	S-cell_line
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	S-protein
.	O

Transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	E-DNA
is	O
regulated	O
in	O
part	O
by	O
cellular	B-protein
factors	E-protein
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	B-protein
ligand	E-protein
(	O
FasL	S-protein
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O

The	O
resultant	O
primer	B-DNA
products	E-DNA
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O

The	O
induction	O
of	O
ICAM-1	S-protein
,	O
VCAM-1	S-protein
,	O
and	O
ELAM-1	S-protein
by	O
TNF	S-protein
in	O
MVEC	S-cell_line
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down-regulated	O
by	O
PAO	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Furthermore	O
,	O
transient-cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	S-protein
(	O
and	O
not	O
Elf-1	S-protein
)	O
can	O
transactivate	O
the	O
c-fes	B-DNA
promoter	E-DNA
in	O
nonmyeloid	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF-kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5-3335	O
(	O
HIV-1	O
Tat	S-protein
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O

With	O
one	O
exception	O
,	O
these	O
were	O
all	O
increases	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	E-cell_type
and	O
monocytes	S-cell_type
and	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	O
receptor	O
transcripts	O
similar	O
to	O
those	O
of	O
normal	B-cell_type
cells	E-cell_type
.	O

We	O
have	O
developed	O
a	O
novel	O
assay	O
to	O
monitor	O
the	O
active	O
,	O
GTP-bound	B-protein
form	E-protein
of	O
Rap1	S-protein
based	O
on	O
the	O
differential	O
affinity	O
of	O
Rap1GTP	S-protein
and	O
Rap1GDP	S-protein
for	O
the	O
Rap	B-protein
binding	I-protein
domain	E-protein
of	O
RalGDS	S-protein
(	O
RBD	S-protein
)	O
.	O

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	B-cell_line
transfected	I-cell_line
cells	E-cell_line
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	S-protein
treatment	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
AP-1	E-protein
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	B-protein
cell	I-protein
Ig	E-protein
production	O
,	O
were	O
reduced	O
by	O
TGF-beta	S-protein
.	O

The	O
action	O
of	O
adenoviral	B-protein
E1A	I-protein
oncoprotein	E-protein
on	O
host	B-DNA
immune-response	I-DNA
genes	E-DNA
has	O
been	O
attributed	O
to	O
interaction	O
with	O
p300/CBP-type	B-protein
transcriptional	I-protein
coactivators	E-protein
in	O
competition	O
with	O
endogenous	B-protein
transcription	I-protein
factors	E-protein
such	O
as	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	E-protein
.	O

A-myb	S-protein
is	O
expressed	O
in	O
a	O
subpopulation	O
of	O
normal	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
activated	O
in	O
vivo	O
and	O
localised	O
in	O
the	O
germinal	O
center	O
of	O
peripheral	O
lymphoid	O
organs	O
and	O
is	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
all	O
other	O
mature	O
or	O
immature	B-cell_type
haematopoietic	I-cell_type
populations	E-cell_type
studied	O
,	O
including	O
bone	B-cell_type
marrow	I-cell_type
cells	E-cell_type
,	O
T	B-cell_type
lymphocytes	E-cell_type
,	O
granulocytes	S-cell_type
,	O
monocytes	S-cell_type
,	O
either	O
at	O
rest	O
or	O
after	O
in	O
vitro	O
activation	O
.	O

The	O
stability	O
of	O
c-Fos	S-protein
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

Expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	E-protein
on	O
alveolar	B-cell_type
lymphocytes	E-cell_type
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O

Platelet	B-protein
glycoprotein	E-protein
(	O
GP	S-protein
)	O
Ib-IX-V	S-protein
is	O
a	O
multisubunit	B-protein
adhesion	I-protein
receptor	E-protein
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	S-protein
-mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor-associated	O
tyrosine	B-protein
kinase	E-protein
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

To	O
determine	O
whether	O
different	O
cellular	B-protein
factors	E-protein
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	S-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	E-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	E-DNA
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

Therefore	O
,	O
activation	O
of	O
Stat3	S-protein
is	O
essential	O
for	O
IL-6	S-protein
-induced	O
macrophage-differentiation	O
and	O
programmed	O
cell	O
death	O
in	O
this	O
model	O
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	B-protein
cell	I-protein
surface	I-protein
antigen	E-protein
expression	O
;	O
(	O
c	O
)	O
down-regulation	O
of	O
c-myc	B-protein
transcripts	E-protein
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
gene	E-DNA
expression	O
.	O

The	O
class	B-protein
II-specific	I-protein
transcription	I-protein
factors	I-protein
RFX	E-protein
and	O
CIITA	S-protein
are	O
also	O
required	O
for	O
expression	O
,	O
as	O
cell	O
lines	O
deficient	O
in	O
these	O
factors	O
failed	O
to	O
allow	O
transcription	O
from	O
the	O
DM	B-DNA
promoters	E-DNA
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
generation	O
,	O
on	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
.	O

As	O
we	O
reported	O
previously	O
,	O
MNDA	B-RNA
mRNA	E-RNA
level	O
in	O
adherent	O
monocytes	S-cell_type
is	O
elevated	O
by	O
IFN-alpha	S-protein
;	O
in	O
this	O
study	O
,	O
we	O
further	O
assessed	O
MNDA	S-protein
expression	O
in	O
in	O
vitro	O
monocyte-derived	O
macrophages	S-cell_type
.	O

Increasing	O
the	O
levels	O
of	O
BCL-2	S-protein
retarded	O
the	O
G0	O
--	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin-dependent	B-protein
kinase	E-protein
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O

Since	O
the	O
AES	B-protein
proteins	E-protein
are	O
part	O
of	O
a	O
set	O
of	O
transcriptional	O
repressors	O
encoded	O
by	O
the	O
Enhancer	B-DNA
of	I-DNA
split	I-DNA
[	I-DNA
E	I-DNA
(	I-DNA
spl	I-DNA
)	I-DNA
]	I-DNA
genes	E-DNA
,	O
and	O
since	O
these	O
repressors	O
are	O
activated	O
to	O
suppress	O
cell	O
differentiation	O
in	O
response	O
to	O
Notch	B-protein
receptors	E-protein
signalling	O
,	O
the	O
AES	O
peptides	O
may	O
represent	O
a	O
novel	O
class	O
of	O
self-antigens	S-protein
that	O
deserve	O
further	O
consideration	O
as	O
tumor	B-protein
Ag	E-protein
in	O
epithelial	O
cancers	O
.	O

Moreover	O
,	O
platelet-activating	B-protein
factor	E-protein
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-DNA
proto-oncogenes	I-DNA
c-fos	E-DNA
and	O
c-jun	S-DNA
.	O

To	O
gain	O
further	O
knowledge	O
of	O
the	O
IL-12R	B-protein
complex	E-protein
and	O
the	O
IL-12	S-protein
signal	O
transduction	O
pathway	O
in	O
cytotoxic	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
we	O
studied	O
a	O
number	O
of	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
that	O
had	O
been	O
transformed	O
to	O
permanent	O
growth	O
with	O
Herpesvirus	O
saimiri	O
,	O
an	O
oncogenic	O
virus	O
of	O
nonhuman	O
primates	O
.	O

Therefore	O
,	O
while	O
the	O
total	O
plasma	B-protein
sialyltransferase	E-protein
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
HL-60	S-cell_line
and	O
KG-1	S-cell_line
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	B-protein
NF-kappaB	I-protein
binding	I-protein
site	E-protein
identified	O
in	O
the	O
bcl-x	B-DNA
promoter	E-DNA
significantly	O
decreased	O
Tax	S-protein
-induced	O
transactivation	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	B-cell_type
marrow-derived	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	E-cell_type
and	O
delay	O
their	O
maturation	O
.	O

Tumors	O
with	O
high	O
Ki-67	S-protein
proliferation	O
indices	O
(	O
>	O
20	O
%	O
)	O
were	O
associated	O
with	O
a	O
higher	O
4-year	O
probability	O
of	O
relapse	O
of	O
disease	O
(	O
55.3	O
%	O
versus	O
79.1	O
%	O
;	O
P	O
=	O
0.003	O
)	O
and	O
death	O
(	O
71	O
%	O
versus	O
95.6	O
%	O
;	O
P	O
=	O
0.00005	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
low	O
Ki-67	S-protein
values	O
.	O

Influence	O
of	O
age	O
on	O
the	O
production	O
of	O
Fos	S-protein
and	O
Jun	S-protein
by	O
influenza	B-cell_type
virus-exposed	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Furthermore	O
,	O
this	O
signaling	O
pathway	O
appears	O
not	O
to	O
rely	O
on	O
protein	B-protein
kinase	I-protein
C	E-protein
.	O

The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF-kappaB	S-protein
in	O
a	O
T-lymphocytic	B-cell_line
cell	I-cell_line
line	E-cell_line
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long-distance	O
effect	O
through	O
subsequent	O
TNF-alpha	S-protein
release	O
.	O

Granzyme	O
B	O
gene	O
transcription	O
is	O
induced	O
in	O
activated	O
lymphocytes	S-cell_type
upon	O
antigenic	O
stimulation	O
,	O
and	O
several	O
regulatory	B-DNA
regions	E-DNA
including	O
CBF	S-protein
,	O
AP-1	S-protein
,	O
and	O
Ikaros	B-DNA
binding	I-DNA
sites	E-DNA
have	O
been	O
shown	O
to	O
be	O
essential	O
in	O
the	O
control	O
of	O
granzyme	B-DNA
B	I-DNA
promoter	E-DNA
activation	O
.	O

Sp	B-protein
family	I-protein
members	E-protein
preferentially	O
interact	O
with	O
the	O
promoter	B-DNA
proximal	I-DNA
repeat	E-DNA
within	O
the	O
HTLV-I	B-DNA
enhancer	E-DNA
.	O

Antiandrogens	O
result	O
in	O
protection	O
of	O
both	O
the	O
hinge	B-protein
region	E-protein
and	O
C-terminus	S-protein
of	O
the	O
androgen	B-protein
receptor	E-protein
agonist	O
proteolytic	O
attack	O
,	O
whereas	O
other	O
studies	O
showed	O
that	O
antiestrogens	O
and	O
antiprogestagens	O
expose	O
the	O
C-terminal	B-protein
end	E-protein
of	O
the	O
ligand	B-protein
binding	I-protein
domain	E-protein
of	O
their	O
respective	O
receptors	O
to	O
protease	S-protein
.	O

Now	O
we	O
report	O
that	O
sublytic	O
TCC	S-protein
induced	O
Ras	S-protein
,	O
Raf-1	S-protein
,	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
1	E-protein
activation	O
in	O
JY25	O
B	O
cell	O
line	O
.	O

Uneven	O
X	S-DNA
inactivation	O
in	O
a	O
female	O
monozygotic	O
twin	O
pair	O
with	O
Fabry	O
disease	O
and	O
discordant	O
expression	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
alpha-galactosidase	B-DNA
A	I-DNA
gene	E-DNA
.	O

Both	O
ATF/CRE	B-DNA
motifs	E-DNA
overlap	O
binding	B-DNA
sequences	E-DNA
for	O
the	O
multifunctional	B-protein
YY1	I-protein
transcription	I-protein
factor	E-protein
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	B-protein
factor	E-protein
binding	O
sites	O
,	O
including	O
a	O
NF-kappa	B-DNA
B	I-DNA
element	E-DNA
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	E-protein
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF-kappa	B-protein
B	E-protein
activation	O
in	O
response	O
to	O
TNF	S-protein
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop-helix	B-protein
motifs	E-protein
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

Our	O
investigation	O
of	O
the	O
human	B-DNA
TCR	I-DNA
beta	I-DNA
gene	E-DNA
uncovers	O
a	O
surprisingly	O
complex	O
and	O
tissue-specific	O
structure	O
at	O
the	O
TCR	B-DNA
Vbeta	I-DNA
8.1	I-DNA
promoter	E-DNA
.	O

Interleukin	B-protein
12	E-protein
(	O
IL-12	S-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
cytokine	E-protein
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	E-protein
.	O

The	O
GTPase	B-protein
Rho	E-protein
is	O
known	O
to	O
mediate	O
the	O
assembly	O
of	O
integrin-containing	O
focal	O
adhesions	O
and	O
actin	O
stress	O
fibers	O
.	O

Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	S-protein
entry	O
into	O
the	O
nucleus	O
.	O

Ca2+-modulating	B-protein
cyclophilin	I-protein
ligand	E-protein
(	O
CAML	S-protein
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B-protein
B-binding	I-protein
protein	E-protein
whose	O
overexpression	O
in	O
T	B-cell_type
cells	E-cell_type
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	B-protein
factors	E-protein
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide-based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T-cell-mediated	O
autoimmune	O
diseases	O
.	O

In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	S-protein
did	O
not	O
cross-react	O
with	O
the	O
CMAT	B-protein
protein	E-protein
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF-kappa	B-protein
B	E-protein
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	B-DNA
B-dependent	I-DNA
genes	E-DNA
in	O
microglia	S-cell_type
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B-protein
gamma	E-protein
,	O
or	O
by	O
LPS	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	B-cell_type
progenitors	E-cell_type
to	O
the	O
monocyte/macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M-CSF	B-protein
receptor	E-protein
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL-4	S-protein
-induced	O
germline	S-DNA
Cepsilon	O
transcription	O
.	O

Cell	O
cycle-dependent	O
initiation	O
and	O
lineage-dependent	O
abrogation	O
of	O
GATA-1	S-protein
expression	O
in	O
pure	B-cell_type
differentiating	I-cell_type
hematopoietic	I-cell_type
progenitors	E-cell_type
.	O

Our	O
results	O
seem	O
to	O
confirm	O
a	O
possible	O
role	O
of	O
the	O
transcriptional	B-protein
complex	I-protein
AP-1	E-protein
in	O
activating	O
GST-pi	B-DNA
promoter	E-DNA
in	O
human	B-cell_type
plasma	I-cell_type
cells	E-cell_type
.	O

Chromosome	B-DNA
1	E-DNA
abnormalities	O
with	O
loss	O
of	O
1p36	S-DNA
have	O
been	O
investigated	O
in	O
95	O
breast-cancer	O
samples	O
by	O
means	O
of	O
a	O
dual-target	O
fluorescence	O
in-situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
using	O
the	O
pUC	B-DNA
1.77	E-DNA
and	O
p1-79	B-DNA
probes	E-DNA
,	O
specific	O
for	O
the	O
1q12	B-DNA
and	I-DNA
1p36	I-DNA
regions	E-DNA
,	O
respectively	O
.	O

TCF-1	B-protein
alpha	E-protein
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA-binding	B-protein
regulatory	I-protein
proteins	E-protein
that	O
share	O
the	O
HMG	B-protein
motif	E-protein
in	O
that	O
it	O
is	O
a	O
highly	B-protein
tissue-specific	I-protein
RNA	I-protein
polymerase	I-protein
II	I-protein
transcription	I-protein
factor	E-protein
.	O

In	O
particular	O
,	O
our	O
findings	O
suggest	O
that	O
local	O
metabolism	O
of	O
steroids	O
by	O
normal	O
as	O
well	O
as	O
leukemic	B-cell_type
myeloid	I-cell_type
cells	E-cell_type
influences	O
their	O
responsiveness	O
to	O
D3	O
and	O
retinoids	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	E-protein
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B-protein
Tax	I-protein
protein	E-protein
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	B-DNA
region	E-DNA
spanning	O
base	B-DNA
pairs	I-DNA
-1	I-DNA
to	I-DNA
-275	E-DNA
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	B-protein
factors	E-protein
,	O
is	O
bound	O
by	O
nuclear	B-protein
factors	I-protein
Sp1	E-protein
and	O
IRBP	S-protein
but	O
not	O
by	O
C/EBPs	S-protein
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB-Sp1	B-DNA
composite	I-DNA
site	E-DNA
in	O
P/I-inducible	B-DNA
fas	I-DNA
promoter	E-DNA
activation	O
was	O
verified	O
by	O
using	O
kappaB-	O
Sp1	S-protein
concatamers	O
(	O
-295	B-DNA
to	I-DNA
-286	E-DNA
)	O
in	O
a	O
thymidine	B-DNA
kinase	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
construct	E-DNA
and	O
native	B-DNA
promoter	I-DNA
constructs	E-DNA
in	O
Jurkat	B-cell_line
cells	E-cell_line
overexpressing	O
IkappaB-alpha	S-protein
.	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	B-protein
receptors	E-protein
.	O

Thus	O
,	O
we	O
propose	O
that	O
GATA-3	S-protein
is	O
permissive	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
full	O
IL-4	S-protein
enhancement	O
and	O
may	O
act	O
through	O
GATA	B-DNA
elements	E-DNA
surrounding	O
the	O
IL-13/IL-4	B-DNA
gene	I-DNA
locus	E-DNA
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	B-cell_line
cells	E-cell_line
using	O
a	O
supernatant	O
from	O
the	O
B	B-cell_line
line	E-cell_line
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	E-RNA
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
components	E-DNA
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	B-DNA
elements	E-DNA
.	O

We	O
have	O
previously	O
found	O
that	O
the	O
normal	O
developmental	O
patterns	O
of	O
globin	B-DNA
gene	E-DNA
expression	O
are	O
recapitulated	O
in	O
an	O
experimental	O
system	O
of	O
primary	B-cell_line
cultures	E-cell_line
that	O
support	O
differentiation	O
of	O
erythroid	B-cell_type
progenitors	E-cell_type
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	B-RNA
and	I-RNA
fibronectin	I-RNA
receptor	I-RNA
mRNA	E-RNA
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	S-protein
addition	O
.	O

Engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	E-protein
for	O
antigen	O
activates	O
phospholipase	B-protein
C	E-protein
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	B-cell_type
cells	E-cell_type
with	O
mutant	B-protein
TNFRI	E-protein
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	B-cell_type
cells	E-cell_type
to	O
activate	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
CN	S-protein
activity	O
is	O
rate-limiting	O
for	O
the	O
activation	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
.	O

However	O
,	O
these	O
cells	O
have	O
been	O
impossible	O
to	O
generate	O
given	O
the	O
requirement	O
of	O
GATA-1	S-protein
for	O
Epo	B-protein
receptor	E-protein
expression	O
and	O
red	B-cell_type
cell	E-cell_type
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O

The	O
role	O
of	O
gamma/delta	B-cell_type
T	I-cell_type
cell	I-cell_type
receptor	I-cell_type
positive	I-cell_type
cells	E-cell_type
in	O
pregnancy	O
.	O

Pretreatment	O
of	O
ACH-2	B-cell_line
T	I-cell_line
cells	E-cell_line
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF-alpha	S-protein
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O

This	O
enzyme	O
releases	O
arachidonic	O
acid	O
and	O
lyso-phospholipids	O
from	O
membranes	O
which	O
are	O
metabolized	O
to	O
eicosanoids	O
and	O
platelet-activating-factor	O
.	O

By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	S-protein
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	S-protein
preincubation	O
.	O

An	O
increase	O
in	O
the	O
intracellular	O
Ca2+	O
concentration	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
Rap1	S-protein
activation	O
since	O
it	O
was	O
induced	O
by	O
agents	O
that	O
increase	O
intracellular	O
Ca2+	O
and	O
inhibited	O
by	O
a	O
Ca2+-chelating	O
agent	O
.	O

Putative	O
cis-acting	B-DNA
control	I-DNA
elements	E-DNA
present	O
within	O
a	O
300-bp	B-DNA
core	I-DNA
promoter	E-DNA
included	O
two	O
ets	B-DNA
sites	E-DNA
,	O
an	O
Sp1	B-DNA
site	E-DNA
,	O
tandem	O
E-box	B-DNA
domains	E-DNA
,	O
two	O
GATA-associated	B-DNA
sites	E-DNA
(	O
CACCC	O
)	O
,	O
an	O
AP-2	B-DNA
binding	I-DNA
site	E-DNA
,	O
and	O
a	O
GATA	B-DNA
element	E-DNA
at	O
-24	S-DNA
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino-terminal	B-protein
portion	E-protein
of	O
Sp140	S-protein
was	O
similar	O
to	O
Sp100	S-protein
,	O
a	O
previously	O
identified	O
NB	B-protein
protein	E-protein
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF-kappaB	S-protein
DNA-binding	O
activity	O
in	O
HIV1	B-cell_type
-infected	I-cell_type
cells	E-cell_type
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	S-protein
protein	O
,	O
the	O
activity	O
of	O
the	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	E-protein
(	O
PKR	S-protein
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	B-protein
subunits	E-protein
in	O
the	O
PLB-985	S-cell_line
and	O
U937	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
models	E-cell_line
.	O

Reconstitution	O
of	O
Jak1	S-protein
expression	O
in	O
E1C3	B-cell_line
cells	E-cell_line
restored	O
the	O
ability	O
of	O
IL-4	S-protein
to	O
induce	O
IRS	S-DNA
and	O
Stat6	S-protein
tyrosine	O
phosphorylation	O
.	O

These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	B-DNA
promoter	E-DNA
is	O
activated	O
.	O

Inhibition	O
of	O
NO	B-protein
synthase	E-protein
(	O
NOS	S-protein
)	O
during	O
the	O
second	O
A/R	O
challenge	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O

The	O
binding	O
of	O
the	O
A6H	B-protein
mAb	E-protein
induced	O
a	O
costimulatory	O
signal	O
in	O
anti-CD3	B-cell_line
activated	I-cell_line
T	I-cell_line
cells	E-cell_line
.	O

Furthermore	O
,	O
endogenous	O
IKK	O
enzymatic	O
activity	O
was	O
significantly	O
elevated	O
in	O
HTLV-1-infected	B-cell_line
and	I-cell_line
Tax-expressing	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O

E2F-1	S-protein
and	O
a	O
cyclin-like	B-protein
DNA	I-protein
repair	I-protein
enzyme	E-protein
,	O
uracil-DNA	B-protein
glycosylase	E-protein
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B-protein
hormone	I-protein
erythropoietin	E-protein
(	O
Epo	S-protein
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-DNA
gene	E-DNA
and	O
its	O
protein	B-protein
products	E-protein
were	O
affected	O
by	O
Epo	S-protein
in	O
splenic	B-cell_type
erythroblasts	E-cell_type
from	O
mice	O
infected	O
with	O
an	O
anemia-inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B-protein
Abs	E-protein
indicated	O
that	O
they	O
contained	O
STAT-3	S-protein
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B-protein
family	E-protein
.	O

In	O
vitro	O
mutagenesis	O
and	O
transient	O
transfection	O
experiments	O
indicate	O
that	O
the	O
C-terminal	B-protein
serine/threonine/proline-rich	I-protein
region	E-protein
of	O
BSAP	S-protein
contains	O
a	O
potent	O
transactivation	B-protein
domain	E-protein
of	O
55	O
amino	O
acids	O
which	O
is	O
active	O
from	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
positions	E-DNA
.	O

After	O
several	O
round	O
of	O
subcloning	O
followed	O
by	O
transfection	O
,	O
oriP	S-DNA
was	O
mapped	O
to	O
a	O
1.955-kb	B-DNA
viral	I-DNA
segment	E-DNA
.	O

Implications	O
for	O
regulation	O
of	O
immunoglobulin	B-protein
heavy	I-protein
chain	E-protein
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	B-DNA
gene	E-DNA
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF-kappaB	S-protein
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF-kappaB	B-cell_type
protects	I-cell_type
EBV-infected	I-cell_type
cells	E-cell_type
from	O
apoptosis	O
induced	O
by	O
TNFalpha	S-protein
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	S-protein
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T-cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T-cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Infection	O
of	O
primary	B-cell_type
B-lymphocytes	E-cell_type
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
leads	O
to	O
growth	O
transformation	O
of	O
these	O
B-cells	S-cell_type
in	O
vitro	O
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	E-cell_type
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

It	O
is	O
suggested	O
that	O
danazol	O
has	O
an	O
anti-estrogenic	O
action	O
to	O
the	O
monocytes	O
through	O
the	O
competition	O
and	O
suppression	O
of	O
estrogen	O
binding	O
sites	O
as	O
seen	O
in	O
the	O
estrogen	O
target	O
organ	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun-B	S-DNA
and	O
fra-1	B-DNA
genes	E-DNA
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60/vinc	S-cell_line
and	O
HL-60/vinc/R	B-cell_line
cells	E-cell_line
,	O
whereas	O
c-fos	S-DNA
expression	O
is	O
attenuated	O
in	O
the	O
HL-60/vinc	O
line	O
.	O

Furthermore	O
,	O
epithelial	O
levels	O
of	O
activated	O
Stat1	S-protein
correlated	O
with	O
levels	O
of	O
expression	O
for	O
epithelial	B-protein
ICAM-1	E-protein
,	O
IRF-1	S-protein
,	O
and	O
Stat1	S-protein
,	O
and	O
in	O
turn	O
,	O
ICAM-1	S-protein
levels	O
correlated	O
with	O
T-cell	O
accumulation	O
in	O
tissue	O
.	O

To	O
determine	O
activation	O
status	O
of	O
the	O
IL-2R	S-protein
-associated	O
(	O
Jak/STAT	S-protein
)	O
pathway	O
in	O
the	O
HTLV-I	B-cell_line
infected	I-cell_line
cells	E-cell_line
,	O
we	O
examined	O
tyrosine	O
phosphorylation	O
of	O
Jak3	S-protein
,	O
STAT3	S-protein
,	O
and	O
STAT5	S-protein
in	O
several	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
and	O
in	O
uncultured	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	E-cell_type
isolated	O
from	O
patients	O
with	O
adult	O
T-cell	O
lymphoma/leukemia	O
(	O
ATLL	O
)	O
.	O

Single-cell	O
reverse	B-protein
transcriptase	E-protein
-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	S-protein
,	O
markers	B-protein
of	I-protein
differentiation	E-protein
,	O
and	O
transcription	B-protein
factors	E-protein
(	O
EKLF	S-protein
,	O
GATA-1	S-protein
,	O
GATA-2	S-protein
,	O
p45	B-protein
NF-E2	E-protein
,	O
PU.1	S-protein
,	O
and	O
SCL/Tal1	S-protein
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	S-protein
.	O

Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	S-protein
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF-AT	B-protein
DNA	I-protein
binding	I-protein
complex	E-protein
.	O

The	O
viral	B-protein
protein	I-protein
Tax	E-protein
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	E-protein
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	B-cell_type
cells	E-cell_type
by	O
HTLV-I	O
.	O

Immediately	O
3	O
'	O
from	O
these	O
NF-AT	B-DNA
motifs	E-DNA
,	O
nonconsensus	B-DNA
sites	E-DNA
are	O
located	O
for	O
the	O
binding	O
of	O
AP-1-like	B-protein
factors	E-protein
.	O

alpha-IFN	S-protein
causes	O
dephosphorylation	O
of	O
pRb	S-protein
and	O
loss	O
of	O
p130	B-protein
phosphorylated	I-protein
Form	I-protein
3	E-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
induction	O
of	O
AP1	S-protein
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	E-protein
(	O
PP1	S-protein
and	O
PP2A	S-protein
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP1	E-protein
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	S-protein
can	O
also	O
activate	O
E2F	S-protein
-mediated	O
transcription	O
independently	O
of	O
p16	B-protein
(	I-protein
INK4A	I-protein
)	E-protein
.	O

4.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX-NHOH	O
and	O
SMX-NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

The	O
5'-UTR	S-DNA
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	S-protein
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O

The	O
GM-CSF	B-DNA
promoter	I-DNA
CBF	I-DNA
site	E-DNA
TGTGGTCA	O
is	O
located	O
51	B-DNA
bp	I-DNA
upstream	E-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
and	O
also	O
overlaps	O
a	O
YY-1	B-DNA
binding	I-DNA
site	E-DNA
.	O

Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O

Treatment	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B-protein
1	I-protein
and	I-protein
2A	E-protein
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	E-protein
,	O
AP-1	S-protein
and	O
a	O
marked	O
increase	O
in	O
NF-kappa	B-protein
B	E-protein
levels	O
.	O

However	O
,	O
in	O
contrast	O
to	O
human	B-cell_type
lymphocytes	E-cell_type
,	O
IFN-gamma	S-protein
production	O
was	O
inhibited	O
and	O
IFN-gamma	B-RNA
mRNA	E-RNA
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	B-cell_type
splenocytes	E-cell_type
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

Identification	O
of	O
two	O
novel	O
regulatory	B-DNA
elements	E-DNA
within	O
the	O
5'-untranslated	B-DNA
region	E-DNA
of	O
the	O
human	B-DNA
A	I-DNA
gamma-globin	I-DNA
gene	E-DNA
.	O

p130	S-protein
,	O
p107	S-protein
,	O
and	O
pRb	S-protein
are	O
differentially	O
regulated	O
in	O
proliferating	B-cell_type
cells	E-cell_type
and	O
during	O
cell	O
cycle	O
arrest	O
by	O
alpha-interferon	S-protein
.	O

Accordingly	O
,	O
we	O
studied	O
the	O
role	O
of	O
NF-kappaB	S-protein
in	O
germline	S-DNA
Cepsilon	O
transcription	O
by	O
using	O
two	O
human	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	E-cell_line
,	O
DND39	S-cell_line
and	O
DG75	S-cell_line
.	O

Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin-dependent	B-cell_type
erythroid	I-cell_type
progenitors	E-cell_type
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	B-cell_line
lines	E-cell_line
established	O
expressed	O
both	O
erythrocytic	B-protein
(	I-protein
globins	I-protein
)	I-protein
and	I-protein
megakaryocytic	I-protein
markers	E-protein
(	O
glycoprotein	B-protein
IIb	E-protein
,	O
platelet	B-protein
factor	I-protein
4	E-protein
)	O
as	O
well	O
as	O
Spi-1	S-protein
and	O
Fli-1	B-protein
transcripts	E-protein
at	O
permissive	O
temperature	O
.	O

The	O
inducible	O
,	O
T	B-DNA
cell-specific	I-DNA
enhancers	E-DNA
of	O
murine	B-DNA
and	I-DNA
human	I-DNA
Interleukin	I-DNA
2	I-DNA
(	I-DNA
Il-2	I-DNA
)	I-DNA
genes	E-DNA
contain	O
the	O
kB-like	B-DNA
sequence	E-DNA
GGGATTTCACC	O
as	O
an	O
essential	B-DNA
cis-acting	I-DNA
enhancer	I-DNA
motif	E-DNA
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	E-protein
,	O
binds	O
to	O
this	O
portion	O
by	O
the	O
two-hybrid	O
system	O
.	O

Differential	O
presentation	O
of	O
peptide	O
by	O
HLA	B-protein
DQ2	I-protein
heterodimers	E-protein
varying	O
at	O
the	O
DQA1	B-DNA
locus	E-DNA
may	O
have	O
relevance	O
to	O
host	O
defense	O
and	O
the	O
pathogenesis	O
of	O
HLA	O
DQ2	S-protein
-associated	O
autoimmune	O
diseases	O
.	O

Upon	O
activation	O
,	O
T	B-cell_type
lymphocytes	E-cell_type
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-RNA
mRNA	E-RNA
in	O
the	O
cells	O
.	O

However	O
,	O
the	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	E-cell_type
(	O
CTL	S-cell_type
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

These	O
observations	O
provide	O
further	O
evidence	O
to	O
suggest	O
a	O
role	O
for	O
intracellular	O
oxidant	O
generation	O
as	O
a	O
regulatory	O
mechanism	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
establish	O
a	O
link	O
between	O
oxidative	O
signalling	O
and	O
other	O
aspects	O
of	O
the	O
intracellular	O
signalling	O
network	O
that	O
is	O
activated	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
.	O

Instead	O
,	O
signal	O
transduction	O
to	O
the	O
human	O
IL-2	B-DNA
gene	E-DNA
became	O
disrupted	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal-1	S-DNA
expression	O
,	O
we	O
investigated	O
tal-1	S-DNA
chromatin	O
structure	O
in	O
erythroid/megakaryocytic	B-cell_line
cell	I-cell_line
lines	E-cell_line
and	O
in	O
T-cell	B-cell_line
lines	E-cell_line
either	O
with	O
or	O
without	O
tal-1	B-DNA
rearrangements	E-DNA
.	O

Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL-1beta	B-protein
protein	E-protein
into	O
the	O
media	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
exposed	O
to	O
FN	S-protein
.	O

We	O
further	O
demonstrate	O
that	O
p105	S-protein
undergoes	O
degradation	O
in	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	E-cell_line
.	O

We	O
show	O
here	O
that	O
in	O
the	O
early	O
phases	O
of	O
apoptosis	O
,	O
pRB	S-protein
is	O
posttranslationally	O
modified	O
by	O
a	O
tissue	O
transglutaminase	O
(	O
tTG	S-protein
)	O
-catalyzed	O
reaction	O
.	O

Thus	O
,	O
STAT1	S-protein
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

These	O
concentrations	O
are	O
lower	O
than	O
concentrations	O
reported	O
to	O
activate	O
effector	O
function	O
of	O
CTL	O
recognizing	O
other	O
epithelial	B-protein
tumor	I-protein
Ag	E-protein
.	O

The	O
activation	O
of	O
NF-kappaB	S-protein
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7.1	B-protein
molecules	E-protein
.	O

Oxidoreductive	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
.	O

Stimulation	O
of	O
human	O
lymphocyte	O
proliferation	O
and	O
CD40	S-protein
antigen	O
expression	O
by	O
phosphorothioate	O
oligonucleotides	O
complementary	O
to	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
genome	E-DNA
.	O

Conversely	O
,	O
SCL	S-protein
expression	O
was	O
up-regulated	O
by	O
Epo	S-protein
and	O
further	O
increased	O
by	O
haemin	O
and	O
delta-ALA	O
.	O

A	O
similar	O
comparison	O
with	O
protease-treated	O
extracts	O
prepared	O
from	O
Jurkat	B-cell_line
cells	E-cell_line
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	S-protein
activity	O
.	O

The	O
cell	O
type-specific	O
activation	O
of	O
STAT3	S-protein
by	O
IFN-gamma	S-protein
was	O
also	O
observed	O
in	O
neutrophils	S-cell_type
that	O
are	O
differentiated	O
in	O
vitro	O
from	O
human	B-cell_type
CD34+	I-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	E-cell_type
.	O

The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all-trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	S-protein
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	E-protein
.	O

Lysates	O
from	O
CD19	S-protein
cross-linked	O
1E8	B-cell_line
cells	E-cell_line
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk-1	B-protein
fusion	I-protein
protein	E-protein
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	O
of	O
Elk-1	B-protein
fusion	I-protein
protein	E-protein
occurred	O
using	O
lysates	O
from	O
CD19	B-cell_line
cross-linked	I-cell_line
BLIN-1	I-cell_line
cells	E-cell_line
.	O

This	O
selective	O
inhibition	O
by	O
IL-10	S-protein
of	O
NF	B-protein
kappa	I-protein
B	E-protein
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose-dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	S-protein
's	O
cytokine	S-protein
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	B-DNA
E6	I-DNA
motif	E-DNA
detected	O
a	O
B-cell-specific	B-protein
complex	E-protein
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	B-cell_type
cells	E-cell_type
and	O
HeLa	B-cell_line
cells	E-cell_line
.	O

The	O
mechanism	O
underlying	O
this	O
association	O
is	O
so	O
far	O
not	O
explored	O
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	S-protein
in	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
thymic	I-cell_type
progenitors	E-cell_type
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	B-protein
anti-TR55	I-protein
antibody	E-protein
was	O
used	O
.	O

Selection	O
of	O
the	O
T	O
cell	O
repertoire	O
.	O

The	O
triptolide-induced	O
apoptosis	O
is	O
accompanied	O
by	O
increase	O
of	O
DEVD-cleavable	O
caspases	S-protein
activity	O
and	O
degradation	O
of	O
caspase	B-protein
substrate	I-protein
poly	I-protein
(	I-protein
ADP-ribose	I-protein
)	I-protein
polymerase	E-protein
(	O
PARP	S-protein
)	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	B-DNA
terminal	I-DNA
repeat	E-DNA
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	B-cell_type
cells	E-cell_type
.	O

Since	O
the	O
IRF-1	S-protein
gene	O
is	O
both	O
virus	O
and	O
IFN	S-protein
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	B-DNA
gene	E-DNA
is	O
functioning	O
in	O
IFN	S-protein
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

Many	O
of	O
Pb	O
's	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	B-protein
factor	E-protein
,	O
NF-kappa	B-protein
B	E-protein
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	B-cell_type
and	I-cell_type
adult	I-cell_type
hematopoietic	I-cell_type
populations	E-cell_type
shows	O
several	O
runt	B-protein
isoforms	E-protein
.	O

This	O
loss	O
of	O
STAT1	S-protein
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

Like	O
Esc	S-protein
,	O
Eed	S-protein
contains	O
six	O
WD-40	B-protein
repeats	E-protein
in	O
the	O
C-terminal	B-protein
half	E-protein
of	O
the	O
protein	O
and	O
is	O
thought	O
to	O
repress	O
homeotic	O
gene	O
expression	O
during	O
mouse	O
embryogenesis	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	S-DNA
,	O
or	O
only	O
the	O
X1-	B-DNA
or	I-DNA
X2-boxes	E-DNA
of	O
HLA-DRA	S-DNA
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	S-DNA
.	O

Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	E-DNA
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	S-protein
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	B-protein
B	E-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	E-protein
and	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	E-protein
are	O
activated	O
after	O
cross-linking	O
CD40	S-protein
on	O
resting	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	E-cell_type
and	O
on	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF-kappaB	S-protein
in	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	S-cell_type
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	O
regulation	O
of	O
GTP-cyclohydrolase	S-protein
.	O

Our	O
results	O
implicate	O
NFIL3/E4BP4	S-protein
(	O
nuclear	B-protein
factor	I-protein
regulated	I-protein
by	I-protein
IL-3/adenovirus	I-protein
E4	I-protein
promoter	I-protein
binding	I-protein
protein	E-protein
)	O
in	O
a	O
distinct	O
growth	O
factor-regulated	O
signaling	O
pathway	O
that	O
is	O
responsible	O
for	O
the	O
survival	O
of	O
early	B-cell_type
B-cell	I-cell_type
progenitors	E-cell_type
,	O
and	O
whose	O
alteration	O
by	O
E2A-HLF	S-protein
leads	O
to	O
childhood	O
B	O
lineage	O
leukemia	O
.	O

Some	O
of	O
the	O
most	O
potent	O
antiinflammatory	O
and	O
immunosuppressive	O
agents	O
are	O
synthetic	O
glucocorticoids	O
.	O

It	O
is	O
supposed	O
that	O
the	O
mechanism	O
of	O
Hm	S-protein
-induced	O
differentiation	O
is	O
distinguished	O
from	O
that	O
of	O
Epo	S-protein
-induced	O
differentiation	O
in	O
K562	B-cell_line
cells	E-cell_line
.	O

A	O
reporter	B-DNA
gene	E-DNA
under	O
the	O
control	O
of	O
a	O
T-cell	B-DNA
antigen	I-DNA
receptor	I-DNA
element	E-DNA
was	O
activated	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B-protein
kinase	I-protein
C	E-protein
,	O
and	O
a	O
calcium	O
ionophore	O
.	O

The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	E-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	E-protein
of	O
VP16	S-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	S-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	E-protein
,	O
and	O
synthetic	O
peptides	O
.	O

Clone	B-cell_line
C3/5	E-cell_line
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	E-protein
)	O
production	O
when	O
challenged	O
with	O
autologous	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	E-cell_line
pulsed	O
with	O
peptide	O
BCR1/25	O
.	O

The	O
partial	B-DNA
cDNA	E-DNA
encodes	O
a	O
protein	O
which	O
is	O
homologous	O
to	O
the	O
C-terminal	B-protein
196	I-protein
amino	I-protein
acids	E-protein
of	O
the	O
36-kDa	B-protein
transcription	I-protein
factor	E-protein
,	O
YB-1	S-protein
.	O

Bik	S-protein
,	O
a	O
novel	O
death-inducing	B-protein
protein	E-protein
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl-2	B-protein
family	I-protein
proteins	E-protein
and	O
interacts	O
with	O
viral	O
and	O
cellular	B-protein
survival-promoting	I-protein
proteins	E-protein
.	O

Activated	O
T-lymphocytes	O
are	O
found	O
early	O
in	O
atherosclerosis	O
lesions	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
role	O
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	B-DNA
site	E-DNA
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B-DNA
promoter	E-DNA
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	S-protein
levels	O
in	O
OCIM1	B-cell_type
cells	E-cell_type
.	O

By	O
using	O
a	O
nucleosome	S-protein
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	S-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	S-protein
(	O
or	O
LEF-1	S-protein
and	O
Ets-1	S-protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B-protein
protein	E-protein
,	O
Sp1	S-protein
.	O

Using	O
in	O
vivo	O
footprinting	O
we	O
identified	O
two	O
sites	O
in	O
the	O
promoter	O
at	O
-45	B-DNA
and	I-DNA
-160	E-DNA
that	O
were	O
occupied	O
only	O
in	O
CD20	S-protein
+	O
B	O
cells	O
.	O

Hence	O
,	O
these	O
cytokines	S-protein
do	O
not	O
simply	O
enhance	O
monocyte	O
differentiation	O
,	O
but	O
have	O
complex	O
and	O
slightly	O
divergent	O
effects	O
that	O
impact	O
on	O
HIV	O
replication	O
probably	O
through	O
cell	O
signaling	O
pathways	O
and	O
nuclear	B-protein
factor-kappaB	E-protein
translocation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV-1	B-DNA
DSE	E-DNA
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	S-protein
and	O
TNFalpha	S-protein
.	O

CD40-stimulated	B-cell_line
human	I-cell_line
B	I-cell_line
lymphocytes	E-cell_line
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

BACKGROUND	O
:	O
Understanding	O
the	O
mechanism	O
of	O
developmental	O
regulation	O
of	O
hemoglobin	S-protein
switching	O
has	O
scientific	O
as	O
well	O
as	O
clinical	O
relevance	O
because	O
of	O
the	O
influence	O
of	O
fetal	O
hemoglobin	S-protein
(	O
HbF	S-protein
)	O
production	O
in	O
adulthood	O
on	O
the	O
clinical	O
manifestation	O
of	O
thalassemia	O
and	O
sickle	O
cell	O
anemia	O
.	O

Interleukin-12	S-protein
(	O
IL-12	S-protein
)	O
is	O
a	O
cytokine	S-protein
that	O
exhibits	O
pleiotropic	O
effects	O
on	O
lymphocytes	S-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	E-cell_type
and	O
has	O
been	O
shown	O
to	O
have	O
promise	O
for	O
the	O
immunotherapy	O
of	O
cancer	O
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	I-protein
B	E-protein
and	O
AP-1	S-protein
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	S-cell_type
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	B-DNA
factors	E-DNA
that	O
regulate	O
multiple	O
T-cell	B-DNA
genes	E-DNA
during	O
thymocyte	O
ontogeny	O
and	O
T-cell	S-cell_type
activation	O
,	O
are	O
described	O
.	O

In	O
both	O
cases	O
,	O
peptide	O
presentation	O
to	O
T	B-cell_type
cells	E-cell_type
via	O
class	B-protein
II	I-protein
molecules	E-protein
was	O
restricted	O
to	O
the	O
basolateral	O
surface	O
.	O

Examination	O
of	O
lymphoid	O
tissues	O
showed	O
a	O
low	O
level	O
of	O
expression	O
in	O
a	O
population	O
of	O
normal	O
mande	B-cell_line
B	I-cell_line
lymphocytes	E-cell_line
but	O
not	O
in	O
germinal	B-cell_type
center	I-cell_type
cells	E-cell_type
or	O
plasma	B-cell_type
cells	E-cell_type
.	O

Human	B-cell_type
monocyte	E-cell_type
binding	O
to	O
fibronectin	S-protein
enhances	O
IFN-gamma	S-protein
-induced	O
early	O
signaling	O
events	O
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

VDR	B-protein
DNA-binding	I-protein
mutants	E-protein
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-protein
DNA-binding	I-protein
domain	E-protein
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	S-protein
expression	O
.	O

Since	O
GH	S-protein
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	S-cell_type
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	S-protein
in	O
granulocyte	B-cell_type
subsets	E-cell_type
.	O

A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	B-DNA
conserved	I-DNA
sequence	E-DNA
(	O
BCS	S-DNA
)	O
,	O
found	O
upstream	O
of	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
B29	I-DNA
promoters	E-DNA
,	O
appears	O
to	O
stimulate	O
B29	S-protein
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O

Chronic	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	E-cell_type
leads	O
to	O
constitutive	O
NF-kappa	B-protein
B	E-protein
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O

Stable	O
expression	O
of	O
Tax	S-protein
in	O
CTLL-2	S-cell_line
transformed	O
cell	O
growth	O
from	O
being	O
IL-2	S-protein
dependent	O
to	O
IL-2	S-protein
independent	O
.	O

Tissue	B-protein
factor	E-protein
(	O
TF	O
)	O
expression	O
by	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	E-cell_type
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF-kappa	B-protein
B	I-protein
p50	E-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF-kappaB	S-protein
occurs	O
through	O
a	O
Tax	S-protein
-independent	O
mechanism	O
in	O
leukemic	B-cell_type
cells	E-cell_type
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF-kappaB	S-protein
subunit	O
activation	O
.	O

A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross-linking	O
followed	O
by	O
SDS-gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	S-protein
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c-myc	O
PuF	B-DNA
site	E-DNA
.	O

We	O
conclude	O
that	O
CBP	S-protein
,	O
a	O
histone	B-protein
acetyltransferase	E-protein
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	B-DNA
II	I-DNA
genes	E-DNA
.	O

Renal	O
cell	O
carcinoma-derived	O
gangliosides	O
suppress	O
nuclear	B-protein
factor-kappaB	E-protein
activation	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	B-cell_line
corneal	I-cell_line
endothelial	I-cell_line
cells	E-cell_line
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	S-protein
(	O
451.4+/-45.4	O
cells/mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156.7+/-27.3	O
cells/mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Using	O
an	O
avidin	B-protein
-biotin	I-protein
peroxidase	E-protein
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+/-	O
3.7	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	B-cell_type
lymphocytes	E-cell_type
,	O
while	O
only	O
0.47	O
+/-	O
0.33	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	B-cell_type
lymphocytes	E-cell_type
reacted	O
with	O
the	O
antibody	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	B-cell_type
beta	I-cell_type
cells	E-cell_type
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Transcription-independent	O
turnover	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	E-RNA
levels	O
.	O

In	O
addition	O
,	O
transcriptional	O
activity	O
of	O
IL-2	S-protein
and	O
metallothionein	B-DNA
enhancer	I-DNA
and	I-DNA
promoter	I-DNA
regions	E-DNA
and	O
transcription	B-protein
factors	I-protein
AP-1	E-protein
,	O
NF-kappaB	S-protein
,	O
and	O
NF-AT	S-protein
were	O
analyzed	O
by	O
chloramphenicol	B-protein
acetyltransferase	E-protein
(	O
CAT	S-protein
)	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
respectively	O
.	O

However	O
,	O
neither	O
TNF	S-protein
or	O
LPS	O
stimulated	O
VCAM-1	S-protein
expression	O
in	O
HUAECs	S-cell_type
.	O

This	O
transcription	B-protein
factor	E-protein
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	B-protein
protein	I-protein
I-kB	E-protein
thereby	O
allowing	O
translocation	O
of	O
NF-kappa	B-protein
B	E-protein
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	B-protein
molecules	E-protein
(	O
e.g	O
.	O
ICAM-1	S-protein
,	O
VCAM-1	S-protein
)	O
,	O
cytokines	S-protein
(	O
TNF	S-protein
,	O
IL-1	S-protein
,	O
IL-6	S-protein
)	O
and	O
enzymes	S-protein
(	O
iNOS	S-protein
)	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	E-protein
(	O
RALDH2	S-protein
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T-ALL	B-cell_line
cell	I-cell_line
lines	E-cell_line
that	O
coexpressed	O
TAL1	S-protein
and	O
LMO	S-protein
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	B-cell_type
cells	E-cell_type
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	B-cell_type
cells	E-cell_type
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-DNA
receptor	I-DNA
gene	E-DNA
in	O
the	O
monocyte	B-cell_type
fraction	E-cell_type
.	O

Furthermore	O
,	O
E1A	B-protein
mutant	I-protein
proteins	E-protein
that	O
can	O
not	O
bind	O
the	O
cellular	B-protein
transcriptional	I-protein
coactivator	E-protein
,	O
p300	S-protein
,	O
and	O
that	O
fail	O
to	O
induce	O
cytolytic	O
susceptibility	O
also	O
failed	O
to	O
sensitize	O
cells	O
to	O
injury-induced	O
apoptosis	O
.	O

The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	S-protein
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O

Hence	O
,	O
the	O
present	O
results	O
show	O
that	O
STAT3	S-protein
serine	O
phosphorylation	O
can	O
be	O
regulated	O
independently	O
of	O
the	O
tyrosine	O
phosphorylation	O
of	O
this	O
molecule	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	B-protein
receptor	E-protein
-initiated	O
signaling	O
events	O
and	O
lymphokine	S-protein
production	O
.	O

The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	O
for	O
cortisol	O
.	O

This	O
enhanced	O
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
coincubation	O
of	O
CD36	S-protein
transfected	O
cells	O
with	O
the	O
human	B-protein
CD36-specific	I-protein
antibody	I-protein
OKM5	E-protein
.	O

Induction	O
of	O
this	O
distal	B-DNA
IL-2	I-DNA
enhancer	E-DNA
differs	O
from	O
induction	O
of	O
the	O
proximal	B-DNA
IL-2	I-DNA
promoter-enhancer	E-DNA
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2+	O
signals	O
.	O

Estrogens	O
and	O
anti-estrogens	O
enhance	O
the	O
number	O
of	O
immunoglobulin	B-cell_type
(	I-cell_type
Ig	I-cell_type
)	I-cell_type
-secreting	I-cell_type
cells	E-cell_type
in	O
pokeweed	B-cell_line
mitogen	I-cell_line
(	I-cell_line
PWM	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
lymphocyte	I-cell_line
cultures	E-cell_line
.	O

NF-kappa	B-protein
B	E-protein
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

The	O
evolutionarily	O
conserved	O
N-terminal	B-protein
half	E-protein
of	O
IBR/F	S-protein
harbors	O
the	O
DNA-binding/dimerization	B-protein
domain	E-protein
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	B-protein
kinase	I-protein
II	I-protein
sites	E-protein
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	B-protein
nuclear	I-protein
localization	I-protein
signal	E-protein
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
III	I-DNA
)	E-DNA
,	O
AP3-L	S-DNA
,	O
and	O
DBF	B-DNA
sites	E-DNA
and	O
in	O
the	O
AP3-L	S-DNA
and	O
DBF-sites	S-DNA
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP-1	B-DNA
(	I-DNA
I	I-DNA
,	I-DNA
II	I-DNA
,	I-DNA
III	I-DNA
)	E-DNA
and	O
AP3-L	B-DNA
sites	E-DNA
and	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3-L	S-DNA
,	O
and	O
DBF	B-DNA
sites	E-DNA
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	B-protein
proteins	E-protein
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O

An	O
insertion	O
mutation	O
was	O
constructed	O
in	O
the	O
rpoS	B-DNA
gene	E-DNA
on	O
the	O
chromosome	O
of	O
L.	O
pneumophila	O
,	O
and	O
the	O
ability	O
of	O
this	O
mutant	O
strain	O
to	O
survive	O
various	O
stress	O
conditions	O
was	O
assayed	O
and	O
compared	O
with	O
results	O
for	O
the	O
wild-type	O
strain	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	E-protein
of	O
the	O
IL-2	B-DNA
gene	E-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

IL-10	S-protein
arrested	O
cells	O
at	O
G0/G1	O
.	O

The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+/-	O
2.02	O
(	O
257.7	O
+/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O

Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	S-protein
and	O
SEB	S-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	E-protein
was	O
down-regulated	O
,	O
IL-2R	B-protein
gamma	E-protein
was	O
slightly	O
up-regulated	O
,	O
while	O
IL-2R	B-protein
alpha	E-protein
remained	O
largely	O
unaffected	O
.	O

IBR	S-protein
is	O
a	O
503-amino-acid-long	B-protein
acidic	I-protein
protein	E-protein
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B-protein
NRF-1/alpha-Pal	I-protein
factor	E-protein
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	B-protein
factors	I-protein
P3A2	E-protein
and	O
erected	B-protein
wing	I-protein
gene	I-protein
product	E-protein
(	O
EWG	S-protein
)	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	B-protein
receptor	E-protein
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

The	O
data	O
further	O
show	O
that	O
these	O
overall	O
topographical	O
distributions	O
are	O
independent	O
of	O
gene	O
transcriptional	O
activity	O
and	O
are	O
conserved	O
in	O
different	B-cell_type
cell	I-cell_type
types	E-cell_type
.	O

The	O
NF-kappa	B-protein
B	I-protein
family	E-protein
of	O
transcription	B-protein
proteins	E-protein
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	B-protein
related	I-protein
polypeptides	E-protein
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	B-DNA
early	I-DNA
region	I-DNA
3	I-DNA
promoter	E-DNA
is	O
mediated	O
by	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
motifs	E-DNA
.	O

Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	B-cell_type
neutrophils	E-cell_type
and	O
eosinophils	S-cell_type
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration-dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM-CSF	S-protein
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	B-DNA
promoter	I-DNA
PMA	E-DNA
in	O
transient	O
transfection	O
experiments	O
.	O

Primed	O
monocytes	S-cell_type
transcribed	O
TNF	B-RNA
mRNA	E-RNA
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	S-cell_type
upon	O
activation	O
with	O
LPS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
Nfil3/E4bp4	S-protein
is	O
regulated	O
as	O
a	O
``	B-DNA
delayed-early	I-DNA
''	I-DNA
IL-3-responsive	I-DNA
gene	E-DNA
,	O
requiring	O
de	O
novo	O
protein	O
synthesis	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	B-DNA
locus	I-DNA
control	I-DNA
region	E-DNA
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta-like	B-DNA
globin	I-DNA
genes	E-DNA
.	O

Bacterial	O
lipopolysaccharide	O
activates	O
nuclear	B-protein
factor-kappaB	E-protein
through	O
interleukin-1	B-protein
signaling	I-protein
mediators	E-protein
in	O
cultured	B-cell_line
human	I-cell_line
dermal	I-cell_line
endothelial	I-cell_line
cells	E-cell_line
and	O
mononuclear	B-cell_type
phagocytes	E-cell_type
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross-linking	O
of	O
CD28	S-protein
(	O
but	O
not	O
CD2	S-protein
,	O
CD5	S-protein
,	O
LFA-1	S-protein
,	O
or	O
CD7	S-protein
)	O
leads	O
to	O
an	O
elevation	O
of	O
c-jun	B-RNA
mRNA	E-RNA
,	O
with	O
only	O
minimal	O
activation	O
of	O
c-fos	S-DNA
expression	O
.	O

A	O
5.5-kilobase	B-DNA
genomic	I-DNA
clone	E-DNA
contained	O
the	O
full-length	O
CD14	B-DNA
coding	I-DNA
sequence	E-DNA
and	O
4.2	B-DNA
kilobases	I-DNA
of	I-DNA
5'-upstream	I-DNA
sequence	E-DNA
.	O

Nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	E-protein
is	O
a	O
redox	B-protein
sensitive	I-protein
cytosolic	I-protein
transcription	I-protein
factor	E-protein
.	O

Contrary	O
to	O
the	O
results	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
-induced	O
NF	B-protein
kappaB	E-protein
activation	O
in	O
astrocytes	S-cell_type
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	B-protein
kappaB	E-protein
activation	O
in	O
astrocytes	S-cell_type
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O

Activation	O
of	O
human	B-cell_type
thymocytes	E-cell_type
after	O
infection	O
by	O
EBV	O
.	O

Expression	O
of	O
the	O
IL-2	B-DNA
gene	E-DNA
requires	O
activation	O
of	O
T	B-cell_type
cells	E-cell_type
through	O
stimulation	O
of	O
the	O
TCR	S-protein
and	O
costimulation	O
through	O
accessory	B-protein
receptors	E-protein
.	O

Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
(	O
PBMC	S-cell_type
)	O
.	O

Characterization	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	E-protein
,	O
the	O
nuclear	B-protein
factor	E-protein
that	O
interacts	O
with	O
the	O
regulatory	O
P	B-DNA
sequence	E-DNA
(	O
5'-CGAAAATTTCC-3	O
'	O
)	O
of	O
the	O
human	B-DNA
interleukin-4	I-DNA
gene	E-DNA
:	O
relationship	O
to	O
NF-kappa	B-protein
B	E-protein
and	O
NF-AT	S-protein
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	B-cell_type
lineage	E-cell_type
has	O
not	O
been	O
determined	O
.	O

The	O
transcription	B-protein
factor	I-protein
GATA-1	E-protein
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O

In	O
all	O
3	O
cases	O
,	O
a	O
characteristic	O
immunophenotype	O
was	O
identified	O
(	O
CD4+	S-protein
,	O
CD13	S-protein
-	O
,	O
CD33+	O
,	O
CD65s+	O
)	O
.	O

Within	O
the	O
PBL	S-cell_type
,	O
Bcd	S-DNA
gene	O
expression	O
was	O
restricted	O
to	O
CD19+	B-cell_type
B-cells	E-cell_type
and	O
absent	O
from	O
CD14+	B-cell_type
monocytes	E-cell_type
and	O
T-cells	S-cell_type
.	O

Both	O
forms	O
have	O
DNA-binding	B-protein
domain	E-protein
,	O
but	O
AML1a	S-protein
lacks	O
a	O
putative	O
transcriptional	O
activation	O
domain	O
which	O
AML1b	S-protein
has	O
.	O

We	O
have	O
determined	O
that	O
the	O
JAK	B-protein
/STAT	E-protein
pathway	O
positively	O
regulates	O
Qp	S-DNA
activity	O
.	O

Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	S-protein
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O

Representational	O
difference	O
analysis	O
has	O
been	O
used	O
to	O
isolate	O
cDNA	B-DNA
clones	E-DNA
corresponding	O
to	O
mRNA	B-RNA
species	E-RNA
activated	O
following	O
stable	O
expression	O
of	O
HOX11	S-protein
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	E-cell_line
.	O

CD14	S-protein
-mediated	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	E-protein
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	B-protein
kinase	E-protein
activity	O
.	O

Intravenous	O
administration	O
of	O
PCr	O
(	O
starting	O
1	O
day	O
before	O
exercise	O
)	O
led	O
to	O
an	O
increase	O
in	O
the	O
total	O
workload	O
(	O
on	O
average	O
by	O
5.8	O
%	O
)	O
and	O
in	O
AT	O
(	O
on	O
average	O
by	O
6.8	O
%	O
)	O
during	O
MPE	O
and	O
to	O
a	O
better	O
tolerance	O
of	O
exercise	O
during	O
PPE	O
.	O

The	O
IL-2Ralpha	B-DNA
promoter	E-DNA
containing	O
the	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
site	E-DNA
was	O
transcriptionally	O
induced	O
by	O
M.	O
tuberculosis	O
and	O
this	O
NF-kappaB	S-protein
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	B-DNA
herpes	I-DNA
thymidine	I-DNA
kinase	I-DNA
(	I-DNA
TK	I-DNA
)	I-DNA
promoter	E-DNA
by	O
M.	O
tuberculosis	O
.	O

We	O
demonstrate	O
here	O
that	O
a	O
third	O
region	O
encompassing	O
a	O
proline	B-protein
rich	I-protein
sequence	E-protein
within	O
the	O
33	O
bp	O
repetitive	O
stretch	O
of	O
LMP1	S-protein
's	O
C-terminus	S-protein
is	O
required	O
for	O
the	O
activation	O
of	O
Janus	B-protein
kinase	I-protein
3	E-protein
(	O
JAK3	S-protein
)	O
.	O

4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	S-protein
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O

The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	B-protein
kDa	E-protein
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	E-protein
and	O
,	O
similar	O
to	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	E-protein
,	O
was	O
upregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Involvement	O
of	O
different	O
transduction	O
pathways	O
in	O
NF-kappa	B-protein
B	E-protein
activation	O
by	O
several	O
inducers	S-DNA
.	O

CD30	S-protein
is	O
a	O
CD40-inducible	B-protein
molecule	E-protein
that	O
negatively	O
regulates	O
CD40-mediated	B-protein
immunoglobulin	E-protein
class	O
switching	O
in	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	E-cell_line
.	O

Additionally	O
,	O
infected	B-cell_type
T	I-cell_type
cells	E-cell_type
displayed	O
lower	O
levels	O
of	O
CD45	S-protein
on	O
their	O
surfaces	O
.	O

By	O
Edman	O
sequencing	O
we	O
could	O
identify	O
a	O
caspase	O
3	O
cleavage	O
site	O
after	O
Asp584	O
(	O
D584AQPQAGR	O
)	O
,	O
generating	O
a	O
22-kDa	O
C-terminal	O
SP1	S-protein
protein	O
fragment	O
which	O
still	O
contains	O
the	O
DNA	O
binding	O
site	O
.	O

The	O
evolutionarily	B-DNA
conserved	I-DNA
sequence	E-DNA
upstream	O
of	O
the	O
human	B-protein
Ig	I-protein
heavy	I-protein
chain	I-protein
S	I-protein
gamma	I-protein
3	I-protein
region	E-protein
is	O
an	O
inducible	B-DNA
promoter	E-DNA
:	O
synergistic	O
activation	O
by	O
CD40	B-protein
ligand	E-protein
and	O
IL-4	S-protein
via	O
cooperative	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
STAT-6	I-DNA
binding	I-DNA
sites	E-DNA
.	O

Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B-DNA
iNOS	I-DNA
promoter	E-DNA
to	O
LPS	O
+/-	O
IFN-gamma	S-protein
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	B-DNA
element	E-DNA
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS/	O
IFN-gamma	S-protein
induced	O
expression	O
of	O
the	O
mouse	B-DNA
iNOS	I-DNA
gene	E-DNA
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	B-protein
factors	E-protein
in	O
human	B-cell_type
macrophages	E-cell_type
(	O
e.g.	O
,	O
an	O
LPS-inducible	B-protein
nuclear	I-protein
factor-kappa	I-protein
B/Rel	I-protein
complex	E-protein
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O

STAT-related	O
transcription	B-protein
factors	E-protein
are	O
constitutively	O
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	E-cell_type
from	O
acute	O
leukemia	O
patients	O
.	O

Two-dimensional	O
electrophoretic	O
analysis	O
of	O
the	O
protein	O
phosphorylation	O
pattern	O
from	O
the	O
B	B-cell_line
cell	I-cell_line
line	I-cell_line
CESS	E-cell_line
demonstrated	O
the	O
identity	O
between	O
the	O
p60	B-protein
protein	E-protein
expressed	O
in	O
this	O
cell	O
line	O
and	O
that	O
expressed	O
in	O
B-CLL	B-cell_line
cells	E-cell_line
.	O

The	O
role	O
of	O
the	O
viral	B-protein
trans-activator	I-protein
Tax	I-protein
protein	E-protein
in	O
the	O
induction	O
of	O
VCAM-1	S-protein
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	B-protein
molecule	E-protein
on	O
Jurkat	B-cell_line
T-cell	I-cell_line
clones	E-cell_line
stably	O
expressing	O
the	O
tax	O
gene	O
.	O

Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
CHO/CD14	S-cell_line
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	E-cell_line
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS-induced	O
TK	O
activity	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	E-cell_line
.	O

This	O
NF-kappaB-like	B-DNA
element	E-DNA
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF-kappaB	B-protein
family	I-protein
proteins	E-protein
in	O
vitro	O
.	O

Rearrangement	O
of	O
at	O
least	O
one	O
of	O
these	O
genes	O
was	O
detected	O
in	O
all	O
cases	O
with	O
balanced	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	E-DNA
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	E-cell_line
with	O
anti-CD3	B-protein
mAb	E-protein
activated	O
both	O
PLD	S-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	E-protein
.	O

BACKGROUND	O
:	O
The	O
class	B-protein
II	I-protein
transactivator	E-protein
(	O
CIITA	S-protein
)	O
is	O
a	O
bi-	B-protein
or	I-protein
multifunctional	I-protein
domain	I-protein
protein	E-protein
that	O
acts	O
as	O
a	O
transcriptional	B-protein
activator	E-protein
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
.	O

All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3-kinase	S-protein
.	O

Although	O
IL-2Rbeta	S-protein
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

Tyrosine	O
phosphorylation	O
of	O
linker	B-protein
proteins	E-protein
enables	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-associated	I-protein
protein	I-protein
tyrosine	I-protein
kinases	E-protein
to	O
phosphorylate	O
and	O
regulate	O
effector	B-protein
molecules	E-protein
that	O
generate	O
second	B-protein
messengers	E-protein
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT-7	B-cell_line
cells	E-cell_line
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT-7	B-cell_line
cells	E-cell_line
)	O
or	O
in	O
receptor	O
turnover	O
.	O

Interleukin	B-protein
16	E-protein
(	O
IL-16	S-protein
)	O
is	O
a	O
chemotactic	B-protein
cytokine	E-protein
that	O
binds	O
to	O
the	O
CD4	B-protein
receptor	E-protein
and	O
affects	O
the	O
activation	O
of	O
T	B-cell_type
cells	E-cell_type
and	O
replication	O
of	O
HIV	O
.	O

A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation-inducing	O
activity	O
towards	O
HL-60	B-cell_line
cells	E-cell_line
and	O
that	O
towards	O
NB4	B-cell_line
cells	E-cell_line
was	O
found	O
.	O

Studies	O
of	O
cell	B-cell_line
lines	E-cell_line
representing	O
endocrine	B-cell_type
,	I-cell_type
fibroblast	I-cell_type
,	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
lineages	E-cell_type
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	B-protein
proteins	E-protein
have	O
suggested	O
that	O
significant	O
E2A	B-protein
protein	E-protein
expression	O
is	O
restricted	O
to	O
B-lymphocytes	S-cell_type
.	O

Similar	O
transfection	O
analysis	O
of	O
the	O
-66	B-DNA
to	I-DNA
-59	I-DNA
region	E-DNA
of	O
the	O
CD11b	B-DNA
promoter	E-DNA
showed	O
Sp3	S-protein
-dependent	O
expression	O
.	O

Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O

A	O
chimeric	B-DNA
TCR	I-DNA
gene	E-DNA
,	O
comprising	O
an	O
anti-hapten	B-protein
single-chain	I-protein
Ab	I-protein
variable	I-protein
fragment	E-protein
fused	O
to	O
the	O
transmembrane	B-protein
and	I-protein
cytoplasmic	I-protein
regions	E-protein
of	O
the	O
human	B-protein
TCR	I-protein
zeta-chain	E-protein
,	O
was	O
used	O
to	O
determine	O
whether	O
the	O
tetracycline-regulatable	O
system	O
could	O
be	O
used	O
to	O
regulate	O
gene	O
expression	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

We	O
also	O
report	O
three	O
additional	O
isoforms	O
of	O
NFATx	S-protein
,	O
designated	O
NFATx2	S-protein
,	O
NFATx3	S-protein
,	O
and	O
NFATx4	S-protein
.	O

The	O
role	O
of	O
Cbl-b	S-protein
is	O
unclear	O
,	O
however	O
.	O

Whether	O
PPAR	O
activators	O
influence	O
the	O
inflammatory	O
responses	O
of	O
ECs	S-cell_type
is	O
unknown	O
.	O

EBV-encoded	B-protein
nuclear	I-protein
antigen	I-protein
(	I-protein
EBNA	I-protein
)	I-protein
-1	E-protein
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	S-protein
are	O
not	O
.	O

We	O
propose	O
that	O
neutrophils	S-cell_type
use	O
both	O
ERK-dependent	O
and	O
ERK-independent	O
pathways	O
to	O
phosphorylate	O
Ser-727	O
on	O
STAT3	S-protein
.	O

Increased	O
interleukin	B-protein
2	E-protein
transcription	O
in	O
murine	B-cell_type
lymphocytes	E-cell_type
by	O
ciprofloxacin	O
.	O

A	O
family	O
of	O
transcriptional	O
activating	O
proteins	O
,	O
the	O
GATA	B-protein
factors	E-protein
,	O
has	O
been	O
shown	O
to	O
bind	O
to	O
a	O
consensus	O
motif	O
through	O
a	O
highly	B-protein
conserved	I-protein
C4	I-protein
zinc	I-protein
finger	I-protein
DNA	I-protein
binding	I-protein
domain	E-protein
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl-arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	S-protein
,	O
but	O
did	O
not	O
augment	O
cytokine-induced	O
VCAM-1	S-protein
expression	O
.	O

IL-4	S-protein
down-regulated	O
mRNA	O
accumulation	O
of	O
the	O
proinflammatory	B-protein
cytokines	I-protein
IL-1	I-protein
beta	E-protein
,	O
IL-8	S-protein
,	O
and	O
TNF-alpha	S-protein
in	O
monocytes	S-cell_type
stimulated	O
with	O
IL-2	S-protein
,	O
IL-3	S-protein
,	O
and	O
GM-CSF	S-protein
.	O

The	O
increase	O
in	O
AP-1	S-protein
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	S-protein
but	O
not	O
that	O
of	O
c-jun	S-protein
.	O

IL-4	S-protein
had	O
no	O
significant	O
effect	O
on	O
HIV	O
reverse	O
transcription	O
.	O

Using	O
human	B-cell_line
B-	I-cell_line
or	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
transfected	O
with	O
ZpCat	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	E-DNA
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	B-DNA
domain	E-DNA
of	O
Zp	S-DNA
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

We	O
conclude	O
that	O
IL-2	S-protein
transcriptional	O
regulation	O
differs	O
in	O
tumor	B-cell_line
cell	I-cell_line
lines	E-cell_line
compared	O
with	O
normal	B-cell_type
T	I-cell_type
cells	E-cell_type
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis-elements	S-DNA
in	O
the	O
IL-2	B-DNA
promoter	E-DNA
.	O

Introduction	O
of	O
the	O
HIV-1	B-DNA
plasmids	E-DNA
in	O
which	O
the	O
GATA	B-DNA
sites	E-DNA
have	O
been	O
mutated	O
into	O
human	O
T	B-cell_type
lymphocytes	E-cell_type
also	O
caused	O
a	O
significant	O
reduction	O
in	O
LTR	S-DNA
-mediated	O
transcription	O
at	O
both	O
the	O
basal	O
level	O
and	O
in	O
(	O
PHA-	O
plus	O
PMA-	O
)	O
stimulated	B-cell_line
T	I-cell_line
cells	E-cell_line
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	B-cell_line
acid-resistant	I-cell_line
acute	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	E-cell_line
(	O
UF-1	S-cell_line
)	O
associated	O
with	O
expression	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	E-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	E-protein
.	O

There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	B-RNA
transcripts	E-RNA
between	O
patients	O
and	O
healthy	O
controls	O
.	O

The	O
effects	O
of	O
either	O
catecholamine	O
on	O
IL-12	S-protein
or	O
IL-10	S-protein
secretion	O
were	O
blocked	O
completely	O
by	O
propranolol	O
,	O
a	O
beta-adrenoreceptor	O
antagonist	O
,	O
indicating	O
that	O
they	O
were	O
mediated	O
by	O
the	O
beta-adrenergic	B-protein
receptor	E-protein
.	O

Neither	O
FKBP	S-protein
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	S-protein
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O

We	O
reasoned	O
that	O
selective	O
IFN	S-protein
responsiveness	O
of	O
the	O
first	O
STAT	B-protein
family	I-protein
member	E-protein
(	O
Stat1	S-protein
)	O
and	O
Stat1-dependent	B-DNA
immune-response	I-DNA
genes	E-DNA
such	O
as	O
intercellular	B-protein
adhesion	I-protein
molecule-1	E-protein
(	O
ICAM-1	S-protein
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	E-protein
(	O
IRF-1	S-protein
)	O
,	O
and	O
Stat1	S-protein
itself	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	E-cell_type
provides	O
a	O
basis	O
for	O
detecting	O
cytokine	S-protein
signaling	O
abnormalities	O
in	O
inflammatory	O
airway	O
disease	O
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	S-protein
or	O
PTK	S-protein
would	O
decrease	O
LPS-induced	O
NF-kappaB	S-protein
DNA	O
binding	O
and	O
TNF-alpha	S-protein
release	O
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	B-RNA
mRNA	E-RNA
induced	O
in	O
primed	B-cell_line
cells	E-cell_line
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	B-cell_line
cells	E-cell_line
(	O
T1/2	O
increased	O
6-8-fold	O
)	O
.	O

We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF-kappaB	S-protein
activation	O
by	O
proinflammatory	B-protein
cytokines	E-protein
was	O
cell	O
specific	O
.	O

We	O
find	O
that	O
mutation	O
of	O
these	O
elements	O
,	O
and	O
particularly	O
the	O
GATA	B-DNA
elements	E-DNA
,	O
results	O
in	O
a	O
decrease	O
or	O
complete	O
loss	O
of	O
DNase	B-protein
I	E-protein
hypersensitivity	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
FCM	O
on	O
the	O
LPS-induced	O
DNA-binding	O
activity	O
of	O
NF-kappaB	S-protein
,	O
by	O
means	O
of	O
electrophoretic	O
shift	O
assay	O
(	O
EMSA	O
)	O
.	O

The	O
only	O
exception	O
is	O
represented	O
by	O
the	O
P3HR1	B-cell_line
cells	E-cell_line
,	O
in	O
which	O
,	O
however	O
,	O
the	O
infection	O
by	O
the	O
variant	O
B	O
does	O
not	O
determine	O
induction	O
of	O
EBV	B-protein
antigens	E-protein
;	O
(	O
2	O
)	O
the	O
presence	O
of	O
the	O
EBV	B-DNA
genome	E-DNA
contributes	O
to	O
the	O
susceptibility	O
of	O
the	O
B	B-cell_line
cell	I-cell_line
lines	E-cell_line
to	O
HHV-6	O
infection	O
,	O
increasing	O
the	O
binding	O
sites	O
and	O
the	O
percentage	O
of	O
infectable	B-cell_type
cells	E-cell_type
,	O
as	O
detected	O
by	O
immunoelectron	O
microscopy	O
;	O
and	O
(	O
3	O
)	O
HHV-6	B-cell_line
infected	I-cell_line
T	I-cell_line
cells	E-cell_line
,	O
transfected	O
with	O
plasmids	S-DNA
bearing	O
the	O
promoter	B-DNA
regions	E-DNA
of	O
the	O
EBV	O
early	O
genes	O
BZLF1	O
and	O
BMRF1	S-DNA
,	O
show	O
a	O
strong	O
transactivation	O
of	O
these	O
promoters	S-DNA
.	O

We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	E-protein
for	O
neutrophils	S-cell_type
(	O
polymorphonuclear	B-cell_type
leukocytes	E-cell_type
)	O
.	O

Thus	O
,	O
signaling	O
in	O
NK3.3	B-cell_line
cells	E-cell_line
is	O
not	O
always	O
identical	O
with	O
that	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	E-cell_type
.	O

NFkappaB	S-protein
activity	O
is	O
independent	O
from	O
FADD	S-protein
,	O
caspases	S-protein
,	O
and	O
apoptosis	O
induction	O
.	O

The	O
mechanism	O
by	O
which	O
estrogen	O
exerts	O
its	O
anti-inflammatory	O
effect	O
is	O
not	O
yet	O
understood	O
.	O

Stimulation	O
of	O
T	B-cell_type
cells	E-cell_type
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	S-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation-related	O
genes	O
.	O

Conversely	O
,	O
inhibition	O
of	O
NF-kappaB	S-protein
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF-kappaB	S-protein
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	S-protein
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	S-protein
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	S-protein
stimulation	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	E-DNA
is	O
seen	O
in	O
monocytes	S-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

No	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
c-Jun-	B-cell_line
and	I-cell_line
GST-pi-positive	I-cell_line
plasma	I-cell_line
cells	E-cell_line
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	S-protein
(	O
SHP2	B-protein
interacting	I-protein
transmembrane	I-protein
adaptor	I-protein
protein	E-protein
)	O
.	O

Cross-linking	O
CD40	S-protein
on	O
B	B-cell_type
cells	E-cell_type
preferentially	O
induces	O
stress-activated	B-protein
protein	I-protein
kinases	E-protein
rather	O
than	O
mitogen-activated	B-protein
protein	I-protein
kinases	E-protein
.	O

This	O
result	O
suggested	O
that	O
PKB/PI3-kinase	S-protein
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and/or	O
proliferation	O
.	O

Hormone	O
binding	O
specificity	O
was	O
assessed	O
by	O
competition	O
studies	O
with	O
various	O
steroid	O
ligands	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	B-protein
alpha	I-protein
A	E-protein
,	O
alpha	B-DNA
B	E-DNA
(	O
AML1	S-DNA
)	O
,	O
and	O
beta	B-DNA
genes	E-DNA
in	O
Jurkat	B-cell_line
cells	E-cell_line
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B-DNA
enhancer	I-DNA
motif	E-DNA
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	E-protein
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	B-protein
alpha	E-protein
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	S-cell_line
,	O
an	O
APL-derived	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
APL	I-cell_type
blasts	E-cell_type
.	O

Cytomegalovirus	B-protein
IE	I-protein
gene	I-protein
products	E-protein
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL-6	B-DNA
promoter	E-DNA
activity	O
in	O
both	O
IL-6	S-protein
CAT	O
and	O
IL-6	O
luciferase	O
assays	O
.	O

T	B-cell_type
lymphocytes	E-cell_type
express	O
several	O
low	B-protein
molecular	I-protein
weight	I-protein
transmembrane	I-protein
adaptor	I-protein
proteins	E-protein
that	O
recruit	O
src	B-protein
homology	I-protein
(	I-protein
SH	I-protein
)	I-protein
2	I-protein
domain-containing	I-protein
intracellular	I-protein
molecules	E-protein
to	O
the	O
cell	O
membrane	O
via	O
tyrosine-based	O
signaling	O
motifs	O
.	O

Lymphocytes	S-cell_type
activated	O
with	O
the	O
OKT3	B-protein
antibody	E-protein
to	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	E-protein
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	S-cell_type
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	S-protein
(	O
PHA	S-protein
)	O
.	O

This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression/repression	O
of	O
differentiation-associated	B-DNA
genes	E-DNA
.	O

The	O
inhibition	O
of	O
apoptosis	O
by	O
curcumin	O
in	O
rat	B-cell_type
thymocytes	E-cell_type
was	O
accompanied	O
by	O
partial	O
suppression	O
of	O
AP-1	S-protein
activity	O
.	O

Proteins	O
of	O
the	O
ATF/	O
CREB	S-protein
class	O
of	O
transcription	B-protein
factors	E-protein
stimulate	O
gene	O
expression	O
of	O
several	O
cell	B-DNA
growth-related	I-DNA
genes	E-DNA
through	O
protein	B-DNA
kinase	I-DNA
A-related	I-DNA
cAMP	I-DNA
response	I-DNA
elements	E-DNA
.	O

We	O
now	O
report	O
that	O
EC	S-cell_type
costimulation	O
causes	O
increased	O
levels	O
of	O
IL-2	B-RNA
mRNA	E-RNA
as	O
a	O
result	O
of	O
increased	O
IL-2	S-protein
transcription	O
in	O
PBL	S-cell_type
.	O

The	O
high	O
concentration	O
of	O
foreign	B-protein
antigen	E-protein
in	O
the	O
lumen	S-cell_type
of	O
the	O
gastrointestinal	O
tract	O
is	O
separated	O
from	O
the	O
underlying	O
lymphocytes	S-cell_type
by	O
a	O
single	O
cell	O
layer	O
of	O
polarized	O
epithelium	O
.	O

Transient-transfection	O
assays	O
showed	O
that	O
bcl-x	B-DNA
promoter	E-DNA
was	O
transactivated	O
by	O
wild-type	B-protein
Tax	E-protein
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	S-protein
and	O
LFA-3	S-protein
costimulation	O
on	O
IL-2	S-protein
expression	O
.	O

Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	S-protein
and	O
suppresses	O
NF-kappaB	S-protein
expression	O
in	O
MNC	S-cell_type
in	O
parallel	O
.	O

Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	B-protein
NF-kappa	I-protein
B	E-protein
and	O
mRNAs	S-RNA
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF-kappa	B-protein
B	E-protein
.	O

Although	O
these	O
heterodimers	S-protein
do	O
not	O
recognize	O
a	O
classical	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	E-DNA
(	O
TRE	S-DNA
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	S-DNA
)	O
,	O
PPAR	S-protein
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B-protein
mutants	E-protein
,	O
including	O
two	O
stop	B-protein
codon	I-protein
mutants	E-protein
and	O
one	O
deletion	B-protein
mutant	E-protein
using	O
replication-competent	B-DNA
HIV-1	I-DNA
constructs	E-DNA
carrying	O
wild-type	B-DNA
or	I-DNA
mutant	I-DNA
LTRs	E-DNA
with	O
modifications	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
and/or	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	E-DNA
.	O

Studies	O
in	O
mice	O
have	O
shown	O
that	O
a	O
monoclonal	B-protein
antibody	E-protein
,	O
conjugated	O
with	O
palmitate	O
to	O
provide	O
a	O
lipid	O
tail	O
,	O
can	O
be	O
inserted	O
into	O
the	O
cell	O
membrane	O
to	O
provide	O
a	O
``	O
surrogate	O
''	O
antigen	O
receptor	O
.	O

Mutations	O
in	O
the	O
Pit-1	B-DNA
gene	E-DNA
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	B-cell_line
cells	E-cell_line
by	O
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	E-DNA
but	O
not	O
by	O
highly	O
expressed	O
Bcl-2	S-protein
.	O

In	O
nonpregnancy	B-cell_line
lymphocytes	E-cell_line
a	O
3-day	O
PHA	S-protein
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor-containing	B-cell_type
cells	E-cell_type
.	O

Rather	O
,	O
analysis	O
of	O
this	O
system	O
has	O
revealed	O
a	O
trans	O
relationship	O
between	O
late	O
gene	O
expression	O
and	O
viral	O
DNA	O
replication	O
and	O
highlights	O
the	O
indirect	O
and	O
complex	O
link	O
between	O
these	O
two	O
events	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

To	O
achieve	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
transactivation	O
by	O
Tax	S-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax-responsive	B-DNA
element	I-DNA
1	E-DNA
(	O
TRE-1	S-DNA
)	O
,	O
we	O
developed	O
a	O
genetic	O
approach	O
with	O
Saccharomyces	O
cerevisiae	O
.	O

These	O
data	O
add	O
further	O
evidence	O
to	O
previous	O
observations	O
from	O
the	O
authors	O
'	O
laboratory	O
that	O
certain	O
tumor	O
characteristics	O
may	O
be	O
associated	O
with	O
reactions	O
of	O
the	O
host	O
with	O
breast	O
cancer	O
.	O

Identification	O
of	O
human	B-DNA
TR2	I-DNA
orphan	I-DNA
receptor	I-DNA
response	I-DNA
element	E-DNA
in	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	E-DNA
of	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
major	I-DNA
late	I-DNA
promoter	E-DNA
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

The	O
Tax	B-protein
protein	E-protein
of	O
HTLV-I	O
,	O
a	O
positive	B-protein
transcriptional	I-protein
activator	E-protein
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	B-DNA
genes	E-DNA
including	O
GM-CSF	S-protein
,	O
IL-2R	B-protein
alpha	E-protein
and	O
IL-2	S-protein
.	O

The	O
GATA-1	S-protein
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co-localization	O
with	O
nuclear	B-protein
antigens	E-protein
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	B-protein
(	I-protein
Spl	I-protein
,	I-protein
c-Jun	I-protein
and	I-protein
TBP	I-protein
)	I-protein
or	I-protein
haemopoietic	I-protein
(	I-protein
NF-E2	I-protein
)	I-protein
transcription	I-protein
factors	E-protein
.	O

While	O
all	O
skeletal	O
muscles	O
expressed	O
the	O
gene	O
,	O
only	O
a	O
subset	O
of	O
myocytes	O
within	O
each	O
muscle	O
were	O
positive	O
,	O
indicating	O
molecular	O
heterogeneity	O
within	O
fetal	O
muscle	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B-protein
factors	E-protein
in	O
T	B-cell_type
cells	E-cell_type
.	O

Various	O
physiologic	O
concentrations	O
of	O
DEX	O
,	O
ISO	O
,	O
or	O
PGE2	O
were	O
added	O
at	O
the	O
time	O
of	O
initiation	O
of	O
the	O
cultures	O
and	O
subsequent	O
proliferation	O
of	O
the	O
unstimulated	O
T	B-cell_type
cells	E-cell_type
was	O
determined	O
.	O

This	O
implicates	O
that	O
the	O
SRG3	S-DNA
may	O
play	O
an	O
important	O
regulatory	O
role	O
during	O
T	O
cell	O
development	O
in	O
thymus	O
.	O

The	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
HLA-DRA	E-DNA
is	O
expressed	O
in	O
B	B-cell_type
cells	E-cell_type
,	O
activated	O
T	B-cell_type
lymphocytes	E-cell_type
,	O
and	O
in	O
antigen-presenting	B-cell_type
cells	E-cell_type
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL-1	B-DNA
beta	I-DNA
gene	E-DNA
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
promoter	E-DNA
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

The	O
production	O
of	O
the	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	E-protein
(	O
GM-CSF	S-protein
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O

We	O
further	O
demonstrate	O
that	O
0.1-0.5	O
microM	O
DMDTC	O
inhibits	O
intracellular	O
IL-2	S-protein
production	O
and	O
decreases	O
surface	O
expression	O
of	O
CD25	S-protein
(	O
the	O
alpha	B-protein
subunit	E-protein
of	O
the	O
IL-2	B-protein
receptor	E-protein
)	O
in	O
T	B-cell_type
cells	E-cell_type
stimulated	O
with	O
phorbol	O
ester	O
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	E-cell_type
.	O

Environmental	O
estrogens	O
or	O
estrogen	O
disrupters	O
have	O
recently	O
received	O
a	O
great	O
deal	O
of	O
attention	O
because	O
of	O
their	O
potential	O
health	O
impact	O
on	O
reproductive	O
tissues	O
.	O

Transgenic	O
expression	O
of	O
PML/RARalpha	S-protein
impairs	O
myelopoiesis	O
.	O

Insertion	O
of	O
this	O
chimeric	B-DNA
promoter	E-DNA
(	O
ISG15	B-DNA
LTR	E-DNA
)	O
upstream	O
of	O
the	O
human	B-DNA
IFNA2	I-DNA
gene	E-DNA
directed	O
high	O
levels	O
of	O
IFN	S-protein
synthesis	O
in	O
Tat-expressing	B-cell_line
cells	E-cell_line
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
-mediated	O
activation	O
.	O

Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O

Cloning	O
and	O
characterization	O
of	O
NF-ATc	S-protein
and	O
NF-ATp	S-protein
:	O
the	O
cytoplasmic	O
components	O
of	O
NF-AT	S-protein
.	O

Extensive	O
mutagenesis	O
of	O
CIITA	S-protein
was	O
undertaken	O
to	O
identify	O
structural	O
motifs	O
required	O
for	O
function	O
.	O

The	O
implantation	O
of	O
trophoblast	B-cell_type
cells	E-cell_type
at	O
extrauterine	O
sites	O
still	O
results	O
in	O
decidualization	O
.	O

We	O
found	O
that	O
:	O
(	O
i	O
)	O
both	O
CTCF	B-RNA
mRNA	E-RNA
and	O
protein	O
are	O
down-regulated	O
during	O
terminal	O
differentiation	O
in	O
most	O
cell	O
lines	O
tested	O
;	O
(	O
ii	O
)	O
CTCF	S-protein
down-regulation	O
is	O
retarded	O
and	O
less	O
pronounced	O
than	O
that	O
of	O
c-myc	S-DNA
;	O
(	O
iii	O
)	O
CTCF	B-protein
protein	E-protein
is	O
differentially	O
phosphorylated	O
and	O
the	O
phosphorylation	O
profiles	O
depend	O
on	O
the	O
differentiation	O
pathway	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine/threonine	B-protein
kinase	E-protein
that	O
phosphorylated	O
the	O
proto-oncogene	B-protein
product	E-protein
,	O
c-Fos	S-protein
,	O
and	O
is	O
termed	O
Fos	B-protein
kinase	E-protein
.	O

Mouse	B-cell_type
,	I-cell_type
rat	I-cell_type
,	I-cell_type
hamster	I-cell_type
,	I-cell_type
and	I-cell_type
human	I-cell_type
cells	E-cell_type
that	O
were	O
rendered	O
cytolytic	O
susceptible	O
by	O
E1A	S-protein
were	O
also	O
sensitized	O
to	O
CL-induced	O
and	O
chemically	O
induced	O
apoptosis	O
.	O

The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene-targeted	O
mice	O
deficient	O
of	O
either	O
Oct-2	S-protein
,	O
Bob1	S-protein
,	O
or	O
both	O
NF-kappaB	S-protein
subunits	O
p50	O
and	O
p52	O
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	B-cell_type
leukocytes	E-cell_type
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B-protein
molecules	E-protein
for	O
leukocytes	S-cell_type
[	O
e.g.	O
,	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	E-protein
(	O
ELAM-1	S-protein
)	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	E-protein
(	O
ICAM-1	S-protein
)	O
]	O
.	O

The	O
expression	O
of	O
TNF-alpha	B-RNA
and	I-RNA
IL-6	I-RNA
mRNAs	E-RNA
was	O
also	O
induced	O
.	O

Since	O
the	O
inhibition	O
of	O
Ca2+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2+	O
mobilization	O
,	O
8-	O
(	O
diethylamino	O
)	O
-octyl-3	O
,	O
4	O
,	O
5-trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR-induced	B-protein
FasL	E-protein
but	O
not	O
Fas	S-protein
,	O
the	O
expression	O
of	O
Fas	S-protein
appears	O
to	O
be	O
independent	O
of	O
Ca2+	O
mobilization	O
.	O

Estrogen	O
decreases	O
TNF	S-protein
gene	O
expression	O
by	O
blocking	O
JNK	S-protein
activity	O
and	O
the	O
resulting	O
production	O
of	O
c-Jun	S-protein
and	O
JunD	S-protein
.	O

Thus	O
,	O
CD30	B-protein
-CD30L	E-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	S-protein
.	O

It	O
is	O
known	O
that	O
the	O
stability	O
of	O
this	O
binding	O
results	O
from	O
cooperative	O
interactions	O
between	O
these	O
proteins	O
.	O

Coactivator	O
OCA-B	S-protein
may	O
undergo	O
a	O
POU-dependent	O
conformational	O
change	O
that	O
exposes	O
its	O
amino	O
terminus	O
,	O
allowing	O
it	O
to	O
recognize	O
specific	O
DNA	B-DNA
sequences	E-DNA
in	O
the	O
major	O
groove	O
within	O
the	O
binding	O
site	O
for	O
Oct-1	S-protein
or	O
Oct-2	S-protein
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	B-cell_line
monocytic	I-cell_line
cells	E-cell_line
results	O
in	O
NF-kappa	B-protein
B	E-protein
activation	O
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	S-DNA
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
serine/threonine	I-protein
kinases	E-protein
,	O
pp70S6K	S-protein
and	O
pp90rsk	S-protein
.	O

B-1	B-cell_type
lymphocytes	E-cell_type
are	O
self-renewing	O
,	O
CD5+	B-cell_type
B	I-cell_type
cells	E-cell_type
that	O
display	O
a	O
propensity	O
for	O
malignant	O
transformation	O
and	O
are	O
the	O
normal	O
counterpart	O
to	O
human	O
chronic	O
lymphocytic	O
leukemias	O
.	O

Regulation	O
of	O
IL-4	S-protein
expression	O
by	O
the	O
transcription	B-protein
factor	I-protein
JunB	E-protein
during	O
T	O
helper	O
cell	O
differentiation	O
.	O

Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	B-DNA
clone	E-DNA
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	B-protein
27-kDa	I-protein
heat	I-protein
shock	I-protein
protein	E-protein
(	O
HSP27	S-protein
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O

Interferon-gamma	S-protein
modulates	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
AP-1	S-protein
and	O
NF-kappa	B-protein
B	E-protein
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	B-cell_type
monocytes	E-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
with	O
phytohemaglutinin	S-protein
(	O
PHA	S-protein
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL-3	B-DNA
gene	E-DNA
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	B-protein
chain	E-protein
gene	O
by	O
analyzing	O
the	O
2.5-kilobase	B-DNA
sequence	E-DNA
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

These	O
results	O
identify	O
a	O
transcriptional	B-DNA
regulatory	I-DNA
element	E-DNA
associated	O
with	O
a	O
nuclease-hypersensitive	B-DNA
site	E-DNA
in	O
the	O
pol	B-DNA
gene	E-DNA
of	O
HIV-1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis-	O
regulatory	B-DNA
elements	E-DNA
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	S-protein
expressed	O
on	O
lung	B-cell_type
fibroblasts	E-cell_type
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	B-cell_type
cells	E-cell_type
.	O

A	O
loss-of-function	O
mutation	O
in	O
Cbl-b	S-protein
disrupted	O
the	O
interaction	O
between	O
Cbl-b	S-protein
and	O
Zap-70	S-protein
and	O
nearly	O
completely	O
abrogated	O
the	O
Cbl-b	S-protein
-mediated	O
activation	O
of	O
NFAT	S-protein
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
immunolabeling	O
of	O
the	O
regulatory	B-protein
subunits	E-protein
(	O
type	O
I	O
and	O
type	O
II	O
)	O
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	E-protein
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	S-DNA
or	O
tumor-suppressor	B-DNA
genes	E-DNA
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

cAMP	O
signaling	O
inhibited	O
Stat1	S-protein
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	O
of	O
DNA	O
binding	O
and	O
down-regulation	O
of	O
Stat1	O
protein	O
and	O
mRNA	O
levels	O
.	O

Characterization	O
of	O
both	O
TCR	B-protein
chains	E-protein
documented	O
a	O
great	O
diversity	O
among	O
those	O
clones	O
and	O
the	O
persistence	O
of	O
clonotypes	O
over	O
a	O
2-yr	O
period	O
.	O

The	O
sense	O
sequence	O
(	O
sequence	O
III	O
)	O
of	O
the	O
X	B-DNA
gene	E-DNA
also	O
enhanced	O
the	O
expression	O
of	O
CD40	B-protein
antigen	E-protein
in	O
patients	O
with	O
hepatitis	O
B	O
.	O

Lt-4	S-protein
reacted	O
with	O
all	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	E-cell_line
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	B-cell_line
cell	I-cell_line
lines	E-cell_line
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O
HTLV-II-bearing	B-cell_line
cell	I-cell_line
line	E-cell_line
.	O

OCA-B	S-protein
associates	O
with	O
the	O
Oct-1	B-protein
POU	I-protein
domain	E-protein
,	O
a	O
bipartite	O
DNA-binding	O
structure	O
containing	O
a	O
POU-specific	B-protein
(	I-protein
POU	I-protein
[	I-protein
S	I-protein
]	I-protein
)	I-protein
domain	E-protein
joined	O
by	O
a	O
flexible	O
linker	O
to	O
a	O
POU	B-protein
homeodomain	E-protein
(	O
POU	B-protein
[	I-protein
H	I-protein
]	E-protein
)	O
.	O

Single	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
androgen	B-DNA
receptor	I-DNA
gene	E-DNA
mutations	O
in	O
patients	O
with	O
androgen	O
insensitivity	O
syndromes	O
:	O
application	O
for	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
therapy	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
STAT1	S-protein
and	O
STAT5	S-protein
by	O
Tax	S-protein
enhances	O
cytokine	S-protein
-induced	O
functions	O
of	O
virus-infected	O
T-cells	S-cell_type
,	O
hence	O
the	O
induction	O
may	O
play	O
a	O
role	O
in	O
IL-2	S-protein
-dependent	O
transformation	O
steps	O
of	O
T-cells	S-cell_type
by	O
HTLV-1	O
.	O

We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S-allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	B-cell_type
pulmonary	I-cell_type
artery	I-cell_type
endothelial	I-cell_type
cells	E-cell_type
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Interleukin-12	S-protein
expression	O
in	O
B	B-cell_type
cells	E-cell_type
by	O
transformation	O
with	O
Epstein-Barr	O
virus	O
.	O

For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
with	O
the	O
reporter	B-DNA
plasmid	I-DNA
p	I-DNA
[	I-DNA
(	I-DNA
TRE	I-DNA
)	I-DNA
3-tk-Luc	I-DNA
]	E-DNA
and	O
found	O
that	O
CCK-8	O
was	O
able	O
to	O
dose-dependently	O
induce	O
luciferase	S-protein
expression	O
related	O
to	O
activator	B-protein
protein-1	E-protein
(	O
AP-1	S-protein
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP-1	B-protein
complex	E-protein
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	O
was	O
obtained	O
with	O
1	O
nM	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O

The	O
pathway	O
whereby	O
EBV	O
infects	O
T	B-cell_type
cells	E-cell_type
as	O
well	O
as	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
T	B-cell_type
cells	E-cell_type
has	O
not	O
been	O
established	O
.	O

While	O
p70	B-protein
I	I-protein
kappa	I-protein
B	I-protein
gamma	E-protein
inhibits	O
p50-	O
,	O
p65-	O
,	O
and	O
c-Rel-mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	E-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	E-protein
are	O
specific	O
for	O
p50	S-protein
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
NF-kappaB/Rel	S-protein
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV-I-transformed	B-cell_line
T	I-cell_line
cells	E-cell_line
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	S-DNA
and	O
certain	O
STAT	B-DNA
enhancers	E-DNA
.	O

These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	B-DNA
promoter	I-DNA
region	E-DNA
of	O
the	O
adult	B-DNA
beta	I-DNA
globin	I-DNA
gene	E-DNA
contribute	O
to	O
its	O
factor-mediated	O
suppression	O
early	O
in	O
development	O
and	O
then	O
may	O
modulate	O
its	O
expression	O
at	O
a	O
later	O
stage	O
.	O

SHP1-DeltaSH2	S-protein
also	O
inhibited	O
events	O
downstream	O
of	O
ZAP-70	S-protein
and	O
Syk	S-protein
,	O
such	O
as	O
activation	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
Erk2	E-protein
and	O
the	O
transcriptional	O
activation	O
of	O
the	O
interleukin-2	B-DNA
gene	E-DNA
.	O

Nuclear	O
and	O
post-nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	E-cell_line
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	B-cell_line
D-resistant	E-cell_line
and	O
wild	B-cell_line
type	I-cell_line
phenotypes	E-cell_line
,	O
respectively	O
.	O

It	O
contains	O
a	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
motif	E-protein
contiguous	O
with	O
a	O
Per-Arnt-Sim	B-protein
(	I-protein
PAS	I-protein
)	I-protein
homology	I-protein
region	E-protein
.	O

We	O
have	O
analyzed	O
de	O
novo	O
radiation-induced	O
translocations	O
between	O
the	O
Xi	S-DNA
and	O
autosomes	S-DNA
to	O
study	O
the	O
maintenance	O
and	O
spreading	O
of	O
X-chromosome	S-DNA
inactivation	O
(	O
X	O
inactivation	O
)	O
in	O
relation	O
to	O
the	O
position	O
of	O
the	O
X-inactivation	O
center	O
(	B-DNA
XIC	I-DNA
)	I-DNA
/XIST	E-DNA
in	O
differentiated	B-cell_type
cells	E-cell_type
.	O

Thus	O
,	O
CIITA	S-protein
not	O
only	O
activates	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	E-DNA
but	O
recruits	O
another	O
B	O
cell-specific	O
coactivator	O
to	O
increase	O
transcriptional	O
activity	O
of	O
class	B-DNA
II	I-DNA
promoters	E-DNA
in	O
B	B-cell_type
cells	E-cell_type
.	O

CD2	S-protein
signalling	O
induces	O
phosphorylation	O
of	O
CREB	S-protein
in	O
primary	B-cell_type
lymphocytes	E-cell_type
.	O

Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor	O
.	O

The	O
cloning	O
of	O
the	O
complementary	B-DNA
DNA	E-DNA
for	O
the	O
50K	B-protein
subunit	E-protein
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	B-protein
105K	I-protein
precursor	E-protein
(	O
p105	S-protein
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

We	O
report	O
here	O
that	O
both	O
NF-M-dependent	B-DNA
promoter	I-DNA
constructs	E-DNA
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M-estrogen	B-cell_line
receptor	I-cell_line
expressing	I-cell_line
progenitors	E-cell_line
.	O

Activity	O
against	O
macrovascular	B-cell_line
EC	E-cell_line
(	O
HUVEC	S-cell_line
)	O
and	O
microvascular	B-cell_line
EC	E-cell_line
(	O
human	B-cell_line
bone	I-cell_line
marrow	I-cell_line
EC	I-cell_line
immortalized	I-cell_line
by	I-cell_line
SV40	E-cell_line
)	O
antigens	O
was	O
detected	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

DC	S-cell_type
can	O
develop	O
in	O
mutant	O
mice	O
lacking	O
mature	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
provided	O
the	O
common	O
precursors	O
are	O
present	O
.	O

These	O
results	O
suggest	O
that	O
IFN-alpha5	S-protein
and	O
IFN-beta	S-protein
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

The	O
role	O
of	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
family	I-DNA
members	E-DNA
in	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	B-protein
NF-kappa	I-protein
B	E-protein
and	O
of	O
the	O
NF-kappa	B-protein
B	E-protein
activated	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
element	E-DNA
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell-activating	O
signals	O
and	O
tax1	S-protein
.	O

The	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	E-protein
is	O
implicated	O
in	O
B	O
cell-specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

This	O
review	O
summarizes	O
data	O
on	O
specific	O
regulation	O
of	O
promoters	S-DNA
and	O
enhancers	S-DNA
by	O
nuclear	B-protein
trans-acting	I-protein
factors	E-protein
in	O
lymphocytes	S-cell_type
.	O

However	O
,	O
we	O
show	O
that	O
mutant	O
forms	O
of	O
E1A	S-protein
that	O
no	O
longer	O
bind	O
p300/CBP	S-protein
can	O
still	O
interact	O
directly	O
with	O
Stat1	S-protein
(	O
via	O
E1A	B-protein
N-terminal	I-protein
and	I-protein
Stat1	I-protein
C-terminal	I-protein
residues	E-protein
)	O
and	O
block	O
IFNgamma-driven	O
,	O
Stat1	S-protein
-dependent	O
gene	O
activation	O
and	O
consequent	O
function	O
during	O
early-phase	O
infection	O
in	O
the	O
natural	B-cell_type
host	I-cell_type
cell	E-cell_type
.	O

CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

Here	O
,	O
we	O
studied	O
whether	O
PPARalpha	S-protein
activation	O
(	O
by	O
means	O
of	O
the	O
selective	O
agonist	O
WY	O
14	O
,	O
643	O
)	O
of	O
endothelial	B-cell_type
cells	E-cell_type
,	O
pivotal	O
in	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
,	O
interfered	O
with	O
LTB4	O
induced	O
adhesion	O
of	O
PMN	B-cell_type
neutrophil	I-cell_type
granulocytes	E-cell_type
in	O
vitro	O
.	O

In	O
contrast	O
,	O
HePTP	S-protein
had	O
no	O
effects	O
on	O
N-terminal	B-protein
c-Jun	I-protein
kinase	E-protein
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O

We	O
found	O
that	O
erythropoietin	S-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	S-protein
,	O
STAT5A	S-protein
,	O
and	O
STAT5B	S-protein
.	O

GATA-2	S-protein
and	O
c-myb	S-protein
were	O
down-regulated	O
by	O
Epo	S-protein
,	O
and	O
GATA-2	S-protein
was	O
further	O
down-modulated	O
by	O
the	O
inducers	O
.	O

Activation	O
of	O
primary	B-cell_type
human	I-cell_type
T-lymphocytes	E-cell_type
through	O
CD2	B-protein
plus	I-protein
CD28	I-protein
adhesion	I-protein
molecules	E-protein
induces	O
long-term	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	E-protein
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	S-cell_type
nor	O
their	O
mannose	O
receptor-mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O

Elevated	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB	S-protein
-mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-protein
beta-chain	E-protein
.	O

This	O
approach	O
uses	O
monoclonal	B-protein
antibodies	E-protein
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT-1	S-protein
.	O

Using	O
site-directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha-helices	S-protein
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	S-protein
.	O

While	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	E-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	E-DNA
by	O
Tpl-2	S-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
NFAT	I-protein
delta418	E-protein
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	S-protein
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	S-protein
-mediated	O
NFAT	S-protein
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin-dependent	O
and	O
independent	O
pathways	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	E-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	S-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	E-protein
(	O
VDR	S-protein
)	O
.	O

Spi-C	S-protein
interacted	O
with	O
DNA	O
similarly	O
to	O
PU.1	S-protein
as	O
judged	O
by	O
methylation	O
interference	O
,	O
band-shift	O
and	O
site	O
selection	O
analysis	O
,	O
and	O
activated	O
transcription	O
of	O
a	O
kappaY	B-DNA
element	I-DNA
reporter	I-DNA
gene	E-DNA
upon	O
co-transfection	O
of	O
HeLa	B-cell_line
cells	E-cell_line
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis-acting	B-DNA
elements	E-DNA
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B-DNA
promoter	I-DNA
construct	E-DNA
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	B-cell_type
cells	E-cell_type
than	O
in	O
extracts	O
from	O
class	B-cell_line
II-negative	I-cell_line
HeLa	I-cell_line
cells	E-cell_line
.	O

Transactivation	O
of	O
PTHrP	S-protein
by	O
Tax	S-protein
was	O
seen	O
in	O
T	B-cell_type
cells	E-cell_type
but	O
not	O
in	O
B-cell	B-cell_line
lines	E-cell_line
or	O
fibroblasts	S-cell_line
.	O

Inhibition	O
by	O
IL-10	S-protein
of	O
proinflammatory	B-protein
cytokine	E-protein
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF-alpha	S-protein
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL-1beta	S-protein
.	O

The	O
octamer	B-DNA
sequence	E-DNA
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	S-DNA
and	O
the	O
enhancer	S-DNA
of	O
Ig	B-DNA
genes	E-DNA
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O

The	O
PEBP2	B-DNA
alpha	I-DNA
A	I-DNA
and	I-DNA
PEBP2	I-DNA
alpha	I-DNA
B	I-DNA
genes	E-DNA
encode	O
the	O
DNA-binding	B-protein
subunit	E-protein
of	O
a	O
murine	B-protein
transcription	I-protein
factor	E-protein
,	O
PEBP2	S-protein
,	O
which	O
is	O
implicated	O
as	O
a	O
T-cell-specific	B-protein
transcriptional	I-protein
regulator	E-protein
.	O

Direct	O
demonstration	O
of	O
NFATp	S-protein
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	B-cell_line
HT-2	I-cell_line
cells	E-cell_line
using	O
a	O
specific	O
NFATp	B-protein
polyclonal	I-protein
antibody	E-protein
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	B-DNA
and	I-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
,	O
contain	O
an	O
octamer	B-DNA
sequence	E-DNA
in	O
the	O
promoter	S-DNA
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Alpha-lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
c-Jun	S-protein
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rat	B-DNA
prolactin	I-DNA
(	I-DNA
rPRL	I-DNA
)	I-DNA
promoter	E-DNA
activity	O
induced	O
by	O
either	O
oncogenic	B-protein
Ras	E-protein
or	O
phorbol	O
esters	O
.	O

With	O
the	O
antibodies	O
Ki-67	S-protein
and	O
anti-p-145	S-protein
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	S-protein
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	E-protein
(	O
VCAM-1	S-protein
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell-monocyte	O
(	O
EC-Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

Evaluation	O
of	O
monoclonal	O
anti-D	O
reagents	O
using	O
D	B-cell_line
variant	I-cell_line
cells	E-cell_line
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine-rich	B-protein
regions	E-protein
called	O
LIM	B-protein
domains	E-protein
,	O
which	O
show	O
homology	O
to	O
zinc-binding	B-protein
proteins	E-protein
and	O
to	O
iron-sulfur	B-protein
centers	E-protein
of	O
ferredoxins	S-protein
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

In	O
contrast	O
,	O
neither	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	E-DNA
nor	O
EA/S	B-DNA
motifs	E-DNA
contributed	O
pronouncedly	O
to	O
Akv	O
MLV	O
transcription	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	E-cell_line
lacking	O
DNA-binding	O
ALF1	S-protein
or	O
HEB	S-protein
and	O
E2A	B-protein
proteins	E-protein
.	O

PML	B-RNA
mRNA	E-RNA
and	O
protein	S-protein
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	S-cell_type
,	O
are	O
consistently	O
induced	O
by	O
growth	B-protein
factor	E-protein
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O

The	O
results	O
obtained	O
by	O
duplication	O
of	O
activation	B-protein
domains	E-protein
or	O
their	O
mixed	O
combination	O
suggest	O
that	O
the	O
domains	O
are	O
functionally	O
independent	O
.	O

On	O
the	O
contrary	O
,	O
32Dcl3	B-cell_line
cells	E-cell_line
stably	O
expressing	O
AML1/ETO	S-DNA
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	S-protein
.	O

Ro	O
09-2210	O
was	O
also	O
able	O
to	O
block	O
antigen-induced	O
IL-2	S-protein
secretion	O
with	O
an	O
IC50	O
=	O
30	O
nM	O
,	O
but	O
was	O
considerably	O
less	O
potent	O
at	O
blocking	O
Ca2+	O
flux	O
stimulated	O
by	O
anti-CD3	S-protein
treatment	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c-erb	B-protein
A	E-protein
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v-erb	B-protein
A	I-protein
protein	E-protein
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	B-protein
61	E-protein
.	O

NGFI-B/nur77	S-protein
binds	O
to	O
the	O
response	B-DNA
element	E-DNA
by	O
monomer	O
or	O
heterodimer	O
with	O
retinoid	B-protein
X	I-protein
receptor	E-protein
(	O
RXR	S-protein
)	O
.	O

We	O
found	O
that	O
a	O
single	O
Ala	O
--	O
>	O
Asp	O
amino	O
acid	O
57	O
substitution	O
in	O
an	O
HLA-DQ3.2	O
molecule	O
regulated	O
binding	O
of	O
an	O
HSV-2	O
VP-16-derived	O
peptide	O
.	O

However	O
,	O
immediately	O
after	O
TcR/CD3	S-protein
cross-linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50.p65	B-protein
heterodimers	E-protein
was	O
observed	O
.	O

This	O
observation	O
directly	O
demonstrates	O
the	O
existence	O
of	O
a	O
Ca2+	B-protein
signal-dependent	I-protein
regulatory	I-protein
element	E-protein
obligatory	O
for	O
expression	O
of	O
some	O
genes	S-DNA
in	O
T	B-cell_type
cells	E-cell_type
but	O
not	O
in	O
fibroblasts	S-cell_type
.	O

These	O
results	O
provide	O
new	O
insights	O
into	O
how	O
gp120	S-protein
can	O
influence	O
the	O
involvement	O
of	O
glial	B-cell_type
cells	E-cell_type
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
complex	O
.	O

The	O
other	O
studied	O
regulatory	B-DNA
element	E-DNA
is	O
the	O
minimal	B-DNA
CD4	I-DNA
silencer	E-DNA
which	O
inhibits	O
CD4	B-DNA
gene	E-DNA
expression	O
in	O
peripheral	B-cell_type
CD8	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	B-cell_type
B	I-cell_type
cells	E-cell_type
contain	O
a	O
novel	O
substoichiometric	O
TAF	S-protein
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	S-protein
isolated	O
from	O
other	O
cell	O
types	O
.	O

Since	O
the	O
CTL	S-cell_type
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B-protein
epitopes	E-protein
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B-protein
epitopes	E-protein
.	O

Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	S-protein
and	O
STAT5b	S-protein
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	E-cell_type
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O

[	O
Estrogen	B-protein
receptor	E-protein
content	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	E-cell_type
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O

TCL1	S-protein
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	S-protein
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O

These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV-1	B-DNA
LTR	E-DNA
,	O
cytokine	S-protein
production	O
,	O
and	O
NF-kappaB	S-protein
in	O
cells	O
of	O
macrophage	B-cell_type
lineage	E-cell_type
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	S-protein
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B-protein
proteins	E-protein
.	O

In	O
contrast	O
,	O
NFAT	S-protein
activation	O
by	O
a	O
G-protein-coupled	B-protein
receptor	E-protein
is	O
not	O
modulated	O
by	O
p95vav	S-protein
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	S-protein
signaling	O
pathways	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	S-protein
expression	O
can	O
be	O
quite	O
different	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6-AP	S-protein
,	O
the	O
p53-conjugating	B-protein
ligase	E-protein
,	O
and	O
from	O
E3	B-protein
alpha	E-protein
,	O
the	O
``	B-protein
N-end	I-protein
rule	I-protein
''	I-protein
ligase	E-protein
.	O

The	O
adherence-dependent	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	E-RNA
levels	O
was	O
also	O
not	O
a	O
consequence	O
of	O
mRNA	S-RNA
stabilization	O
events	O
.	O

The	O
data	O
suggest	O
that	O
CD4+	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	E-cell_type
from	O
patients	O
with	O
early	O
untreated	O
RA	O
manifest	O
an	O
intrinsic	O
abnormality	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
specific	O
cytokine-producing	B-cell_type
effector	I-cell_type
cells	E-cell_type
that	O
might	O
contribute	O
to	O
the	O
characteristic	O
Th1-dominated	O
chronic	O
(	O
auto	O
)	O
immune	O
inflammation	O
in	O
RA	O
.	O

The	O
lack	O
of	O
Jak3	S-protein
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	S-protein
to	O
activate	O
Stat6	S-protein
in	O
the	O
EBV-transformed	B-cell_line
cell	I-cell_line
line	E-cell_line
from	O
the	O
patient.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-protein
c	E-protein
are	O
dependent	O
on	O
Jak3	S-protein
and	O
that	O
Jak3	S-protein
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O

The	O
CD34+	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
KG1	E-cell_line
differentiates	O
into	O
dendritic-like	O
cells	O
in	O
response	O
to	O
granulocyte-macrophage	B-protein
CSF	E-protein
plus	O
TNF-alpha	S-protein
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF-alpha	S-protein
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	B-DNA
response	I-DNA
element	E-DNA
(	O
CD28RE	S-DNA
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	B-DNA
promoter	I-DNA
proximal	I-DNA
AP-1-binding	I-DNA
site	E-DNA
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	B-protein
T-cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
TCF-1	E-protein
(	O
for	O
T-Cell	B-protein
Factor-1	E-protein
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	B-DNA
response	I-DNA
element	E-DNA
(	O
TCE	S-DNA
)	O
located	O
within	O
the	O
IL-2	B-DNA
promoter	E-DNA
.	O

Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide-induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF-kappa	B-protein
B	E-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF-kappa	B-protein
B	I-protein
inhibitor	E-protein
``	O
I	B-protein
kappa	I-protein
B	E-protein
``	O
,	O
blocking	O
the	O
translocation	O
of	O
NF-kappa	B-protein
B	E-protein
into	O
the	O
nuclear	O
compartment	O
.	O

The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	B-protein
regulatory	I-protein
protein	I-protein
kinase	I-protein
glycogen	I-protein
synthase	I-protein
kinase-3beta	E-protein
(	O
GSK-3beta	S-protein
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta-catenin	S-protein
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK-3beta	S-protein
in	O
Tcf-mediated	O
transcription	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Spi-C	B-RNA
RNA	E-RNA
was	O
expressed	O
in	O
mature	B-cell_type
B	I-cell_type
lymphocytes	E-cell_type
and	O
at	O
lower	O
levels	O
in	O
macrophages	S-cell_type
.	O

The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O

Phytohemagglutinin	S-protein
(	O
PHA	S-protein
)	O
-induced	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
from	O
the	O
sensitive	O
but	O
not	O
the	O
resistant	O
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	B-cell_type
lymphocytes	E-cell_type
containing	O
constitutive	O
nuclear	O
NF-kappa	B-protein
B	E-protein
revealed	O
constitutively	O
phosphorylated	O
p65	S-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL-2	S-protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	S-protein
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	E-DNA
.	O

These	O
results	O
add	O
to	O
our	O
knowledge	O
about	O
the	O
molecules	O
implicated	O
along	O
the	O
monocytic	O
differentiation	O
and	O
growth	O
arrest	O
of	O
leukemic	B-cell_type
cells	E-cell_type
and	O
provide	O
a	O
first	O
step	O
in	O
the	O
study	O
of	O
their	O
respective	O
roles	O
.	O

Taken	O
together	O
,	O
we	O
report	O
that	O
IL-2	S-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	S-protein
and	O
an	O
as	O
yet	O
undefined	O
84-kDa	B-protein
protein	E-protein
in	O
antigen-specific	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	E-cell_line
.	O

Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	S-protein
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	E-protein
NF-E2	O
.	O

In	O
addition	O
,	O
the	O
macrophage	O
transcription	B-protein
factor	E-protein
PU.1	O
binds	O
the	O
CD11b	B-DNA
promoter	E-DNA
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	B-DNA
site	E-DNA
.	O

STAT5-	B-protein
and	I-protein
STAT1-related	I-protein
factors	E-protein
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	B-protein
,	I-protein
STAT3-	I-protein
,	I-protein
and	I-protein
STAT5-related	I-protein
proteins	E-protein
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	B-protein
variant	E-protein
of	O
the	O
human	B-protein
IL-4	I-protein
receptor	I-protein
alpha-chain	E-protein
in	O
IgE	S-protein
synthesis	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	B-protein
subunit	E-protein
of	O
NF-kappa	B-protein
B	E-protein
block	O
CD11b	S-protein
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL-60	B-cell_line
granulocytes	E-cell_line
.	O

Inhibition	O
of	O
T	B-cell_type
cell	E-cell_type
and	O
promotion	O
of	O
natural	O
killer	O
cell	O
development	O
by	O
the	O
dominant	B-protein
negative	I-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
Id3	E-protein
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF-kappa	B-protein
B	E-protein
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
.	O

We	O
have	O
found	O
that	O
in	O
nodular	O
lymphocyte	O
predominance	O
HD	O
(	O
NLPHD	O
)	O
tumor	B-cell_type
cells	E-cell_type
consistently	O
display	O
the	O
BCL-6	S-protein
(	O
+	O
)	O
/	O
syn-1	S-protein
(	O
-	O
)	O
phenotype	O
,	O
indicating	O
their	O
derivation	O
from	O
GC	B-cell_type
B	I-cell_type
cells	E-cell_type
.	O

Unexpectedly	O
,	O
the	O
17q	B-DNA
breakpoints	E-DNA
in	O
four	O
CMPD1	O
translocation	O
cases	O
previously	O
analyzed	O
by	O
us	O
and	O
others	O
map	O
50	O
kb	O
or	O
more	O
from	O
SOX9	S-DNA
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	S-protein
and	O
CD28	S-protein
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B-protein
kappa	I-protein
B	E-protein
phosphorylation	O
and	O
NF-kappa	B-protein
B	E-protein
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	S-protein
activation	O
and	O
c-Jun	S-protein
phosphorylation	O
on	O
the	O
other	O
.	O

The	O
B3	B-protein
factor	E-protein
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA-DRA	B-DNA
and	I-DNA
DQB	I-DNA
reporter	I-DNA
constructs	E-DNA
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis-elements	S-DNA
located	O
between	O
-141	B-DNA
base	I-DNA
pairs	E-DNA
and	O
the	O
transcription	B-DNA
initiation	I-DNA
site	E-DNA
.	O

Long	O
term	O
culture	O
of	O
TPA-differentiated	B-cell_type
U-937	I-cell_type
cells	E-cell_type
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32-36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O

Activation	O
of	O
individual	O
CD4+	B-cell_line
T	I-cell_line
cells	E-cell_line
results	O
in	O
differential	O
lymphokine	S-protein
expression	O
:	O
interleukin	B-protein
2	E-protein
(	O
IL-2	S-protein
)	O
is	O
preferentially	O
produced	O
by	O
T	B-cell_line
helper	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
TH1	I-cell_line
)	I-cell_line
cells	E-cell_line
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	S-protein
is	O
synthesized	O
by	O
TH2	B-cell_line
cells	E-cell_line
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	S-protein
,	O
p56	B-protein
(	I-protein
lck	I-protein
)	E-protein
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	S-protein
,	O
T	B-cell_type
lymphocytes	E-cell_type
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	S-protein
therapy	O
[	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	E-protein
,	O
IFN	B-protein
alpha	E-protein
-containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O

The	O
extent	O
to	O
which	O
analog	O
activity	O
was	O
increased	O
after	O
cotreatment	O
with	O
RA	O
was	O
inversely	O
related	O
to	O
potency	O
.	O

LFA-3	S-protein
induced	O
moderate	O
levels	O
of	O
AP-1	S-protein
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B-protein
B	E-protein
,	O
while	O
B7	S-protein
costimulation	O
strongly	O
induced	O
both	O
AP-1	S-protein
and	O
substantially	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	E-protein
.	O

ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	B-cell_line
cells	E-cell_line
into	O
mature	B-cell_type
granulocytes	E-cell_type
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O

Separation	O
of	O
oxidant-initiated	O
and	O
redox-regulated	O
steps	O
in	O
the	O
NF-kappa	B-protein
B	E-protein
signal	O
transduction	O
pathway	O
.	O

Senescent	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cultures	E-cell_line
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	B-cell_line
passage	I-cell_line
cells	E-cell_line
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

Transcriptional	O
inhibition	O
by	O
interleukin-6	S-protein
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	E-protein
in	O
macrophages	S-cell_type
derived	O
from	O
human	B-cell_type
peripheral	I-cell_type
monocytes	E-cell_type
and	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	S-DNA
and	O
BR4	S-DNA
located	O
at	O
positions	O
-102	O
to	O
-73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL-5	S-protein
expression	O
in	O
T	B-cell_type
cells	E-cell_type
.	O

Taken	O
together	O
,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O
require	O
further	O
analysis	O
:	O
(	O
1	O
)	O
expression	O
of	O
Id2	B-RNA
mRNA	E-RNA
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV-I	O
or	O
-II	O
;	O
(	O
2	O
)	O
T-cells	O
usually	O
express	O
either	O
Id2	S-protein
or	O
Id3	B-RNA
mRNA	E-RNA
,	O
but	O
B-cells	O
often	O
express	O
both	O
simultaneously	O
;	O
(	O
3	O
)	O
non-dividing	O
,	O
normal	O
PBL	S-cell_type
express	O
high	O
levels	O
of	O
Id2	S-protein
and	O
no	O
Id3	B-RNA
mRNA	E-RNA
;	O
and	O
with	O
the	O
onset	O
of	O
cellular	O
proliferation	O
,	O
levels	O
of	O
Id2	B-RNA
mRNA	E-RNA
decrease	O
while	O
levels	O
of	O
Id3	B-RNA
mRNA	E-RNA
increase	O
,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	S-DNA
is	O
disparate	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	S-protein
in	O
T	B-cell_type
lymphocytes	E-cell_type
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Genetic	O
mapping	O
studies	O
within	O
the	O
E1A	B-DNA
gene	E-DNA
demonstrated	O
that	O
expression	O
of	O
only	O
the	O
first	O
exon	O
of	O
E1A	S-DNA
was	O
sufficient	O
to	O
inhibit	O
IFN	S-protein
-MCP	O
.	O

In	O
contrast	O
,	O
prostaglandin	O
I2	O
(	O
PGI2	O
)	O
,	O
a	O
strong	O
negative	O
regulator	O
of	O
platelet	S-cell_type
function	O
,	O
inhibited	O
agonist-induced	O
as	O
well	O
as	O
Ca2+-induced	O
activation	O
of	O
Rap1	S-protein
.	O

Structure	O
and	O
function	O
analysis	O
of	O
the	O
human	B-DNA
myeloid	I-DNA
cell	I-DNA
nuclear	I-DNA
differentiation	I-DNA
antigen	I-DNA
promoter	E-DNA
:	O
evidence	O
for	O
the	O
role	O
of	O
Sp1	S-protein
and	O
not	O
of	O
c-Myb	S-protein
or	O
PU.1	S-protein
in	O
myelomonocytic	O
lineage-specific	O
expression	O
.	O

TCL1	B-DNA
oncogene	E-DNA
expression	O
in	O
AIDS-related	O
lymphomas	O
and	O
lymphoid	O
tissues	O
.	O

We	O
identified	O
a	O
cell-type-specific	O
differential	O
response	O
:	O
CREB	B-DNA
,	I-DNA
CTF	I-DNA
,	I-DNA
OTF-1	I-DNA
,	I-DNA
OFT-2	I-DNA
,	I-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
genes	E-DNA
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	E-cell_line
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	S-cell_type
no	O
significant	O
changes	O
were	O
detected	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	B-DNA
beta	E-DNA
and	O
MYH11	S-DNA
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	B-RNA
transcripts	E-RNA
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

The	O
NFAT	S-protein
-luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	S-protein
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

What	O
is	O
the	O
role	O
of	O
CyA	O
in	O
the	O
activation	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	E-protein
(	O
TGF-beta	S-protein
)	O
,	O
particularly	O
in	O
relationship	O
to	O
nephrotoxicity	O
and	O
fibrogenesis	O
?	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	S-cell_type
to	O
production	O
of	O
cytokines	S-protein
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B-cell_line
lac-Z	I-cell_line
transfectants	E-cell_line
,	O
and	O
in	O
human	B-cell_type
lymphocytes	E-cell_type
.	O

PEBP2	B-protein
alpha	I-protein
B	E-protein
is	O
the	O
murine	B-protein
counterpart	E-protein
of	O
human	B-protein
AML1	E-protein
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	B-DNA
;	I-DNA
21	I-DNA
and	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
chromosome	I-DNA
translocations	E-DNA
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

This	O
NF-kappaB	B-protein
binding	I-protein
complex	E-protein
is	O
composed	O
of	O
transcriptionally	B-protein
active	I-protein
p65	I-protein
(	I-protein
RelA	I-protein
)	I-protein
/p50	I-protein
heterodimers	E-protein
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB-alpha	S-protein
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel/kappaB	S-protein
in	O
the	O
cytoplasm	O
.	O

We	O
have	O
cloned	O
the	O
IBR	B-DNA
cDNA	E-DNA
and	O
studied	O
the	O
relationship	O
of	O
IBR	S-protein
and	O
IBF	S-protein
.	O

The	O
response	O
of	O
mammalian	B-cell_type
cells	E-cell_type
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	B-protein
regulatory	I-protein
proteins	E-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
(	O
NF-kappa	B-protein
B	E-protein
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	B-DNA
response	I-DNA
genes	E-DNA
.	O

In	O
contrast	O
,	O
CD38	S-protein
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL-60R	B-cell_line
cells	E-cell_line
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-protein
beta	E-protein
,	O
RAR	B-protein
gamma	E-protein
,	O
or	O
RXR	B-protein
alpha	I-protein
receptor	E-protein
.	O

Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O

Lymphocytes	S-cell_line
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage-induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O

The	O
expression	O
of	O
NDP	B-protein
kinase	E-protein
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O

Exogenous	O
recombinant	B-protein
Tat	I-protein
protein	E-protein
was	O
also	O
able	O
to	O
upregulate	O
c-fos	B-DNA
promoter	E-DNA
activity	O
in	O
serum-activated	O
Jurkat	O
and	O
U937	B-cell_line
cells	E-cell_line
,	O
as	O
well	O
as	O
endogenous	O
c-fos	B-RNA
mRNA	E-RNA
expression	O
and	O
c-Fos	S-protein
protein	O
synthesis	O
in	O
both	O
serum-activated	B-cell_line
cell	I-cell_line
lines	E-cell_line
and	O
primary	B-cell_type
PBMC	E-cell_type
.	O

Co-treatment	O
of	O
IL-4	S-protein
and	O
IFN-gamma	S-protein
induced	O
,	O
in	O
addition	O
to	O
the	O
two	O
distinct	O
complexes	O
,	O
a	O
new	O
complex	O
with	O
an	O
intermediate	O
mobility	O
.	O

The	O
functional	O
domains	O
of	O
HS-40	S-DNA
were	O
also	O
mapped	O
.	O

In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	E-cell_type
,	O
nuclear	B-protein
STAT	I-protein
proteins	E-protein
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-protein
Abs	E-protein
.	O

HL-60	B-cell_line
cells	E-cell_line
were	O
found	O
to	O
express	O
mafK	B-RNA
mRNA	E-RNA
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF-E2	B-protein
complex	E-protein
in	O
the	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
glucocorticoids	O
such	O
as	O
budesonide	O
,	O
by	O
virtue	O
of	O
their	O
high	O
GCR	S-protein
binding	O
affinities	O
and	O
greater	O
ability	O
to	O
suppress	O
lymphocyte	O
proliferation	O
,	O
may	O
therefore	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
difficult-to-control	O
asthma	O
.	O

In	O
particular	O
,	O
the	O
part	O
played	O
by	O
the	O
retinoid	B-protein
X	I-protein
receptors	E-protein
(	O
RXRs	S-protein
)	O
,	O
which	O
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
nuclear	I-protein
receptor	I-protein
family	E-protein
,	O
has	O
not	O
been	O
explored	O
.	O

Additionally	O
,	O
CoCl2	O
caused	O
a	O
two-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	E-cell_line
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	B-protein
endothelial	I-protein
cell	I-protein
adhesion	I-protein
molecules	E-protein
(	O
PECAM-1	S-protein
)	O
.	O

A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	B-protein
negative	I-protein
effector	E-protein
on	O
DNA-binding	O
activity	O
of	O
Oct-2	S-protein
.	O

In	O
stably	B-cell_line
transformed	I-cell_line
erythroblasts	E-cell_line
coexpressing	O
the	O
v-erbA	B-protein
oncoprotein	E-protein
and	O
the	O
c-erbA/T3	B-protein
receptor	E-protein
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c-erbA	S-protein
activity	O
is	O
dominant	O
over	O
v-erbA	S-protein
.	O

Oct-2	S-protein
expressed	O
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac+to	O
Lac-	O
.	O

These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF/LEF	S-protein
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	B-protein
box	I-protein
proteins	E-protein
in	O
lymphoid	O
development	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF-kappaB	S-protein
induction	O
in	O
the	O
up-regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM-1	S-protein
and	O
CD71	S-protein
by	O
LMP1	S-protein
.	O

Thus	O
,	O
although	O
CD3	S-protein
,	O
CD28	S-protein
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	B-protein
molecules	E-protein
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	S-protein
.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	B-cell_line
(	I-cell_line
Jurkat	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	B-cell_line
(	I-cell_line
CCRF-CEM	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	E-cell_line
.	O

Differanisole	O
A	O
and	O
9-cis	O
retinoic	O
acid	O
(	O
9cisRA	O
)	O
synergistically	O
inhibited	O
the	O
growth	O
and	O
induced	O
functional	O
and	O
morphologic	O
differentiation	O
of	O
HL-60	B-cell_line
and	I-cell_line
NB4	I-cell_line
cells	E-cell_line
,	O
whereas	O
the	O
combined	O
treatment	O
with	O
differanisole	O
A	O
and	O
all-trans	O
retinoic	O
acid	O
or	O
1alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
was	O
less	O
effective	O
.	O

Helenalin	O
inhibits	O
NF-kappaB	S-protein
activation	O
in	O
response	O
to	O
four	O
different	O
stimuli	O
in	O
T-cells	S-cell_type
,	O
B-cells	S-cell_type
and	O
epithelial	B-cell_type
cells	E-cell_type
and	O
abrogates	O
kappaB	S-protein
-driven	O
gene	O
expression	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl-2	B-protein
muteins	E-protein
that	O
have	O
noncleavable	B-protein
alterations	E-protein
surrounding	O
the	O
HIV	B-protein
protease	I-protein
cleavage	I-protein
site	E-protein
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	S-protein
activity	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	E-cell_type
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	S-protein
activation	O
pathway	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	S-protein
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	B-DNA
NFAT-driven	I-DNA
reporter	I-DNA
gene	E-DNA
in	O
stimulated	B-cell_line
Jurkat	I-cell_line
cells	E-cell_line
in	O
a	O
CsA-sensitive	O
manner	O
.	O

It	O
is	O
demonstrated	O
here	O
with	O
human	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
and	O
monocytes	S-cell_type
that	O
different	O
stimuli	O
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	E-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	E-protein
,	O
with	O
concomitant	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	E-RNA
and	O
protein	O
synthesis	O
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	S-protein
plus	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
dimer	E-protein
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK-1	O
and	O
SAP-1	S-protein
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	E-DNA
that	O
interacts	O
with	O
the	O
serum	B-protein
response	I-protein
factor	E-protein
.	O

Interferons	S-protein
exert	O
their	O
antiviral	O
,	O
antiproliferative	O
and	O
immunoregulatory	S-protein
activities	O
by	O
stimulating	O
the	O
expression	O
of	O
several	O
genes	O
.	O

The	O
sequence	O
between	O
position	O
-42	B-DNA
and	I-DNA
-76	I-DNA
base	I-DNA
pairs	E-DNA
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B-protein
4	E-protein
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	B-cell_line
cells	E-cell_line
,	O
which	O
do	O
not	O
express	O
alpha	B-protein
4	E-protein
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	E-protein
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

c-Myb	B-protein
protein	E-protein
was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	E-cell_type
in	O
which	O
the	O
enhancer	S-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	O
rex	B-DNA
gene	E-DNA
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	S-protein
,	O
and	O
by	O
analogy	O
HTLV-II	O
p24rex	S-protein
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax/rex	B-RNA
mRNA	E-RNA
.	O

HLA-DQB1	B-DNA
codon	I-DNA
57	E-DNA
is	O
critical	O
for	O
peptide	O
binding	O
and	O
recognition	O
.	O

Stimulation	O
of	O
mouse	B-cell_type
B	I-cell_type
cells	E-cell_type
with	O
anti-IgM	B-protein
or	I-protein
IgD	I-protein
antibodies	E-protein
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B-protein
ligand	E-protein
led	O
to	O
a	O
five-fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	B-RNA
mRNA	E-RNA
levels	O
.	O

Double-stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	E-cell_line
(	O
CEM	S-cell_line
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF-kappa	B-protein
B	E-protein
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	O
involve	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
.	O

Core	B-protein
binding	I-protein
factor	E-protein
(	O
CBF	S-protein
)	O
,	O
also	O
known	O
as	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2	E-protein
and	O
SL3	B-protein
enhancer	I-protein
factor	I-protein
1	E-protein
,	O
is	O
a	O
mammalian	B-protein
transcription	I-protein
factor	E-protein
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	S-DNA
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

The	O
role	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	E-protein
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Cutting	O
edge	O
:	O
TCR	S-protein
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	S-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	B-protein
Ets	I-protein
family	I-protein
members	E-protein
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	B-cell_type
and	I-cell_type
activated	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Whereas	O
the	O
NF-kappaB	S-protein
binding	O
activity	O
in	O
Tax-expressing	B-cell_line
T-cell	I-cell_line
lines	E-cell_line
consisted	O
mostly	O
of	O
p50/c-Rel	S-protein
,	O
fresh	O
ATL	O
samples	O
contained	O
p50/p50	B-protein
and	I-protein
p50/p65	I-protein
heterodimers	E-protein
.	O

Addition	O
of	O
TPA	O
causes	O
an	O
otherwise	O
ineffective	O
dose	O
of	O
1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
to	O
induce	O
differentiation	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U-937	S-cell_line
and	O
HeLa	B-cell_line
cells	E-cell_line
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	B-DNA
site	E-DNA
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	S-protein
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	B-protein
kinase	I-protein
C	E-protein
is	O
involved	O
.	O

In	O
vitro	O
,	O
thrombin-stimulated	B-cell_type
fixed	I-cell_type
platelets	E-cell_type
bound	O
to	O
neutrophils	S-cell_type
and	O
monocytes	S-cell_type
.	O

In	O
this	O
study	O
,	O
transient	O
cotransfection	O
of	O
several	O
GPIX	B-DNA
promoter/reporter	I-DNA
constructs	E-DNA
into	O
293T	B-cell_line
kidney	I-cell_line
fibroblasts	E-cell_line
with	O
a	O
Fli-1	B-DNA
expression	I-DNA
vector	E-DNA
shows	O
that	O
the	O
oncogenic	O
protein	O
Fli-1	S-protein
can	O
transactivate	O
the	O
GPIX	B-DNA
promoter	E-DNA
when	O
an	O
intact	O
GPIX	B-DNA
Ets	I-DNA
site	E-DNA
is	O
present	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence-specific	O
DNA-binding	O
characteristics	O
of	O
EF1	S-protein
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	B-cell_type
cell	I-cell_type
types	E-cell_type
.	O

Inhibition	O
of	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	E-protein
-induced	O
T-cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O

Using	O
our	O
previously	O
established	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
model	I-cell_line
A1.1	E-cell_line
,	O
we	O
show	O
that	O
specific	O
protein	B-protein
kinase	I-protein
C	E-protein
(	O
PKC	S-protein
)	O
inhibitors	O
could	O
block	O
activation-induced	O
Fas	S-protein
expression	O
and	O
apoptosis	O
.	O

The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O

Inhibition	O
effects	O
versus	O
time	O
were	O
described	O
by	O
a	O
pharmacodynamic	O
model	O
using	O
MPL	O
concentrations	O
in	O
plasma	S-cell_type
as	O
an	O
input	O
function	O
.	O

[	O
Corticoids	O
and	O
allergy	O
]	O

Two	O
other	O
members	O
of	O
the	O
family	O
have	O
been	O
cloned	O
more	O
recently	O
,	O
A-myb	S-protein
and	O
B-myb	S-protein
,	O
which	O
show	O
sequence	O
homology	O
with	O
c-myb	S-DNA
in	O
several	O
domains	O
,	O
of	O
which	O
the	O
DNA	B-protein
binding	I-protein
domain	E-protein
as	O
well	O
as	O
other	O
regulatory	B-protein
domains	E-protein
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
activates	O
proenkephalin	O
transcription	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

Induction	O
of	O
TF	B-RNA
mRNA	E-RNA
expression	O
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	O
by	O
the	O
lysophospholipid	O
.	O

Transient	O
overexpression	O
of	O
hTAFII105	S-protein
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	B-cell_type
cells	E-cell_type
.	O

Interleukin-10	S-protein
(	O
IL-10	S-protein
)	O
helps	O
maintain	O
polarized	B-cell_type
T-helper	I-cell_type
cells	E-cell_type
in	O
a	O
T-helper	B-cell_type
lymphocyte	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
phenotype	E-cell_type
.	O

A	O
chimeric	O
IL-6	B-protein
receptor	E-protein
,	O
comprised	O
of	O
the	O
intracellular	B-protein
tail	E-protein
of	O
the	O
IL-6	B-protein
receptor	I-protein
subunit	I-protein
gp130	E-protein
fused	O
to	O
the	O
extracellular	B-protein
domain	E-protein
of	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	I-protein
EGF	I-protein
)	I-protein
receptor	E-protein
,	O
was	O
stably	O
transfected	O
into	O
SKW6.4	B-cell_line
cells	E-cell_line
.	O

Thus	O
,	O
p21ras	S-protein
regulation	O
of	O
NFAT	S-protein
in	O
T	B-cell_type
cells	E-cell_type
requires	O
the	O
activity	O
of	O
multiple	O
effector	O
pathways	O
including	O
those	O
regulated	O
by	O
MAPKK-1	B-protein
/ERK-2	E-protein
and	O
Rac-1	S-protein
.	O

A	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	E-cell_line
,	O
PEER	S-cell_line
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

We	O
also	O
demonstrate	O
that	O
gp120	S-protein
-mediated	O
ICAM-1	S-protein
expression	O
has	O
functional	O
significance	O
,	O
as	O
it	O
enhances	O
the	O
ability	O
of	O
monocytic	B-cell_type
cells	E-cell_type
to	O
bind	O
to	O
gp120-stimulated	B-cell_type
human	I-cell_type
astrocytes	E-cell_type
in	O
an	O
ICAM-1	S-protein
/beta	O
2	O
integrin	S-protein
-dependent	O
fashion	O
.	O

Sensitivity	O
against	O
various	O
enzyme	O
inhibitors	O
suggests	O
that	O
components	O
of	O
the	O
signal	O
transduction	O
pathway	O
are	O
shared	O
by	O
all	O
three	O
cytokines	S-protein
.	O

The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O

Upon	O
TPA	O
treatment	O
,	O
the	O
activity	O
of	O
ERK1	S-protein
and	O
ERK2	S-protein
rapidly	O
increased	O
,	O
with	O
maximal	O
induction	O
between	O
1	O
and	O
3	O
h	O
,	O
while	O
ERK2	S-protein
protein	O
levels	O
remained	O
constant	O
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	S-DNA
expression	O
with	O
that	O
of	O
mouse	B-DNA
ADA	E-DNA
and	O
human	B-DNA
ADA	I-DNA
LCR	E-DNA
-directed	O
transgene	O
expression	O
.	O

IL-2	B-DNA
gene	E-DNA
transcription	O
is	O
affected	O
by	O
several	O
nuclear	B-protein
proteins	E-protein
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
components	E-protein
(	O
c-Rel	S-protein
,	O
p65	S-protein
(	O
RelA	S-protein
)	O
,	O
and	O
p50	S-protein
(	O
NF-kappa	B-protein
B1	E-protein
)	O
)	O
and	O
NF-kappa	B-protein
B	E-protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

Strikingly	O
,	O
despite	O
the	O
observed	O
repertoire	O
heterogeneity	O
,	O
all	O
clones	O
displayed	O
a	O
narrow	O
range	O
of	O
MHC	S-protein
/peptide	O
density	O
requirements	O
in	O
cytotoxicity	O
assays	O
(	O
ED50	O
between	O
9	O
and	O
36	O
nM	O
)	O
.	O

Tyrphostin	O
AG-490	O
inhibits	O
cytokine-mediated	O
JAK3	B-protein
/STAT5a/b	E-protein
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen-activated	O
human	O
T	B-cell_type
cells	E-cell_type
.	O

These	O
findings	O
suggest	O
that	O
PRE-I	S-DNA
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	B-DNA
gene	E-DNA
expression	O
levels	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	S-protein
and	O
p65	S-protein
provided	O
considerable	O
protection	O
from	O
TCR-mediated	O
apoptosis	O
.	O

H-89	O
substantially	O
suppressed	O
LPS-induced	O
TNF	B-RNA
mRNA	E-RNA
accumulation	O
in	O
unprimed	B-cell_line
cells	E-cell_line
,	O
but	O
had	O
no	O
effect	O
on	O
primed	B-cell_line
monocytes	E-cell_line
following	O
LPS	O
stimulation	O
.	O

Because	O
this	O
region	O
of	O
Stat3alpha	S-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	S-protein
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	O
with	O
Stat3alpha	S-protein
for	O
Stat3	B-DNA
binding	I-DNA
sites	E-DNA
in	O
these	O

Nuclear	B-protein
NF-ATp	E-protein
is	O
a	O
hallmark	O
of	O
unstimulated	B-cell_type
B	I-cell_type
cells	E-cell_type
from	O
B-CLL	O
patients	O
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	B-DNA
promoter	E-DNA
and	O
the	O
NF-AT	S-DNA
,	O
but	O
not	O
the	O
AP-1	S-DNA
and	O
NF-kB	B-DNA
plasmids	E-DNA
.	O

These	O
findings	O
establish	O
that	O
STAT1	S-protein
and	O
STAT5	S-protein
,	O
and	O
possibly	O
STAT3	S-protein
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
precursor	B-cell_type
B	I-cell_type
cells	E-cell_type
with	O
IL-7	S-protein
.	O

The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O
sites	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O

Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	B-protein
activators	E-protein
,	O
RelA	S-protein
and	O
NF-ATp	S-protein
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
stimulation	O
on	O
IL4	S-protein
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	B-cell_line
cells	E-cell_line
.	O

Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	S-protein
expression	O
involving	O
NK-chi	B-protein
B	E-protein
and	O
NF-IL6	S-protein
.	O

None	O
of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O

Furthermore	O
,	O
overexpression	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
NF-AT	S-protein
,	O
but	O
not	O
Jun	B-protein
,	I-protein
Fos	I-protein
,	I-protein
NF-kappaB	I-protein
,	I-protein
Oct	I-protein
or	I-protein
Ets	I-protein
family	I-protein
members	E-protein
,	O
renders	O
the	O
interleukin-2	B-DNA
enhancer	E-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	E-cell_line
resistant	O
to	O
FK506	O
and	O
cyclosporin	O
A	O
.	O

Interferon-alpha	S-protein
(	O
IFN-alpha	S-protein
)	O
is	O
a	O
pleiotropic	B-protein
cytokine	E-protein
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	S-protein
functions	O
.	O

In	O
T	B-cell_line
cell	I-cell_line
hybridomas	E-cell_line
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	B-cell_type
T	I-cell_type
cells	E-cell_type
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl-2	S-protein
and	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Despite	O
progress	O
in	O
understanding	O
the	O
death	O
signals	O
transduced	O
from	O
Fas	S-protein
,	O
very	O
little	O
is	O
known	O
with	O
regard	O
to	O
the	O
mechanisms	O
by	O
which	O
Fas	S-protein
expression	O
is	O
regulated	O
.	O

We	O
have	O
used	O
a	O
DNA-binding/immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	B-protein
glucocorticoid	I-protein
receptor	E-protein
(	O
hGR	S-protein
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40	S-protein
-mediated	O
cell	O
survival	O
proceeds	O
through	O
NF-kappaB	S-protein
-dependent	O
up-regulation	O
of	O
Bcl-2	B-protein
family	I-protein
members	E-protein
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	B-cell_type
monocyte	E-cell_type
to	O
a	O
tissue	B-cell_type
macrophage	E-cell_type
.	O

Moreover	O
,	O
ANG	B-protein
II	E-protein
stimulated	O
NF-kappaB	S-protein
activation	O
in	O
human	B-cell_type
monocytes	E-cell_type
,	O
but	O
not	O
in	O
lymphocytes	S-cell_type
from	O
the	O
same	O
preparation	O
.	O

Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X-linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O

The	O
correlation	O
between	O
C5a-induced	O
kappaB	S-protein
binding	O
activity	O
and	O
IL-8	S-protein
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	B-cell_line
macrophage	I-cell_line
cells	E-cell_line
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	B-DNA
sequence	E-DNA
from	O
IkappaBalpha	S-protein
and	O
IL-8	B-DNA
promoter	I-DNA
regions	E-DNA
.	O

BACKGROUND	O
:	O
Polyaromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
associated	O
with	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
are	O
found	O
in	O
the	O
atmospheric	O
urban	O
pollution	O
.	O

Deletion	O
of	O
the	O
EBNA2-dependent	B-DNA
enhancer	E-DNA
located	O
upstream	O
of	O
Cp	S-DNA
resulted	O
in	O
a	O
ca.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	S-DNA
activity	O
in	O
the	O
LCLs	S-cell_line
assayed	O
.	O

We	O
conclude	O
that	O
the	O
MAP	B-protein
kinase	E-protein
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	S-protein
,	O
MEK1	S-protein
,	O
and	O
ERK1	S-protein
and	O
ERK2	S-protein
functions	O
in	O
the	O
stimulation	O
IL-2	B-DNA
gene	E-DNA
transcription	O
in	O
activated	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

We	O
showed	O
that	O
IL-12	S-protein
had	O
a	O
direct	O
effect	O
on	O
IRF-1	S-protein
,	O
an	O
effect	O
not	O
mediated	O
indirectly	O
by	O
the	O
induction	O
of	O
IFN-gamma	S-protein
production	O
.	O

Ubiquitinylation	O
of	O
transcription	B-protein
factors	I-protein
c-Jun	E-protein
and	O
c-Fos	S-protein
using	O
reconstituted	B-protein
ubiquitinylating	I-protein
enzymes	E-protein
.	O

The	O
interacting	O
surfaces	O
are	O
located	O
on	O
the	O
catalytic	B-protein
domain	E-protein
of	O
the	O
calcineurin	B-protein
A	I-protein
chain	E-protein
and	O
on	O
an	O
86-amino	B-protein
acid	I-protein
fragment	E-protein
of	O
the	O
NFAT	B-protein
regulatory	I-protein
domain	E-protein
.	O

BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	S-protein
by	O
cytokines	S-protein
is	O
mediated	O
by	O
STAT	B-protein
transcription	I-protein
factors	E-protein
.	O

Although	O
glucocorticosteroids	O
are	O
a	O
very	O
effective	O
treatment	O
for	O
asthma	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
a	O
small	O
proportion	O
of	O
patients	O
are	O
resistant	O
to	O
their	O
therapeutic	O
effects	O
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	B-protein
B	E-protein
and	O
NF-AT	S-protein
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	S-protein
stimulation	O
.	O

We	O
term	O
the	O
LYSP100	S-DNA
structures	O
``	O
LANDs	O
,	O
''	O
for	O
LYSP100	S-DNA
-associated	O
nuclear	O
domains	O
.	O

In	O
contrast	O
to	O
the	O
type	B-protein
I	I-protein
receptor	E-protein
,	O
the	O
type	B-protein
II	I-protein
IL-1R	E-protein
has	O
a	O
small	O
cytoplasmic	B-protein
tail	E-protein
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal-transducing	S-protein
or	O
a	O
regulatory	B-protein
molecule	E-protein
.	O

Here	O
,	O
using	O
the	O
murine	B-cell_line
B-cell	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
A20	E-cell_line
,	O
we	O
show	O
that	O
the	O
TNF-alpha	B-DNA
gene	E-DNA
is	O
regulated	O
in	O
a	O
cell-type-specific	O
manner	O
.	O

Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	E-cell_type
.	O

These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	B-cell_type
alveolar	I-cell_type
macrophages	E-cell_type
,	O
monocyte-derived	B-cell_type
macrophages	E-cell_type
,	O
and	O
promonocytic	B-cell_line
THP-1	I-cell_line
cells	E-cell_line
.	O

The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	B-cell_type
cells	E-cell_type
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O

Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

Mutations	O
in	O
the	O
relevant	O
NF-kappa	B-protein
B	E-protein
and	O
AP-1	B-DNA
binding	I-DNA
sites	E-DNA
eliminated	O
these	O
responses	O
.	O

We	O
found	O
that	O
overexpression	O
of	O
IkappaB-alpha	S-protein
in	O
endothelial	B-cell_type
cells	E-cell_type
using	O
a	O
recombinant	O
adenovirus	O
prevented	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF-alpha	S-protein
)	O
-induced	O
degradation	O
of	O
IkappaB-alpha	S-protein
and	O
suppressed	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	E-protein
(	O
VCAM-1	S-protein
)	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	E-protein
(	O
ICAM-1	S-protein
)	O
,	O
and	O
E-selectin	B-RNA
mRNA	E-RNA
and	O
surface	O
protein	O
expression	O
and	O
the	O
upregulation	O
of	O
transcripts	O
for	O
the	O
chemokines	B-protein
monocyte	I-protein
chemoattractant	I-protein
protein	I-protein
1	E-protein
(	O
MCP-1	S-protein
)	O
and	O
growth-related	B-protein
activity-alpha	E-protein
(	O
GRO-alpha	S-protein
)	O
by	O
TNF-alpha	S-protein
.	O

Phosphatidyl	B-protein
inositol	I-protein
3-kinase	E-protein
(	O
PI3K	S-protein
)	O
is	O
activated	O
by	O
IL-2	S-protein
.	O

Further	O
,	O
cotransfection	O
analysis	O
in	O
Drosophila	B-cell_line
cells	E-cell_line
showed	O
that	O
Sp3	S-protein
,	O
as	O
was	O
previously	O
shown	O
for	O
Sp1	S-protein
,	O
also	O
synergizes	O
with	O
c-Jun	S-protein
to	O
activate	O
CD11c	S-DNA
.	O

In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	B-protein
receptors	E-protein
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O

In	O
all	O
cells	O
tested	O
,	O
IL-10	S-protein
activated	O
Stat1	S-protein
and	O
Stat3	S-protein
and	O
induced	O
the	O
formation	O
of	O
three	O
distinct	O
DNA	B-protein
binding	I-protein
complexes	E-protein
that	O
contained	O
different	O
combinations	O
of	O
these	O
two	O
transcription	B-protein
factors	E-protein
.	O

Granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O

An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	E-cell_type
.	O

All	O
of	O
the	O
radiation-induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein-tyrosine	B-protein
kinase	I-protein
inhibitors	I-protein
genistein	I-protein
and	I-protein
herbimycin	I-protein
A	E-protein
.	O

We	O
present	O
evidence	O
that	O
IBR	S-protein
and	O
IBF	S-protein
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	B-protein
factors	E-protein
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	B-DNA
helper	I-DNA
cell	I-DNA
cytokine	I-DNA
gene	E-DNA
expression	O
.	O

However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	O
capable	O
of	O
causing	O
complete	O
T	O
cell	O
activation	O
.	O

Glucocorticoid	B-protein
receptors	E-protein
in	O
mononuclear	B-cell_type
cells	E-cell_type
of	O
patients	O
with	O
sepsis	O
.	O

Galectin-3	O
is	O
a	O
beta-galactoside-binding	B-protein
lectin	E-protein
previously	O
designated	O
as	O
epsilon	B-protein
BP	E-protein
(	O
IgE-binding	B-protein
protein	E-protein
)	O
,	O
CBP35	S-protein
,	O
Mac-2	S-protein
,	O
L-29	S-protein
,	O
and	O
L-34	S-protein
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	E-protein
is	O
expressed	O
in	O
Th2	B-cell_line
but	I-cell_line
not	I-cell_line
Th1	I-cell_line
cells	E-cell_line
and	O
is	O
crucial	O
for	O
activation	O
of	O
the	O
IL-5	B-DNA
promoter	E-DNA
by	O
different	O
stimuli	O
.	O

However	O
,	O
anti-	O
CD45	S-protein
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

The	O
level	O
of	O
SP140	B-RNA
mRNA	E-RNA
in	O
myeloid	B-cell_line
precursor	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL60	E-cell_line
and	O
NB4	S-cell_line
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

cDNA	B-DNA
microarrays	E-DNA
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	B-cell_type
mammary	I-cell_type
epithelial	I-cell_type
cells	E-cell_type
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

We	O
have	O
studied	O
mutations	O
in	O
the	O
5	B-DNA
'	I-DNA
noncoding	I-DNA
region	E-DNA
of	O
the	O
Bcl6	B-DNA
gene	E-DNA
in	O
different	O
subtypes	O
of	O
lymphomas	O
.	O

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	B-cell_type
cells	E-cell_type
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	S-protein
and	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	S-protein
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	B-cell_type
/macrophages	E-cell_type
are	O
partially	O
understood	O
.	O

There	O
was	O
no	O
correlation	O
between	O
glucocorticosteroid	B-protein
receptor	E-protein
number	O
and	O
SLE	O
disease	O
activity	O
.	O

Tumor	O
cells	O
in	O
9	O
GCT	O
expressed	O
inhibin	O
A	O
.	O

Using	O
flow	O
cytometry	O
analysis	O
,	O
NE	S-protein
was	O
shown	O
to	O
trigger	O
a	O
time-dependent	O
binding	O
of	O
PAC-1	S-protein
and	O
AP-5	S-protein
,	O
two	O
monoclonal	B-protein
antibodies	E-protein
specific	O
for	O
the	O
activated	O
and	O
ligand-occupied	O
conformers	O
of	O
alphaIIbbeta3	S-protein
.	O

Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	S-protein
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Monocyte/macrophages	S-cell_type
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O

The	O
RanQ69L	S-protein
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	S-protein
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	B-protein
pore	I-protein
complex	E-protein
(	O
NPC	S-protein
)	O
in	O
association	O
with	O
the	O
p62	B-protein
complex	E-protein
and	O
Can/Nup214	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	B-cell_type
and	I-cell_type
NK	I-cell_type
cell	I-cell_type
lineages	E-cell_type
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid/NK	O
acute	O
leukemia	O
.	O

These	O
results	O
suggest	O
that	O
p2l	B-protein
(	I-protein
ras	I-protein
)	E-protein
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	B-cell_type
cells	E-cell_type
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-protein
oncogene	I-protein
product	E-protein
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O

Patients	O
with	O
one	O
type	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	E-protein
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B-protein
II	I-protein
transactivator	E-protein
(	O
CIITA	S-protein
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	B-DNA
class	I-DNA
II	I-DNA
genes	E-DNA
,	O
HLA-DR	B-DNA
,	I-DNA
-DQ	I-DNA
,	I-DNA
and	I-DNA
-DP	E-DNA
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

The	O
STP	B-protein
oncoproteins	E-protein
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	I-protein
TRAF	I-protein
)	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
or	I-protein
3	E-protein
.	O

Tax	O
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	B-protein
factors	E-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	E-protein
of	O
enhancer-binding	B-protein
proteins	E-protein
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	S-DNA
contains	O
a	O
nucleosome-free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	B-DNA
region	E-DNA
and	O
a	O
large	O
region	O
(	O
255	B-DNA
nucleotides	E-DNA
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
CD27	S-protein
/CD70	O
interaction	O
in	O
B	O
cell	O
IgE	S-protein
synthesis	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	S-protein
,	O
p52	S-protein
,	O
and	O
RelB	S-protein
proteins	O
in	O
human	B-cell_type
accessory	I-cell_type
cells	E-cell_type
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

Expression	O
and	O
role	O
of	O
PML	B-DNA
gene	E-DNA
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B-protein
and	I-protein
Rb	I-protein
proteins	E-protein
in	O
erythropoiesis	O
.	O

Since	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	E-DNA
has	O
a	O
base	O
difference	O
within	O
the	O
GC-box	S-DNA
,	O
we	O
speculate	O
that	O
this	O
may	O
explain	O
why	O
the	O
human	O
promoter	O
is	O
weak	O
and	O
that	O
an	O
upstream	B-DNA
enhancer	E-DNA
is	O
required	O
for	O
the	O
induction	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
gene	E-DNA
.	O

We	O
demonstrated	O
that	O
IL-12	S-protein
directly	O
up-regulates	O
IRF-1	S-protein
to	O
the	O
same	O
extent	O
as	O
IFN-alpha	S-protein
in	O
normal	O
human	O
T	B-cell_type
cells	E-cell_type
and	O
in	O
NK	B-cell_type
cells	E-cell_type
.	O

Direct	O
sequencing	O
of	O
the	O
viral	B-DNA
genomes	E-DNA
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	S-protein
-virus	O
.	O

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	B-cell_type
cell	E-cell_type
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	E-protein
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	B-protein
molecules	E-protein
and	O
chemoattractants	S-protein
.	O

The	O
ability	O
to	O
induce	O
anergy	O
in	O
antigen-specific	B-cell_type
T	I-cell_type
cells	E-cell_type
has	O
potential	O
therapeutic	O
value	O
for	O
altering	O
pathologic	O
immune	O
responses	O
.	O

Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	B-protein
region	E-protein
and	O
an	O
``	O
arginine	B-protein
element	E-protein
``	O
(	O
RRLPIF	S-protein
)	O
at	O
the	O
carboxyl	B-protein
terminus	E-protein
.	O

Induction	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	E-protein
by	O
the	O
cytokine	B-protein
tumor	I-protein
necrosis	I-protein
factor-alpha	E-protein
(	O
TNF	S-protein
)	O
can	O
occur	O
independently	O
of	O
protein	B-protein
kinase	I-protein
C	E-protein
and	O
activation	O
of	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	E-protein
(	O
PTK	S-protein
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	E-protein
(	O
VCAM-1	S-protein
)	O
by	O
interleukin-4	S-protein
(	O
IL-4	S-protein
)	O
on	O
endothelial	B-cell_type
cells	E-cell_type
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA-1	S-protein
and	O
the	O
ER	S-protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N-terminal	B-protein
activation	I-protein
domain	E-protein
of	O
GATA-1	S-protein
.	O

Analysis	O
of	O
these	O
PBLs	S-cell_type
revealed	O
that	O
activation	O
of	O
the	O
NF-kappaB	S-protein
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL-2	S-protein
.	O

PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	S-protein
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
so-far-unrecognized	O
SP-1	B-DNA
site	E-DNA
in	O
the	O
human	B-DNA
IL-1beta	I-DNA
promoter	E-DNA
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	S-cell_type
.	O

Although	O
all	O
nm23	B-protein
proteins	E-protein
contain	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	E-protein
activity	O
,	O
it	O
has	O
not	O
been	O
established	O
that	O
the	O
enzyme	O
activity	O
mediated	O
the	O
various	O
functions	O
of	O
nm23	B-protein
proteins	E-protein
.	O

BMT	O
inhibited	O
the	O
replication	O
of	O
HIV-1	O
in	O
both	O
laboratory	O
and	O
primary	O
isolates	O
in	O
vitro	O
.	O

Abnormalities	O
of	O
p16	B-DNA
,	I-DNA
p15	I-DNA
and	I-DNA
CDK4	I-DNA
genes	E-DNA
in	O
recurrent	O
malignant	O
astrocytomas	O
.	O

The	O
glucocorticoid-induced	O
reduction	O
of	O
IL-12	S-protein
production	O
was	O
antagonized	O
by	O
RU	O
486	O
,	O
a	O
glucocorticoid-receptor	O
antagonist	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

To	O
identify	O
an	O
EBNA2	B-DNA
dependent	I-DNA
cis-acting	I-DNA
element	E-DNA
,	O
various	O
TP1	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
constructs	E-DNA
were	O
transfected	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
EBNA2	B-DNA
expression	I-DNA
vector	E-DNA
into	O
the	O
established	O
B-cell	B-cell_line
line	I-cell_line
BL41-P3HR1	E-cell_line
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
human	O
herpesvirus	O
which	O
latently	O
infects	O
B	B-cell_type
lymphocytes	E-cell_type
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	B-protein
signaling	I-protein
proteins	E-protein
,	O
including	O
Vav	S-protein
,	O
Cbl	S-protein
,	O
p85	B-protein
phosphoinositide	I-protein
3-kinase	E-protein
,	O
and	O
the	O
Src	B-protein
family	I-protein
kinases	I-protein
Lck	E-protein
and	O
Fyn	S-protein
.	O

Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor-induced	O
Erk2	B-protein
kinase	E-protein
activation	O
in	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	E-cell_line
by	O
Syk	S-protein
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	S-protein
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

Addition	O
of	O
r-hTBP-1	S-protein
to	O
U1	B-cell_line
cells	E-cell_line
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B-protein
antigen	E-protein
production	O
by	O
15	O
%	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Hemin	O
induction	O
of	O
K562	B-cell_line
cells	E-cell_line
does	O
not	O
facilitate	O
the	O
binding	O
of	O
NF-E2	S-protein
to	O
its	O
recognition	O
site	O
.	O

Treatment	O
of	O
B	B-cell_type
lymphocytes	E-cell_type
with	O
the	O
cytokine	B-protein
IL-4	E-protein
(	O
IL-4	S-protein
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up-regulation	O
of	O
VDR	S-protein
expression	O
but	O
fails	O
to	O
generate	O
vitamin	B-protein
D-responsive	I-protein
element	I-protein
(	I-protein
VDRE	I-protein
)	I-protein
-reactive	I-protein
nuclear	I-protein
protein	I-protein
complexes	E-protein
or	O
to	O
initiate	O
the	O
genomic	O
transcription	O
of	O
25-hydroxyvitamin	B-protein
D3	I-protein
24-hydroxylase	E-protein
.	O

We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross-linking	O
induced	O
TNF-alpha	S-protein
release	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	E-cell_type
and	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
MM6	E-cell_line
.	O

A	O
molecular	O
basis	O
for	O
the	O
pathogenesis	O
of	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
.	O

CD3	S-protein
,	O
CD2	S-protein
,	O
and	O
CD28	S-protein
are	O
functionally	O
distinct	O
receptors	O
on	O
T	B-cell_type
lymphocytes	E-cell_type
.	O

In	O
monocytic	B-cell_type
cells	E-cell_type
,	O
IL-1beta	S-protein
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5-LOX	B-protein
enzyme	E-protein
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O

Inhibition	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down-regulation	O
of	O
c-fos	S-DNA
and	O
c-jun	S-DNA
(	O
AP-1	S-DNA
)	O
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B-protein
proteins	E-protein
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	B-cell_line
immortalized	I-cell_line
Tax-expressing	I-cell_line
human	I-cell_line
T-lymphocyte	I-cell_line
line	E-cell_line
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	S-DNA
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	S-protein
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	E-DNA
is	O
a	O
novel	O
transcriptional	B-DNA
enhancer	I-DNA
element	E-DNA
that	O
is	O
similar	O
in	O
its	O
cell-type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	B-DNA
element	E-DNA
.	O

It	O
is	O
identical	O
to	O
the	O
Spi-1	B-DNA
oncogene	E-DNA
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O

Forty-eight	O
hours	O
after	O
transfection	O
,	O
EC	S-cell_type
were	O
stimulated	O
with	O
NK	B-cell_type
cells	E-cell_type
or	O
NK	B-cell_type
cell	I-cell_type
membrane	I-cell_type
extracts	E-cell_type
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	S-protein
assay	O
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	S-protein
,	O
p52	S-protein
,	O
p65	S-protein
,	O
and	O
cRel	S-protein
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	S-protein
and	O
p52	S-protein
correlates	O
with	O
negative	O
function	O
.	O

pIL-5	B-DNA
(	I-DNA
-511	I-DNA
)	I-DNA
Luc	E-DNA
was	O
transcribed	O
by	O
T-cell	B-cell_line
hybridomas	E-cell_line
derived	O
from	O
fusion	O
between	O
IL-5-producing	B-cell_line
T-cell	I-cell_line
clones	E-cell_line
and	O
an	O
IL-5	B-cell_line
gene-nonexpressing	I-cell_line
T-cell	I-cell_line
line	E-cell_line
,	O
but	O
not	O
by	O
hybridomas	S-cell_line
derived	O
from	O
IL-5-nonproducing	B-cell_line
T-cell	I-cell_line
clones	E-cell_line
.	O

DOR1	S-protein
ligation	O
by	O
a	O
specific	O
DOR1	S-protein
agonist	O
,	O
deltorphin	O
,	O
augmented	O
IL-2	S-protein
secretion	O
by	O
synergizing	O
with	O
signals	O
from	O
TCR-CD3	S-protein
and	O
CD28	S-protein
.	O

We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	B-DNA
region	E-DNA
of	O
the	O
IL-10	B-DNA
gene	E-DNA
and	O
four	O
in	O
the	O
TGF-beta	B-DNA
gene	I-DNA
promoters	E-DNA
(	O
3	O
in	O
TGF-beta1	S-DNA
and	O
1	O
in	O
TGF-beta2	S-DNA
)	O
.	O

Moreover	O
,	O
the	O
steroid	B-protein
receptor	E-protein
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	E-protein
mobilized	O
in	O
tolerant	B-cell_line
cells	E-cell_line
is	O
functionally	O
inactive	O
in	O
that	O
NF-kappa	B-DNA
B-dependent	I-DNA
luciferase	I-DNA
constructs	E-DNA
containing	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	E-DNA
or	O
the	O
TNF	B-DNA
5'-region	E-DNA
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O

The	O
Ikaros	B-DNA
gene	E-DNA
,	O
which	O
encodes	O
a	O
family	O
of	O
hemopoietic-specific	B-protein
zinc	I-protein
finger	I-protein
proteins	E-protein
,	O
is	O
described	O
as	O
a	O
central	O
regulator	O
of	O
lymphocyte	O
differentiation	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
alterations	O
was	O
studied	O
by	O
comparing	O
the	O
FISH	O
results	O
with	O
several	O
parameters	O
currently	O
used	O
in	O
breast-cancer	O
pathology	O
.	O

These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF-kappaB	S-protein
and	O
STAT6	S-protein
may	O
be	O
required	O
for	O
induction	O
of	O
germline	S-DNA
Cepsilon	O
transcription	O
by	O
IL-4	S-protein
,	O
and	O
that	O
CD40	S-protein
-mediated	O
NF-kappaB	S-protein
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	S-DNA
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	S-protein
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	E-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	E-protein
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

One	O
ATF/CRE	B-DNA
motif	E-DNA
is	O
located	O
in	O
the	O
distal	B-DNA
promoter	E-DNA
at	O
the	O
nuclear	B-DNA
matrix-associated	I-DNA
Site	I-DNA
IV	E-DNA
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	B-DNA
promoter	E-DNA
at	O
Site	B-DNA
I	E-DNA
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	E-protein
(	O
but	O
not	O
Oct-1	S-protein
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

The	O
5'-positive	B-DNA
regulatory	I-DNA
unit	E-DNA
,	O
consisting	O
of	O
the	O
promoter	S-DNA
and	O
the	O
5	B-DNA
'	I-DNA
enhancer	E-DNA
,	O
is	O
already	O
active	O
at	O
the	O
CD4	S-protein
-	O
CD8	S-protein
-double-negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O

In	O
contrast	O
,	O
in	O
DOX-treated	B-cell_line
cells	E-cell_line
,	O
the	O
transcription	O
rate	O
of	O
these	O
genes	S-DNA
was	O
unchanged	O
in	O
comparison	O
with	O
control	B-cell_type
cells	E-cell_type
.	O

[	O
The	O
role	O
of	O
glucocorticoid	B-protein
receptors	E-protein
and	O
HLA	B-protein
antigens	E-protein
in	O
the	O
pathogenesis	O
of	O
Cushing	O
's	O
syndrome	O
]	O

Expression	O
of	O
the	O
alpha-chain	S-protein
of	O
IL-2Ralpha	S-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	E-cell_type
(	O
PBM	S-cell_type
)	O
was	O
induced	O
by	O
M.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Jurkat	B-cell_line
cells	E-cell_line
were	O
transfected	O
with	O
plasmids	S-DNA
containing	O
either	O
the	O
intact	O
IL-2	B-DNA
promoter	E-DNA
or	O
its	O
AP-1	B-DNA
,	I-DNA
NF-AT	I-DNA
,	I-DNA
and	I-DNA
NF-kB	I-DNA
motifs	E-DNA
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP-B	O
or	O
XP-D	O
.	O

Additionally	O
,	O
Nef	B-cell_line
expressing	I-cell_line
cells	E-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV-1	B-DNA
AP-1	I-DNA
DNA	I-DNA
recognition	I-DNA
sequences	E-DNA
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	B-protein
acetyltransferase	E-protein
(	O
CAT	S-protein
)	O
gene	O
.	O

A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	B-protein
gland	I-protein
factor-Stat5	E-protein
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	S-protein
and	O
PRL	S-protein
with	O
their	O
respective	O
receptors	O
.	O

In	O
the	O
past	O
few	O
years	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
defining	O
the	O
tyrosine	O
kinases	O
that	O
are	O
activated	O
by	O
the	O
IL-3/IL-5/GM-CSF	B-protein
receptor	I-protein
beta-subunit	E-protein
in	O
eosinophils	S-cell_type
.	O

Once	O
in	O
the	O
nucleus	O
,	O
NF-ATc	S-protein
interacts	O
with	O
NF-ATn	S-protein
to	O
form	O
an	O
active	B-protein
transcriptional	I-protein
complex	E-protein
.	O

To	O
understand	O
the	O
diminished	O
T	O
cell	O
response	O
to	O
activation	O
signals	O
,	O
we	O
measured	O
nucleoprotein	O
DNA-binding	O
activities	O
regulating	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
Pax-5	B-DNA
gene	E-DNA
is	O
alternatively	O
spliced	O
during	O
B-cell	O
development	O
.	O

Simultaneous	O
analysis	O
of	O
close	O
to	O
600	B-DNA
genes	E-DNA
indicated	O
highest	O
increase	O
in	O
the	O
expression	O
of	O
certain	O
transcription	B-protein
,	I-protein
differentiation	I-protein
and	I-protein
proliferation	I-protein
factors	E-protein
.	O

As	O
a	O
result	O
of	O
its	O
transforming	O
abilities	O
,	O
activated	B-protein
Ras	E-protein
is	O
expressed	O
in	O
a	O
great	O
number	O
of	O
cancers	O
.	O

One	O
transformation	B-protein
effector	I-protein
site	E-protein
(	O
TES1	S-protein
)	O
,	O
located	O
within	O
the	O
membrane	B-protein
proximal	I-protein
45	I-protein
residues	E-protein
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	E-protein
.	O

The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	B-DNA
binding	I-DNA
sequence	E-DNA
for	O
the	O
Ets	B-protein
family	E-protein
of	O
transcription	B-protein
factors	E-protein
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	E-DNA
in	O
the	O
promoters	S-DNA
and	O
enhancers	S-DNA
of	O
many	O
inducible	B-DNA
T-cell	I-DNA
genes	E-DNA
.	O

We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE-	B-DNA
ring	I-DNA
chromosomes	E-DNA
to	O
determine	O
whether	O
genes	S-DNA
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	B-DNA
X	E-DNA
are	O
expressed	O
from	O
these	O
chromosomes	S-DNA
.	O

The	O
TT-selected	B-cell_line
T	I-cell_line
cell	I-cell_line
line	E-cell_line
could	O
be	O
rendered	O
unresponsive	O
to	O
its	O
dominant	O
epitope	O
in	O
a	O
dose-dependent	O
manner	O
(	O
IC50	O
=	O
0.03	O
microg/ml	O
)	O
.	O

A	O
synthetic	O
thrombin	B-protein
receptor	E-protein
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	S-protein
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

These	O
data	O
indicated	O
that	O
two	O
NF-kappaB-binding	B-DNA
sites	E-DNA
,	O
which	O
are	O
located	O
between	O
-3134	B-DNA
and	I-DNA
-3059	E-DNA
,	O
are	O
critical	O
for	O
the	O
activation	O
of	O
proIL-1beta	B-DNA
gene	E-DNA
transcription	O
.	O

Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	B-DNA
DNA	E-DNA
encoding	O
the	O
histone	B-protein
deacetylase	I-protein
catalytic	I-protein
subunit	E-protein
(	O
HD1	S-protein
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O

We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	S-protein
,	O
Z	B-protein
(	I-protein
S186A	I-protein
)	E-protein
,	O
that	O
was	O
not	O
impaired	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O

The	O
recently	O
cloned	O
TCL1	B-DNA
gene	E-DNA
,	O
also	O
involved	O
in	O
translocations	O
and	O
inversions	O
associated	O
with	O
T-cell	O
proliferations	O
,	O
codes	O
for	O
a	O
14-kD	B-protein
protein	E-protein
that	O
displays	O
significant	O
homology	O
with	O
p13MTCP1	S-protein
.	O

Using	O
the	O
wild-type	B-protein
or	I-protein
mutated	I-protein
human	I-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	E-protein
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

Leukocytes	S-cell_type
migrated	O
most	O
rapidly	O
at	O
night	O
.	O

For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid-specific	O
expression	O
of	O
a	O
thermosensitive	B-protein
SV40	I-protein
T	I-protein
antigen	E-protein
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	E-protein
of	O
transcription	B-protein
factors	E-protein
,	O
pleiotropic	B-protein
regulators	E-protein
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	B-cell_type
cells	E-cell_type
to	O
epitopes	O
of	O
thyrotropin	B-protein
receptor	E-protein
in	O
autoimmune	O
thyroid	O
diseases	O
?	O

A	O
frameshift	O
mutation	O
in	O
the	O
3'-end	O
of	O
the	O
XPB	B-DNA
gene	E-DNA
is	O
responsible	O
for	O
a	O
concurrence	O
of	O
two	O
disorders	O
:	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
and	O
Cockayne	O
's	O
syndrome	O
(	O
CS	O
)	O
.	O

The	O
entry	O
of	O
microorganisms	O
into	O
the	O
body	O
induces	O
inflammatory	O
processes	O
.	O

Examination	O
of	O
IkappaB	B-protein
alpha	E-protein
regulation	O
revealed	O
that	O
TNF-alpha	S-protein
-mediated	O
degradation	O
of	O
IkappaB	B-protein
alpha	E-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	E-cell_type
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	S-protein
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	E-DNA
that	O
increased	O
c-myb	S-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

In	O
consequence	O
,	O
the	O
alternative	B-RNA
La	I-RNA
mRNA	E-RNA
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

The	O
presence	O
of	O
an	O
AP-1	S-protein
protein	O
in	O
the	O
NF-AT	S-protein
protein	O
complex	O
may	O
regulate	O
NF-AT	S-protein
-binding	O
activity	O
through	O
protein-protein	O
interaction	O
.	O

CD30	S-protein
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor/nerve	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
superfamily	E-protein
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34+	B-cell_type
progenitor	E-cell_type
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O

Studies	O
with	O
motheaten	O
mice	O
,	O
which	O
lack	O
the	O
SHP1	B-protein
protein	I-protein
tyrosine	I-protein
phosphatase	E-protein
,	O
indicate	O
that	O
this	O
enzyme	O
plays	O
an	O
important	O
negative	O
role	O
in	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	E-protein
(	O
TCR	S-protein
)	O
signaling	O
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	S-protein
on	O
glucocorticoid	B-protein
receptor	E-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	E-cell_type
]	O

Both	O
U	B-cell_line
alpha	I-cell_line
A	E-cell_line
and	O
alpha	O
B5A	S-cell_line
also	O
failed	O
to	O
respond	O
to	O
another	O
modulating	O
agent	O
,	O
1	O
alpha	O
,	O
25-dihydroxycholecalciferol	O
(	O
DHCC	O
)	O
,	O
but	O
only	O
U	B-cell_line
alpha	I-cell_line
S	E-cell_line
and	O
not	O
alpha	B-protein
G2S	E-protein
showed	O
an	O
enhanced	O
response	O
to	O
DHCC	O
.	O

We	O
investigated	O
which	O
STAT	B-protein
complexes	E-protein
are	O
formed	O
upon	O
stimulation	O
of	O
B	B-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
BCP-ALL	I-cell_line
)	I-cell_line
cells	E-cell_line
with	O
IL-7	S-protein
.	O

We	O
determined	O
that	O
the	O
protein-binding	B-DNA
region	E-DNA
on	O
the	O
LMP	B-DNA
promoter	E-DNA
was	O
within	O
a	O
42	B-DNA
bp	I-DNA
fragment	E-DNA
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	B-DNA
transcriptional	I-DNA
start	I-DNA
site	E-DNA
.	O

Cloning	O
a	O
cDNA	S-DNA
from	O
human	O
NK/T	B-cell_type
cells	E-cell_type
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

The	O
host	O
mechanisms	O
regulated	O
by	O
such	O
permissivity	O
factors	O
are	O
potential	O
targets	O
for	O
anti-HIV-1	O
therapy	O
.	O

A	O
cell-type-independent	B-DNA
lipopolysaccharide	I-DNA
(	I-DNA
LPS	I-DNA
)	I-DNA
-responsive	I-DNA
enhancer	I-DNA
element	E-DNA
located	O
between	O
-3757	B-DNA
and	I-DNA
-2729	I-DNA
bp	I-DNA
upstream	E-DNA
from	O
the	O
transcription	B-DNA
start	I-DNA
site	E-DNA
(	O
cap	B-DNA
site	E-DNA
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	B-cell_line
monocytes	E-cell_line
.	O

The	O
single	O
promoter	B-DNA
region	E-DNA
in	O
the	O
cloned	O
genome	O
[	O
Noteborn	O
et	O
al.	O
,	O
J.	O
Virol.	O
65	O
(	O
1991	O
)	O
3131-3139	O
]	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
in	O
chicken	B-cell_type
T-cells	E-cell_type
was	O
analysed	O
via	O
CAT	S-protein
assays	O
.	O

Our	O
study	O
in	O
differentiated	B-cell_type
cells	E-cell_type
provides	O
a	O
visual	O
demonstration	O
that	O
physical	O
separation	O
from	O
XIC/XIST	S-DNA
does	O
not	O
result	O
in	O
reactivation	O
of	O
inactive	B-DNA
X-chromosome	E-DNA
material	O
and	O
that	O
X	O
inactivation	O
is	O
not	O
spread	O
to	O
the	O
translocated	B-DNA
autosomes	E-DNA
irrespective	O
of	O
the	O
position	O
of	O
XIC/XIST	S-DNA
.	O

The	O
IL-2	B-DNA
and	I-DNA
the	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	E-DNA
are	O
both	O
expressed	O
transiently	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O

The	O
half-life	O
of	O
c-jun	B-RNA
mRNA	E-RNA
was	O
similar	O
(	O
45-50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	B-cell_line
acid-induced	I-cell_line
cells	E-cell_line
.	O

Our	O
data	O
suggests	O
that	O
NF-kappaB	S-protein
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	S-cell_type
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Conversely	O
,	O
classic	O
HD	O
(	O
CHD	O
)	O
is	O
heterogeneous	O
because	O
the	O
tumor	B-cell_type
cells	E-cell_type
of	O
a	O
fraction	O
of	O
CHD	O
display	O
the	O
BCL-6	S-protein
(	O
-	O
)	O
/	O
syn-1	S-protein
(	O
+	O
)	O
phenotype	O
of	O
post-GC	O
B-cells	O
,	O
whereas	O
another	O
fraction	O
of	O
CHD	O
is	O
constituted	O
by	O
a	O
mixture	O
of	O
tumor	B-cell_type
cells	E-cell_type
reflecting	O
the	O
GC	O
(	O
BCL-6	S-protein
(	O
+	O
)	O
/	O
syn-1	S-protein
(	O
-	O
)	O
)	O
or	O
post-GC	O
(	O
BCL-6	S-protein
(	O
-	O
)	O
/	O
syn-1	S-protein
(	O
+	O
)	O
)	O
phenotypes	O
.	O

Monitoring	O
DPD	S-protein
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O

However	O
,	O
within	O
the	O
B-cell	B-cell_type
lineage	E-cell_type
,	O
ERP	S-protein
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B-lymphocyte	S-cell_type
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B-cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	B-DNA
pi	I-DNA
site	E-DNA
.	O

Recently	O
,	O
it	O
was	O
suggested	O
that	O
activation	O
of	O
the	O
alpha	B-protein
isoform	E-protein
of	O
PPAR	S-protein
by	O
the	O
potent	O
proinflammatory	O
mediator	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
enhanced	O
degradation	O
of	O
this	O
eicosanoid	O
,	O
offersuggesting	O
a	O
new	O
aspect	O
of	O
down-regulation	O
of	O
inflammation	O
.	O

In	O
contrast	O
,	O
development	O
into	O
NK	B-cell_type
cells	E-cell_type
in	O
an	O
FTOC	O
is	O
enhanced	O
.	O

TNF	S-protein
-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
Syk	S-protein
-mediated	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	E-protein
-induced	O
MAPK	S-protein
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3-5	O
min	O
.	O

METHODS	O
:	O
Stable	O
transfectants	O
of	O
the	O
porcine	B-cell_line
vascular	I-cell_line
endothelial	I-cell_line
cell	I-cell_line
line	I-cell_line
PIEC	E-cell_line
with	O
mutated	O
CIITA	B-DNA
constructs	E-DNA
were	O
tested	O
for	O
SLA-DR	S-protein
and	O
SLA-DQ	S-protein
induction	O
by	O
recombinant	B-protein
porcine	I-protein
interferon-gamma	E-protein
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O

Additionally	O
,	O
in	O
lymphocytes	S-cell_type
expressing	O
SOCS-3	S-protein
but	O
not	O
CIS	S-protein
,	O
IL-2	S-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5b	S-protein
was	O
markedly	O
reduced	O
,	O
while	O
there	O
was	O
only	O
a	O
weak	O
effect	O
on	O
IL-3-mediated	B-protein
STAT5b	E-protein
tyrosine	O
phosphorylation	O
.	O

UV-induced	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
was	O
blocked	O
by	O
CD3	S-protein
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	B-protein
surface	I-protein
molecules	E-protein
in	O
biological	O
responses	O
to	O
UV	O
.	O

Total	O
cellular	O
PKC	S-protein
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O

Therefore	O
,	O
activation	O
of	O
STAT5A	S-protein
predominates	O
compared	O
to	O
STAT5B	S-protein
when	O
assayed	O
by	O
direct	O
immunoprecipitation	O
and	O
by	O
evaluation	O
of	O
bound	O
STATs	S-protein
to	O
immobilized	O
GRR	S-DNA
.	O

Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	B-protein
p49	E-protein
and	O
heterodimeric	B-protein
p49/p65	E-protein
for	O
binding	O
to	O
the	O
HIV	B-DNA
kappa	I-DNA
B	I-DNA
site	E-DNA
.	O

Nucleolin	S-protein
is	O
an	O
abundant	B-protein
nucleolar	I-protein
protein	E-protein
which	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
rDNA	S-DNA
transcription	O
or	O
organization	O
,	O
or	O
rRNA	S-RNA
processing	O
.	O

IL-6	S-protein
-induced	O
apoptosis	O
,	O
but	O
not	O
macrophage-differentiation	O
,	O
was	O
blocked	O
by	O
continuously	O
expressed	O
BCL2	S-protein
.	O

The	O
CMAT	S-protein
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c-myb	S-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c-Myb	S-protein
and	O
Ets	S-protein
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	B-cell_line
cells	E-cell_line
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O

RESULTS	O
:	O
Phorbol-myristate-acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent-age	O
of	O
IL-2+	B-cell_line
cells	E-cell_line
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	B-cell_type
cells	E-cell_type
.	O

The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	E-protein
(	O
NF-AT	S-protein
)	O
3	O
is	O
an	O
inducible	O
DNA-binding	B-protein
protein	E-protein
that	O
is	O
essential	O
for	O
transcriptional	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	E-DNA
during	O
T	O
cell	O
activation	O
.	O

Activated	B-cell_type
mononuclear	I-cell_type
cells	E-cell_type
,	O
particularly	O
B	B-cell_type
cells	E-cell_type
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV-inductive	B-protein
cytokines	E-protein
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

For	O
this	O
purpose	O
,	O
81	O
pentadecamer	O
peptides	O
covering	O
the	O
complete	O
491-amino-acid	B-protein
sequence	E-protein
of	O
IE-1	S-protein
were	O
tested	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
of	O
anti-HCMV	O
immunoglobulin	O
G-seropositive	O
donors	O
.	O

In	O
the	O
second	O
series	O
we	O
observed	O
the	O
following	O
:	O
at	O
the	O
end	O
of	O
the	O
first	O
month	O
of	O
bed	O
rest	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	E-protein
and	O
receptor	O
affinity	O
significantly	O
increased	O
;	O
at	O
the	O
beginning	O
of	O
the	O
third	O
month	O
of	O
bed	O
rest	O
specific	O
glucocorticoid	O
binding	O
significantly	O
decreased	O
and	O
circadian	O
rhythms	O
of	O
adrenocorticotropin	O
and	O
cortisol	O
in	O
blood	O
varied	O
markedly	O
;	O
at	O
the	O
end	O
of	O
the	O
sixth	O
month	O
of	O
bed	O
rest	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	E-protein
returned	O
to	O
prebed	O
rest	O
levels	O
and	O
dissociation	O
constant	O
decreased	O
.	O

Interestingly	O
,	O
an	O
inducible	O
footprint	O
between	O
-183	B-DNA
and	I-DNA
-196	E-DNA
was	O
consistently	O
observed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	E-cell_line
and	O
CD45RA	B-cell_type
and	I-cell_type
CD45R0	I-cell_type
T	I-cell_type
helper	I-cell_type
subsets	E-cell_type
upon	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate+	O
phytohemagglutinin	S-protein
(	O
PMA+	O
PHA	S-protein
)	O
that	O
was	O
highly	O
sensitive	O
to	O
treatment	O
with	O
corticosteroids	O
.	O

X	O
chromosome	O
inactivation	O
and	O
polymorphism	O
of	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
HUMARA	I-DNA
)	I-DNA
gene	E-DNA
has	O
been	O
applied	O
for	O
analyzing	O
the	O
clonality	O
of	O
blood	B-cell_type
cells	E-cell_type
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O

Furthermore	O
,	O
the	O
NFKB2	S-protein
precursor	O
is	O
physically	O
associated	O
with	O
c-Rel	S-protein
and	O
with	O
Tax	S-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
cells	E-cell_type
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	S-protein
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	S-protein
and	O
NGFI-A/Egr-1	S-protein
using	O
a	O
TRE1	B-DNA
probe	E-DNA
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	E-protein
in	O
IL-5	B-DNA
promoter	E-DNA
activation	O
in	O
EL-4	B-cell_line
cells	E-cell_line
,	O
which	O
express	O
both	O
Th1-	B-protein
and	I-protein
Th2-type	I-protein
cytokines	E-protein
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B-protein
E	E-protein
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	S-protein
.	O

However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	B-protein
and	I-protein
transmembrane	I-protein
regions	E-protein
of	O
the	O
human	B-protein
type	I-protein
II	I-protein
interleukin-1	E-protein
fused	O
to	O
the	O
cytoplasmic	B-protein
domain	E-protein
of	O
the	O
human	B-protein
type	I-protein
I	I-protein
IL-1R	E-protein
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	B-protein
I	I-protein
IL-1R	E-protein
.	O

We	O
directly	O
tested	O
the	O
amino	O
acid	O
polymorphism	O
at	O
this	O
site	O
as	O
a	O
determinant	O
for	O
peptide	O
binding	O
and	O
for	O
antigen-specific	O
T	O
cell	O
stimulation	O
.	O

LPS	O
core-	B-protein
and	I-protein
O-side	I-protein
chain-specific	I-protein
mAbs	E-protein
inhibited	O
mCD14	S-protein
-mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

Gangliosides	O
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	B-RNA
transcripts	E-RNA
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	E-protein
was	O
blocked	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2-50	O
Gy	O
results	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
human	B-cell_line
KG-1	I-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	E-cell_line
and	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursor	I-cell_type
cells	E-cell_type
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

NF-AT	S-protein
does	O
not	O
directly	O
bind	O
to	O
this	O
element	O
.	O

The	O
TCF-1	B-DNA
alpha	I-DNA
cDNA	E-DNA
contains	O
a	O
single	O
68-amino-acid	B-protein
domain	E-protein
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	B-protein
group	E-protein
(	O
HMG	S-protein
)	O
and	O
nonhistone	B-protein
chromosomal	I-protein
proteins	E-protein
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid-regulated	O
expression	O
of	O
an	O
endogenous	O
thymocyte-specific	B-DNA
gene	E-DNA
called	O
GIG18	S-DNA
.	O

The	O
p13MTCP1	B-protein
protein	E-protein
was	O
detected	O
in	O
the	O
three	O
T-cell	O
proliferations	O
with	O
MTCP1	B-DNA
rearrangements	E-DNA
because	O
of	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
,	O
but	O
neither	O
in	O
normal	O
resting	O
and	O
activated	B-cell_type
lymphocytes	E-cell_type
nor	O
in	O
the	O
other	O
T-cell	S-cell_type
leukemias	O
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R-associated	B-protein
kinase	I-protein
(	I-protein
IRAK	I-protein
)	E-protein
is	O
recruited	O
to	O
the	O
TLR2	S-protein
complex	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	B-DNA
box	E-DNA
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	B-DNA
promoter	E-DNA
,	O
the	O
DRA	B-DNA
``	I-DNA
octamer	I-DNA
''	E-DNA
does	O
not	O
utilize	O
OTF-2	S-protein
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	B-DNA
promoters	E-DNA
in	O
B	B-cell_type
cells	E-cell_type
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	B-protein
protein	E-protein
,	O
IL-4	S-protein
induced	O
robust	O
Janus	B-protein
kinase	I-protein
3	E-protein
(	O
JAK3	S-protein
)	O
activity	O
in	O
BL-2	B-cell_line
cells	E-cell_line
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel-related	B-protein
factors	E-protein
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
element	E-DNA
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	S-protein
in	O
response	O
to	O
LPS	O
.	O

Toxicity	O
was	O
measured	O
by	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
.	O

Surprisingly	O
,	O
however	O
,	O
neither	O
of	O
these	O
proteins	O
bound	O
in	O
vitro	O
to	O
EBS1	O
or	O
EBS2	S-DNA
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
,	O
however	O
,	O
is	O
unknown	O
.	O

Blockade	O
of	O
the	O
DNA-binding	B-protein
complexes	E-protein
with	O
an	O
anti-Fos	B-protein
mAb	E-protein
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	S-protein
in	O
the	O
AP-1	B-protein
complexes	E-protein
induced	O
by	O
anti-AIM	B-protein
mAb	E-protein
.	O

Our	O
results	O
support	O
the	O
idea	O
that	O
human	B-protein
CD36	E-protein
mediates	O
signal	O
transduction	O
events	O
in	O
response	O
to	O
Ox	O
LDL	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	B-protein
messengers	E-protein
involved	O
in	O
this	O
PGE2-dependent	O
up-regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O

The	O
prolactin	B-protein
receptor	E-protein
,	O
a	O
member	O
of	O
the	O
hematopoietin/cytokine	B-protein
receptor	I-protein
superfamily	E-protein
,	O
is	O
ubiquitously	O
expressed	O
by	O
cells	O
in	O
the	O
immune	O
system	O
.	O

Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman-Gallwey	O
score	O
after	O
1	O
year	O
:	O
4.1	O
+/-	O
0.5	O
versus	O
14.1	O
+/-	O
0.9	O
)	O
.	O

We	O
recently	O
reported	O
that	O
human	B-cell_type
alveolar	I-cell_type
macrophages	E-cell_type
do	O
not	O
express	O
AP-1	S-protein
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A.	O
B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G.	O
W.	O
(	O
1998	O
)	O
Am.	O
J.	O
Physiol.	O
275	O
,	O
L389-L397	O
)	O
.	O

IRF-1	S-protein
is	O
a	O
transcription	B-protein
factor	E-protein
regulated	O
by	O
IFNs	S-protein
that	O
is	O
also	O
essential	O
for	O
Th1	S-cell_type
responses	O
.	O

Inhibition	O
of	O
GATA-3	S-protein
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	B-cell_type
cells	E-cell_type
,	O
but	O
not	O
in	O
fibroblasts	S-cell_type
.	O

PGE2	S-protein
enhanced	O
the	O
complex	O
formation	O
with	O
NF-AT	B-DNA
,	I-DNA
AP-1	I-DNA
and	I-DNA
CLE0	I-DNA
sequences	E-DNA
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti-CD3	B-protein
mAb	E-protein
or	O
PMA/A23187	O
stimulation	O
.	O

The	O
presence	O
of	O
ras	O
mutations	O
has	O
been	O
correlated	O
with	O
a	O
poor	O
prognosis	O
and	O
negative	O
clinical	O
outcome	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	S-protein
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	B-protein
receptor	E-protein
as	O
well	O
as	O
IL-18	B-protein
receptor	E-protein
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	S-DNA
or	O
kappa	B-DNA
B-like	I-DNA
sites	E-DNA
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2+	O
)	O
-independent	O
stimuli	O
.	O

Both	O
the	O
preleukemic	O
state	O
and	O
the	O
leukemia	O
could	O
be	O
transplanted	O
to	O
nontransgenic	O
mice	O
,	O
and	O
the	O
transplanted	O
preleukemia	O
could	O
progress	O
to	O
APL	O
.	O

A	O
TBP	O
mutant	O
defective	O
in	O
interaction	O
with	O
TBP-associated	B-protein
factor	I-protein
TAFII250	E-protein
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	B-protein
activation	I-protein
domain	E-protein
.	O

Macrophages	S-cell_type
and	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
infiltrated	O
the	O
tumor	O
in	O
moderate	O
numbers	O
with	O
occasional	O
lymphoid	O
aggregate	O
formation	O
.	O

We	O
found	O
that	O
EPO	S-protein
did	O
not	O
activate	O
Stat1alpha	S-protein
or	O
Stat3	S-protein
in	O
UT-7/GM	B-cell_line
cells	E-cell_line
.	O

STAT3	S-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	E-protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	S-protein
or	O
growth	B-protein
factors	E-protein
.	O

This	O
prompted	O
us	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
BCL-6	B-protein
protein	E-protein
in	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
,	O
focusing	O
on	O
the	O
nodular	O
lymphocyte	O
predominance	O
subtype	O
(	O
NLPHD	O
)	O
,	O
which	O
differs	O
from	O
classical	O
HD	O
by	O
virtue	O
of	O
the	O
B-cell	O
nature	O
of	O
the	O
malignant	B-cell_type
cell	I-cell_type
population	E-cell_type
(	O
so-called	O
L	B-cell_type
&	I-cell_type
H	I-cell_type
cells	E-cell_type
)	O
and	O
its	O
relationship	O
with	O
germinal	O
centers	O
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB-dependent	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	E-cell_type
requires	O
activation	O
of	O
IKK2	S-protein
.	O

The	O
use	O
of	O
glucocorticoids	O
in	O
acute	O
lymphoblastic	O
leukemia	O
of	O
childhood	O
.	O

Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co-ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	E-protein
,	O
IL-beta	S-protein
,	O
and	O
IL-6	S-protein
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	E-RNA
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL-10	S-protein
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O

Activation	O
of	O
IFN-gamma-responsive	B-DNA
genes	E-DNA
requires	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcriptional	O
factor	O
STAT-1alpha	S-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-1alpha	E-protein
)	O
.	O

A	O
2-kb	B-DNA
VDR	I-DNA
cDNA	I-DNA
insert	E-DNA
(	O
including	O
the	O
complete	O
VDR	B-DNA
coding	I-DNA
region	E-DNA
)	O
was	O
cloned	O
in	O
an	O
antisense	O
orientation	O
into	O
the	O
EBV	O
episomal	O
vector	O
pMEP4	O
under	O
the	O
control	O
of	O
an	O
inducible	B-DNA
promoter	E-DNA
and	O
transfected	O
into	O
U937	S-cell_line
.	O

Treatment	O
with	O
wild-type	O
and	O
rough	O
mutant	O
forms	O
of	O
LPS	O
and	O
synthetic	O
lipid	O
A	O
resulted	O
in	O
JNK	S-protein
activation	O
,	O
while	O
pretreatment	O
with	O
the	O
tyrosine	B-protein
kinase	E-protein
inhibitor	O
herbimycin	O
A	O
inhibited	O
this	O
response	O
.	O

Constitutively	B-protein
active	I-protein
SHP1-DeltaSH2	E-protein
had	O
a	O
more	O
pronounced	O
effect	O
on	O
ZAP-70	S-protein
and	O
Syk	S-protein
,	O
even	O
when	O
expressed	O
at	O
near	O
physiological	O
levels	O
.	O

Costimulation	O
of	O
T	B-cell_type
cells	E-cell_type
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	S-protein
leads	O
to	O
high	O
level	O
IL-2	S-protein
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

The	O
expression	O
of	O
the	O
M-CSF	B-DNA
gene	E-DNA
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
chromosome	I-DNA
1	E-DNA
(	O
lp	S-DNA
)	O
,	O
was	O
also	O
investigated	O
.	O

Thus	O
,	O
tg	B-protein
epsilon26	E-protein
mice	O
provide	O
a	O
novel	O
mouse	O
model	O
in	O
that	O
lineage	O
choice	O
between	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	E-cell_type
is	O
genetically	O
defective	O
.	O

This	O
review	O
will	O
concentrate	O
on	O
this	O
topic	O
and	O
on	O
its	O
role	O
for	O
the	O
regulation	O
of	O
eosinophil	O
apoptosis	O
.	O

A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O

Inhibition	O
of	O
apoptosis	O
in	O
eosinophils	S-cell_type
by	O
cytokines	S-protein
such	O
as	O
IL-5	S-protein
and	O
GM-CSF	S-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
and	O
parasitic	O
disorders	O
.	O

However	O
,	O
while	O
HUVECs	S-cell_line
contained	O
endothelial	O
NOS	B-protein
protein	E-protein
,	O
no	O
inducible	O
NOS	S-protein
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	B-cell_type
cells	E-cell_type
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	B-protein
factors	E-protein
to	O
the	O
Egr-1	B-DNA
and	I-DNA
kappaB3	I-DNA
sites	E-DNA
,	O
which	O
were	O
identified	O
as	O
Egr-1	S-protein
and	O
p50/p65	S-protein
,	O
respectively	O
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	S-protein
expression	O
,	O
freshly	O
isolated	O
human	B-cell_type
monocytes	E-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	E-cell_line
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	S-protein
,	O
a	O
signal	B-protein
transduction	I-protein
molecule	E-protein
that	O
is	O
also	O
utilized	O
by	O
TNFR1	S-protein
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	S-protein
and	O
transcription	B-protein
factors	E-protein
.	O

IL-2	S-protein
induced	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	S-protein
and	O
STAT5	S-protein
of	O
a	O
HTLV-1-transformed	O
cell	O
line	O
and	O
then	O
stimulated	O
its	O
proliferation	O
.	O

A	O
novel	B-cell_type
B-cell	E-cell_type
derived	O
(	O
Bcd	S-DNA
)	O
oncogene	S-DNA
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B-CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	S-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	S-protein
repression	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	B-protein
necrosis	I-protein
factor	E-protein
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	S-cell_type
.	O

Under	O
these	O
conditions	O
HUVEC	B-protein
adhesion	I-protein
molecules	E-protein
,	O
E-selectin	S-protein
,	O
VCAM-1	S-protein
and	O
ICAM-1	S-protein
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	S-protein
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	E-protein
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	E-protein
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic-pituitary-adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-protein
receptor	E-protein
number	O
and	O
affinity	O
.	O

However	O
,	O
in	O
mutant	O
mice	O
lacking	O
functional	O
Ikaros	B-protein
transcription	I-protein
factors	E-protein
,	O
there	O
are	O
deficiencies	O
in	O
lymphoid	B-cell_type
precursor	I-cell_type
cells	E-cell_type
,	O
in	O
mature	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
and	O
in	O
DC	S-cell_type
.	O

Its	O
N-terminal	B-protein
region	E-protein
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	B-protein
binding	I-protein
domain	E-protein
.	O

Prolactin	S-protein
and	O
interleukin-2	B-protein
receptors	E-protein
in	O
T	B-cell_type
lymphocytes	E-cell_type
signal	O
through	O
a	O
MGF-STAT5-like	B-protein
transcription	I-protein
factor	E-protein
.	O

In	O
monocytic	B-protein
THP-1	I-protein
cells	I-protein
TNF-alpha	E-protein
induced	O
two	O
nuclear	B-protein
complexes	E-protein
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM-1	B-DNA
kappa	I-DNA
B	I-DNA
site	E-DNA
.	O

Neuronal	B-protein
(	I-protein
type	I-protein
I	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	E-protein
regulates	O
nuclear	B-protein
factor	I-protein
kappaB	E-protein
activity	O
and	O
immunologic	B-protein
(	I-protein
type	I-protein
II	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	E-protein
expression	O
.	O

Inefficient	O
DNA	O
replication	O
is	O
also	O
found	O
in	O
another	O
monocyte	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O

Inhibition	O
of	O
protein	B-protein
phosphatases	E-protein
by	O
okadaic	O
acid	O
induces	O
AP1	S-protein
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Most	O
interestingly	O
,	O
the	O
N-terminal	B-protein
SH2	I-protein
domain	E-protein
had	O
an	O
inhibitory	O
effect	O
,	O
whereas	O
a	O
mutant	B-protein
p85	E-protein
containing	O
only	O
the	O
two	B-protein
SH2	I-protein
domains	E-protein
enhanced	O
basal	O
NFAT	S-protein
activity	O
in	O
a	O
Ras	S-protein
-dependent	O
manner	O
.	O

Identification	O
of	O
an	O
ionomycin/cyclosporin	B-DNA
A-responsive	I-DNA
element	E-DNA
within	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
enhancer	E-DNA
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	B-DNA
and	I-DNA
the	I-DNA
kappaB3	I-DNA
sites	E-DNA
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c-Jun	B-protein
complexes	E-protein
and	O
p50/p65	S-protein
.	O

DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
GR	E-protein
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Three	O
VZV-susceptible	O
donors	O
were	O
tested	O
,	O
and	O
all	O
demonstrated	O
an	O
in	O
vitro	O
response	O
to	O
multiple	O
VZV	O
peptides	O
.	O

We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O

Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram-positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	S-protein
in	O
macrophages	S-cell_type
through	O
CD14	S-protein
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O

Lymphocytes	S-cell_type
of	O
non-pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre-term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+/-	O
1	O
,	O
3	O
+/-	O
2	O
and	O
5	O
+/-	O
4	O
fmol/mg	O
respectively	O
.	O

Domain	B-DNA
B	E-DNA
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B-DNA
EB1-responsive	I-DNA
element	E-DNA
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040-3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	S-protein
and	O
R	S-protein
,	O
an	O
EBV	B-protein
early	I-protein
product	E-protein
encoded	O
by	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
BRLF1	E-DNA
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313-321	O
,	O
1990	O
)	O
.	O

REVs	O
do	O
not	O
encode	O
a	O
transactivator	O
targeted	O
to	O
the	O
viral	B-DNA
LTR	E-DNA
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	O
express	O
factors	O
that	O
preferentially	O
enhance	O
expression	O
from	O
REV	O
or	O
avian	B-DNA
sarcoma/leukemia	I-DNA
virus	I-DNA
LTRs	E-DNA
.	O

p49	S-protein
has	O
a	O
approximately	O
18-fold-lower	O
affinity	O
for	O
the	O
HIV	O
kappa	B-DNA
B	I-DNA
site	E-DNA
(	O
KD	O
=	O
69.1	O
pM	O
)	O
than	O
does	O
the	O
approximately	O
50-kDa	O
protein	O
NFKB1	B-protein
(	I-protein
p50	I-protein
)	E-protein
derived	O
from	O
p105	S-protein
(	O
KD	O
=	O
3.9	O
pM	O
)	O
.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O
as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	B-DNA
gene	E-DNA
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	B-DNA
genome	E-DNA
.	O

Nuclear	O
run-on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c-jun	O
and	O
c-fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA-induced	O
expression	O
of	O
c-jun	S-DNA
and	O
c-fos	S-protein
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA-induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O

B-myb	S-protein
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
,	O
but	O
,	O
unlike	O
c-myb	S-DNA
,	O
it	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
blasts	E-cell_type
can	O
be	O
stimulated	O
via	O
the	O
CD28	B-protein
surface	I-protein
molecule	E-protein
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	B-cell_type
T	I-cell_type
cells	E-cell_type
to	O
CD28	S-protein
activation	O
in	O
isolation	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	S-protein
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	B-protein
B	E-protein
with	O
its	O
recognition	B-DNA
sequence	E-DNA
and	O
on	O
NF-kappa	B-protein
B	E-protein
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	B-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cell	I-cell_line
lines	E-cell_line
(	O
19D	S-cell_line
and	O
9J	S-cell_line
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-DNA
expression	I-DNA
vector	E-DNA
.	O

Antibodies	O
against	O
the	O
NF-kappa	B-protein
B	E-protein
and	O
Rel	O
proteins	O
and	O
UV	O
cross-linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c-Rel	S-protein
and	O
p65	O
and	O
the	O
absence	O
of	O
p50	S-protein
in	O
the	O
TF	B-protein
complex	E-protein
and	O
further	O
showed	O
that	O
c-Rel/p65	B-protein
heterodimers	E-protein
selectively	O
bound	O
to	O
the	O
TF	B-DNA
kappa	I-DNA
B-like	I-DNA
site	E-DNA
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

Mutation	O
of	O
the	O
CBF1/RBP-Jkappa	B-protein
binding	I-protein
site	E-protein
in	O
EBNA3C	S-protein
abrogated	O
repression	O
,	O
strongly	O
suggesting	O
that	O
CBF1/RBP-Jkappa	S-protein
is	O
necessary	O
for	O
targeting	O
the	O
viral	O
protein	O
to	O
Cp	S-DNA
.	O

We	O
evaluated	O
49	O
female	O
patients	O
with	O
MPD	O
and	O
informative	O
at	O
the	O
X-linked	B-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
AR	I-DNA
)	I-DNA
locus	E-DNA
to	O
establish	O
the	O
X	B-DNA
chromosome	E-DNA
inactivation	O
pattern	O
of	O
hemopoietic	B-cell_type
cells	E-cell_type
.	O

Recently	O
,	O
these	O
G-protein-coupled	B-protein
serpentine	I-protein
receptors	E-protein
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	S-cell_type
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	B-protein
protein	E-protein
binds	O
to	O
the	O
microB	B-DNA
DNA	I-DNA
motif	E-DNA
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	S-DNA
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF-kappa	B-protein
B	E-protein
activity	O
with	O
cell-permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF-kappa	B-protein
B1	I-protein
dimers	E-protein
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	B-cell_type
normal	I-cell_type
human	I-cell_type
PBL	E-cell_type
.	O

The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	B-protein
receptor	E-protein
(	O
GR	S-protein
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O

Tcf-1	S-protein
-mediated	O
transcription	O
in	O
T	B-cell_type
lymphocytes	E-cell_type
:	O
differential	O
role	O
for	O
glycogen	B-protein
synthase	I-protein
kinase-3	E-protein
in	O
fibroblasts	S-cell_type
and	O
T	B-cell_type
cells	E-cell_type
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF-kappa	B-protein
B	E-protein
functional	O
activity	O
is	O
independent	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
(	O
MAD3	S-protein
)	O
-	O
NF-kappa	B-protein
B	E-protein
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	B-protein
kappa	I-protein
B	E-protein
nuclear	O
translocation	O
.	O

High	O
levels	O
of	O
cytokine	S-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	E-cell_type
also	O
required	O
both	O
TCR	S-protein
and	O
costimulatory	O
signals	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	B-RNA
mRNA	E-RNA
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

PD98059	O
inhibited	O
GM-CSF	S-protein
-dependent	O
proliferation	O
of	O
MO7e	B-cell_type
cells	E-cell_type
.	O

Mononuclear	B-cell_type
phagocytes	E-cell_type
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
conclude	O
,	O
rather	O
,	O
that	O
alpha	B-protein
4	I-protein
beta	I-protein
1	E-protein
in	O
freshly	B-cell_type
isolated	I-cell_type
T	I-cell_type
cells	E-cell_type
delivers	O
a	O
distinct	O
signal	O
that	O
synergizes	O
early	O
with	O
signals	O
initiated	O
by	O
TCR/CD3	S-protein
ligation	O
to	O
induce	O
DNA	O
binding	O
of	O
multiple	O
transcription	B-protein
factors	E-protein
required	O
for	O
cytokine	B-DNA
gene	E-DNA
induction	O
.	O

Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	E-protein
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	E-protein
in	O
fibroblasts	S-cell_type
.	O

Protein-tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B-protein
1beta	E-protein
and	O
NFkappaB	S-protein
activation	O
,	O
but	O
not	O
NFkappaB	S-protein
nuclear	O
translocation	O
.	O

The	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
independent	I-DNA
cis-acting	I-DNA
sequences	E-DNA
in	O
HIV-1	B-DNA
LTR	E-DNA
responsive	O
to	O
T-cell	O
activation	O
.	O

The	O
normal	O
upper	O
limit	O
of	O
ER	S-protein
content	O
in	O
lymphocytes	S-cell_type
,	O
expressed	O
by	O
fmol/micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O

To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	O
aspirin	O
nor	O
salicylate	O
)	O
produced	O
a	O
concentration-dependent	O
inhibition	O
of	O
COX-2	S-protein
protein	O
expression	O
in	O
peripheral	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
cells	E-cell_type
.	O

With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	B-DNA
cDNAs	E-DNA
encoding	O
EBF	S-protein
or	O
a	O
covalent	O
homodimer	O
of	O
E47	S-protein
,	O
individually	O
or	O
together	O
,	O
into	O
immature	B-cell_line
hematopoietic	I-cell_line
Ba/F3	I-cell_line
cells	E-cell_line
,	O
which	O
lack	O
both	O
factors	O
.	O

CD8+	B-cell_type
T	I-cell_type
lymphocytes	E-cell_type
of	O
HIV-1	O
infected	O
individuals	O
produce	O
a	O
soluble	B-protein
factor	E-protein
that	O
efficiently	O
suppresses	O
HIV-1	O
replication	O
at	O
the	O
transcriptional	O
level	O
.	O

Treatment	O
of	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cell	I-cell_line
(	I-cell_line
HUVEC	I-cell_line
)	I-cell_line
monolayers	E-cell_line
for	O
6	O
hours	O
with	O
0.2	O
mmol/L	O
diamide	O
and	O
1	O
mmol/L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O

Ras	S-protein
can	O
initiate	O
Rac-1	S-protein
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	E-protein
function	O
independently	O
of	O
PtdIns	B-protein
3-kinase	E-protein
activity	O
.	O

The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

In	O
addition	O
,	O
IL-2	S-protein
but	O
not	O
IL-12	S-protein
induced	O
nuclear	B-protein
factors	I-protein
NF-kappa	I-protein
B	E-protein
and	O
AP1	S-protein
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B-protein
binding	I-protein
protein	I-protein
complexes	E-protein
is	O
correlated	O
with	O
IFN-gamma	O
and	O
GM-CSF	O
gene	O
expression	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML-9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

IL-6	O
levels	O
in	O
all	O
IBD	O
groups	O
with	O
and	O
without	O
steroids	O
were	O
significantly	O
different	O
from	O
those	O
in	O
control	O
subjects	O
.	O

Erythroid-specific	B-RNA
mRNAs	E-RNA
encoding	O
gamma-globin	S-protein
and	O
erythroid	B-protein
delta-aminolevulinate	I-protein
synthase	E-protein
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	S-cell_type
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	S-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

Reactivity	O
with	O
the	O
tegument	B-protein
protein	E-protein
encoded	O
by	O
UL21	S-DNA
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O

Tal-1	B-DNA
gene	E-DNA
encodes	O
a	O
putative	O
transcription	B-protein
factor	E-protein
with	O
a	O
basic	B-protein
helix-loop-helix	I-protein
domain	E-protein
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	E-cell_type
.	O

Clonality	O
analysis	O
using	O
X-chromosome	S-DNA
inactivation	O
at	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	E-DNA
(	O
Humara	S-DNA
)	O
.	O

In	O
vitro	O
DNase	B-protein
I	E-protein
footprinting	O
analysis	O
revealed	O
six	O
hGATA-3	B-DNA
binding	I-DNA
sites	E-DNA
in	O
the	O
U3	B-DNA
region	E-DNA
(	O
the	O
transcriptional	B-DNA
regulatory	I-DNA
domain	E-DNA
)	O
of	O
the	O
HIV-1	B-DNA
LTR	E-DNA
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF-kappaB	S-protein
requires	O
dual	O
signals	O
.	O

We	O
also	O
observed	O
that	O
cell	B-cell_type
surface	I-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
cells	E-cell_type
with	O
rearranged	B-DNA
TCR	I-DNA
genes	E-DNA
developed	O
from	O
Id3-transduced	S-cell_line
but	O
not	O
from	O
control-transduced	B-cell_line
pre-T	I-cell_line
cells	E-cell_line
in	O
an	O
FTOC	S-cell_line
.	O

Involvement	O
of	O
Rel	B-protein
,	I-protein
Fos	I-protein
,	I-protein
and	I-protein
Jun	I-protein
proteins	E-protein
in	O
binding	O
activity	O
to	O
the	O
IL-2	B-DNA
promoter	I-DNA
CD28	I-DNA
response	I-DNA
element/AP-1	I-DNA
sequence	E-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

Calcineurin	S-protein
stimulates	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	E-DNA
by	O
enhancing	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B/MAD3	E-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	E-protein
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF-kappa	B-protein
B	E-protein
DNA	O
binding	O
activity	O
.	O

The	O
IL-2	B-DNA
octamer	I-DNA
motif	E-DNA
is	O
a	O
composite	O
cis-element	S-DNA
which	O
binds	O
Oct-1	S-protein
and	O
Oct-2	S-protein
as	O
well	O
as	O
a	O
TPA/Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-inducible	I-protein
nuclear	I-protein
factor	E-protein
,	O
previously	O
termed	O
octamer-associated	B-protein
protein	E-protein
(	O
OAP40	S-protein
)	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	B-DNA
gene	E-DNA
isolated	O
from	O
human	B-cell_type
T	I-cell_type
cells	E-cell_type
that	O
predicts	O
a	O
protein	O
of	O
968	B-protein
amino	I-protein
acids	E-protein
.	O

Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta-HSD	B-protein
IV	E-protein
or	O
DNA-PK	B-RNA
(	I-RNA
CS	I-RNA
)	I-RNA
mRNA	E-RNA
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O

These	O
findings	O
support	O
a	O
model	O
in	O
which	O
gamma	B-protein
(	I-protein
c	I-protein
)	E-protein
serves	O
primarily	O
to	O
activate	O
signal	O
transduction	O
by	O
the	O
IL-7R	B-protein
complex	E-protein
,	O
while	O
IL-7R	B-protein
alpha	E-protein
determines	O
specific	O
signaling	O
events	O
through	O
its	O
association	O
with	O
cytoplasmic	B-protein
signaling	I-protein
molecules	E-protein
.	O

Depending	O
on	O
the	O
type	O
of	O
lymphocytes	S-cell_type
,	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
fall	O
roughly	O
in	O
two	O
categories	O
:	O
induction	O
of	O
``	O
death	O
genes	O
''	O
by	O
the	O
activated	O
GR	S-protein
(	O
I	B-protein
kappa	I-protein
B	E-protein
,	O
c-jun	S-protein
)	O
or	O
repression	O
of	O
survival	B-protein
factors	E-protein
(	O
AP-1	S-protein
,	O
c-Myc	S-protein
)	O
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	S-RNA
encoding	O
c-Fos	S-protein
,	O
a	O
common	O
component	O
of	O
AP-1	S-protein
and	O
observed	O
that	O
it	O
was	O
indeed	O
up-regulated	O
in	O
infected	B-cell_type
cells	E-cell_type
.	O

Demonstration	O
of	O
estrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	E-protein
as	O
well	O
as	O
Ki-67	B-protein
and	I-protein
p-145	I-protein
antigens	E-protein
in	O
single	B-cell_type
tumor	I-cell_type
cells	E-cell_type
from	O
blood	O
and	O
pleural	O
effusions	O
using	O
a	O
slide	O
assay	O
.	O

Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	B-DNA
EBV	I-DNA
DNA	E-DNA
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O

RANTES	S-protein
(	O
regulated	B-protein
upon	I-protein
activation	I-protein
,	I-protein
normal	I-protein
T	I-protein
cell	I-protein
expressed	I-protein
and	I-protein
secreted	E-protein
)	O
is	O
a	O
cytokine	S-protein
that	O
belongs	O
to	O
the	O
beta-chemokine	B-protein
family	E-protein
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+/CD45RO	B-cell_type
T	I-cell_type
cells	E-cell_type
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8+	B-cell_type
and	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	E-cell_type
as	O
well	O
as	O
monocytes/macrophages	S-cell_type
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage-tropic	O
strains	O
of	O
HIV	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	E-cell_type
.	O

In	O
contrast	O
to	O
T	B-cell_type
cells	E-cell_type
,	O
in	O
fibroblasts	B-protein
PILOT	E-protein
gene	O
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	B-DNA
LTR	E-DNA
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	B-DNA
box	E-DNA
.	O

HIV	O
type	O
1	O
protease	S-protein
activation	O
of	O
NF-kappa	B-protein
B	E-protein
within	O
T	B-cell_type
lymphoid	I-cell_type
cells	E-cell_type
.	O

Involvement	O
of	O
intracellular	O
Ca2+	O
in	O
oxidant-induced	O
NF-kappa	B-protein
B	E-protein
activation	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
line	E-cell_line
,	O
clone	B-cell_line
13	E-cell_line
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	S-protein
in	O
the	O
absence	O
of	O
HLA-DR	S-DNA
and	O
HLA-DP	S-DNA
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT-7/GMT	S-cell_line
,	O
from	O
the	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
UT-7/GM	E-cell_line
(	O
N.	O
Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021-4033	O
,	O
1997	O
)	O
.	O

The	O
effect	O
of	O
temperature	O
,	O
beta	B-protein
2-microglobulin	E-protein
(	O
beta	B-protein
2-m	E-protein
)	O
and	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
on	O
the	O
binding	O
and	O
the	O
stability	O
of	O
the	O
HLA/peptide	B-protein
complex	E-protein
was	O
studied	O
.	O

